<Metabolites><creation_date>2005-11-16 15:48:42 UTC</creation_date><update_date>22:02:55</update_date><version>4</version><name>Cholesterol</name><accession>HMDB0000067</accession><completion_status>In progress</completion_status><ranges><range><sex>Both</sex><age><min_age>0</min_age><max_age>64</max_age></age><ethnicity>NA</ethnicity><unit>Um</unit><min_range>0</min_range><max_range>6700.0</max_range><diseases><disease>Gallbladder disease<references><reference><reference_text>Lapidus A, Akerlund JE, Einarsson C: Gallbladder bile composition in patients with Crohn 's disease. World J Gastroenterol. 2006 Jan 7;12(1):70-4.</reference_text><pubmed_id>16440420</pubmed_id></reference><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference><reference><reference_text>Mizuno S, Tazuma S, Kajiyama G: Stabilization of biliary lipid particles by ursodeoxycholic acid. Prolonged nucleation time in human gallbladder bile. Dig Dis Sci. 1993 Apr;38(4):684-93.</reference_text><pubmed_id>8462368</pubmed_id></reference><reference><reference_text>Hillebrant CG, Axelson M, Bjorkhem I, Wang FH, Nyberg B, Einarsson C: Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients. Eur J Clin Invest. 1998 Apr;28(4):324-8.</reference_text><pubmed_id>9615912</pubmed_id></reference></references></disease><disease>Cholelithiasis<references><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference></references></disease><disease>Stomach cancer<references><reference><reference_text>Higashijima H, Ichimiya H, Nakano T, Yamashita H, Kuroki S, Satoh H, Chijiiwa K, Tanaka M: Deconjugation of bilirubin accelerates coprecipitation of cholesterol, fatty acids, and mucin in human bile--in vitro study. J Gastroenterol. 1996 Dec;31(6):828-35.</reference_text><pubmed_id>9027647</pubmed_id></reference><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Song H, Peng JS, Dong-Sheng Y, Yang ZL, Liu HL, Zeng YK, Shi XP, Lu BY: Serum metabolic profiling of human gastric cancer based on gas chromatography/mass spectrometry. Braz J Med Biol Res. 2012 Jan;45(1):78-85. Epub 2011 Nov 25.</reference_text><pubmed_id>22124703</pubmed_id></reference><reference><reference_text>Yu L, Aa J, Xu J, Sun M, Qian S, Cheng L, Yang S, Shi R: Metabolomic phenotype of gastric cancer and precancerous stages based on gas chromatography time-of-flight mass spectrometry. J Gastroenterol Hepatol. 2011 Aug;26(8):1290-7. doi: 10.1111/j.1440-1746.2011.06724.x.</reference_text><pubmed_id>21443661</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference></references></disease><disease>Acute myelogenous leukemia<references><reference><reference_text>Tatidis L, Vitols S, Gruber A, Paul C, Axelson M: Cholesterol catabolism in patients with acute myelogenous leukemia and hypocholesterolemia: suppressed levels of a circulating marker for bile acid synthesis. Cancer Lett. 2001 Sep 20;170(2):169-75.</reference_text><pubmed_id>11463495</pubmed_id></reference></references></disease><disease>Hypercholesterolemia<references><reference><reference_text>Thelen KM, Laaksonen R, Paiva H, Lehtimaki T, Lutjohann D: High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels. J Clin Pharmacol. 2006 Jul;46(7):812-6.</reference_text><pubmed_id>16809807</pubmed_id></reference><reference><reference_text>Tamasawa N, Tamasawa A, Takebe K: Higher levels of plasma cholesterol sulfate in patients with liver cirrhosis and hypercholesterolemia. Lipids. 1993 Sep;28(9):833-6.</reference_text><pubmed_id>8231659</pubmed_id></reference><reference><reference_text>Kim DH, Lee KJ, Heo GS: Analysis of cholesterol and cholesteryl esters in human serum using capillary supercritical fluid chromatography. J Chromatogr B Biomed Appl. 1994 Apr 22;655(1):1-8.</reference_text><pubmed_id>8061816</pubmed_id></reference><reference><reference_text>Authors unspecified: Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med. 1988 Jan;148(1):36-69.</reference_text><pubmed_id>3422148</pubmed_id></reference></references></disease><disease>Cholesteryl ester storage disease<references><reference><reference_text>Rassoul F, Richter V, Lohse P, Naumann A, Purschwitz K, Keller E: Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease. Int J Clin Pharmacol Ther. 2001 May;39(5):199-204.</reference_text><pubmed_id>11380065</pubmed_id></reference><reference><reference_text>Chatrath H, Keilin S, Attar BM: Cholesterol ester storage disease (CESD) diagnosed in an asymptomatic adult. Dig Dis Sci. 2009 Jan;54(1):168-73. doi: 10.1007/s10620-008-0310-2. Epub 2008 May 14.</reference_text><pubmed_id>18478331</pubmed_id></reference><reference><reference_text>Bernstein DL, Hulkova H, Bialer MG, Desnick RJ: Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol. 2013 Jun;58(6):1230-43. doi: 10.1016/j.jhep.2013.02.014. Epub 2013 Feb 26.</reference_text><pubmed_id>23485521</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Cystinosis<references><reference><reference_text>Ueda M, O'Brien K, Rosing DR, Ling A, Kleta R, McAreavey D, Bernardini I, Gahl WA: Coronary artery and other vascular calcifications in patients with cystinosis after kidney transplantation. Clin J Am Soc Nephrol. 2006 May;1(3):555-62. Epub 2006 Feb 8.</reference_text><pubmed_id>17699259</pubmed_id></reference><reference><reference_text>Gahl WA, Bernardini I, Dalakas M, Rizzo WB, Harper GS, Hoeg JM, Hurko O, Bernar J: Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome. J Clin Invest. 1988 Feb;81(2):549-60.</reference_text><pubmed_id>3276734</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Smith-Lemli-Opitz syndrome<references><reference><reference_text>van Rooij A, Nijenhuis AA, Wijburg FA, Schutgens RB: Highly increased CSF concentrations of cholesterol precursors in Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 1997 Aug;20(4):578-80.</reference_text><pubmed_id>9266395</pubmed_id></reference><reference><reference_text>Honda M, Tint GS, Honda A, Salen G, Shefer S, Batta AK, Matsuzaki Y, Tanaka N: Regulation of cholesterol biosynthetic pathway in patients with the Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2000 Jul;23(5):464-74.</reference_text><pubmed_id>10947201</pubmed_id></reference><reference><reference_text>Rossi M, Federico G, Corso G, Parenti G, Battagliese A, Frascogna AR, Della Casa R, Dello Russo A, Strisciuglio P, Saggese G, Andria G: Vitamin D status in patients affected by Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2005;28(1):69-80.</reference_text><pubmed_id>15702407</pubmed_id></reference><reference><reference_text>Johnson DW, ten Brink HJ, Jakobs C: A rapid screening procedure for cholesterol and dehydrocholesterol by electrospray ionization tandem mass spectrometry. J Lipid Res. 2001 Oct;42(10):1699-705.</reference_text><pubmed_id>11590227</pubmed_id></reference></references></disease><disease>Prostate cancer<references><reference><reference_text>Nyman DW, Suzanne Stratton M, Kopplin MJ, Dalkin BL, Nagle RB, Jay Gandolfi A: Selenium and selenomethionine levels in prostate cancer patients. Cancer Detect Prev. 2004;28(1):8-16.</reference_text><pubmed_id>15041072</pubmed_id></reference><reference><reference_text>Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, Egevad L, Tjonneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, Palli D, Vineis P, Tumino R, Berrino F, Kiemeney L, Bueno-de-Mesquita HB, Quiros JR, Gonzalez CA, Martinez C, Larranaga N, Chirlaque MD, Ardanaz E, Stattin P, Hallmans G, Khaw KT, Bingham S, Slimani N, Ferrari P, Rinaldi S, Riboli E: Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr. 2007 Sep;86(3):672-81.</reference_text><pubmed_id>17823432</pubmed_id></reference><reference><reference_text>Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762.</reference_text><pubmed_id>19212411</pubmed_id></reference><reference><reference_text>Puah CM, Williams G, Ghanadian R: Urinary unconjugated 5 alpha-androstane-3 alpha, 17 beta-diol in patients with prostatic tumours. Urol Res. 1982;10(2):81-4.</reference_text><pubmed_id>6180540</pubmed_id></reference><reference><reference_text>Thysell E, Surowiec I, Hornberg E, Crnalic S, Widmark A, Johansson AI, Stattin P, Bergh A, Moritz T, Antti H, Wikstrom P: Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One. 2010 Dec 3;5(12):e14175. doi: 10.1371/journal.pone.0014175.</reference_text><pubmed_id>21151972</pubmed_id></reference><reference><reference_text>Soliman LC, Hui Y, Hewavitharana AK, Chen DD: Monitoring potential prostate cancer biomarkers in urine by capillary electrophoresis-tandem mass spectrometry. J Chromatogr A. 2012 Dec 7;1267:162-9. doi: 10.1016/j.chroma.2012.07.021. Epub 2012 Jul 14.</reference_text><pubmed_id>22824219</pubmed_id></reference><reference><reference_text>Madu CO, Lu Y: Novel diagnostic biomarkers for prostate cancer. J Cancer. 2010 Oct 6;1:150-77.</reference_text><pubmed_id>20975847</pubmed_id></reference></references></disease><disease>Schizophrenia<references><reference><reference_text>Harnryd C, Bjerkenstedt L, Grimm VE, Sedvall G: Reduction of MOPEG levels in cerebrospinal fluid of psychotic women after electroconvulsive treatment. Psychopharmacology (Berl). 1979 Aug 8;64(2):131-4.</reference_text><pubmed_id>115032</pubmed_id></reference><reference><reference_text>Kobayashi K, Koide Y, Yoshino K, Shohmori T: [P-hydroxyphenylacetic acid concentrations in cerebrospinal fluid]. No To Shinkei. 1982 Aug;34(8):769-74.</reference_text><pubmed_id>7126379</pubmed_id></reference><reference><reference_text>Alfredsson G, Wiesel FA: Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology (Berl). 1989;99(3):322-7.</reference_text><pubmed_id>2480613</pubmed_id></reference><reference><reference_text>Heresco-Levy U, Bar G, Levin R, Ermilov M, Ebstein RP, Javitt DC: High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. Schizophr Res. 2007 Mar;91(1-3):14-21. Epub 2007 Feb 2.</reference_text><pubmed_id>17276036</pubmed_id></reference><reference><reference_text>Walker EF, Bonsall R, Walder DJ: Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis. Neuropsychiatry Neuropsychol Behav Neurol. 2002 Mar;15(1):10-7.</reference_text><pubmed_id>11877547</pubmed_id></reference><reference><reference_text>Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M: Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry. 2003 Jun;60(6):572-6.</reference_text><pubmed_id>12796220</pubmed_id></reference><reference><reference_text>Do KQ, Lauer CJ, Schreiber W, Zollinger M, Gutteck-Amsler U, Cuenod M, Holsboer F: gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem. 1995 Dec;65(6):2652-62.</reference_text><pubmed_id>7595563</pubmed_id></reference><reference><reference_text>Nikisch G, Baumann P, Wiedemann G, Kiessling B, Weisser H, Hertel A, Yoshitake T, Kehr J, Mathe AA: Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF. J Clin Psychopharmacol. 2010 Oct;30(5):496-503. doi: 10.1097/JCP.0b013e3181f2288e.</reference_text><pubmed_id>20814316</pubmed_id></reference><reference><reference_text>Fukushima T, Iizuka H, Yokota A, Suzuki T, Ohno C, Kono Y, Nishikiori M, Seki A, Ichiba H, Watanabe Y, Hongo S, Utsunomiya M, Nakatani M, Sadamoto K, Yoshio T: Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One. 2014 Jul 8;9(7):e101652. doi: 10.1371/journal.pone.0101652. eCollection 2014.</reference_text><pubmed_id>25004141</pubmed_id></reference><reference><reference_text>Koike S, Bundo M, Iwamoto K, Suga M, Kuwabara H, Ohashi Y, Shinoda K, Takano Y, Iwashiro N, Satomura Y, Nagai T, Natsubori T, Tada M, Yamasue H, Kasai K: A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study. Transl Psychiatry. 2014 Apr 8;4:e379. doi: 10.1038/tp.2014.19.</reference_text><pubmed_id>24713860</pubmed_id></reference><reference><reference_text>Ballesteros A, Summerfelt A, Du X, Jiang P, Chiappelli J, Tagamets M, O'Donnell P, Kochunov P, Hong LE: Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia. Clin Neurophysiol. 2013 Nov;124(11):2209-15. doi: 10.1016/j.clinph.2013.05.021. Epub 2013 Jun 30.</reference_text><pubmed_id>23823132</pubmed_id></reference><reference><reference_text>Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel FA: Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry. 1985 Sep;147:276-82.</reference_text><pubmed_id>2415198</pubmed_id></reference><reference><reference_text>Pickar D, Breier A, Hsiao JK, Doran AR, Wolkowitz OM, Pato CN, Konicki PE, Potter WZ: Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Arch Gen Psychiatry. 1990 Jul;47(7):641-8.</reference_text><pubmed_id>1694425</pubmed_id></reference><reference><reference_text>Prell GD, Green JP, Kaufmann CA, Khandelwal JK, Morrishow AM, Kirch DG, Linnoila M, Wyatt RJ: Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res. 1995 Jan;14(2):93-104.</reference_text><pubmed_id>7711000</pubmed_id></reference><reference><reference_text>Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B: Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology. 2009;59(2):123-9. doi: 10.1159/000213565. Epub 2009 Apr 22.</reference_text><pubmed_id>19390223</pubmed_id></reference><reference><reference_text>Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K, Cao Y, Wang X, Qiu Y, Su M, Zhao A, Wang P, Yang P, Wu J, Feng G, He L, Jia W, Wan C: Potential metabolite markers of schizophrenia. Mol Psychiatry. 2013 Jan;18(1):67-78. doi: 10.1038/mp.2011.131. Epub 2011 Oct 25.</reference_text><pubmed_id>22024767</pubmed_id></reference><reference><reference_text>Xuan J, Pan G, Qiu Y, Yang L, Su M, Liu Y, Chen J, Feng G, Fang Y, Jia W, Xing Q, He L: Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. J Proteome Res. 2011 Dec 2;10(12):5433-43. doi: 10.1021/pr2006796. Epub 2011 Nov  8.</reference_text><pubmed_id>22007635</pubmed_id></reference><reference><reference_text>Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM, Rothermundt M, Bogerts B, Koethe D, Kranaster L, Ohrmann P, Suslow T, McAllister G, Spain M, Barnes A, van Beveren NJ, Baron-Cohen S, Steiner J, Torrey FE, Yolken RH, Bahn S: Identification of a biological signature for schizophrenia in serum. Mol Psychiatry. 2012 May;17(5):494-502. doi: 10.1038/mp.2011.42. Epub 2011 Apr 12.</reference_text><pubmed_id>21483431</pubmed_id></reference><reference><reference_text>Mathe AA, Eberhard G, Saaf J, Wetterberg L: Plasma prostaglandin E2 metabolite--measured as 11-deoxy-15-keto-13,14-dihydro-11 beta,16 xi-cyclo-PGE2--in twins with schizophrenic disorder. Biol Psychiatry. 1986 Sep;21(11):1024-30.</reference_text><pubmed_id>3741918</pubmed_id></reference><reference><reference_text>Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N: Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct. 2002 Jun;20(2):171-5.</reference_text><pubmed_id>11979513</pubmed_id></reference><reference><reference_text>Zumarraga M, Davila R, Basterreche N, Arrue A, Goienetxea B, Zamalloa MI, Erkoreka L, Bustamante S, Inchausti L, Gonzalez-Torres MA, Guimon J: Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients. Neurochem Int. 2010 May-Jun;56(6-7):774-9. doi: 10.1016/j.neuint.2010.02.015. Epub 2010 Mar 4.</reference_text><pubmed_id>20206656</pubmed_id></reference><reference><reference_text>Peters JG: Dopamine, noradrenaline and serotonin spinal fluid metabolites in temporal lobe epileptic patients with schizophrenic symptomatology. Eur Neurol. 1979;18(1):15-8.</reference_text><pubmed_id>436860</pubmed_id></reference><reference><reference_text>Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, Rozen S, Krishnan RR, McEvoy J, Kaddurah-Daouk R: Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry. 2010 Sep;15(9):938-53. doi: 10.1038/mp.2009.33. Epub 2009 Apr 28.</reference_text><pubmed_id>19401681</pubmed_id></reference><reference><reference_text>Gattaz WF, Waldmeier P, Beckmann H: CSF monoamine metabolites in schizophrenic patients. Acta Psychiatr Scand. 1982 Nov;66(5):350-60.</reference_text><pubmed_id>6184954</pubmed_id></reference><reference><reference_text>Nilsson-Todd LK, Nordin C, Jonsson EG, Skogh E, Erhardt S: Cerebrospinal fluid kynurenic acid in male patients with schizophrenia - correlation with monoamine metabolites. Acta Neuropsychiatr. 2007 Feb;19(1):45-52. doi: 10.1111/j.1601-5215.2006.00170.x.</reference_text><pubmed_id>26952797</pubmed_id></reference><reference><reference_text>Cai HL, Li HD, Yan XZ, Sun B, Zhang Q, Yan M, Zhang WY, Jiang P, Zhu RH, Liu YP, Fang PF, Xu P, Yuan HY, Zhang XH, Hu L, Yang W, Ye HS: Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naive schizophrenia patients after treatment with risperidone. J Proteome Res. 2012 Aug 3;11(8):4338-50. doi: 10.1021/pr300459d. Epub 2012 Jul 26.</reference_text><pubmed_id>22800120</pubmed_id></reference><reference><reference_text>Al Awam K, Haussleiter IS, Dudley E, Donev R, Brune M, Juckel G, Thome J: Multiplatform metabolome and proteome profiling identifies serum metabolite and protein signatures as prospective biomarkers for schizophrenia. J Neural Transm (Vienna). 2015 Aug;122 Suppl 1:S111-22. doi: 10.1007/s00702-014-1224-0. Epub 2014 May 1.</reference_text><pubmed_id>24789758</pubmed_id></reference><reference><reference_text>Bicikova M, Hill M, Ripova D, Mohr P, Hampl R: Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia. J Steroid Biochem Mol Biol. 2013 Jan;133:77-83. doi: 10.1016/j.jsbmb.2012.08.009. Epub 2012 Aug 24.</reference_text><pubmed_id>22944140</pubmed_id></reference><reference><reference_text>He Y, Yu Z, Giegling I, Xie L, Hartmann AM, Prehn C, Adamski J, Kahn R, Li Y, Illig T, Wang-Sattler R, Rujescu D: Schizophrenia shows a unique metabolomics signature in plasma. Transl Psychiatry. 2012 Aug 14;2:e149. doi: 10.1038/tp.2012.76.</reference_text><pubmed_id>22892715</pubmed_id></reference><reference><reference_text>Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KR: Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):934-45. Epub 2007 Apr 17.</reference_text><pubmed_id>17440431</pubmed_id></reference><reference><reference_text>Fryar-Williams S, Strobel JE: Biomarkers of a five-domain translational substrate for schizophrenia and schizoaffective psychosis. Biomark Res. 2015 Feb 6;3:3. doi: 10.1186/s40364-015-0028-1. eCollection 2015.</reference_text><pubmed_id>25729574</pubmed_id></reference><reference><reference_text>Oresic M, Seppanen-Laakso T, Sun D, Tang J, Therman S, Viehman R, Mustonen U, van Erp TG, Hyotylainen T, Thompson P, Toga AW, Huttunen MO, Suvisaari J, Kaprio J, Lonnqvist J, Cannon TD: Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia. Genome Med. 2012 Jan 18;4(1):1. doi: 10.1186/gm300.</reference_text><pubmed_id>22257447</pubmed_id></reference></references></disease><disease>Primary hypomagnesemia<references><reference><reference_text>Jin-no Y, Kamiya Y, Okada M, Hirako M, Takada N, Kawaguchi M: Primary hypomagnesemia caused by isolated magnesium malabsorption: atypical case in adult. Intern Med. 1999 Mar;38(3):261-5.</reference_text><pubmed_id>10337938</pubmed_id></reference><reference><reference_text>Vainsel M, Vandevelde G, Smulders J, Vosters M, Hubain P, Loeb H: Tetany due to hypomagnesaemia with secondary hypocalcaemia. Arch Dis Child. 1970 Apr;45(240):254-8.</reference_text><pubmed_id>5419995</pubmed_id></reference><reference><reference_text>Shalev H, Phillip M, Galil A, Carmi R, Landau D: Clinical presentation and outcome in primary familial hypomagnesaemia. Arch Dis Child. 1998 Feb;78(2):127-30.</reference_text><pubmed_id>9579153</pubmed_id></reference><reference><reference_text>Kari JA, Farouq M, Alshaya HO: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Pediatr Nephrol. 2003 Jun;18(6):506-10. Epub 2003 Apr 29.</reference_text><pubmed_id>12720080</pubmed_id></reference></references></disease><disease>Hyperlipoproteinemia<references><reference><reference_text>Sinha S, Misra A, Kumar V, Jagannathan NR, Bal CS, Pandey RM, Singhania R, Deepak: Proton magnetic resonance spectroscopy and single photon emission computed tomography study of the brain in asymptomatic young hyperlipidaemic Asian Indians in North India show early abnormalities. Clin Endocrinol (Oxf). 2004 Aug;61(2):182-9.</reference_text><pubmed_id>15272912</pubmed_id></reference><reference><reference_text>Nelson RH: Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013 Mar</reference_text><pubmed_id>40(1):195-211. doi: 10.1016/j.pop.2012.11.003. Epub 2012 Dec  4.</pubmed_id></reference><reference><reference_text>Cantin B, Boudriau S, Bertrand M, Brun LD, Gagne C, Rogers PA, Ven Murthy MR, Lupien PJ, Julien P: Hemolysis in primary lipoprotein lipase deficiency. Metabolism. 1995 May;44(5):652-8.</reference_text><pubmed_id>7752915</pubmed_id></reference></references></disease><disease>Abetalipoproteinemia<references><reference><reference_text>Dawson G, Kruski AW, Scanu AM: Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J Lipid Res. 1976 Mar;17(2):125-31.</reference_text><pubmed_id>178813</pubmed_id></reference><reference><reference_text>Lazaro RP, Dentinger MP, Rodichok LD, Barron KD, Satya-Murti S: Muscle pathology in Bassen-Kornzweig syndrome and vitamin E deficiency. Am J Clin Pathol. 1986 Sep;86(3):378-87.</reference_text><pubmed_id>2944375</pubmed_id></reference></references></disease><disease>Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis<references><reference><reference_text>Breckenridge WC, Alaupovic P, Cox DW, Little JA: Apolipoprotein and lipoprotein concentrations in familial apolipoprotein C-II deficiency. Atherosclerosis. 1982 Aug;44(2):223-35.</reference_text><pubmed_id>7138621</pubmed_id></reference><reference><reference_text>Fukami M, Hasegawa T, Horikawa R, Ohashi T, Nishimura G, Homma K, Ogata T: Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr Res. 2006 Feb;59(2):276-80. doi: 10.1203/01.pdr.0000195825.31504.28.</reference_text><pubmed_id>16439592</pubmed_id></reference></references></disease><disease>Cerebrotendinous xanthomatosis<references><reference><reference_text>Halperin G, Elisaf M, Leitersdorf E, Harats D: A new method for determination of serum cholestanol by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2000 Jun 9;742(2):345-52.</reference_text><pubmed_id>10901139</pubmed_id></reference><reference><reference_text>Siman-Tov T, Meiner V, Gadoth N: Could steroids mask the diagnosis of cerebrotendinous xanthomatosis? J Neurol Sci. 2006 Apr 15;243(1-2):83-6. Epub 2006 Jan 30.</reference_text><pubmed_id>16445943</pubmed_id></reference><reference><reference_text>Agrawal NK, Garg S: Cerebrotendinous xanthomatosis: a rare disorder with a rare presentation. BMJ Case Rep. 2012 Sep 21;2012. pii: bcr-2012-006202. doi: 10.1136/bcr-2012-006202.</reference_text><pubmed_id>23001091</pubmed_id></reference></references></disease><disease>3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency<references><reference><reference_text>Thompson GN, Hsu BY, Pitt JJ, Treacy E, Stanley CA: Fasting hypoketotic coma in a child with deficiency of mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase. N Engl J Med. 1997 Oct 23;337(17):1203-7. doi: 10.1056/NEJM199710233371704.</reference_text><pubmed_id>9337379</pubmed_id></reference><reference><reference_text>Morris AA, Lascelles CV, Olpin SE, Lake BD, Leonard JV, Quant PA: Hepatic mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme a synthase deficiency. Pediatr Res. 1998 Sep;44(3):392-6. doi: 10.1203/00006450-199809000-00021.</reference_text><pubmed_id>9727719</pubmed_id></reference><reference><reference_text>Conboy E, Vairo F, Schultz M, Agre K, Ridsdale R, Deyle D, Oglesbee D, Gavrilov D, Klee EW, Lanpher B: Mitochondrial 3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency: Unique Presenting Laboratory Values and a Review of Biochemical and Clinical Features. JIMD Rep. 2017 Oct 14. doi: 10.1007/8904_2017_59.</reference_text><pubmed_id>29030856</pubmed_id></reference></references></disease><disease>Hypercholesterolemia, familial<references><reference><reference_text>Kwiterovich PO Jr, Fredrickson DS, Levy RI: Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest. 1974 May;53(5):1237-49. doi: 10.1172/JCI107670.</reference_text><pubmed_id>4363406</pubmed_id></reference></references></disease><disease>SC4MOL deficiency<references><reference><reference_text>He M, Kratz LE, Michel JJ, Vallejo AN, Ferris L, Kelley RI, Hoover JJ, Jukic D, Gibson KM, Wolfe LA, Ramachandran D, Zwick ME, Vockley J: Mutations in the human SC4MOL gene encoding a methyl sterol oxidase cause psoriasiform dermatitis, microcephaly, and developmental delay. J Clin Invest. 2011 Mar;121(3):976-84. doi: 10.1172/JCI42650.</reference_text><pubmed_id>21285510</pubmed_id></reference></references></disease><disease>Chondrodysplasia punctata, X-linked dominant<references><reference><reference_text>Aughton DJ, Kelley RI, Metzenberg A, Pureza V, Pauli RM: X-linked dominant chondrodysplasia punctata (CDPX2) caused by single gene mosaicism in a male. Am J Med Genet A. 2003 Jan 30;116A(3):255-60. doi: 10.1002/ajmg.a.10852.</reference_text><pubmed_id>12503102</pubmed_id></reference></references></disease><disease>Desmosterolosis<references><reference><reference_text>Andersson HC, Kratz L, Kelley R: Desmosterolosis presenting with multiple congenital anomalies and profound developmental delay. Am J Med Genet. 2002 Dec 15;113(4):315-9. doi: 10.1002/ajmg.b.10873.</reference_text><pubmed_id>12457401</pubmed_id></reference></references></disease><disease>Donohue Syndrome<references><reference><reference_text>Nijim Y, Awni Y, Adawi A, Bowirrat A: Classic Case Report of Donohue Syndrome (Leprechaunism; OMIM *246200): The Impact of Consanguineous Mating. Medicine (Baltimore). 2016 Feb;95(6):e2710. doi: 10.1097/MD.0000000000002710.</reference_text><pubmed_id>26871809</pubmed_id></reference></references></disease><disease>Leptin Deficiency or Dysfunction<references><reference><reference_text>Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O'Rahilly S: Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999 Sep 16;341(12):879-84. doi: 10.1056/NEJM199909163411204.</reference_text><pubmed_id>10486419</pubmed_id></reference></references></disease><disease>Duchenne Muscular Dystrophy<references><reference><reference_text>Nakagawa T, Takeuchi A, Kakiuchi R, Lee T, Yagi M, Awano H, Iijima K, Takeshima Y, Urade Y, Matsuo M: A prostaglandin D2 metabolite is elevated in the urine of Duchenne muscular dystrophy patients and increases further from 8 years old. Clin Chim Acta. 2013 Aug 23;423:10-4. doi: 10.1016/j.cca.2013.03.031. Epub 2013 Apr 19.</reference_text><pubmed_id>23603101</pubmed_id></reference><reference><reference_text>Srivastava NK, Pradhan S, Mittal B, Gowda GA: High resolution NMR based analysis of serum lipids in Duchenne muscular dystrophy patients and its possible diagnostic significance. NMR Biomed. 2010 Jan;23(1):13-22. doi: 10.1002/nbm.1419.</reference_text><pubmed_id>19787747</pubmed_id></reference><reference><reference_text>Horster I, Weigt-Usinger K, Carmann C, Chobanyan-Jurgens K, Kohler C, Schara U, Kayacelebi AA, Beckmann B, Tsikas D, Lucke T: The L-arginine/NO pathway and homoarginine are altered in Duchenne muscular dystrophy and improved by glucocorticoids. Amino Acids. 2015 Sep;47(9):1853-63. doi: 10.1007/s00726-015-2018-x. Epub 2015 Jun 12.</reference_text><pubmed_id>26066683</pubmed_id></reference></references></disease><disease>Lecithin:cholesterol Acyltransferase Deficiency<references><reference><reference_text>Idzior-Walus B, Sieradzki J, Kostner G, Malecki MT, Klupa T, Wesolowska T, Rostworowski W, Hartwich J, Walus M, Kiec AD, Naruszewicz M: Familial lecithin-cholesterol acyltransferase deficiency: biochemical characteristics and molecular analysis of a new LCAT mutation in a Polish family. Atherosclerosis. 2006 Apr;185(2):413-20. Epub 2005 Jul 26.</reference_text><pubmed_id>16051254</pubmed_id></reference></references></disease><disease>Lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lipodystrophy, Congenital Generalized<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Oculocerebrorenal syndrome<references><reference><reference_text>Charnas LR, Bernardini I, Rader D, Hoeg JM, Gahl WA: Clinical and laboratory findings in the oculocerebrorenal syndrome of Lowe, with special reference to growth and renal function. N Engl J Med. 1991 May 9;324(19):1318-25. doi: 10.1056/NEJM199105093241904.</reference_text><pubmed_id>2017228</pubmed_id></reference></references></disease><disease>Familial partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lathosterolosis<references><reference><reference_text>Brunetti-Pierri N, Corso G, Rossi M, Ferrari P, Balli F, Rivasi F, Annunziata I, Ballabio A, Russo AD, Andria G, Parenti G: Lathosterolosis, a novel multiple-malformation/mental retardation syndrome due to deficiency of 3beta-hydroxysteroid-delta5-desaturase. Am J Hum Genet. 2002 Oct;71(4):952-8. Epub 2002 Aug 20.</reference_text><pubmed_id>12189593</pubmed_id></reference><reference><reference_text>Ho AC, Fung CW, Siu TS, Ma OC, Lam CW, Tam S, Wong VC: Lathosterolosis: a disorder of cholesterol biosynthesis resembling smith-lemli-opitz syndrome. JIMD Rep. 2014;12:129-34. doi: 10.1007/8904_2013_255. Epub 2013 Oct 20.</reference_text><pubmed_id>24142275</pubmed_id></reference></references></disease><disease>Partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Multiple sclerosis<references><reference><reference_text>Lutz NW, Viola A, Malikova I, Confort-Gouny S, Audoin B, Ranjeva JP, Pelletier J, Cozzone PJ: Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One. 2007 Jul 4;2(7):e595.</reference_text><pubmed_id>17611627</pubmed_id></reference><reference><reference_text>Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U, Hillert J, Bjorkhem I: Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med. 2004 Feb;42(2):186-91.</reference_text><pubmed_id>15061359</pubmed_id></reference><reference><reference_text>Leoni V, Lutjohann D, Masterman T: Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis. J Lipid Res. 2005 Feb;46(2):191-5. Epub 2004 Dec 1.</reference_text><pubmed_id>15576852</pubmed_id></reference><reference><reference_text>Calabrese V, Scapagnini G, Ravagna A, Bella R, Butterfield DA, Calvani M, Pennisi G, Giuffrida Stella AM: Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem Res. 2003 Sep;28(9):1321-8.</reference_text><pubmed_id>12938853</pubmed_id></reference><reference><reference_text>Shaw CE, Dunbar PR, Macaulay HA, Neale TJ: Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol. 1995 Jan;242(2):53-8.</reference_text><pubmed_id>7707089</pubmed_id></reference><reference><reference_text>Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.</reference_text><pubmed_id>17384003</pubmed_id></reference><reference><reference_text>Syburra C, Passi S: Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh (1999). 1999 May-Jun;71(3):112-5.</reference_text><pubmed_id>10609336</pubmed_id></reference><reference><reference_text>Forte G, Visconti A, Santucci S, Ghazaryan A, Figa-Talamanca L, Cannoni S, Bocca B, Pino A, Violante N, Alimonti A, Salvetti M, Ristori G: Quantification of chemical elements in blood of patients affected by multiple sclerosis. Ann Ist Super Sanita. 2005;41(2):213-6.</reference_text><pubmed_id>16244395</pubmed_id></reference><reference><reference_text>Toncev G, Milicic B, Toncev S, Samardzic G: Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol. 2002 May;9(3):221-6.</reference_text><pubmed_id>11985629</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, Bamonti F, Capello E, Mancardi GL, Scarpini E: Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res. 2010 May 28;1333:64-71. doi: 10.1016/j.brainres.2010.03.073. Epub 2010 Mar 27.</reference_text><pubmed_id>20347721</pubmed_id></reference><reference><reference_text>Matsushita T, Isobe N, Kawajiri M, Mogi M, Tsukuda K, Horiuchi M, Ohyagi Y, Kira J: CSF angiotensin II and angiotensin-converting enzyme levels in anti-aquaporin-4 autoimmunity. J Neurol Sci. 2010 Aug 15;295(1-2):41-5. doi: 10.1016/j.jns.2010.05.014. Epub 2010 Jun 11.</reference_text><pubmed_id>20541774</pubmed_id></reference><reference><reference_text>Ghabaee M, Jabedari B, Al-E-Eshagh N, Ghaffarpour M, Asadi F: Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients. Int J Neurosci. 2010 Apr;120(4):301-4. doi: 10.3109/00207451003695690.</reference_text><pubmed_id>20374079</pubmed_id></reference><reference><reference_text>Kawajiri M, Mogi M, Osoegawa M, Matsuoka T, Tsukuda K, Kohara K, Horiuchi M, Miki T, Kira JI: Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler. 2008 May;14(4):557-60. doi: 10.1177/1352458507085760.</reference_text><pubmed_id>18562510</pubmed_id></reference><reference><reference_text>Visconti A, Cotichini R, Cannoni S, Bocca B, Forte G, Ghazaryan A, Santucci S, D'Ippolito C, Stazi MA, Salvetti M, Alimonti A, Ristori G: Concentration of elements in serum of patients affected by multiple sclerosis with first demyelinating episode: a six-month longitudinal follow-up study. Ann Ist Super Sanita. 2005;41(2):217-22.</reference_text><pubmed_id>16244396</pubmed_id></reference></references></disease><disease>Inflammatory bowel disease<references><reference><reference_text>Lee T, Clavel T, Smirnov K, Schmidt A, Lagkouvardos I, Walker A, Lucio M, Michalke B, Schmitt-Kopplin P, Fedorak R, Haller D: Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. 2017 May;66(5):863-871. doi: 10.1136/gutjnl-2015-309940. Epub 2016 Feb 4.</reference_text><pubmed_id>26848182</pubmed_id></reference><reference><reference_text>Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158.</reference_text><pubmed_id>27609529</pubmed_id></reference></references></disease><disease>Colorectal cancer<references><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B: Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009 Apr;22(3):342-8. doi: 10.1002/nbm.1345.</reference_text><pubmed_id>19006102</pubmed_id></reference><reference><reference_text>Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP: Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One. 2013 Aug 6;8(8):e70803. doi: 10.1371/journal.pone.0070803. Print 2013.</reference_text><pubmed_id>23940645</pubmed_id></reference><reference><reference_text>Phua LC, Chue XP, Koh PK, Cheah PY, Ho HK, Chan EC: Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biol Ther. 2014 Apr;15(4):389-97. doi: 10.4161/cbt.27625. Epub 2014 Jan 14.</reference_text><pubmed_id>24424155</pubmed_id></reference><reference><reference_text>Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB: Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010 Feb 15;8:13. doi: 10.1186/1741-7015-8-13.</reference_text><pubmed_id>20156336</pubmed_id></reference><reference><reference_text>Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, Ni Y, Zhao A, Xu LX, Cai S, Jia W: Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res. 2009 Oct;8(10):4844-50. doi: 10.1021/pr9004162.</reference_text><pubmed_id>19678709</pubmed_id></reference><reference><reference_text>Cheng Y, Xie G, Chen T, Qiu Y, Zou X, Zheng M, Tan B, Feng B, Dong T, He P, Zhao L, Zhao A, Xu LX, Zhang Y, Jia W: Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res. 2012 Feb 3;11(2):1354-63. doi: 10.1021/pr201001a. Epub 2011 Dec 28.</reference_text><pubmed_id>22148915</pubmed_id></reference><reference><reference_text>Ni Y, Xie G, Jia W: Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res. 2014 Sep 5;13(9):3857-70. doi: 10.1021/pr500443c. Epub 2014 Aug 14.</reference_text><pubmed_id>25105552</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference><reference><reference_text>Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18.</reference_text><pubmed_id>25037050</pubmed_id></reference><reference><reference_text>Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016.</reference_text><pubmed_id>27015276</pubmed_id></reference><reference><reference_text>Lin Y, Ma C, Liu C, Wang Z, Yang J, Liu X, Shen Z, Wu R: NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer. Oncotarget. 2016 May 17;7(20):29454-64. doi: 10.18632/oncotarget.8762.</reference_text><pubmed_id>27107423</pubmed_id></reference><reference><reference_text>Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016.</reference_text><pubmed_id>27275383</pubmed_id></reference><reference><reference_text>Wang X, Wang J, Rao B, Deng L: Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals. Exp Ther Med. 2017 Jun;13(6):2848-2854. doi: 10.3892/etm.2017.4367. Epub 2017 Apr 20.</reference_text><pubmed_id>28587349</pubmed_id></reference><reference><reference_text>Silke Matysik, Caroline Ivanne Le Roy, Gerhard Liebisch, Sandrine Paule Claus. Metabolomics of fecal samples: A practical consideration. Trends in Food Science &amp; Technology. Vol. 57, Part B, Nov. 2016, p.244-255: http://www.sciencedirect.com/science/article/pii/S0924224416301984</reference_text><pubmed_id>28587349</pubmed_id></reference></references></disease><disease>Gallbladder disease<references><reference><reference_text>Lapidus A, Akerlund JE, Einarsson C: Gallbladder bile composition in patients with Crohn 's disease. World J Gastroenterol. 2006 Jan 7;12(1):70-4.</reference_text><pubmed_id>16440420</pubmed_id></reference><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference><reference><reference_text>Mizuno S, Tazuma S, Kajiyama G: Stabilization of biliary lipid particles by ursodeoxycholic acid. Prolonged nucleation time in human gallbladder bile. Dig Dis Sci. 1993 Apr;38(4):684-93.</reference_text><pubmed_id>8462368</pubmed_id></reference><reference><reference_text>Hillebrant CG, Axelson M, Bjorkhem I, Wang FH, Nyberg B, Einarsson C: Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients. Eur J Clin Invest. 1998 Apr;28(4):324-8.</reference_text><pubmed_id>9615912</pubmed_id></reference></references></disease><disease>Cholelithiasis<references><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference></references></disease><disease>Stomach cancer<references><reference><reference_text>Higashijima H, Ichimiya H, Nakano T, Yamashita H, Kuroki S, Satoh H, Chijiiwa K, Tanaka M: Deconjugation of bilirubin accelerates coprecipitation of cholesterol, fatty acids, and mucin in human bile--in vitro study. J Gastroenterol. 1996 Dec;31(6):828-35.</reference_text><pubmed_id>9027647</pubmed_id></reference><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Song H, Peng JS, Dong-Sheng Y, Yang ZL, Liu HL, Zeng YK, Shi XP, Lu BY: Serum metabolic profiling of human gastric cancer based on gas chromatography/mass spectrometry. Braz J Med Biol Res. 2012 Jan;45(1):78-85. Epub 2011 Nov 25.</reference_text><pubmed_id>22124703</pubmed_id></reference><reference><reference_text>Yu L, Aa J, Xu J, Sun M, Qian S, Cheng L, Yang S, Shi R: Metabolomic phenotype of gastric cancer and precancerous stages based on gas chromatography time-of-flight mass spectrometry. J Gastroenterol Hepatol. 2011 Aug;26(8):1290-7. doi: 10.1111/j.1440-1746.2011.06724.x.</reference_text><pubmed_id>21443661</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference></references></disease><disease>Acute myelogenous leukemia<references><reference><reference_text>Tatidis L, Vitols S, Gruber A, Paul C, Axelson M: Cholesterol catabolism in patients with acute myelogenous leukemia and hypocholesterolemia: suppressed levels of a circulating marker for bile acid synthesis. Cancer Lett. 2001 Sep 20;170(2):169-75.</reference_text><pubmed_id>11463495</pubmed_id></reference></references></disease><disease>Hypercholesterolemia<references><reference><reference_text>Thelen KM, Laaksonen R, Paiva H, Lehtimaki T, Lutjohann D: High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels. J Clin Pharmacol. 2006 Jul;46(7):812-6.</reference_text><pubmed_id>16809807</pubmed_id></reference><reference><reference_text>Tamasawa N, Tamasawa A, Takebe K: Higher levels of plasma cholesterol sulfate in patients with liver cirrhosis and hypercholesterolemia. Lipids. 1993 Sep;28(9):833-6.</reference_text><pubmed_id>8231659</pubmed_id></reference><reference><reference_text>Kim DH, Lee KJ, Heo GS: Analysis of cholesterol and cholesteryl esters in human serum using capillary supercritical fluid chromatography. J Chromatogr B Biomed Appl. 1994 Apr 22;655(1):1-8.</reference_text><pubmed_id>8061816</pubmed_id></reference><reference><reference_text>Authors unspecified: Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med. 1988 Jan;148(1):36-69.</reference_text><pubmed_id>3422148</pubmed_id></reference></references></disease><disease>Cholesteryl ester storage disease<references><reference><reference_text>Rassoul F, Richter V, Lohse P, Naumann A, Purschwitz K, Keller E: Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease. Int J Clin Pharmacol Ther. 2001 May;39(5):199-204.</reference_text><pubmed_id>11380065</pubmed_id></reference><reference><reference_text>Chatrath H, Keilin S, Attar BM: Cholesterol ester storage disease (CESD) diagnosed in an asymptomatic adult. Dig Dis Sci. 2009 Jan;54(1):168-73. doi: 10.1007/s10620-008-0310-2. Epub 2008 May 14.</reference_text><pubmed_id>18478331</pubmed_id></reference><reference><reference_text>Bernstein DL, Hulkova H, Bialer MG, Desnick RJ: Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol. 2013 Jun;58(6):1230-43. doi: 10.1016/j.jhep.2013.02.014. Epub 2013 Feb 26.</reference_text><pubmed_id>23485521</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Cystinosis<references><reference><reference_text>Ueda M, O'Brien K, Rosing DR, Ling A, Kleta R, McAreavey D, Bernardini I, Gahl WA: Coronary artery and other vascular calcifications in patients with cystinosis after kidney transplantation. Clin J Am Soc Nephrol. 2006 May;1(3):555-62. Epub 2006 Feb 8.</reference_text><pubmed_id>17699259</pubmed_id></reference><reference><reference_text>Gahl WA, Bernardini I, Dalakas M, Rizzo WB, Harper GS, Hoeg JM, Hurko O, Bernar J: Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome. J Clin Invest. 1988 Feb;81(2):549-60.</reference_text><pubmed_id>3276734</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Smith-Lemli-Opitz syndrome<references><reference><reference_text>van Rooij A, Nijenhuis AA, Wijburg FA, Schutgens RB: Highly increased CSF concentrations of cholesterol precursors in Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 1997 Aug;20(4):578-80.</reference_text><pubmed_id>9266395</pubmed_id></reference><reference><reference_text>Honda M, Tint GS, Honda A, Salen G, Shefer S, Batta AK, Matsuzaki Y, Tanaka N: Regulation of cholesterol biosynthetic pathway in patients with the Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2000 Jul;23(5):464-74.</reference_text><pubmed_id>10947201</pubmed_id></reference><reference><reference_text>Rossi M, Federico G, Corso G, Parenti G, Battagliese A, Frascogna AR, Della Casa R, Dello Russo A, Strisciuglio P, Saggese G, Andria G: Vitamin D status in patients affected by Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2005;28(1):69-80.</reference_text><pubmed_id>15702407</pubmed_id></reference><reference><reference_text>Johnson DW, ten Brink HJ, Jakobs C: A rapid screening procedure for cholesterol and dehydrocholesterol by electrospray ionization tandem mass spectrometry. J Lipid Res. 2001 Oct;42(10):1699-705.</reference_text><pubmed_id>11590227</pubmed_id></reference></references></disease><disease>Prostate cancer<references><reference><reference_text>Nyman DW, Suzanne Stratton M, Kopplin MJ, Dalkin BL, Nagle RB, Jay Gandolfi A: Selenium and selenomethionine levels in prostate cancer patients. Cancer Detect Prev. 2004;28(1):8-16.</reference_text><pubmed_id>15041072</pubmed_id></reference><reference><reference_text>Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, Egevad L, Tjonneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, Palli D, Vineis P, Tumino R, Berrino F, Kiemeney L, Bueno-de-Mesquita HB, Quiros JR, Gonzalez CA, Martinez C, Larranaga N, Chirlaque MD, Ardanaz E, Stattin P, Hallmans G, Khaw KT, Bingham S, Slimani N, Ferrari P, Rinaldi S, Riboli E: Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr. 2007 Sep;86(3):672-81.</reference_text><pubmed_id>17823432</pubmed_id></reference><reference><reference_text>Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762.</reference_text><pubmed_id>19212411</pubmed_id></reference><reference><reference_text>Puah CM, Williams G, Ghanadian R: Urinary unconjugated 5 alpha-androstane-3 alpha, 17 beta-diol in patients with prostatic tumours. Urol Res. 1982;10(2):81-4.</reference_text><pubmed_id>6180540</pubmed_id></reference><reference><reference_text>Thysell E, Surowiec I, Hornberg E, Crnalic S, Widmark A, Johansson AI, Stattin P, Bergh A, Moritz T, Antti H, Wikstrom P: Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One. 2010 Dec 3;5(12):e14175. doi: 10.1371/journal.pone.0014175.</reference_text><pubmed_id>21151972</pubmed_id></reference><reference><reference_text>Soliman LC, Hui Y, Hewavitharana AK, Chen DD: Monitoring potential prostate cancer biomarkers in urine by capillary electrophoresis-tandem mass spectrometry. J Chromatogr A. 2012 Dec 7;1267:162-9. doi: 10.1016/j.chroma.2012.07.021. Epub 2012 Jul 14.</reference_text><pubmed_id>22824219</pubmed_id></reference><reference><reference_text>Madu CO, Lu Y: Novel diagnostic biomarkers for prostate cancer. J Cancer. 2010 Oct 6;1:150-77.</reference_text><pubmed_id>20975847</pubmed_id></reference></references></disease><disease>Schizophrenia<references><reference><reference_text>Harnryd C, Bjerkenstedt L, Grimm VE, Sedvall G: Reduction of MOPEG levels in cerebrospinal fluid of psychotic women after electroconvulsive treatment. Psychopharmacology (Berl). 1979 Aug 8;64(2):131-4.</reference_text><pubmed_id>115032</pubmed_id></reference><reference><reference_text>Kobayashi K, Koide Y, Yoshino K, Shohmori T: [P-hydroxyphenylacetic acid concentrations in cerebrospinal fluid]. No To Shinkei. 1982 Aug;34(8):769-74.</reference_text><pubmed_id>7126379</pubmed_id></reference><reference><reference_text>Alfredsson G, Wiesel FA: Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology (Berl). 1989;99(3):322-7.</reference_text><pubmed_id>2480613</pubmed_id></reference><reference><reference_text>Heresco-Levy U, Bar G, Levin R, Ermilov M, Ebstein RP, Javitt DC: High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. Schizophr Res. 2007 Mar;91(1-3):14-21. Epub 2007 Feb 2.</reference_text><pubmed_id>17276036</pubmed_id></reference><reference><reference_text>Walker EF, Bonsall R, Walder DJ: Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis. Neuropsychiatry Neuropsychol Behav Neurol. 2002 Mar;15(1):10-7.</reference_text><pubmed_id>11877547</pubmed_id></reference><reference><reference_text>Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M: Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry. 2003 Jun;60(6):572-6.</reference_text><pubmed_id>12796220</pubmed_id></reference><reference><reference_text>Do KQ, Lauer CJ, Schreiber W, Zollinger M, Gutteck-Amsler U, Cuenod M, Holsboer F: gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem. 1995 Dec;65(6):2652-62.</reference_text><pubmed_id>7595563</pubmed_id></reference><reference><reference_text>Nikisch G, Baumann P, Wiedemann G, Kiessling B, Weisser H, Hertel A, Yoshitake T, Kehr J, Mathe AA: Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF. J Clin Psychopharmacol. 2010 Oct;30(5):496-503. doi: 10.1097/JCP.0b013e3181f2288e.</reference_text><pubmed_id>20814316</pubmed_id></reference><reference><reference_text>Fukushima T, Iizuka H, Yokota A, Suzuki T, Ohno C, Kono Y, Nishikiori M, Seki A, Ichiba H, Watanabe Y, Hongo S, Utsunomiya M, Nakatani M, Sadamoto K, Yoshio T: Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One. 2014 Jul 8;9(7):e101652. doi: 10.1371/journal.pone.0101652. eCollection 2014.</reference_text><pubmed_id>25004141</pubmed_id></reference><reference><reference_text>Koike S, Bundo M, Iwamoto K, Suga M, Kuwabara H, Ohashi Y, Shinoda K, Takano Y, Iwashiro N, Satomura Y, Nagai T, Natsubori T, Tada M, Yamasue H, Kasai K: A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study. Transl Psychiatry. 2014 Apr 8;4:e379. doi: 10.1038/tp.2014.19.</reference_text><pubmed_id>24713860</pubmed_id></reference><reference><reference_text>Ballesteros A, Summerfelt A, Du X, Jiang P, Chiappelli J, Tagamets M, O'Donnell P, Kochunov P, Hong LE: Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia. Clin Neurophysiol. 2013 Nov;124(11):2209-15. doi: 10.1016/j.clinph.2013.05.021. Epub 2013 Jun 30.</reference_text><pubmed_id>23823132</pubmed_id></reference><reference><reference_text>Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel FA: Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry. 1985 Sep;147:276-82.</reference_text><pubmed_id>2415198</pubmed_id></reference><reference><reference_text>Pickar D, Breier A, Hsiao JK, Doran AR, Wolkowitz OM, Pato CN, Konicki PE, Potter WZ: Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Arch Gen Psychiatry. 1990 Jul;47(7):641-8.</reference_text><pubmed_id>1694425</pubmed_id></reference><reference><reference_text>Prell GD, Green JP, Kaufmann CA, Khandelwal JK, Morrishow AM, Kirch DG, Linnoila M, Wyatt RJ: Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res. 1995 Jan;14(2):93-104.</reference_text><pubmed_id>7711000</pubmed_id></reference><reference><reference_text>Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B: Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology. 2009;59(2):123-9. doi: 10.1159/000213565. Epub 2009 Apr 22.</reference_text><pubmed_id>19390223</pubmed_id></reference><reference><reference_text>Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K, Cao Y, Wang X, Qiu Y, Su M, Zhao A, Wang P, Yang P, Wu J, Feng G, He L, Jia W, Wan C: Potential metabolite markers of schizophrenia. Mol Psychiatry. 2013 Jan;18(1):67-78. doi: 10.1038/mp.2011.131. Epub 2011 Oct 25.</reference_text><pubmed_id>22024767</pubmed_id></reference><reference><reference_text>Xuan J, Pan G, Qiu Y, Yang L, Su M, Liu Y, Chen J, Feng G, Fang Y, Jia W, Xing Q, He L: Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. J Proteome Res. 2011 Dec 2;10(12):5433-43. doi: 10.1021/pr2006796. Epub 2011 Nov  8.</reference_text><pubmed_id>22007635</pubmed_id></reference><reference><reference_text>Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM, Rothermundt M, Bogerts B, Koethe D, Kranaster L, Ohrmann P, Suslow T, McAllister G, Spain M, Barnes A, van Beveren NJ, Baron-Cohen S, Steiner J, Torrey FE, Yolken RH, Bahn S: Identification of a biological signature for schizophrenia in serum. Mol Psychiatry. 2012 May;17(5):494-502. doi: 10.1038/mp.2011.42. Epub 2011 Apr 12.</reference_text><pubmed_id>21483431</pubmed_id></reference><reference><reference_text>Mathe AA, Eberhard G, Saaf J, Wetterberg L: Plasma prostaglandin E2 metabolite--measured as 11-deoxy-15-keto-13,14-dihydro-11 beta,16 xi-cyclo-PGE2--in twins with schizophrenic disorder. Biol Psychiatry. 1986 Sep;21(11):1024-30.</reference_text><pubmed_id>3741918</pubmed_id></reference><reference><reference_text>Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N: Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct. 2002 Jun;20(2):171-5.</reference_text><pubmed_id>11979513</pubmed_id></reference><reference><reference_text>Zumarraga M, Davila R, Basterreche N, Arrue A, Goienetxea B, Zamalloa MI, Erkoreka L, Bustamante S, Inchausti L, Gonzalez-Torres MA, Guimon J: Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients. Neurochem Int. 2010 May-Jun;56(6-7):774-9. doi: 10.1016/j.neuint.2010.02.015. Epub 2010 Mar 4.</reference_text><pubmed_id>20206656</pubmed_id></reference><reference><reference_text>Peters JG: Dopamine, noradrenaline and serotonin spinal fluid metabolites in temporal lobe epileptic patients with schizophrenic symptomatology. Eur Neurol. 1979;18(1):15-8.</reference_text><pubmed_id>436860</pubmed_id></reference><reference><reference_text>Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, Rozen S, Krishnan RR, McEvoy J, Kaddurah-Daouk R: Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry. 2010 Sep;15(9):938-53. doi: 10.1038/mp.2009.33. Epub 2009 Apr 28.</reference_text><pubmed_id>19401681</pubmed_id></reference><reference><reference_text>Gattaz WF, Waldmeier P, Beckmann H: CSF monoamine metabolites in schizophrenic patients. Acta Psychiatr Scand. 1982 Nov;66(5):350-60.</reference_text><pubmed_id>6184954</pubmed_id></reference><reference><reference_text>Nilsson-Todd LK, Nordin C, Jonsson EG, Skogh E, Erhardt S: Cerebrospinal fluid kynurenic acid in male patients with schizophrenia - correlation with monoamine metabolites. Acta Neuropsychiatr. 2007 Feb;19(1):45-52. doi: 10.1111/j.1601-5215.2006.00170.x.</reference_text><pubmed_id>26952797</pubmed_id></reference><reference><reference_text>Cai HL, Li HD, Yan XZ, Sun B, Zhang Q, Yan M, Zhang WY, Jiang P, Zhu RH, Liu YP, Fang PF, Xu P, Yuan HY, Zhang XH, Hu L, Yang W, Ye HS: Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naive schizophrenia patients after treatment with risperidone. J Proteome Res. 2012 Aug 3;11(8):4338-50. doi: 10.1021/pr300459d. Epub 2012 Jul 26.</reference_text><pubmed_id>22800120</pubmed_id></reference><reference><reference_text>Al Awam K, Haussleiter IS, Dudley E, Donev R, Brune M, Juckel G, Thome J: Multiplatform metabolome and proteome profiling identifies serum metabolite and protein signatures as prospective biomarkers for schizophrenia. J Neural Transm (Vienna). 2015 Aug;122 Suppl 1:S111-22. doi: 10.1007/s00702-014-1224-0. Epub 2014 May 1.</reference_text><pubmed_id>24789758</pubmed_id></reference><reference><reference_text>Bicikova M, Hill M, Ripova D, Mohr P, Hampl R: Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia. J Steroid Biochem Mol Biol. 2013 Jan;133:77-83. doi: 10.1016/j.jsbmb.2012.08.009. Epub 2012 Aug 24.</reference_text><pubmed_id>22944140</pubmed_id></reference><reference><reference_text>He Y, Yu Z, Giegling I, Xie L, Hartmann AM, Prehn C, Adamski J, Kahn R, Li Y, Illig T, Wang-Sattler R, Rujescu D: Schizophrenia shows a unique metabolomics signature in plasma. Transl Psychiatry. 2012 Aug 14;2:e149. doi: 10.1038/tp.2012.76.</reference_text><pubmed_id>22892715</pubmed_id></reference><reference><reference_text>Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KR: Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):934-45. Epub 2007 Apr 17.</reference_text><pubmed_id>17440431</pubmed_id></reference><reference><reference_text>Fryar-Williams S, Strobel JE: Biomarkers of a five-domain translational substrate for schizophrenia and schizoaffective psychosis. Biomark Res. 2015 Feb 6;3:3. doi: 10.1186/s40364-015-0028-1. eCollection 2015.</reference_text><pubmed_id>25729574</pubmed_id></reference><reference><reference_text>Oresic M, Seppanen-Laakso T, Sun D, Tang J, Therman S, Viehman R, Mustonen U, van Erp TG, Hyotylainen T, Thompson P, Toga AW, Huttunen MO, Suvisaari J, Kaprio J, Lonnqvist J, Cannon TD: Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia. Genome Med. 2012 Jan 18;4(1):1. doi: 10.1186/gm300.</reference_text><pubmed_id>22257447</pubmed_id></reference></references></disease><disease>Primary hypomagnesemia<references><reference><reference_text>Jin-no Y, Kamiya Y, Okada M, Hirako M, Takada N, Kawaguchi M: Primary hypomagnesemia caused by isolated magnesium malabsorption: atypical case in adult. Intern Med. 1999 Mar;38(3):261-5.</reference_text><pubmed_id>10337938</pubmed_id></reference><reference><reference_text>Vainsel M, Vandevelde G, Smulders J, Vosters M, Hubain P, Loeb H: Tetany due to hypomagnesaemia with secondary hypocalcaemia. Arch Dis Child. 1970 Apr;45(240):254-8.</reference_text><pubmed_id>5419995</pubmed_id></reference><reference><reference_text>Shalev H, Phillip M, Galil A, Carmi R, Landau D: Clinical presentation and outcome in primary familial hypomagnesaemia. Arch Dis Child. 1998 Feb;78(2):127-30.</reference_text><pubmed_id>9579153</pubmed_id></reference><reference><reference_text>Kari JA, Farouq M, Alshaya HO: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Pediatr Nephrol. 2003 Jun;18(6):506-10. Epub 2003 Apr 29.</reference_text><pubmed_id>12720080</pubmed_id></reference></references></disease><disease>Hyperlipoproteinemia<references><reference><reference_text>Sinha S, Misra A, Kumar V, Jagannathan NR, Bal CS, Pandey RM, Singhania R, Deepak: Proton magnetic resonance spectroscopy and single photon emission computed tomography study of the brain in asymptomatic young hyperlipidaemic Asian Indians in North India show early abnormalities. Clin Endocrinol (Oxf). 2004 Aug;61(2):182-9.</reference_text><pubmed_id>15272912</pubmed_id></reference><reference><reference_text>Nelson RH: Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013 Mar</reference_text><pubmed_id>40(1):195-211. doi: 10.1016/j.pop.2012.11.003. Epub 2012 Dec  4.</pubmed_id></reference><reference><reference_text>Cantin B, Boudriau S, Bertrand M, Brun LD, Gagne C, Rogers PA, Ven Murthy MR, Lupien PJ, Julien P: Hemolysis in primary lipoprotein lipase deficiency. Metabolism. 1995 May;44(5):652-8.</reference_text><pubmed_id>7752915</pubmed_id></reference></references></disease><disease>Abetalipoproteinemia<references><reference><reference_text>Dawson G, Kruski AW, Scanu AM: Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J Lipid Res. 1976 Mar;17(2):125-31.</reference_text><pubmed_id>178813</pubmed_id></reference><reference><reference_text>Lazaro RP, Dentinger MP, Rodichok LD, Barron KD, Satya-Murti S: Muscle pathology in Bassen-Kornzweig syndrome and vitamin E deficiency. Am J Clin Pathol. 1986 Sep;86(3):378-87.</reference_text><pubmed_id>2944375</pubmed_id></reference></references></disease><disease>Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis<references><reference><reference_text>Breckenridge WC, Alaupovic P, Cox DW, Little JA: Apolipoprotein and lipoprotein concentrations in familial apolipoprotein C-II deficiency. Atherosclerosis. 1982 Aug;44(2):223-35.</reference_text><pubmed_id>7138621</pubmed_id></reference><reference><reference_text>Fukami M, Hasegawa T, Horikawa R, Ohashi T, Nishimura G, Homma K, Ogata T: Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr Res. 2006 Feb;59(2):276-80. doi: 10.1203/01.pdr.0000195825.31504.28.</reference_text><pubmed_id>16439592</pubmed_id></reference></references></disease><disease>Cerebrotendinous xanthomatosis<references><reference><reference_text>Halperin G, Elisaf M, Leitersdorf E, Harats D: A new method for determination of serum cholestanol by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2000 Jun 9;742(2):345-52.</reference_text><pubmed_id>10901139</pubmed_id></reference><reference><reference_text>Siman-Tov T, Meiner V, Gadoth N: Could steroids mask the diagnosis of cerebrotendinous xanthomatosis? J Neurol Sci. 2006 Apr 15;243(1-2):83-6. Epub 2006 Jan 30.</reference_text><pubmed_id>16445943</pubmed_id></reference><reference><reference_text>Agrawal NK, Garg S: Cerebrotendinous xanthomatosis: a rare disorder with a rare presentation. BMJ Case Rep. 2012 Sep 21;2012. pii: bcr-2012-006202. doi: 10.1136/bcr-2012-006202.</reference_text><pubmed_id>23001091</pubmed_id></reference></references></disease><disease>3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency<references><reference><reference_text>Thompson GN, Hsu BY, Pitt JJ, Treacy E, Stanley CA: Fasting hypoketotic coma in a child with deficiency of mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase. N Engl J Med. 1997 Oct 23;337(17):1203-7. doi: 10.1056/NEJM199710233371704.</reference_text><pubmed_id>9337379</pubmed_id></reference><reference><reference_text>Morris AA, Lascelles CV, Olpin SE, Lake BD, Leonard JV, Quant PA: Hepatic mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme a synthase deficiency. Pediatr Res. 1998 Sep;44(3):392-6. doi: 10.1203/00006450-199809000-00021.</reference_text><pubmed_id>9727719</pubmed_id></reference><reference><reference_text>Conboy E, Vairo F, Schultz M, Agre K, Ridsdale R, Deyle D, Oglesbee D, Gavrilov D, Klee EW, Lanpher B: Mitochondrial 3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency: Unique Presenting Laboratory Values and a Review of Biochemical and Clinical Features. JIMD Rep. 2017 Oct 14. doi: 10.1007/8904_2017_59.</reference_text><pubmed_id>29030856</pubmed_id></reference></references></disease><disease>Hypercholesterolemia, familial<references><reference><reference_text>Kwiterovich PO Jr, Fredrickson DS, Levy RI: Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest. 1974 May;53(5):1237-49. doi: 10.1172/JCI107670.</reference_text><pubmed_id>4363406</pubmed_id></reference></references></disease><disease>SC4MOL deficiency<references><reference><reference_text>He M, Kratz LE, Michel JJ, Vallejo AN, Ferris L, Kelley RI, Hoover JJ, Jukic D, Gibson KM, Wolfe LA, Ramachandran D, Zwick ME, Vockley J: Mutations in the human SC4MOL gene encoding a methyl sterol oxidase cause psoriasiform dermatitis, microcephaly, and developmental delay. J Clin Invest. 2011 Mar;121(3):976-84. doi: 10.1172/JCI42650.</reference_text><pubmed_id>21285510</pubmed_id></reference></references></disease><disease>Chondrodysplasia punctata, X-linked dominant<references><reference><reference_text>Aughton DJ, Kelley RI, Metzenberg A, Pureza V, Pauli RM: X-linked dominant chondrodysplasia punctata (CDPX2) caused by single gene mosaicism in a male. Am J Med Genet A. 2003 Jan 30;116A(3):255-60. doi: 10.1002/ajmg.a.10852.</reference_text><pubmed_id>12503102</pubmed_id></reference></references></disease><disease>Desmosterolosis<references><reference><reference_text>Andersson HC, Kratz L, Kelley R: Desmosterolosis presenting with multiple congenital anomalies and profound developmental delay. Am J Med Genet. 2002 Dec 15;113(4):315-9. doi: 10.1002/ajmg.b.10873.</reference_text><pubmed_id>12457401</pubmed_id></reference></references></disease><disease>Donohue Syndrome<references><reference><reference_text>Nijim Y, Awni Y, Adawi A, Bowirrat A: Classic Case Report of Donohue Syndrome (Leprechaunism; OMIM *246200): The Impact of Consanguineous Mating. Medicine (Baltimore). 2016 Feb;95(6):e2710. doi: 10.1097/MD.0000000000002710.</reference_text><pubmed_id>26871809</pubmed_id></reference></references></disease><disease>Leptin Deficiency or Dysfunction<references><reference><reference_text>Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O'Rahilly S: Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999 Sep 16;341(12):879-84. doi: 10.1056/NEJM199909163411204.</reference_text><pubmed_id>10486419</pubmed_id></reference></references></disease><disease>Duchenne Muscular Dystrophy<references><reference><reference_text>Nakagawa T, Takeuchi A, Kakiuchi R, Lee T, Yagi M, Awano H, Iijima K, Takeshima Y, Urade Y, Matsuo M: A prostaglandin D2 metabolite is elevated in the urine of Duchenne muscular dystrophy patients and increases further from 8 years old. Clin Chim Acta. 2013 Aug 23;423:10-4. doi: 10.1016/j.cca.2013.03.031. Epub 2013 Apr 19.</reference_text><pubmed_id>23603101</pubmed_id></reference><reference><reference_text>Srivastava NK, Pradhan S, Mittal B, Gowda GA: High resolution NMR based analysis of serum lipids in Duchenne muscular dystrophy patients and its possible diagnostic significance. NMR Biomed. 2010 Jan;23(1):13-22. doi: 10.1002/nbm.1419.</reference_text><pubmed_id>19787747</pubmed_id></reference><reference><reference_text>Horster I, Weigt-Usinger K, Carmann C, Chobanyan-Jurgens K, Kohler C, Schara U, Kayacelebi AA, Beckmann B, Tsikas D, Lucke T: The L-arginine/NO pathway and homoarginine are altered in Duchenne muscular dystrophy and improved by glucocorticoids. Amino Acids. 2015 Sep;47(9):1853-63. doi: 10.1007/s00726-015-2018-x. Epub 2015 Jun 12.</reference_text><pubmed_id>26066683</pubmed_id></reference></references></disease><disease>Lecithin:cholesterol Acyltransferase Deficiency<references><reference><reference_text>Idzior-Walus B, Sieradzki J, Kostner G, Malecki MT, Klupa T, Wesolowska T, Rostworowski W, Hartwich J, Walus M, Kiec AD, Naruszewicz M: Familial lecithin-cholesterol acyltransferase deficiency: biochemical characteristics and molecular analysis of a new LCAT mutation in a Polish family. Atherosclerosis. 2006 Apr;185(2):413-20. Epub 2005 Jul 26.</reference_text><pubmed_id>16051254</pubmed_id></reference></references></disease><disease>Lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lipodystrophy, Congenital Generalized<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Oculocerebrorenal syndrome<references><reference><reference_text>Charnas LR, Bernardini I, Rader D, Hoeg JM, Gahl WA: Clinical and laboratory findings in the oculocerebrorenal syndrome of Lowe, with special reference to growth and renal function. N Engl J Med. 1991 May 9;324(19):1318-25. doi: 10.1056/NEJM199105093241904.</reference_text><pubmed_id>2017228</pubmed_id></reference></references></disease><disease>Familial partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lathosterolosis<references><reference><reference_text>Brunetti-Pierri N, Corso G, Rossi M, Ferrari P, Balli F, Rivasi F, Annunziata I, Ballabio A, Russo AD, Andria G, Parenti G: Lathosterolosis, a novel multiple-malformation/mental retardation syndrome due to deficiency of 3beta-hydroxysteroid-delta5-desaturase. Am J Hum Genet. 2002 Oct;71(4):952-8. Epub 2002 Aug 20.</reference_text><pubmed_id>12189593</pubmed_id></reference><reference><reference_text>Ho AC, Fung CW, Siu TS, Ma OC, Lam CW, Tam S, Wong VC: Lathosterolosis: a disorder of cholesterol biosynthesis resembling smith-lemli-opitz syndrome. JIMD Rep. 2014;12:129-34. doi: 10.1007/8904_2013_255. Epub 2013 Oct 20.</reference_text><pubmed_id>24142275</pubmed_id></reference></references></disease><disease>Partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Multiple sclerosis<references><reference><reference_text>Lutz NW, Viola A, Malikova I, Confort-Gouny S, Audoin B, Ranjeva JP, Pelletier J, Cozzone PJ: Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One. 2007 Jul 4;2(7):e595.</reference_text><pubmed_id>17611627</pubmed_id></reference><reference><reference_text>Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U, Hillert J, Bjorkhem I: Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med. 2004 Feb;42(2):186-91.</reference_text><pubmed_id>15061359</pubmed_id></reference><reference><reference_text>Leoni V, Lutjohann D, Masterman T: Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis. J Lipid Res. 2005 Feb;46(2):191-5. Epub 2004 Dec 1.</reference_text><pubmed_id>15576852</pubmed_id></reference><reference><reference_text>Calabrese V, Scapagnini G, Ravagna A, Bella R, Butterfield DA, Calvani M, Pennisi G, Giuffrida Stella AM: Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem Res. 2003 Sep;28(9):1321-8.</reference_text><pubmed_id>12938853</pubmed_id></reference><reference><reference_text>Shaw CE, Dunbar PR, Macaulay HA, Neale TJ: Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol. 1995 Jan;242(2):53-8.</reference_text><pubmed_id>7707089</pubmed_id></reference><reference><reference_text>Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.</reference_text><pubmed_id>17384003</pubmed_id></reference><reference><reference_text>Syburra C, Passi S: Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh (1999). 1999 May-Jun;71(3):112-5.</reference_text><pubmed_id>10609336</pubmed_id></reference><reference><reference_text>Forte G, Visconti A, Santucci S, Ghazaryan A, Figa-Talamanca L, Cannoni S, Bocca B, Pino A, Violante N, Alimonti A, Salvetti M, Ristori G: Quantification of chemical elements in blood of patients affected by multiple sclerosis. Ann Ist Super Sanita. 2005;41(2):213-6.</reference_text><pubmed_id>16244395</pubmed_id></reference><reference><reference_text>Toncev G, Milicic B, Toncev S, Samardzic G: Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol. 2002 May;9(3):221-6.</reference_text><pubmed_id>11985629</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, Bamonti F, Capello E, Mancardi GL, Scarpini E: Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res. 2010 May 28;1333:64-71. doi: 10.1016/j.brainres.2010.03.073. Epub 2010 Mar 27.</reference_text><pubmed_id>20347721</pubmed_id></reference><reference><reference_text>Matsushita T, Isobe N, Kawajiri M, Mogi M, Tsukuda K, Horiuchi M, Ohyagi Y, Kira J: CSF angiotensin II and angiotensin-converting enzyme levels in anti-aquaporin-4 autoimmunity. J Neurol Sci. 2010 Aug 15;295(1-2):41-5. doi: 10.1016/j.jns.2010.05.014. Epub 2010 Jun 11.</reference_text><pubmed_id>20541774</pubmed_id></reference><reference><reference_text>Ghabaee M, Jabedari B, Al-E-Eshagh N, Ghaffarpour M, Asadi F: Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients. Int J Neurosci. 2010 Apr;120(4):301-4. doi: 10.3109/00207451003695690.</reference_text><pubmed_id>20374079</pubmed_id></reference><reference><reference_text>Kawajiri M, Mogi M, Osoegawa M, Matsuoka T, Tsukuda K, Kohara K, Horiuchi M, Miki T, Kira JI: Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler. 2008 May;14(4):557-60. doi: 10.1177/1352458507085760.</reference_text><pubmed_id>18562510</pubmed_id></reference><reference><reference_text>Visconti A, Cotichini R, Cannoni S, Bocca B, Forte G, Ghazaryan A, Santucci S, D'Ippolito C, Stazi MA, Salvetti M, Alimonti A, Ristori G: Concentration of elements in serum of patients affected by multiple sclerosis with first demyelinating episode: a six-month longitudinal follow-up study. Ann Ist Super Sanita. 2005;41(2):217-22.</reference_text><pubmed_id>16244396</pubmed_id></reference></references></disease><disease>Inflammatory bowel disease<references><reference><reference_text>Lee T, Clavel T, Smirnov K, Schmidt A, Lagkouvardos I, Walker A, Lucio M, Michalke B, Schmitt-Kopplin P, Fedorak R, Haller D: Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. 2017 May;66(5):863-871. doi: 10.1136/gutjnl-2015-309940. Epub 2016 Feb 4.</reference_text><pubmed_id>26848182</pubmed_id></reference><reference><reference_text>Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158.</reference_text><pubmed_id>27609529</pubmed_id></reference></references></disease><disease>Colorectal cancer<references><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B: Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009 Apr;22(3):342-8. doi: 10.1002/nbm.1345.</reference_text><pubmed_id>19006102</pubmed_id></reference><reference><reference_text>Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP: Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One. 2013 Aug 6;8(8):e70803. doi: 10.1371/journal.pone.0070803. Print 2013.</reference_text><pubmed_id>23940645</pubmed_id></reference><reference><reference_text>Phua LC, Chue XP, Koh PK, Cheah PY, Ho HK, Chan EC: Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biol Ther. 2014 Apr;15(4):389-97. doi: 10.4161/cbt.27625. Epub 2014 Jan 14.</reference_text><pubmed_id>24424155</pubmed_id></reference><reference><reference_text>Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB: Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010 Feb 15;8:13. doi: 10.1186/1741-7015-8-13.</reference_text><pubmed_id>20156336</pubmed_id></reference><reference><reference_text>Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, Ni Y, Zhao A, Xu LX, Cai S, Jia W: Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res. 2009 Oct;8(10):4844-50. doi: 10.1021/pr9004162.</reference_text><pubmed_id>19678709</pubmed_id></reference><reference><reference_text>Cheng Y, Xie G, Chen T, Qiu Y, Zou X, Zheng M, Tan B, Feng B, Dong T, He P, Zhao L, Zhao A, Xu LX, Zhang Y, Jia W: Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res. 2012 Feb 3;11(2):1354-63. doi: 10.1021/pr201001a. Epub 2011 Dec 28.</reference_text><pubmed_id>22148915</pubmed_id></reference><reference><reference_text>Ni Y, Xie G, Jia W: Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res. 2014 Sep 5;13(9):3857-70. doi: 10.1021/pr500443c. Epub 2014 Aug 14.</reference_text><pubmed_id>25105552</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference><reference><reference_text>Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18.</reference_text><pubmed_id>25037050</pubmed_id></reference><reference><reference_text>Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016.</reference_text><pubmed_id>27015276</pubmed_id></reference><reference><reference_text>Lin Y, Ma C, Liu C, Wang Z, Yang J, Liu X, Shen Z, Wu R: NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer. Oncotarget. 2016 May 17;7(20):29454-64. doi: 10.18632/oncotarget.8762.</reference_text><pubmed_id>27107423</pubmed_id></reference><reference><reference_text>Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016.</reference_text><pubmed_id>27275383</pubmed_id></reference><reference><reference_text>Wang X, Wang J, Rao B, Deng L: Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals. Exp Ther Med. 2017 Jun;13(6):2848-2854. doi: 10.3892/etm.2017.4367. Epub 2017 Apr 20.</reference_text><pubmed_id>28587349</pubmed_id></reference><reference><reference_text>Silke Matysik, Caroline Ivanne Le Roy, Gerhard Liebisch, Sandrine Paule Claus. Metabolomics of fecal samples: A practical consideration. Trends in Food Science &amp; Technology. Vol. 57, Part B, Nov. 2016, p.244-255: http://www.sciencedirect.com/science/article/pii/S0924224416301984</reference_text><pubmed_id>28587349</pubmed_id></reference></references></disease><disease>Gallbladder disease<references><reference><reference_text>Lapidus A, Akerlund JE, Einarsson C: Gallbladder bile composition in patients with Crohn 's disease. World J Gastroenterol. 2006 Jan 7;12(1):70-4.</reference_text><pubmed_id>16440420</pubmed_id></reference><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference><reference><reference_text>Mizuno S, Tazuma S, Kajiyama G: Stabilization of biliary lipid particles by ursodeoxycholic acid. Prolonged nucleation time in human gallbladder bile. Dig Dis Sci. 1993 Apr;38(4):684-93.</reference_text><pubmed_id>8462368</pubmed_id></reference><reference><reference_text>Hillebrant CG, Axelson M, Bjorkhem I, Wang FH, Nyberg B, Einarsson C: Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients. Eur J Clin Invest. 1998 Apr;28(4):324-8.</reference_text><pubmed_id>9615912</pubmed_id></reference></references></disease><disease>Cholelithiasis<references><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference></references></disease><disease>Stomach cancer<references><reference><reference_text>Higashijima H, Ichimiya H, Nakano T, Yamashita H, Kuroki S, Satoh H, Chijiiwa K, Tanaka M: Deconjugation of bilirubin accelerates coprecipitation of cholesterol, fatty acids, and mucin in human bile--in vitro study. J Gastroenterol. 1996 Dec;31(6):828-35.</reference_text><pubmed_id>9027647</pubmed_id></reference><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Song H, Peng JS, Dong-Sheng Y, Yang ZL, Liu HL, Zeng YK, Shi XP, Lu BY: Serum metabolic profiling of human gastric cancer based on gas chromatography/mass spectrometry. Braz J Med Biol Res. 2012 Jan;45(1):78-85. Epub 2011 Nov 25.</reference_text><pubmed_id>22124703</pubmed_id></reference><reference><reference_text>Yu L, Aa J, Xu J, Sun M, Qian S, Cheng L, Yang S, Shi R: Metabolomic phenotype of gastric cancer and precancerous stages based on gas chromatography time-of-flight mass spectrometry. J Gastroenterol Hepatol. 2011 Aug;26(8):1290-7. doi: 10.1111/j.1440-1746.2011.06724.x.</reference_text><pubmed_id>21443661</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference></references></disease><disease>Acute myelogenous leukemia<references><reference><reference_text>Tatidis L, Vitols S, Gruber A, Paul C, Axelson M: Cholesterol catabolism in patients with acute myelogenous leukemia and hypocholesterolemia: suppressed levels of a circulating marker for bile acid synthesis. Cancer Lett. 2001 Sep 20;170(2):169-75.</reference_text><pubmed_id>11463495</pubmed_id></reference></references></disease><disease>Hypercholesterolemia<references><reference><reference_text>Thelen KM, Laaksonen R, Paiva H, Lehtimaki T, Lutjohann D: High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels. J Clin Pharmacol. 2006 Jul;46(7):812-6.</reference_text><pubmed_id>16809807</pubmed_id></reference><reference><reference_text>Tamasawa N, Tamasawa A, Takebe K: Higher levels of plasma cholesterol sulfate in patients with liver cirrhosis and hypercholesterolemia. Lipids. 1993 Sep;28(9):833-6.</reference_text><pubmed_id>8231659</pubmed_id></reference><reference><reference_text>Kim DH, Lee KJ, Heo GS: Analysis of cholesterol and cholesteryl esters in human serum using capillary supercritical fluid chromatography. J Chromatogr B Biomed Appl. 1994 Apr 22;655(1):1-8.</reference_text><pubmed_id>8061816</pubmed_id></reference><reference><reference_text>Authors unspecified: Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med. 1988 Jan;148(1):36-69.</reference_text><pubmed_id>3422148</pubmed_id></reference></references></disease><disease>Cholesteryl ester storage disease<references><reference><reference_text>Rassoul F, Richter V, Lohse P, Naumann A, Purschwitz K, Keller E: Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease. Int J Clin Pharmacol Ther. 2001 May;39(5):199-204.</reference_text><pubmed_id>11380065</pubmed_id></reference><reference><reference_text>Chatrath H, Keilin S, Attar BM: Cholesterol ester storage disease (CESD) diagnosed in an asymptomatic adult. Dig Dis Sci. 2009 Jan;54(1):168-73. doi: 10.1007/s10620-008-0310-2. Epub 2008 May 14.</reference_text><pubmed_id>18478331</pubmed_id></reference><reference><reference_text>Bernstein DL, Hulkova H, Bialer MG, Desnick RJ: Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol. 2013 Jun;58(6):1230-43. doi: 10.1016/j.jhep.2013.02.014. Epub 2013 Feb 26.</reference_text><pubmed_id>23485521</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Cystinosis<references><reference><reference_text>Ueda M, O'Brien K, Rosing DR, Ling A, Kleta R, McAreavey D, Bernardini I, Gahl WA: Coronary artery and other vascular calcifications in patients with cystinosis after kidney transplantation. Clin J Am Soc Nephrol. 2006 May;1(3):555-62. Epub 2006 Feb 8.</reference_text><pubmed_id>17699259</pubmed_id></reference><reference><reference_text>Gahl WA, Bernardini I, Dalakas M, Rizzo WB, Harper GS, Hoeg JM, Hurko O, Bernar J: Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome. J Clin Invest. 1988 Feb;81(2):549-60.</reference_text><pubmed_id>3276734</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Smith-Lemli-Opitz syndrome<references><reference><reference_text>van Rooij A, Nijenhuis AA, Wijburg FA, Schutgens RB: Highly increased CSF concentrations of cholesterol precursors in Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 1997 Aug;20(4):578-80.</reference_text><pubmed_id>9266395</pubmed_id></reference><reference><reference_text>Honda M, Tint GS, Honda A, Salen G, Shefer S, Batta AK, Matsuzaki Y, Tanaka N: Regulation of cholesterol biosynthetic pathway in patients with the Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2000 Jul;23(5):464-74.</reference_text><pubmed_id>10947201</pubmed_id></reference><reference><reference_text>Rossi M, Federico G, Corso G, Parenti G, Battagliese A, Frascogna AR, Della Casa R, Dello Russo A, Strisciuglio P, Saggese G, Andria G: Vitamin D status in patients affected by Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2005;28(1):69-80.</reference_text><pubmed_id>15702407</pubmed_id></reference><reference><reference_text>Johnson DW, ten Brink HJ, Jakobs C: A rapid screening procedure for cholesterol and dehydrocholesterol by electrospray ionization tandem mass spectrometry. J Lipid Res. 2001 Oct;42(10):1699-705.</reference_text><pubmed_id>11590227</pubmed_id></reference></references></disease><disease>Prostate cancer<references><reference><reference_text>Nyman DW, Suzanne Stratton M, Kopplin MJ, Dalkin BL, Nagle RB, Jay Gandolfi A: Selenium and selenomethionine levels in prostate cancer patients. Cancer Detect Prev. 2004;28(1):8-16.</reference_text><pubmed_id>15041072</pubmed_id></reference><reference><reference_text>Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, Egevad L, Tjonneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, Palli D, Vineis P, Tumino R, Berrino F, Kiemeney L, Bueno-de-Mesquita HB, Quiros JR, Gonzalez CA, Martinez C, Larranaga N, Chirlaque MD, Ardanaz E, Stattin P, Hallmans G, Khaw KT, Bingham S, Slimani N, Ferrari P, Rinaldi S, Riboli E: Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr. 2007 Sep;86(3):672-81.</reference_text><pubmed_id>17823432</pubmed_id></reference><reference><reference_text>Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762.</reference_text><pubmed_id>19212411</pubmed_id></reference><reference><reference_text>Puah CM, Williams G, Ghanadian R: Urinary unconjugated 5 alpha-androstane-3 alpha, 17 beta-diol in patients with prostatic tumours. Urol Res. 1982;10(2):81-4.</reference_text><pubmed_id>6180540</pubmed_id></reference><reference><reference_text>Thysell E, Surowiec I, Hornberg E, Crnalic S, Widmark A, Johansson AI, Stattin P, Bergh A, Moritz T, Antti H, Wikstrom P: Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One. 2010 Dec 3;5(12):e14175. doi: 10.1371/journal.pone.0014175.</reference_text><pubmed_id>21151972</pubmed_id></reference><reference><reference_text>Soliman LC, Hui Y, Hewavitharana AK, Chen DD: Monitoring potential prostate cancer biomarkers in urine by capillary electrophoresis-tandem mass spectrometry. J Chromatogr A. 2012 Dec 7;1267:162-9. doi: 10.1016/j.chroma.2012.07.021. Epub 2012 Jul 14.</reference_text><pubmed_id>22824219</pubmed_id></reference><reference><reference_text>Madu CO, Lu Y: Novel diagnostic biomarkers for prostate cancer. J Cancer. 2010 Oct 6;1:150-77.</reference_text><pubmed_id>20975847</pubmed_id></reference></references></disease><disease>Schizophrenia<references><reference><reference_text>Harnryd C, Bjerkenstedt L, Grimm VE, Sedvall G: Reduction of MOPEG levels in cerebrospinal fluid of psychotic women after electroconvulsive treatment. Psychopharmacology (Berl). 1979 Aug 8;64(2):131-4.</reference_text><pubmed_id>115032</pubmed_id></reference><reference><reference_text>Kobayashi K, Koide Y, Yoshino K, Shohmori T: [P-hydroxyphenylacetic acid concentrations in cerebrospinal fluid]. No To Shinkei. 1982 Aug;34(8):769-74.</reference_text><pubmed_id>7126379</pubmed_id></reference><reference><reference_text>Alfredsson G, Wiesel FA: Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology (Berl). 1989;99(3):322-7.</reference_text><pubmed_id>2480613</pubmed_id></reference><reference><reference_text>Heresco-Levy U, Bar G, Levin R, Ermilov M, Ebstein RP, Javitt DC: High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. Schizophr Res. 2007 Mar;91(1-3):14-21. Epub 2007 Feb 2.</reference_text><pubmed_id>17276036</pubmed_id></reference><reference><reference_text>Walker EF, Bonsall R, Walder DJ: Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis. Neuropsychiatry Neuropsychol Behav Neurol. 2002 Mar;15(1):10-7.</reference_text><pubmed_id>11877547</pubmed_id></reference><reference><reference_text>Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M: Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry. 2003 Jun;60(6):572-6.</reference_text><pubmed_id>12796220</pubmed_id></reference><reference><reference_text>Do KQ, Lauer CJ, Schreiber W, Zollinger M, Gutteck-Amsler U, Cuenod M, Holsboer F: gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem. 1995 Dec;65(6):2652-62.</reference_text><pubmed_id>7595563</pubmed_id></reference><reference><reference_text>Nikisch G, Baumann P, Wiedemann G, Kiessling B, Weisser H, Hertel A, Yoshitake T, Kehr J, Mathe AA: Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF. J Clin Psychopharmacol. 2010 Oct;30(5):496-503. doi: 10.1097/JCP.0b013e3181f2288e.</reference_text><pubmed_id>20814316</pubmed_id></reference><reference><reference_text>Fukushima T, Iizuka H, Yokota A, Suzuki T, Ohno C, Kono Y, Nishikiori M, Seki A, Ichiba H, Watanabe Y, Hongo S, Utsunomiya M, Nakatani M, Sadamoto K, Yoshio T: Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One. 2014 Jul 8;9(7):e101652. doi: 10.1371/journal.pone.0101652. eCollection 2014.</reference_text><pubmed_id>25004141</pubmed_id></reference><reference><reference_text>Koike S, Bundo M, Iwamoto K, Suga M, Kuwabara H, Ohashi Y, Shinoda K, Takano Y, Iwashiro N, Satomura Y, Nagai T, Natsubori T, Tada M, Yamasue H, Kasai K: A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study. Transl Psychiatry. 2014 Apr 8;4:e379. doi: 10.1038/tp.2014.19.</reference_text><pubmed_id>24713860</pubmed_id></reference><reference><reference_text>Ballesteros A, Summerfelt A, Du X, Jiang P, Chiappelli J, Tagamets M, O'Donnell P, Kochunov P, Hong LE: Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia. Clin Neurophysiol. 2013 Nov;124(11):2209-15. doi: 10.1016/j.clinph.2013.05.021. Epub 2013 Jun 30.</reference_text><pubmed_id>23823132</pubmed_id></reference><reference><reference_text>Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel FA: Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry. 1985 Sep;147:276-82.</reference_text><pubmed_id>2415198</pubmed_id></reference><reference><reference_text>Pickar D, Breier A, Hsiao JK, Doran AR, Wolkowitz OM, Pato CN, Konicki PE, Potter WZ: Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Arch Gen Psychiatry. 1990 Jul;47(7):641-8.</reference_text><pubmed_id>1694425</pubmed_id></reference><reference><reference_text>Prell GD, Green JP, Kaufmann CA, Khandelwal JK, Morrishow AM, Kirch DG, Linnoila M, Wyatt RJ: Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res. 1995 Jan;14(2):93-104.</reference_text><pubmed_id>7711000</pubmed_id></reference><reference><reference_text>Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B: Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology. 2009;59(2):123-9. doi: 10.1159/000213565. Epub 2009 Apr 22.</reference_text><pubmed_id>19390223</pubmed_id></reference><reference><reference_text>Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K, Cao Y, Wang X, Qiu Y, Su M, Zhao A, Wang P, Yang P, Wu J, Feng G, He L, Jia W, Wan C: Potential metabolite markers of schizophrenia. Mol Psychiatry. 2013 Jan;18(1):67-78. doi: 10.1038/mp.2011.131. Epub 2011 Oct 25.</reference_text><pubmed_id>22024767</pubmed_id></reference><reference><reference_text>Xuan J, Pan G, Qiu Y, Yang L, Su M, Liu Y, Chen J, Feng G, Fang Y, Jia W, Xing Q, He L: Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. J Proteome Res. 2011 Dec 2;10(12):5433-43. doi: 10.1021/pr2006796. Epub 2011 Nov  8.</reference_text><pubmed_id>22007635</pubmed_id></reference><reference><reference_text>Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM, Rothermundt M, Bogerts B, Koethe D, Kranaster L, Ohrmann P, Suslow T, McAllister G, Spain M, Barnes A, van Beveren NJ, Baron-Cohen S, Steiner J, Torrey FE, Yolken RH, Bahn S: Identification of a biological signature for schizophrenia in serum. Mol Psychiatry. 2012 May;17(5):494-502. doi: 10.1038/mp.2011.42. Epub 2011 Apr 12.</reference_text><pubmed_id>21483431</pubmed_id></reference><reference><reference_text>Mathe AA, Eberhard G, Saaf J, Wetterberg L: Plasma prostaglandin E2 metabolite--measured as 11-deoxy-15-keto-13,14-dihydro-11 beta,16 xi-cyclo-PGE2--in twins with schizophrenic disorder. Biol Psychiatry. 1986 Sep;21(11):1024-30.</reference_text><pubmed_id>3741918</pubmed_id></reference><reference><reference_text>Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N: Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct. 2002 Jun;20(2):171-5.</reference_text><pubmed_id>11979513</pubmed_id></reference><reference><reference_text>Zumarraga M, Davila R, Basterreche N, Arrue A, Goienetxea B, Zamalloa MI, Erkoreka L, Bustamante S, Inchausti L, Gonzalez-Torres MA, Guimon J: Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients. Neurochem Int. 2010 May-Jun;56(6-7):774-9. doi: 10.1016/j.neuint.2010.02.015. Epub 2010 Mar 4.</reference_text><pubmed_id>20206656</pubmed_id></reference><reference><reference_text>Peters JG: Dopamine, noradrenaline and serotonin spinal fluid metabolites in temporal lobe epileptic patients with schizophrenic symptomatology. Eur Neurol. 1979;18(1):15-8.</reference_text><pubmed_id>436860</pubmed_id></reference><reference><reference_text>Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, Rozen S, Krishnan RR, McEvoy J, Kaddurah-Daouk R: Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry. 2010 Sep;15(9):938-53. doi: 10.1038/mp.2009.33. Epub 2009 Apr 28.</reference_text><pubmed_id>19401681</pubmed_id></reference><reference><reference_text>Gattaz WF, Waldmeier P, Beckmann H: CSF monoamine metabolites in schizophrenic patients. Acta Psychiatr Scand. 1982 Nov;66(5):350-60.</reference_text><pubmed_id>6184954</pubmed_id></reference><reference><reference_text>Nilsson-Todd LK, Nordin C, Jonsson EG, Skogh E, Erhardt S: Cerebrospinal fluid kynurenic acid in male patients with schizophrenia - correlation with monoamine metabolites. Acta Neuropsychiatr. 2007 Feb;19(1):45-52. doi: 10.1111/j.1601-5215.2006.00170.x.</reference_text><pubmed_id>26952797</pubmed_id></reference><reference><reference_text>Cai HL, Li HD, Yan XZ, Sun B, Zhang Q, Yan M, Zhang WY, Jiang P, Zhu RH, Liu YP, Fang PF, Xu P, Yuan HY, Zhang XH, Hu L, Yang W, Ye HS: Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naive schizophrenia patients after treatment with risperidone. J Proteome Res. 2012 Aug 3;11(8):4338-50. doi: 10.1021/pr300459d. Epub 2012 Jul 26.</reference_text><pubmed_id>22800120</pubmed_id></reference><reference><reference_text>Al Awam K, Haussleiter IS, Dudley E, Donev R, Brune M, Juckel G, Thome J: Multiplatform metabolome and proteome profiling identifies serum metabolite and protein signatures as prospective biomarkers for schizophrenia. J Neural Transm (Vienna). 2015 Aug;122 Suppl 1:S111-22. doi: 10.1007/s00702-014-1224-0. Epub 2014 May 1.</reference_text><pubmed_id>24789758</pubmed_id></reference><reference><reference_text>Bicikova M, Hill M, Ripova D, Mohr P, Hampl R: Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia. J Steroid Biochem Mol Biol. 2013 Jan;133:77-83. doi: 10.1016/j.jsbmb.2012.08.009. Epub 2012 Aug 24.</reference_text><pubmed_id>22944140</pubmed_id></reference><reference><reference_text>He Y, Yu Z, Giegling I, Xie L, Hartmann AM, Prehn C, Adamski J, Kahn R, Li Y, Illig T, Wang-Sattler R, Rujescu D: Schizophrenia shows a unique metabolomics signature in plasma. Transl Psychiatry. 2012 Aug 14;2:e149. doi: 10.1038/tp.2012.76.</reference_text><pubmed_id>22892715</pubmed_id></reference><reference><reference_text>Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KR: Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):934-45. Epub 2007 Apr 17.</reference_text><pubmed_id>17440431</pubmed_id></reference><reference><reference_text>Fryar-Williams S, Strobel JE: Biomarkers of a five-domain translational substrate for schizophrenia and schizoaffective psychosis. Biomark Res. 2015 Feb 6;3:3. doi: 10.1186/s40364-015-0028-1. eCollection 2015.</reference_text><pubmed_id>25729574</pubmed_id></reference><reference><reference_text>Oresic M, Seppanen-Laakso T, Sun D, Tang J, Therman S, Viehman R, Mustonen U, van Erp TG, Hyotylainen T, Thompson P, Toga AW, Huttunen MO, Suvisaari J, Kaprio J, Lonnqvist J, Cannon TD: Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia. Genome Med. 2012 Jan 18;4(1):1. doi: 10.1186/gm300.</reference_text><pubmed_id>22257447</pubmed_id></reference></references></disease><disease>Primary hypomagnesemia<references><reference><reference_text>Jin-no Y, Kamiya Y, Okada M, Hirako M, Takada N, Kawaguchi M: Primary hypomagnesemia caused by isolated magnesium malabsorption: atypical case in adult. Intern Med. 1999 Mar;38(3):261-5.</reference_text><pubmed_id>10337938</pubmed_id></reference><reference><reference_text>Vainsel M, Vandevelde G, Smulders J, Vosters M, Hubain P, Loeb H: Tetany due to hypomagnesaemia with secondary hypocalcaemia. Arch Dis Child. 1970 Apr;45(240):254-8.</reference_text><pubmed_id>5419995</pubmed_id></reference><reference><reference_text>Shalev H, Phillip M, Galil A, Carmi R, Landau D: Clinical presentation and outcome in primary familial hypomagnesaemia. Arch Dis Child. 1998 Feb;78(2):127-30.</reference_text><pubmed_id>9579153</pubmed_id></reference><reference><reference_text>Kari JA, Farouq M, Alshaya HO: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Pediatr Nephrol. 2003 Jun;18(6):506-10. Epub 2003 Apr 29.</reference_text><pubmed_id>12720080</pubmed_id></reference></references></disease><disease>Hyperlipoproteinemia<references><reference><reference_text>Sinha S, Misra A, Kumar V, Jagannathan NR, Bal CS, Pandey RM, Singhania R, Deepak: Proton magnetic resonance spectroscopy and single photon emission computed tomography study of the brain in asymptomatic young hyperlipidaemic Asian Indians in North India show early abnormalities. Clin Endocrinol (Oxf). 2004 Aug;61(2):182-9.</reference_text><pubmed_id>15272912</pubmed_id></reference><reference><reference_text>Nelson RH: Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013 Mar</reference_text><pubmed_id>40(1):195-211. doi: 10.1016/j.pop.2012.11.003. Epub 2012 Dec  4.</pubmed_id></reference><reference><reference_text>Cantin B, Boudriau S, Bertrand M, Brun LD, Gagne C, Rogers PA, Ven Murthy MR, Lupien PJ, Julien P: Hemolysis in primary lipoprotein lipase deficiency. Metabolism. 1995 May;44(5):652-8.</reference_text><pubmed_id>7752915</pubmed_id></reference></references></disease><disease>Abetalipoproteinemia<references><reference><reference_text>Dawson G, Kruski AW, Scanu AM: Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J Lipid Res. 1976 Mar;17(2):125-31.</reference_text><pubmed_id>178813</pubmed_id></reference><reference><reference_text>Lazaro RP, Dentinger MP, Rodichok LD, Barron KD, Satya-Murti S: Muscle pathology in Bassen-Kornzweig syndrome and vitamin E deficiency. Am J Clin Pathol. 1986 Sep;86(3):378-87.</reference_text><pubmed_id>2944375</pubmed_id></reference></references></disease><disease>Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis<references><reference><reference_text>Breckenridge WC, Alaupovic P, Cox DW, Little JA: Apolipoprotein and lipoprotein concentrations in familial apolipoprotein C-II deficiency. Atherosclerosis. 1982 Aug;44(2):223-35.</reference_text><pubmed_id>7138621</pubmed_id></reference><reference><reference_text>Fukami M, Hasegawa T, Horikawa R, Ohashi T, Nishimura G, Homma K, Ogata T: Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr Res. 2006 Feb;59(2):276-80. doi: 10.1203/01.pdr.0000195825.31504.28.</reference_text><pubmed_id>16439592</pubmed_id></reference></references></disease><disease>Cerebrotendinous xanthomatosis<references><reference><reference_text>Halperin G, Elisaf M, Leitersdorf E, Harats D: A new method for determination of serum cholestanol by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2000 Jun 9;742(2):345-52.</reference_text><pubmed_id>10901139</pubmed_id></reference><reference><reference_text>Siman-Tov T, Meiner V, Gadoth N: Could steroids mask the diagnosis of cerebrotendinous xanthomatosis? J Neurol Sci. 2006 Apr 15;243(1-2):83-6. Epub 2006 Jan 30.</reference_text><pubmed_id>16445943</pubmed_id></reference><reference><reference_text>Agrawal NK, Garg S: Cerebrotendinous xanthomatosis: a rare disorder with a rare presentation. BMJ Case Rep. 2012 Sep 21;2012. pii: bcr-2012-006202. doi: 10.1136/bcr-2012-006202.</reference_text><pubmed_id>23001091</pubmed_id></reference></references></disease><disease>3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency<references><reference><reference_text>Thompson GN, Hsu BY, Pitt JJ, Treacy E, Stanley CA: Fasting hypoketotic coma in a child with deficiency of mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase. N Engl J Med. 1997 Oct 23;337(17):1203-7. doi: 10.1056/NEJM199710233371704.</reference_text><pubmed_id>9337379</pubmed_id></reference><reference><reference_text>Morris AA, Lascelles CV, Olpin SE, Lake BD, Leonard JV, Quant PA: Hepatic mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme a synthase deficiency. Pediatr Res. 1998 Sep;44(3):392-6. doi: 10.1203/00006450-199809000-00021.</reference_text><pubmed_id>9727719</pubmed_id></reference><reference><reference_text>Conboy E, Vairo F, Schultz M, Agre K, Ridsdale R, Deyle D, Oglesbee D, Gavrilov D, Klee EW, Lanpher B: Mitochondrial 3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency: Unique Presenting Laboratory Values and a Review of Biochemical and Clinical Features. JIMD Rep. 2017 Oct 14. doi: 10.1007/8904_2017_59.</reference_text><pubmed_id>29030856</pubmed_id></reference></references></disease><disease>Hypercholesterolemia, familial<references><reference><reference_text>Kwiterovich PO Jr, Fredrickson DS, Levy RI: Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest. 1974 May;53(5):1237-49. doi: 10.1172/JCI107670.</reference_text><pubmed_id>4363406</pubmed_id></reference></references></disease><disease>SC4MOL deficiency<references><reference><reference_text>He M, Kratz LE, Michel JJ, Vallejo AN, Ferris L, Kelley RI, Hoover JJ, Jukic D, Gibson KM, Wolfe LA, Ramachandran D, Zwick ME, Vockley J: Mutations in the human SC4MOL gene encoding a methyl sterol oxidase cause psoriasiform dermatitis, microcephaly, and developmental delay. J Clin Invest. 2011 Mar;121(3):976-84. doi: 10.1172/JCI42650.</reference_text><pubmed_id>21285510</pubmed_id></reference></references></disease><disease>Chondrodysplasia punctata, X-linked dominant<references><reference><reference_text>Aughton DJ, Kelley RI, Metzenberg A, Pureza V, Pauli RM: X-linked dominant chondrodysplasia punctata (CDPX2) caused by single gene mosaicism in a male. Am J Med Genet A. 2003 Jan 30;116A(3):255-60. doi: 10.1002/ajmg.a.10852.</reference_text><pubmed_id>12503102</pubmed_id></reference></references></disease><disease>Desmosterolosis<references><reference><reference_text>Andersson HC, Kratz L, Kelley R: Desmosterolosis presenting with multiple congenital anomalies and profound developmental delay. Am J Med Genet. 2002 Dec 15;113(4):315-9. doi: 10.1002/ajmg.b.10873.</reference_text><pubmed_id>12457401</pubmed_id></reference></references></disease><disease>Donohue Syndrome<references><reference><reference_text>Nijim Y, Awni Y, Adawi A, Bowirrat A: Classic Case Report of Donohue Syndrome (Leprechaunism; OMIM *246200): The Impact of Consanguineous Mating. Medicine (Baltimore). 2016 Feb;95(6):e2710. doi: 10.1097/MD.0000000000002710.</reference_text><pubmed_id>26871809</pubmed_id></reference></references></disease><disease>Leptin Deficiency or Dysfunction<references><reference><reference_text>Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O'Rahilly S: Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999 Sep 16;341(12):879-84. doi: 10.1056/NEJM199909163411204.</reference_text><pubmed_id>10486419</pubmed_id></reference></references></disease><disease>Duchenne Muscular Dystrophy<references><reference><reference_text>Nakagawa T, Takeuchi A, Kakiuchi R, Lee T, Yagi M, Awano H, Iijima K, Takeshima Y, Urade Y, Matsuo M: A prostaglandin D2 metabolite is elevated in the urine of Duchenne muscular dystrophy patients and increases further from 8 years old. Clin Chim Acta. 2013 Aug 23;423:10-4. doi: 10.1016/j.cca.2013.03.031. Epub 2013 Apr 19.</reference_text><pubmed_id>23603101</pubmed_id></reference><reference><reference_text>Srivastava NK, Pradhan S, Mittal B, Gowda GA: High resolution NMR based analysis of serum lipids in Duchenne muscular dystrophy patients and its possible diagnostic significance. NMR Biomed. 2010 Jan;23(1):13-22. doi: 10.1002/nbm.1419.</reference_text><pubmed_id>19787747</pubmed_id></reference><reference><reference_text>Horster I, Weigt-Usinger K, Carmann C, Chobanyan-Jurgens K, Kohler C, Schara U, Kayacelebi AA, Beckmann B, Tsikas D, Lucke T: The L-arginine/NO pathway and homoarginine are altered in Duchenne muscular dystrophy and improved by glucocorticoids. Amino Acids. 2015 Sep;47(9):1853-63. doi: 10.1007/s00726-015-2018-x. Epub 2015 Jun 12.</reference_text><pubmed_id>26066683</pubmed_id></reference></references></disease><disease>Lecithin:cholesterol Acyltransferase Deficiency<references><reference><reference_text>Idzior-Walus B, Sieradzki J, Kostner G, Malecki MT, Klupa T, Wesolowska T, Rostworowski W, Hartwich J, Walus M, Kiec AD, Naruszewicz M: Familial lecithin-cholesterol acyltransferase deficiency: biochemical characteristics and molecular analysis of a new LCAT mutation in a Polish family. Atherosclerosis. 2006 Apr;185(2):413-20. Epub 2005 Jul 26.</reference_text><pubmed_id>16051254</pubmed_id></reference></references></disease><disease>Lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lipodystrophy, Congenital Generalized<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Oculocerebrorenal syndrome<references><reference><reference_text>Charnas LR, Bernardini I, Rader D, Hoeg JM, Gahl WA: Clinical and laboratory findings in the oculocerebrorenal syndrome of Lowe, with special reference to growth and renal function. N Engl J Med. 1991 May 9;324(19):1318-25. doi: 10.1056/NEJM199105093241904.</reference_text><pubmed_id>2017228</pubmed_id></reference></references></disease><disease>Familial partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lathosterolosis<references><reference><reference_text>Brunetti-Pierri N, Corso G, Rossi M, Ferrari P, Balli F, Rivasi F, Annunziata I, Ballabio A, Russo AD, Andria G, Parenti G: Lathosterolosis, a novel multiple-malformation/mental retardation syndrome due to deficiency of 3beta-hydroxysteroid-delta5-desaturase. Am J Hum Genet. 2002 Oct;71(4):952-8. Epub 2002 Aug 20.</reference_text><pubmed_id>12189593</pubmed_id></reference><reference><reference_text>Ho AC, Fung CW, Siu TS, Ma OC, Lam CW, Tam S, Wong VC: Lathosterolosis: a disorder of cholesterol biosynthesis resembling smith-lemli-opitz syndrome. JIMD Rep. 2014;12:129-34. doi: 10.1007/8904_2013_255. Epub 2013 Oct 20.</reference_text><pubmed_id>24142275</pubmed_id></reference></references></disease><disease>Partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Multiple sclerosis<references><reference><reference_text>Lutz NW, Viola A, Malikova I, Confort-Gouny S, Audoin B, Ranjeva JP, Pelletier J, Cozzone PJ: Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One. 2007 Jul 4;2(7):e595.</reference_text><pubmed_id>17611627</pubmed_id></reference><reference><reference_text>Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U, Hillert J, Bjorkhem I: Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med. 2004 Feb;42(2):186-91.</reference_text><pubmed_id>15061359</pubmed_id></reference><reference><reference_text>Leoni V, Lutjohann D, Masterman T: Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis. J Lipid Res. 2005 Feb;46(2):191-5. Epub 2004 Dec 1.</reference_text><pubmed_id>15576852</pubmed_id></reference><reference><reference_text>Calabrese V, Scapagnini G, Ravagna A, Bella R, Butterfield DA, Calvani M, Pennisi G, Giuffrida Stella AM: Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem Res. 2003 Sep;28(9):1321-8.</reference_text><pubmed_id>12938853</pubmed_id></reference><reference><reference_text>Shaw CE, Dunbar PR, Macaulay HA, Neale TJ: Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol. 1995 Jan;242(2):53-8.</reference_text><pubmed_id>7707089</pubmed_id></reference><reference><reference_text>Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.</reference_text><pubmed_id>17384003</pubmed_id></reference><reference><reference_text>Syburra C, Passi S: Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh (1999). 1999 May-Jun;71(3):112-5.</reference_text><pubmed_id>10609336</pubmed_id></reference><reference><reference_text>Forte G, Visconti A, Santucci S, Ghazaryan A, Figa-Talamanca L, Cannoni S, Bocca B, Pino A, Violante N, Alimonti A, Salvetti M, Ristori G: Quantification of chemical elements in blood of patients affected by multiple sclerosis. Ann Ist Super Sanita. 2005;41(2):213-6.</reference_text><pubmed_id>16244395</pubmed_id></reference><reference><reference_text>Toncev G, Milicic B, Toncev S, Samardzic G: Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol. 2002 May;9(3):221-6.</reference_text><pubmed_id>11985629</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, Bamonti F, Capello E, Mancardi GL, Scarpini E: Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res. 2010 May 28;1333:64-71. doi: 10.1016/j.brainres.2010.03.073. Epub 2010 Mar 27.</reference_text><pubmed_id>20347721</pubmed_id></reference><reference><reference_text>Matsushita T, Isobe N, Kawajiri M, Mogi M, Tsukuda K, Horiuchi M, Ohyagi Y, Kira J: CSF angiotensin II and angiotensin-converting enzyme levels in anti-aquaporin-4 autoimmunity. J Neurol Sci. 2010 Aug 15;295(1-2):41-5. doi: 10.1016/j.jns.2010.05.014. Epub 2010 Jun 11.</reference_text><pubmed_id>20541774</pubmed_id></reference><reference><reference_text>Ghabaee M, Jabedari B, Al-E-Eshagh N, Ghaffarpour M, Asadi F: Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients. Int J Neurosci. 2010 Apr;120(4):301-4. doi: 10.3109/00207451003695690.</reference_text><pubmed_id>20374079</pubmed_id></reference><reference><reference_text>Kawajiri M, Mogi M, Osoegawa M, Matsuoka T, Tsukuda K, Kohara K, Horiuchi M, Miki T, Kira JI: Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler. 2008 May;14(4):557-60. doi: 10.1177/1352458507085760.</reference_text><pubmed_id>18562510</pubmed_id></reference><reference><reference_text>Visconti A, Cotichini R, Cannoni S, Bocca B, Forte G, Ghazaryan A, Santucci S, D'Ippolito C, Stazi MA, Salvetti M, Alimonti A, Ristori G: Concentration of elements in serum of patients affected by multiple sclerosis with first demyelinating episode: a six-month longitudinal follow-up study. Ann Ist Super Sanita. 2005;41(2):217-22.</reference_text><pubmed_id>16244396</pubmed_id></reference></references></disease><disease>Inflammatory bowel disease<references><reference><reference_text>Lee T, Clavel T, Smirnov K, Schmidt A, Lagkouvardos I, Walker A, Lucio M, Michalke B, Schmitt-Kopplin P, Fedorak R, Haller D: Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. 2017 May;66(5):863-871. doi: 10.1136/gutjnl-2015-309940. Epub 2016 Feb 4.</reference_text><pubmed_id>26848182</pubmed_id></reference><reference><reference_text>Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158.</reference_text><pubmed_id>27609529</pubmed_id></reference></references></disease><disease>Colorectal cancer<references><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B: Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009 Apr;22(3):342-8. doi: 10.1002/nbm.1345.</reference_text><pubmed_id>19006102</pubmed_id></reference><reference><reference_text>Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP: Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One. 2013 Aug 6;8(8):e70803. doi: 10.1371/journal.pone.0070803. Print 2013.</reference_text><pubmed_id>23940645</pubmed_id></reference><reference><reference_text>Phua LC, Chue XP, Koh PK, Cheah PY, Ho HK, Chan EC: Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biol Ther. 2014 Apr;15(4):389-97. doi: 10.4161/cbt.27625. Epub 2014 Jan 14.</reference_text><pubmed_id>24424155</pubmed_id></reference><reference><reference_text>Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB: Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010 Feb 15;8:13. doi: 10.1186/1741-7015-8-13.</reference_text><pubmed_id>20156336</pubmed_id></reference><reference><reference_text>Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, Ni Y, Zhao A, Xu LX, Cai S, Jia W: Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res. 2009 Oct;8(10):4844-50. doi: 10.1021/pr9004162.</reference_text><pubmed_id>19678709</pubmed_id></reference><reference><reference_text>Cheng Y, Xie G, Chen T, Qiu Y, Zou X, Zheng M, Tan B, Feng B, Dong T, He P, Zhao L, Zhao A, Xu LX, Zhang Y, Jia W: Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res. 2012 Feb 3;11(2):1354-63. doi: 10.1021/pr201001a. Epub 2011 Dec 28.</reference_text><pubmed_id>22148915</pubmed_id></reference><reference><reference_text>Ni Y, Xie G, Jia W: Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res. 2014 Sep 5;13(9):3857-70. doi: 10.1021/pr500443c. Epub 2014 Aug 14.</reference_text><pubmed_id>25105552</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference><reference><reference_text>Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18.</reference_text><pubmed_id>25037050</pubmed_id></reference><reference><reference_text>Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016.</reference_text><pubmed_id>27015276</pubmed_id></reference><reference><reference_text>Lin Y, Ma C, Liu C, Wang Z, Yang J, Liu X, Shen Z, Wu R: NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer. Oncotarget. 2016 May 17;7(20):29454-64. doi: 10.18632/oncotarget.8762.</reference_text><pubmed_id>27107423</pubmed_id></reference><reference><reference_text>Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016.</reference_text><pubmed_id>27275383</pubmed_id></reference><reference><reference_text>Wang X, Wang J, Rao B, Deng L: Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals. Exp Ther Med. 2017 Jun;13(6):2848-2854. doi: 10.3892/etm.2017.4367. Epub 2017 Apr 20.</reference_text><pubmed_id>28587349</pubmed_id></reference><reference><reference_text>Silke Matysik, Caroline Ivanne Le Roy, Gerhard Liebisch, Sandrine Paule Claus. Metabolomics of fecal samples: A practical consideration. Trends in Food Science &amp; Technology. Vol. 57, Part B, Nov. 2016, p.244-255: http://www.sciencedirect.com/science/article/pii/S0924224416301984</reference_text><pubmed_id>28587349</pubmed_id></reference></references></disease><disease>Gallbladder disease<references><reference><reference_text>Lapidus A, Akerlund JE, Einarsson C: Gallbladder bile composition in patients with Crohn 's disease. World J Gastroenterol. 2006 Jan 7;12(1):70-4.</reference_text><pubmed_id>16440420</pubmed_id></reference><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference><reference><reference_text>Mizuno S, Tazuma S, Kajiyama G: Stabilization of biliary lipid particles by ursodeoxycholic acid. Prolonged nucleation time in human gallbladder bile. Dig Dis Sci. 1993 Apr;38(4):684-93.</reference_text><pubmed_id>8462368</pubmed_id></reference><reference><reference_text>Hillebrant CG, Axelson M, Bjorkhem I, Wang FH, Nyberg B, Einarsson C: Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients. Eur J Clin Invest. 1998 Apr;28(4):324-8.</reference_text><pubmed_id>9615912</pubmed_id></reference></references></disease><disease>Cholelithiasis<references><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference></references></disease><disease>Stomach cancer<references><reference><reference_text>Higashijima H, Ichimiya H, Nakano T, Yamashita H, Kuroki S, Satoh H, Chijiiwa K, Tanaka M: Deconjugation of bilirubin accelerates coprecipitation of cholesterol, fatty acids, and mucin in human bile--in vitro study. J Gastroenterol. 1996 Dec;31(6):828-35.</reference_text><pubmed_id>9027647</pubmed_id></reference><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Song H, Peng JS, Dong-Sheng Y, Yang ZL, Liu HL, Zeng YK, Shi XP, Lu BY: Serum metabolic profiling of human gastric cancer based on gas chromatography/mass spectrometry. Braz J Med Biol Res. 2012 Jan;45(1):78-85. Epub 2011 Nov 25.</reference_text><pubmed_id>22124703</pubmed_id></reference><reference><reference_text>Yu L, Aa J, Xu J, Sun M, Qian S, Cheng L, Yang S, Shi R: Metabolomic phenotype of gastric cancer and precancerous stages based on gas chromatography time-of-flight mass spectrometry. J Gastroenterol Hepatol. 2011 Aug;26(8):1290-7. doi: 10.1111/j.1440-1746.2011.06724.x.</reference_text><pubmed_id>21443661</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference></references></disease><disease>Acute myelogenous leukemia<references><reference><reference_text>Tatidis L, Vitols S, Gruber A, Paul C, Axelson M: Cholesterol catabolism in patients with acute myelogenous leukemia and hypocholesterolemia: suppressed levels of a circulating marker for bile acid synthesis. Cancer Lett. 2001 Sep 20;170(2):169-75.</reference_text><pubmed_id>11463495</pubmed_id></reference></references></disease><disease>Hypercholesterolemia<references><reference><reference_text>Thelen KM, Laaksonen R, Paiva H, Lehtimaki T, Lutjohann D: High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels. J Clin Pharmacol. 2006 Jul;46(7):812-6.</reference_text><pubmed_id>16809807</pubmed_id></reference><reference><reference_text>Tamasawa N, Tamasawa A, Takebe K: Higher levels of plasma cholesterol sulfate in patients with liver cirrhosis and hypercholesterolemia. Lipids. 1993 Sep;28(9):833-6.</reference_text><pubmed_id>8231659</pubmed_id></reference><reference><reference_text>Kim DH, Lee KJ, Heo GS: Analysis of cholesterol and cholesteryl esters in human serum using capillary supercritical fluid chromatography. J Chromatogr B Biomed Appl. 1994 Apr 22;655(1):1-8.</reference_text><pubmed_id>8061816</pubmed_id></reference><reference><reference_text>Authors unspecified: Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med. 1988 Jan;148(1):36-69.</reference_text><pubmed_id>3422148</pubmed_id></reference></references></disease><disease>Cholesteryl ester storage disease<references><reference><reference_text>Rassoul F, Richter V, Lohse P, Naumann A, Purschwitz K, Keller E: Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease. Int J Clin Pharmacol Ther. 2001 May;39(5):199-204.</reference_text><pubmed_id>11380065</pubmed_id></reference><reference><reference_text>Chatrath H, Keilin S, Attar BM: Cholesterol ester storage disease (CESD) diagnosed in an asymptomatic adult. Dig Dis Sci. 2009 Jan;54(1):168-73. doi: 10.1007/s10620-008-0310-2. Epub 2008 May 14.</reference_text><pubmed_id>18478331</pubmed_id></reference><reference><reference_text>Bernstein DL, Hulkova H, Bialer MG, Desnick RJ: Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol. 2013 Jun;58(6):1230-43. doi: 10.1016/j.jhep.2013.02.014. Epub 2013 Feb 26.</reference_text><pubmed_id>23485521</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Cystinosis<references><reference><reference_text>Ueda M, O'Brien K, Rosing DR, Ling A, Kleta R, McAreavey D, Bernardini I, Gahl WA: Coronary artery and other vascular calcifications in patients with cystinosis after kidney transplantation. Clin J Am Soc Nephrol. 2006 May;1(3):555-62. Epub 2006 Feb 8.</reference_text><pubmed_id>17699259</pubmed_id></reference><reference><reference_text>Gahl WA, Bernardini I, Dalakas M, Rizzo WB, Harper GS, Hoeg JM, Hurko O, Bernar J: Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome. J Clin Invest. 1988 Feb;81(2):549-60.</reference_text><pubmed_id>3276734</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Smith-Lemli-Opitz syndrome<references><reference><reference_text>van Rooij A, Nijenhuis AA, Wijburg FA, Schutgens RB: Highly increased CSF concentrations of cholesterol precursors in Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 1997 Aug;20(4):578-80.</reference_text><pubmed_id>9266395</pubmed_id></reference><reference><reference_text>Honda M, Tint GS, Honda A, Salen G, Shefer S, Batta AK, Matsuzaki Y, Tanaka N: Regulation of cholesterol biosynthetic pathway in patients with the Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2000 Jul;23(5):464-74.</reference_text><pubmed_id>10947201</pubmed_id></reference><reference><reference_text>Rossi M, Federico G, Corso G, Parenti G, Battagliese A, Frascogna AR, Della Casa R, Dello Russo A, Strisciuglio P, Saggese G, Andria G: Vitamin D status in patients affected by Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2005;28(1):69-80.</reference_text><pubmed_id>15702407</pubmed_id></reference><reference><reference_text>Johnson DW, ten Brink HJ, Jakobs C: A rapid screening procedure for cholesterol and dehydrocholesterol by electrospray ionization tandem mass spectrometry. J Lipid Res. 2001 Oct;42(10):1699-705.</reference_text><pubmed_id>11590227</pubmed_id></reference></references></disease><disease>Prostate cancer<references><reference><reference_text>Nyman DW, Suzanne Stratton M, Kopplin MJ, Dalkin BL, Nagle RB, Jay Gandolfi A: Selenium and selenomethionine levels in prostate cancer patients. Cancer Detect Prev. 2004;28(1):8-16.</reference_text><pubmed_id>15041072</pubmed_id></reference><reference><reference_text>Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, Egevad L, Tjonneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, Palli D, Vineis P, Tumino R, Berrino F, Kiemeney L, Bueno-de-Mesquita HB, Quiros JR, Gonzalez CA, Martinez C, Larranaga N, Chirlaque MD, Ardanaz E, Stattin P, Hallmans G, Khaw KT, Bingham S, Slimani N, Ferrari P, Rinaldi S, Riboli E: Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr. 2007 Sep;86(3):672-81.</reference_text><pubmed_id>17823432</pubmed_id></reference><reference><reference_text>Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762.</reference_text><pubmed_id>19212411</pubmed_id></reference><reference><reference_text>Puah CM, Williams G, Ghanadian R: Urinary unconjugated 5 alpha-androstane-3 alpha, 17 beta-diol in patients with prostatic tumours. Urol Res. 1982;10(2):81-4.</reference_text><pubmed_id>6180540</pubmed_id></reference><reference><reference_text>Thysell E, Surowiec I, Hornberg E, Crnalic S, Widmark A, Johansson AI, Stattin P, Bergh A, Moritz T, Antti H, Wikstrom P: Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One. 2010 Dec 3;5(12):e14175. doi: 10.1371/journal.pone.0014175.</reference_text><pubmed_id>21151972</pubmed_id></reference><reference><reference_text>Soliman LC, Hui Y, Hewavitharana AK, Chen DD: Monitoring potential prostate cancer biomarkers in urine by capillary electrophoresis-tandem mass spectrometry. J Chromatogr A. 2012 Dec 7;1267:162-9. doi: 10.1016/j.chroma.2012.07.021. Epub 2012 Jul 14.</reference_text><pubmed_id>22824219</pubmed_id></reference><reference><reference_text>Madu CO, Lu Y: Novel diagnostic biomarkers for prostate cancer. J Cancer. 2010 Oct 6;1:150-77.</reference_text><pubmed_id>20975847</pubmed_id></reference></references></disease><disease>Schizophrenia<references><reference><reference_text>Harnryd C, Bjerkenstedt L, Grimm VE, Sedvall G: Reduction of MOPEG levels in cerebrospinal fluid of psychotic women after electroconvulsive treatment. Psychopharmacology (Berl). 1979 Aug 8;64(2):131-4.</reference_text><pubmed_id>115032</pubmed_id></reference><reference><reference_text>Kobayashi K, Koide Y, Yoshino K, Shohmori T: [P-hydroxyphenylacetic acid concentrations in cerebrospinal fluid]. No To Shinkei. 1982 Aug;34(8):769-74.</reference_text><pubmed_id>7126379</pubmed_id></reference><reference><reference_text>Alfredsson G, Wiesel FA: Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology (Berl). 1989;99(3):322-7.</reference_text><pubmed_id>2480613</pubmed_id></reference><reference><reference_text>Heresco-Levy U, Bar G, Levin R, Ermilov M, Ebstein RP, Javitt DC: High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. Schizophr Res. 2007 Mar;91(1-3):14-21. Epub 2007 Feb 2.</reference_text><pubmed_id>17276036</pubmed_id></reference><reference><reference_text>Walker EF, Bonsall R, Walder DJ: Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis. Neuropsychiatry Neuropsychol Behav Neurol. 2002 Mar;15(1):10-7.</reference_text><pubmed_id>11877547</pubmed_id></reference><reference><reference_text>Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M: Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry. 2003 Jun;60(6):572-6.</reference_text><pubmed_id>12796220</pubmed_id></reference><reference><reference_text>Do KQ, Lauer CJ, Schreiber W, Zollinger M, Gutteck-Amsler U, Cuenod M, Holsboer F: gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem. 1995 Dec;65(6):2652-62.</reference_text><pubmed_id>7595563</pubmed_id></reference><reference><reference_text>Nikisch G, Baumann P, Wiedemann G, Kiessling B, Weisser H, Hertel A, Yoshitake T, Kehr J, Mathe AA: Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF. J Clin Psychopharmacol. 2010 Oct;30(5):496-503. doi: 10.1097/JCP.0b013e3181f2288e.</reference_text><pubmed_id>20814316</pubmed_id></reference><reference><reference_text>Fukushima T, Iizuka H, Yokota A, Suzuki T, Ohno C, Kono Y, Nishikiori M, Seki A, Ichiba H, Watanabe Y, Hongo S, Utsunomiya M, Nakatani M, Sadamoto K, Yoshio T: Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One. 2014 Jul 8;9(7):e101652. doi: 10.1371/journal.pone.0101652. eCollection 2014.</reference_text><pubmed_id>25004141</pubmed_id></reference><reference><reference_text>Koike S, Bundo M, Iwamoto K, Suga M, Kuwabara H, Ohashi Y, Shinoda K, Takano Y, Iwashiro N, Satomura Y, Nagai T, Natsubori T, Tada M, Yamasue H, Kasai K: A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study. Transl Psychiatry. 2014 Apr 8;4:e379. doi: 10.1038/tp.2014.19.</reference_text><pubmed_id>24713860</pubmed_id></reference><reference><reference_text>Ballesteros A, Summerfelt A, Du X, Jiang P, Chiappelli J, Tagamets M, O'Donnell P, Kochunov P, Hong LE: Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia. Clin Neurophysiol. 2013 Nov;124(11):2209-15. doi: 10.1016/j.clinph.2013.05.021. Epub 2013 Jun 30.</reference_text><pubmed_id>23823132</pubmed_id></reference><reference><reference_text>Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel FA: Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry. 1985 Sep;147:276-82.</reference_text><pubmed_id>2415198</pubmed_id></reference><reference><reference_text>Pickar D, Breier A, Hsiao JK, Doran AR, Wolkowitz OM, Pato CN, Konicki PE, Potter WZ: Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Arch Gen Psychiatry. 1990 Jul;47(7):641-8.</reference_text><pubmed_id>1694425</pubmed_id></reference><reference><reference_text>Prell GD, Green JP, Kaufmann CA, Khandelwal JK, Morrishow AM, Kirch DG, Linnoila M, Wyatt RJ: Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res. 1995 Jan;14(2):93-104.</reference_text><pubmed_id>7711000</pubmed_id></reference><reference><reference_text>Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B: Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology. 2009;59(2):123-9. doi: 10.1159/000213565. Epub 2009 Apr 22.</reference_text><pubmed_id>19390223</pubmed_id></reference><reference><reference_text>Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K, Cao Y, Wang X, Qiu Y, Su M, Zhao A, Wang P, Yang P, Wu J, Feng G, He L, Jia W, Wan C: Potential metabolite markers of schizophrenia. Mol Psychiatry. 2013 Jan;18(1):67-78. doi: 10.1038/mp.2011.131. Epub 2011 Oct 25.</reference_text><pubmed_id>22024767</pubmed_id></reference><reference><reference_text>Xuan J, Pan G, Qiu Y, Yang L, Su M, Liu Y, Chen J, Feng G, Fang Y, Jia W, Xing Q, He L: Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. J Proteome Res. 2011 Dec 2;10(12):5433-43. doi: 10.1021/pr2006796. Epub 2011 Nov  8.</reference_text><pubmed_id>22007635</pubmed_id></reference><reference><reference_text>Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM, Rothermundt M, Bogerts B, Koethe D, Kranaster L, Ohrmann P, Suslow T, McAllister G, Spain M, Barnes A, van Beveren NJ, Baron-Cohen S, Steiner J, Torrey FE, Yolken RH, Bahn S: Identification of a biological signature for schizophrenia in serum. Mol Psychiatry. 2012 May;17(5):494-502. doi: 10.1038/mp.2011.42. Epub 2011 Apr 12.</reference_text><pubmed_id>21483431</pubmed_id></reference><reference><reference_text>Mathe AA, Eberhard G, Saaf J, Wetterberg L: Plasma prostaglandin E2 metabolite--measured as 11-deoxy-15-keto-13,14-dihydro-11 beta,16 xi-cyclo-PGE2--in twins with schizophrenic disorder. Biol Psychiatry. 1986 Sep;21(11):1024-30.</reference_text><pubmed_id>3741918</pubmed_id></reference><reference><reference_text>Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N: Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct. 2002 Jun;20(2):171-5.</reference_text><pubmed_id>11979513</pubmed_id></reference><reference><reference_text>Zumarraga M, Davila R, Basterreche N, Arrue A, Goienetxea B, Zamalloa MI, Erkoreka L, Bustamante S, Inchausti L, Gonzalez-Torres MA, Guimon J: Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients. Neurochem Int. 2010 May-Jun;56(6-7):774-9. doi: 10.1016/j.neuint.2010.02.015. Epub 2010 Mar 4.</reference_text><pubmed_id>20206656</pubmed_id></reference><reference><reference_text>Peters JG: Dopamine, noradrenaline and serotonin spinal fluid metabolites in temporal lobe epileptic patients with schizophrenic symptomatology. Eur Neurol. 1979;18(1):15-8.</reference_text><pubmed_id>436860</pubmed_id></reference><reference><reference_text>Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, Rozen S, Krishnan RR, McEvoy J, Kaddurah-Daouk R: Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry. 2010 Sep;15(9):938-53. doi: 10.1038/mp.2009.33. Epub 2009 Apr 28.</reference_text><pubmed_id>19401681</pubmed_id></reference><reference><reference_text>Gattaz WF, Waldmeier P, Beckmann H: CSF monoamine metabolites in schizophrenic patients. Acta Psychiatr Scand. 1982 Nov;66(5):350-60.</reference_text><pubmed_id>6184954</pubmed_id></reference><reference><reference_text>Nilsson-Todd LK, Nordin C, Jonsson EG, Skogh E, Erhardt S: Cerebrospinal fluid kynurenic acid in male patients with schizophrenia - correlation with monoamine metabolites. Acta Neuropsychiatr. 2007 Feb;19(1):45-52. doi: 10.1111/j.1601-5215.2006.00170.x.</reference_text><pubmed_id>26952797</pubmed_id></reference><reference><reference_text>Cai HL, Li HD, Yan XZ, Sun B, Zhang Q, Yan M, Zhang WY, Jiang P, Zhu RH, Liu YP, Fang PF, Xu P, Yuan HY, Zhang XH, Hu L, Yang W, Ye HS: Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naive schizophrenia patients after treatment with risperidone. J Proteome Res. 2012 Aug 3;11(8):4338-50. doi: 10.1021/pr300459d. Epub 2012 Jul 26.</reference_text><pubmed_id>22800120</pubmed_id></reference><reference><reference_text>Al Awam K, Haussleiter IS, Dudley E, Donev R, Brune M, Juckel G, Thome J: Multiplatform metabolome and proteome profiling identifies serum metabolite and protein signatures as prospective biomarkers for schizophrenia. J Neural Transm (Vienna). 2015 Aug;122 Suppl 1:S111-22. doi: 10.1007/s00702-014-1224-0. Epub 2014 May 1.</reference_text><pubmed_id>24789758</pubmed_id></reference><reference><reference_text>Bicikova M, Hill M, Ripova D, Mohr P, Hampl R: Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia. J Steroid Biochem Mol Biol. 2013 Jan;133:77-83. doi: 10.1016/j.jsbmb.2012.08.009. Epub 2012 Aug 24.</reference_text><pubmed_id>22944140</pubmed_id></reference><reference><reference_text>He Y, Yu Z, Giegling I, Xie L, Hartmann AM, Prehn C, Adamski J, Kahn R, Li Y, Illig T, Wang-Sattler R, Rujescu D: Schizophrenia shows a unique metabolomics signature in plasma. Transl Psychiatry. 2012 Aug 14;2:e149. doi: 10.1038/tp.2012.76.</reference_text><pubmed_id>22892715</pubmed_id></reference><reference><reference_text>Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KR: Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):934-45. Epub 2007 Apr 17.</reference_text><pubmed_id>17440431</pubmed_id></reference><reference><reference_text>Fryar-Williams S, Strobel JE: Biomarkers of a five-domain translational substrate for schizophrenia and schizoaffective psychosis. Biomark Res. 2015 Feb 6;3:3. doi: 10.1186/s40364-015-0028-1. eCollection 2015.</reference_text><pubmed_id>25729574</pubmed_id></reference><reference><reference_text>Oresic M, Seppanen-Laakso T, Sun D, Tang J, Therman S, Viehman R, Mustonen U, van Erp TG, Hyotylainen T, Thompson P, Toga AW, Huttunen MO, Suvisaari J, Kaprio J, Lonnqvist J, Cannon TD: Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia. Genome Med. 2012 Jan 18;4(1):1. doi: 10.1186/gm300.</reference_text><pubmed_id>22257447</pubmed_id></reference></references></disease><disease>Primary hypomagnesemia<references><reference><reference_text>Jin-no Y, Kamiya Y, Okada M, Hirako M, Takada N, Kawaguchi M: Primary hypomagnesemia caused by isolated magnesium malabsorption: atypical case in adult. Intern Med. 1999 Mar;38(3):261-5.</reference_text><pubmed_id>10337938</pubmed_id></reference><reference><reference_text>Vainsel M, Vandevelde G, Smulders J, Vosters M, Hubain P, Loeb H: Tetany due to hypomagnesaemia with secondary hypocalcaemia. Arch Dis Child. 1970 Apr;45(240):254-8.</reference_text><pubmed_id>5419995</pubmed_id></reference><reference><reference_text>Shalev H, Phillip M, Galil A, Carmi R, Landau D: Clinical presentation and outcome in primary familial hypomagnesaemia. Arch Dis Child. 1998 Feb;78(2):127-30.</reference_text><pubmed_id>9579153</pubmed_id></reference><reference><reference_text>Kari JA, Farouq M, Alshaya HO: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Pediatr Nephrol. 2003 Jun;18(6):506-10. Epub 2003 Apr 29.</reference_text><pubmed_id>12720080</pubmed_id></reference></references></disease><disease>Hyperlipoproteinemia<references><reference><reference_text>Sinha S, Misra A, Kumar V, Jagannathan NR, Bal CS, Pandey RM, Singhania R, Deepak: Proton magnetic resonance spectroscopy and single photon emission computed tomography study of the brain in asymptomatic young hyperlipidaemic Asian Indians in North India show early abnormalities. Clin Endocrinol (Oxf). 2004 Aug;61(2):182-9.</reference_text><pubmed_id>15272912</pubmed_id></reference><reference><reference_text>Nelson RH: Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013 Mar</reference_text><pubmed_id>40(1):195-211. doi: 10.1016/j.pop.2012.11.003. Epub 2012 Dec  4.</pubmed_id></reference><reference><reference_text>Cantin B, Boudriau S, Bertrand M, Brun LD, Gagne C, Rogers PA, Ven Murthy MR, Lupien PJ, Julien P: Hemolysis in primary lipoprotein lipase deficiency. Metabolism. 1995 May;44(5):652-8.</reference_text><pubmed_id>7752915</pubmed_id></reference></references></disease><disease>Abetalipoproteinemia<references><reference><reference_text>Dawson G, Kruski AW, Scanu AM: Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J Lipid Res. 1976 Mar;17(2):125-31.</reference_text><pubmed_id>178813</pubmed_id></reference><reference><reference_text>Lazaro RP, Dentinger MP, Rodichok LD, Barron KD, Satya-Murti S: Muscle pathology in Bassen-Kornzweig syndrome and vitamin E deficiency. Am J Clin Pathol. 1986 Sep;86(3):378-87.</reference_text><pubmed_id>2944375</pubmed_id></reference></references></disease><disease>Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis<references><reference><reference_text>Breckenridge WC, Alaupovic P, Cox DW, Little JA: Apolipoprotein and lipoprotein concentrations in familial apolipoprotein C-II deficiency. Atherosclerosis. 1982 Aug;44(2):223-35.</reference_text><pubmed_id>7138621</pubmed_id></reference><reference><reference_text>Fukami M, Hasegawa T, Horikawa R, Ohashi T, Nishimura G, Homma K, Ogata T: Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr Res. 2006 Feb;59(2):276-80. doi: 10.1203/01.pdr.0000195825.31504.28.</reference_text><pubmed_id>16439592</pubmed_id></reference></references></disease><disease>Cerebrotendinous xanthomatosis<references><reference><reference_text>Halperin G, Elisaf M, Leitersdorf E, Harats D: A new method for determination of serum cholestanol by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2000 Jun 9;742(2):345-52.</reference_text><pubmed_id>10901139</pubmed_id></reference><reference><reference_text>Siman-Tov T, Meiner V, Gadoth N: Could steroids mask the diagnosis of cerebrotendinous xanthomatosis? J Neurol Sci. 2006 Apr 15;243(1-2):83-6. Epub 2006 Jan 30.</reference_text><pubmed_id>16445943</pubmed_id></reference><reference><reference_text>Agrawal NK, Garg S: Cerebrotendinous xanthomatosis: a rare disorder with a rare presentation. BMJ Case Rep. 2012 Sep 21;2012. pii: bcr-2012-006202. doi: 10.1136/bcr-2012-006202.</reference_text><pubmed_id>23001091</pubmed_id></reference></references></disease><disease>3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency<references><reference><reference_text>Thompson GN, Hsu BY, Pitt JJ, Treacy E, Stanley CA: Fasting hypoketotic coma in a child with deficiency of mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase. N Engl J Med. 1997 Oct 23;337(17):1203-7. doi: 10.1056/NEJM199710233371704.</reference_text><pubmed_id>9337379</pubmed_id></reference><reference><reference_text>Morris AA, Lascelles CV, Olpin SE, Lake BD, Leonard JV, Quant PA: Hepatic mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme a synthase deficiency. Pediatr Res. 1998 Sep;44(3):392-6. doi: 10.1203/00006450-199809000-00021.</reference_text><pubmed_id>9727719</pubmed_id></reference><reference><reference_text>Conboy E, Vairo F, Schultz M, Agre K, Ridsdale R, Deyle D, Oglesbee D, Gavrilov D, Klee EW, Lanpher B: Mitochondrial 3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency: Unique Presenting Laboratory Values and a Review of Biochemical and Clinical Features. JIMD Rep. 2017 Oct 14. doi: 10.1007/8904_2017_59.</reference_text><pubmed_id>29030856</pubmed_id></reference></references></disease><disease>Hypercholesterolemia, familial<references><reference><reference_text>Kwiterovich PO Jr, Fredrickson DS, Levy RI: Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest. 1974 May;53(5):1237-49. doi: 10.1172/JCI107670.</reference_text><pubmed_id>4363406</pubmed_id></reference></references></disease><disease>SC4MOL deficiency<references><reference><reference_text>He M, Kratz LE, Michel JJ, Vallejo AN, Ferris L, Kelley RI, Hoover JJ, Jukic D, Gibson KM, Wolfe LA, Ramachandran D, Zwick ME, Vockley J: Mutations in the human SC4MOL gene encoding a methyl sterol oxidase cause psoriasiform dermatitis, microcephaly, and developmental delay. J Clin Invest. 2011 Mar;121(3):976-84. doi: 10.1172/JCI42650.</reference_text><pubmed_id>21285510</pubmed_id></reference></references></disease><disease>Chondrodysplasia punctata, X-linked dominant<references><reference><reference_text>Aughton DJ, Kelley RI, Metzenberg A, Pureza V, Pauli RM: X-linked dominant chondrodysplasia punctata (CDPX2) caused by single gene mosaicism in a male. Am J Med Genet A. 2003 Jan 30;116A(3):255-60. doi: 10.1002/ajmg.a.10852.</reference_text><pubmed_id>12503102</pubmed_id></reference></references></disease><disease>Desmosterolosis<references><reference><reference_text>Andersson HC, Kratz L, Kelley R: Desmosterolosis presenting with multiple congenital anomalies and profound developmental delay. Am J Med Genet. 2002 Dec 15;113(4):315-9. doi: 10.1002/ajmg.b.10873.</reference_text><pubmed_id>12457401</pubmed_id></reference></references></disease><disease>Donohue Syndrome<references><reference><reference_text>Nijim Y, Awni Y, Adawi A, Bowirrat A: Classic Case Report of Donohue Syndrome (Leprechaunism; OMIM *246200): The Impact of Consanguineous Mating. Medicine (Baltimore). 2016 Feb;95(6):e2710. doi: 10.1097/MD.0000000000002710.</reference_text><pubmed_id>26871809</pubmed_id></reference></references></disease><disease>Leptin Deficiency or Dysfunction<references><reference><reference_text>Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O'Rahilly S: Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999 Sep 16;341(12):879-84. doi: 10.1056/NEJM199909163411204.</reference_text><pubmed_id>10486419</pubmed_id></reference></references></disease><disease>Duchenne Muscular Dystrophy<references><reference><reference_text>Nakagawa T, Takeuchi A, Kakiuchi R, Lee T, Yagi M, Awano H, Iijima K, Takeshima Y, Urade Y, Matsuo M: A prostaglandin D2 metabolite is elevated in the urine of Duchenne muscular dystrophy patients and increases further from 8 years old. Clin Chim Acta. 2013 Aug 23;423:10-4. doi: 10.1016/j.cca.2013.03.031. Epub 2013 Apr 19.</reference_text><pubmed_id>23603101</pubmed_id></reference><reference><reference_text>Srivastava NK, Pradhan S, Mittal B, Gowda GA: High resolution NMR based analysis of serum lipids in Duchenne muscular dystrophy patients and its possible diagnostic significance. NMR Biomed. 2010 Jan;23(1):13-22. doi: 10.1002/nbm.1419.</reference_text><pubmed_id>19787747</pubmed_id></reference><reference><reference_text>Horster I, Weigt-Usinger K, Carmann C, Chobanyan-Jurgens K, Kohler C, Schara U, Kayacelebi AA, Beckmann B, Tsikas D, Lucke T: The L-arginine/NO pathway and homoarginine are altered in Duchenne muscular dystrophy and improved by glucocorticoids. Amino Acids. 2015 Sep;47(9):1853-63. doi: 10.1007/s00726-015-2018-x. Epub 2015 Jun 12.</reference_text><pubmed_id>26066683</pubmed_id></reference></references></disease><disease>Lecithin:cholesterol Acyltransferase Deficiency<references><reference><reference_text>Idzior-Walus B, Sieradzki J, Kostner G, Malecki MT, Klupa T, Wesolowska T, Rostworowski W, Hartwich J, Walus M, Kiec AD, Naruszewicz M: Familial lecithin-cholesterol acyltransferase deficiency: biochemical characteristics and molecular analysis of a new LCAT mutation in a Polish family. Atherosclerosis. 2006 Apr;185(2):413-20. Epub 2005 Jul 26.</reference_text><pubmed_id>16051254</pubmed_id></reference></references></disease><disease>Lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lipodystrophy, Congenital Generalized<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Oculocerebrorenal syndrome<references><reference><reference_text>Charnas LR, Bernardini I, Rader D, Hoeg JM, Gahl WA: Clinical and laboratory findings in the oculocerebrorenal syndrome of Lowe, with special reference to growth and renal function. N Engl J Med. 1991 May 9;324(19):1318-25. doi: 10.1056/NEJM199105093241904.</reference_text><pubmed_id>2017228</pubmed_id></reference></references></disease><disease>Familial partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lathosterolosis<references><reference><reference_text>Brunetti-Pierri N, Corso G, Rossi M, Ferrari P, Balli F, Rivasi F, Annunziata I, Ballabio A, Russo AD, Andria G, Parenti G: Lathosterolosis, a novel multiple-malformation/mental retardation syndrome due to deficiency of 3beta-hydroxysteroid-delta5-desaturase. Am J Hum Genet. 2002 Oct;71(4):952-8. Epub 2002 Aug 20.</reference_text><pubmed_id>12189593</pubmed_id></reference><reference><reference_text>Ho AC, Fung CW, Siu TS, Ma OC, Lam CW, Tam S, Wong VC: Lathosterolosis: a disorder of cholesterol biosynthesis resembling smith-lemli-opitz syndrome. JIMD Rep. 2014;12:129-34. doi: 10.1007/8904_2013_255. Epub 2013 Oct 20.</reference_text><pubmed_id>24142275</pubmed_id></reference></references></disease><disease>Partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Multiple sclerosis<references><reference><reference_text>Lutz NW, Viola A, Malikova I, Confort-Gouny S, Audoin B, Ranjeva JP, Pelletier J, Cozzone PJ: Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One. 2007 Jul 4;2(7):e595.</reference_text><pubmed_id>17611627</pubmed_id></reference><reference><reference_text>Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U, Hillert J, Bjorkhem I: Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med. 2004 Feb;42(2):186-91.</reference_text><pubmed_id>15061359</pubmed_id></reference><reference><reference_text>Leoni V, Lutjohann D, Masterman T: Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis. J Lipid Res. 2005 Feb;46(2):191-5. Epub 2004 Dec 1.</reference_text><pubmed_id>15576852</pubmed_id></reference><reference><reference_text>Calabrese V, Scapagnini G, Ravagna A, Bella R, Butterfield DA, Calvani M, Pennisi G, Giuffrida Stella AM: Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem Res. 2003 Sep;28(9):1321-8.</reference_text><pubmed_id>12938853</pubmed_id></reference><reference><reference_text>Shaw CE, Dunbar PR, Macaulay HA, Neale TJ: Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol. 1995 Jan;242(2):53-8.</reference_text><pubmed_id>7707089</pubmed_id></reference><reference><reference_text>Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.</reference_text><pubmed_id>17384003</pubmed_id></reference><reference><reference_text>Syburra C, Passi S: Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh (1999). 1999 May-Jun;71(3):112-5.</reference_text><pubmed_id>10609336</pubmed_id></reference><reference><reference_text>Forte G, Visconti A, Santucci S, Ghazaryan A, Figa-Talamanca L, Cannoni S, Bocca B, Pino A, Violante N, Alimonti A, Salvetti M, Ristori G: Quantification of chemical elements in blood of patients affected by multiple sclerosis. Ann Ist Super Sanita. 2005;41(2):213-6.</reference_text><pubmed_id>16244395</pubmed_id></reference><reference><reference_text>Toncev G, Milicic B, Toncev S, Samardzic G: Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol. 2002 May;9(3):221-6.</reference_text><pubmed_id>11985629</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, Bamonti F, Capello E, Mancardi GL, Scarpini E: Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res. 2010 May 28;1333:64-71. doi: 10.1016/j.brainres.2010.03.073. Epub 2010 Mar 27.</reference_text><pubmed_id>20347721</pubmed_id></reference><reference><reference_text>Matsushita T, Isobe N, Kawajiri M, Mogi M, Tsukuda K, Horiuchi M, Ohyagi Y, Kira J: CSF angiotensin II and angiotensin-converting enzyme levels in anti-aquaporin-4 autoimmunity. J Neurol Sci. 2010 Aug 15;295(1-2):41-5. doi: 10.1016/j.jns.2010.05.014. Epub 2010 Jun 11.</reference_text><pubmed_id>20541774</pubmed_id></reference><reference><reference_text>Ghabaee M, Jabedari B, Al-E-Eshagh N, Ghaffarpour M, Asadi F: Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients. Int J Neurosci. 2010 Apr;120(4):301-4. doi: 10.3109/00207451003695690.</reference_text><pubmed_id>20374079</pubmed_id></reference><reference><reference_text>Kawajiri M, Mogi M, Osoegawa M, Matsuoka T, Tsukuda K, Kohara K, Horiuchi M, Miki T, Kira JI: Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler. 2008 May;14(4):557-60. doi: 10.1177/1352458507085760.</reference_text><pubmed_id>18562510</pubmed_id></reference><reference><reference_text>Visconti A, Cotichini R, Cannoni S, Bocca B, Forte G, Ghazaryan A, Santucci S, D'Ippolito C, Stazi MA, Salvetti M, Alimonti A, Ristori G: Concentration of elements in serum of patients affected by multiple sclerosis with first demyelinating episode: a six-month longitudinal follow-up study. Ann Ist Super Sanita. 2005;41(2):217-22.</reference_text><pubmed_id>16244396</pubmed_id></reference></references></disease><disease>Inflammatory bowel disease<references><reference><reference_text>Lee T, Clavel T, Smirnov K, Schmidt A, Lagkouvardos I, Walker A, Lucio M, Michalke B, Schmitt-Kopplin P, Fedorak R, Haller D: Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. 2017 May;66(5):863-871. doi: 10.1136/gutjnl-2015-309940. Epub 2016 Feb 4.</reference_text><pubmed_id>26848182</pubmed_id></reference><reference><reference_text>Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158.</reference_text><pubmed_id>27609529</pubmed_id></reference></references></disease><disease>Colorectal cancer<references><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B: Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009 Apr;22(3):342-8. doi: 10.1002/nbm.1345.</reference_text><pubmed_id>19006102</pubmed_id></reference><reference><reference_text>Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP: Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One. 2013 Aug 6;8(8):e70803. doi: 10.1371/journal.pone.0070803. Print 2013.</reference_text><pubmed_id>23940645</pubmed_id></reference><reference><reference_text>Phua LC, Chue XP, Koh PK, Cheah PY, Ho HK, Chan EC: Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biol Ther. 2014 Apr;15(4):389-97. doi: 10.4161/cbt.27625. Epub 2014 Jan 14.</reference_text><pubmed_id>24424155</pubmed_id></reference><reference><reference_text>Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB: Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010 Feb 15;8:13. doi: 10.1186/1741-7015-8-13.</reference_text><pubmed_id>20156336</pubmed_id></reference><reference><reference_text>Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, Ni Y, Zhao A, Xu LX, Cai S, Jia W: Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res. 2009 Oct;8(10):4844-50. doi: 10.1021/pr9004162.</reference_text><pubmed_id>19678709</pubmed_id></reference><reference><reference_text>Cheng Y, Xie G, Chen T, Qiu Y, Zou X, Zheng M, Tan B, Feng B, Dong T, He P, Zhao L, Zhao A, Xu LX, Zhang Y, Jia W: Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res. 2012 Feb 3;11(2):1354-63. doi: 10.1021/pr201001a. Epub 2011 Dec 28.</reference_text><pubmed_id>22148915</pubmed_id></reference><reference><reference_text>Ni Y, Xie G, Jia W: Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res. 2014 Sep 5;13(9):3857-70. doi: 10.1021/pr500443c. Epub 2014 Aug 14.</reference_text><pubmed_id>25105552</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference><reference><reference_text>Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18.</reference_text><pubmed_id>25037050</pubmed_id></reference><reference><reference_text>Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016.</reference_text><pubmed_id>27015276</pubmed_id></reference><reference><reference_text>Lin Y, Ma C, Liu C, Wang Z, Yang J, Liu X, Shen Z, Wu R: NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer. Oncotarget. 2016 May 17;7(20):29454-64. doi: 10.18632/oncotarget.8762.</reference_text><pubmed_id>27107423</pubmed_id></reference><reference><reference_text>Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016.</reference_text><pubmed_id>27275383</pubmed_id></reference><reference><reference_text>Wang X, Wang J, Rao B, Deng L: Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals. Exp Ther Med. 2017 Jun;13(6):2848-2854. doi: 10.3892/etm.2017.4367. Epub 2017 Apr 20.</reference_text><pubmed_id>28587349</pubmed_id></reference><reference><reference_text>Silke Matysik, Caroline Ivanne Le Roy, Gerhard Liebisch, Sandrine Paule Claus. Metabolomics of fecal samples: A practical consideration. Trends in Food Science &amp; Technology. Vol. 57, Part B, Nov. 2016, p.244-255: http://www.sciencedirect.com/science/article/pii/S0924224416301984</reference_text><pubmed_id>28587349</pubmed_id></reference></references></disease><disease>Gallbladder disease<references><reference><reference_text>Lapidus A, Akerlund JE, Einarsson C: Gallbladder bile composition in patients with Crohn 's disease. World J Gastroenterol. 2006 Jan 7;12(1):70-4.</reference_text><pubmed_id>16440420</pubmed_id></reference><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference><reference><reference_text>Mizuno S, Tazuma S, Kajiyama G: Stabilization of biliary lipid particles by ursodeoxycholic acid. Prolonged nucleation time in human gallbladder bile. Dig Dis Sci. 1993 Apr;38(4):684-93.</reference_text><pubmed_id>8462368</pubmed_id></reference><reference><reference_text>Hillebrant CG, Axelson M, Bjorkhem I, Wang FH, Nyberg B, Einarsson C: Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients. Eur J Clin Invest. 1998 Apr;28(4):324-8.</reference_text><pubmed_id>9615912</pubmed_id></reference></references></disease><disease>Cholelithiasis<references><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference></references></disease><disease>Stomach cancer<references><reference><reference_text>Higashijima H, Ichimiya H, Nakano T, Yamashita H, Kuroki S, Satoh H, Chijiiwa K, Tanaka M: Deconjugation of bilirubin accelerates coprecipitation of cholesterol, fatty acids, and mucin in human bile--in vitro study. J Gastroenterol. 1996 Dec;31(6):828-35.</reference_text><pubmed_id>9027647</pubmed_id></reference><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Song H, Peng JS, Dong-Sheng Y, Yang ZL, Liu HL, Zeng YK, Shi XP, Lu BY: Serum metabolic profiling of human gastric cancer based on gas chromatography/mass spectrometry. Braz J Med Biol Res. 2012 Jan;45(1):78-85. Epub 2011 Nov 25.</reference_text><pubmed_id>22124703</pubmed_id></reference><reference><reference_text>Yu L, Aa J, Xu J, Sun M, Qian S, Cheng L, Yang S, Shi R: Metabolomic phenotype of gastric cancer and precancerous stages based on gas chromatography time-of-flight mass spectrometry. J Gastroenterol Hepatol. 2011 Aug;26(8):1290-7. doi: 10.1111/j.1440-1746.2011.06724.x.</reference_text><pubmed_id>21443661</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference></references></disease><disease>Acute myelogenous leukemia<references><reference><reference_text>Tatidis L, Vitols S, Gruber A, Paul C, Axelson M: Cholesterol catabolism in patients with acute myelogenous leukemia and hypocholesterolemia: suppressed levels of a circulating marker for bile acid synthesis. Cancer Lett. 2001 Sep 20;170(2):169-75.</reference_text><pubmed_id>11463495</pubmed_id></reference></references></disease><disease>Hypercholesterolemia<references><reference><reference_text>Thelen KM, Laaksonen R, Paiva H, Lehtimaki T, Lutjohann D: High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels. J Clin Pharmacol. 2006 Jul;46(7):812-6.</reference_text><pubmed_id>16809807</pubmed_id></reference><reference><reference_text>Tamasawa N, Tamasawa A, Takebe K: Higher levels of plasma cholesterol sulfate in patients with liver cirrhosis and hypercholesterolemia. Lipids. 1993 Sep;28(9):833-6.</reference_text><pubmed_id>8231659</pubmed_id></reference><reference><reference_text>Kim DH, Lee KJ, Heo GS: Analysis of cholesterol and cholesteryl esters in human serum using capillary supercritical fluid chromatography. J Chromatogr B Biomed Appl. 1994 Apr 22;655(1):1-8.</reference_text><pubmed_id>8061816</pubmed_id></reference><reference><reference_text>Authors unspecified: Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med. 1988 Jan;148(1):36-69.</reference_text><pubmed_id>3422148</pubmed_id></reference></references></disease><disease>Cholesteryl ester storage disease<references><reference><reference_text>Rassoul F, Richter V, Lohse P, Naumann A, Purschwitz K, Keller E: Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease. Int J Clin Pharmacol Ther. 2001 May;39(5):199-204.</reference_text><pubmed_id>11380065</pubmed_id></reference><reference><reference_text>Chatrath H, Keilin S, Attar BM: Cholesterol ester storage disease (CESD) diagnosed in an asymptomatic adult. Dig Dis Sci. 2009 Jan;54(1):168-73. doi: 10.1007/s10620-008-0310-2. Epub 2008 May 14.</reference_text><pubmed_id>18478331</pubmed_id></reference><reference><reference_text>Bernstein DL, Hulkova H, Bialer MG, Desnick RJ: Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol. 2013 Jun;58(6):1230-43. doi: 10.1016/j.jhep.2013.02.014. Epub 2013 Feb 26.</reference_text><pubmed_id>23485521</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Cystinosis<references><reference><reference_text>Ueda M, O'Brien K, Rosing DR, Ling A, Kleta R, McAreavey D, Bernardini I, Gahl WA: Coronary artery and other vascular calcifications in patients with cystinosis after kidney transplantation. Clin J Am Soc Nephrol. 2006 May;1(3):555-62. Epub 2006 Feb 8.</reference_text><pubmed_id>17699259</pubmed_id></reference><reference><reference_text>Gahl WA, Bernardini I, Dalakas M, Rizzo WB, Harper GS, Hoeg JM, Hurko O, Bernar J: Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome. J Clin Invest. 1988 Feb;81(2):549-60.</reference_text><pubmed_id>3276734</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Smith-Lemli-Opitz syndrome<references><reference><reference_text>van Rooij A, Nijenhuis AA, Wijburg FA, Schutgens RB: Highly increased CSF concentrations of cholesterol precursors in Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 1997 Aug;20(4):578-80.</reference_text><pubmed_id>9266395</pubmed_id></reference><reference><reference_text>Honda M, Tint GS, Honda A, Salen G, Shefer S, Batta AK, Matsuzaki Y, Tanaka N: Regulation of cholesterol biosynthetic pathway in patients with the Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2000 Jul;23(5):464-74.</reference_text><pubmed_id>10947201</pubmed_id></reference><reference><reference_text>Rossi M, Federico G, Corso G, Parenti G, Battagliese A, Frascogna AR, Della Casa R, Dello Russo A, Strisciuglio P, Saggese G, Andria G: Vitamin D status in patients affected by Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2005;28(1):69-80.</reference_text><pubmed_id>15702407</pubmed_id></reference><reference><reference_text>Johnson DW, ten Brink HJ, Jakobs C: A rapid screening procedure for cholesterol and dehydrocholesterol by electrospray ionization tandem mass spectrometry. J Lipid Res. 2001 Oct;42(10):1699-705.</reference_text><pubmed_id>11590227</pubmed_id></reference></references></disease><disease>Prostate cancer<references><reference><reference_text>Nyman DW, Suzanne Stratton M, Kopplin MJ, Dalkin BL, Nagle RB, Jay Gandolfi A: Selenium and selenomethionine levels in prostate cancer patients. Cancer Detect Prev. 2004;28(1):8-16.</reference_text><pubmed_id>15041072</pubmed_id></reference><reference><reference_text>Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, Egevad L, Tjonneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, Palli D, Vineis P, Tumino R, Berrino F, Kiemeney L, Bueno-de-Mesquita HB, Quiros JR, Gonzalez CA, Martinez C, Larranaga N, Chirlaque MD, Ardanaz E, Stattin P, Hallmans G, Khaw KT, Bingham S, Slimani N, Ferrari P, Rinaldi S, Riboli E: Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr. 2007 Sep;86(3):672-81.</reference_text><pubmed_id>17823432</pubmed_id></reference><reference><reference_text>Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762.</reference_text><pubmed_id>19212411</pubmed_id></reference><reference><reference_text>Puah CM, Williams G, Ghanadian R: Urinary unconjugated 5 alpha-androstane-3 alpha, 17 beta-diol in patients with prostatic tumours. Urol Res. 1982;10(2):81-4.</reference_text><pubmed_id>6180540</pubmed_id></reference><reference><reference_text>Thysell E, Surowiec I, Hornberg E, Crnalic S, Widmark A, Johansson AI, Stattin P, Bergh A, Moritz T, Antti H, Wikstrom P: Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One. 2010 Dec 3;5(12):e14175. doi: 10.1371/journal.pone.0014175.</reference_text><pubmed_id>21151972</pubmed_id></reference><reference><reference_text>Soliman LC, Hui Y, Hewavitharana AK, Chen DD: Monitoring potential prostate cancer biomarkers in urine by capillary electrophoresis-tandem mass spectrometry. J Chromatogr A. 2012 Dec 7;1267:162-9. doi: 10.1016/j.chroma.2012.07.021. Epub 2012 Jul 14.</reference_text><pubmed_id>22824219</pubmed_id></reference><reference><reference_text>Madu CO, Lu Y: Novel diagnostic biomarkers for prostate cancer. J Cancer. 2010 Oct 6;1:150-77.</reference_text><pubmed_id>20975847</pubmed_id></reference></references></disease><disease>Schizophrenia<references><reference><reference_text>Harnryd C, Bjerkenstedt L, Grimm VE, Sedvall G: Reduction of MOPEG levels in cerebrospinal fluid of psychotic women after electroconvulsive treatment. Psychopharmacology (Berl). 1979 Aug 8;64(2):131-4.</reference_text><pubmed_id>115032</pubmed_id></reference><reference><reference_text>Kobayashi K, Koide Y, Yoshino K, Shohmori T: [P-hydroxyphenylacetic acid concentrations in cerebrospinal fluid]. No To Shinkei. 1982 Aug;34(8):769-74.</reference_text><pubmed_id>7126379</pubmed_id></reference><reference><reference_text>Alfredsson G, Wiesel FA: Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology (Berl). 1989;99(3):322-7.</reference_text><pubmed_id>2480613</pubmed_id></reference><reference><reference_text>Heresco-Levy U, Bar G, Levin R, Ermilov M, Ebstein RP, Javitt DC: High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. Schizophr Res. 2007 Mar;91(1-3):14-21. Epub 2007 Feb 2.</reference_text><pubmed_id>17276036</pubmed_id></reference><reference><reference_text>Walker EF, Bonsall R, Walder DJ: Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis. Neuropsychiatry Neuropsychol Behav Neurol. 2002 Mar;15(1):10-7.</reference_text><pubmed_id>11877547</pubmed_id></reference><reference><reference_text>Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M: Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry. 2003 Jun;60(6):572-6.</reference_text><pubmed_id>12796220</pubmed_id></reference><reference><reference_text>Do KQ, Lauer CJ, Schreiber W, Zollinger M, Gutteck-Amsler U, Cuenod M, Holsboer F: gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem. 1995 Dec;65(6):2652-62.</reference_text><pubmed_id>7595563</pubmed_id></reference><reference><reference_text>Nikisch G, Baumann P, Wiedemann G, Kiessling B, Weisser H, Hertel A, Yoshitake T, Kehr J, Mathe AA: Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF. J Clin Psychopharmacol. 2010 Oct;30(5):496-503. doi: 10.1097/JCP.0b013e3181f2288e.</reference_text><pubmed_id>20814316</pubmed_id></reference><reference><reference_text>Fukushima T, Iizuka H, Yokota A, Suzuki T, Ohno C, Kono Y, Nishikiori M, Seki A, Ichiba H, Watanabe Y, Hongo S, Utsunomiya M, Nakatani M, Sadamoto K, Yoshio T: Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One. 2014 Jul 8;9(7):e101652. doi: 10.1371/journal.pone.0101652. eCollection 2014.</reference_text><pubmed_id>25004141</pubmed_id></reference><reference><reference_text>Koike S, Bundo M, Iwamoto K, Suga M, Kuwabara H, Ohashi Y, Shinoda K, Takano Y, Iwashiro N, Satomura Y, Nagai T, Natsubori T, Tada M, Yamasue H, Kasai K: A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study. Transl Psychiatry. 2014 Apr 8;4:e379. doi: 10.1038/tp.2014.19.</reference_text><pubmed_id>24713860</pubmed_id></reference><reference><reference_text>Ballesteros A, Summerfelt A, Du X, Jiang P, Chiappelli J, Tagamets M, O'Donnell P, Kochunov P, Hong LE: Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia. Clin Neurophysiol. 2013 Nov;124(11):2209-15. doi: 10.1016/j.clinph.2013.05.021. Epub 2013 Jun 30.</reference_text><pubmed_id>23823132</pubmed_id></reference><reference><reference_text>Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel FA: Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry. 1985 Sep;147:276-82.</reference_text><pubmed_id>2415198</pubmed_id></reference><reference><reference_text>Pickar D, Breier A, Hsiao JK, Doran AR, Wolkowitz OM, Pato CN, Konicki PE, Potter WZ: Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Arch Gen Psychiatry. 1990 Jul;47(7):641-8.</reference_text><pubmed_id>1694425</pubmed_id></reference><reference><reference_text>Prell GD, Green JP, Kaufmann CA, Khandelwal JK, Morrishow AM, Kirch DG, Linnoila M, Wyatt RJ: Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res. 1995 Jan;14(2):93-104.</reference_text><pubmed_id>7711000</pubmed_id></reference><reference><reference_text>Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B: Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology. 2009;59(2):123-9. doi: 10.1159/000213565. Epub 2009 Apr 22.</reference_text><pubmed_id>19390223</pubmed_id></reference><reference><reference_text>Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K, Cao Y, Wang X, Qiu Y, Su M, Zhao A, Wang P, Yang P, Wu J, Feng G, He L, Jia W, Wan C: Potential metabolite markers of schizophrenia. Mol Psychiatry. 2013 Jan;18(1):67-78. doi: 10.1038/mp.2011.131. Epub 2011 Oct 25.</reference_text><pubmed_id>22024767</pubmed_id></reference><reference><reference_text>Xuan J, Pan G, Qiu Y, Yang L, Su M, Liu Y, Chen J, Feng G, Fang Y, Jia W, Xing Q, He L: Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. J Proteome Res. 2011 Dec 2;10(12):5433-43. doi: 10.1021/pr2006796. Epub 2011 Nov  8.</reference_text><pubmed_id>22007635</pubmed_id></reference><reference><reference_text>Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM, Rothermundt M, Bogerts B, Koethe D, Kranaster L, Ohrmann P, Suslow T, McAllister G, Spain M, Barnes A, van Beveren NJ, Baron-Cohen S, Steiner J, Torrey FE, Yolken RH, Bahn S: Identification of a biological signature for schizophrenia in serum. Mol Psychiatry. 2012 May;17(5):494-502. doi: 10.1038/mp.2011.42. Epub 2011 Apr 12.</reference_text><pubmed_id>21483431</pubmed_id></reference><reference><reference_text>Mathe AA, Eberhard G, Saaf J, Wetterberg L: Plasma prostaglandin E2 metabolite--measured as 11-deoxy-15-keto-13,14-dihydro-11 beta,16 xi-cyclo-PGE2--in twins with schizophrenic disorder. Biol Psychiatry. 1986 Sep;21(11):1024-30.</reference_text><pubmed_id>3741918</pubmed_id></reference><reference><reference_text>Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N: Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct. 2002 Jun;20(2):171-5.</reference_text><pubmed_id>11979513</pubmed_id></reference><reference><reference_text>Zumarraga M, Davila R, Basterreche N, Arrue A, Goienetxea B, Zamalloa MI, Erkoreka L, Bustamante S, Inchausti L, Gonzalez-Torres MA, Guimon J: Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients. Neurochem Int. 2010 May-Jun;56(6-7):774-9. doi: 10.1016/j.neuint.2010.02.015. Epub 2010 Mar 4.</reference_text><pubmed_id>20206656</pubmed_id></reference><reference><reference_text>Peters JG: Dopamine, noradrenaline and serotonin spinal fluid metabolites in temporal lobe epileptic patients with schizophrenic symptomatology. Eur Neurol. 1979;18(1):15-8.</reference_text><pubmed_id>436860</pubmed_id></reference><reference><reference_text>Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, Rozen S, Krishnan RR, McEvoy J, Kaddurah-Daouk R: Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry. 2010 Sep;15(9):938-53. doi: 10.1038/mp.2009.33. Epub 2009 Apr 28.</reference_text><pubmed_id>19401681</pubmed_id></reference><reference><reference_text>Gattaz WF, Waldmeier P, Beckmann H: CSF monoamine metabolites in schizophrenic patients. Acta Psychiatr Scand. 1982 Nov;66(5):350-60.</reference_text><pubmed_id>6184954</pubmed_id></reference><reference><reference_text>Nilsson-Todd LK, Nordin C, Jonsson EG, Skogh E, Erhardt S: Cerebrospinal fluid kynurenic acid in male patients with schizophrenia - correlation with monoamine metabolites. Acta Neuropsychiatr. 2007 Feb;19(1):45-52. doi: 10.1111/j.1601-5215.2006.00170.x.</reference_text><pubmed_id>26952797</pubmed_id></reference><reference><reference_text>Cai HL, Li HD, Yan XZ, Sun B, Zhang Q, Yan M, Zhang WY, Jiang P, Zhu RH, Liu YP, Fang PF, Xu P, Yuan HY, Zhang XH, Hu L, Yang W, Ye HS: Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naive schizophrenia patients after treatment with risperidone. J Proteome Res. 2012 Aug 3;11(8):4338-50. doi: 10.1021/pr300459d. Epub 2012 Jul 26.</reference_text><pubmed_id>22800120</pubmed_id></reference><reference><reference_text>Al Awam K, Haussleiter IS, Dudley E, Donev R, Brune M, Juckel G, Thome J: Multiplatform metabolome and proteome profiling identifies serum metabolite and protein signatures as prospective biomarkers for schizophrenia. J Neural Transm (Vienna). 2015 Aug;122 Suppl 1:S111-22. doi: 10.1007/s00702-014-1224-0. Epub 2014 May 1.</reference_text><pubmed_id>24789758</pubmed_id></reference><reference><reference_text>Bicikova M, Hill M, Ripova D, Mohr P, Hampl R: Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia. J Steroid Biochem Mol Biol. 2013 Jan;133:77-83. doi: 10.1016/j.jsbmb.2012.08.009. Epub 2012 Aug 24.</reference_text><pubmed_id>22944140</pubmed_id></reference><reference><reference_text>He Y, Yu Z, Giegling I, Xie L, Hartmann AM, Prehn C, Adamski J, Kahn R, Li Y, Illig T, Wang-Sattler R, Rujescu D: Schizophrenia shows a unique metabolomics signature in plasma. Transl Psychiatry. 2012 Aug 14;2:e149. doi: 10.1038/tp.2012.76.</reference_text><pubmed_id>22892715</pubmed_id></reference><reference><reference_text>Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KR: Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):934-45. Epub 2007 Apr 17.</reference_text><pubmed_id>17440431</pubmed_id></reference><reference><reference_text>Fryar-Williams S, Strobel JE: Biomarkers of a five-domain translational substrate for schizophrenia and schizoaffective psychosis. Biomark Res. 2015 Feb 6;3:3. doi: 10.1186/s40364-015-0028-1. eCollection 2015.</reference_text><pubmed_id>25729574</pubmed_id></reference><reference><reference_text>Oresic M, Seppanen-Laakso T, Sun D, Tang J, Therman S, Viehman R, Mustonen U, van Erp TG, Hyotylainen T, Thompson P, Toga AW, Huttunen MO, Suvisaari J, Kaprio J, Lonnqvist J, Cannon TD: Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia. Genome Med. 2012 Jan 18;4(1):1. doi: 10.1186/gm300.</reference_text><pubmed_id>22257447</pubmed_id></reference></references></disease><disease>Primary hypomagnesemia<references><reference><reference_text>Jin-no Y, Kamiya Y, Okada M, Hirako M, Takada N, Kawaguchi M: Primary hypomagnesemia caused by isolated magnesium malabsorption: atypical case in adult. Intern Med. 1999 Mar;38(3):261-5.</reference_text><pubmed_id>10337938</pubmed_id></reference><reference><reference_text>Vainsel M, Vandevelde G, Smulders J, Vosters M, Hubain P, Loeb H: Tetany due to hypomagnesaemia with secondary hypocalcaemia. Arch Dis Child. 1970 Apr;45(240):254-8.</reference_text><pubmed_id>5419995</pubmed_id></reference><reference><reference_text>Shalev H, Phillip M, Galil A, Carmi R, Landau D: Clinical presentation and outcome in primary familial hypomagnesaemia. Arch Dis Child. 1998 Feb;78(2):127-30.</reference_text><pubmed_id>9579153</pubmed_id></reference><reference><reference_text>Kari JA, Farouq M, Alshaya HO: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Pediatr Nephrol. 2003 Jun;18(6):506-10. Epub 2003 Apr 29.</reference_text><pubmed_id>12720080</pubmed_id></reference></references></disease><disease>Hyperlipoproteinemia<references><reference><reference_text>Sinha S, Misra A, Kumar V, Jagannathan NR, Bal CS, Pandey RM, Singhania R, Deepak: Proton magnetic resonance spectroscopy and single photon emission computed tomography study of the brain in asymptomatic young hyperlipidaemic Asian Indians in North India show early abnormalities. Clin Endocrinol (Oxf). 2004 Aug;61(2):182-9.</reference_text><pubmed_id>15272912</pubmed_id></reference><reference><reference_text>Nelson RH: Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013 Mar</reference_text><pubmed_id>40(1):195-211. doi: 10.1016/j.pop.2012.11.003. Epub 2012 Dec  4.</pubmed_id></reference><reference><reference_text>Cantin B, Boudriau S, Bertrand M, Brun LD, Gagne C, Rogers PA, Ven Murthy MR, Lupien PJ, Julien P: Hemolysis in primary lipoprotein lipase deficiency. Metabolism. 1995 May;44(5):652-8.</reference_text><pubmed_id>7752915</pubmed_id></reference></references></disease><disease>Abetalipoproteinemia<references><reference><reference_text>Dawson G, Kruski AW, Scanu AM: Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J Lipid Res. 1976 Mar;17(2):125-31.</reference_text><pubmed_id>178813</pubmed_id></reference><reference><reference_text>Lazaro RP, Dentinger MP, Rodichok LD, Barron KD, Satya-Murti S: Muscle pathology in Bassen-Kornzweig syndrome and vitamin E deficiency. Am J Clin Pathol. 1986 Sep;86(3):378-87.</reference_text><pubmed_id>2944375</pubmed_id></reference></references></disease><disease>Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis<references><reference><reference_text>Breckenridge WC, Alaupovic P, Cox DW, Little JA: Apolipoprotein and lipoprotein concentrations in familial apolipoprotein C-II deficiency. Atherosclerosis. 1982 Aug;44(2):223-35.</reference_text><pubmed_id>7138621</pubmed_id></reference><reference><reference_text>Fukami M, Hasegawa T, Horikawa R, Ohashi T, Nishimura G, Homma K, Ogata T: Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr Res. 2006 Feb;59(2):276-80. doi: 10.1203/01.pdr.0000195825.31504.28.</reference_text><pubmed_id>16439592</pubmed_id></reference></references></disease><disease>Cerebrotendinous xanthomatosis<references><reference><reference_text>Halperin G, Elisaf M, Leitersdorf E, Harats D: A new method for determination of serum cholestanol by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2000 Jun 9;742(2):345-52.</reference_text><pubmed_id>10901139</pubmed_id></reference><reference><reference_text>Siman-Tov T, Meiner V, Gadoth N: Could steroids mask the diagnosis of cerebrotendinous xanthomatosis? J Neurol Sci. 2006 Apr 15;243(1-2):83-6. Epub 2006 Jan 30.</reference_text><pubmed_id>16445943</pubmed_id></reference><reference><reference_text>Agrawal NK, Garg S: Cerebrotendinous xanthomatosis: a rare disorder with a rare presentation. BMJ Case Rep. 2012 Sep 21;2012. pii: bcr-2012-006202. doi: 10.1136/bcr-2012-006202.</reference_text><pubmed_id>23001091</pubmed_id></reference></references></disease><disease>3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency<references><reference><reference_text>Thompson GN, Hsu BY, Pitt JJ, Treacy E, Stanley CA: Fasting hypoketotic coma in a child with deficiency of mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase. N Engl J Med. 1997 Oct 23;337(17):1203-7. doi: 10.1056/NEJM199710233371704.</reference_text><pubmed_id>9337379</pubmed_id></reference><reference><reference_text>Morris AA, Lascelles CV, Olpin SE, Lake BD, Leonard JV, Quant PA: Hepatic mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme a synthase deficiency. Pediatr Res. 1998 Sep;44(3):392-6. doi: 10.1203/00006450-199809000-00021.</reference_text><pubmed_id>9727719</pubmed_id></reference><reference><reference_text>Conboy E, Vairo F, Schultz M, Agre K, Ridsdale R, Deyle D, Oglesbee D, Gavrilov D, Klee EW, Lanpher B: Mitochondrial 3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency: Unique Presenting Laboratory Values and a Review of Biochemical and Clinical Features. JIMD Rep. 2017 Oct 14. doi: 10.1007/8904_2017_59.</reference_text><pubmed_id>29030856</pubmed_id></reference></references></disease><disease>Hypercholesterolemia, familial<references><reference><reference_text>Kwiterovich PO Jr, Fredrickson DS, Levy RI: Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest. 1974 May;53(5):1237-49. doi: 10.1172/JCI107670.</reference_text><pubmed_id>4363406</pubmed_id></reference></references></disease><disease>SC4MOL deficiency<references><reference><reference_text>He M, Kratz LE, Michel JJ, Vallejo AN, Ferris L, Kelley RI, Hoover JJ, Jukic D, Gibson KM, Wolfe LA, Ramachandran D, Zwick ME, Vockley J: Mutations in the human SC4MOL gene encoding a methyl sterol oxidase cause psoriasiform dermatitis, microcephaly, and developmental delay. J Clin Invest. 2011 Mar;121(3):976-84. doi: 10.1172/JCI42650.</reference_text><pubmed_id>21285510</pubmed_id></reference></references></disease><disease>Chondrodysplasia punctata, X-linked dominant<references><reference><reference_text>Aughton DJ, Kelley RI, Metzenberg A, Pureza V, Pauli RM: X-linked dominant chondrodysplasia punctata (CDPX2) caused by single gene mosaicism in a male. Am J Med Genet A. 2003 Jan 30;116A(3):255-60. doi: 10.1002/ajmg.a.10852.</reference_text><pubmed_id>12503102</pubmed_id></reference></references></disease><disease>Desmosterolosis<references><reference><reference_text>Andersson HC, Kratz L, Kelley R: Desmosterolosis presenting with multiple congenital anomalies and profound developmental delay. Am J Med Genet. 2002 Dec 15;113(4):315-9. doi: 10.1002/ajmg.b.10873.</reference_text><pubmed_id>12457401</pubmed_id></reference></references></disease><disease>Donohue Syndrome<references><reference><reference_text>Nijim Y, Awni Y, Adawi A, Bowirrat A: Classic Case Report of Donohue Syndrome (Leprechaunism; OMIM *246200): The Impact of Consanguineous Mating. Medicine (Baltimore). 2016 Feb;95(6):e2710. doi: 10.1097/MD.0000000000002710.</reference_text><pubmed_id>26871809</pubmed_id></reference></references></disease><disease>Leptin Deficiency or Dysfunction<references><reference><reference_text>Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O'Rahilly S: Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999 Sep 16;341(12):879-84. doi: 10.1056/NEJM199909163411204.</reference_text><pubmed_id>10486419</pubmed_id></reference></references></disease><disease>Duchenne Muscular Dystrophy<references><reference><reference_text>Nakagawa T, Takeuchi A, Kakiuchi R, Lee T, Yagi M, Awano H, Iijima K, Takeshima Y, Urade Y, Matsuo M: A prostaglandin D2 metabolite is elevated in the urine of Duchenne muscular dystrophy patients and increases further from 8 years old. Clin Chim Acta. 2013 Aug 23;423:10-4. doi: 10.1016/j.cca.2013.03.031. Epub 2013 Apr 19.</reference_text><pubmed_id>23603101</pubmed_id></reference><reference><reference_text>Srivastava NK, Pradhan S, Mittal B, Gowda GA: High resolution NMR based analysis of serum lipids in Duchenne muscular dystrophy patients and its possible diagnostic significance. NMR Biomed. 2010 Jan;23(1):13-22. doi: 10.1002/nbm.1419.</reference_text><pubmed_id>19787747</pubmed_id></reference><reference><reference_text>Horster I, Weigt-Usinger K, Carmann C, Chobanyan-Jurgens K, Kohler C, Schara U, Kayacelebi AA, Beckmann B, Tsikas D, Lucke T: The L-arginine/NO pathway and homoarginine are altered in Duchenne muscular dystrophy and improved by glucocorticoids. Amino Acids. 2015 Sep;47(9):1853-63. doi: 10.1007/s00726-015-2018-x. Epub 2015 Jun 12.</reference_text><pubmed_id>26066683</pubmed_id></reference></references></disease><disease>Lecithin:cholesterol Acyltransferase Deficiency<references><reference><reference_text>Idzior-Walus B, Sieradzki J, Kostner G, Malecki MT, Klupa T, Wesolowska T, Rostworowski W, Hartwich J, Walus M, Kiec AD, Naruszewicz M: Familial lecithin-cholesterol acyltransferase deficiency: biochemical characteristics and molecular analysis of a new LCAT mutation in a Polish family. Atherosclerosis. 2006 Apr;185(2):413-20. Epub 2005 Jul 26.</reference_text><pubmed_id>16051254</pubmed_id></reference></references></disease><disease>Lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lipodystrophy, Congenital Generalized<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Oculocerebrorenal syndrome<references><reference><reference_text>Charnas LR, Bernardini I, Rader D, Hoeg JM, Gahl WA: Clinical and laboratory findings in the oculocerebrorenal syndrome of Lowe, with special reference to growth and renal function. N Engl J Med. 1991 May 9;324(19):1318-25. doi: 10.1056/NEJM199105093241904.</reference_text><pubmed_id>2017228</pubmed_id></reference></references></disease><disease>Familial partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lathosterolosis<references><reference><reference_text>Brunetti-Pierri N, Corso G, Rossi M, Ferrari P, Balli F, Rivasi F, Annunziata I, Ballabio A, Russo AD, Andria G, Parenti G: Lathosterolosis, a novel multiple-malformation/mental retardation syndrome due to deficiency of 3beta-hydroxysteroid-delta5-desaturase. Am J Hum Genet. 2002 Oct;71(4):952-8. Epub 2002 Aug 20.</reference_text><pubmed_id>12189593</pubmed_id></reference><reference><reference_text>Ho AC, Fung CW, Siu TS, Ma OC, Lam CW, Tam S, Wong VC: Lathosterolosis: a disorder of cholesterol biosynthesis resembling smith-lemli-opitz syndrome. JIMD Rep. 2014;12:129-34. doi: 10.1007/8904_2013_255. Epub 2013 Oct 20.</reference_text><pubmed_id>24142275</pubmed_id></reference></references></disease><disease>Partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Multiple sclerosis<references><reference><reference_text>Lutz NW, Viola A, Malikova I, Confort-Gouny S, Audoin B, Ranjeva JP, Pelletier J, Cozzone PJ: Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One. 2007 Jul 4;2(7):e595.</reference_text><pubmed_id>17611627</pubmed_id></reference><reference><reference_text>Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U, Hillert J, Bjorkhem I: Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med. 2004 Feb;42(2):186-91.</reference_text><pubmed_id>15061359</pubmed_id></reference><reference><reference_text>Leoni V, Lutjohann D, Masterman T: Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis. J Lipid Res. 2005 Feb;46(2):191-5. Epub 2004 Dec 1.</reference_text><pubmed_id>15576852</pubmed_id></reference><reference><reference_text>Calabrese V, Scapagnini G, Ravagna A, Bella R, Butterfield DA, Calvani M, Pennisi G, Giuffrida Stella AM: Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem Res. 2003 Sep;28(9):1321-8.</reference_text><pubmed_id>12938853</pubmed_id></reference><reference><reference_text>Shaw CE, Dunbar PR, Macaulay HA, Neale TJ: Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol. 1995 Jan;242(2):53-8.</reference_text><pubmed_id>7707089</pubmed_id></reference><reference><reference_text>Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.</reference_text><pubmed_id>17384003</pubmed_id></reference><reference><reference_text>Syburra C, Passi S: Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh (1999). 1999 May-Jun;71(3):112-5.</reference_text><pubmed_id>10609336</pubmed_id></reference><reference><reference_text>Forte G, Visconti A, Santucci S, Ghazaryan A, Figa-Talamanca L, Cannoni S, Bocca B, Pino A, Violante N, Alimonti A, Salvetti M, Ristori G: Quantification of chemical elements in blood of patients affected by multiple sclerosis. Ann Ist Super Sanita. 2005;41(2):213-6.</reference_text><pubmed_id>16244395</pubmed_id></reference><reference><reference_text>Toncev G, Milicic B, Toncev S, Samardzic G: Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol. 2002 May;9(3):221-6.</reference_text><pubmed_id>11985629</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, Bamonti F, Capello E, Mancardi GL, Scarpini E: Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res. 2010 May 28;1333:64-71. doi: 10.1016/j.brainres.2010.03.073. Epub 2010 Mar 27.</reference_text><pubmed_id>20347721</pubmed_id></reference><reference><reference_text>Matsushita T, Isobe N, Kawajiri M, Mogi M, Tsukuda K, Horiuchi M, Ohyagi Y, Kira J: CSF angiotensin II and angiotensin-converting enzyme levels in anti-aquaporin-4 autoimmunity. J Neurol Sci. 2010 Aug 15;295(1-2):41-5. doi: 10.1016/j.jns.2010.05.014. Epub 2010 Jun 11.</reference_text><pubmed_id>20541774</pubmed_id></reference><reference><reference_text>Ghabaee M, Jabedari B, Al-E-Eshagh N, Ghaffarpour M, Asadi F: Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients. Int J Neurosci. 2010 Apr;120(4):301-4. doi: 10.3109/00207451003695690.</reference_text><pubmed_id>20374079</pubmed_id></reference><reference><reference_text>Kawajiri M, Mogi M, Osoegawa M, Matsuoka T, Tsukuda K, Kohara K, Horiuchi M, Miki T, Kira JI: Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler. 2008 May;14(4):557-60. doi: 10.1177/1352458507085760.</reference_text><pubmed_id>18562510</pubmed_id></reference><reference><reference_text>Visconti A, Cotichini R, Cannoni S, Bocca B, Forte G, Ghazaryan A, Santucci S, D'Ippolito C, Stazi MA, Salvetti M, Alimonti A, Ristori G: Concentration of elements in serum of patients affected by multiple sclerosis with first demyelinating episode: a six-month longitudinal follow-up study. Ann Ist Super Sanita. 2005;41(2):217-22.</reference_text><pubmed_id>16244396</pubmed_id></reference></references></disease><disease>Inflammatory bowel disease<references><reference><reference_text>Lee T, Clavel T, Smirnov K, Schmidt A, Lagkouvardos I, Walker A, Lucio M, Michalke B, Schmitt-Kopplin P, Fedorak R, Haller D: Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. 2017 May;66(5):863-871. doi: 10.1136/gutjnl-2015-309940. Epub 2016 Feb 4.</reference_text><pubmed_id>26848182</pubmed_id></reference><reference><reference_text>Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158.</reference_text><pubmed_id>27609529</pubmed_id></reference></references></disease><disease>Colorectal cancer<references><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B: Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009 Apr;22(3):342-8. doi: 10.1002/nbm.1345.</reference_text><pubmed_id>19006102</pubmed_id></reference><reference><reference_text>Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP: Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One. 2013 Aug 6;8(8):e70803. doi: 10.1371/journal.pone.0070803. Print 2013.</reference_text><pubmed_id>23940645</pubmed_id></reference><reference><reference_text>Phua LC, Chue XP, Koh PK, Cheah PY, Ho HK, Chan EC: Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biol Ther. 2014 Apr;15(4):389-97. doi: 10.4161/cbt.27625. Epub 2014 Jan 14.</reference_text><pubmed_id>24424155</pubmed_id></reference><reference><reference_text>Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB: Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010 Feb 15;8:13. doi: 10.1186/1741-7015-8-13.</reference_text><pubmed_id>20156336</pubmed_id></reference><reference><reference_text>Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, Ni Y, Zhao A, Xu LX, Cai S, Jia W: Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res. 2009 Oct;8(10):4844-50. doi: 10.1021/pr9004162.</reference_text><pubmed_id>19678709</pubmed_id></reference><reference><reference_text>Cheng Y, Xie G, Chen T, Qiu Y, Zou X, Zheng M, Tan B, Feng B, Dong T, He P, Zhao L, Zhao A, Xu LX, Zhang Y, Jia W: Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res. 2012 Feb 3;11(2):1354-63. doi: 10.1021/pr201001a. Epub 2011 Dec 28.</reference_text><pubmed_id>22148915</pubmed_id></reference><reference><reference_text>Ni Y, Xie G, Jia W: Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res. 2014 Sep 5;13(9):3857-70. doi: 10.1021/pr500443c. Epub 2014 Aug 14.</reference_text><pubmed_id>25105552</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference><reference><reference_text>Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18.</reference_text><pubmed_id>25037050</pubmed_id></reference><reference><reference_text>Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016.</reference_text><pubmed_id>27015276</pubmed_id></reference><reference><reference_text>Lin Y, Ma C, Liu C, Wang Z, Yang J, Liu X, Shen Z, Wu R: NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer. Oncotarget. 2016 May 17;7(20):29454-64. doi: 10.18632/oncotarget.8762.</reference_text><pubmed_id>27107423</pubmed_id></reference><reference><reference_text>Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016.</reference_text><pubmed_id>27275383</pubmed_id></reference><reference><reference_text>Wang X, Wang J, Rao B, Deng L: Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals. Exp Ther Med. 2017 Jun;13(6):2848-2854. doi: 10.3892/etm.2017.4367. Epub 2017 Apr 20.</reference_text><pubmed_id>28587349</pubmed_id></reference><reference><reference_text>Silke Matysik, Caroline Ivanne Le Roy, Gerhard Liebisch, Sandrine Paule Claus. Metabolomics of fecal samples: A practical consideration. Trends in Food Science &amp; Technology. Vol. 57, Part B, Nov. 2016, p.244-255: http://www.sciencedirect.com/science/article/pii/S0924224416301984</reference_text><pubmed_id>28587349</pubmed_id></reference></references></disease><disease>Gallbladder disease<references><reference><reference_text>Lapidus A, Akerlund JE, Einarsson C: Gallbladder bile composition in patients with Crohn 's disease. World J Gastroenterol. 2006 Jan 7;12(1):70-4.</reference_text><pubmed_id>16440420</pubmed_id></reference><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference><reference><reference_text>Mizuno S, Tazuma S, Kajiyama G: Stabilization of biliary lipid particles by ursodeoxycholic acid. Prolonged nucleation time in human gallbladder bile. Dig Dis Sci. 1993 Apr;38(4):684-93.</reference_text><pubmed_id>8462368</pubmed_id></reference><reference><reference_text>Hillebrant CG, Axelson M, Bjorkhem I, Wang FH, Nyberg B, Einarsson C: Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients. Eur J Clin Invest. 1998 Apr;28(4):324-8.</reference_text><pubmed_id>9615912</pubmed_id></reference></references></disease><disease>Cholelithiasis<references><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference></references></disease><disease>Stomach cancer<references><reference><reference_text>Higashijima H, Ichimiya H, Nakano T, Yamashita H, Kuroki S, Satoh H, Chijiiwa K, Tanaka M: Deconjugation of bilirubin accelerates coprecipitation of cholesterol, fatty acids, and mucin in human bile--in vitro study. J Gastroenterol. 1996 Dec;31(6):828-35.</reference_text><pubmed_id>9027647</pubmed_id></reference><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Song H, Peng JS, Dong-Sheng Y, Yang ZL, Liu HL, Zeng YK, Shi XP, Lu BY: Serum metabolic profiling of human gastric cancer based on gas chromatography/mass spectrometry. Braz J Med Biol Res. 2012 Jan;45(1):78-85. Epub 2011 Nov 25.</reference_text><pubmed_id>22124703</pubmed_id></reference><reference><reference_text>Yu L, Aa J, Xu J, Sun M, Qian S, Cheng L, Yang S, Shi R: Metabolomic phenotype of gastric cancer and precancerous stages based on gas chromatography time-of-flight mass spectrometry. J Gastroenterol Hepatol. 2011 Aug;26(8):1290-7. doi: 10.1111/j.1440-1746.2011.06724.x.</reference_text><pubmed_id>21443661</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference></references></disease><disease>Acute myelogenous leukemia<references><reference><reference_text>Tatidis L, Vitols S, Gruber A, Paul C, Axelson M: Cholesterol catabolism in patients with acute myelogenous leukemia and hypocholesterolemia: suppressed levels of a circulating marker for bile acid synthesis. Cancer Lett. 2001 Sep 20;170(2):169-75.</reference_text><pubmed_id>11463495</pubmed_id></reference></references></disease><disease>Hypercholesterolemia<references><reference><reference_text>Thelen KM, Laaksonen R, Paiva H, Lehtimaki T, Lutjohann D: High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels. J Clin Pharmacol. 2006 Jul;46(7):812-6.</reference_text><pubmed_id>16809807</pubmed_id></reference><reference><reference_text>Tamasawa N, Tamasawa A, Takebe K: Higher levels of plasma cholesterol sulfate in patients with liver cirrhosis and hypercholesterolemia. Lipids. 1993 Sep;28(9):833-6.</reference_text><pubmed_id>8231659</pubmed_id></reference><reference><reference_text>Kim DH, Lee KJ, Heo GS: Analysis of cholesterol and cholesteryl esters in human serum using capillary supercritical fluid chromatography. J Chromatogr B Biomed Appl. 1994 Apr 22;655(1):1-8.</reference_text><pubmed_id>8061816</pubmed_id></reference><reference><reference_text>Authors unspecified: Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med. 1988 Jan;148(1):36-69.</reference_text><pubmed_id>3422148</pubmed_id></reference></references></disease><disease>Cholesteryl ester storage disease<references><reference><reference_text>Rassoul F, Richter V, Lohse P, Naumann A, Purschwitz K, Keller E: Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease. Int J Clin Pharmacol Ther. 2001 May;39(5):199-204.</reference_text><pubmed_id>11380065</pubmed_id></reference><reference><reference_text>Chatrath H, Keilin S, Attar BM: Cholesterol ester storage disease (CESD) diagnosed in an asymptomatic adult. Dig Dis Sci. 2009 Jan;54(1):168-73. doi: 10.1007/s10620-008-0310-2. Epub 2008 May 14.</reference_text><pubmed_id>18478331</pubmed_id></reference><reference><reference_text>Bernstein DL, Hulkova H, Bialer MG, Desnick RJ: Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol. 2013 Jun;58(6):1230-43. doi: 10.1016/j.jhep.2013.02.014. Epub 2013 Feb 26.</reference_text><pubmed_id>23485521</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Cystinosis<references><reference><reference_text>Ueda M, O'Brien K, Rosing DR, Ling A, Kleta R, McAreavey D, Bernardini I, Gahl WA: Coronary artery and other vascular calcifications in patients with cystinosis after kidney transplantation. Clin J Am Soc Nephrol. 2006 May;1(3):555-62. Epub 2006 Feb 8.</reference_text><pubmed_id>17699259</pubmed_id></reference><reference><reference_text>Gahl WA, Bernardini I, Dalakas M, Rizzo WB, Harper GS, Hoeg JM, Hurko O, Bernar J: Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome. J Clin Invest. 1988 Feb;81(2):549-60.</reference_text><pubmed_id>3276734</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Smith-Lemli-Opitz syndrome<references><reference><reference_text>van Rooij A, Nijenhuis AA, Wijburg FA, Schutgens RB: Highly increased CSF concentrations of cholesterol precursors in Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 1997 Aug;20(4):578-80.</reference_text><pubmed_id>9266395</pubmed_id></reference><reference><reference_text>Honda M, Tint GS, Honda A, Salen G, Shefer S, Batta AK, Matsuzaki Y, Tanaka N: Regulation of cholesterol biosynthetic pathway in patients with the Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2000 Jul;23(5):464-74.</reference_text><pubmed_id>10947201</pubmed_id></reference><reference><reference_text>Rossi M, Federico G, Corso G, Parenti G, Battagliese A, Frascogna AR, Della Casa R, Dello Russo A, Strisciuglio P, Saggese G, Andria G: Vitamin D status in patients affected by Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2005;28(1):69-80.</reference_text><pubmed_id>15702407</pubmed_id></reference><reference><reference_text>Johnson DW, ten Brink HJ, Jakobs C: A rapid screening procedure for cholesterol and dehydrocholesterol by electrospray ionization tandem mass spectrometry. J Lipid Res. 2001 Oct;42(10):1699-705.</reference_text><pubmed_id>11590227</pubmed_id></reference></references></disease><disease>Prostate cancer<references><reference><reference_text>Nyman DW, Suzanne Stratton M, Kopplin MJ, Dalkin BL, Nagle RB, Jay Gandolfi A: Selenium and selenomethionine levels in prostate cancer patients. Cancer Detect Prev. 2004;28(1):8-16.</reference_text><pubmed_id>15041072</pubmed_id></reference><reference><reference_text>Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, Egevad L, Tjonneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, Palli D, Vineis P, Tumino R, Berrino F, Kiemeney L, Bueno-de-Mesquita HB, Quiros JR, Gonzalez CA, Martinez C, Larranaga N, Chirlaque MD, Ardanaz E, Stattin P, Hallmans G, Khaw KT, Bingham S, Slimani N, Ferrari P, Rinaldi S, Riboli E: Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr. 2007 Sep;86(3):672-81.</reference_text><pubmed_id>17823432</pubmed_id></reference><reference><reference_text>Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762.</reference_text><pubmed_id>19212411</pubmed_id></reference><reference><reference_text>Puah CM, Williams G, Ghanadian R: Urinary unconjugated 5 alpha-androstane-3 alpha, 17 beta-diol in patients with prostatic tumours. Urol Res. 1982;10(2):81-4.</reference_text><pubmed_id>6180540</pubmed_id></reference><reference><reference_text>Thysell E, Surowiec I, Hornberg E, Crnalic S, Widmark A, Johansson AI, Stattin P, Bergh A, Moritz T, Antti H, Wikstrom P: Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One. 2010 Dec 3;5(12):e14175. doi: 10.1371/journal.pone.0014175.</reference_text><pubmed_id>21151972</pubmed_id></reference><reference><reference_text>Soliman LC, Hui Y, Hewavitharana AK, Chen DD: Monitoring potential prostate cancer biomarkers in urine by capillary electrophoresis-tandem mass spectrometry. J Chromatogr A. 2012 Dec 7;1267:162-9. doi: 10.1016/j.chroma.2012.07.021. Epub 2012 Jul 14.</reference_text><pubmed_id>22824219</pubmed_id></reference><reference><reference_text>Madu CO, Lu Y: Novel diagnostic biomarkers for prostate cancer. J Cancer. 2010 Oct 6;1:150-77.</reference_text><pubmed_id>20975847</pubmed_id></reference></references></disease><disease>Schizophrenia<references><reference><reference_text>Harnryd C, Bjerkenstedt L, Grimm VE, Sedvall G: Reduction of MOPEG levels in cerebrospinal fluid of psychotic women after electroconvulsive treatment. Psychopharmacology (Berl). 1979 Aug 8;64(2):131-4.</reference_text><pubmed_id>115032</pubmed_id></reference><reference><reference_text>Kobayashi K, Koide Y, Yoshino K, Shohmori T: [P-hydroxyphenylacetic acid concentrations in cerebrospinal fluid]. No To Shinkei. 1982 Aug;34(8):769-74.</reference_text><pubmed_id>7126379</pubmed_id></reference><reference><reference_text>Alfredsson G, Wiesel FA: Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology (Berl). 1989;99(3):322-7.</reference_text><pubmed_id>2480613</pubmed_id></reference><reference><reference_text>Heresco-Levy U, Bar G, Levin R, Ermilov M, Ebstein RP, Javitt DC: High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. Schizophr Res. 2007 Mar;91(1-3):14-21. Epub 2007 Feb 2.</reference_text><pubmed_id>17276036</pubmed_id></reference><reference><reference_text>Walker EF, Bonsall R, Walder DJ: Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis. Neuropsychiatry Neuropsychol Behav Neurol. 2002 Mar;15(1):10-7.</reference_text><pubmed_id>11877547</pubmed_id></reference><reference><reference_text>Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M: Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry. 2003 Jun;60(6):572-6.</reference_text><pubmed_id>12796220</pubmed_id></reference><reference><reference_text>Do KQ, Lauer CJ, Schreiber W, Zollinger M, Gutteck-Amsler U, Cuenod M, Holsboer F: gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem. 1995 Dec;65(6):2652-62.</reference_text><pubmed_id>7595563</pubmed_id></reference><reference><reference_text>Nikisch G, Baumann P, Wiedemann G, Kiessling B, Weisser H, Hertel A, Yoshitake T, Kehr J, Mathe AA: Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF. J Clin Psychopharmacol. 2010 Oct;30(5):496-503. doi: 10.1097/JCP.0b013e3181f2288e.</reference_text><pubmed_id>20814316</pubmed_id></reference><reference><reference_text>Fukushima T, Iizuka H, Yokota A, Suzuki T, Ohno C, Kono Y, Nishikiori M, Seki A, Ichiba H, Watanabe Y, Hongo S, Utsunomiya M, Nakatani M, Sadamoto K, Yoshio T: Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One. 2014 Jul 8;9(7):e101652. doi: 10.1371/journal.pone.0101652. eCollection 2014.</reference_text><pubmed_id>25004141</pubmed_id></reference><reference><reference_text>Koike S, Bundo M, Iwamoto K, Suga M, Kuwabara H, Ohashi Y, Shinoda K, Takano Y, Iwashiro N, Satomura Y, Nagai T, Natsubori T, Tada M, Yamasue H, Kasai K: A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study. Transl Psychiatry. 2014 Apr 8;4:e379. doi: 10.1038/tp.2014.19.</reference_text><pubmed_id>24713860</pubmed_id></reference><reference><reference_text>Ballesteros A, Summerfelt A, Du X, Jiang P, Chiappelli J, Tagamets M, O'Donnell P, Kochunov P, Hong LE: Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia. Clin Neurophysiol. 2013 Nov;124(11):2209-15. doi: 10.1016/j.clinph.2013.05.021. Epub 2013 Jun 30.</reference_text><pubmed_id>23823132</pubmed_id></reference><reference><reference_text>Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel FA: Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry. 1985 Sep;147:276-82.</reference_text><pubmed_id>2415198</pubmed_id></reference><reference><reference_text>Pickar D, Breier A, Hsiao JK, Doran AR, Wolkowitz OM, Pato CN, Konicki PE, Potter WZ: Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Arch Gen Psychiatry. 1990 Jul;47(7):641-8.</reference_text><pubmed_id>1694425</pubmed_id></reference><reference><reference_text>Prell GD, Green JP, Kaufmann CA, Khandelwal JK, Morrishow AM, Kirch DG, Linnoila M, Wyatt RJ: Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res. 1995 Jan;14(2):93-104.</reference_text><pubmed_id>7711000</pubmed_id></reference><reference><reference_text>Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B: Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology. 2009;59(2):123-9. doi: 10.1159/000213565. Epub 2009 Apr 22.</reference_text><pubmed_id>19390223</pubmed_id></reference><reference><reference_text>Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K, Cao Y, Wang X, Qiu Y, Su M, Zhao A, Wang P, Yang P, Wu J, Feng G, He L, Jia W, Wan C: Potential metabolite markers of schizophrenia. Mol Psychiatry. 2013 Jan;18(1):67-78. doi: 10.1038/mp.2011.131. Epub 2011 Oct 25.</reference_text><pubmed_id>22024767</pubmed_id></reference><reference><reference_text>Xuan J, Pan G, Qiu Y, Yang L, Su M, Liu Y, Chen J, Feng G, Fang Y, Jia W, Xing Q, He L: Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. J Proteome Res. 2011 Dec 2;10(12):5433-43. doi: 10.1021/pr2006796. Epub 2011 Nov  8.</reference_text><pubmed_id>22007635</pubmed_id></reference><reference><reference_text>Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM, Rothermundt M, Bogerts B, Koethe D, Kranaster L, Ohrmann P, Suslow T, McAllister G, Spain M, Barnes A, van Beveren NJ, Baron-Cohen S, Steiner J, Torrey FE, Yolken RH, Bahn S: Identification of a biological signature for schizophrenia in serum. Mol Psychiatry. 2012 May;17(5):494-502. doi: 10.1038/mp.2011.42. Epub 2011 Apr 12.</reference_text><pubmed_id>21483431</pubmed_id></reference><reference><reference_text>Mathe AA, Eberhard G, Saaf J, Wetterberg L: Plasma prostaglandin E2 metabolite--measured as 11-deoxy-15-keto-13,14-dihydro-11 beta,16 xi-cyclo-PGE2--in twins with schizophrenic disorder. Biol Psychiatry. 1986 Sep;21(11):1024-30.</reference_text><pubmed_id>3741918</pubmed_id></reference><reference><reference_text>Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N: Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct. 2002 Jun;20(2):171-5.</reference_text><pubmed_id>11979513</pubmed_id></reference><reference><reference_text>Zumarraga M, Davila R, Basterreche N, Arrue A, Goienetxea B, Zamalloa MI, Erkoreka L, Bustamante S, Inchausti L, Gonzalez-Torres MA, Guimon J: Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients. Neurochem Int. 2010 May-Jun;56(6-7):774-9. doi: 10.1016/j.neuint.2010.02.015. Epub 2010 Mar 4.</reference_text><pubmed_id>20206656</pubmed_id></reference><reference><reference_text>Peters JG: Dopamine, noradrenaline and serotonin spinal fluid metabolites in temporal lobe epileptic patients with schizophrenic symptomatology. Eur Neurol. 1979;18(1):15-8.</reference_text><pubmed_id>436860</pubmed_id></reference><reference><reference_text>Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, Rozen S, Krishnan RR, McEvoy J, Kaddurah-Daouk R: Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry. 2010 Sep;15(9):938-53. doi: 10.1038/mp.2009.33. Epub 2009 Apr 28.</reference_text><pubmed_id>19401681</pubmed_id></reference><reference><reference_text>Gattaz WF, Waldmeier P, Beckmann H: CSF monoamine metabolites in schizophrenic patients. Acta Psychiatr Scand. 1982 Nov;66(5):350-60.</reference_text><pubmed_id>6184954</pubmed_id></reference><reference><reference_text>Nilsson-Todd LK, Nordin C, Jonsson EG, Skogh E, Erhardt S: Cerebrospinal fluid kynurenic acid in male patients with schizophrenia - correlation with monoamine metabolites. Acta Neuropsychiatr. 2007 Feb;19(1):45-52. doi: 10.1111/j.1601-5215.2006.00170.x.</reference_text><pubmed_id>26952797</pubmed_id></reference><reference><reference_text>Cai HL, Li HD, Yan XZ, Sun B, Zhang Q, Yan M, Zhang WY, Jiang P, Zhu RH, Liu YP, Fang PF, Xu P, Yuan HY, Zhang XH, Hu L, Yang W, Ye HS: Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naive schizophrenia patients after treatment with risperidone. J Proteome Res. 2012 Aug 3;11(8):4338-50. doi: 10.1021/pr300459d. Epub 2012 Jul 26.</reference_text><pubmed_id>22800120</pubmed_id></reference><reference><reference_text>Al Awam K, Haussleiter IS, Dudley E, Donev R, Brune M, Juckel G, Thome J: Multiplatform metabolome and proteome profiling identifies serum metabolite and protein signatures as prospective biomarkers for schizophrenia. J Neural Transm (Vienna). 2015 Aug;122 Suppl 1:S111-22. doi: 10.1007/s00702-014-1224-0. Epub 2014 May 1.</reference_text><pubmed_id>24789758</pubmed_id></reference><reference><reference_text>Bicikova M, Hill M, Ripova D, Mohr P, Hampl R: Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia. J Steroid Biochem Mol Biol. 2013 Jan;133:77-83. doi: 10.1016/j.jsbmb.2012.08.009. Epub 2012 Aug 24.</reference_text><pubmed_id>22944140</pubmed_id></reference><reference><reference_text>He Y, Yu Z, Giegling I, Xie L, Hartmann AM, Prehn C, Adamski J, Kahn R, Li Y, Illig T, Wang-Sattler R, Rujescu D: Schizophrenia shows a unique metabolomics signature in plasma. Transl Psychiatry. 2012 Aug 14;2:e149. doi: 10.1038/tp.2012.76.</reference_text><pubmed_id>22892715</pubmed_id></reference><reference><reference_text>Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KR: Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):934-45. Epub 2007 Apr 17.</reference_text><pubmed_id>17440431</pubmed_id></reference><reference><reference_text>Fryar-Williams S, Strobel JE: Biomarkers of a five-domain translational substrate for schizophrenia and schizoaffective psychosis. Biomark Res. 2015 Feb 6;3:3. doi: 10.1186/s40364-015-0028-1. eCollection 2015.</reference_text><pubmed_id>25729574</pubmed_id></reference><reference><reference_text>Oresic M, Seppanen-Laakso T, Sun D, Tang J, Therman S, Viehman R, Mustonen U, van Erp TG, Hyotylainen T, Thompson P, Toga AW, Huttunen MO, Suvisaari J, Kaprio J, Lonnqvist J, Cannon TD: Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia. Genome Med. 2012 Jan 18;4(1):1. doi: 10.1186/gm300.</reference_text><pubmed_id>22257447</pubmed_id></reference></references></disease><disease>Primary hypomagnesemia<references><reference><reference_text>Jin-no Y, Kamiya Y, Okada M, Hirako M, Takada N, Kawaguchi M: Primary hypomagnesemia caused by isolated magnesium malabsorption: atypical case in adult. Intern Med. 1999 Mar;38(3):261-5.</reference_text><pubmed_id>10337938</pubmed_id></reference><reference><reference_text>Vainsel M, Vandevelde G, Smulders J, Vosters M, Hubain P, Loeb H: Tetany due to hypomagnesaemia with secondary hypocalcaemia. Arch Dis Child. 1970 Apr;45(240):254-8.</reference_text><pubmed_id>5419995</pubmed_id></reference><reference><reference_text>Shalev H, Phillip M, Galil A, Carmi R, Landau D: Clinical presentation and outcome in primary familial hypomagnesaemia. Arch Dis Child. 1998 Feb;78(2):127-30.</reference_text><pubmed_id>9579153</pubmed_id></reference><reference><reference_text>Kari JA, Farouq M, Alshaya HO: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Pediatr Nephrol. 2003 Jun;18(6):506-10. Epub 2003 Apr 29.</reference_text><pubmed_id>12720080</pubmed_id></reference></references></disease><disease>Hyperlipoproteinemia<references><reference><reference_text>Sinha S, Misra A, Kumar V, Jagannathan NR, Bal CS, Pandey RM, Singhania R, Deepak: Proton magnetic resonance spectroscopy and single photon emission computed tomography study of the brain in asymptomatic young hyperlipidaemic Asian Indians in North India show early abnormalities. Clin Endocrinol (Oxf). 2004 Aug;61(2):182-9.</reference_text><pubmed_id>15272912</pubmed_id></reference><reference><reference_text>Nelson RH: Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013 Mar</reference_text><pubmed_id>40(1):195-211. doi: 10.1016/j.pop.2012.11.003. Epub 2012 Dec  4.</pubmed_id></reference><reference><reference_text>Cantin B, Boudriau S, Bertrand M, Brun LD, Gagne C, Rogers PA, Ven Murthy MR, Lupien PJ, Julien P: Hemolysis in primary lipoprotein lipase deficiency. Metabolism. 1995 May;44(5):652-8.</reference_text><pubmed_id>7752915</pubmed_id></reference></references></disease><disease>Abetalipoproteinemia<references><reference><reference_text>Dawson G, Kruski AW, Scanu AM: Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J Lipid Res. 1976 Mar;17(2):125-31.</reference_text><pubmed_id>178813</pubmed_id></reference><reference><reference_text>Lazaro RP, Dentinger MP, Rodichok LD, Barron KD, Satya-Murti S: Muscle pathology in Bassen-Kornzweig syndrome and vitamin E deficiency. Am J Clin Pathol. 1986 Sep;86(3):378-87.</reference_text><pubmed_id>2944375</pubmed_id></reference></references></disease><disease>Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis<references><reference><reference_text>Breckenridge WC, Alaupovic P, Cox DW, Little JA: Apolipoprotein and lipoprotein concentrations in familial apolipoprotein C-II deficiency. Atherosclerosis. 1982 Aug;44(2):223-35.</reference_text><pubmed_id>7138621</pubmed_id></reference><reference><reference_text>Fukami M, Hasegawa T, Horikawa R, Ohashi T, Nishimura G, Homma K, Ogata T: Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr Res. 2006 Feb;59(2):276-80. doi: 10.1203/01.pdr.0000195825.31504.28.</reference_text><pubmed_id>16439592</pubmed_id></reference></references></disease><disease>Cerebrotendinous xanthomatosis<references><reference><reference_text>Halperin G, Elisaf M, Leitersdorf E, Harats D: A new method for determination of serum cholestanol by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2000 Jun 9;742(2):345-52.</reference_text><pubmed_id>10901139</pubmed_id></reference><reference><reference_text>Siman-Tov T, Meiner V, Gadoth N: Could steroids mask the diagnosis of cerebrotendinous xanthomatosis? J Neurol Sci. 2006 Apr 15;243(1-2):83-6. Epub 2006 Jan 30.</reference_text><pubmed_id>16445943</pubmed_id></reference><reference><reference_text>Agrawal NK, Garg S: Cerebrotendinous xanthomatosis: a rare disorder with a rare presentation. BMJ Case Rep. 2012 Sep 21;2012. pii: bcr-2012-006202. doi: 10.1136/bcr-2012-006202.</reference_text><pubmed_id>23001091</pubmed_id></reference></references></disease><disease>3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency<references><reference><reference_text>Thompson GN, Hsu BY, Pitt JJ, Treacy E, Stanley CA: Fasting hypoketotic coma in a child with deficiency of mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase. N Engl J Med. 1997 Oct 23;337(17):1203-7. doi: 10.1056/NEJM199710233371704.</reference_text><pubmed_id>9337379</pubmed_id></reference><reference><reference_text>Morris AA, Lascelles CV, Olpin SE, Lake BD, Leonard JV, Quant PA: Hepatic mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme a synthase deficiency. Pediatr Res. 1998 Sep;44(3):392-6. doi: 10.1203/00006450-199809000-00021.</reference_text><pubmed_id>9727719</pubmed_id></reference><reference><reference_text>Conboy E, Vairo F, Schultz M, Agre K, Ridsdale R, Deyle D, Oglesbee D, Gavrilov D, Klee EW, Lanpher B: Mitochondrial 3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency: Unique Presenting Laboratory Values and a Review of Biochemical and Clinical Features. JIMD Rep. 2017 Oct 14. doi: 10.1007/8904_2017_59.</reference_text><pubmed_id>29030856</pubmed_id></reference></references></disease><disease>Hypercholesterolemia, familial<references><reference><reference_text>Kwiterovich PO Jr, Fredrickson DS, Levy RI: Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest. 1974 May;53(5):1237-49. doi: 10.1172/JCI107670.</reference_text><pubmed_id>4363406</pubmed_id></reference></references></disease><disease>SC4MOL deficiency<references><reference><reference_text>He M, Kratz LE, Michel JJ, Vallejo AN, Ferris L, Kelley RI, Hoover JJ, Jukic D, Gibson KM, Wolfe LA, Ramachandran D, Zwick ME, Vockley J: Mutations in the human SC4MOL gene encoding a methyl sterol oxidase cause psoriasiform dermatitis, microcephaly, and developmental delay. J Clin Invest. 2011 Mar;121(3):976-84. doi: 10.1172/JCI42650.</reference_text><pubmed_id>21285510</pubmed_id></reference></references></disease><disease>Chondrodysplasia punctata, X-linked dominant<references><reference><reference_text>Aughton DJ, Kelley RI, Metzenberg A, Pureza V, Pauli RM: X-linked dominant chondrodysplasia punctata (CDPX2) caused by single gene mosaicism in a male. Am J Med Genet A. 2003 Jan 30;116A(3):255-60. doi: 10.1002/ajmg.a.10852.</reference_text><pubmed_id>12503102</pubmed_id></reference></references></disease><disease>Desmosterolosis<references><reference><reference_text>Andersson HC, Kratz L, Kelley R: Desmosterolosis presenting with multiple congenital anomalies and profound developmental delay. Am J Med Genet. 2002 Dec 15;113(4):315-9. doi: 10.1002/ajmg.b.10873.</reference_text><pubmed_id>12457401</pubmed_id></reference></references></disease><disease>Donohue Syndrome<references><reference><reference_text>Nijim Y, Awni Y, Adawi A, Bowirrat A: Classic Case Report of Donohue Syndrome (Leprechaunism; OMIM *246200): The Impact of Consanguineous Mating. Medicine (Baltimore). 2016 Feb;95(6):e2710. doi: 10.1097/MD.0000000000002710.</reference_text><pubmed_id>26871809</pubmed_id></reference></references></disease><disease>Leptin Deficiency or Dysfunction<references><reference><reference_text>Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O'Rahilly S: Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999 Sep 16;341(12):879-84. doi: 10.1056/NEJM199909163411204.</reference_text><pubmed_id>10486419</pubmed_id></reference></references></disease><disease>Duchenne Muscular Dystrophy<references><reference><reference_text>Nakagawa T, Takeuchi A, Kakiuchi R, Lee T, Yagi M, Awano H, Iijima K, Takeshima Y, Urade Y, Matsuo M: A prostaglandin D2 metabolite is elevated in the urine of Duchenne muscular dystrophy patients and increases further from 8 years old. Clin Chim Acta. 2013 Aug 23;423:10-4. doi: 10.1016/j.cca.2013.03.031. Epub 2013 Apr 19.</reference_text><pubmed_id>23603101</pubmed_id></reference><reference><reference_text>Srivastava NK, Pradhan S, Mittal B, Gowda GA: High resolution NMR based analysis of serum lipids in Duchenne muscular dystrophy patients and its possible diagnostic significance. NMR Biomed. 2010 Jan;23(1):13-22. doi: 10.1002/nbm.1419.</reference_text><pubmed_id>19787747</pubmed_id></reference><reference><reference_text>Horster I, Weigt-Usinger K, Carmann C, Chobanyan-Jurgens K, Kohler C, Schara U, Kayacelebi AA, Beckmann B, Tsikas D, Lucke T: The L-arginine/NO pathway and homoarginine are altered in Duchenne muscular dystrophy and improved by glucocorticoids. Amino Acids. 2015 Sep;47(9):1853-63. doi: 10.1007/s00726-015-2018-x. Epub 2015 Jun 12.</reference_text><pubmed_id>26066683</pubmed_id></reference></references></disease><disease>Lecithin:cholesterol Acyltransferase Deficiency<references><reference><reference_text>Idzior-Walus B, Sieradzki J, Kostner G, Malecki MT, Klupa T, Wesolowska T, Rostworowski W, Hartwich J, Walus M, Kiec AD, Naruszewicz M: Familial lecithin-cholesterol acyltransferase deficiency: biochemical characteristics and molecular analysis of a new LCAT mutation in a Polish family. Atherosclerosis. 2006 Apr;185(2):413-20. Epub 2005 Jul 26.</reference_text><pubmed_id>16051254</pubmed_id></reference></references></disease><disease>Lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lipodystrophy, Congenital Generalized<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Oculocerebrorenal syndrome<references><reference><reference_text>Charnas LR, Bernardini I, Rader D, Hoeg JM, Gahl WA: Clinical and laboratory findings in the oculocerebrorenal syndrome of Lowe, with special reference to growth and renal function. N Engl J Med. 1991 May 9;324(19):1318-25. doi: 10.1056/NEJM199105093241904.</reference_text><pubmed_id>2017228</pubmed_id></reference></references></disease><disease>Familial partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lathosterolosis<references><reference><reference_text>Brunetti-Pierri N, Corso G, Rossi M, Ferrari P, Balli F, Rivasi F, Annunziata I, Ballabio A, Russo AD, Andria G, Parenti G: Lathosterolosis, a novel multiple-malformation/mental retardation syndrome due to deficiency of 3beta-hydroxysteroid-delta5-desaturase. Am J Hum Genet. 2002 Oct;71(4):952-8. Epub 2002 Aug 20.</reference_text><pubmed_id>12189593</pubmed_id></reference><reference><reference_text>Ho AC, Fung CW, Siu TS, Ma OC, Lam CW, Tam S, Wong VC: Lathosterolosis: a disorder of cholesterol biosynthesis resembling smith-lemli-opitz syndrome. JIMD Rep. 2014;12:129-34. doi: 10.1007/8904_2013_255. Epub 2013 Oct 20.</reference_text><pubmed_id>24142275</pubmed_id></reference></references></disease><disease>Partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Multiple sclerosis<references><reference><reference_text>Lutz NW, Viola A, Malikova I, Confort-Gouny S, Audoin B, Ranjeva JP, Pelletier J, Cozzone PJ: Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One. 2007 Jul 4;2(7):e595.</reference_text><pubmed_id>17611627</pubmed_id></reference><reference><reference_text>Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U, Hillert J, Bjorkhem I: Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med. 2004 Feb;42(2):186-91.</reference_text><pubmed_id>15061359</pubmed_id></reference><reference><reference_text>Leoni V, Lutjohann D, Masterman T: Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis. J Lipid Res. 2005 Feb;46(2):191-5. Epub 2004 Dec 1.</reference_text><pubmed_id>15576852</pubmed_id></reference><reference><reference_text>Calabrese V, Scapagnini G, Ravagna A, Bella R, Butterfield DA, Calvani M, Pennisi G, Giuffrida Stella AM: Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem Res. 2003 Sep;28(9):1321-8.</reference_text><pubmed_id>12938853</pubmed_id></reference><reference><reference_text>Shaw CE, Dunbar PR, Macaulay HA, Neale TJ: Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol. 1995 Jan;242(2):53-8.</reference_text><pubmed_id>7707089</pubmed_id></reference><reference><reference_text>Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.</reference_text><pubmed_id>17384003</pubmed_id></reference><reference><reference_text>Syburra C, Passi S: Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh (1999). 1999 May-Jun;71(3):112-5.</reference_text><pubmed_id>10609336</pubmed_id></reference><reference><reference_text>Forte G, Visconti A, Santucci S, Ghazaryan A, Figa-Talamanca L, Cannoni S, Bocca B, Pino A, Violante N, Alimonti A, Salvetti M, Ristori G: Quantification of chemical elements in blood of patients affected by multiple sclerosis. Ann Ist Super Sanita. 2005;41(2):213-6.</reference_text><pubmed_id>16244395</pubmed_id></reference><reference><reference_text>Toncev G, Milicic B, Toncev S, Samardzic G: Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol. 2002 May;9(3):221-6.</reference_text><pubmed_id>11985629</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, Bamonti F, Capello E, Mancardi GL, Scarpini E: Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res. 2010 May 28;1333:64-71. doi: 10.1016/j.brainres.2010.03.073. Epub 2010 Mar 27.</reference_text><pubmed_id>20347721</pubmed_id></reference><reference><reference_text>Matsushita T, Isobe N, Kawajiri M, Mogi M, Tsukuda K, Horiuchi M, Ohyagi Y, Kira J: CSF angiotensin II and angiotensin-converting enzyme levels in anti-aquaporin-4 autoimmunity. J Neurol Sci. 2010 Aug 15;295(1-2):41-5. doi: 10.1016/j.jns.2010.05.014. Epub 2010 Jun 11.</reference_text><pubmed_id>20541774</pubmed_id></reference><reference><reference_text>Ghabaee M, Jabedari B, Al-E-Eshagh N, Ghaffarpour M, Asadi F: Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients. Int J Neurosci. 2010 Apr;120(4):301-4. doi: 10.3109/00207451003695690.</reference_text><pubmed_id>20374079</pubmed_id></reference><reference><reference_text>Kawajiri M, Mogi M, Osoegawa M, Matsuoka T, Tsukuda K, Kohara K, Horiuchi M, Miki T, Kira JI: Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler. 2008 May;14(4):557-60. doi: 10.1177/1352458507085760.</reference_text><pubmed_id>18562510</pubmed_id></reference><reference><reference_text>Visconti A, Cotichini R, Cannoni S, Bocca B, Forte G, Ghazaryan A, Santucci S, D'Ippolito C, Stazi MA, Salvetti M, Alimonti A, Ristori G: Concentration of elements in serum of patients affected by multiple sclerosis with first demyelinating episode: a six-month longitudinal follow-up study. Ann Ist Super Sanita. 2005;41(2):217-22.</reference_text><pubmed_id>16244396</pubmed_id></reference></references></disease><disease>Inflammatory bowel disease<references><reference><reference_text>Lee T, Clavel T, Smirnov K, Schmidt A, Lagkouvardos I, Walker A, Lucio M, Michalke B, Schmitt-Kopplin P, Fedorak R, Haller D: Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. 2017 May;66(5):863-871. doi: 10.1136/gutjnl-2015-309940. Epub 2016 Feb 4.</reference_text><pubmed_id>26848182</pubmed_id></reference><reference><reference_text>Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158.</reference_text><pubmed_id>27609529</pubmed_id></reference></references></disease><disease>Colorectal cancer<references><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B: Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009 Apr;22(3):342-8. doi: 10.1002/nbm.1345.</reference_text><pubmed_id>19006102</pubmed_id></reference><reference><reference_text>Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP: Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One. 2013 Aug 6;8(8):e70803. doi: 10.1371/journal.pone.0070803. Print 2013.</reference_text><pubmed_id>23940645</pubmed_id></reference><reference><reference_text>Phua LC, Chue XP, Koh PK, Cheah PY, Ho HK, Chan EC: Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biol Ther. 2014 Apr;15(4):389-97. doi: 10.4161/cbt.27625. Epub 2014 Jan 14.</reference_text><pubmed_id>24424155</pubmed_id></reference><reference><reference_text>Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB: Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010 Feb 15;8:13. doi: 10.1186/1741-7015-8-13.</reference_text><pubmed_id>20156336</pubmed_id></reference><reference><reference_text>Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, Ni Y, Zhao A, Xu LX, Cai S, Jia W: Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res. 2009 Oct;8(10):4844-50. doi: 10.1021/pr9004162.</reference_text><pubmed_id>19678709</pubmed_id></reference><reference><reference_text>Cheng Y, Xie G, Chen T, Qiu Y, Zou X, Zheng M, Tan B, Feng B, Dong T, He P, Zhao L, Zhao A, Xu LX, Zhang Y, Jia W: Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res. 2012 Feb 3;11(2):1354-63. doi: 10.1021/pr201001a. Epub 2011 Dec 28.</reference_text><pubmed_id>22148915</pubmed_id></reference><reference><reference_text>Ni Y, Xie G, Jia W: Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res. 2014 Sep 5;13(9):3857-70. doi: 10.1021/pr500443c. Epub 2014 Aug 14.</reference_text><pubmed_id>25105552</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference><reference><reference_text>Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18.</reference_text><pubmed_id>25037050</pubmed_id></reference><reference><reference_text>Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016.</reference_text><pubmed_id>27015276</pubmed_id></reference><reference><reference_text>Lin Y, Ma C, Liu C, Wang Z, Yang J, Liu X, Shen Z, Wu R: NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer. Oncotarget. 2016 May 17;7(20):29454-64. doi: 10.18632/oncotarget.8762.</reference_text><pubmed_id>27107423</pubmed_id></reference><reference><reference_text>Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016.</reference_text><pubmed_id>27275383</pubmed_id></reference><reference><reference_text>Wang X, Wang J, Rao B, Deng L: Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals. Exp Ther Med. 2017 Jun;13(6):2848-2854. doi: 10.3892/etm.2017.4367. Epub 2017 Apr 20.</reference_text><pubmed_id>28587349</pubmed_id></reference><reference><reference_text>Silke Matysik, Caroline Ivanne Le Roy, Gerhard Liebisch, Sandrine Paule Claus. Metabolomics of fecal samples: A practical consideration. Trends in Food Science &amp; Technology. Vol. 57, Part B, Nov. 2016, p.244-255: http://www.sciencedirect.com/science/article/pii/S0924224416301984</reference_text><pubmed_id>28587349</pubmed_id></reference></references></disease><disease>Gallbladder disease<references><reference><reference_text>Lapidus A, Akerlund JE, Einarsson C: Gallbladder bile composition in patients with Crohn 's disease. World J Gastroenterol. 2006 Jan 7;12(1):70-4.</reference_text><pubmed_id>16440420</pubmed_id></reference><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference><reference><reference_text>Mizuno S, Tazuma S, Kajiyama G: Stabilization of biliary lipid particles by ursodeoxycholic acid. Prolonged nucleation time in human gallbladder bile. Dig Dis Sci. 1993 Apr;38(4):684-93.</reference_text><pubmed_id>8462368</pubmed_id></reference><reference><reference_text>Hillebrant CG, Axelson M, Bjorkhem I, Wang FH, Nyberg B, Einarsson C: Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients. Eur J Clin Invest. 1998 Apr;28(4):324-8.</reference_text><pubmed_id>9615912</pubmed_id></reference></references></disease><disease>Cholelithiasis<references><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference></references></disease><disease>Stomach cancer<references><reference><reference_text>Higashijima H, Ichimiya H, Nakano T, Yamashita H, Kuroki S, Satoh H, Chijiiwa K, Tanaka M: Deconjugation of bilirubin accelerates coprecipitation of cholesterol, fatty acids, and mucin in human bile--in vitro study. J Gastroenterol. 1996 Dec;31(6):828-35.</reference_text><pubmed_id>9027647</pubmed_id></reference><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Song H, Peng JS, Dong-Sheng Y, Yang ZL, Liu HL, Zeng YK, Shi XP, Lu BY: Serum metabolic profiling of human gastric cancer based on gas chromatography/mass spectrometry. Braz J Med Biol Res. 2012 Jan;45(1):78-85. Epub 2011 Nov 25.</reference_text><pubmed_id>22124703</pubmed_id></reference><reference><reference_text>Yu L, Aa J, Xu J, Sun M, Qian S, Cheng L, Yang S, Shi R: Metabolomic phenotype of gastric cancer and precancerous stages based on gas chromatography time-of-flight mass spectrometry. J Gastroenterol Hepatol. 2011 Aug;26(8):1290-7. doi: 10.1111/j.1440-1746.2011.06724.x.</reference_text><pubmed_id>21443661</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference></references></disease><disease>Acute myelogenous leukemia<references><reference><reference_text>Tatidis L, Vitols S, Gruber A, Paul C, Axelson M: Cholesterol catabolism in patients with acute myelogenous leukemia and hypocholesterolemia: suppressed levels of a circulating marker for bile acid synthesis. Cancer Lett. 2001 Sep 20;170(2):169-75.</reference_text><pubmed_id>11463495</pubmed_id></reference></references></disease><disease>Hypercholesterolemia<references><reference><reference_text>Thelen KM, Laaksonen R, Paiva H, Lehtimaki T, Lutjohann D: High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels. J Clin Pharmacol. 2006 Jul;46(7):812-6.</reference_text><pubmed_id>16809807</pubmed_id></reference><reference><reference_text>Tamasawa N, Tamasawa A, Takebe K: Higher levels of plasma cholesterol sulfate in patients with liver cirrhosis and hypercholesterolemia. Lipids. 1993 Sep;28(9):833-6.</reference_text><pubmed_id>8231659</pubmed_id></reference><reference><reference_text>Kim DH, Lee KJ, Heo GS: Analysis of cholesterol and cholesteryl esters in human serum using capillary supercritical fluid chromatography. J Chromatogr B Biomed Appl. 1994 Apr 22;655(1):1-8.</reference_text><pubmed_id>8061816</pubmed_id></reference><reference><reference_text>Authors unspecified: Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med. 1988 Jan;148(1):36-69.</reference_text><pubmed_id>3422148</pubmed_id></reference></references></disease><disease>Cholesteryl ester storage disease<references><reference><reference_text>Rassoul F, Richter V, Lohse P, Naumann A, Purschwitz K, Keller E: Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease. Int J Clin Pharmacol Ther. 2001 May;39(5):199-204.</reference_text><pubmed_id>11380065</pubmed_id></reference><reference><reference_text>Chatrath H, Keilin S, Attar BM: Cholesterol ester storage disease (CESD) diagnosed in an asymptomatic adult. Dig Dis Sci. 2009 Jan;54(1):168-73. doi: 10.1007/s10620-008-0310-2. Epub 2008 May 14.</reference_text><pubmed_id>18478331</pubmed_id></reference><reference><reference_text>Bernstein DL, Hulkova H, Bialer MG, Desnick RJ: Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol. 2013 Jun;58(6):1230-43. doi: 10.1016/j.jhep.2013.02.014. Epub 2013 Feb 26.</reference_text><pubmed_id>23485521</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Cystinosis<references><reference><reference_text>Ueda M, O'Brien K, Rosing DR, Ling A, Kleta R, McAreavey D, Bernardini I, Gahl WA: Coronary artery and other vascular calcifications in patients with cystinosis after kidney transplantation. Clin J Am Soc Nephrol. 2006 May;1(3):555-62. Epub 2006 Feb 8.</reference_text><pubmed_id>17699259</pubmed_id></reference><reference><reference_text>Gahl WA, Bernardini I, Dalakas M, Rizzo WB, Harper GS, Hoeg JM, Hurko O, Bernar J: Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome. J Clin Invest. 1988 Feb;81(2):549-60.</reference_text><pubmed_id>3276734</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Smith-Lemli-Opitz syndrome<references><reference><reference_text>van Rooij A, Nijenhuis AA, Wijburg FA, Schutgens RB: Highly increased CSF concentrations of cholesterol precursors in Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 1997 Aug;20(4):578-80.</reference_text><pubmed_id>9266395</pubmed_id></reference><reference><reference_text>Honda M, Tint GS, Honda A, Salen G, Shefer S, Batta AK, Matsuzaki Y, Tanaka N: Regulation of cholesterol biosynthetic pathway in patients with the Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2000 Jul;23(5):464-74.</reference_text><pubmed_id>10947201</pubmed_id></reference><reference><reference_text>Rossi M, Federico G, Corso G, Parenti G, Battagliese A, Frascogna AR, Della Casa R, Dello Russo A, Strisciuglio P, Saggese G, Andria G: Vitamin D status in patients affected by Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2005;28(1):69-80.</reference_text><pubmed_id>15702407</pubmed_id></reference><reference><reference_text>Johnson DW, ten Brink HJ, Jakobs C: A rapid screening procedure for cholesterol and dehydrocholesterol by electrospray ionization tandem mass spectrometry. J Lipid Res. 2001 Oct;42(10):1699-705.</reference_text><pubmed_id>11590227</pubmed_id></reference></references></disease><disease>Prostate cancer<references><reference><reference_text>Nyman DW, Suzanne Stratton M, Kopplin MJ, Dalkin BL, Nagle RB, Jay Gandolfi A: Selenium and selenomethionine levels in prostate cancer patients. Cancer Detect Prev. 2004;28(1):8-16.</reference_text><pubmed_id>15041072</pubmed_id></reference><reference><reference_text>Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, Egevad L, Tjonneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, Palli D, Vineis P, Tumino R, Berrino F, Kiemeney L, Bueno-de-Mesquita HB, Quiros JR, Gonzalez CA, Martinez C, Larranaga N, Chirlaque MD, Ardanaz E, Stattin P, Hallmans G, Khaw KT, Bingham S, Slimani N, Ferrari P, Rinaldi S, Riboli E: Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr. 2007 Sep;86(3):672-81.</reference_text><pubmed_id>17823432</pubmed_id></reference><reference><reference_text>Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762.</reference_text><pubmed_id>19212411</pubmed_id></reference><reference><reference_text>Puah CM, Williams G, Ghanadian R: Urinary unconjugated 5 alpha-androstane-3 alpha, 17 beta-diol in patients with prostatic tumours. Urol Res. 1982;10(2):81-4.</reference_text><pubmed_id>6180540</pubmed_id></reference><reference><reference_text>Thysell E, Surowiec I, Hornberg E, Crnalic S, Widmark A, Johansson AI, Stattin P, Bergh A, Moritz T, Antti H, Wikstrom P: Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One. 2010 Dec 3;5(12):e14175. doi: 10.1371/journal.pone.0014175.</reference_text><pubmed_id>21151972</pubmed_id></reference><reference><reference_text>Soliman LC, Hui Y, Hewavitharana AK, Chen DD: Monitoring potential prostate cancer biomarkers in urine by capillary electrophoresis-tandem mass spectrometry. J Chromatogr A. 2012 Dec 7;1267:162-9. doi: 10.1016/j.chroma.2012.07.021. Epub 2012 Jul 14.</reference_text><pubmed_id>22824219</pubmed_id></reference><reference><reference_text>Madu CO, Lu Y: Novel diagnostic biomarkers for prostate cancer. J Cancer. 2010 Oct 6;1:150-77.</reference_text><pubmed_id>20975847</pubmed_id></reference></references></disease><disease>Schizophrenia<references><reference><reference_text>Harnryd C, Bjerkenstedt L, Grimm VE, Sedvall G: Reduction of MOPEG levels in cerebrospinal fluid of psychotic women after electroconvulsive treatment. Psychopharmacology (Berl). 1979 Aug 8;64(2):131-4.</reference_text><pubmed_id>115032</pubmed_id></reference><reference><reference_text>Kobayashi K, Koide Y, Yoshino K, Shohmori T: [P-hydroxyphenylacetic acid concentrations in cerebrospinal fluid]. No To Shinkei. 1982 Aug;34(8):769-74.</reference_text><pubmed_id>7126379</pubmed_id></reference><reference><reference_text>Alfredsson G, Wiesel FA: Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology (Berl). 1989;99(3):322-7.</reference_text><pubmed_id>2480613</pubmed_id></reference><reference><reference_text>Heresco-Levy U, Bar G, Levin R, Ermilov M, Ebstein RP, Javitt DC: High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. Schizophr Res. 2007 Mar;91(1-3):14-21. Epub 2007 Feb 2.</reference_text><pubmed_id>17276036</pubmed_id></reference><reference><reference_text>Walker EF, Bonsall R, Walder DJ: Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis. Neuropsychiatry Neuropsychol Behav Neurol. 2002 Mar;15(1):10-7.</reference_text><pubmed_id>11877547</pubmed_id></reference><reference><reference_text>Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M: Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry. 2003 Jun;60(6):572-6.</reference_text><pubmed_id>12796220</pubmed_id></reference><reference><reference_text>Do KQ, Lauer CJ, Schreiber W, Zollinger M, Gutteck-Amsler U, Cuenod M, Holsboer F: gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem. 1995 Dec;65(6):2652-62.</reference_text><pubmed_id>7595563</pubmed_id></reference><reference><reference_text>Nikisch G, Baumann P, Wiedemann G, Kiessling B, Weisser H, Hertel A, Yoshitake T, Kehr J, Mathe AA: Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF. J Clin Psychopharmacol. 2010 Oct;30(5):496-503. doi: 10.1097/JCP.0b013e3181f2288e.</reference_text><pubmed_id>20814316</pubmed_id></reference><reference><reference_text>Fukushima T, Iizuka H, Yokota A, Suzuki T, Ohno C, Kono Y, Nishikiori M, Seki A, Ichiba H, Watanabe Y, Hongo S, Utsunomiya M, Nakatani M, Sadamoto K, Yoshio T: Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One. 2014 Jul 8;9(7):e101652. doi: 10.1371/journal.pone.0101652. eCollection 2014.</reference_text><pubmed_id>25004141</pubmed_id></reference><reference><reference_text>Koike S, Bundo M, Iwamoto K, Suga M, Kuwabara H, Ohashi Y, Shinoda K, Takano Y, Iwashiro N, Satomura Y, Nagai T, Natsubori T, Tada M, Yamasue H, Kasai K: A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study. Transl Psychiatry. 2014 Apr 8;4:e379. doi: 10.1038/tp.2014.19.</reference_text><pubmed_id>24713860</pubmed_id></reference><reference><reference_text>Ballesteros A, Summerfelt A, Du X, Jiang P, Chiappelli J, Tagamets M, O'Donnell P, Kochunov P, Hong LE: Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia. Clin Neurophysiol. 2013 Nov;124(11):2209-15. doi: 10.1016/j.clinph.2013.05.021. Epub 2013 Jun 30.</reference_text><pubmed_id>23823132</pubmed_id></reference><reference><reference_text>Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel FA: Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry. 1985 Sep;147:276-82.</reference_text><pubmed_id>2415198</pubmed_id></reference><reference><reference_text>Pickar D, Breier A, Hsiao JK, Doran AR, Wolkowitz OM, Pato CN, Konicki PE, Potter WZ: Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Arch Gen Psychiatry. 1990 Jul;47(7):641-8.</reference_text><pubmed_id>1694425</pubmed_id></reference><reference><reference_text>Prell GD, Green JP, Kaufmann CA, Khandelwal JK, Morrishow AM, Kirch DG, Linnoila M, Wyatt RJ: Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res. 1995 Jan;14(2):93-104.</reference_text><pubmed_id>7711000</pubmed_id></reference><reference><reference_text>Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B: Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology. 2009;59(2):123-9. doi: 10.1159/000213565. Epub 2009 Apr 22.</reference_text><pubmed_id>19390223</pubmed_id></reference><reference><reference_text>Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K, Cao Y, Wang X, Qiu Y, Su M, Zhao A, Wang P, Yang P, Wu J, Feng G, He L, Jia W, Wan C: Potential metabolite markers of schizophrenia. Mol Psychiatry. 2013 Jan;18(1):67-78. doi: 10.1038/mp.2011.131. Epub 2011 Oct 25.</reference_text><pubmed_id>22024767</pubmed_id></reference><reference><reference_text>Xuan J, Pan G, Qiu Y, Yang L, Su M, Liu Y, Chen J, Feng G, Fang Y, Jia W, Xing Q, He L: Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. J Proteome Res. 2011 Dec 2;10(12):5433-43. doi: 10.1021/pr2006796. Epub 2011 Nov  8.</reference_text><pubmed_id>22007635</pubmed_id></reference><reference><reference_text>Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM, Rothermundt M, Bogerts B, Koethe D, Kranaster L, Ohrmann P, Suslow T, McAllister G, Spain M, Barnes A, van Beveren NJ, Baron-Cohen S, Steiner J, Torrey FE, Yolken RH, Bahn S: Identification of a biological signature for schizophrenia in serum. Mol Psychiatry. 2012 May;17(5):494-502. doi: 10.1038/mp.2011.42. Epub 2011 Apr 12.</reference_text><pubmed_id>21483431</pubmed_id></reference><reference><reference_text>Mathe AA, Eberhard G, Saaf J, Wetterberg L: Plasma prostaglandin E2 metabolite--measured as 11-deoxy-15-keto-13,14-dihydro-11 beta,16 xi-cyclo-PGE2--in twins with schizophrenic disorder. Biol Psychiatry. 1986 Sep;21(11):1024-30.</reference_text><pubmed_id>3741918</pubmed_id></reference><reference><reference_text>Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N: Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct. 2002 Jun;20(2):171-5.</reference_text><pubmed_id>11979513</pubmed_id></reference><reference><reference_text>Zumarraga M, Davila R, Basterreche N, Arrue A, Goienetxea B, Zamalloa MI, Erkoreka L, Bustamante S, Inchausti L, Gonzalez-Torres MA, Guimon J: Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients. Neurochem Int. 2010 May-Jun;56(6-7):774-9. doi: 10.1016/j.neuint.2010.02.015. Epub 2010 Mar 4.</reference_text><pubmed_id>20206656</pubmed_id></reference><reference><reference_text>Peters JG: Dopamine, noradrenaline and serotonin spinal fluid metabolites in temporal lobe epileptic patients with schizophrenic symptomatology. Eur Neurol. 1979;18(1):15-8.</reference_text><pubmed_id>436860</pubmed_id></reference><reference><reference_text>Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, Rozen S, Krishnan RR, McEvoy J, Kaddurah-Daouk R: Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry. 2010 Sep;15(9):938-53. doi: 10.1038/mp.2009.33. Epub 2009 Apr 28.</reference_text><pubmed_id>19401681</pubmed_id></reference><reference><reference_text>Gattaz WF, Waldmeier P, Beckmann H: CSF monoamine metabolites in schizophrenic patients. Acta Psychiatr Scand. 1982 Nov;66(5):350-60.</reference_text><pubmed_id>6184954</pubmed_id></reference><reference><reference_text>Nilsson-Todd LK, Nordin C, Jonsson EG, Skogh E, Erhardt S: Cerebrospinal fluid kynurenic acid in male patients with schizophrenia - correlation with monoamine metabolites. Acta Neuropsychiatr. 2007 Feb;19(1):45-52. doi: 10.1111/j.1601-5215.2006.00170.x.</reference_text><pubmed_id>26952797</pubmed_id></reference><reference><reference_text>Cai HL, Li HD, Yan XZ, Sun B, Zhang Q, Yan M, Zhang WY, Jiang P, Zhu RH, Liu YP, Fang PF, Xu P, Yuan HY, Zhang XH, Hu L, Yang W, Ye HS: Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naive schizophrenia patients after treatment with risperidone. J Proteome Res. 2012 Aug 3;11(8):4338-50. doi: 10.1021/pr300459d. Epub 2012 Jul 26.</reference_text><pubmed_id>22800120</pubmed_id></reference><reference><reference_text>Al Awam K, Haussleiter IS, Dudley E, Donev R, Brune M, Juckel G, Thome J: Multiplatform metabolome and proteome profiling identifies serum metabolite and protein signatures as prospective biomarkers for schizophrenia. J Neural Transm (Vienna). 2015 Aug;122 Suppl 1:S111-22. doi: 10.1007/s00702-014-1224-0. Epub 2014 May 1.</reference_text><pubmed_id>24789758</pubmed_id></reference><reference><reference_text>Bicikova M, Hill M, Ripova D, Mohr P, Hampl R: Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia. J Steroid Biochem Mol Biol. 2013 Jan;133:77-83. doi: 10.1016/j.jsbmb.2012.08.009. Epub 2012 Aug 24.</reference_text><pubmed_id>22944140</pubmed_id></reference><reference><reference_text>He Y, Yu Z, Giegling I, Xie L, Hartmann AM, Prehn C, Adamski J, Kahn R, Li Y, Illig T, Wang-Sattler R, Rujescu D: Schizophrenia shows a unique metabolomics signature in plasma. Transl Psychiatry. 2012 Aug 14;2:e149. doi: 10.1038/tp.2012.76.</reference_text><pubmed_id>22892715</pubmed_id></reference><reference><reference_text>Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KR: Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):934-45. Epub 2007 Apr 17.</reference_text><pubmed_id>17440431</pubmed_id></reference><reference><reference_text>Fryar-Williams S, Strobel JE: Biomarkers of a five-domain translational substrate for schizophrenia and schizoaffective psychosis. Biomark Res. 2015 Feb 6;3:3. doi: 10.1186/s40364-015-0028-1. eCollection 2015.</reference_text><pubmed_id>25729574</pubmed_id></reference><reference><reference_text>Oresic M, Seppanen-Laakso T, Sun D, Tang J, Therman S, Viehman R, Mustonen U, van Erp TG, Hyotylainen T, Thompson P, Toga AW, Huttunen MO, Suvisaari J, Kaprio J, Lonnqvist J, Cannon TD: Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia. Genome Med. 2012 Jan 18;4(1):1. doi: 10.1186/gm300.</reference_text><pubmed_id>22257447</pubmed_id></reference></references></disease><disease>Primary hypomagnesemia<references><reference><reference_text>Jin-no Y, Kamiya Y, Okada M, Hirako M, Takada N, Kawaguchi M: Primary hypomagnesemia caused by isolated magnesium malabsorption: atypical case in adult. Intern Med. 1999 Mar;38(3):261-5.</reference_text><pubmed_id>10337938</pubmed_id></reference><reference><reference_text>Vainsel M, Vandevelde G, Smulders J, Vosters M, Hubain P, Loeb H: Tetany due to hypomagnesaemia with secondary hypocalcaemia. Arch Dis Child. 1970 Apr;45(240):254-8.</reference_text><pubmed_id>5419995</pubmed_id></reference><reference><reference_text>Shalev H, Phillip M, Galil A, Carmi R, Landau D: Clinical presentation and outcome in primary familial hypomagnesaemia. Arch Dis Child. 1998 Feb;78(2):127-30.</reference_text><pubmed_id>9579153</pubmed_id></reference><reference><reference_text>Kari JA, Farouq M, Alshaya HO: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Pediatr Nephrol. 2003 Jun;18(6):506-10. Epub 2003 Apr 29.</reference_text><pubmed_id>12720080</pubmed_id></reference></references></disease><disease>Hyperlipoproteinemia<references><reference><reference_text>Sinha S, Misra A, Kumar V, Jagannathan NR, Bal CS, Pandey RM, Singhania R, Deepak: Proton magnetic resonance spectroscopy and single photon emission computed tomography study of the brain in asymptomatic young hyperlipidaemic Asian Indians in North India show early abnormalities. Clin Endocrinol (Oxf). 2004 Aug;61(2):182-9.</reference_text><pubmed_id>15272912</pubmed_id></reference><reference><reference_text>Nelson RH: Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013 Mar</reference_text><pubmed_id>40(1):195-211. doi: 10.1016/j.pop.2012.11.003. Epub 2012 Dec  4.</pubmed_id></reference><reference><reference_text>Cantin B, Boudriau S, Bertrand M, Brun LD, Gagne C, Rogers PA, Ven Murthy MR, Lupien PJ, Julien P: Hemolysis in primary lipoprotein lipase deficiency. Metabolism. 1995 May;44(5):652-8.</reference_text><pubmed_id>7752915</pubmed_id></reference></references></disease><disease>Abetalipoproteinemia<references><reference><reference_text>Dawson G, Kruski AW, Scanu AM: Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J Lipid Res. 1976 Mar;17(2):125-31.</reference_text><pubmed_id>178813</pubmed_id></reference><reference><reference_text>Lazaro RP, Dentinger MP, Rodichok LD, Barron KD, Satya-Murti S: Muscle pathology in Bassen-Kornzweig syndrome and vitamin E deficiency. Am J Clin Pathol. 1986 Sep;86(3):378-87.</reference_text><pubmed_id>2944375</pubmed_id></reference></references></disease><disease>Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis<references><reference><reference_text>Breckenridge WC, Alaupovic P, Cox DW, Little JA: Apolipoprotein and lipoprotein concentrations in familial apolipoprotein C-II deficiency. Atherosclerosis. 1982 Aug;44(2):223-35.</reference_text><pubmed_id>7138621</pubmed_id></reference><reference><reference_text>Fukami M, Hasegawa T, Horikawa R, Ohashi T, Nishimura G, Homma K, Ogata T: Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr Res. 2006 Feb;59(2):276-80. doi: 10.1203/01.pdr.0000195825.31504.28.</reference_text><pubmed_id>16439592</pubmed_id></reference></references></disease><disease>Cerebrotendinous xanthomatosis<references><reference><reference_text>Halperin G, Elisaf M, Leitersdorf E, Harats D: A new method for determination of serum cholestanol by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2000 Jun 9;742(2):345-52.</reference_text><pubmed_id>10901139</pubmed_id></reference><reference><reference_text>Siman-Tov T, Meiner V, Gadoth N: Could steroids mask the diagnosis of cerebrotendinous xanthomatosis? J Neurol Sci. 2006 Apr 15;243(1-2):83-6. Epub 2006 Jan 30.</reference_text><pubmed_id>16445943</pubmed_id></reference><reference><reference_text>Agrawal NK, Garg S: Cerebrotendinous xanthomatosis: a rare disorder with a rare presentation. BMJ Case Rep. 2012 Sep 21;2012. pii: bcr-2012-006202. doi: 10.1136/bcr-2012-006202.</reference_text><pubmed_id>23001091</pubmed_id></reference></references></disease><disease>3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency<references><reference><reference_text>Thompson GN, Hsu BY, Pitt JJ, Treacy E, Stanley CA: Fasting hypoketotic coma in a child with deficiency of mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase. N Engl J Med. 1997 Oct 23;337(17):1203-7. doi: 10.1056/NEJM199710233371704.</reference_text><pubmed_id>9337379</pubmed_id></reference><reference><reference_text>Morris AA, Lascelles CV, Olpin SE, Lake BD, Leonard JV, Quant PA: Hepatic mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme a synthase deficiency. Pediatr Res. 1998 Sep;44(3):392-6. doi: 10.1203/00006450-199809000-00021.</reference_text><pubmed_id>9727719</pubmed_id></reference><reference><reference_text>Conboy E, Vairo F, Schultz M, Agre K, Ridsdale R, Deyle D, Oglesbee D, Gavrilov D, Klee EW, Lanpher B: Mitochondrial 3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency: Unique Presenting Laboratory Values and a Review of Biochemical and Clinical Features. JIMD Rep. 2017 Oct 14. doi: 10.1007/8904_2017_59.</reference_text><pubmed_id>29030856</pubmed_id></reference></references></disease><disease>Hypercholesterolemia, familial<references><reference><reference_text>Kwiterovich PO Jr, Fredrickson DS, Levy RI: Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest. 1974 May;53(5):1237-49. doi: 10.1172/JCI107670.</reference_text><pubmed_id>4363406</pubmed_id></reference></references></disease><disease>SC4MOL deficiency<references><reference><reference_text>He M, Kratz LE, Michel JJ, Vallejo AN, Ferris L, Kelley RI, Hoover JJ, Jukic D, Gibson KM, Wolfe LA, Ramachandran D, Zwick ME, Vockley J: Mutations in the human SC4MOL gene encoding a methyl sterol oxidase cause psoriasiform dermatitis, microcephaly, and developmental delay. J Clin Invest. 2011 Mar;121(3):976-84. doi: 10.1172/JCI42650.</reference_text><pubmed_id>21285510</pubmed_id></reference></references></disease><disease>Chondrodysplasia punctata, X-linked dominant<references><reference><reference_text>Aughton DJ, Kelley RI, Metzenberg A, Pureza V, Pauli RM: X-linked dominant chondrodysplasia punctata (CDPX2) caused by single gene mosaicism in a male. Am J Med Genet A. 2003 Jan 30;116A(3):255-60. doi: 10.1002/ajmg.a.10852.</reference_text><pubmed_id>12503102</pubmed_id></reference></references></disease><disease>Desmosterolosis<references><reference><reference_text>Andersson HC, Kratz L, Kelley R: Desmosterolosis presenting with multiple congenital anomalies and profound developmental delay. Am J Med Genet. 2002 Dec 15;113(4):315-9. doi: 10.1002/ajmg.b.10873.</reference_text><pubmed_id>12457401</pubmed_id></reference></references></disease><disease>Donohue Syndrome<references><reference><reference_text>Nijim Y, Awni Y, Adawi A, Bowirrat A: Classic Case Report of Donohue Syndrome (Leprechaunism; OMIM *246200): The Impact of Consanguineous Mating. Medicine (Baltimore). 2016 Feb;95(6):e2710. doi: 10.1097/MD.0000000000002710.</reference_text><pubmed_id>26871809</pubmed_id></reference></references></disease><disease>Leptin Deficiency or Dysfunction<references><reference><reference_text>Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O'Rahilly S: Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999 Sep 16;341(12):879-84. doi: 10.1056/NEJM199909163411204.</reference_text><pubmed_id>10486419</pubmed_id></reference></references></disease><disease>Duchenne Muscular Dystrophy<references><reference><reference_text>Nakagawa T, Takeuchi A, Kakiuchi R, Lee T, Yagi M, Awano H, Iijima K, Takeshima Y, Urade Y, Matsuo M: A prostaglandin D2 metabolite is elevated in the urine of Duchenne muscular dystrophy patients and increases further from 8 years old. Clin Chim Acta. 2013 Aug 23;423:10-4. doi: 10.1016/j.cca.2013.03.031. Epub 2013 Apr 19.</reference_text><pubmed_id>23603101</pubmed_id></reference><reference><reference_text>Srivastava NK, Pradhan S, Mittal B, Gowda GA: High resolution NMR based analysis of serum lipids in Duchenne muscular dystrophy patients and its possible diagnostic significance. NMR Biomed. 2010 Jan;23(1):13-22. doi: 10.1002/nbm.1419.</reference_text><pubmed_id>19787747</pubmed_id></reference><reference><reference_text>Horster I, Weigt-Usinger K, Carmann C, Chobanyan-Jurgens K, Kohler C, Schara U, Kayacelebi AA, Beckmann B, Tsikas D, Lucke T: The L-arginine/NO pathway and homoarginine are altered in Duchenne muscular dystrophy and improved by glucocorticoids. Amino Acids. 2015 Sep;47(9):1853-63. doi: 10.1007/s00726-015-2018-x. Epub 2015 Jun 12.</reference_text><pubmed_id>26066683</pubmed_id></reference></references></disease><disease>Lecithin:cholesterol Acyltransferase Deficiency<references><reference><reference_text>Idzior-Walus B, Sieradzki J, Kostner G, Malecki MT, Klupa T, Wesolowska T, Rostworowski W, Hartwich J, Walus M, Kiec AD, Naruszewicz M: Familial lecithin-cholesterol acyltransferase deficiency: biochemical characteristics and molecular analysis of a new LCAT mutation in a Polish family. Atherosclerosis. 2006 Apr;185(2):413-20. Epub 2005 Jul 26.</reference_text><pubmed_id>16051254</pubmed_id></reference></references></disease><disease>Lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lipodystrophy, Congenital Generalized<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Oculocerebrorenal syndrome<references><reference><reference_text>Charnas LR, Bernardini I, Rader D, Hoeg JM, Gahl WA: Clinical and laboratory findings in the oculocerebrorenal syndrome of Lowe, with special reference to growth and renal function. N Engl J Med. 1991 May 9;324(19):1318-25. doi: 10.1056/NEJM199105093241904.</reference_text><pubmed_id>2017228</pubmed_id></reference></references></disease><disease>Familial partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lathosterolosis<references><reference><reference_text>Brunetti-Pierri N, Corso G, Rossi M, Ferrari P, Balli F, Rivasi F, Annunziata I, Ballabio A, Russo AD, Andria G, Parenti G: Lathosterolosis, a novel multiple-malformation/mental retardation syndrome due to deficiency of 3beta-hydroxysteroid-delta5-desaturase. Am J Hum Genet. 2002 Oct;71(4):952-8. Epub 2002 Aug 20.</reference_text><pubmed_id>12189593</pubmed_id></reference><reference><reference_text>Ho AC, Fung CW, Siu TS, Ma OC, Lam CW, Tam S, Wong VC: Lathosterolosis: a disorder of cholesterol biosynthesis resembling smith-lemli-opitz syndrome. JIMD Rep. 2014;12:129-34. doi: 10.1007/8904_2013_255. Epub 2013 Oct 20.</reference_text><pubmed_id>24142275</pubmed_id></reference></references></disease><disease>Partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Multiple sclerosis<references><reference><reference_text>Lutz NW, Viola A, Malikova I, Confort-Gouny S, Audoin B, Ranjeva JP, Pelletier J, Cozzone PJ: Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One. 2007 Jul 4;2(7):e595.</reference_text><pubmed_id>17611627</pubmed_id></reference><reference><reference_text>Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U, Hillert J, Bjorkhem I: Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med. 2004 Feb;42(2):186-91.</reference_text><pubmed_id>15061359</pubmed_id></reference><reference><reference_text>Leoni V, Lutjohann D, Masterman T: Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis. J Lipid Res. 2005 Feb;46(2):191-5. Epub 2004 Dec 1.</reference_text><pubmed_id>15576852</pubmed_id></reference><reference><reference_text>Calabrese V, Scapagnini G, Ravagna A, Bella R, Butterfield DA, Calvani M, Pennisi G, Giuffrida Stella AM: Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem Res. 2003 Sep;28(9):1321-8.</reference_text><pubmed_id>12938853</pubmed_id></reference><reference><reference_text>Shaw CE, Dunbar PR, Macaulay HA, Neale TJ: Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol. 1995 Jan;242(2):53-8.</reference_text><pubmed_id>7707089</pubmed_id></reference><reference><reference_text>Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.</reference_text><pubmed_id>17384003</pubmed_id></reference><reference><reference_text>Syburra C, Passi S: Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh (1999). 1999 May-Jun;71(3):112-5.</reference_text><pubmed_id>10609336</pubmed_id></reference><reference><reference_text>Forte G, Visconti A, Santucci S, Ghazaryan A, Figa-Talamanca L, Cannoni S, Bocca B, Pino A, Violante N, Alimonti A, Salvetti M, Ristori G: Quantification of chemical elements in blood of patients affected by multiple sclerosis. Ann Ist Super Sanita. 2005;41(2):213-6.</reference_text><pubmed_id>16244395</pubmed_id></reference><reference><reference_text>Toncev G, Milicic B, Toncev S, Samardzic G: Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol. 2002 May;9(3):221-6.</reference_text><pubmed_id>11985629</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, Bamonti F, Capello E, Mancardi GL, Scarpini E: Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res. 2010 May 28;1333:64-71. doi: 10.1016/j.brainres.2010.03.073. Epub 2010 Mar 27.</reference_text><pubmed_id>20347721</pubmed_id></reference><reference><reference_text>Matsushita T, Isobe N, Kawajiri M, Mogi M, Tsukuda K, Horiuchi M, Ohyagi Y, Kira J: CSF angiotensin II and angiotensin-converting enzyme levels in anti-aquaporin-4 autoimmunity. J Neurol Sci. 2010 Aug 15;295(1-2):41-5. doi: 10.1016/j.jns.2010.05.014. Epub 2010 Jun 11.</reference_text><pubmed_id>20541774</pubmed_id></reference><reference><reference_text>Ghabaee M, Jabedari B, Al-E-Eshagh N, Ghaffarpour M, Asadi F: Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients. Int J Neurosci. 2010 Apr;120(4):301-4. doi: 10.3109/00207451003695690.</reference_text><pubmed_id>20374079</pubmed_id></reference><reference><reference_text>Kawajiri M, Mogi M, Osoegawa M, Matsuoka T, Tsukuda K, Kohara K, Horiuchi M, Miki T, Kira JI: Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler. 2008 May;14(4):557-60. doi: 10.1177/1352458507085760.</reference_text><pubmed_id>18562510</pubmed_id></reference><reference><reference_text>Visconti A, Cotichini R, Cannoni S, Bocca B, Forte G, Ghazaryan A, Santucci S, D'Ippolito C, Stazi MA, Salvetti M, Alimonti A, Ristori G: Concentration of elements in serum of patients affected by multiple sclerosis with first demyelinating episode: a six-month longitudinal follow-up study. Ann Ist Super Sanita. 2005;41(2):217-22.</reference_text><pubmed_id>16244396</pubmed_id></reference></references></disease><disease>Inflammatory bowel disease<references><reference><reference_text>Lee T, Clavel T, Smirnov K, Schmidt A, Lagkouvardos I, Walker A, Lucio M, Michalke B, Schmitt-Kopplin P, Fedorak R, Haller D: Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. 2017 May;66(5):863-871. doi: 10.1136/gutjnl-2015-309940. Epub 2016 Feb 4.</reference_text><pubmed_id>26848182</pubmed_id></reference><reference><reference_text>Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158.</reference_text><pubmed_id>27609529</pubmed_id></reference></references></disease><disease>Colorectal cancer<references><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B: Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009 Apr;22(3):342-8. doi: 10.1002/nbm.1345.</reference_text><pubmed_id>19006102</pubmed_id></reference><reference><reference_text>Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP: Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One. 2013 Aug 6;8(8):e70803. doi: 10.1371/journal.pone.0070803. Print 2013.</reference_text><pubmed_id>23940645</pubmed_id></reference><reference><reference_text>Phua LC, Chue XP, Koh PK, Cheah PY, Ho HK, Chan EC: Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biol Ther. 2014 Apr;15(4):389-97. doi: 10.4161/cbt.27625. Epub 2014 Jan 14.</reference_text><pubmed_id>24424155</pubmed_id></reference><reference><reference_text>Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB: Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010 Feb 15;8:13. doi: 10.1186/1741-7015-8-13.</reference_text><pubmed_id>20156336</pubmed_id></reference><reference><reference_text>Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, Ni Y, Zhao A, Xu LX, Cai S, Jia W: Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res. 2009 Oct;8(10):4844-50. doi: 10.1021/pr9004162.</reference_text><pubmed_id>19678709</pubmed_id></reference><reference><reference_text>Cheng Y, Xie G, Chen T, Qiu Y, Zou X, Zheng M, Tan B, Feng B, Dong T, He P, Zhao L, Zhao A, Xu LX, Zhang Y, Jia W: Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res. 2012 Feb 3;11(2):1354-63. doi: 10.1021/pr201001a. Epub 2011 Dec 28.</reference_text><pubmed_id>22148915</pubmed_id></reference><reference><reference_text>Ni Y, Xie G, Jia W: Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res. 2014 Sep 5;13(9):3857-70. doi: 10.1021/pr500443c. Epub 2014 Aug 14.</reference_text><pubmed_id>25105552</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference><reference><reference_text>Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18.</reference_text><pubmed_id>25037050</pubmed_id></reference><reference><reference_text>Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016.</reference_text><pubmed_id>27015276</pubmed_id></reference><reference><reference_text>Lin Y, Ma C, Liu C, Wang Z, Yang J, Liu X, Shen Z, Wu R: NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer. Oncotarget. 2016 May 17;7(20):29454-64. doi: 10.18632/oncotarget.8762.</reference_text><pubmed_id>27107423</pubmed_id></reference><reference><reference_text>Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016.</reference_text><pubmed_id>27275383</pubmed_id></reference><reference><reference_text>Wang X, Wang J, Rao B, Deng L: Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals. Exp Ther Med. 2017 Jun;13(6):2848-2854. doi: 10.3892/etm.2017.4367. Epub 2017 Apr 20.</reference_text><pubmed_id>28587349</pubmed_id></reference><reference><reference_text>Silke Matysik, Caroline Ivanne Le Roy, Gerhard Liebisch, Sandrine Paule Claus. Metabolomics of fecal samples: A practical consideration. Trends in Food Science &amp; Technology. Vol. 57, Part B, Nov. 2016, p.244-255: http://www.sciencedirect.com/science/article/pii/S0924224416301984</reference_text><pubmed_id>28587349</pubmed_id></reference></references></disease><disease>Gallbladder disease<references><reference><reference_text>Lapidus A, Akerlund JE, Einarsson C: Gallbladder bile composition in patients with Crohn 's disease. World J Gastroenterol. 2006 Jan 7;12(1):70-4.</reference_text><pubmed_id>16440420</pubmed_id></reference><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference><reference><reference_text>Mizuno S, Tazuma S, Kajiyama G: Stabilization of biliary lipid particles by ursodeoxycholic acid. Prolonged nucleation time in human gallbladder bile. Dig Dis Sci. 1993 Apr;38(4):684-93.</reference_text><pubmed_id>8462368</pubmed_id></reference><reference><reference_text>Hillebrant CG, Axelson M, Bjorkhem I, Wang FH, Nyberg B, Einarsson C: Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients. Eur J Clin Invest. 1998 Apr;28(4):324-8.</reference_text><pubmed_id>9615912</pubmed_id></reference></references></disease><disease>Cholelithiasis<references><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference></references></disease><disease>Stomach cancer<references><reference><reference_text>Higashijima H, Ichimiya H, Nakano T, Yamashita H, Kuroki S, Satoh H, Chijiiwa K, Tanaka M: Deconjugation of bilirubin accelerates coprecipitation of cholesterol, fatty acids, and mucin in human bile--in vitro study. J Gastroenterol. 1996 Dec;31(6):828-35.</reference_text><pubmed_id>9027647</pubmed_id></reference><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Song H, Peng JS, Dong-Sheng Y, Yang ZL, Liu HL, Zeng YK, Shi XP, Lu BY: Serum metabolic profiling of human gastric cancer based on gas chromatography/mass spectrometry. Braz J Med Biol Res. 2012 Jan;45(1):78-85. Epub 2011 Nov 25.</reference_text><pubmed_id>22124703</pubmed_id></reference><reference><reference_text>Yu L, Aa J, Xu J, Sun M, Qian S, Cheng L, Yang S, Shi R: Metabolomic phenotype of gastric cancer and precancerous stages based on gas chromatography time-of-flight mass spectrometry. J Gastroenterol Hepatol. 2011 Aug;26(8):1290-7. doi: 10.1111/j.1440-1746.2011.06724.x.</reference_text><pubmed_id>21443661</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference></references></disease><disease>Acute myelogenous leukemia<references><reference><reference_text>Tatidis L, Vitols S, Gruber A, Paul C, Axelson M: Cholesterol catabolism in patients with acute myelogenous leukemia and hypocholesterolemia: suppressed levels of a circulating marker for bile acid synthesis. Cancer Lett. 2001 Sep 20;170(2):169-75.</reference_text><pubmed_id>11463495</pubmed_id></reference></references></disease><disease>Hypercholesterolemia<references><reference><reference_text>Thelen KM, Laaksonen R, Paiva H, Lehtimaki T, Lutjohann D: High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels. J Clin Pharmacol. 2006 Jul;46(7):812-6.</reference_text><pubmed_id>16809807</pubmed_id></reference><reference><reference_text>Tamasawa N, Tamasawa A, Takebe K: Higher levels of plasma cholesterol sulfate in patients with liver cirrhosis and hypercholesterolemia. Lipids. 1993 Sep;28(9):833-6.</reference_text><pubmed_id>8231659</pubmed_id></reference><reference><reference_text>Kim DH, Lee KJ, Heo GS: Analysis of cholesterol and cholesteryl esters in human serum using capillary supercritical fluid chromatography. J Chromatogr B Biomed Appl. 1994 Apr 22;655(1):1-8.</reference_text><pubmed_id>8061816</pubmed_id></reference><reference><reference_text>Authors unspecified: Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med. 1988 Jan;148(1):36-69.</reference_text><pubmed_id>3422148</pubmed_id></reference></references></disease><disease>Cholesteryl ester storage disease<references><reference><reference_text>Rassoul F, Richter V, Lohse P, Naumann A, Purschwitz K, Keller E: Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease. Int J Clin Pharmacol Ther. 2001 May;39(5):199-204.</reference_text><pubmed_id>11380065</pubmed_id></reference><reference><reference_text>Chatrath H, Keilin S, Attar BM: Cholesterol ester storage disease (CESD) diagnosed in an asymptomatic adult. Dig Dis Sci. 2009 Jan;54(1):168-73. doi: 10.1007/s10620-008-0310-2. Epub 2008 May 14.</reference_text><pubmed_id>18478331</pubmed_id></reference><reference><reference_text>Bernstein DL, Hulkova H, Bialer MG, Desnick RJ: Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol. 2013 Jun;58(6):1230-43. doi: 10.1016/j.jhep.2013.02.014. Epub 2013 Feb 26.</reference_text><pubmed_id>23485521</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Cystinosis<references><reference><reference_text>Ueda M, O'Brien K, Rosing DR, Ling A, Kleta R, McAreavey D, Bernardini I, Gahl WA: Coronary artery and other vascular calcifications in patients with cystinosis after kidney transplantation. Clin J Am Soc Nephrol. 2006 May;1(3):555-62. Epub 2006 Feb 8.</reference_text><pubmed_id>17699259</pubmed_id></reference><reference><reference_text>Gahl WA, Bernardini I, Dalakas M, Rizzo WB, Harper GS, Hoeg JM, Hurko O, Bernar J: Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome. J Clin Invest. 1988 Feb;81(2):549-60.</reference_text><pubmed_id>3276734</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Smith-Lemli-Opitz syndrome<references><reference><reference_text>van Rooij A, Nijenhuis AA, Wijburg FA, Schutgens RB: Highly increased CSF concentrations of cholesterol precursors in Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 1997 Aug;20(4):578-80.</reference_text><pubmed_id>9266395</pubmed_id></reference><reference><reference_text>Honda M, Tint GS, Honda A, Salen G, Shefer S, Batta AK, Matsuzaki Y, Tanaka N: Regulation of cholesterol biosynthetic pathway in patients with the Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2000 Jul;23(5):464-74.</reference_text><pubmed_id>10947201</pubmed_id></reference><reference><reference_text>Rossi M, Federico G, Corso G, Parenti G, Battagliese A, Frascogna AR, Della Casa R, Dello Russo A, Strisciuglio P, Saggese G, Andria G: Vitamin D status in patients affected by Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2005;28(1):69-80.</reference_text><pubmed_id>15702407</pubmed_id></reference><reference><reference_text>Johnson DW, ten Brink HJ, Jakobs C: A rapid screening procedure for cholesterol and dehydrocholesterol by electrospray ionization tandem mass spectrometry. J Lipid Res. 2001 Oct;42(10):1699-705.</reference_text><pubmed_id>11590227</pubmed_id></reference></references></disease><disease>Prostate cancer<references><reference><reference_text>Nyman DW, Suzanne Stratton M, Kopplin MJ, Dalkin BL, Nagle RB, Jay Gandolfi A: Selenium and selenomethionine levels in prostate cancer patients. Cancer Detect Prev. 2004;28(1):8-16.</reference_text><pubmed_id>15041072</pubmed_id></reference><reference><reference_text>Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, Egevad L, Tjonneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, Palli D, Vineis P, Tumino R, Berrino F, Kiemeney L, Bueno-de-Mesquita HB, Quiros JR, Gonzalez CA, Martinez C, Larranaga N, Chirlaque MD, Ardanaz E, Stattin P, Hallmans G, Khaw KT, Bingham S, Slimani N, Ferrari P, Rinaldi S, Riboli E: Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr. 2007 Sep;86(3):672-81.</reference_text><pubmed_id>17823432</pubmed_id></reference><reference><reference_text>Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762.</reference_text><pubmed_id>19212411</pubmed_id></reference><reference><reference_text>Puah CM, Williams G, Ghanadian R: Urinary unconjugated 5 alpha-androstane-3 alpha, 17 beta-diol in patients with prostatic tumours. Urol Res. 1982;10(2):81-4.</reference_text><pubmed_id>6180540</pubmed_id></reference><reference><reference_text>Thysell E, Surowiec I, Hornberg E, Crnalic S, Widmark A, Johansson AI, Stattin P, Bergh A, Moritz T, Antti H, Wikstrom P: Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One. 2010 Dec 3;5(12):e14175. doi: 10.1371/journal.pone.0014175.</reference_text><pubmed_id>21151972</pubmed_id></reference><reference><reference_text>Soliman LC, Hui Y, Hewavitharana AK, Chen DD: Monitoring potential prostate cancer biomarkers in urine by capillary electrophoresis-tandem mass spectrometry. J Chromatogr A. 2012 Dec 7;1267:162-9. doi: 10.1016/j.chroma.2012.07.021. Epub 2012 Jul 14.</reference_text><pubmed_id>22824219</pubmed_id></reference><reference><reference_text>Madu CO, Lu Y: Novel diagnostic biomarkers for prostate cancer. J Cancer. 2010 Oct 6;1:150-77.</reference_text><pubmed_id>20975847</pubmed_id></reference></references></disease><disease>Schizophrenia<references><reference><reference_text>Harnryd C, Bjerkenstedt L, Grimm VE, Sedvall G: Reduction of MOPEG levels in cerebrospinal fluid of psychotic women after electroconvulsive treatment. Psychopharmacology (Berl). 1979 Aug 8;64(2):131-4.</reference_text><pubmed_id>115032</pubmed_id></reference><reference><reference_text>Kobayashi K, Koide Y, Yoshino K, Shohmori T: [P-hydroxyphenylacetic acid concentrations in cerebrospinal fluid]. No To Shinkei. 1982 Aug;34(8):769-74.</reference_text><pubmed_id>7126379</pubmed_id></reference><reference><reference_text>Alfredsson G, Wiesel FA: Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology (Berl). 1989;99(3):322-7.</reference_text><pubmed_id>2480613</pubmed_id></reference><reference><reference_text>Heresco-Levy U, Bar G, Levin R, Ermilov M, Ebstein RP, Javitt DC: High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. Schizophr Res. 2007 Mar;91(1-3):14-21. Epub 2007 Feb 2.</reference_text><pubmed_id>17276036</pubmed_id></reference><reference><reference_text>Walker EF, Bonsall R, Walder DJ: Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis. Neuropsychiatry Neuropsychol Behav Neurol. 2002 Mar;15(1):10-7.</reference_text><pubmed_id>11877547</pubmed_id></reference><reference><reference_text>Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M: Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry. 2003 Jun;60(6):572-6.</reference_text><pubmed_id>12796220</pubmed_id></reference><reference><reference_text>Do KQ, Lauer CJ, Schreiber W, Zollinger M, Gutteck-Amsler U, Cuenod M, Holsboer F: gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem. 1995 Dec;65(6):2652-62.</reference_text><pubmed_id>7595563</pubmed_id></reference><reference><reference_text>Nikisch G, Baumann P, Wiedemann G, Kiessling B, Weisser H, Hertel A, Yoshitake T, Kehr J, Mathe AA: Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF. J Clin Psychopharmacol. 2010 Oct;30(5):496-503. doi: 10.1097/JCP.0b013e3181f2288e.</reference_text><pubmed_id>20814316</pubmed_id></reference><reference><reference_text>Fukushima T, Iizuka H, Yokota A, Suzuki T, Ohno C, Kono Y, Nishikiori M, Seki A, Ichiba H, Watanabe Y, Hongo S, Utsunomiya M, Nakatani M, Sadamoto K, Yoshio T: Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One. 2014 Jul 8;9(7):e101652. doi: 10.1371/journal.pone.0101652. eCollection 2014.</reference_text><pubmed_id>25004141</pubmed_id></reference><reference><reference_text>Koike S, Bundo M, Iwamoto K, Suga M, Kuwabara H, Ohashi Y, Shinoda K, Takano Y, Iwashiro N, Satomura Y, Nagai T, Natsubori T, Tada M, Yamasue H, Kasai K: A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study. Transl Psychiatry. 2014 Apr 8;4:e379. doi: 10.1038/tp.2014.19.</reference_text><pubmed_id>24713860</pubmed_id></reference><reference><reference_text>Ballesteros A, Summerfelt A, Du X, Jiang P, Chiappelli J, Tagamets M, O'Donnell P, Kochunov P, Hong LE: Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia. Clin Neurophysiol. 2013 Nov;124(11):2209-15. doi: 10.1016/j.clinph.2013.05.021. Epub 2013 Jun 30.</reference_text><pubmed_id>23823132</pubmed_id></reference><reference><reference_text>Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel FA: Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry. 1985 Sep;147:276-82.</reference_text><pubmed_id>2415198</pubmed_id></reference><reference><reference_text>Pickar D, Breier A, Hsiao JK, Doran AR, Wolkowitz OM, Pato CN, Konicki PE, Potter WZ: Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Arch Gen Psychiatry. 1990 Jul;47(7):641-8.</reference_text><pubmed_id>1694425</pubmed_id></reference><reference><reference_text>Prell GD, Green JP, Kaufmann CA, Khandelwal JK, Morrishow AM, Kirch DG, Linnoila M, Wyatt RJ: Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res. 1995 Jan;14(2):93-104.</reference_text><pubmed_id>7711000</pubmed_id></reference><reference><reference_text>Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B: Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology. 2009;59(2):123-9. doi: 10.1159/000213565. Epub 2009 Apr 22.</reference_text><pubmed_id>19390223</pubmed_id></reference><reference><reference_text>Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K, Cao Y, Wang X, Qiu Y, Su M, Zhao A, Wang P, Yang P, Wu J, Feng G, He L, Jia W, Wan C: Potential metabolite markers of schizophrenia. Mol Psychiatry. 2013 Jan;18(1):67-78. doi: 10.1038/mp.2011.131. Epub 2011 Oct 25.</reference_text><pubmed_id>22024767</pubmed_id></reference><reference><reference_text>Xuan J, Pan G, Qiu Y, Yang L, Su M, Liu Y, Chen J, Feng G, Fang Y, Jia W, Xing Q, He L: Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. J Proteome Res. 2011 Dec 2;10(12):5433-43. doi: 10.1021/pr2006796. Epub 2011 Nov  8.</reference_text><pubmed_id>22007635</pubmed_id></reference><reference><reference_text>Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM, Rothermundt M, Bogerts B, Koethe D, Kranaster L, Ohrmann P, Suslow T, McAllister G, Spain M, Barnes A, van Beveren NJ, Baron-Cohen S, Steiner J, Torrey FE, Yolken RH, Bahn S: Identification of a biological signature for schizophrenia in serum. Mol Psychiatry. 2012 May;17(5):494-502. doi: 10.1038/mp.2011.42. Epub 2011 Apr 12.</reference_text><pubmed_id>21483431</pubmed_id></reference><reference><reference_text>Mathe AA, Eberhard G, Saaf J, Wetterberg L: Plasma prostaglandin E2 metabolite--measured as 11-deoxy-15-keto-13,14-dihydro-11 beta,16 xi-cyclo-PGE2--in twins with schizophrenic disorder. Biol Psychiatry. 1986 Sep;21(11):1024-30.</reference_text><pubmed_id>3741918</pubmed_id></reference><reference><reference_text>Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N: Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct. 2002 Jun;20(2):171-5.</reference_text><pubmed_id>11979513</pubmed_id></reference><reference><reference_text>Zumarraga M, Davila R, Basterreche N, Arrue A, Goienetxea B, Zamalloa MI, Erkoreka L, Bustamante S, Inchausti L, Gonzalez-Torres MA, Guimon J: Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients. Neurochem Int. 2010 May-Jun;56(6-7):774-9. doi: 10.1016/j.neuint.2010.02.015. Epub 2010 Mar 4.</reference_text><pubmed_id>20206656</pubmed_id></reference><reference><reference_text>Peters JG: Dopamine, noradrenaline and serotonin spinal fluid metabolites in temporal lobe epileptic patients with schizophrenic symptomatology. Eur Neurol. 1979;18(1):15-8.</reference_text><pubmed_id>436860</pubmed_id></reference><reference><reference_text>Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, Rozen S, Krishnan RR, McEvoy J, Kaddurah-Daouk R: Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry. 2010 Sep;15(9):938-53. doi: 10.1038/mp.2009.33. Epub 2009 Apr 28.</reference_text><pubmed_id>19401681</pubmed_id></reference><reference><reference_text>Gattaz WF, Waldmeier P, Beckmann H: CSF monoamine metabolites in schizophrenic patients. Acta Psychiatr Scand. 1982 Nov;66(5):350-60.</reference_text><pubmed_id>6184954</pubmed_id></reference><reference><reference_text>Nilsson-Todd LK, Nordin C, Jonsson EG, Skogh E, Erhardt S: Cerebrospinal fluid kynurenic acid in male patients with schizophrenia - correlation with monoamine metabolites. Acta Neuropsychiatr. 2007 Feb;19(1):45-52. doi: 10.1111/j.1601-5215.2006.00170.x.</reference_text><pubmed_id>26952797</pubmed_id></reference><reference><reference_text>Cai HL, Li HD, Yan XZ, Sun B, Zhang Q, Yan M, Zhang WY, Jiang P, Zhu RH, Liu YP, Fang PF, Xu P, Yuan HY, Zhang XH, Hu L, Yang W, Ye HS: Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naive schizophrenia patients after treatment with risperidone. J Proteome Res. 2012 Aug 3;11(8):4338-50. doi: 10.1021/pr300459d. Epub 2012 Jul 26.</reference_text><pubmed_id>22800120</pubmed_id></reference><reference><reference_text>Al Awam K, Haussleiter IS, Dudley E, Donev R, Brune M, Juckel G, Thome J: Multiplatform metabolome and proteome profiling identifies serum metabolite and protein signatures as prospective biomarkers for schizophrenia. J Neural Transm (Vienna). 2015 Aug;122 Suppl 1:S111-22. doi: 10.1007/s00702-014-1224-0. Epub 2014 May 1.</reference_text><pubmed_id>24789758</pubmed_id></reference><reference><reference_text>Bicikova M, Hill M, Ripova D, Mohr P, Hampl R: Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia. J Steroid Biochem Mol Biol. 2013 Jan;133:77-83. doi: 10.1016/j.jsbmb.2012.08.009. Epub 2012 Aug 24.</reference_text><pubmed_id>22944140</pubmed_id></reference><reference><reference_text>He Y, Yu Z, Giegling I, Xie L, Hartmann AM, Prehn C, Adamski J, Kahn R, Li Y, Illig T, Wang-Sattler R, Rujescu D: Schizophrenia shows a unique metabolomics signature in plasma. Transl Psychiatry. 2012 Aug 14;2:e149. doi: 10.1038/tp.2012.76.</reference_text><pubmed_id>22892715</pubmed_id></reference><reference><reference_text>Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KR: Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):934-45. Epub 2007 Apr 17.</reference_text><pubmed_id>17440431</pubmed_id></reference><reference><reference_text>Fryar-Williams S, Strobel JE: Biomarkers of a five-domain translational substrate for schizophrenia and schizoaffective psychosis. Biomark Res. 2015 Feb 6;3:3. doi: 10.1186/s40364-015-0028-1. eCollection 2015.</reference_text><pubmed_id>25729574</pubmed_id></reference><reference><reference_text>Oresic M, Seppanen-Laakso T, Sun D, Tang J, Therman S, Viehman R, Mustonen U, van Erp TG, Hyotylainen T, Thompson P, Toga AW, Huttunen MO, Suvisaari J, Kaprio J, Lonnqvist J, Cannon TD: Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia. Genome Med. 2012 Jan 18;4(1):1. doi: 10.1186/gm300.</reference_text><pubmed_id>22257447</pubmed_id></reference></references></disease><disease>Primary hypomagnesemia<references><reference><reference_text>Jin-no Y, Kamiya Y, Okada M, Hirako M, Takada N, Kawaguchi M: Primary hypomagnesemia caused by isolated magnesium malabsorption: atypical case in adult. Intern Med. 1999 Mar;38(3):261-5.</reference_text><pubmed_id>10337938</pubmed_id></reference><reference><reference_text>Vainsel M, Vandevelde G, Smulders J, Vosters M, Hubain P, Loeb H: Tetany due to hypomagnesaemia with secondary hypocalcaemia. Arch Dis Child. 1970 Apr;45(240):254-8.</reference_text><pubmed_id>5419995</pubmed_id></reference><reference><reference_text>Shalev H, Phillip M, Galil A, Carmi R, Landau D: Clinical presentation and outcome in primary familial hypomagnesaemia. Arch Dis Child. 1998 Feb;78(2):127-30.</reference_text><pubmed_id>9579153</pubmed_id></reference><reference><reference_text>Kari JA, Farouq M, Alshaya HO: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Pediatr Nephrol. 2003 Jun;18(6):506-10. Epub 2003 Apr 29.</reference_text><pubmed_id>12720080</pubmed_id></reference></references></disease><disease>Hyperlipoproteinemia<references><reference><reference_text>Sinha S, Misra A, Kumar V, Jagannathan NR, Bal CS, Pandey RM, Singhania R, Deepak: Proton magnetic resonance spectroscopy and single photon emission computed tomography study of the brain in asymptomatic young hyperlipidaemic Asian Indians in North India show early abnormalities. Clin Endocrinol (Oxf). 2004 Aug;61(2):182-9.</reference_text><pubmed_id>15272912</pubmed_id></reference><reference><reference_text>Nelson RH: Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013 Mar</reference_text><pubmed_id>40(1):195-211. doi: 10.1016/j.pop.2012.11.003. Epub 2012 Dec  4.</pubmed_id></reference><reference><reference_text>Cantin B, Boudriau S, Bertrand M, Brun LD, Gagne C, Rogers PA, Ven Murthy MR, Lupien PJ, Julien P: Hemolysis in primary lipoprotein lipase deficiency. Metabolism. 1995 May;44(5):652-8.</reference_text><pubmed_id>7752915</pubmed_id></reference></references></disease><disease>Abetalipoproteinemia<references><reference><reference_text>Dawson G, Kruski AW, Scanu AM: Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J Lipid Res. 1976 Mar;17(2):125-31.</reference_text><pubmed_id>178813</pubmed_id></reference><reference><reference_text>Lazaro RP, Dentinger MP, Rodichok LD, Barron KD, Satya-Murti S: Muscle pathology in Bassen-Kornzweig syndrome and vitamin E deficiency. Am J Clin Pathol. 1986 Sep;86(3):378-87.</reference_text><pubmed_id>2944375</pubmed_id></reference></references></disease><disease>Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis<references><reference><reference_text>Breckenridge WC, Alaupovic P, Cox DW, Little JA: Apolipoprotein and lipoprotein concentrations in familial apolipoprotein C-II deficiency. Atherosclerosis. 1982 Aug;44(2):223-35.</reference_text><pubmed_id>7138621</pubmed_id></reference><reference><reference_text>Fukami M, Hasegawa T, Horikawa R, Ohashi T, Nishimura G, Homma K, Ogata T: Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr Res. 2006 Feb;59(2):276-80. doi: 10.1203/01.pdr.0000195825.31504.28.</reference_text><pubmed_id>16439592</pubmed_id></reference></references></disease><disease>Cerebrotendinous xanthomatosis<references><reference><reference_text>Halperin G, Elisaf M, Leitersdorf E, Harats D: A new method for determination of serum cholestanol by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2000 Jun 9;742(2):345-52.</reference_text><pubmed_id>10901139</pubmed_id></reference><reference><reference_text>Siman-Tov T, Meiner V, Gadoth N: Could steroids mask the diagnosis of cerebrotendinous xanthomatosis? J Neurol Sci. 2006 Apr 15;243(1-2):83-6. Epub 2006 Jan 30.</reference_text><pubmed_id>16445943</pubmed_id></reference><reference><reference_text>Agrawal NK, Garg S: Cerebrotendinous xanthomatosis: a rare disorder with a rare presentation. BMJ Case Rep. 2012 Sep 21;2012. pii: bcr-2012-006202. doi: 10.1136/bcr-2012-006202.</reference_text><pubmed_id>23001091</pubmed_id></reference></references></disease><disease>3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency<references><reference><reference_text>Thompson GN, Hsu BY, Pitt JJ, Treacy E, Stanley CA: Fasting hypoketotic coma in a child with deficiency of mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase. N Engl J Med. 1997 Oct 23;337(17):1203-7. doi: 10.1056/NEJM199710233371704.</reference_text><pubmed_id>9337379</pubmed_id></reference><reference><reference_text>Morris AA, Lascelles CV, Olpin SE, Lake BD, Leonard JV, Quant PA: Hepatic mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme a synthase deficiency. Pediatr Res. 1998 Sep;44(3):392-6. doi: 10.1203/00006450-199809000-00021.</reference_text><pubmed_id>9727719</pubmed_id></reference><reference><reference_text>Conboy E, Vairo F, Schultz M, Agre K, Ridsdale R, Deyle D, Oglesbee D, Gavrilov D, Klee EW, Lanpher B: Mitochondrial 3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency: Unique Presenting Laboratory Values and a Review of Biochemical and Clinical Features. JIMD Rep. 2017 Oct 14. doi: 10.1007/8904_2017_59.</reference_text><pubmed_id>29030856</pubmed_id></reference></references></disease><disease>Hypercholesterolemia, familial<references><reference><reference_text>Kwiterovich PO Jr, Fredrickson DS, Levy RI: Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest. 1974 May;53(5):1237-49. doi: 10.1172/JCI107670.</reference_text><pubmed_id>4363406</pubmed_id></reference></references></disease><disease>SC4MOL deficiency<references><reference><reference_text>He M, Kratz LE, Michel JJ, Vallejo AN, Ferris L, Kelley RI, Hoover JJ, Jukic D, Gibson KM, Wolfe LA, Ramachandran D, Zwick ME, Vockley J: Mutations in the human SC4MOL gene encoding a methyl sterol oxidase cause psoriasiform dermatitis, microcephaly, and developmental delay. J Clin Invest. 2011 Mar;121(3):976-84. doi: 10.1172/JCI42650.</reference_text><pubmed_id>21285510</pubmed_id></reference></references></disease><disease>Chondrodysplasia punctata, X-linked dominant<references><reference><reference_text>Aughton DJ, Kelley RI, Metzenberg A, Pureza V, Pauli RM: X-linked dominant chondrodysplasia punctata (CDPX2) caused by single gene mosaicism in a male. Am J Med Genet A. 2003 Jan 30;116A(3):255-60. doi: 10.1002/ajmg.a.10852.</reference_text><pubmed_id>12503102</pubmed_id></reference></references></disease><disease>Desmosterolosis<references><reference><reference_text>Andersson HC, Kratz L, Kelley R: Desmosterolosis presenting with multiple congenital anomalies and profound developmental delay. Am J Med Genet. 2002 Dec 15;113(4):315-9. doi: 10.1002/ajmg.b.10873.</reference_text><pubmed_id>12457401</pubmed_id></reference></references></disease><disease>Donohue Syndrome<references><reference><reference_text>Nijim Y, Awni Y, Adawi A, Bowirrat A: Classic Case Report of Donohue Syndrome (Leprechaunism; OMIM *246200): The Impact of Consanguineous Mating. Medicine (Baltimore). 2016 Feb;95(6):e2710. doi: 10.1097/MD.0000000000002710.</reference_text><pubmed_id>26871809</pubmed_id></reference></references></disease><disease>Leptin Deficiency or Dysfunction<references><reference><reference_text>Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O'Rahilly S: Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999 Sep 16;341(12):879-84. doi: 10.1056/NEJM199909163411204.</reference_text><pubmed_id>10486419</pubmed_id></reference></references></disease><disease>Duchenne Muscular Dystrophy<references><reference><reference_text>Nakagawa T, Takeuchi A, Kakiuchi R, Lee T, Yagi M, Awano H, Iijima K, Takeshima Y, Urade Y, Matsuo M: A prostaglandin D2 metabolite is elevated in the urine of Duchenne muscular dystrophy patients and increases further from 8 years old. Clin Chim Acta. 2013 Aug 23;423:10-4. doi: 10.1016/j.cca.2013.03.031. Epub 2013 Apr 19.</reference_text><pubmed_id>23603101</pubmed_id></reference><reference><reference_text>Srivastava NK, Pradhan S, Mittal B, Gowda GA: High resolution NMR based analysis of serum lipids in Duchenne muscular dystrophy patients and its possible diagnostic significance. NMR Biomed. 2010 Jan;23(1):13-22. doi: 10.1002/nbm.1419.</reference_text><pubmed_id>19787747</pubmed_id></reference><reference><reference_text>Horster I, Weigt-Usinger K, Carmann C, Chobanyan-Jurgens K, Kohler C, Schara U, Kayacelebi AA, Beckmann B, Tsikas D, Lucke T: The L-arginine/NO pathway and homoarginine are altered in Duchenne muscular dystrophy and improved by glucocorticoids. Amino Acids. 2015 Sep;47(9):1853-63. doi: 10.1007/s00726-015-2018-x. Epub 2015 Jun 12.</reference_text><pubmed_id>26066683</pubmed_id></reference></references></disease><disease>Lecithin:cholesterol Acyltransferase Deficiency<references><reference><reference_text>Idzior-Walus B, Sieradzki J, Kostner G, Malecki MT, Klupa T, Wesolowska T, Rostworowski W, Hartwich J, Walus M, Kiec AD, Naruszewicz M: Familial lecithin-cholesterol acyltransferase deficiency: biochemical characteristics and molecular analysis of a new LCAT mutation in a Polish family. Atherosclerosis. 2006 Apr;185(2):413-20. Epub 2005 Jul 26.</reference_text><pubmed_id>16051254</pubmed_id></reference></references></disease><disease>Lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lipodystrophy, Congenital Generalized<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Oculocerebrorenal syndrome<references><reference><reference_text>Charnas LR, Bernardini I, Rader D, Hoeg JM, Gahl WA: Clinical and laboratory findings in the oculocerebrorenal syndrome of Lowe, with special reference to growth and renal function. N Engl J Med. 1991 May 9;324(19):1318-25. doi: 10.1056/NEJM199105093241904.</reference_text><pubmed_id>2017228</pubmed_id></reference></references></disease><disease>Familial partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lathosterolosis<references><reference><reference_text>Brunetti-Pierri N, Corso G, Rossi M, Ferrari P, Balli F, Rivasi F, Annunziata I, Ballabio A, Russo AD, Andria G, Parenti G: Lathosterolosis, a novel multiple-malformation/mental retardation syndrome due to deficiency of 3beta-hydroxysteroid-delta5-desaturase. Am J Hum Genet. 2002 Oct;71(4):952-8. Epub 2002 Aug 20.</reference_text><pubmed_id>12189593</pubmed_id></reference><reference><reference_text>Ho AC, Fung CW, Siu TS, Ma OC, Lam CW, Tam S, Wong VC: Lathosterolosis: a disorder of cholesterol biosynthesis resembling smith-lemli-opitz syndrome. JIMD Rep. 2014;12:129-34. doi: 10.1007/8904_2013_255. Epub 2013 Oct 20.</reference_text><pubmed_id>24142275</pubmed_id></reference></references></disease><disease>Partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Multiple sclerosis<references><reference><reference_text>Lutz NW, Viola A, Malikova I, Confort-Gouny S, Audoin B, Ranjeva JP, Pelletier J, Cozzone PJ: Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One. 2007 Jul 4;2(7):e595.</reference_text><pubmed_id>17611627</pubmed_id></reference><reference><reference_text>Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U, Hillert J, Bjorkhem I: Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med. 2004 Feb;42(2):186-91.</reference_text><pubmed_id>15061359</pubmed_id></reference><reference><reference_text>Leoni V, Lutjohann D, Masterman T: Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis. J Lipid Res. 2005 Feb;46(2):191-5. Epub 2004 Dec 1.</reference_text><pubmed_id>15576852</pubmed_id></reference><reference><reference_text>Calabrese V, Scapagnini G, Ravagna A, Bella R, Butterfield DA, Calvani M, Pennisi G, Giuffrida Stella AM: Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem Res. 2003 Sep;28(9):1321-8.</reference_text><pubmed_id>12938853</pubmed_id></reference><reference><reference_text>Shaw CE, Dunbar PR, Macaulay HA, Neale TJ: Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol. 1995 Jan;242(2):53-8.</reference_text><pubmed_id>7707089</pubmed_id></reference><reference><reference_text>Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.</reference_text><pubmed_id>17384003</pubmed_id></reference><reference><reference_text>Syburra C, Passi S: Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh (1999). 1999 May-Jun;71(3):112-5.</reference_text><pubmed_id>10609336</pubmed_id></reference><reference><reference_text>Forte G, Visconti A, Santucci S, Ghazaryan A, Figa-Talamanca L, Cannoni S, Bocca B, Pino A, Violante N, Alimonti A, Salvetti M, Ristori G: Quantification of chemical elements in blood of patients affected by multiple sclerosis. Ann Ist Super Sanita. 2005;41(2):213-6.</reference_text><pubmed_id>16244395</pubmed_id></reference><reference><reference_text>Toncev G, Milicic B, Toncev S, Samardzic G: Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol. 2002 May;9(3):221-6.</reference_text><pubmed_id>11985629</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, Bamonti F, Capello E, Mancardi GL, Scarpini E: Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res. 2010 May 28;1333:64-71. doi: 10.1016/j.brainres.2010.03.073. Epub 2010 Mar 27.</reference_text><pubmed_id>20347721</pubmed_id></reference><reference><reference_text>Matsushita T, Isobe N, Kawajiri M, Mogi M, Tsukuda K, Horiuchi M, Ohyagi Y, Kira J: CSF angiotensin II and angiotensin-converting enzyme levels in anti-aquaporin-4 autoimmunity. J Neurol Sci. 2010 Aug 15;295(1-2):41-5. doi: 10.1016/j.jns.2010.05.014. Epub 2010 Jun 11.</reference_text><pubmed_id>20541774</pubmed_id></reference><reference><reference_text>Ghabaee M, Jabedari B, Al-E-Eshagh N, Ghaffarpour M, Asadi F: Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients. Int J Neurosci. 2010 Apr;120(4):301-4. doi: 10.3109/00207451003695690.</reference_text><pubmed_id>20374079</pubmed_id></reference><reference><reference_text>Kawajiri M, Mogi M, Osoegawa M, Matsuoka T, Tsukuda K, Kohara K, Horiuchi M, Miki T, Kira JI: Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler. 2008 May;14(4):557-60. doi: 10.1177/1352458507085760.</reference_text><pubmed_id>18562510</pubmed_id></reference><reference><reference_text>Visconti A, Cotichini R, Cannoni S, Bocca B, Forte G, Ghazaryan A, Santucci S, D'Ippolito C, Stazi MA, Salvetti M, Alimonti A, Ristori G: Concentration of elements in serum of patients affected by multiple sclerosis with first demyelinating episode: a six-month longitudinal follow-up study. Ann Ist Super Sanita. 2005;41(2):217-22.</reference_text><pubmed_id>16244396</pubmed_id></reference></references></disease><disease>Inflammatory bowel disease<references><reference><reference_text>Lee T, Clavel T, Smirnov K, Schmidt A, Lagkouvardos I, Walker A, Lucio M, Michalke B, Schmitt-Kopplin P, Fedorak R, Haller D: Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. 2017 May;66(5):863-871. doi: 10.1136/gutjnl-2015-309940. Epub 2016 Feb 4.</reference_text><pubmed_id>26848182</pubmed_id></reference><reference><reference_text>Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158.</reference_text><pubmed_id>27609529</pubmed_id></reference></references></disease><disease>Colorectal cancer<references><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B: Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009 Apr;22(3):342-8. doi: 10.1002/nbm.1345.</reference_text><pubmed_id>19006102</pubmed_id></reference><reference><reference_text>Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP: Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One. 2013 Aug 6;8(8):e70803. doi: 10.1371/journal.pone.0070803. Print 2013.</reference_text><pubmed_id>23940645</pubmed_id></reference><reference><reference_text>Phua LC, Chue XP, Koh PK, Cheah PY, Ho HK, Chan EC: Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biol Ther. 2014 Apr;15(4):389-97. doi: 10.4161/cbt.27625. Epub 2014 Jan 14.</reference_text><pubmed_id>24424155</pubmed_id></reference><reference><reference_text>Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB: Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010 Feb 15;8:13. doi: 10.1186/1741-7015-8-13.</reference_text><pubmed_id>20156336</pubmed_id></reference><reference><reference_text>Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, Ni Y, Zhao A, Xu LX, Cai S, Jia W: Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res. 2009 Oct;8(10):4844-50. doi: 10.1021/pr9004162.</reference_text><pubmed_id>19678709</pubmed_id></reference><reference><reference_text>Cheng Y, Xie G, Chen T, Qiu Y, Zou X, Zheng M, Tan B, Feng B, Dong T, He P, Zhao L, Zhao A, Xu LX, Zhang Y, Jia W: Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res. 2012 Feb 3;11(2):1354-63. doi: 10.1021/pr201001a. Epub 2011 Dec 28.</reference_text><pubmed_id>22148915</pubmed_id></reference><reference><reference_text>Ni Y, Xie G, Jia W: Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res. 2014 Sep 5;13(9):3857-70. doi: 10.1021/pr500443c. Epub 2014 Aug 14.</reference_text><pubmed_id>25105552</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference><reference><reference_text>Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18.</reference_text><pubmed_id>25037050</pubmed_id></reference><reference><reference_text>Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016.</reference_text><pubmed_id>27015276</pubmed_id></reference><reference><reference_text>Lin Y, Ma C, Liu C, Wang Z, Yang J, Liu X, Shen Z, Wu R: NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer. Oncotarget. 2016 May 17;7(20):29454-64. doi: 10.18632/oncotarget.8762.</reference_text><pubmed_id>27107423</pubmed_id></reference><reference><reference_text>Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016.</reference_text><pubmed_id>27275383</pubmed_id></reference><reference><reference_text>Wang X, Wang J, Rao B, Deng L: Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals. Exp Ther Med. 2017 Jun;13(6):2848-2854. doi: 10.3892/etm.2017.4367. Epub 2017 Apr 20.</reference_text><pubmed_id>28587349</pubmed_id></reference><reference><reference_text>Silke Matysik, Caroline Ivanne Le Roy, Gerhard Liebisch, Sandrine Paule Claus. Metabolomics of fecal samples: A practical consideration. Trends in Food Science &amp; Technology. Vol. 57, Part B, Nov. 2016, p.244-255: http://www.sciencedirect.com/science/article/pii/S0924224416301984</reference_text><pubmed_id>28587349</pubmed_id></reference></references></disease><disease>Gallbladder disease<references><reference><reference_text>Lapidus A, Akerlund JE, Einarsson C: Gallbladder bile composition in patients with Crohn 's disease. World J Gastroenterol. 2006 Jan 7;12(1):70-4.</reference_text><pubmed_id>16440420</pubmed_id></reference><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference><reference><reference_text>Mizuno S, Tazuma S, Kajiyama G: Stabilization of biliary lipid particles by ursodeoxycholic acid. Prolonged nucleation time in human gallbladder bile. Dig Dis Sci. 1993 Apr;38(4):684-93.</reference_text><pubmed_id>8462368</pubmed_id></reference><reference><reference_text>Hillebrant CG, Axelson M, Bjorkhem I, Wang FH, Nyberg B, Einarsson C: Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients. Eur J Clin Invest. 1998 Apr;28(4):324-8.</reference_text><pubmed_id>9615912</pubmed_id></reference></references></disease><disease>Cholelithiasis<references><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference></references></disease><disease>Stomach cancer<references><reference><reference_text>Higashijima H, Ichimiya H, Nakano T, Yamashita H, Kuroki S, Satoh H, Chijiiwa K, Tanaka M: Deconjugation of bilirubin accelerates coprecipitation of cholesterol, fatty acids, and mucin in human bile--in vitro study. J Gastroenterol. 1996 Dec;31(6):828-35.</reference_text><pubmed_id>9027647</pubmed_id></reference><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Song H, Peng JS, Dong-Sheng Y, Yang ZL, Liu HL, Zeng YK, Shi XP, Lu BY: Serum metabolic profiling of human gastric cancer based on gas chromatography/mass spectrometry. Braz J Med Biol Res. 2012 Jan;45(1):78-85. Epub 2011 Nov 25.</reference_text><pubmed_id>22124703</pubmed_id></reference><reference><reference_text>Yu L, Aa J, Xu J, Sun M, Qian S, Cheng L, Yang S, Shi R: Metabolomic phenotype of gastric cancer and precancerous stages based on gas chromatography time-of-flight mass spectrometry. J Gastroenterol Hepatol. 2011 Aug;26(8):1290-7. doi: 10.1111/j.1440-1746.2011.06724.x.</reference_text><pubmed_id>21443661</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference></references></disease><disease>Acute myelogenous leukemia<references><reference><reference_text>Tatidis L, Vitols S, Gruber A, Paul C, Axelson M: Cholesterol catabolism in patients with acute myelogenous leukemia and hypocholesterolemia: suppressed levels of a circulating marker for bile acid synthesis. Cancer Lett. 2001 Sep 20;170(2):169-75.</reference_text><pubmed_id>11463495</pubmed_id></reference></references></disease><disease>Hypercholesterolemia<references><reference><reference_text>Thelen KM, Laaksonen R, Paiva H, Lehtimaki T, Lutjohann D: High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels. J Clin Pharmacol. 2006 Jul;46(7):812-6.</reference_text><pubmed_id>16809807</pubmed_id></reference><reference><reference_text>Tamasawa N, Tamasawa A, Takebe K: Higher levels of plasma cholesterol sulfate in patients with liver cirrhosis and hypercholesterolemia. Lipids. 1993 Sep;28(9):833-6.</reference_text><pubmed_id>8231659</pubmed_id></reference><reference><reference_text>Kim DH, Lee KJ, Heo GS: Analysis of cholesterol and cholesteryl esters in human serum using capillary supercritical fluid chromatography. J Chromatogr B Biomed Appl. 1994 Apr 22;655(1):1-8.</reference_text><pubmed_id>8061816</pubmed_id></reference><reference><reference_text>Authors unspecified: Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med. 1988 Jan;148(1):36-69.</reference_text><pubmed_id>3422148</pubmed_id></reference></references></disease><disease>Cholesteryl ester storage disease<references><reference><reference_text>Rassoul F, Richter V, Lohse P, Naumann A, Purschwitz K, Keller E: Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease. Int J Clin Pharmacol Ther. 2001 May;39(5):199-204.</reference_text><pubmed_id>11380065</pubmed_id></reference><reference><reference_text>Chatrath H, Keilin S, Attar BM: Cholesterol ester storage disease (CESD) diagnosed in an asymptomatic adult. Dig Dis Sci. 2009 Jan;54(1):168-73. doi: 10.1007/s10620-008-0310-2. Epub 2008 May 14.</reference_text><pubmed_id>18478331</pubmed_id></reference><reference><reference_text>Bernstein DL, Hulkova H, Bialer MG, Desnick RJ: Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol. 2013 Jun;58(6):1230-43. doi: 10.1016/j.jhep.2013.02.014. Epub 2013 Feb 26.</reference_text><pubmed_id>23485521</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Cystinosis<references><reference><reference_text>Ueda M, O'Brien K, Rosing DR, Ling A, Kleta R, McAreavey D, Bernardini I, Gahl WA: Coronary artery and other vascular calcifications in patients with cystinosis after kidney transplantation. Clin J Am Soc Nephrol. 2006 May;1(3):555-62. Epub 2006 Feb 8.</reference_text><pubmed_id>17699259</pubmed_id></reference><reference><reference_text>Gahl WA, Bernardini I, Dalakas M, Rizzo WB, Harper GS, Hoeg JM, Hurko O, Bernar J: Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome. J Clin Invest. 1988 Feb;81(2):549-60.</reference_text><pubmed_id>3276734</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Smith-Lemli-Opitz syndrome<references><reference><reference_text>van Rooij A, Nijenhuis AA, Wijburg FA, Schutgens RB: Highly increased CSF concentrations of cholesterol precursors in Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 1997 Aug;20(4):578-80.</reference_text><pubmed_id>9266395</pubmed_id></reference><reference><reference_text>Honda M, Tint GS, Honda A, Salen G, Shefer S, Batta AK, Matsuzaki Y, Tanaka N: Regulation of cholesterol biosynthetic pathway in patients with the Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2000 Jul;23(5):464-74.</reference_text><pubmed_id>10947201</pubmed_id></reference><reference><reference_text>Rossi M, Federico G, Corso G, Parenti G, Battagliese A, Frascogna AR, Della Casa R, Dello Russo A, Strisciuglio P, Saggese G, Andria G: Vitamin D status in patients affected by Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2005;28(1):69-80.</reference_text><pubmed_id>15702407</pubmed_id></reference><reference><reference_text>Johnson DW, ten Brink HJ, Jakobs C: A rapid screening procedure for cholesterol and dehydrocholesterol by electrospray ionization tandem mass spectrometry. J Lipid Res. 2001 Oct;42(10):1699-705.</reference_text><pubmed_id>11590227</pubmed_id></reference></references></disease><disease>Prostate cancer<references><reference><reference_text>Nyman DW, Suzanne Stratton M, Kopplin MJ, Dalkin BL, Nagle RB, Jay Gandolfi A: Selenium and selenomethionine levels in prostate cancer patients. Cancer Detect Prev. 2004;28(1):8-16.</reference_text><pubmed_id>15041072</pubmed_id></reference><reference><reference_text>Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, Egevad L, Tjonneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, Palli D, Vineis P, Tumino R, Berrino F, Kiemeney L, Bueno-de-Mesquita HB, Quiros JR, Gonzalez CA, Martinez C, Larranaga N, Chirlaque MD, Ardanaz E, Stattin P, Hallmans G, Khaw KT, Bingham S, Slimani N, Ferrari P, Rinaldi S, Riboli E: Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr. 2007 Sep;86(3):672-81.</reference_text><pubmed_id>17823432</pubmed_id></reference><reference><reference_text>Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762.</reference_text><pubmed_id>19212411</pubmed_id></reference><reference><reference_text>Puah CM, Williams G, Ghanadian R: Urinary unconjugated 5 alpha-androstane-3 alpha, 17 beta-diol in patients with prostatic tumours. Urol Res. 1982;10(2):81-4.</reference_text><pubmed_id>6180540</pubmed_id></reference><reference><reference_text>Thysell E, Surowiec I, Hornberg E, Crnalic S, Widmark A, Johansson AI, Stattin P, Bergh A, Moritz T, Antti H, Wikstrom P: Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One. 2010 Dec 3;5(12):e14175. doi: 10.1371/journal.pone.0014175.</reference_text><pubmed_id>21151972</pubmed_id></reference><reference><reference_text>Soliman LC, Hui Y, Hewavitharana AK, Chen DD: Monitoring potential prostate cancer biomarkers in urine by capillary electrophoresis-tandem mass spectrometry. J Chromatogr A. 2012 Dec 7;1267:162-9. doi: 10.1016/j.chroma.2012.07.021. Epub 2012 Jul 14.</reference_text><pubmed_id>22824219</pubmed_id></reference><reference><reference_text>Madu CO, Lu Y: Novel diagnostic biomarkers for prostate cancer. J Cancer. 2010 Oct 6;1:150-77.</reference_text><pubmed_id>20975847</pubmed_id></reference></references></disease><disease>Schizophrenia<references><reference><reference_text>Harnryd C, Bjerkenstedt L, Grimm VE, Sedvall G: Reduction of MOPEG levels in cerebrospinal fluid of psychotic women after electroconvulsive treatment. Psychopharmacology (Berl). 1979 Aug 8;64(2):131-4.</reference_text><pubmed_id>115032</pubmed_id></reference><reference><reference_text>Kobayashi K, Koide Y, Yoshino K, Shohmori T: [P-hydroxyphenylacetic acid concentrations in cerebrospinal fluid]. No To Shinkei. 1982 Aug;34(8):769-74.</reference_text><pubmed_id>7126379</pubmed_id></reference><reference><reference_text>Alfredsson G, Wiesel FA: Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology (Berl). 1989;99(3):322-7.</reference_text><pubmed_id>2480613</pubmed_id></reference><reference><reference_text>Heresco-Levy U, Bar G, Levin R, Ermilov M, Ebstein RP, Javitt DC: High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. Schizophr Res. 2007 Mar;91(1-3):14-21. Epub 2007 Feb 2.</reference_text><pubmed_id>17276036</pubmed_id></reference><reference><reference_text>Walker EF, Bonsall R, Walder DJ: Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis. Neuropsychiatry Neuropsychol Behav Neurol. 2002 Mar;15(1):10-7.</reference_text><pubmed_id>11877547</pubmed_id></reference><reference><reference_text>Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M: Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry. 2003 Jun;60(6):572-6.</reference_text><pubmed_id>12796220</pubmed_id></reference><reference><reference_text>Do KQ, Lauer CJ, Schreiber W, Zollinger M, Gutteck-Amsler U, Cuenod M, Holsboer F: gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem. 1995 Dec;65(6):2652-62.</reference_text><pubmed_id>7595563</pubmed_id></reference><reference><reference_text>Nikisch G, Baumann P, Wiedemann G, Kiessling B, Weisser H, Hertel A, Yoshitake T, Kehr J, Mathe AA: Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF. J Clin Psychopharmacol. 2010 Oct;30(5):496-503. doi: 10.1097/JCP.0b013e3181f2288e.</reference_text><pubmed_id>20814316</pubmed_id></reference><reference><reference_text>Fukushima T, Iizuka H, Yokota A, Suzuki T, Ohno C, Kono Y, Nishikiori M, Seki A, Ichiba H, Watanabe Y, Hongo S, Utsunomiya M, Nakatani M, Sadamoto K, Yoshio T: Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One. 2014 Jul 8;9(7):e101652. doi: 10.1371/journal.pone.0101652. eCollection 2014.</reference_text><pubmed_id>25004141</pubmed_id></reference><reference><reference_text>Koike S, Bundo M, Iwamoto K, Suga M, Kuwabara H, Ohashi Y, Shinoda K, Takano Y, Iwashiro N, Satomura Y, Nagai T, Natsubori T, Tada M, Yamasue H, Kasai K: A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study. Transl Psychiatry. 2014 Apr 8;4:e379. doi: 10.1038/tp.2014.19.</reference_text><pubmed_id>24713860</pubmed_id></reference><reference><reference_text>Ballesteros A, Summerfelt A, Du X, Jiang P, Chiappelli J, Tagamets M, O'Donnell P, Kochunov P, Hong LE: Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia. Clin Neurophysiol. 2013 Nov;124(11):2209-15. doi: 10.1016/j.clinph.2013.05.021. Epub 2013 Jun 30.</reference_text><pubmed_id>23823132</pubmed_id></reference><reference><reference_text>Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel FA: Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry. 1985 Sep;147:276-82.</reference_text><pubmed_id>2415198</pubmed_id></reference><reference><reference_text>Pickar D, Breier A, Hsiao JK, Doran AR, Wolkowitz OM, Pato CN, Konicki PE, Potter WZ: Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Arch Gen Psychiatry. 1990 Jul;47(7):641-8.</reference_text><pubmed_id>1694425</pubmed_id></reference><reference><reference_text>Prell GD, Green JP, Kaufmann CA, Khandelwal JK, Morrishow AM, Kirch DG, Linnoila M, Wyatt RJ: Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res. 1995 Jan;14(2):93-104.</reference_text><pubmed_id>7711000</pubmed_id></reference><reference><reference_text>Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B: Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology. 2009;59(2):123-9. doi: 10.1159/000213565. Epub 2009 Apr 22.</reference_text><pubmed_id>19390223</pubmed_id></reference><reference><reference_text>Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K, Cao Y, Wang X, Qiu Y, Su M, Zhao A, Wang P, Yang P, Wu J, Feng G, He L, Jia W, Wan C: Potential metabolite markers of schizophrenia. Mol Psychiatry. 2013 Jan;18(1):67-78. doi: 10.1038/mp.2011.131. Epub 2011 Oct 25.</reference_text><pubmed_id>22024767</pubmed_id></reference><reference><reference_text>Xuan J, Pan G, Qiu Y, Yang L, Su M, Liu Y, Chen J, Feng G, Fang Y, Jia W, Xing Q, He L: Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. J Proteome Res. 2011 Dec 2;10(12):5433-43. doi: 10.1021/pr2006796. Epub 2011 Nov  8.</reference_text><pubmed_id>22007635</pubmed_id></reference><reference><reference_text>Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM, Rothermundt M, Bogerts B, Koethe D, Kranaster L, Ohrmann P, Suslow T, McAllister G, Spain M, Barnes A, van Beveren NJ, Baron-Cohen S, Steiner J, Torrey FE, Yolken RH, Bahn S: Identification of a biological signature for schizophrenia in serum. Mol Psychiatry. 2012 May;17(5):494-502. doi: 10.1038/mp.2011.42. Epub 2011 Apr 12.</reference_text><pubmed_id>21483431</pubmed_id></reference><reference><reference_text>Mathe AA, Eberhard G, Saaf J, Wetterberg L: Plasma prostaglandin E2 metabolite--measured as 11-deoxy-15-keto-13,14-dihydro-11 beta,16 xi-cyclo-PGE2--in twins with schizophrenic disorder. Biol Psychiatry. 1986 Sep;21(11):1024-30.</reference_text><pubmed_id>3741918</pubmed_id></reference><reference><reference_text>Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N: Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct. 2002 Jun;20(2):171-5.</reference_text><pubmed_id>11979513</pubmed_id></reference><reference><reference_text>Zumarraga M, Davila R, Basterreche N, Arrue A, Goienetxea B, Zamalloa MI, Erkoreka L, Bustamante S, Inchausti L, Gonzalez-Torres MA, Guimon J: Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients. Neurochem Int. 2010 May-Jun;56(6-7):774-9. doi: 10.1016/j.neuint.2010.02.015. Epub 2010 Mar 4.</reference_text><pubmed_id>20206656</pubmed_id></reference><reference><reference_text>Peters JG: Dopamine, noradrenaline and serotonin spinal fluid metabolites in temporal lobe epileptic patients with schizophrenic symptomatology. Eur Neurol. 1979;18(1):15-8.</reference_text><pubmed_id>436860</pubmed_id></reference><reference><reference_text>Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, Rozen S, Krishnan RR, McEvoy J, Kaddurah-Daouk R: Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry. 2010 Sep;15(9):938-53. doi: 10.1038/mp.2009.33. Epub 2009 Apr 28.</reference_text><pubmed_id>19401681</pubmed_id></reference><reference><reference_text>Gattaz WF, Waldmeier P, Beckmann H: CSF monoamine metabolites in schizophrenic patients. Acta Psychiatr Scand. 1982 Nov;66(5):350-60.</reference_text><pubmed_id>6184954</pubmed_id></reference><reference><reference_text>Nilsson-Todd LK, Nordin C, Jonsson EG, Skogh E, Erhardt S: Cerebrospinal fluid kynurenic acid in male patients with schizophrenia - correlation with monoamine metabolites. Acta Neuropsychiatr. 2007 Feb;19(1):45-52. doi: 10.1111/j.1601-5215.2006.00170.x.</reference_text><pubmed_id>26952797</pubmed_id></reference><reference><reference_text>Cai HL, Li HD, Yan XZ, Sun B, Zhang Q, Yan M, Zhang WY, Jiang P, Zhu RH, Liu YP, Fang PF, Xu P, Yuan HY, Zhang XH, Hu L, Yang W, Ye HS: Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naive schizophrenia patients after treatment with risperidone. J Proteome Res. 2012 Aug 3;11(8):4338-50. doi: 10.1021/pr300459d. Epub 2012 Jul 26.</reference_text><pubmed_id>22800120</pubmed_id></reference><reference><reference_text>Al Awam K, Haussleiter IS, Dudley E, Donev R, Brune M, Juckel G, Thome J: Multiplatform metabolome and proteome profiling identifies serum metabolite and protein signatures as prospective biomarkers for schizophrenia. J Neural Transm (Vienna). 2015 Aug;122 Suppl 1:S111-22. doi: 10.1007/s00702-014-1224-0. Epub 2014 May 1.</reference_text><pubmed_id>24789758</pubmed_id></reference><reference><reference_text>Bicikova M, Hill M, Ripova D, Mohr P, Hampl R: Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia. J Steroid Biochem Mol Biol. 2013 Jan;133:77-83. doi: 10.1016/j.jsbmb.2012.08.009. Epub 2012 Aug 24.</reference_text><pubmed_id>22944140</pubmed_id></reference><reference><reference_text>He Y, Yu Z, Giegling I, Xie L, Hartmann AM, Prehn C, Adamski J, Kahn R, Li Y, Illig T, Wang-Sattler R, Rujescu D: Schizophrenia shows a unique metabolomics signature in plasma. Transl Psychiatry. 2012 Aug 14;2:e149. doi: 10.1038/tp.2012.76.</reference_text><pubmed_id>22892715</pubmed_id></reference><reference><reference_text>Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KR: Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):934-45. Epub 2007 Apr 17.</reference_text><pubmed_id>17440431</pubmed_id></reference><reference><reference_text>Fryar-Williams S, Strobel JE: Biomarkers of a five-domain translational substrate for schizophrenia and schizoaffective psychosis. Biomark Res. 2015 Feb 6;3:3. doi: 10.1186/s40364-015-0028-1. eCollection 2015.</reference_text><pubmed_id>25729574</pubmed_id></reference><reference><reference_text>Oresic M, Seppanen-Laakso T, Sun D, Tang J, Therman S, Viehman R, Mustonen U, van Erp TG, Hyotylainen T, Thompson P, Toga AW, Huttunen MO, Suvisaari J, Kaprio J, Lonnqvist J, Cannon TD: Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia. Genome Med. 2012 Jan 18;4(1):1. doi: 10.1186/gm300.</reference_text><pubmed_id>22257447</pubmed_id></reference></references></disease><disease>Primary hypomagnesemia<references><reference><reference_text>Jin-no Y, Kamiya Y, Okada M, Hirako M, Takada N, Kawaguchi M: Primary hypomagnesemia caused by isolated magnesium malabsorption: atypical case in adult. Intern Med. 1999 Mar;38(3):261-5.</reference_text><pubmed_id>10337938</pubmed_id></reference><reference><reference_text>Vainsel M, Vandevelde G, Smulders J, Vosters M, Hubain P, Loeb H: Tetany due to hypomagnesaemia with secondary hypocalcaemia. Arch Dis Child. 1970 Apr;45(240):254-8.</reference_text><pubmed_id>5419995</pubmed_id></reference><reference><reference_text>Shalev H, Phillip M, Galil A, Carmi R, Landau D: Clinical presentation and outcome in primary familial hypomagnesaemia. Arch Dis Child. 1998 Feb;78(2):127-30.</reference_text><pubmed_id>9579153</pubmed_id></reference><reference><reference_text>Kari JA, Farouq M, Alshaya HO: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Pediatr Nephrol. 2003 Jun;18(6):506-10. Epub 2003 Apr 29.</reference_text><pubmed_id>12720080</pubmed_id></reference></references></disease><disease>Hyperlipoproteinemia<references><reference><reference_text>Sinha S, Misra A, Kumar V, Jagannathan NR, Bal CS, Pandey RM, Singhania R, Deepak: Proton magnetic resonance spectroscopy and single photon emission computed tomography study of the brain in asymptomatic young hyperlipidaemic Asian Indians in North India show early abnormalities. Clin Endocrinol (Oxf). 2004 Aug;61(2):182-9.</reference_text><pubmed_id>15272912</pubmed_id></reference><reference><reference_text>Nelson RH: Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013 Mar</reference_text><pubmed_id>40(1):195-211. doi: 10.1016/j.pop.2012.11.003. Epub 2012 Dec  4.</pubmed_id></reference><reference><reference_text>Cantin B, Boudriau S, Bertrand M, Brun LD, Gagne C, Rogers PA, Ven Murthy MR, Lupien PJ, Julien P: Hemolysis in primary lipoprotein lipase deficiency. Metabolism. 1995 May;44(5):652-8.</reference_text><pubmed_id>7752915</pubmed_id></reference></references></disease><disease>Abetalipoproteinemia<references><reference><reference_text>Dawson G, Kruski AW, Scanu AM: Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J Lipid Res. 1976 Mar;17(2):125-31.</reference_text><pubmed_id>178813</pubmed_id></reference><reference><reference_text>Lazaro RP, Dentinger MP, Rodichok LD, Barron KD, Satya-Murti S: Muscle pathology in Bassen-Kornzweig syndrome and vitamin E deficiency. Am J Clin Pathol. 1986 Sep;86(3):378-87.</reference_text><pubmed_id>2944375</pubmed_id></reference></references></disease><disease>Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis<references><reference><reference_text>Breckenridge WC, Alaupovic P, Cox DW, Little JA: Apolipoprotein and lipoprotein concentrations in familial apolipoprotein C-II deficiency. Atherosclerosis. 1982 Aug;44(2):223-35.</reference_text><pubmed_id>7138621</pubmed_id></reference><reference><reference_text>Fukami M, Hasegawa T, Horikawa R, Ohashi T, Nishimura G, Homma K, Ogata T: Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr Res. 2006 Feb;59(2):276-80. doi: 10.1203/01.pdr.0000195825.31504.28.</reference_text><pubmed_id>16439592</pubmed_id></reference></references></disease><disease>Cerebrotendinous xanthomatosis<references><reference><reference_text>Halperin G, Elisaf M, Leitersdorf E, Harats D: A new method for determination of serum cholestanol by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2000 Jun 9;742(2):345-52.</reference_text><pubmed_id>10901139</pubmed_id></reference><reference><reference_text>Siman-Tov T, Meiner V, Gadoth N: Could steroids mask the diagnosis of cerebrotendinous xanthomatosis? J Neurol Sci. 2006 Apr 15;243(1-2):83-6. Epub 2006 Jan 30.</reference_text><pubmed_id>16445943</pubmed_id></reference><reference><reference_text>Agrawal NK, Garg S: Cerebrotendinous xanthomatosis: a rare disorder with a rare presentation. BMJ Case Rep. 2012 Sep 21;2012. pii: bcr-2012-006202. doi: 10.1136/bcr-2012-006202.</reference_text><pubmed_id>23001091</pubmed_id></reference></references></disease><disease>3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency<references><reference><reference_text>Thompson GN, Hsu BY, Pitt JJ, Treacy E, Stanley CA: Fasting hypoketotic coma in a child with deficiency of mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase. N Engl J Med. 1997 Oct 23;337(17):1203-7. doi: 10.1056/NEJM199710233371704.</reference_text><pubmed_id>9337379</pubmed_id></reference><reference><reference_text>Morris AA, Lascelles CV, Olpin SE, Lake BD, Leonard JV, Quant PA: Hepatic mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme a synthase deficiency. Pediatr Res. 1998 Sep;44(3):392-6. doi: 10.1203/00006450-199809000-00021.</reference_text><pubmed_id>9727719</pubmed_id></reference><reference><reference_text>Conboy E, Vairo F, Schultz M, Agre K, Ridsdale R, Deyle D, Oglesbee D, Gavrilov D, Klee EW, Lanpher B: Mitochondrial 3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency: Unique Presenting Laboratory Values and a Review of Biochemical and Clinical Features. JIMD Rep. 2017 Oct 14. doi: 10.1007/8904_2017_59.</reference_text><pubmed_id>29030856</pubmed_id></reference></references></disease><disease>Hypercholesterolemia, familial<references><reference><reference_text>Kwiterovich PO Jr, Fredrickson DS, Levy RI: Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest. 1974 May;53(5):1237-49. doi: 10.1172/JCI107670.</reference_text><pubmed_id>4363406</pubmed_id></reference></references></disease><disease>SC4MOL deficiency<references><reference><reference_text>He M, Kratz LE, Michel JJ, Vallejo AN, Ferris L, Kelley RI, Hoover JJ, Jukic D, Gibson KM, Wolfe LA, Ramachandran D, Zwick ME, Vockley J: Mutations in the human SC4MOL gene encoding a methyl sterol oxidase cause psoriasiform dermatitis, microcephaly, and developmental delay. J Clin Invest. 2011 Mar;121(3):976-84. doi: 10.1172/JCI42650.</reference_text><pubmed_id>21285510</pubmed_id></reference></references></disease><disease>Chondrodysplasia punctata, X-linked dominant<references><reference><reference_text>Aughton DJ, Kelley RI, Metzenberg A, Pureza V, Pauli RM: X-linked dominant chondrodysplasia punctata (CDPX2) caused by single gene mosaicism in a male. Am J Med Genet A. 2003 Jan 30;116A(3):255-60. doi: 10.1002/ajmg.a.10852.</reference_text><pubmed_id>12503102</pubmed_id></reference></references></disease><disease>Desmosterolosis<references><reference><reference_text>Andersson HC, Kratz L, Kelley R: Desmosterolosis presenting with multiple congenital anomalies and profound developmental delay. Am J Med Genet. 2002 Dec 15;113(4):315-9. doi: 10.1002/ajmg.b.10873.</reference_text><pubmed_id>12457401</pubmed_id></reference></references></disease><disease>Donohue Syndrome<references><reference><reference_text>Nijim Y, Awni Y, Adawi A, Bowirrat A: Classic Case Report of Donohue Syndrome (Leprechaunism; OMIM *246200): The Impact of Consanguineous Mating. Medicine (Baltimore). 2016 Feb;95(6):e2710. doi: 10.1097/MD.0000000000002710.</reference_text><pubmed_id>26871809</pubmed_id></reference></references></disease><disease>Leptin Deficiency or Dysfunction<references><reference><reference_text>Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O'Rahilly S: Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999 Sep 16;341(12):879-84. doi: 10.1056/NEJM199909163411204.</reference_text><pubmed_id>10486419</pubmed_id></reference></references></disease><disease>Duchenne Muscular Dystrophy<references><reference><reference_text>Nakagawa T, Takeuchi A, Kakiuchi R, Lee T, Yagi M, Awano H, Iijima K, Takeshima Y, Urade Y, Matsuo M: A prostaglandin D2 metabolite is elevated in the urine of Duchenne muscular dystrophy patients and increases further from 8 years old. Clin Chim Acta. 2013 Aug 23;423:10-4. doi: 10.1016/j.cca.2013.03.031. Epub 2013 Apr 19.</reference_text><pubmed_id>23603101</pubmed_id></reference><reference><reference_text>Srivastava NK, Pradhan S, Mittal B, Gowda GA: High resolution NMR based analysis of serum lipids in Duchenne muscular dystrophy patients and its possible diagnostic significance. NMR Biomed. 2010 Jan;23(1):13-22. doi: 10.1002/nbm.1419.</reference_text><pubmed_id>19787747</pubmed_id></reference><reference><reference_text>Horster I, Weigt-Usinger K, Carmann C, Chobanyan-Jurgens K, Kohler C, Schara U, Kayacelebi AA, Beckmann B, Tsikas D, Lucke T: The L-arginine/NO pathway and homoarginine are altered in Duchenne muscular dystrophy and improved by glucocorticoids. Amino Acids. 2015 Sep;47(9):1853-63. doi: 10.1007/s00726-015-2018-x. Epub 2015 Jun 12.</reference_text><pubmed_id>26066683</pubmed_id></reference></references></disease><disease>Lecithin:cholesterol Acyltransferase Deficiency<references><reference><reference_text>Idzior-Walus B, Sieradzki J, Kostner G, Malecki MT, Klupa T, Wesolowska T, Rostworowski W, Hartwich J, Walus M, Kiec AD, Naruszewicz M: Familial lecithin-cholesterol acyltransferase deficiency: biochemical characteristics and molecular analysis of a new LCAT mutation in a Polish family. Atherosclerosis. 2006 Apr;185(2):413-20. Epub 2005 Jul 26.</reference_text><pubmed_id>16051254</pubmed_id></reference></references></disease><disease>Lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lipodystrophy, Congenital Generalized<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Oculocerebrorenal syndrome<references><reference><reference_text>Charnas LR, Bernardini I, Rader D, Hoeg JM, Gahl WA: Clinical and laboratory findings in the oculocerebrorenal syndrome of Lowe, with special reference to growth and renal function. N Engl J Med. 1991 May 9;324(19):1318-25. doi: 10.1056/NEJM199105093241904.</reference_text><pubmed_id>2017228</pubmed_id></reference></references></disease><disease>Familial partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lathosterolosis<references><reference><reference_text>Brunetti-Pierri N, Corso G, Rossi M, Ferrari P, Balli F, Rivasi F, Annunziata I, Ballabio A, Russo AD, Andria G, Parenti G: Lathosterolosis, a novel multiple-malformation/mental retardation syndrome due to deficiency of 3beta-hydroxysteroid-delta5-desaturase. Am J Hum Genet. 2002 Oct;71(4):952-8. Epub 2002 Aug 20.</reference_text><pubmed_id>12189593</pubmed_id></reference><reference><reference_text>Ho AC, Fung CW, Siu TS, Ma OC, Lam CW, Tam S, Wong VC: Lathosterolosis: a disorder of cholesterol biosynthesis resembling smith-lemli-opitz syndrome. JIMD Rep. 2014;12:129-34. doi: 10.1007/8904_2013_255. Epub 2013 Oct 20.</reference_text><pubmed_id>24142275</pubmed_id></reference></references></disease><disease>Partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Multiple sclerosis<references><reference><reference_text>Lutz NW, Viola A, Malikova I, Confort-Gouny S, Audoin B, Ranjeva JP, Pelletier J, Cozzone PJ: Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One. 2007 Jul 4;2(7):e595.</reference_text><pubmed_id>17611627</pubmed_id></reference><reference><reference_text>Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U, Hillert J, Bjorkhem I: Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med. 2004 Feb;42(2):186-91.</reference_text><pubmed_id>15061359</pubmed_id></reference><reference><reference_text>Leoni V, Lutjohann D, Masterman T: Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis. J Lipid Res. 2005 Feb;46(2):191-5. Epub 2004 Dec 1.</reference_text><pubmed_id>15576852</pubmed_id></reference><reference><reference_text>Calabrese V, Scapagnini G, Ravagna A, Bella R, Butterfield DA, Calvani M, Pennisi G, Giuffrida Stella AM: Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem Res. 2003 Sep;28(9):1321-8.</reference_text><pubmed_id>12938853</pubmed_id></reference><reference><reference_text>Shaw CE, Dunbar PR, Macaulay HA, Neale TJ: Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol. 1995 Jan;242(2):53-8.</reference_text><pubmed_id>7707089</pubmed_id></reference><reference><reference_text>Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.</reference_text><pubmed_id>17384003</pubmed_id></reference><reference><reference_text>Syburra C, Passi S: Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh (1999). 1999 May-Jun;71(3):112-5.</reference_text><pubmed_id>10609336</pubmed_id></reference><reference><reference_text>Forte G, Visconti A, Santucci S, Ghazaryan A, Figa-Talamanca L, Cannoni S, Bocca B, Pino A, Violante N, Alimonti A, Salvetti M, Ristori G: Quantification of chemical elements in blood of patients affected by multiple sclerosis. Ann Ist Super Sanita. 2005;41(2):213-6.</reference_text><pubmed_id>16244395</pubmed_id></reference><reference><reference_text>Toncev G, Milicic B, Toncev S, Samardzic G: Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol. 2002 May;9(3):221-6.</reference_text><pubmed_id>11985629</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, Bamonti F, Capello E, Mancardi GL, Scarpini E: Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res. 2010 May 28;1333:64-71. doi: 10.1016/j.brainres.2010.03.073. Epub 2010 Mar 27.</reference_text><pubmed_id>20347721</pubmed_id></reference><reference><reference_text>Matsushita T, Isobe N, Kawajiri M, Mogi M, Tsukuda K, Horiuchi M, Ohyagi Y, Kira J: CSF angiotensin II and angiotensin-converting enzyme levels in anti-aquaporin-4 autoimmunity. J Neurol Sci. 2010 Aug 15;295(1-2):41-5. doi: 10.1016/j.jns.2010.05.014. Epub 2010 Jun 11.</reference_text><pubmed_id>20541774</pubmed_id></reference><reference><reference_text>Ghabaee M, Jabedari B, Al-E-Eshagh N, Ghaffarpour M, Asadi F: Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients. Int J Neurosci. 2010 Apr;120(4):301-4. doi: 10.3109/00207451003695690.</reference_text><pubmed_id>20374079</pubmed_id></reference><reference><reference_text>Kawajiri M, Mogi M, Osoegawa M, Matsuoka T, Tsukuda K, Kohara K, Horiuchi M, Miki T, Kira JI: Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler. 2008 May;14(4):557-60. doi: 10.1177/1352458507085760.</reference_text><pubmed_id>18562510</pubmed_id></reference><reference><reference_text>Visconti A, Cotichini R, Cannoni S, Bocca B, Forte G, Ghazaryan A, Santucci S, D'Ippolito C, Stazi MA, Salvetti M, Alimonti A, Ristori G: Concentration of elements in serum of patients affected by multiple sclerosis with first demyelinating episode: a six-month longitudinal follow-up study. Ann Ist Super Sanita. 2005;41(2):217-22.</reference_text><pubmed_id>16244396</pubmed_id></reference></references></disease><disease>Inflammatory bowel disease<references><reference><reference_text>Lee T, Clavel T, Smirnov K, Schmidt A, Lagkouvardos I, Walker A, Lucio M, Michalke B, Schmitt-Kopplin P, Fedorak R, Haller D: Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. 2017 May;66(5):863-871. doi: 10.1136/gutjnl-2015-309940. Epub 2016 Feb 4.</reference_text><pubmed_id>26848182</pubmed_id></reference><reference><reference_text>Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158.</reference_text><pubmed_id>27609529</pubmed_id></reference></references></disease><disease>Colorectal cancer<references><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B: Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009 Apr;22(3):342-8. doi: 10.1002/nbm.1345.</reference_text><pubmed_id>19006102</pubmed_id></reference><reference><reference_text>Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP: Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One. 2013 Aug 6;8(8):e70803. doi: 10.1371/journal.pone.0070803. Print 2013.</reference_text><pubmed_id>23940645</pubmed_id></reference><reference><reference_text>Phua LC, Chue XP, Koh PK, Cheah PY, Ho HK, Chan EC: Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biol Ther. 2014 Apr;15(4):389-97. doi: 10.4161/cbt.27625. Epub 2014 Jan 14.</reference_text><pubmed_id>24424155</pubmed_id></reference><reference><reference_text>Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB: Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010 Feb 15;8:13. doi: 10.1186/1741-7015-8-13.</reference_text><pubmed_id>20156336</pubmed_id></reference><reference><reference_text>Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, Ni Y, Zhao A, Xu LX, Cai S, Jia W: Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res. 2009 Oct;8(10):4844-50. doi: 10.1021/pr9004162.</reference_text><pubmed_id>19678709</pubmed_id></reference><reference><reference_text>Cheng Y, Xie G, Chen T, Qiu Y, Zou X, Zheng M, Tan B, Feng B, Dong T, He P, Zhao L, Zhao A, Xu LX, Zhang Y, Jia W: Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res. 2012 Feb 3;11(2):1354-63. doi: 10.1021/pr201001a. Epub 2011 Dec 28.</reference_text><pubmed_id>22148915</pubmed_id></reference><reference><reference_text>Ni Y, Xie G, Jia W: Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res. 2014 Sep 5;13(9):3857-70. doi: 10.1021/pr500443c. Epub 2014 Aug 14.</reference_text><pubmed_id>25105552</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference><reference><reference_text>Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18.</reference_text><pubmed_id>25037050</pubmed_id></reference><reference><reference_text>Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016.</reference_text><pubmed_id>27015276</pubmed_id></reference><reference><reference_text>Lin Y, Ma C, Liu C, Wang Z, Yang J, Liu X, Shen Z, Wu R: NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer. Oncotarget. 2016 May 17;7(20):29454-64. doi: 10.18632/oncotarget.8762.</reference_text><pubmed_id>27107423</pubmed_id></reference><reference><reference_text>Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016.</reference_text><pubmed_id>27275383</pubmed_id></reference><reference><reference_text>Wang X, Wang J, Rao B, Deng L: Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals. Exp Ther Med. 2017 Jun;13(6):2848-2854. doi: 10.3892/etm.2017.4367. Epub 2017 Apr 20.</reference_text><pubmed_id>28587349</pubmed_id></reference><reference><reference_text>Silke Matysik, Caroline Ivanne Le Roy, Gerhard Liebisch, Sandrine Paule Claus. Metabolomics of fecal samples: A practical consideration. Trends in Food Science &amp; Technology. Vol. 57, Part B, Nov. 2016, p.244-255: http://www.sciencedirect.com/science/article/pii/S0924224416301984</reference_text><pubmed_id>28587349</pubmed_id></reference></references></disease><disease>Gallbladder disease<references><reference><reference_text>Lapidus A, Akerlund JE, Einarsson C: Gallbladder bile composition in patients with Crohn 's disease. World J Gastroenterol. 2006 Jan 7;12(1):70-4.</reference_text><pubmed_id>16440420</pubmed_id></reference><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference><reference><reference_text>Mizuno S, Tazuma S, Kajiyama G: Stabilization of biliary lipid particles by ursodeoxycholic acid. Prolonged nucleation time in human gallbladder bile. Dig Dis Sci. 1993 Apr;38(4):684-93.</reference_text><pubmed_id>8462368</pubmed_id></reference><reference><reference_text>Hillebrant CG, Axelson M, Bjorkhem I, Wang FH, Nyberg B, Einarsson C: Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients. Eur J Clin Invest. 1998 Apr;28(4):324-8.</reference_text><pubmed_id>9615912</pubmed_id></reference></references></disease><disease>Cholelithiasis<references><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference></references></disease><disease>Stomach cancer<references><reference><reference_text>Higashijima H, Ichimiya H, Nakano T, Yamashita H, Kuroki S, Satoh H, Chijiiwa K, Tanaka M: Deconjugation of bilirubin accelerates coprecipitation of cholesterol, fatty acids, and mucin in human bile--in vitro study. J Gastroenterol. 1996 Dec;31(6):828-35.</reference_text><pubmed_id>9027647</pubmed_id></reference><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Song H, Peng JS, Dong-Sheng Y, Yang ZL, Liu HL, Zeng YK, Shi XP, Lu BY: Serum metabolic profiling of human gastric cancer based on gas chromatography/mass spectrometry. Braz J Med Biol Res. 2012 Jan;45(1):78-85. Epub 2011 Nov 25.</reference_text><pubmed_id>22124703</pubmed_id></reference><reference><reference_text>Yu L, Aa J, Xu J, Sun M, Qian S, Cheng L, Yang S, Shi R: Metabolomic phenotype of gastric cancer and precancerous stages based on gas chromatography time-of-flight mass spectrometry. J Gastroenterol Hepatol. 2011 Aug;26(8):1290-7. doi: 10.1111/j.1440-1746.2011.06724.x.</reference_text><pubmed_id>21443661</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference></references></disease><disease>Acute myelogenous leukemia<references><reference><reference_text>Tatidis L, Vitols S, Gruber A, Paul C, Axelson M: Cholesterol catabolism in patients with acute myelogenous leukemia and hypocholesterolemia: suppressed levels of a circulating marker for bile acid synthesis. Cancer Lett. 2001 Sep 20;170(2):169-75.</reference_text><pubmed_id>11463495</pubmed_id></reference></references></disease><disease>Hypercholesterolemia<references><reference><reference_text>Thelen KM, Laaksonen R, Paiva H, Lehtimaki T, Lutjohann D: High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels. J Clin Pharmacol. 2006 Jul;46(7):812-6.</reference_text><pubmed_id>16809807</pubmed_id></reference><reference><reference_text>Tamasawa N, Tamasawa A, Takebe K: Higher levels of plasma cholesterol sulfate in patients with liver cirrhosis and hypercholesterolemia. Lipids. 1993 Sep;28(9):833-6.</reference_text><pubmed_id>8231659</pubmed_id></reference><reference><reference_text>Kim DH, Lee KJ, Heo GS: Analysis of cholesterol and cholesteryl esters in human serum using capillary supercritical fluid chromatography. J Chromatogr B Biomed Appl. 1994 Apr 22;655(1):1-8.</reference_text><pubmed_id>8061816</pubmed_id></reference><reference><reference_text>Authors unspecified: Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med. 1988 Jan;148(1):36-69.</reference_text><pubmed_id>3422148</pubmed_id></reference></references></disease><disease>Cholesteryl ester storage disease<references><reference><reference_text>Rassoul F, Richter V, Lohse P, Naumann A, Purschwitz K, Keller E: Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease. Int J Clin Pharmacol Ther. 2001 May;39(5):199-204.</reference_text><pubmed_id>11380065</pubmed_id></reference><reference><reference_text>Chatrath H, Keilin S, Attar BM: Cholesterol ester storage disease (CESD) diagnosed in an asymptomatic adult. Dig Dis Sci. 2009 Jan;54(1):168-73. doi: 10.1007/s10620-008-0310-2. Epub 2008 May 14.</reference_text><pubmed_id>18478331</pubmed_id></reference><reference><reference_text>Bernstein DL, Hulkova H, Bialer MG, Desnick RJ: Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol. 2013 Jun;58(6):1230-43. doi: 10.1016/j.jhep.2013.02.014. Epub 2013 Feb 26.</reference_text><pubmed_id>23485521</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Cystinosis<references><reference><reference_text>Ueda M, O'Brien K, Rosing DR, Ling A, Kleta R, McAreavey D, Bernardini I, Gahl WA: Coronary artery and other vascular calcifications in patients with cystinosis after kidney transplantation. Clin J Am Soc Nephrol. 2006 May;1(3):555-62. Epub 2006 Feb 8.</reference_text><pubmed_id>17699259</pubmed_id></reference><reference><reference_text>Gahl WA, Bernardini I, Dalakas M, Rizzo WB, Harper GS, Hoeg JM, Hurko O, Bernar J: Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome. J Clin Invest. 1988 Feb;81(2):549-60.</reference_text><pubmed_id>3276734</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Smith-Lemli-Opitz syndrome<references><reference><reference_text>van Rooij A, Nijenhuis AA, Wijburg FA, Schutgens RB: Highly increased CSF concentrations of cholesterol precursors in Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 1997 Aug;20(4):578-80.</reference_text><pubmed_id>9266395</pubmed_id></reference><reference><reference_text>Honda M, Tint GS, Honda A, Salen G, Shefer S, Batta AK, Matsuzaki Y, Tanaka N: Regulation of cholesterol biosynthetic pathway in patients with the Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2000 Jul;23(5):464-74.</reference_text><pubmed_id>10947201</pubmed_id></reference><reference><reference_text>Rossi M, Federico G, Corso G, Parenti G, Battagliese A, Frascogna AR, Della Casa R, Dello Russo A, Strisciuglio P, Saggese G, Andria G: Vitamin D status in patients affected by Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2005;28(1):69-80.</reference_text><pubmed_id>15702407</pubmed_id></reference><reference><reference_text>Johnson DW, ten Brink HJ, Jakobs C: A rapid screening procedure for cholesterol and dehydrocholesterol by electrospray ionization tandem mass spectrometry. J Lipid Res. 2001 Oct;42(10):1699-705.</reference_text><pubmed_id>11590227</pubmed_id></reference></references></disease><disease>Prostate cancer<references><reference><reference_text>Nyman DW, Suzanne Stratton M, Kopplin MJ, Dalkin BL, Nagle RB, Jay Gandolfi A: Selenium and selenomethionine levels in prostate cancer patients. Cancer Detect Prev. 2004;28(1):8-16.</reference_text><pubmed_id>15041072</pubmed_id></reference><reference><reference_text>Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, Egevad L, Tjonneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, Palli D, Vineis P, Tumino R, Berrino F, Kiemeney L, Bueno-de-Mesquita HB, Quiros JR, Gonzalez CA, Martinez C, Larranaga N, Chirlaque MD, Ardanaz E, Stattin P, Hallmans G, Khaw KT, Bingham S, Slimani N, Ferrari P, Rinaldi S, Riboli E: Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr. 2007 Sep;86(3):672-81.</reference_text><pubmed_id>17823432</pubmed_id></reference><reference><reference_text>Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762.</reference_text><pubmed_id>19212411</pubmed_id></reference><reference><reference_text>Puah CM, Williams G, Ghanadian R: Urinary unconjugated 5 alpha-androstane-3 alpha, 17 beta-diol in patients with prostatic tumours. Urol Res. 1982;10(2):81-4.</reference_text><pubmed_id>6180540</pubmed_id></reference><reference><reference_text>Thysell E, Surowiec I, Hornberg E, Crnalic S, Widmark A, Johansson AI, Stattin P, Bergh A, Moritz T, Antti H, Wikstrom P: Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One. 2010 Dec 3;5(12):e14175. doi: 10.1371/journal.pone.0014175.</reference_text><pubmed_id>21151972</pubmed_id></reference><reference><reference_text>Soliman LC, Hui Y, Hewavitharana AK, Chen DD: Monitoring potential prostate cancer biomarkers in urine by capillary electrophoresis-tandem mass spectrometry. J Chromatogr A. 2012 Dec 7;1267:162-9. doi: 10.1016/j.chroma.2012.07.021. Epub 2012 Jul 14.</reference_text><pubmed_id>22824219</pubmed_id></reference><reference><reference_text>Madu CO, Lu Y: Novel diagnostic biomarkers for prostate cancer. J Cancer. 2010 Oct 6;1:150-77.</reference_text><pubmed_id>20975847</pubmed_id></reference></references></disease><disease>Schizophrenia<references><reference><reference_text>Harnryd C, Bjerkenstedt L, Grimm VE, Sedvall G: Reduction of MOPEG levels in cerebrospinal fluid of psychotic women after electroconvulsive treatment. Psychopharmacology (Berl). 1979 Aug 8;64(2):131-4.</reference_text><pubmed_id>115032</pubmed_id></reference><reference><reference_text>Kobayashi K, Koide Y, Yoshino K, Shohmori T: [P-hydroxyphenylacetic acid concentrations in cerebrospinal fluid]. No To Shinkei. 1982 Aug;34(8):769-74.</reference_text><pubmed_id>7126379</pubmed_id></reference><reference><reference_text>Alfredsson G, Wiesel FA: Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology (Berl). 1989;99(3):322-7.</reference_text><pubmed_id>2480613</pubmed_id></reference><reference><reference_text>Heresco-Levy U, Bar G, Levin R, Ermilov M, Ebstein RP, Javitt DC: High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. Schizophr Res. 2007 Mar;91(1-3):14-21. Epub 2007 Feb 2.</reference_text><pubmed_id>17276036</pubmed_id></reference><reference><reference_text>Walker EF, Bonsall R, Walder DJ: Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis. Neuropsychiatry Neuropsychol Behav Neurol. 2002 Mar;15(1):10-7.</reference_text><pubmed_id>11877547</pubmed_id></reference><reference><reference_text>Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M: Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry. 2003 Jun;60(6):572-6.</reference_text><pubmed_id>12796220</pubmed_id></reference><reference><reference_text>Do KQ, Lauer CJ, Schreiber W, Zollinger M, Gutteck-Amsler U, Cuenod M, Holsboer F: gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem. 1995 Dec;65(6):2652-62.</reference_text><pubmed_id>7595563</pubmed_id></reference><reference><reference_text>Nikisch G, Baumann P, Wiedemann G, Kiessling B, Weisser H, Hertel A, Yoshitake T, Kehr J, Mathe AA: Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF. J Clin Psychopharmacol. 2010 Oct;30(5):496-503. doi: 10.1097/JCP.0b013e3181f2288e.</reference_text><pubmed_id>20814316</pubmed_id></reference><reference><reference_text>Fukushima T, Iizuka H, Yokota A, Suzuki T, Ohno C, Kono Y, Nishikiori M, Seki A, Ichiba H, Watanabe Y, Hongo S, Utsunomiya M, Nakatani M, Sadamoto K, Yoshio T: Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One. 2014 Jul 8;9(7):e101652. doi: 10.1371/journal.pone.0101652. eCollection 2014.</reference_text><pubmed_id>25004141</pubmed_id></reference><reference><reference_text>Koike S, Bundo M, Iwamoto K, Suga M, Kuwabara H, Ohashi Y, Shinoda K, Takano Y, Iwashiro N, Satomura Y, Nagai T, Natsubori T, Tada M, Yamasue H, Kasai K: A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study. Transl Psychiatry. 2014 Apr 8;4:e379. doi: 10.1038/tp.2014.19.</reference_text><pubmed_id>24713860</pubmed_id></reference><reference><reference_text>Ballesteros A, Summerfelt A, Du X, Jiang P, Chiappelli J, Tagamets M, O'Donnell P, Kochunov P, Hong LE: Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia. Clin Neurophysiol. 2013 Nov;124(11):2209-15. doi: 10.1016/j.clinph.2013.05.021. Epub 2013 Jun 30.</reference_text><pubmed_id>23823132</pubmed_id></reference><reference><reference_text>Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel FA: Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry. 1985 Sep;147:276-82.</reference_text><pubmed_id>2415198</pubmed_id></reference><reference><reference_text>Pickar D, Breier A, Hsiao JK, Doran AR, Wolkowitz OM, Pato CN, Konicki PE, Potter WZ: Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Arch Gen Psychiatry. 1990 Jul;47(7):641-8.</reference_text><pubmed_id>1694425</pubmed_id></reference><reference><reference_text>Prell GD, Green JP, Kaufmann CA, Khandelwal JK, Morrishow AM, Kirch DG, Linnoila M, Wyatt RJ: Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res. 1995 Jan;14(2):93-104.</reference_text><pubmed_id>7711000</pubmed_id></reference><reference><reference_text>Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B: Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology. 2009;59(2):123-9. doi: 10.1159/000213565. Epub 2009 Apr 22.</reference_text><pubmed_id>19390223</pubmed_id></reference><reference><reference_text>Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K, Cao Y, Wang X, Qiu Y, Su M, Zhao A, Wang P, Yang P, Wu J, Feng G, He L, Jia W, Wan C: Potential metabolite markers of schizophrenia. Mol Psychiatry. 2013 Jan;18(1):67-78. doi: 10.1038/mp.2011.131. Epub 2011 Oct 25.</reference_text><pubmed_id>22024767</pubmed_id></reference><reference><reference_text>Xuan J, Pan G, Qiu Y, Yang L, Su M, Liu Y, Chen J, Feng G, Fang Y, Jia W, Xing Q, He L: Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. J Proteome Res. 2011 Dec 2;10(12):5433-43. doi: 10.1021/pr2006796. Epub 2011 Nov  8.</reference_text><pubmed_id>22007635</pubmed_id></reference><reference><reference_text>Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM, Rothermundt M, Bogerts B, Koethe D, Kranaster L, Ohrmann P, Suslow T, McAllister G, Spain M, Barnes A, van Beveren NJ, Baron-Cohen S, Steiner J, Torrey FE, Yolken RH, Bahn S: Identification of a biological signature for schizophrenia in serum. Mol Psychiatry. 2012 May;17(5):494-502. doi: 10.1038/mp.2011.42. Epub 2011 Apr 12.</reference_text><pubmed_id>21483431</pubmed_id></reference><reference><reference_text>Mathe AA, Eberhard G, Saaf J, Wetterberg L: Plasma prostaglandin E2 metabolite--measured as 11-deoxy-15-keto-13,14-dihydro-11 beta,16 xi-cyclo-PGE2--in twins with schizophrenic disorder. Biol Psychiatry. 1986 Sep;21(11):1024-30.</reference_text><pubmed_id>3741918</pubmed_id></reference><reference><reference_text>Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N: Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct. 2002 Jun;20(2):171-5.</reference_text><pubmed_id>11979513</pubmed_id></reference><reference><reference_text>Zumarraga M, Davila R, Basterreche N, Arrue A, Goienetxea B, Zamalloa MI, Erkoreka L, Bustamante S, Inchausti L, Gonzalez-Torres MA, Guimon J: Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients. Neurochem Int. 2010 May-Jun;56(6-7):774-9. doi: 10.1016/j.neuint.2010.02.015. Epub 2010 Mar 4.</reference_text><pubmed_id>20206656</pubmed_id></reference><reference><reference_text>Peters JG: Dopamine, noradrenaline and serotonin spinal fluid metabolites in temporal lobe epileptic patients with schizophrenic symptomatology. Eur Neurol. 1979;18(1):15-8.</reference_text><pubmed_id>436860</pubmed_id></reference><reference><reference_text>Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, Rozen S, Krishnan RR, McEvoy J, Kaddurah-Daouk R: Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry. 2010 Sep;15(9):938-53. doi: 10.1038/mp.2009.33. Epub 2009 Apr 28.</reference_text><pubmed_id>19401681</pubmed_id></reference><reference><reference_text>Gattaz WF, Waldmeier P, Beckmann H: CSF monoamine metabolites in schizophrenic patients. Acta Psychiatr Scand. 1982 Nov;66(5):350-60.</reference_text><pubmed_id>6184954</pubmed_id></reference><reference><reference_text>Nilsson-Todd LK, Nordin C, Jonsson EG, Skogh E, Erhardt S: Cerebrospinal fluid kynurenic acid in male patients with schizophrenia - correlation with monoamine metabolites. Acta Neuropsychiatr. 2007 Feb;19(1):45-52. doi: 10.1111/j.1601-5215.2006.00170.x.</reference_text><pubmed_id>26952797</pubmed_id></reference><reference><reference_text>Cai HL, Li HD, Yan XZ, Sun B, Zhang Q, Yan M, Zhang WY, Jiang P, Zhu RH, Liu YP, Fang PF, Xu P, Yuan HY, Zhang XH, Hu L, Yang W, Ye HS: Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naive schizophrenia patients after treatment with risperidone. J Proteome Res. 2012 Aug 3;11(8):4338-50. doi: 10.1021/pr300459d. Epub 2012 Jul 26.</reference_text><pubmed_id>22800120</pubmed_id></reference><reference><reference_text>Al Awam K, Haussleiter IS, Dudley E, Donev R, Brune M, Juckel G, Thome J: Multiplatform metabolome and proteome profiling identifies serum metabolite and protein signatures as prospective biomarkers for schizophrenia. J Neural Transm (Vienna). 2015 Aug;122 Suppl 1:S111-22. doi: 10.1007/s00702-014-1224-0. Epub 2014 May 1.</reference_text><pubmed_id>24789758</pubmed_id></reference><reference><reference_text>Bicikova M, Hill M, Ripova D, Mohr P, Hampl R: Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia. J Steroid Biochem Mol Biol. 2013 Jan;133:77-83. doi: 10.1016/j.jsbmb.2012.08.009. Epub 2012 Aug 24.</reference_text><pubmed_id>22944140</pubmed_id></reference><reference><reference_text>He Y, Yu Z, Giegling I, Xie L, Hartmann AM, Prehn C, Adamski J, Kahn R, Li Y, Illig T, Wang-Sattler R, Rujescu D: Schizophrenia shows a unique metabolomics signature in plasma. Transl Psychiatry. 2012 Aug 14;2:e149. doi: 10.1038/tp.2012.76.</reference_text><pubmed_id>22892715</pubmed_id></reference><reference><reference_text>Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KR: Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):934-45. Epub 2007 Apr 17.</reference_text><pubmed_id>17440431</pubmed_id></reference><reference><reference_text>Fryar-Williams S, Strobel JE: Biomarkers of a five-domain translational substrate for schizophrenia and schizoaffective psychosis. Biomark Res. 2015 Feb 6;3:3. doi: 10.1186/s40364-015-0028-1. eCollection 2015.</reference_text><pubmed_id>25729574</pubmed_id></reference><reference><reference_text>Oresic M, Seppanen-Laakso T, Sun D, Tang J, Therman S, Viehman R, Mustonen U, van Erp TG, Hyotylainen T, Thompson P, Toga AW, Huttunen MO, Suvisaari J, Kaprio J, Lonnqvist J, Cannon TD: Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia. Genome Med. 2012 Jan 18;4(1):1. doi: 10.1186/gm300.</reference_text><pubmed_id>22257447</pubmed_id></reference></references></disease><disease>Primary hypomagnesemia<references><reference><reference_text>Jin-no Y, Kamiya Y, Okada M, Hirako M, Takada N, Kawaguchi M: Primary hypomagnesemia caused by isolated magnesium malabsorption: atypical case in adult. Intern Med. 1999 Mar;38(3):261-5.</reference_text><pubmed_id>10337938</pubmed_id></reference><reference><reference_text>Vainsel M, Vandevelde G, Smulders J, Vosters M, Hubain P, Loeb H: Tetany due to hypomagnesaemia with secondary hypocalcaemia. Arch Dis Child. 1970 Apr;45(240):254-8.</reference_text><pubmed_id>5419995</pubmed_id></reference><reference><reference_text>Shalev H, Phillip M, Galil A, Carmi R, Landau D: Clinical presentation and outcome in primary familial hypomagnesaemia. Arch Dis Child. 1998 Feb;78(2):127-30.</reference_text><pubmed_id>9579153</pubmed_id></reference><reference><reference_text>Kari JA, Farouq M, Alshaya HO: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Pediatr Nephrol. 2003 Jun;18(6):506-10. Epub 2003 Apr 29.</reference_text><pubmed_id>12720080</pubmed_id></reference></references></disease><disease>Hyperlipoproteinemia<references><reference><reference_text>Sinha S, Misra A, Kumar V, Jagannathan NR, Bal CS, Pandey RM, Singhania R, Deepak: Proton magnetic resonance spectroscopy and single photon emission computed tomography study of the brain in asymptomatic young hyperlipidaemic Asian Indians in North India show early abnormalities. Clin Endocrinol (Oxf). 2004 Aug;61(2):182-9.</reference_text><pubmed_id>15272912</pubmed_id></reference><reference><reference_text>Nelson RH: Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013 Mar</reference_text><pubmed_id>40(1):195-211. doi: 10.1016/j.pop.2012.11.003. Epub 2012 Dec  4.</pubmed_id></reference><reference><reference_text>Cantin B, Boudriau S, Bertrand M, Brun LD, Gagne C, Rogers PA, Ven Murthy MR, Lupien PJ, Julien P: Hemolysis in primary lipoprotein lipase deficiency. Metabolism. 1995 May;44(5):652-8.</reference_text><pubmed_id>7752915</pubmed_id></reference></references></disease><disease>Abetalipoproteinemia<references><reference><reference_text>Dawson G, Kruski AW, Scanu AM: Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J Lipid Res. 1976 Mar;17(2):125-31.</reference_text><pubmed_id>178813</pubmed_id></reference><reference><reference_text>Lazaro RP, Dentinger MP, Rodichok LD, Barron KD, Satya-Murti S: Muscle pathology in Bassen-Kornzweig syndrome and vitamin E deficiency. Am J Clin Pathol. 1986 Sep;86(3):378-87.</reference_text><pubmed_id>2944375</pubmed_id></reference></references></disease><disease>Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis<references><reference><reference_text>Breckenridge WC, Alaupovic P, Cox DW, Little JA: Apolipoprotein and lipoprotein concentrations in familial apolipoprotein C-II deficiency. Atherosclerosis. 1982 Aug;44(2):223-35.</reference_text><pubmed_id>7138621</pubmed_id></reference><reference><reference_text>Fukami M, Hasegawa T, Horikawa R, Ohashi T, Nishimura G, Homma K, Ogata T: Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr Res. 2006 Feb;59(2):276-80. doi: 10.1203/01.pdr.0000195825.31504.28.</reference_text><pubmed_id>16439592</pubmed_id></reference></references></disease><disease>Cerebrotendinous xanthomatosis<references><reference><reference_text>Halperin G, Elisaf M, Leitersdorf E, Harats D: A new method for determination of serum cholestanol by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2000 Jun 9;742(2):345-52.</reference_text><pubmed_id>10901139</pubmed_id></reference><reference><reference_text>Siman-Tov T, Meiner V, Gadoth N: Could steroids mask the diagnosis of cerebrotendinous xanthomatosis? J Neurol Sci. 2006 Apr 15;243(1-2):83-6. Epub 2006 Jan 30.</reference_text><pubmed_id>16445943</pubmed_id></reference><reference><reference_text>Agrawal NK, Garg S: Cerebrotendinous xanthomatosis: a rare disorder with a rare presentation. BMJ Case Rep. 2012 Sep 21;2012. pii: bcr-2012-006202. doi: 10.1136/bcr-2012-006202.</reference_text><pubmed_id>23001091</pubmed_id></reference></references></disease><disease>3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency<references><reference><reference_text>Thompson GN, Hsu BY, Pitt JJ, Treacy E, Stanley CA: Fasting hypoketotic coma in a child with deficiency of mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase. N Engl J Med. 1997 Oct 23;337(17):1203-7. doi: 10.1056/NEJM199710233371704.</reference_text><pubmed_id>9337379</pubmed_id></reference><reference><reference_text>Morris AA, Lascelles CV, Olpin SE, Lake BD, Leonard JV, Quant PA: Hepatic mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme a synthase deficiency. Pediatr Res. 1998 Sep;44(3):392-6. doi: 10.1203/00006450-199809000-00021.</reference_text><pubmed_id>9727719</pubmed_id></reference><reference><reference_text>Conboy E, Vairo F, Schultz M, Agre K, Ridsdale R, Deyle D, Oglesbee D, Gavrilov D, Klee EW, Lanpher B: Mitochondrial 3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency: Unique Presenting Laboratory Values and a Review of Biochemical and Clinical Features. JIMD Rep. 2017 Oct 14. doi: 10.1007/8904_2017_59.</reference_text><pubmed_id>29030856</pubmed_id></reference></references></disease><disease>Hypercholesterolemia, familial<references><reference><reference_text>Kwiterovich PO Jr, Fredrickson DS, Levy RI: Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest. 1974 May;53(5):1237-49. doi: 10.1172/JCI107670.</reference_text><pubmed_id>4363406</pubmed_id></reference></references></disease><disease>SC4MOL deficiency<references><reference><reference_text>He M, Kratz LE, Michel JJ, Vallejo AN, Ferris L, Kelley RI, Hoover JJ, Jukic D, Gibson KM, Wolfe LA, Ramachandran D, Zwick ME, Vockley J: Mutations in the human SC4MOL gene encoding a methyl sterol oxidase cause psoriasiform dermatitis, microcephaly, and developmental delay. J Clin Invest. 2011 Mar;121(3):976-84. doi: 10.1172/JCI42650.</reference_text><pubmed_id>21285510</pubmed_id></reference></references></disease><disease>Chondrodysplasia punctata, X-linked dominant<references><reference><reference_text>Aughton DJ, Kelley RI, Metzenberg A, Pureza V, Pauli RM: X-linked dominant chondrodysplasia punctata (CDPX2) caused by single gene mosaicism in a male. Am J Med Genet A. 2003 Jan 30;116A(3):255-60. doi: 10.1002/ajmg.a.10852.</reference_text><pubmed_id>12503102</pubmed_id></reference></references></disease><disease>Desmosterolosis<references><reference><reference_text>Andersson HC, Kratz L, Kelley R: Desmosterolosis presenting with multiple congenital anomalies and profound developmental delay. Am J Med Genet. 2002 Dec 15;113(4):315-9. doi: 10.1002/ajmg.b.10873.</reference_text><pubmed_id>12457401</pubmed_id></reference></references></disease><disease>Donohue Syndrome<references><reference><reference_text>Nijim Y, Awni Y, Adawi A, Bowirrat A: Classic Case Report of Donohue Syndrome (Leprechaunism; OMIM *246200): The Impact of Consanguineous Mating. Medicine (Baltimore). 2016 Feb;95(6):e2710. doi: 10.1097/MD.0000000000002710.</reference_text><pubmed_id>26871809</pubmed_id></reference></references></disease><disease>Leptin Deficiency or Dysfunction<references><reference><reference_text>Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O'Rahilly S: Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999 Sep 16;341(12):879-84. doi: 10.1056/NEJM199909163411204.</reference_text><pubmed_id>10486419</pubmed_id></reference></references></disease><disease>Duchenne Muscular Dystrophy<references><reference><reference_text>Nakagawa T, Takeuchi A, Kakiuchi R, Lee T, Yagi M, Awano H, Iijima K, Takeshima Y, Urade Y, Matsuo M: A prostaglandin D2 metabolite is elevated in the urine of Duchenne muscular dystrophy patients and increases further from 8 years old. Clin Chim Acta. 2013 Aug 23;423:10-4. doi: 10.1016/j.cca.2013.03.031. Epub 2013 Apr 19.</reference_text><pubmed_id>23603101</pubmed_id></reference><reference><reference_text>Srivastava NK, Pradhan S, Mittal B, Gowda GA: High resolution NMR based analysis of serum lipids in Duchenne muscular dystrophy patients and its possible diagnostic significance. NMR Biomed. 2010 Jan;23(1):13-22. doi: 10.1002/nbm.1419.</reference_text><pubmed_id>19787747</pubmed_id></reference><reference><reference_text>Horster I, Weigt-Usinger K, Carmann C, Chobanyan-Jurgens K, Kohler C, Schara U, Kayacelebi AA, Beckmann B, Tsikas D, Lucke T: The L-arginine/NO pathway and homoarginine are altered in Duchenne muscular dystrophy and improved by glucocorticoids. Amino Acids. 2015 Sep;47(9):1853-63. doi: 10.1007/s00726-015-2018-x. Epub 2015 Jun 12.</reference_text><pubmed_id>26066683</pubmed_id></reference></references></disease><disease>Lecithin:cholesterol Acyltransferase Deficiency<references><reference><reference_text>Idzior-Walus B, Sieradzki J, Kostner G, Malecki MT, Klupa T, Wesolowska T, Rostworowski W, Hartwich J, Walus M, Kiec AD, Naruszewicz M: Familial lecithin-cholesterol acyltransferase deficiency: biochemical characteristics and molecular analysis of a new LCAT mutation in a Polish family. Atherosclerosis. 2006 Apr;185(2):413-20. Epub 2005 Jul 26.</reference_text><pubmed_id>16051254</pubmed_id></reference></references></disease><disease>Lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lipodystrophy, Congenital Generalized<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Oculocerebrorenal syndrome<references><reference><reference_text>Charnas LR, Bernardini I, Rader D, Hoeg JM, Gahl WA: Clinical and laboratory findings in the oculocerebrorenal syndrome of Lowe, with special reference to growth and renal function. N Engl J Med. 1991 May 9;324(19):1318-25. doi: 10.1056/NEJM199105093241904.</reference_text><pubmed_id>2017228</pubmed_id></reference></references></disease><disease>Familial partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lathosterolosis<references><reference><reference_text>Brunetti-Pierri N, Corso G, Rossi M, Ferrari P, Balli F, Rivasi F, Annunziata I, Ballabio A, Russo AD, Andria G, Parenti G: Lathosterolosis, a novel multiple-malformation/mental retardation syndrome due to deficiency of 3beta-hydroxysteroid-delta5-desaturase. Am J Hum Genet. 2002 Oct;71(4):952-8. Epub 2002 Aug 20.</reference_text><pubmed_id>12189593</pubmed_id></reference><reference><reference_text>Ho AC, Fung CW, Siu TS, Ma OC, Lam CW, Tam S, Wong VC: Lathosterolosis: a disorder of cholesterol biosynthesis resembling smith-lemli-opitz syndrome. JIMD Rep. 2014;12:129-34. doi: 10.1007/8904_2013_255. Epub 2013 Oct 20.</reference_text><pubmed_id>24142275</pubmed_id></reference></references></disease><disease>Partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Multiple sclerosis<references><reference><reference_text>Lutz NW, Viola A, Malikova I, Confort-Gouny S, Audoin B, Ranjeva JP, Pelletier J, Cozzone PJ: Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One. 2007 Jul 4;2(7):e595.</reference_text><pubmed_id>17611627</pubmed_id></reference><reference><reference_text>Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U, Hillert J, Bjorkhem I: Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med. 2004 Feb;42(2):186-91.</reference_text><pubmed_id>15061359</pubmed_id></reference><reference><reference_text>Leoni V, Lutjohann D, Masterman T: Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis. J Lipid Res. 2005 Feb;46(2):191-5. Epub 2004 Dec 1.</reference_text><pubmed_id>15576852</pubmed_id></reference><reference><reference_text>Calabrese V, Scapagnini G, Ravagna A, Bella R, Butterfield DA, Calvani M, Pennisi G, Giuffrida Stella AM: Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem Res. 2003 Sep;28(9):1321-8.</reference_text><pubmed_id>12938853</pubmed_id></reference><reference><reference_text>Shaw CE, Dunbar PR, Macaulay HA, Neale TJ: Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol. 1995 Jan;242(2):53-8.</reference_text><pubmed_id>7707089</pubmed_id></reference><reference><reference_text>Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.</reference_text><pubmed_id>17384003</pubmed_id></reference><reference><reference_text>Syburra C, Passi S: Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh (1999). 1999 May-Jun;71(3):112-5.</reference_text><pubmed_id>10609336</pubmed_id></reference><reference><reference_text>Forte G, Visconti A, Santucci S, Ghazaryan A, Figa-Talamanca L, Cannoni S, Bocca B, Pino A, Violante N, Alimonti A, Salvetti M, Ristori G: Quantification of chemical elements in blood of patients affected by multiple sclerosis. Ann Ist Super Sanita. 2005;41(2):213-6.</reference_text><pubmed_id>16244395</pubmed_id></reference><reference><reference_text>Toncev G, Milicic B, Toncev S, Samardzic G: Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol. 2002 May;9(3):221-6.</reference_text><pubmed_id>11985629</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, Bamonti F, Capello E, Mancardi GL, Scarpini E: Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res. 2010 May 28;1333:64-71. doi: 10.1016/j.brainres.2010.03.073. Epub 2010 Mar 27.</reference_text><pubmed_id>20347721</pubmed_id></reference><reference><reference_text>Matsushita T, Isobe N, Kawajiri M, Mogi M, Tsukuda K, Horiuchi M, Ohyagi Y, Kira J: CSF angiotensin II and angiotensin-converting enzyme levels in anti-aquaporin-4 autoimmunity. J Neurol Sci. 2010 Aug 15;295(1-2):41-5. doi: 10.1016/j.jns.2010.05.014. Epub 2010 Jun 11.</reference_text><pubmed_id>20541774</pubmed_id></reference><reference><reference_text>Ghabaee M, Jabedari B, Al-E-Eshagh N, Ghaffarpour M, Asadi F: Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients. Int J Neurosci. 2010 Apr;120(4):301-4. doi: 10.3109/00207451003695690.</reference_text><pubmed_id>20374079</pubmed_id></reference><reference><reference_text>Kawajiri M, Mogi M, Osoegawa M, Matsuoka T, Tsukuda K, Kohara K, Horiuchi M, Miki T, Kira JI: Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler. 2008 May;14(4):557-60. doi: 10.1177/1352458507085760.</reference_text><pubmed_id>18562510</pubmed_id></reference><reference><reference_text>Visconti A, Cotichini R, Cannoni S, Bocca B, Forte G, Ghazaryan A, Santucci S, D'Ippolito C, Stazi MA, Salvetti M, Alimonti A, Ristori G: Concentration of elements in serum of patients affected by multiple sclerosis with first demyelinating episode: a six-month longitudinal follow-up study. Ann Ist Super Sanita. 2005;41(2):217-22.</reference_text><pubmed_id>16244396</pubmed_id></reference></references></disease><disease>Inflammatory bowel disease<references><reference><reference_text>Lee T, Clavel T, Smirnov K, Schmidt A, Lagkouvardos I, Walker A, Lucio M, Michalke B, Schmitt-Kopplin P, Fedorak R, Haller D: Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. 2017 May;66(5):863-871. doi: 10.1136/gutjnl-2015-309940. Epub 2016 Feb 4.</reference_text><pubmed_id>26848182</pubmed_id></reference><reference><reference_text>Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158.</reference_text><pubmed_id>27609529</pubmed_id></reference></references></disease><disease>Colorectal cancer<references><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B: Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009 Apr;22(3):342-8. doi: 10.1002/nbm.1345.</reference_text><pubmed_id>19006102</pubmed_id></reference><reference><reference_text>Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP: Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One. 2013 Aug 6;8(8):e70803. doi: 10.1371/journal.pone.0070803. Print 2013.</reference_text><pubmed_id>23940645</pubmed_id></reference><reference><reference_text>Phua LC, Chue XP, Koh PK, Cheah PY, Ho HK, Chan EC: Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biol Ther. 2014 Apr;15(4):389-97. doi: 10.4161/cbt.27625. Epub 2014 Jan 14.</reference_text><pubmed_id>24424155</pubmed_id></reference><reference><reference_text>Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB: Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010 Feb 15;8:13. doi: 10.1186/1741-7015-8-13.</reference_text><pubmed_id>20156336</pubmed_id></reference><reference><reference_text>Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, Ni Y, Zhao A, Xu LX, Cai S, Jia W: Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res. 2009 Oct;8(10):4844-50. doi: 10.1021/pr9004162.</reference_text><pubmed_id>19678709</pubmed_id></reference><reference><reference_text>Cheng Y, Xie G, Chen T, Qiu Y, Zou X, Zheng M, Tan B, Feng B, Dong T, He P, Zhao L, Zhao A, Xu LX, Zhang Y, Jia W: Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res. 2012 Feb 3;11(2):1354-63. doi: 10.1021/pr201001a. Epub 2011 Dec 28.</reference_text><pubmed_id>22148915</pubmed_id></reference><reference><reference_text>Ni Y, Xie G, Jia W: Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res. 2014 Sep 5;13(9):3857-70. doi: 10.1021/pr500443c. Epub 2014 Aug 14.</reference_text><pubmed_id>25105552</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference><reference><reference_text>Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18.</reference_text><pubmed_id>25037050</pubmed_id></reference><reference><reference_text>Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016.</reference_text><pubmed_id>27015276</pubmed_id></reference><reference><reference_text>Lin Y, Ma C, Liu C, Wang Z, Yang J, Liu X, Shen Z, Wu R: NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer. Oncotarget. 2016 May 17;7(20):29454-64. doi: 10.18632/oncotarget.8762.</reference_text><pubmed_id>27107423</pubmed_id></reference><reference><reference_text>Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016.</reference_text><pubmed_id>27275383</pubmed_id></reference><reference><reference_text>Wang X, Wang J, Rao B, Deng L: Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals. Exp Ther Med. 2017 Jun;13(6):2848-2854. doi: 10.3892/etm.2017.4367. Epub 2017 Apr 20.</reference_text><pubmed_id>28587349</pubmed_id></reference><reference><reference_text>Silke Matysik, Caroline Ivanne Le Roy, Gerhard Liebisch, Sandrine Paule Claus. Metabolomics of fecal samples: A practical consideration. Trends in Food Science &amp; Technology. Vol. 57, Part B, Nov. 2016, p.244-255: http://www.sciencedirect.com/science/article/pii/S0924224416301984</reference_text><pubmed_id>28587349</pubmed_id></reference></references></disease><disease>Gallbladder disease<references><reference><reference_text>Lapidus A, Akerlund JE, Einarsson C: Gallbladder bile composition in patients with Crohn 's disease. World J Gastroenterol. 2006 Jan 7;12(1):70-4.</reference_text><pubmed_id>16440420</pubmed_id></reference><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference><reference><reference_text>Mizuno S, Tazuma S, Kajiyama G: Stabilization of biliary lipid particles by ursodeoxycholic acid. Prolonged nucleation time in human gallbladder bile. Dig Dis Sci. 1993 Apr;38(4):684-93.</reference_text><pubmed_id>8462368</pubmed_id></reference><reference><reference_text>Hillebrant CG, Axelson M, Bjorkhem I, Wang FH, Nyberg B, Einarsson C: Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients. Eur J Clin Invest. 1998 Apr;28(4):324-8.</reference_text><pubmed_id>9615912</pubmed_id></reference></references></disease><disease>Cholelithiasis<references><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference></references></disease><disease>Stomach cancer<references><reference><reference_text>Higashijima H, Ichimiya H, Nakano T, Yamashita H, Kuroki S, Satoh H, Chijiiwa K, Tanaka M: Deconjugation of bilirubin accelerates coprecipitation of cholesterol, fatty acids, and mucin in human bile--in vitro study. J Gastroenterol. 1996 Dec;31(6):828-35.</reference_text><pubmed_id>9027647</pubmed_id></reference><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Song H, Peng JS, Dong-Sheng Y, Yang ZL, Liu HL, Zeng YK, Shi XP, Lu BY: Serum metabolic profiling of human gastric cancer based on gas chromatography/mass spectrometry. Braz J Med Biol Res. 2012 Jan;45(1):78-85. Epub 2011 Nov 25.</reference_text><pubmed_id>22124703</pubmed_id></reference><reference><reference_text>Yu L, Aa J, Xu J, Sun M, Qian S, Cheng L, Yang S, Shi R: Metabolomic phenotype of gastric cancer and precancerous stages based on gas chromatography time-of-flight mass spectrometry. J Gastroenterol Hepatol. 2011 Aug;26(8):1290-7. doi: 10.1111/j.1440-1746.2011.06724.x.</reference_text><pubmed_id>21443661</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference></references></disease><disease>Acute myelogenous leukemia<references><reference><reference_text>Tatidis L, Vitols S, Gruber A, Paul C, Axelson M: Cholesterol catabolism in patients with acute myelogenous leukemia and hypocholesterolemia: suppressed levels of a circulating marker for bile acid synthesis. Cancer Lett. 2001 Sep 20;170(2):169-75.</reference_text><pubmed_id>11463495</pubmed_id></reference></references></disease><disease>Hypercholesterolemia<references><reference><reference_text>Thelen KM, Laaksonen R, Paiva H, Lehtimaki T, Lutjohann D: High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels. J Clin Pharmacol. 2006 Jul;46(7):812-6.</reference_text><pubmed_id>16809807</pubmed_id></reference><reference><reference_text>Tamasawa N, Tamasawa A, Takebe K: Higher levels of plasma cholesterol sulfate in patients with liver cirrhosis and hypercholesterolemia. Lipids. 1993 Sep;28(9):833-6.</reference_text><pubmed_id>8231659</pubmed_id></reference><reference><reference_text>Kim DH, Lee KJ, Heo GS: Analysis of cholesterol and cholesteryl esters in human serum using capillary supercritical fluid chromatography. J Chromatogr B Biomed Appl. 1994 Apr 22;655(1):1-8.</reference_text><pubmed_id>8061816</pubmed_id></reference><reference><reference_text>Authors unspecified: Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med. 1988 Jan;148(1):36-69.</reference_text><pubmed_id>3422148</pubmed_id></reference></references></disease><disease>Cholesteryl ester storage disease<references><reference><reference_text>Rassoul F, Richter V, Lohse P, Naumann A, Purschwitz K, Keller E: Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease. Int J Clin Pharmacol Ther. 2001 May;39(5):199-204.</reference_text><pubmed_id>11380065</pubmed_id></reference><reference><reference_text>Chatrath H, Keilin S, Attar BM: Cholesterol ester storage disease (CESD) diagnosed in an asymptomatic adult. Dig Dis Sci. 2009 Jan;54(1):168-73. doi: 10.1007/s10620-008-0310-2. Epub 2008 May 14.</reference_text><pubmed_id>18478331</pubmed_id></reference><reference><reference_text>Bernstein DL, Hulkova H, Bialer MG, Desnick RJ: Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol. 2013 Jun;58(6):1230-43. doi: 10.1016/j.jhep.2013.02.014. Epub 2013 Feb 26.</reference_text><pubmed_id>23485521</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Cystinosis<references><reference><reference_text>Ueda M, O'Brien K, Rosing DR, Ling A, Kleta R, McAreavey D, Bernardini I, Gahl WA: Coronary artery and other vascular calcifications in patients with cystinosis after kidney transplantation. Clin J Am Soc Nephrol. 2006 May;1(3):555-62. Epub 2006 Feb 8.</reference_text><pubmed_id>17699259</pubmed_id></reference><reference><reference_text>Gahl WA, Bernardini I, Dalakas M, Rizzo WB, Harper GS, Hoeg JM, Hurko O, Bernar J: Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome. J Clin Invest. 1988 Feb;81(2):549-60.</reference_text><pubmed_id>3276734</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Smith-Lemli-Opitz syndrome<references><reference><reference_text>van Rooij A, Nijenhuis AA, Wijburg FA, Schutgens RB: Highly increased CSF concentrations of cholesterol precursors in Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 1997 Aug;20(4):578-80.</reference_text><pubmed_id>9266395</pubmed_id></reference><reference><reference_text>Honda M, Tint GS, Honda A, Salen G, Shefer S, Batta AK, Matsuzaki Y, Tanaka N: Regulation of cholesterol biosynthetic pathway in patients with the Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2000 Jul;23(5):464-74.</reference_text><pubmed_id>10947201</pubmed_id></reference><reference><reference_text>Rossi M, Federico G, Corso G, Parenti G, Battagliese A, Frascogna AR, Della Casa R, Dello Russo A, Strisciuglio P, Saggese G, Andria G: Vitamin D status in patients affected by Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2005;28(1):69-80.</reference_text><pubmed_id>15702407</pubmed_id></reference><reference><reference_text>Johnson DW, ten Brink HJ, Jakobs C: A rapid screening procedure for cholesterol and dehydrocholesterol by electrospray ionization tandem mass spectrometry. J Lipid Res. 2001 Oct;42(10):1699-705.</reference_text><pubmed_id>11590227</pubmed_id></reference></references></disease><disease>Prostate cancer<references><reference><reference_text>Nyman DW, Suzanne Stratton M, Kopplin MJ, Dalkin BL, Nagle RB, Jay Gandolfi A: Selenium and selenomethionine levels in prostate cancer patients. Cancer Detect Prev. 2004;28(1):8-16.</reference_text><pubmed_id>15041072</pubmed_id></reference><reference><reference_text>Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, Egevad L, Tjonneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, Palli D, Vineis P, Tumino R, Berrino F, Kiemeney L, Bueno-de-Mesquita HB, Quiros JR, Gonzalez CA, Martinez C, Larranaga N, Chirlaque MD, Ardanaz E, Stattin P, Hallmans G, Khaw KT, Bingham S, Slimani N, Ferrari P, Rinaldi S, Riboli E: Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr. 2007 Sep;86(3):672-81.</reference_text><pubmed_id>17823432</pubmed_id></reference><reference><reference_text>Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762.</reference_text><pubmed_id>19212411</pubmed_id></reference><reference><reference_text>Puah CM, Williams G, Ghanadian R: Urinary unconjugated 5 alpha-androstane-3 alpha, 17 beta-diol in patients with prostatic tumours. Urol Res. 1982;10(2):81-4.</reference_text><pubmed_id>6180540</pubmed_id></reference><reference><reference_text>Thysell E, Surowiec I, Hornberg E, Crnalic S, Widmark A, Johansson AI, Stattin P, Bergh A, Moritz T, Antti H, Wikstrom P: Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One. 2010 Dec 3;5(12):e14175. doi: 10.1371/journal.pone.0014175.</reference_text><pubmed_id>21151972</pubmed_id></reference><reference><reference_text>Soliman LC, Hui Y, Hewavitharana AK, Chen DD: Monitoring potential prostate cancer biomarkers in urine by capillary electrophoresis-tandem mass spectrometry. J Chromatogr A. 2012 Dec 7;1267:162-9. doi: 10.1016/j.chroma.2012.07.021. Epub 2012 Jul 14.</reference_text><pubmed_id>22824219</pubmed_id></reference><reference><reference_text>Madu CO, Lu Y: Novel diagnostic biomarkers for prostate cancer. J Cancer. 2010 Oct 6;1:150-77.</reference_text><pubmed_id>20975847</pubmed_id></reference></references></disease><disease>Schizophrenia<references><reference><reference_text>Harnryd C, Bjerkenstedt L, Grimm VE, Sedvall G: Reduction of MOPEG levels in cerebrospinal fluid of psychotic women after electroconvulsive treatment. Psychopharmacology (Berl). 1979 Aug 8;64(2):131-4.</reference_text><pubmed_id>115032</pubmed_id></reference><reference><reference_text>Kobayashi K, Koide Y, Yoshino K, Shohmori T: [P-hydroxyphenylacetic acid concentrations in cerebrospinal fluid]. No To Shinkei. 1982 Aug;34(8):769-74.</reference_text><pubmed_id>7126379</pubmed_id></reference><reference><reference_text>Alfredsson G, Wiesel FA: Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology (Berl). 1989;99(3):322-7.</reference_text><pubmed_id>2480613</pubmed_id></reference><reference><reference_text>Heresco-Levy U, Bar G, Levin R, Ermilov M, Ebstein RP, Javitt DC: High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. Schizophr Res. 2007 Mar;91(1-3):14-21. Epub 2007 Feb 2.</reference_text><pubmed_id>17276036</pubmed_id></reference><reference><reference_text>Walker EF, Bonsall R, Walder DJ: Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis. Neuropsychiatry Neuropsychol Behav Neurol. 2002 Mar;15(1):10-7.</reference_text><pubmed_id>11877547</pubmed_id></reference><reference><reference_text>Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M: Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry. 2003 Jun;60(6):572-6.</reference_text><pubmed_id>12796220</pubmed_id></reference><reference><reference_text>Do KQ, Lauer CJ, Schreiber W, Zollinger M, Gutteck-Amsler U, Cuenod M, Holsboer F: gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem. 1995 Dec;65(6):2652-62.</reference_text><pubmed_id>7595563</pubmed_id></reference><reference><reference_text>Nikisch G, Baumann P, Wiedemann G, Kiessling B, Weisser H, Hertel A, Yoshitake T, Kehr J, Mathe AA: Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF. J Clin Psychopharmacol. 2010 Oct;30(5):496-503. doi: 10.1097/JCP.0b013e3181f2288e.</reference_text><pubmed_id>20814316</pubmed_id></reference><reference><reference_text>Fukushima T, Iizuka H, Yokota A, Suzuki T, Ohno C, Kono Y, Nishikiori M, Seki A, Ichiba H, Watanabe Y, Hongo S, Utsunomiya M, Nakatani M, Sadamoto K, Yoshio T: Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One. 2014 Jul 8;9(7):e101652. doi: 10.1371/journal.pone.0101652. eCollection 2014.</reference_text><pubmed_id>25004141</pubmed_id></reference><reference><reference_text>Koike S, Bundo M, Iwamoto K, Suga M, Kuwabara H, Ohashi Y, Shinoda K, Takano Y, Iwashiro N, Satomura Y, Nagai T, Natsubori T, Tada M, Yamasue H, Kasai K: A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study. Transl Psychiatry. 2014 Apr 8;4:e379. doi: 10.1038/tp.2014.19.</reference_text><pubmed_id>24713860</pubmed_id></reference><reference><reference_text>Ballesteros A, Summerfelt A, Du X, Jiang P, Chiappelli J, Tagamets M, O'Donnell P, Kochunov P, Hong LE: Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia. Clin Neurophysiol. 2013 Nov;124(11):2209-15. doi: 10.1016/j.clinph.2013.05.021. Epub 2013 Jun 30.</reference_text><pubmed_id>23823132</pubmed_id></reference><reference><reference_text>Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel FA: Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry. 1985 Sep;147:276-82.</reference_text><pubmed_id>2415198</pubmed_id></reference><reference><reference_text>Pickar D, Breier A, Hsiao JK, Doran AR, Wolkowitz OM, Pato CN, Konicki PE, Potter WZ: Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Arch Gen Psychiatry. 1990 Jul;47(7):641-8.</reference_text><pubmed_id>1694425</pubmed_id></reference><reference><reference_text>Prell GD, Green JP, Kaufmann CA, Khandelwal JK, Morrishow AM, Kirch DG, Linnoila M, Wyatt RJ: Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res. 1995 Jan;14(2):93-104.</reference_text><pubmed_id>7711000</pubmed_id></reference><reference><reference_text>Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B: Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology. 2009;59(2):123-9. doi: 10.1159/000213565. Epub 2009 Apr 22.</reference_text><pubmed_id>19390223</pubmed_id></reference><reference><reference_text>Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K, Cao Y, Wang X, Qiu Y, Su M, Zhao A, Wang P, Yang P, Wu J, Feng G, He L, Jia W, Wan C: Potential metabolite markers of schizophrenia. Mol Psychiatry. 2013 Jan;18(1):67-78. doi: 10.1038/mp.2011.131. Epub 2011 Oct 25.</reference_text><pubmed_id>22024767</pubmed_id></reference><reference><reference_text>Xuan J, Pan G, Qiu Y, Yang L, Su M, Liu Y, Chen J, Feng G, Fang Y, Jia W, Xing Q, He L: Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. J Proteome Res. 2011 Dec 2;10(12):5433-43. doi: 10.1021/pr2006796. Epub 2011 Nov  8.</reference_text><pubmed_id>22007635</pubmed_id></reference><reference><reference_text>Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM, Rothermundt M, Bogerts B, Koethe D, Kranaster L, Ohrmann P, Suslow T, McAllister G, Spain M, Barnes A, van Beveren NJ, Baron-Cohen S, Steiner J, Torrey FE, Yolken RH, Bahn S: Identification of a biological signature for schizophrenia in serum. Mol Psychiatry. 2012 May;17(5):494-502. doi: 10.1038/mp.2011.42. Epub 2011 Apr 12.</reference_text><pubmed_id>21483431</pubmed_id></reference><reference><reference_text>Mathe AA, Eberhard G, Saaf J, Wetterberg L: Plasma prostaglandin E2 metabolite--measured as 11-deoxy-15-keto-13,14-dihydro-11 beta,16 xi-cyclo-PGE2--in twins with schizophrenic disorder. Biol Psychiatry. 1986 Sep;21(11):1024-30.</reference_text><pubmed_id>3741918</pubmed_id></reference><reference><reference_text>Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N: Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct. 2002 Jun;20(2):171-5.</reference_text><pubmed_id>11979513</pubmed_id></reference><reference><reference_text>Zumarraga M, Davila R, Basterreche N, Arrue A, Goienetxea B, Zamalloa MI, Erkoreka L, Bustamante S, Inchausti L, Gonzalez-Torres MA, Guimon J: Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients. Neurochem Int. 2010 May-Jun;56(6-7):774-9. doi: 10.1016/j.neuint.2010.02.015. Epub 2010 Mar 4.</reference_text><pubmed_id>20206656</pubmed_id></reference><reference><reference_text>Peters JG: Dopamine, noradrenaline and serotonin spinal fluid metabolites in temporal lobe epileptic patients with schizophrenic symptomatology. Eur Neurol. 1979;18(1):15-8.</reference_text><pubmed_id>436860</pubmed_id></reference><reference><reference_text>Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, Rozen S, Krishnan RR, McEvoy J, Kaddurah-Daouk R: Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry. 2010 Sep;15(9):938-53. doi: 10.1038/mp.2009.33. Epub 2009 Apr 28.</reference_text><pubmed_id>19401681</pubmed_id></reference><reference><reference_text>Gattaz WF, Waldmeier P, Beckmann H: CSF monoamine metabolites in schizophrenic patients. Acta Psychiatr Scand. 1982 Nov;66(5):350-60.</reference_text><pubmed_id>6184954</pubmed_id></reference><reference><reference_text>Nilsson-Todd LK, Nordin C, Jonsson EG, Skogh E, Erhardt S: Cerebrospinal fluid kynurenic acid in male patients with schizophrenia - correlation with monoamine metabolites. Acta Neuropsychiatr. 2007 Feb;19(1):45-52. doi: 10.1111/j.1601-5215.2006.00170.x.</reference_text><pubmed_id>26952797</pubmed_id></reference><reference><reference_text>Cai HL, Li HD, Yan XZ, Sun B, Zhang Q, Yan M, Zhang WY, Jiang P, Zhu RH, Liu YP, Fang PF, Xu P, Yuan HY, Zhang XH, Hu L, Yang W, Ye HS: Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naive schizophrenia patients after treatment with risperidone. J Proteome Res. 2012 Aug 3;11(8):4338-50. doi: 10.1021/pr300459d. Epub 2012 Jul 26.</reference_text><pubmed_id>22800120</pubmed_id></reference><reference><reference_text>Al Awam K, Haussleiter IS, Dudley E, Donev R, Brune M, Juckel G, Thome J: Multiplatform metabolome and proteome profiling identifies serum metabolite and protein signatures as prospective biomarkers for schizophrenia. J Neural Transm (Vienna). 2015 Aug;122 Suppl 1:S111-22. doi: 10.1007/s00702-014-1224-0. Epub 2014 May 1.</reference_text><pubmed_id>24789758</pubmed_id></reference><reference><reference_text>Bicikova M, Hill M, Ripova D, Mohr P, Hampl R: Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia. J Steroid Biochem Mol Biol. 2013 Jan;133:77-83. doi: 10.1016/j.jsbmb.2012.08.009. Epub 2012 Aug 24.</reference_text><pubmed_id>22944140</pubmed_id></reference><reference><reference_text>He Y, Yu Z, Giegling I, Xie L, Hartmann AM, Prehn C, Adamski J, Kahn R, Li Y, Illig T, Wang-Sattler R, Rujescu D: Schizophrenia shows a unique metabolomics signature in plasma. Transl Psychiatry. 2012 Aug 14;2:e149. doi: 10.1038/tp.2012.76.</reference_text><pubmed_id>22892715</pubmed_id></reference><reference><reference_text>Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KR: Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):934-45. Epub 2007 Apr 17.</reference_text><pubmed_id>17440431</pubmed_id></reference><reference><reference_text>Fryar-Williams S, Strobel JE: Biomarkers of a five-domain translational substrate for schizophrenia and schizoaffective psychosis. Biomark Res. 2015 Feb 6;3:3. doi: 10.1186/s40364-015-0028-1. eCollection 2015.</reference_text><pubmed_id>25729574</pubmed_id></reference><reference><reference_text>Oresic M, Seppanen-Laakso T, Sun D, Tang J, Therman S, Viehman R, Mustonen U, van Erp TG, Hyotylainen T, Thompson P, Toga AW, Huttunen MO, Suvisaari J, Kaprio J, Lonnqvist J, Cannon TD: Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia. Genome Med. 2012 Jan 18;4(1):1. doi: 10.1186/gm300.</reference_text><pubmed_id>22257447</pubmed_id></reference></references></disease><disease>Primary hypomagnesemia<references><reference><reference_text>Jin-no Y, Kamiya Y, Okada M, Hirako M, Takada N, Kawaguchi M: Primary hypomagnesemia caused by isolated magnesium malabsorption: atypical case in adult. Intern Med. 1999 Mar;38(3):261-5.</reference_text><pubmed_id>10337938</pubmed_id></reference><reference><reference_text>Vainsel M, Vandevelde G, Smulders J, Vosters M, Hubain P, Loeb H: Tetany due to hypomagnesaemia with secondary hypocalcaemia. Arch Dis Child. 1970 Apr;45(240):254-8.</reference_text><pubmed_id>5419995</pubmed_id></reference><reference><reference_text>Shalev H, Phillip M, Galil A, Carmi R, Landau D: Clinical presentation and outcome in primary familial hypomagnesaemia. Arch Dis Child. 1998 Feb;78(2):127-30.</reference_text><pubmed_id>9579153</pubmed_id></reference><reference><reference_text>Kari JA, Farouq M, Alshaya HO: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Pediatr Nephrol. 2003 Jun;18(6):506-10. Epub 2003 Apr 29.</reference_text><pubmed_id>12720080</pubmed_id></reference></references></disease><disease>Hyperlipoproteinemia<references><reference><reference_text>Sinha S, Misra A, Kumar V, Jagannathan NR, Bal CS, Pandey RM, Singhania R, Deepak: Proton magnetic resonance spectroscopy and single photon emission computed tomography study of the brain in asymptomatic young hyperlipidaemic Asian Indians in North India show early abnormalities. Clin Endocrinol (Oxf). 2004 Aug;61(2):182-9.</reference_text><pubmed_id>15272912</pubmed_id></reference><reference><reference_text>Nelson RH: Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013 Mar</reference_text><pubmed_id>40(1):195-211. doi: 10.1016/j.pop.2012.11.003. Epub 2012 Dec  4.</pubmed_id></reference><reference><reference_text>Cantin B, Boudriau S, Bertrand M, Brun LD, Gagne C, Rogers PA, Ven Murthy MR, Lupien PJ, Julien P: Hemolysis in primary lipoprotein lipase deficiency. Metabolism. 1995 May;44(5):652-8.</reference_text><pubmed_id>7752915</pubmed_id></reference></references></disease><disease>Abetalipoproteinemia<references><reference><reference_text>Dawson G, Kruski AW, Scanu AM: Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J Lipid Res. 1976 Mar;17(2):125-31.</reference_text><pubmed_id>178813</pubmed_id></reference><reference><reference_text>Lazaro RP, Dentinger MP, Rodichok LD, Barron KD, Satya-Murti S: Muscle pathology in Bassen-Kornzweig syndrome and vitamin E deficiency. Am J Clin Pathol. 1986 Sep;86(3):378-87.</reference_text><pubmed_id>2944375</pubmed_id></reference></references></disease><disease>Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis<references><reference><reference_text>Breckenridge WC, Alaupovic P, Cox DW, Little JA: Apolipoprotein and lipoprotein concentrations in familial apolipoprotein C-II deficiency. Atherosclerosis. 1982 Aug;44(2):223-35.</reference_text><pubmed_id>7138621</pubmed_id></reference><reference><reference_text>Fukami M, Hasegawa T, Horikawa R, Ohashi T, Nishimura G, Homma K, Ogata T: Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr Res. 2006 Feb;59(2):276-80. doi: 10.1203/01.pdr.0000195825.31504.28.</reference_text><pubmed_id>16439592</pubmed_id></reference></references></disease><disease>Cerebrotendinous xanthomatosis<references><reference><reference_text>Halperin G, Elisaf M, Leitersdorf E, Harats D: A new method for determination of serum cholestanol by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2000 Jun 9;742(2):345-52.</reference_text><pubmed_id>10901139</pubmed_id></reference><reference><reference_text>Siman-Tov T, Meiner V, Gadoth N: Could steroids mask the diagnosis of cerebrotendinous xanthomatosis? J Neurol Sci. 2006 Apr 15;243(1-2):83-6. Epub 2006 Jan 30.</reference_text><pubmed_id>16445943</pubmed_id></reference><reference><reference_text>Agrawal NK, Garg S: Cerebrotendinous xanthomatosis: a rare disorder with a rare presentation. BMJ Case Rep. 2012 Sep 21;2012. pii: bcr-2012-006202. doi: 10.1136/bcr-2012-006202.</reference_text><pubmed_id>23001091</pubmed_id></reference></references></disease><disease>3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency<references><reference><reference_text>Thompson GN, Hsu BY, Pitt JJ, Treacy E, Stanley CA: Fasting hypoketotic coma in a child with deficiency of mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase. N Engl J Med. 1997 Oct 23;337(17):1203-7. doi: 10.1056/NEJM199710233371704.</reference_text><pubmed_id>9337379</pubmed_id></reference><reference><reference_text>Morris AA, Lascelles CV, Olpin SE, Lake BD, Leonard JV, Quant PA: Hepatic mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme a synthase deficiency. Pediatr Res. 1998 Sep;44(3):392-6. doi: 10.1203/00006450-199809000-00021.</reference_text><pubmed_id>9727719</pubmed_id></reference><reference><reference_text>Conboy E, Vairo F, Schultz M, Agre K, Ridsdale R, Deyle D, Oglesbee D, Gavrilov D, Klee EW, Lanpher B: Mitochondrial 3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency: Unique Presenting Laboratory Values and a Review of Biochemical and Clinical Features. JIMD Rep. 2017 Oct 14. doi: 10.1007/8904_2017_59.</reference_text><pubmed_id>29030856</pubmed_id></reference></references></disease><disease>Hypercholesterolemia, familial<references><reference><reference_text>Kwiterovich PO Jr, Fredrickson DS, Levy RI: Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest. 1974 May;53(5):1237-49. doi: 10.1172/JCI107670.</reference_text><pubmed_id>4363406</pubmed_id></reference></references></disease><disease>SC4MOL deficiency<references><reference><reference_text>He M, Kratz LE, Michel JJ, Vallejo AN, Ferris L, Kelley RI, Hoover JJ, Jukic D, Gibson KM, Wolfe LA, Ramachandran D, Zwick ME, Vockley J: Mutations in the human SC4MOL gene encoding a methyl sterol oxidase cause psoriasiform dermatitis, microcephaly, and developmental delay. J Clin Invest. 2011 Mar;121(3):976-84. doi: 10.1172/JCI42650.</reference_text><pubmed_id>21285510</pubmed_id></reference></references></disease><disease>Chondrodysplasia punctata, X-linked dominant<references><reference><reference_text>Aughton DJ, Kelley RI, Metzenberg A, Pureza V, Pauli RM: X-linked dominant chondrodysplasia punctata (CDPX2) caused by single gene mosaicism in a male. Am J Med Genet A. 2003 Jan 30;116A(3):255-60. doi: 10.1002/ajmg.a.10852.</reference_text><pubmed_id>12503102</pubmed_id></reference></references></disease><disease>Desmosterolosis<references><reference><reference_text>Andersson HC, Kratz L, Kelley R: Desmosterolosis presenting with multiple congenital anomalies and profound developmental delay. Am J Med Genet. 2002 Dec 15;113(4):315-9. doi: 10.1002/ajmg.b.10873.</reference_text><pubmed_id>12457401</pubmed_id></reference></references></disease><disease>Donohue Syndrome<references><reference><reference_text>Nijim Y, Awni Y, Adawi A, Bowirrat A: Classic Case Report of Donohue Syndrome (Leprechaunism; OMIM *246200): The Impact of Consanguineous Mating. Medicine (Baltimore). 2016 Feb;95(6):e2710. doi: 10.1097/MD.0000000000002710.</reference_text><pubmed_id>26871809</pubmed_id></reference></references></disease><disease>Leptin Deficiency or Dysfunction<references><reference><reference_text>Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O'Rahilly S: Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999 Sep 16;341(12):879-84. doi: 10.1056/NEJM199909163411204.</reference_text><pubmed_id>10486419</pubmed_id></reference></references></disease><disease>Duchenne Muscular Dystrophy<references><reference><reference_text>Nakagawa T, Takeuchi A, Kakiuchi R, Lee T, Yagi M, Awano H, Iijima K, Takeshima Y, Urade Y, Matsuo M: A prostaglandin D2 metabolite is elevated in the urine of Duchenne muscular dystrophy patients and increases further from 8 years old. Clin Chim Acta. 2013 Aug 23;423:10-4. doi: 10.1016/j.cca.2013.03.031. Epub 2013 Apr 19.</reference_text><pubmed_id>23603101</pubmed_id></reference><reference><reference_text>Srivastava NK, Pradhan S, Mittal B, Gowda GA: High resolution NMR based analysis of serum lipids in Duchenne muscular dystrophy patients and its possible diagnostic significance. NMR Biomed. 2010 Jan;23(1):13-22. doi: 10.1002/nbm.1419.</reference_text><pubmed_id>19787747</pubmed_id></reference><reference><reference_text>Horster I, Weigt-Usinger K, Carmann C, Chobanyan-Jurgens K, Kohler C, Schara U, Kayacelebi AA, Beckmann B, Tsikas D, Lucke T: The L-arginine/NO pathway and homoarginine are altered in Duchenne muscular dystrophy and improved by glucocorticoids. Amino Acids. 2015 Sep;47(9):1853-63. doi: 10.1007/s00726-015-2018-x. Epub 2015 Jun 12.</reference_text><pubmed_id>26066683</pubmed_id></reference></references></disease><disease>Lecithin:cholesterol Acyltransferase Deficiency<references><reference><reference_text>Idzior-Walus B, Sieradzki J, Kostner G, Malecki MT, Klupa T, Wesolowska T, Rostworowski W, Hartwich J, Walus M, Kiec AD, Naruszewicz M: Familial lecithin-cholesterol acyltransferase deficiency: biochemical characteristics and molecular analysis of a new LCAT mutation in a Polish family. Atherosclerosis. 2006 Apr;185(2):413-20. Epub 2005 Jul 26.</reference_text><pubmed_id>16051254</pubmed_id></reference></references></disease><disease>Lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lipodystrophy, Congenital Generalized<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Oculocerebrorenal syndrome<references><reference><reference_text>Charnas LR, Bernardini I, Rader D, Hoeg JM, Gahl WA: Clinical and laboratory findings in the oculocerebrorenal syndrome of Lowe, with special reference to growth and renal function. N Engl J Med. 1991 May 9;324(19):1318-25. doi: 10.1056/NEJM199105093241904.</reference_text><pubmed_id>2017228</pubmed_id></reference></references></disease><disease>Familial partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lathosterolosis<references><reference><reference_text>Brunetti-Pierri N, Corso G, Rossi M, Ferrari P, Balli F, Rivasi F, Annunziata I, Ballabio A, Russo AD, Andria G, Parenti G: Lathosterolosis, a novel multiple-malformation/mental retardation syndrome due to deficiency of 3beta-hydroxysteroid-delta5-desaturase. Am J Hum Genet. 2002 Oct;71(4):952-8. Epub 2002 Aug 20.</reference_text><pubmed_id>12189593</pubmed_id></reference><reference><reference_text>Ho AC, Fung CW, Siu TS, Ma OC, Lam CW, Tam S, Wong VC: Lathosterolosis: a disorder of cholesterol biosynthesis resembling smith-lemli-opitz syndrome. JIMD Rep. 2014;12:129-34. doi: 10.1007/8904_2013_255. Epub 2013 Oct 20.</reference_text><pubmed_id>24142275</pubmed_id></reference></references></disease><disease>Partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Multiple sclerosis<references><reference><reference_text>Lutz NW, Viola A, Malikova I, Confort-Gouny S, Audoin B, Ranjeva JP, Pelletier J, Cozzone PJ: Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One. 2007 Jul 4;2(7):e595.</reference_text><pubmed_id>17611627</pubmed_id></reference><reference><reference_text>Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U, Hillert J, Bjorkhem I: Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med. 2004 Feb;42(2):186-91.</reference_text><pubmed_id>15061359</pubmed_id></reference><reference><reference_text>Leoni V, Lutjohann D, Masterman T: Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis. J Lipid Res. 2005 Feb;46(2):191-5. Epub 2004 Dec 1.</reference_text><pubmed_id>15576852</pubmed_id></reference><reference><reference_text>Calabrese V, Scapagnini G, Ravagna A, Bella R, Butterfield DA, Calvani M, Pennisi G, Giuffrida Stella AM: Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem Res. 2003 Sep;28(9):1321-8.</reference_text><pubmed_id>12938853</pubmed_id></reference><reference><reference_text>Shaw CE, Dunbar PR, Macaulay HA, Neale TJ: Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol. 1995 Jan;242(2):53-8.</reference_text><pubmed_id>7707089</pubmed_id></reference><reference><reference_text>Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.</reference_text><pubmed_id>17384003</pubmed_id></reference><reference><reference_text>Syburra C, Passi S: Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh (1999). 1999 May-Jun;71(3):112-5.</reference_text><pubmed_id>10609336</pubmed_id></reference><reference><reference_text>Forte G, Visconti A, Santucci S, Ghazaryan A, Figa-Talamanca L, Cannoni S, Bocca B, Pino A, Violante N, Alimonti A, Salvetti M, Ristori G: Quantification of chemical elements in blood of patients affected by multiple sclerosis. Ann Ist Super Sanita. 2005;41(2):213-6.</reference_text><pubmed_id>16244395</pubmed_id></reference><reference><reference_text>Toncev G, Milicic B, Toncev S, Samardzic G: Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol. 2002 May;9(3):221-6.</reference_text><pubmed_id>11985629</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, Bamonti F, Capello E, Mancardi GL, Scarpini E: Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res. 2010 May 28;1333:64-71. doi: 10.1016/j.brainres.2010.03.073. Epub 2010 Mar 27.</reference_text><pubmed_id>20347721</pubmed_id></reference><reference><reference_text>Matsushita T, Isobe N, Kawajiri M, Mogi M, Tsukuda K, Horiuchi M, Ohyagi Y, Kira J: CSF angiotensin II and angiotensin-converting enzyme levels in anti-aquaporin-4 autoimmunity. J Neurol Sci. 2010 Aug 15;295(1-2):41-5. doi: 10.1016/j.jns.2010.05.014. Epub 2010 Jun 11.</reference_text><pubmed_id>20541774</pubmed_id></reference><reference><reference_text>Ghabaee M, Jabedari B, Al-E-Eshagh N, Ghaffarpour M, Asadi F: Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients. Int J Neurosci. 2010 Apr;120(4):301-4. doi: 10.3109/00207451003695690.</reference_text><pubmed_id>20374079</pubmed_id></reference><reference><reference_text>Kawajiri M, Mogi M, Osoegawa M, Matsuoka T, Tsukuda K, Kohara K, Horiuchi M, Miki T, Kira JI: Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler. 2008 May;14(4):557-60. doi: 10.1177/1352458507085760.</reference_text><pubmed_id>18562510</pubmed_id></reference><reference><reference_text>Visconti A, Cotichini R, Cannoni S, Bocca B, Forte G, Ghazaryan A, Santucci S, D'Ippolito C, Stazi MA, Salvetti M, Alimonti A, Ristori G: Concentration of elements in serum of patients affected by multiple sclerosis with first demyelinating episode: a six-month longitudinal follow-up study. Ann Ist Super Sanita. 2005;41(2):217-22.</reference_text><pubmed_id>16244396</pubmed_id></reference></references></disease><disease>Inflammatory bowel disease<references><reference><reference_text>Lee T, Clavel T, Smirnov K, Schmidt A, Lagkouvardos I, Walker A, Lucio M, Michalke B, Schmitt-Kopplin P, Fedorak R, Haller D: Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. 2017 May;66(5):863-871. doi: 10.1136/gutjnl-2015-309940. Epub 2016 Feb 4.</reference_text><pubmed_id>26848182</pubmed_id></reference><reference><reference_text>Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158.</reference_text><pubmed_id>27609529</pubmed_id></reference></references></disease><disease>Colorectal cancer<references><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B: Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009 Apr;22(3):342-8. doi: 10.1002/nbm.1345.</reference_text><pubmed_id>19006102</pubmed_id></reference><reference><reference_text>Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP: Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One. 2013 Aug 6;8(8):e70803. doi: 10.1371/journal.pone.0070803. Print 2013.</reference_text><pubmed_id>23940645</pubmed_id></reference><reference><reference_text>Phua LC, Chue XP, Koh PK, Cheah PY, Ho HK, Chan EC: Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biol Ther. 2014 Apr;15(4):389-97. doi: 10.4161/cbt.27625. Epub 2014 Jan 14.</reference_text><pubmed_id>24424155</pubmed_id></reference><reference><reference_text>Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB: Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010 Feb 15;8:13. doi: 10.1186/1741-7015-8-13.</reference_text><pubmed_id>20156336</pubmed_id></reference><reference><reference_text>Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, Ni Y, Zhao A, Xu LX, Cai S, Jia W: Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res. 2009 Oct;8(10):4844-50. doi: 10.1021/pr9004162.</reference_text><pubmed_id>19678709</pubmed_id></reference><reference><reference_text>Cheng Y, Xie G, Chen T, Qiu Y, Zou X, Zheng M, Tan B, Feng B, Dong T, He P, Zhao L, Zhao A, Xu LX, Zhang Y, Jia W: Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res. 2012 Feb 3;11(2):1354-63. doi: 10.1021/pr201001a. Epub 2011 Dec 28.</reference_text><pubmed_id>22148915</pubmed_id></reference><reference><reference_text>Ni Y, Xie G, Jia W: Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res. 2014 Sep 5;13(9):3857-70. doi: 10.1021/pr500443c. Epub 2014 Aug 14.</reference_text><pubmed_id>25105552</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference><reference><reference_text>Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18.</reference_text><pubmed_id>25037050</pubmed_id></reference><reference><reference_text>Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016.</reference_text><pubmed_id>27015276</pubmed_id></reference><reference><reference_text>Lin Y, Ma C, Liu C, Wang Z, Yang J, Liu X, Shen Z, Wu R: NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer. Oncotarget. 2016 May 17;7(20):29454-64. doi: 10.18632/oncotarget.8762.</reference_text><pubmed_id>27107423</pubmed_id></reference><reference><reference_text>Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016.</reference_text><pubmed_id>27275383</pubmed_id></reference><reference><reference_text>Wang X, Wang J, Rao B, Deng L: Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals. Exp Ther Med. 2017 Jun;13(6):2848-2854. doi: 10.3892/etm.2017.4367. Epub 2017 Apr 20.</reference_text><pubmed_id>28587349</pubmed_id></reference><reference><reference_text>Silke Matysik, Caroline Ivanne Le Roy, Gerhard Liebisch, Sandrine Paule Claus. Metabolomics of fecal samples: A practical consideration. Trends in Food Science &amp; Technology. Vol. 57, Part B, Nov. 2016, p.244-255: http://www.sciencedirect.com/science/article/pii/S0924224416301984</reference_text><pubmed_id>28587349</pubmed_id></reference></references></disease><disease>Gallbladder disease<references><reference><reference_text>Lapidus A, Akerlund JE, Einarsson C: Gallbladder bile composition in patients with Crohn 's disease. World J Gastroenterol. 2006 Jan 7;12(1):70-4.</reference_text><pubmed_id>16440420</pubmed_id></reference><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference><reference><reference_text>Mizuno S, Tazuma S, Kajiyama G: Stabilization of biliary lipid particles by ursodeoxycholic acid. Prolonged nucleation time in human gallbladder bile. Dig Dis Sci. 1993 Apr;38(4):684-93.</reference_text><pubmed_id>8462368</pubmed_id></reference><reference><reference_text>Hillebrant CG, Axelson M, Bjorkhem I, Wang FH, Nyberg B, Einarsson C: Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients. Eur J Clin Invest. 1998 Apr;28(4):324-8.</reference_text><pubmed_id>9615912</pubmed_id></reference></references></disease><disease>Cholelithiasis<references><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference></references></disease><disease>Stomach cancer<references><reference><reference_text>Higashijima H, Ichimiya H, Nakano T, Yamashita H, Kuroki S, Satoh H, Chijiiwa K, Tanaka M: Deconjugation of bilirubin accelerates coprecipitation of cholesterol, fatty acids, and mucin in human bile--in vitro study. J Gastroenterol. 1996 Dec;31(6):828-35.</reference_text><pubmed_id>9027647</pubmed_id></reference><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Song H, Peng JS, Dong-Sheng Y, Yang ZL, Liu HL, Zeng YK, Shi XP, Lu BY: Serum metabolic profiling of human gastric cancer based on gas chromatography/mass spectrometry. Braz J Med Biol Res. 2012 Jan;45(1):78-85. Epub 2011 Nov 25.</reference_text><pubmed_id>22124703</pubmed_id></reference><reference><reference_text>Yu L, Aa J, Xu J, Sun M, Qian S, Cheng L, Yang S, Shi R: Metabolomic phenotype of gastric cancer and precancerous stages based on gas chromatography time-of-flight mass spectrometry. J Gastroenterol Hepatol. 2011 Aug;26(8):1290-7. doi: 10.1111/j.1440-1746.2011.06724.x.</reference_text><pubmed_id>21443661</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference></references></disease><disease>Acute myelogenous leukemia<references><reference><reference_text>Tatidis L, Vitols S, Gruber A, Paul C, Axelson M: Cholesterol catabolism in patients with acute myelogenous leukemia and hypocholesterolemia: suppressed levels of a circulating marker for bile acid synthesis. Cancer Lett. 2001 Sep 20;170(2):169-75.</reference_text><pubmed_id>11463495</pubmed_id></reference></references></disease><disease>Hypercholesterolemia<references><reference><reference_text>Thelen KM, Laaksonen R, Paiva H, Lehtimaki T, Lutjohann D: High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels. J Clin Pharmacol. 2006 Jul;46(7):812-6.</reference_text><pubmed_id>16809807</pubmed_id></reference><reference><reference_text>Tamasawa N, Tamasawa A, Takebe K: Higher levels of plasma cholesterol sulfate in patients with liver cirrhosis and hypercholesterolemia. Lipids. 1993 Sep;28(9):833-6.</reference_text><pubmed_id>8231659</pubmed_id></reference><reference><reference_text>Kim DH, Lee KJ, Heo GS: Analysis of cholesterol and cholesteryl esters in human serum using capillary supercritical fluid chromatography. J Chromatogr B Biomed Appl. 1994 Apr 22;655(1):1-8.</reference_text><pubmed_id>8061816</pubmed_id></reference><reference><reference_text>Authors unspecified: Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med. 1988 Jan;148(1):36-69.</reference_text><pubmed_id>3422148</pubmed_id></reference></references></disease><disease>Cholesteryl ester storage disease<references><reference><reference_text>Rassoul F, Richter V, Lohse P, Naumann A, Purschwitz K, Keller E: Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease. Int J Clin Pharmacol Ther. 2001 May;39(5):199-204.</reference_text><pubmed_id>11380065</pubmed_id></reference><reference><reference_text>Chatrath H, Keilin S, Attar BM: Cholesterol ester storage disease (CESD) diagnosed in an asymptomatic adult. Dig Dis Sci. 2009 Jan;54(1):168-73. doi: 10.1007/s10620-008-0310-2. Epub 2008 May 14.</reference_text><pubmed_id>18478331</pubmed_id></reference><reference><reference_text>Bernstein DL, Hulkova H, Bialer MG, Desnick RJ: Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol. 2013 Jun;58(6):1230-43. doi: 10.1016/j.jhep.2013.02.014. Epub 2013 Feb 26.</reference_text><pubmed_id>23485521</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Cystinosis<references><reference><reference_text>Ueda M, O'Brien K, Rosing DR, Ling A, Kleta R, McAreavey D, Bernardini I, Gahl WA: Coronary artery and other vascular calcifications in patients with cystinosis after kidney transplantation. Clin J Am Soc Nephrol. 2006 May;1(3):555-62. Epub 2006 Feb 8.</reference_text><pubmed_id>17699259</pubmed_id></reference><reference><reference_text>Gahl WA, Bernardini I, Dalakas M, Rizzo WB, Harper GS, Hoeg JM, Hurko O, Bernar J: Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome. J Clin Invest. 1988 Feb;81(2):549-60.</reference_text><pubmed_id>3276734</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Smith-Lemli-Opitz syndrome<references><reference><reference_text>van Rooij A, Nijenhuis AA, Wijburg FA, Schutgens RB: Highly increased CSF concentrations of cholesterol precursors in Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 1997 Aug;20(4):578-80.</reference_text><pubmed_id>9266395</pubmed_id></reference><reference><reference_text>Honda M, Tint GS, Honda A, Salen G, Shefer S, Batta AK, Matsuzaki Y, Tanaka N: Regulation of cholesterol biosynthetic pathway in patients with the Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2000 Jul;23(5):464-74.</reference_text><pubmed_id>10947201</pubmed_id></reference><reference><reference_text>Rossi M, Federico G, Corso G, Parenti G, Battagliese A, Frascogna AR, Della Casa R, Dello Russo A, Strisciuglio P, Saggese G, Andria G: Vitamin D status in patients affected by Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2005;28(1):69-80.</reference_text><pubmed_id>15702407</pubmed_id></reference><reference><reference_text>Johnson DW, ten Brink HJ, Jakobs C: A rapid screening procedure for cholesterol and dehydrocholesterol by electrospray ionization tandem mass spectrometry. J Lipid Res. 2001 Oct;42(10):1699-705.</reference_text><pubmed_id>11590227</pubmed_id></reference></references></disease><disease>Prostate cancer<references><reference><reference_text>Nyman DW, Suzanne Stratton M, Kopplin MJ, Dalkin BL, Nagle RB, Jay Gandolfi A: Selenium and selenomethionine levels in prostate cancer patients. Cancer Detect Prev. 2004;28(1):8-16.</reference_text><pubmed_id>15041072</pubmed_id></reference><reference><reference_text>Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, Egevad L, Tjonneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, Palli D, Vineis P, Tumino R, Berrino F, Kiemeney L, Bueno-de-Mesquita HB, Quiros JR, Gonzalez CA, Martinez C, Larranaga N, Chirlaque MD, Ardanaz E, Stattin P, Hallmans G, Khaw KT, Bingham S, Slimani N, Ferrari P, Rinaldi S, Riboli E: Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr. 2007 Sep;86(3):672-81.</reference_text><pubmed_id>17823432</pubmed_id></reference><reference><reference_text>Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762.</reference_text><pubmed_id>19212411</pubmed_id></reference><reference><reference_text>Puah CM, Williams G, Ghanadian R: Urinary unconjugated 5 alpha-androstane-3 alpha, 17 beta-diol in patients with prostatic tumours. Urol Res. 1982;10(2):81-4.</reference_text><pubmed_id>6180540</pubmed_id></reference><reference><reference_text>Thysell E, Surowiec I, Hornberg E, Crnalic S, Widmark A, Johansson AI, Stattin P, Bergh A, Moritz T, Antti H, Wikstrom P: Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One. 2010 Dec 3;5(12):e14175. doi: 10.1371/journal.pone.0014175.</reference_text><pubmed_id>21151972</pubmed_id></reference><reference><reference_text>Soliman LC, Hui Y, Hewavitharana AK, Chen DD: Monitoring potential prostate cancer biomarkers in urine by capillary electrophoresis-tandem mass spectrometry. J Chromatogr A. 2012 Dec 7;1267:162-9. doi: 10.1016/j.chroma.2012.07.021. Epub 2012 Jul 14.</reference_text><pubmed_id>22824219</pubmed_id></reference><reference><reference_text>Madu CO, Lu Y: Novel diagnostic biomarkers for prostate cancer. J Cancer. 2010 Oct 6;1:150-77.</reference_text><pubmed_id>20975847</pubmed_id></reference></references></disease><disease>Schizophrenia<references><reference><reference_text>Harnryd C, Bjerkenstedt L, Grimm VE, Sedvall G: Reduction of MOPEG levels in cerebrospinal fluid of psychotic women after electroconvulsive treatment. Psychopharmacology (Berl). 1979 Aug 8;64(2):131-4.</reference_text><pubmed_id>115032</pubmed_id></reference><reference><reference_text>Kobayashi K, Koide Y, Yoshino K, Shohmori T: [P-hydroxyphenylacetic acid concentrations in cerebrospinal fluid]. No To Shinkei. 1982 Aug;34(8):769-74.</reference_text><pubmed_id>7126379</pubmed_id></reference><reference><reference_text>Alfredsson G, Wiesel FA: Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology (Berl). 1989;99(3):322-7.</reference_text><pubmed_id>2480613</pubmed_id></reference><reference><reference_text>Heresco-Levy U, Bar G, Levin R, Ermilov M, Ebstein RP, Javitt DC: High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. Schizophr Res. 2007 Mar;91(1-3):14-21. Epub 2007 Feb 2.</reference_text><pubmed_id>17276036</pubmed_id></reference><reference><reference_text>Walker EF, Bonsall R, Walder DJ: Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis. Neuropsychiatry Neuropsychol Behav Neurol. 2002 Mar;15(1):10-7.</reference_text><pubmed_id>11877547</pubmed_id></reference><reference><reference_text>Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M: Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry. 2003 Jun;60(6):572-6.</reference_text><pubmed_id>12796220</pubmed_id></reference><reference><reference_text>Do KQ, Lauer CJ, Schreiber W, Zollinger M, Gutteck-Amsler U, Cuenod M, Holsboer F: gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem. 1995 Dec;65(6):2652-62.</reference_text><pubmed_id>7595563</pubmed_id></reference><reference><reference_text>Nikisch G, Baumann P, Wiedemann G, Kiessling B, Weisser H, Hertel A, Yoshitake T, Kehr J, Mathe AA: Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF. J Clin Psychopharmacol. 2010 Oct;30(5):496-503. doi: 10.1097/JCP.0b013e3181f2288e.</reference_text><pubmed_id>20814316</pubmed_id></reference><reference><reference_text>Fukushima T, Iizuka H, Yokota A, Suzuki T, Ohno C, Kono Y, Nishikiori M, Seki A, Ichiba H, Watanabe Y, Hongo S, Utsunomiya M, Nakatani M, Sadamoto K, Yoshio T: Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One. 2014 Jul 8;9(7):e101652. doi: 10.1371/journal.pone.0101652. eCollection 2014.</reference_text><pubmed_id>25004141</pubmed_id></reference><reference><reference_text>Koike S, Bundo M, Iwamoto K, Suga M, Kuwabara H, Ohashi Y, Shinoda K, Takano Y, Iwashiro N, Satomura Y, Nagai T, Natsubori T, Tada M, Yamasue H, Kasai K: A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study. Transl Psychiatry. 2014 Apr 8;4:e379. doi: 10.1038/tp.2014.19.</reference_text><pubmed_id>24713860</pubmed_id></reference><reference><reference_text>Ballesteros A, Summerfelt A, Du X, Jiang P, Chiappelli J, Tagamets M, O'Donnell P, Kochunov P, Hong LE: Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia. Clin Neurophysiol. 2013 Nov;124(11):2209-15. doi: 10.1016/j.clinph.2013.05.021. Epub 2013 Jun 30.</reference_text><pubmed_id>23823132</pubmed_id></reference><reference><reference_text>Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel FA: Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry. 1985 Sep;147:276-82.</reference_text><pubmed_id>2415198</pubmed_id></reference><reference><reference_text>Pickar D, Breier A, Hsiao JK, Doran AR, Wolkowitz OM, Pato CN, Konicki PE, Potter WZ: Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Arch Gen Psychiatry. 1990 Jul;47(7):641-8.</reference_text><pubmed_id>1694425</pubmed_id></reference><reference><reference_text>Prell GD, Green JP, Kaufmann CA, Khandelwal JK, Morrishow AM, Kirch DG, Linnoila M, Wyatt RJ: Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res. 1995 Jan;14(2):93-104.</reference_text><pubmed_id>7711000</pubmed_id></reference><reference><reference_text>Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B: Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology. 2009;59(2):123-9. doi: 10.1159/000213565. Epub 2009 Apr 22.</reference_text><pubmed_id>19390223</pubmed_id></reference><reference><reference_text>Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K, Cao Y, Wang X, Qiu Y, Su M, Zhao A, Wang P, Yang P, Wu J, Feng G, He L, Jia W, Wan C: Potential metabolite markers of schizophrenia. Mol Psychiatry. 2013 Jan;18(1):67-78. doi: 10.1038/mp.2011.131. Epub 2011 Oct 25.</reference_text><pubmed_id>22024767</pubmed_id></reference><reference><reference_text>Xuan J, Pan G, Qiu Y, Yang L, Su M, Liu Y, Chen J, Feng G, Fang Y, Jia W, Xing Q, He L: Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. J Proteome Res. 2011 Dec 2;10(12):5433-43. doi: 10.1021/pr2006796. Epub 2011 Nov  8.</reference_text><pubmed_id>22007635</pubmed_id></reference><reference><reference_text>Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM, Rothermundt M, Bogerts B, Koethe D, Kranaster L, Ohrmann P, Suslow T, McAllister G, Spain M, Barnes A, van Beveren NJ, Baron-Cohen S, Steiner J, Torrey FE, Yolken RH, Bahn S: Identification of a biological signature for schizophrenia in serum. Mol Psychiatry. 2012 May;17(5):494-502. doi: 10.1038/mp.2011.42. Epub 2011 Apr 12.</reference_text><pubmed_id>21483431</pubmed_id></reference><reference><reference_text>Mathe AA, Eberhard G, Saaf J, Wetterberg L: Plasma prostaglandin E2 metabolite--measured as 11-deoxy-15-keto-13,14-dihydro-11 beta,16 xi-cyclo-PGE2--in twins with schizophrenic disorder. Biol Psychiatry. 1986 Sep;21(11):1024-30.</reference_text><pubmed_id>3741918</pubmed_id></reference><reference><reference_text>Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N: Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct. 2002 Jun;20(2):171-5.</reference_text><pubmed_id>11979513</pubmed_id></reference><reference><reference_text>Zumarraga M, Davila R, Basterreche N, Arrue A, Goienetxea B, Zamalloa MI, Erkoreka L, Bustamante S, Inchausti L, Gonzalez-Torres MA, Guimon J: Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients. Neurochem Int. 2010 May-Jun;56(6-7):774-9. doi: 10.1016/j.neuint.2010.02.015. Epub 2010 Mar 4.</reference_text><pubmed_id>20206656</pubmed_id></reference><reference><reference_text>Peters JG: Dopamine, noradrenaline and serotonin spinal fluid metabolites in temporal lobe epileptic patients with schizophrenic symptomatology. Eur Neurol. 1979;18(1):15-8.</reference_text><pubmed_id>436860</pubmed_id></reference><reference><reference_text>Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, Rozen S, Krishnan RR, McEvoy J, Kaddurah-Daouk R: Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry. 2010 Sep;15(9):938-53. doi: 10.1038/mp.2009.33. Epub 2009 Apr 28.</reference_text><pubmed_id>19401681</pubmed_id></reference><reference><reference_text>Gattaz WF, Waldmeier P, Beckmann H: CSF monoamine metabolites in schizophrenic patients. Acta Psychiatr Scand. 1982 Nov;66(5):350-60.</reference_text><pubmed_id>6184954</pubmed_id></reference><reference><reference_text>Nilsson-Todd LK, Nordin C, Jonsson EG, Skogh E, Erhardt S: Cerebrospinal fluid kynurenic acid in male patients with schizophrenia - correlation with monoamine metabolites. Acta Neuropsychiatr. 2007 Feb;19(1):45-52. doi: 10.1111/j.1601-5215.2006.00170.x.</reference_text><pubmed_id>26952797</pubmed_id></reference><reference><reference_text>Cai HL, Li HD, Yan XZ, Sun B, Zhang Q, Yan M, Zhang WY, Jiang P, Zhu RH, Liu YP, Fang PF, Xu P, Yuan HY, Zhang XH, Hu L, Yang W, Ye HS: Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naive schizophrenia patients after treatment with risperidone. J Proteome Res. 2012 Aug 3;11(8):4338-50. doi: 10.1021/pr300459d. Epub 2012 Jul 26.</reference_text><pubmed_id>22800120</pubmed_id></reference><reference><reference_text>Al Awam K, Haussleiter IS, Dudley E, Donev R, Brune M, Juckel G, Thome J: Multiplatform metabolome and proteome profiling identifies serum metabolite and protein signatures as prospective biomarkers for schizophrenia. J Neural Transm (Vienna). 2015 Aug;122 Suppl 1:S111-22. doi: 10.1007/s00702-014-1224-0. Epub 2014 May 1.</reference_text><pubmed_id>24789758</pubmed_id></reference><reference><reference_text>Bicikova M, Hill M, Ripova D, Mohr P, Hampl R: Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia. J Steroid Biochem Mol Biol. 2013 Jan;133:77-83. doi: 10.1016/j.jsbmb.2012.08.009. Epub 2012 Aug 24.</reference_text><pubmed_id>22944140</pubmed_id></reference><reference><reference_text>He Y, Yu Z, Giegling I, Xie L, Hartmann AM, Prehn C, Adamski J, Kahn R, Li Y, Illig T, Wang-Sattler R, Rujescu D: Schizophrenia shows a unique metabolomics signature in plasma. Transl Psychiatry. 2012 Aug 14;2:e149. doi: 10.1038/tp.2012.76.</reference_text><pubmed_id>22892715</pubmed_id></reference><reference><reference_text>Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KR: Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):934-45. Epub 2007 Apr 17.</reference_text><pubmed_id>17440431</pubmed_id></reference><reference><reference_text>Fryar-Williams S, Strobel JE: Biomarkers of a five-domain translational substrate for schizophrenia and schizoaffective psychosis. Biomark Res. 2015 Feb 6;3:3. doi: 10.1186/s40364-015-0028-1. eCollection 2015.</reference_text><pubmed_id>25729574</pubmed_id></reference><reference><reference_text>Oresic M, Seppanen-Laakso T, Sun D, Tang J, Therman S, Viehman R, Mustonen U, van Erp TG, Hyotylainen T, Thompson P, Toga AW, Huttunen MO, Suvisaari J, Kaprio J, Lonnqvist J, Cannon TD: Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia. Genome Med. 2012 Jan 18;4(1):1. doi: 10.1186/gm300.</reference_text><pubmed_id>22257447</pubmed_id></reference></references></disease><disease>Primary hypomagnesemia<references><reference><reference_text>Jin-no Y, Kamiya Y, Okada M, Hirako M, Takada N, Kawaguchi M: Primary hypomagnesemia caused by isolated magnesium malabsorption: atypical case in adult. Intern Med. 1999 Mar;38(3):261-5.</reference_text><pubmed_id>10337938</pubmed_id></reference><reference><reference_text>Vainsel M, Vandevelde G, Smulders J, Vosters M, Hubain P, Loeb H: Tetany due to hypomagnesaemia with secondary hypocalcaemia. Arch Dis Child. 1970 Apr;45(240):254-8.</reference_text><pubmed_id>5419995</pubmed_id></reference><reference><reference_text>Shalev H, Phillip M, Galil A, Carmi R, Landau D: Clinical presentation and outcome in primary familial hypomagnesaemia. Arch Dis Child. 1998 Feb;78(2):127-30.</reference_text><pubmed_id>9579153</pubmed_id></reference><reference><reference_text>Kari JA, Farouq M, Alshaya HO: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Pediatr Nephrol. 2003 Jun;18(6):506-10. Epub 2003 Apr 29.</reference_text><pubmed_id>12720080</pubmed_id></reference></references></disease><disease>Hyperlipoproteinemia<references><reference><reference_text>Sinha S, Misra A, Kumar V, Jagannathan NR, Bal CS, Pandey RM, Singhania R, Deepak: Proton magnetic resonance spectroscopy and single photon emission computed tomography study of the brain in asymptomatic young hyperlipidaemic Asian Indians in North India show early abnormalities. Clin Endocrinol (Oxf). 2004 Aug;61(2):182-9.</reference_text><pubmed_id>15272912</pubmed_id></reference><reference><reference_text>Nelson RH: Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013 Mar</reference_text><pubmed_id>40(1):195-211. doi: 10.1016/j.pop.2012.11.003. Epub 2012 Dec  4.</pubmed_id></reference><reference><reference_text>Cantin B, Boudriau S, Bertrand M, Brun LD, Gagne C, Rogers PA, Ven Murthy MR, Lupien PJ, Julien P: Hemolysis in primary lipoprotein lipase deficiency. Metabolism. 1995 May;44(5):652-8.</reference_text><pubmed_id>7752915</pubmed_id></reference></references></disease><disease>Abetalipoproteinemia<references><reference><reference_text>Dawson G, Kruski AW, Scanu AM: Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J Lipid Res. 1976 Mar;17(2):125-31.</reference_text><pubmed_id>178813</pubmed_id></reference><reference><reference_text>Lazaro RP, Dentinger MP, Rodichok LD, Barron KD, Satya-Murti S: Muscle pathology in Bassen-Kornzweig syndrome and vitamin E deficiency. Am J Clin Pathol. 1986 Sep;86(3):378-87.</reference_text><pubmed_id>2944375</pubmed_id></reference></references></disease><disease>Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis<references><reference><reference_text>Breckenridge WC, Alaupovic P, Cox DW, Little JA: Apolipoprotein and lipoprotein concentrations in familial apolipoprotein C-II deficiency. Atherosclerosis. 1982 Aug;44(2):223-35.</reference_text><pubmed_id>7138621</pubmed_id></reference><reference><reference_text>Fukami M, Hasegawa T, Horikawa R, Ohashi T, Nishimura G, Homma K, Ogata T: Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr Res. 2006 Feb;59(2):276-80. doi: 10.1203/01.pdr.0000195825.31504.28.</reference_text><pubmed_id>16439592</pubmed_id></reference></references></disease><disease>Cerebrotendinous xanthomatosis<references><reference><reference_text>Halperin G, Elisaf M, Leitersdorf E, Harats D: A new method for determination of serum cholestanol by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2000 Jun 9;742(2):345-52.</reference_text><pubmed_id>10901139</pubmed_id></reference><reference><reference_text>Siman-Tov T, Meiner V, Gadoth N: Could steroids mask the diagnosis of cerebrotendinous xanthomatosis? J Neurol Sci. 2006 Apr 15;243(1-2):83-6. Epub 2006 Jan 30.</reference_text><pubmed_id>16445943</pubmed_id></reference><reference><reference_text>Agrawal NK, Garg S: Cerebrotendinous xanthomatosis: a rare disorder with a rare presentation. BMJ Case Rep. 2012 Sep 21;2012. pii: bcr-2012-006202. doi: 10.1136/bcr-2012-006202.</reference_text><pubmed_id>23001091</pubmed_id></reference></references></disease><disease>3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency<references><reference><reference_text>Thompson GN, Hsu BY, Pitt JJ, Treacy E, Stanley CA: Fasting hypoketotic coma in a child with deficiency of mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase. N Engl J Med. 1997 Oct 23;337(17):1203-7. doi: 10.1056/NEJM199710233371704.</reference_text><pubmed_id>9337379</pubmed_id></reference><reference><reference_text>Morris AA, Lascelles CV, Olpin SE, Lake BD, Leonard JV, Quant PA: Hepatic mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme a synthase deficiency. Pediatr Res. 1998 Sep;44(3):392-6. doi: 10.1203/00006450-199809000-00021.</reference_text><pubmed_id>9727719</pubmed_id></reference><reference><reference_text>Conboy E, Vairo F, Schultz M, Agre K, Ridsdale R, Deyle D, Oglesbee D, Gavrilov D, Klee EW, Lanpher B: Mitochondrial 3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency: Unique Presenting Laboratory Values and a Review of Biochemical and Clinical Features. JIMD Rep. 2017 Oct 14. doi: 10.1007/8904_2017_59.</reference_text><pubmed_id>29030856</pubmed_id></reference></references></disease><disease>Hypercholesterolemia, familial<references><reference><reference_text>Kwiterovich PO Jr, Fredrickson DS, Levy RI: Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest. 1974 May;53(5):1237-49. doi: 10.1172/JCI107670.</reference_text><pubmed_id>4363406</pubmed_id></reference></references></disease><disease>SC4MOL deficiency<references><reference><reference_text>He M, Kratz LE, Michel JJ, Vallejo AN, Ferris L, Kelley RI, Hoover JJ, Jukic D, Gibson KM, Wolfe LA, Ramachandran D, Zwick ME, Vockley J: Mutations in the human SC4MOL gene encoding a methyl sterol oxidase cause psoriasiform dermatitis, microcephaly, and developmental delay. J Clin Invest. 2011 Mar;121(3):976-84. doi: 10.1172/JCI42650.</reference_text><pubmed_id>21285510</pubmed_id></reference></references></disease><disease>Chondrodysplasia punctata, X-linked dominant<references><reference><reference_text>Aughton DJ, Kelley RI, Metzenberg A, Pureza V, Pauli RM: X-linked dominant chondrodysplasia punctata (CDPX2) caused by single gene mosaicism in a male. Am J Med Genet A. 2003 Jan 30;116A(3):255-60. doi: 10.1002/ajmg.a.10852.</reference_text><pubmed_id>12503102</pubmed_id></reference></references></disease><disease>Desmosterolosis<references><reference><reference_text>Andersson HC, Kratz L, Kelley R: Desmosterolosis presenting with multiple congenital anomalies and profound developmental delay. Am J Med Genet. 2002 Dec 15;113(4):315-9. doi: 10.1002/ajmg.b.10873.</reference_text><pubmed_id>12457401</pubmed_id></reference></references></disease><disease>Donohue Syndrome<references><reference><reference_text>Nijim Y, Awni Y, Adawi A, Bowirrat A: Classic Case Report of Donohue Syndrome (Leprechaunism; OMIM *246200): The Impact of Consanguineous Mating. Medicine (Baltimore). 2016 Feb;95(6):e2710. doi: 10.1097/MD.0000000000002710.</reference_text><pubmed_id>26871809</pubmed_id></reference></references></disease><disease>Leptin Deficiency or Dysfunction<references><reference><reference_text>Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O'Rahilly S: Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999 Sep 16;341(12):879-84. doi: 10.1056/NEJM199909163411204.</reference_text><pubmed_id>10486419</pubmed_id></reference></references></disease><disease>Duchenne Muscular Dystrophy<references><reference><reference_text>Nakagawa T, Takeuchi A, Kakiuchi R, Lee T, Yagi M, Awano H, Iijima K, Takeshima Y, Urade Y, Matsuo M: A prostaglandin D2 metabolite is elevated in the urine of Duchenne muscular dystrophy patients and increases further from 8 years old. Clin Chim Acta. 2013 Aug 23;423:10-4. doi: 10.1016/j.cca.2013.03.031. Epub 2013 Apr 19.</reference_text><pubmed_id>23603101</pubmed_id></reference><reference><reference_text>Srivastava NK, Pradhan S, Mittal B, Gowda GA: High resolution NMR based analysis of serum lipids in Duchenne muscular dystrophy patients and its possible diagnostic significance. NMR Biomed. 2010 Jan;23(1):13-22. doi: 10.1002/nbm.1419.</reference_text><pubmed_id>19787747</pubmed_id></reference><reference><reference_text>Horster I, Weigt-Usinger K, Carmann C, Chobanyan-Jurgens K, Kohler C, Schara U, Kayacelebi AA, Beckmann B, Tsikas D, Lucke T: The L-arginine/NO pathway and homoarginine are altered in Duchenne muscular dystrophy and improved by glucocorticoids. Amino Acids. 2015 Sep;47(9):1853-63. doi: 10.1007/s00726-015-2018-x. Epub 2015 Jun 12.</reference_text><pubmed_id>26066683</pubmed_id></reference></references></disease><disease>Lecithin:cholesterol Acyltransferase Deficiency<references><reference><reference_text>Idzior-Walus B, Sieradzki J, Kostner G, Malecki MT, Klupa T, Wesolowska T, Rostworowski W, Hartwich J, Walus M, Kiec AD, Naruszewicz M: Familial lecithin-cholesterol acyltransferase deficiency: biochemical characteristics and molecular analysis of a new LCAT mutation in a Polish family. Atherosclerosis. 2006 Apr;185(2):413-20. Epub 2005 Jul 26.</reference_text><pubmed_id>16051254</pubmed_id></reference></references></disease><disease>Lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lipodystrophy, Congenital Generalized<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Oculocerebrorenal syndrome<references><reference><reference_text>Charnas LR, Bernardini I, Rader D, Hoeg JM, Gahl WA: Clinical and laboratory findings in the oculocerebrorenal syndrome of Lowe, with special reference to growth and renal function. N Engl J Med. 1991 May 9;324(19):1318-25. doi: 10.1056/NEJM199105093241904.</reference_text><pubmed_id>2017228</pubmed_id></reference></references></disease><disease>Familial partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lathosterolosis<references><reference><reference_text>Brunetti-Pierri N, Corso G, Rossi M, Ferrari P, Balli F, Rivasi F, Annunziata I, Ballabio A, Russo AD, Andria G, Parenti G: Lathosterolosis, a novel multiple-malformation/mental retardation syndrome due to deficiency of 3beta-hydroxysteroid-delta5-desaturase. Am J Hum Genet. 2002 Oct;71(4):952-8. Epub 2002 Aug 20.</reference_text><pubmed_id>12189593</pubmed_id></reference><reference><reference_text>Ho AC, Fung CW, Siu TS, Ma OC, Lam CW, Tam S, Wong VC: Lathosterolosis: a disorder of cholesterol biosynthesis resembling smith-lemli-opitz syndrome. JIMD Rep. 2014;12:129-34. doi: 10.1007/8904_2013_255. Epub 2013 Oct 20.</reference_text><pubmed_id>24142275</pubmed_id></reference></references></disease><disease>Partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Multiple sclerosis<references><reference><reference_text>Lutz NW, Viola A, Malikova I, Confort-Gouny S, Audoin B, Ranjeva JP, Pelletier J, Cozzone PJ: Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One. 2007 Jul 4;2(7):e595.</reference_text><pubmed_id>17611627</pubmed_id></reference><reference><reference_text>Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U, Hillert J, Bjorkhem I: Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med. 2004 Feb;42(2):186-91.</reference_text><pubmed_id>15061359</pubmed_id></reference><reference><reference_text>Leoni V, Lutjohann D, Masterman T: Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis. J Lipid Res. 2005 Feb;46(2):191-5. Epub 2004 Dec 1.</reference_text><pubmed_id>15576852</pubmed_id></reference><reference><reference_text>Calabrese V, Scapagnini G, Ravagna A, Bella R, Butterfield DA, Calvani M, Pennisi G, Giuffrida Stella AM: Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem Res. 2003 Sep;28(9):1321-8.</reference_text><pubmed_id>12938853</pubmed_id></reference><reference><reference_text>Shaw CE, Dunbar PR, Macaulay HA, Neale TJ: Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol. 1995 Jan;242(2):53-8.</reference_text><pubmed_id>7707089</pubmed_id></reference><reference><reference_text>Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.</reference_text><pubmed_id>17384003</pubmed_id></reference><reference><reference_text>Syburra C, Passi S: Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh (1999). 1999 May-Jun;71(3):112-5.</reference_text><pubmed_id>10609336</pubmed_id></reference><reference><reference_text>Forte G, Visconti A, Santucci S, Ghazaryan A, Figa-Talamanca L, Cannoni S, Bocca B, Pino A, Violante N, Alimonti A, Salvetti M, Ristori G: Quantification of chemical elements in blood of patients affected by multiple sclerosis. Ann Ist Super Sanita. 2005;41(2):213-6.</reference_text><pubmed_id>16244395</pubmed_id></reference><reference><reference_text>Toncev G, Milicic B, Toncev S, Samardzic G: Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol. 2002 May;9(3):221-6.</reference_text><pubmed_id>11985629</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, Bamonti F, Capello E, Mancardi GL, Scarpini E: Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res. 2010 May 28;1333:64-71. doi: 10.1016/j.brainres.2010.03.073. Epub 2010 Mar 27.</reference_text><pubmed_id>20347721</pubmed_id></reference><reference><reference_text>Matsushita T, Isobe N, Kawajiri M, Mogi M, Tsukuda K, Horiuchi M, Ohyagi Y, Kira J: CSF angiotensin II and angiotensin-converting enzyme levels in anti-aquaporin-4 autoimmunity. J Neurol Sci. 2010 Aug 15;295(1-2):41-5. doi: 10.1016/j.jns.2010.05.014. Epub 2010 Jun 11.</reference_text><pubmed_id>20541774</pubmed_id></reference><reference><reference_text>Ghabaee M, Jabedari B, Al-E-Eshagh N, Ghaffarpour M, Asadi F: Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients. Int J Neurosci. 2010 Apr;120(4):301-4. doi: 10.3109/00207451003695690.</reference_text><pubmed_id>20374079</pubmed_id></reference><reference><reference_text>Kawajiri M, Mogi M, Osoegawa M, Matsuoka T, Tsukuda K, Kohara K, Horiuchi M, Miki T, Kira JI: Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler. 2008 May;14(4):557-60. doi: 10.1177/1352458507085760.</reference_text><pubmed_id>18562510</pubmed_id></reference><reference><reference_text>Visconti A, Cotichini R, Cannoni S, Bocca B, Forte G, Ghazaryan A, Santucci S, D'Ippolito C, Stazi MA, Salvetti M, Alimonti A, Ristori G: Concentration of elements in serum of patients affected by multiple sclerosis with first demyelinating episode: a six-month longitudinal follow-up study. Ann Ist Super Sanita. 2005;41(2):217-22.</reference_text><pubmed_id>16244396</pubmed_id></reference></references></disease><disease>Inflammatory bowel disease<references><reference><reference_text>Lee T, Clavel T, Smirnov K, Schmidt A, Lagkouvardos I, Walker A, Lucio M, Michalke B, Schmitt-Kopplin P, Fedorak R, Haller D: Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. 2017 May;66(5):863-871. doi: 10.1136/gutjnl-2015-309940. Epub 2016 Feb 4.</reference_text><pubmed_id>26848182</pubmed_id></reference><reference><reference_text>Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158.</reference_text><pubmed_id>27609529</pubmed_id></reference></references></disease><disease>Colorectal cancer<references><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B: Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009 Apr;22(3):342-8. doi: 10.1002/nbm.1345.</reference_text><pubmed_id>19006102</pubmed_id></reference><reference><reference_text>Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP: Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One. 2013 Aug 6;8(8):e70803. doi: 10.1371/journal.pone.0070803. Print 2013.</reference_text><pubmed_id>23940645</pubmed_id></reference><reference><reference_text>Phua LC, Chue XP, Koh PK, Cheah PY, Ho HK, Chan EC: Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biol Ther. 2014 Apr;15(4):389-97. doi: 10.4161/cbt.27625. Epub 2014 Jan 14.</reference_text><pubmed_id>24424155</pubmed_id></reference><reference><reference_text>Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB: Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010 Feb 15;8:13. doi: 10.1186/1741-7015-8-13.</reference_text><pubmed_id>20156336</pubmed_id></reference><reference><reference_text>Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, Ni Y, Zhao A, Xu LX, Cai S, Jia W: Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res. 2009 Oct;8(10):4844-50. doi: 10.1021/pr9004162.</reference_text><pubmed_id>19678709</pubmed_id></reference><reference><reference_text>Cheng Y, Xie G, Chen T, Qiu Y, Zou X, Zheng M, Tan B, Feng B, Dong T, He P, Zhao L, Zhao A, Xu LX, Zhang Y, Jia W: Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res. 2012 Feb 3;11(2):1354-63. doi: 10.1021/pr201001a. Epub 2011 Dec 28.</reference_text><pubmed_id>22148915</pubmed_id></reference><reference><reference_text>Ni Y, Xie G, Jia W: Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res. 2014 Sep 5;13(9):3857-70. doi: 10.1021/pr500443c. Epub 2014 Aug 14.</reference_text><pubmed_id>25105552</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference><reference><reference_text>Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18.</reference_text><pubmed_id>25037050</pubmed_id></reference><reference><reference_text>Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016.</reference_text><pubmed_id>27015276</pubmed_id></reference><reference><reference_text>Lin Y, Ma C, Liu C, Wang Z, Yang J, Liu X, Shen Z, Wu R: NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer. Oncotarget. 2016 May 17;7(20):29454-64. doi: 10.18632/oncotarget.8762.</reference_text><pubmed_id>27107423</pubmed_id></reference><reference><reference_text>Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016.</reference_text><pubmed_id>27275383</pubmed_id></reference><reference><reference_text>Wang X, Wang J, Rao B, Deng L: Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals. Exp Ther Med. 2017 Jun;13(6):2848-2854. doi: 10.3892/etm.2017.4367. Epub 2017 Apr 20.</reference_text><pubmed_id>28587349</pubmed_id></reference><reference><reference_text>Silke Matysik, Caroline Ivanne Le Roy, Gerhard Liebisch, Sandrine Paule Claus. Metabolomics of fecal samples: A practical consideration. Trends in Food Science &amp; Technology. Vol. 57, Part B, Nov. 2016, p.244-255: http://www.sciencedirect.com/science/article/pii/S0924224416301984</reference_text><pubmed_id>28587349</pubmed_id></reference></references></disease><disease>Gallbladder disease<references><reference><reference_text>Lapidus A, Akerlund JE, Einarsson C: Gallbladder bile composition in patients with Crohn 's disease. World J Gastroenterol. 2006 Jan 7;12(1):70-4.</reference_text><pubmed_id>16440420</pubmed_id></reference><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference><reference><reference_text>Mizuno S, Tazuma S, Kajiyama G: Stabilization of biliary lipid particles by ursodeoxycholic acid. Prolonged nucleation time in human gallbladder bile. Dig Dis Sci. 1993 Apr;38(4):684-93.</reference_text><pubmed_id>8462368</pubmed_id></reference><reference><reference_text>Hillebrant CG, Axelson M, Bjorkhem I, Wang FH, Nyberg B, Einarsson C: Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients. Eur J Clin Invest. 1998 Apr;28(4):324-8.</reference_text><pubmed_id>9615912</pubmed_id></reference></references></disease><disease>Cholelithiasis<references><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference></references></disease><disease>Stomach cancer<references><reference><reference_text>Higashijima H, Ichimiya H, Nakano T, Yamashita H, Kuroki S, Satoh H, Chijiiwa K, Tanaka M: Deconjugation of bilirubin accelerates coprecipitation of cholesterol, fatty acids, and mucin in human bile--in vitro study. J Gastroenterol. 1996 Dec;31(6):828-35.</reference_text><pubmed_id>9027647</pubmed_id></reference><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Song H, Peng JS, Dong-Sheng Y, Yang ZL, Liu HL, Zeng YK, Shi XP, Lu BY: Serum metabolic profiling of human gastric cancer based on gas chromatography/mass spectrometry. Braz J Med Biol Res. 2012 Jan;45(1):78-85. Epub 2011 Nov 25.</reference_text><pubmed_id>22124703</pubmed_id></reference><reference><reference_text>Yu L, Aa J, Xu J, Sun M, Qian S, Cheng L, Yang S, Shi R: Metabolomic phenotype of gastric cancer and precancerous stages based on gas chromatography time-of-flight mass spectrometry. J Gastroenterol Hepatol. 2011 Aug;26(8):1290-7. doi: 10.1111/j.1440-1746.2011.06724.x.</reference_text><pubmed_id>21443661</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference></references></disease><disease>Acute myelogenous leukemia<references><reference><reference_text>Tatidis L, Vitols S, Gruber A, Paul C, Axelson M: Cholesterol catabolism in patients with acute myelogenous leukemia and hypocholesterolemia: suppressed levels of a circulating marker for bile acid synthesis. Cancer Lett. 2001 Sep 20;170(2):169-75.</reference_text><pubmed_id>11463495</pubmed_id></reference></references></disease><disease>Hypercholesterolemia<references><reference><reference_text>Thelen KM, Laaksonen R, Paiva H, Lehtimaki T, Lutjohann D: High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels. J Clin Pharmacol. 2006 Jul;46(7):812-6.</reference_text><pubmed_id>16809807</pubmed_id></reference><reference><reference_text>Tamasawa N, Tamasawa A, Takebe K: Higher levels of plasma cholesterol sulfate in patients with liver cirrhosis and hypercholesterolemia. Lipids. 1993 Sep;28(9):833-6.</reference_text><pubmed_id>8231659</pubmed_id></reference><reference><reference_text>Kim DH, Lee KJ, Heo GS: Analysis of cholesterol and cholesteryl esters in human serum using capillary supercritical fluid chromatography. J Chromatogr B Biomed Appl. 1994 Apr 22;655(1):1-8.</reference_text><pubmed_id>8061816</pubmed_id></reference><reference><reference_text>Authors unspecified: Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med. 1988 Jan;148(1):36-69.</reference_text><pubmed_id>3422148</pubmed_id></reference></references></disease><disease>Cholesteryl ester storage disease<references><reference><reference_text>Rassoul F, Richter V, Lohse P, Naumann A, Purschwitz K, Keller E: Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease. Int J Clin Pharmacol Ther. 2001 May;39(5):199-204.</reference_text><pubmed_id>11380065</pubmed_id></reference><reference><reference_text>Chatrath H, Keilin S, Attar BM: Cholesterol ester storage disease (CESD) diagnosed in an asymptomatic adult. Dig Dis Sci. 2009 Jan;54(1):168-73. doi: 10.1007/s10620-008-0310-2. Epub 2008 May 14.</reference_text><pubmed_id>18478331</pubmed_id></reference><reference><reference_text>Bernstein DL, Hulkova H, Bialer MG, Desnick RJ: Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol. 2013 Jun;58(6):1230-43. doi: 10.1016/j.jhep.2013.02.014. Epub 2013 Feb 26.</reference_text><pubmed_id>23485521</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Cystinosis<references><reference><reference_text>Ueda M, O'Brien K, Rosing DR, Ling A, Kleta R, McAreavey D, Bernardini I, Gahl WA: Coronary artery and other vascular calcifications in patients with cystinosis after kidney transplantation. Clin J Am Soc Nephrol. 2006 May;1(3):555-62. Epub 2006 Feb 8.</reference_text><pubmed_id>17699259</pubmed_id></reference><reference><reference_text>Gahl WA, Bernardini I, Dalakas M, Rizzo WB, Harper GS, Hoeg JM, Hurko O, Bernar J: Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome. J Clin Invest. 1988 Feb;81(2):549-60.</reference_text><pubmed_id>3276734</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Smith-Lemli-Opitz syndrome<references><reference><reference_text>van Rooij A, Nijenhuis AA, Wijburg FA, Schutgens RB: Highly increased CSF concentrations of cholesterol precursors in Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 1997 Aug;20(4):578-80.</reference_text><pubmed_id>9266395</pubmed_id></reference><reference><reference_text>Honda M, Tint GS, Honda A, Salen G, Shefer S, Batta AK, Matsuzaki Y, Tanaka N: Regulation of cholesterol biosynthetic pathway in patients with the Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2000 Jul;23(5):464-74.</reference_text><pubmed_id>10947201</pubmed_id></reference><reference><reference_text>Rossi M, Federico G, Corso G, Parenti G, Battagliese A, Frascogna AR, Della Casa R, Dello Russo A, Strisciuglio P, Saggese G, Andria G: Vitamin D status in patients affected by Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2005;28(1):69-80.</reference_text><pubmed_id>15702407</pubmed_id></reference><reference><reference_text>Johnson DW, ten Brink HJ, Jakobs C: A rapid screening procedure for cholesterol and dehydrocholesterol by electrospray ionization tandem mass spectrometry. J Lipid Res. 2001 Oct;42(10):1699-705.</reference_text><pubmed_id>11590227</pubmed_id></reference></references></disease><disease>Prostate cancer<references><reference><reference_text>Nyman DW, Suzanne Stratton M, Kopplin MJ, Dalkin BL, Nagle RB, Jay Gandolfi A: Selenium and selenomethionine levels in prostate cancer patients. Cancer Detect Prev. 2004;28(1):8-16.</reference_text><pubmed_id>15041072</pubmed_id></reference><reference><reference_text>Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, Egevad L, Tjonneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, Palli D, Vineis P, Tumino R, Berrino F, Kiemeney L, Bueno-de-Mesquita HB, Quiros JR, Gonzalez CA, Martinez C, Larranaga N, Chirlaque MD, Ardanaz E, Stattin P, Hallmans G, Khaw KT, Bingham S, Slimani N, Ferrari P, Rinaldi S, Riboli E: Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr. 2007 Sep;86(3):672-81.</reference_text><pubmed_id>17823432</pubmed_id></reference><reference><reference_text>Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762.</reference_text><pubmed_id>19212411</pubmed_id></reference><reference><reference_text>Puah CM, Williams G, Ghanadian R: Urinary unconjugated 5 alpha-androstane-3 alpha, 17 beta-diol in patients with prostatic tumours. Urol Res. 1982;10(2):81-4.</reference_text><pubmed_id>6180540</pubmed_id></reference><reference><reference_text>Thysell E, Surowiec I, Hornberg E, Crnalic S, Widmark A, Johansson AI, Stattin P, Bergh A, Moritz T, Antti H, Wikstrom P: Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One. 2010 Dec 3;5(12):e14175. doi: 10.1371/journal.pone.0014175.</reference_text><pubmed_id>21151972</pubmed_id></reference><reference><reference_text>Soliman LC, Hui Y, Hewavitharana AK, Chen DD: Monitoring potential prostate cancer biomarkers in urine by capillary electrophoresis-tandem mass spectrometry. J Chromatogr A. 2012 Dec 7;1267:162-9. doi: 10.1016/j.chroma.2012.07.021. Epub 2012 Jul 14.</reference_text><pubmed_id>22824219</pubmed_id></reference><reference><reference_text>Madu CO, Lu Y: Novel diagnostic biomarkers for prostate cancer. J Cancer. 2010 Oct 6;1:150-77.</reference_text><pubmed_id>20975847</pubmed_id></reference></references></disease><disease>Schizophrenia<references><reference><reference_text>Harnryd C, Bjerkenstedt L, Grimm VE, Sedvall G: Reduction of MOPEG levels in cerebrospinal fluid of psychotic women after electroconvulsive treatment. Psychopharmacology (Berl). 1979 Aug 8;64(2):131-4.</reference_text><pubmed_id>115032</pubmed_id></reference><reference><reference_text>Kobayashi K, Koide Y, Yoshino K, Shohmori T: [P-hydroxyphenylacetic acid concentrations in cerebrospinal fluid]. No To Shinkei. 1982 Aug;34(8):769-74.</reference_text><pubmed_id>7126379</pubmed_id></reference><reference><reference_text>Alfredsson G, Wiesel FA: Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology (Berl). 1989;99(3):322-7.</reference_text><pubmed_id>2480613</pubmed_id></reference><reference><reference_text>Heresco-Levy U, Bar G, Levin R, Ermilov M, Ebstein RP, Javitt DC: High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. Schizophr Res. 2007 Mar;91(1-3):14-21. Epub 2007 Feb 2.</reference_text><pubmed_id>17276036</pubmed_id></reference><reference><reference_text>Walker EF, Bonsall R, Walder DJ: Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis. Neuropsychiatry Neuropsychol Behav Neurol. 2002 Mar;15(1):10-7.</reference_text><pubmed_id>11877547</pubmed_id></reference><reference><reference_text>Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M: Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry. 2003 Jun;60(6):572-6.</reference_text><pubmed_id>12796220</pubmed_id></reference><reference><reference_text>Do KQ, Lauer CJ, Schreiber W, Zollinger M, Gutteck-Amsler U, Cuenod M, Holsboer F: gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem. 1995 Dec;65(6):2652-62.</reference_text><pubmed_id>7595563</pubmed_id></reference><reference><reference_text>Nikisch G, Baumann P, Wiedemann G, Kiessling B, Weisser H, Hertel A, Yoshitake T, Kehr J, Mathe AA: Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF. J Clin Psychopharmacol. 2010 Oct;30(5):496-503. doi: 10.1097/JCP.0b013e3181f2288e.</reference_text><pubmed_id>20814316</pubmed_id></reference><reference><reference_text>Fukushima T, Iizuka H, Yokota A, Suzuki T, Ohno C, Kono Y, Nishikiori M, Seki A, Ichiba H, Watanabe Y, Hongo S, Utsunomiya M, Nakatani M, Sadamoto K, Yoshio T: Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One. 2014 Jul 8;9(7):e101652. doi: 10.1371/journal.pone.0101652. eCollection 2014.</reference_text><pubmed_id>25004141</pubmed_id></reference><reference><reference_text>Koike S, Bundo M, Iwamoto K, Suga M, Kuwabara H, Ohashi Y, Shinoda K, Takano Y, Iwashiro N, Satomura Y, Nagai T, Natsubori T, Tada M, Yamasue H, Kasai K: A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study. Transl Psychiatry. 2014 Apr 8;4:e379. doi: 10.1038/tp.2014.19.</reference_text><pubmed_id>24713860</pubmed_id></reference><reference><reference_text>Ballesteros A, Summerfelt A, Du X, Jiang P, Chiappelli J, Tagamets M, O'Donnell P, Kochunov P, Hong LE: Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia. Clin Neurophysiol. 2013 Nov;124(11):2209-15. doi: 10.1016/j.clinph.2013.05.021. Epub 2013 Jun 30.</reference_text><pubmed_id>23823132</pubmed_id></reference><reference><reference_text>Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel FA: Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry. 1985 Sep;147:276-82.</reference_text><pubmed_id>2415198</pubmed_id></reference><reference><reference_text>Pickar D, Breier A, Hsiao JK, Doran AR, Wolkowitz OM, Pato CN, Konicki PE, Potter WZ: Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Arch Gen Psychiatry. 1990 Jul;47(7):641-8.</reference_text><pubmed_id>1694425</pubmed_id></reference><reference><reference_text>Prell GD, Green JP, Kaufmann CA, Khandelwal JK, Morrishow AM, Kirch DG, Linnoila M, Wyatt RJ: Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res. 1995 Jan;14(2):93-104.</reference_text><pubmed_id>7711000</pubmed_id></reference><reference><reference_text>Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B: Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology. 2009;59(2):123-9. doi: 10.1159/000213565. Epub 2009 Apr 22.</reference_text><pubmed_id>19390223</pubmed_id></reference><reference><reference_text>Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K, Cao Y, Wang X, Qiu Y, Su M, Zhao A, Wang P, Yang P, Wu J, Feng G, He L, Jia W, Wan C: Potential metabolite markers of schizophrenia. Mol Psychiatry. 2013 Jan;18(1):67-78. doi: 10.1038/mp.2011.131. Epub 2011 Oct 25.</reference_text><pubmed_id>22024767</pubmed_id></reference><reference><reference_text>Xuan J, Pan G, Qiu Y, Yang L, Su M, Liu Y, Chen J, Feng G, Fang Y, Jia W, Xing Q, He L: Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. J Proteome Res. 2011 Dec 2;10(12):5433-43. doi: 10.1021/pr2006796. Epub 2011 Nov  8.</reference_text><pubmed_id>22007635</pubmed_id></reference><reference><reference_text>Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM, Rothermundt M, Bogerts B, Koethe D, Kranaster L, Ohrmann P, Suslow T, McAllister G, Spain M, Barnes A, van Beveren NJ, Baron-Cohen S, Steiner J, Torrey FE, Yolken RH, Bahn S: Identification of a biological signature for schizophrenia in serum. Mol Psychiatry. 2012 May;17(5):494-502. doi: 10.1038/mp.2011.42. Epub 2011 Apr 12.</reference_text><pubmed_id>21483431</pubmed_id></reference><reference><reference_text>Mathe AA, Eberhard G, Saaf J, Wetterberg L: Plasma prostaglandin E2 metabolite--measured as 11-deoxy-15-keto-13,14-dihydro-11 beta,16 xi-cyclo-PGE2--in twins with schizophrenic disorder. Biol Psychiatry. 1986 Sep;21(11):1024-30.</reference_text><pubmed_id>3741918</pubmed_id></reference><reference><reference_text>Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N: Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct. 2002 Jun;20(2):171-5.</reference_text><pubmed_id>11979513</pubmed_id></reference><reference><reference_text>Zumarraga M, Davila R, Basterreche N, Arrue A, Goienetxea B, Zamalloa MI, Erkoreka L, Bustamante S, Inchausti L, Gonzalez-Torres MA, Guimon J: Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients. Neurochem Int. 2010 May-Jun;56(6-7):774-9. doi: 10.1016/j.neuint.2010.02.015. Epub 2010 Mar 4.</reference_text><pubmed_id>20206656</pubmed_id></reference><reference><reference_text>Peters JG: Dopamine, noradrenaline and serotonin spinal fluid metabolites in temporal lobe epileptic patients with schizophrenic symptomatology. Eur Neurol. 1979;18(1):15-8.</reference_text><pubmed_id>436860</pubmed_id></reference><reference><reference_text>Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, Rozen S, Krishnan RR, McEvoy J, Kaddurah-Daouk R: Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry. 2010 Sep;15(9):938-53. doi: 10.1038/mp.2009.33. Epub 2009 Apr 28.</reference_text><pubmed_id>19401681</pubmed_id></reference><reference><reference_text>Gattaz WF, Waldmeier P, Beckmann H: CSF monoamine metabolites in schizophrenic patients. Acta Psychiatr Scand. 1982 Nov;66(5):350-60.</reference_text><pubmed_id>6184954</pubmed_id></reference><reference><reference_text>Nilsson-Todd LK, Nordin C, Jonsson EG, Skogh E, Erhardt S: Cerebrospinal fluid kynurenic acid in male patients with schizophrenia - correlation with monoamine metabolites. Acta Neuropsychiatr. 2007 Feb;19(1):45-52. doi: 10.1111/j.1601-5215.2006.00170.x.</reference_text><pubmed_id>26952797</pubmed_id></reference><reference><reference_text>Cai HL, Li HD, Yan XZ, Sun B, Zhang Q, Yan M, Zhang WY, Jiang P, Zhu RH, Liu YP, Fang PF, Xu P, Yuan HY, Zhang XH, Hu L, Yang W, Ye HS: Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naive schizophrenia patients after treatment with risperidone. J Proteome Res. 2012 Aug 3;11(8):4338-50. doi: 10.1021/pr300459d. Epub 2012 Jul 26.</reference_text><pubmed_id>22800120</pubmed_id></reference><reference><reference_text>Al Awam K, Haussleiter IS, Dudley E, Donev R, Brune M, Juckel G, Thome J: Multiplatform metabolome and proteome profiling identifies serum metabolite and protein signatures as prospective biomarkers for schizophrenia. J Neural Transm (Vienna). 2015 Aug;122 Suppl 1:S111-22. doi: 10.1007/s00702-014-1224-0. Epub 2014 May 1.</reference_text><pubmed_id>24789758</pubmed_id></reference><reference><reference_text>Bicikova M, Hill M, Ripova D, Mohr P, Hampl R: Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia. J Steroid Biochem Mol Biol. 2013 Jan;133:77-83. doi: 10.1016/j.jsbmb.2012.08.009. Epub 2012 Aug 24.</reference_text><pubmed_id>22944140</pubmed_id></reference><reference><reference_text>He Y, Yu Z, Giegling I, Xie L, Hartmann AM, Prehn C, Adamski J, Kahn R, Li Y, Illig T, Wang-Sattler R, Rujescu D: Schizophrenia shows a unique metabolomics signature in plasma. Transl Psychiatry. 2012 Aug 14;2:e149. doi: 10.1038/tp.2012.76.</reference_text><pubmed_id>22892715</pubmed_id></reference><reference><reference_text>Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KR: Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):934-45. Epub 2007 Apr 17.</reference_text><pubmed_id>17440431</pubmed_id></reference><reference><reference_text>Fryar-Williams S, Strobel JE: Biomarkers of a five-domain translational substrate for schizophrenia and schizoaffective psychosis. Biomark Res. 2015 Feb 6;3:3. doi: 10.1186/s40364-015-0028-1. eCollection 2015.</reference_text><pubmed_id>25729574</pubmed_id></reference><reference><reference_text>Oresic M, Seppanen-Laakso T, Sun D, Tang J, Therman S, Viehman R, Mustonen U, van Erp TG, Hyotylainen T, Thompson P, Toga AW, Huttunen MO, Suvisaari J, Kaprio J, Lonnqvist J, Cannon TD: Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia. Genome Med. 2012 Jan 18;4(1):1. doi: 10.1186/gm300.</reference_text><pubmed_id>22257447</pubmed_id></reference></references></disease><disease>Primary hypomagnesemia<references><reference><reference_text>Jin-no Y, Kamiya Y, Okada M, Hirako M, Takada N, Kawaguchi M: Primary hypomagnesemia caused by isolated magnesium malabsorption: atypical case in adult. Intern Med. 1999 Mar;38(3):261-5.</reference_text><pubmed_id>10337938</pubmed_id></reference><reference><reference_text>Vainsel M, Vandevelde G, Smulders J, Vosters M, Hubain P, Loeb H: Tetany due to hypomagnesaemia with secondary hypocalcaemia. Arch Dis Child. 1970 Apr;45(240):254-8.</reference_text><pubmed_id>5419995</pubmed_id></reference><reference><reference_text>Shalev H, Phillip M, Galil A, Carmi R, Landau D: Clinical presentation and outcome in primary familial hypomagnesaemia. Arch Dis Child. 1998 Feb;78(2):127-30.</reference_text><pubmed_id>9579153</pubmed_id></reference><reference><reference_text>Kari JA, Farouq M, Alshaya HO: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Pediatr Nephrol. 2003 Jun;18(6):506-10. Epub 2003 Apr 29.</reference_text><pubmed_id>12720080</pubmed_id></reference></references></disease><disease>Hyperlipoproteinemia<references><reference><reference_text>Sinha S, Misra A, Kumar V, Jagannathan NR, Bal CS, Pandey RM, Singhania R, Deepak: Proton magnetic resonance spectroscopy and single photon emission computed tomography study of the brain in asymptomatic young hyperlipidaemic Asian Indians in North India show early abnormalities. Clin Endocrinol (Oxf). 2004 Aug;61(2):182-9.</reference_text><pubmed_id>15272912</pubmed_id></reference><reference><reference_text>Nelson RH: Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013 Mar</reference_text><pubmed_id>40(1):195-211. doi: 10.1016/j.pop.2012.11.003. Epub 2012 Dec  4.</pubmed_id></reference><reference><reference_text>Cantin B, Boudriau S, Bertrand M, Brun LD, Gagne C, Rogers PA, Ven Murthy MR, Lupien PJ, Julien P: Hemolysis in primary lipoprotein lipase deficiency. Metabolism. 1995 May;44(5):652-8.</reference_text><pubmed_id>7752915</pubmed_id></reference></references></disease><disease>Abetalipoproteinemia<references><reference><reference_text>Dawson G, Kruski AW, Scanu AM: Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J Lipid Res. 1976 Mar;17(2):125-31.</reference_text><pubmed_id>178813</pubmed_id></reference><reference><reference_text>Lazaro RP, Dentinger MP, Rodichok LD, Barron KD, Satya-Murti S: Muscle pathology in Bassen-Kornzweig syndrome and vitamin E deficiency. Am J Clin Pathol. 1986 Sep;86(3):378-87.</reference_text><pubmed_id>2944375</pubmed_id></reference></references></disease><disease>Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis<references><reference><reference_text>Breckenridge WC, Alaupovic P, Cox DW, Little JA: Apolipoprotein and lipoprotein concentrations in familial apolipoprotein C-II deficiency. Atherosclerosis. 1982 Aug;44(2):223-35.</reference_text><pubmed_id>7138621</pubmed_id></reference><reference><reference_text>Fukami M, Hasegawa T, Horikawa R, Ohashi T, Nishimura G, Homma K, Ogata T: Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr Res. 2006 Feb;59(2):276-80. doi: 10.1203/01.pdr.0000195825.31504.28.</reference_text><pubmed_id>16439592</pubmed_id></reference></references></disease><disease>Cerebrotendinous xanthomatosis<references><reference><reference_text>Halperin G, Elisaf M, Leitersdorf E, Harats D: A new method for determination of serum cholestanol by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2000 Jun 9;742(2):345-52.</reference_text><pubmed_id>10901139</pubmed_id></reference><reference><reference_text>Siman-Tov T, Meiner V, Gadoth N: Could steroids mask the diagnosis of cerebrotendinous xanthomatosis? J Neurol Sci. 2006 Apr 15;243(1-2):83-6. Epub 2006 Jan 30.</reference_text><pubmed_id>16445943</pubmed_id></reference><reference><reference_text>Agrawal NK, Garg S: Cerebrotendinous xanthomatosis: a rare disorder with a rare presentation. BMJ Case Rep. 2012 Sep 21;2012. pii: bcr-2012-006202. doi: 10.1136/bcr-2012-006202.</reference_text><pubmed_id>23001091</pubmed_id></reference></references></disease><disease>3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency<references><reference><reference_text>Thompson GN, Hsu BY, Pitt JJ, Treacy E, Stanley CA: Fasting hypoketotic coma in a child with deficiency of mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase. N Engl J Med. 1997 Oct 23;337(17):1203-7. doi: 10.1056/NEJM199710233371704.</reference_text><pubmed_id>9337379</pubmed_id></reference><reference><reference_text>Morris AA, Lascelles CV, Olpin SE, Lake BD, Leonard JV, Quant PA: Hepatic mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme a synthase deficiency. Pediatr Res. 1998 Sep;44(3):392-6. doi: 10.1203/00006450-199809000-00021.</reference_text><pubmed_id>9727719</pubmed_id></reference><reference><reference_text>Conboy E, Vairo F, Schultz M, Agre K, Ridsdale R, Deyle D, Oglesbee D, Gavrilov D, Klee EW, Lanpher B: Mitochondrial 3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency: Unique Presenting Laboratory Values and a Review of Biochemical and Clinical Features. JIMD Rep. 2017 Oct 14. doi: 10.1007/8904_2017_59.</reference_text><pubmed_id>29030856</pubmed_id></reference></references></disease><disease>Hypercholesterolemia, familial<references><reference><reference_text>Kwiterovich PO Jr, Fredrickson DS, Levy RI: Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest. 1974 May;53(5):1237-49. doi: 10.1172/JCI107670.</reference_text><pubmed_id>4363406</pubmed_id></reference></references></disease><disease>SC4MOL deficiency<references><reference><reference_text>He M, Kratz LE, Michel JJ, Vallejo AN, Ferris L, Kelley RI, Hoover JJ, Jukic D, Gibson KM, Wolfe LA, Ramachandran D, Zwick ME, Vockley J: Mutations in the human SC4MOL gene encoding a methyl sterol oxidase cause psoriasiform dermatitis, microcephaly, and developmental delay. J Clin Invest. 2011 Mar;121(3):976-84. doi: 10.1172/JCI42650.</reference_text><pubmed_id>21285510</pubmed_id></reference></references></disease><disease>Chondrodysplasia punctata, X-linked dominant<references><reference><reference_text>Aughton DJ, Kelley RI, Metzenberg A, Pureza V, Pauli RM: X-linked dominant chondrodysplasia punctata (CDPX2) caused by single gene mosaicism in a male. Am J Med Genet A. 2003 Jan 30;116A(3):255-60. doi: 10.1002/ajmg.a.10852.</reference_text><pubmed_id>12503102</pubmed_id></reference></references></disease><disease>Desmosterolosis<references><reference><reference_text>Andersson HC, Kratz L, Kelley R: Desmosterolosis presenting with multiple congenital anomalies and profound developmental delay. Am J Med Genet. 2002 Dec 15;113(4):315-9. doi: 10.1002/ajmg.b.10873.</reference_text><pubmed_id>12457401</pubmed_id></reference></references></disease><disease>Donohue Syndrome<references><reference><reference_text>Nijim Y, Awni Y, Adawi A, Bowirrat A: Classic Case Report of Donohue Syndrome (Leprechaunism; OMIM *246200): The Impact of Consanguineous Mating. Medicine (Baltimore). 2016 Feb;95(6):e2710. doi: 10.1097/MD.0000000000002710.</reference_text><pubmed_id>26871809</pubmed_id></reference></references></disease><disease>Leptin Deficiency or Dysfunction<references><reference><reference_text>Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O'Rahilly S: Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999 Sep 16;341(12):879-84. doi: 10.1056/NEJM199909163411204.</reference_text><pubmed_id>10486419</pubmed_id></reference></references></disease><disease>Duchenne Muscular Dystrophy<references><reference><reference_text>Nakagawa T, Takeuchi A, Kakiuchi R, Lee T, Yagi M, Awano H, Iijima K, Takeshima Y, Urade Y, Matsuo M: A prostaglandin D2 metabolite is elevated in the urine of Duchenne muscular dystrophy patients and increases further from 8 years old. Clin Chim Acta. 2013 Aug 23;423:10-4. doi: 10.1016/j.cca.2013.03.031. Epub 2013 Apr 19.</reference_text><pubmed_id>23603101</pubmed_id></reference><reference><reference_text>Srivastava NK, Pradhan S, Mittal B, Gowda GA: High resolution NMR based analysis of serum lipids in Duchenne muscular dystrophy patients and its possible diagnostic significance. NMR Biomed. 2010 Jan;23(1):13-22. doi: 10.1002/nbm.1419.</reference_text><pubmed_id>19787747</pubmed_id></reference><reference><reference_text>Horster I, Weigt-Usinger K, Carmann C, Chobanyan-Jurgens K, Kohler C, Schara U, Kayacelebi AA, Beckmann B, Tsikas D, Lucke T: The L-arginine/NO pathway and homoarginine are altered in Duchenne muscular dystrophy and improved by glucocorticoids. Amino Acids. 2015 Sep;47(9):1853-63. doi: 10.1007/s00726-015-2018-x. Epub 2015 Jun 12.</reference_text><pubmed_id>26066683</pubmed_id></reference></references></disease><disease>Lecithin:cholesterol Acyltransferase Deficiency<references><reference><reference_text>Idzior-Walus B, Sieradzki J, Kostner G, Malecki MT, Klupa T, Wesolowska T, Rostworowski W, Hartwich J, Walus M, Kiec AD, Naruszewicz M: Familial lecithin-cholesterol acyltransferase deficiency: biochemical characteristics and molecular analysis of a new LCAT mutation in a Polish family. Atherosclerosis. 2006 Apr;185(2):413-20. Epub 2005 Jul 26.</reference_text><pubmed_id>16051254</pubmed_id></reference></references></disease><disease>Lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lipodystrophy, Congenital Generalized<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Oculocerebrorenal syndrome<references><reference><reference_text>Charnas LR, Bernardini I, Rader D, Hoeg JM, Gahl WA: Clinical and laboratory findings in the oculocerebrorenal syndrome of Lowe, with special reference to growth and renal function. N Engl J Med. 1991 May 9;324(19):1318-25. doi: 10.1056/NEJM199105093241904.</reference_text><pubmed_id>2017228</pubmed_id></reference></references></disease><disease>Familial partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lathosterolosis<references><reference><reference_text>Brunetti-Pierri N, Corso G, Rossi M, Ferrari P, Balli F, Rivasi F, Annunziata I, Ballabio A, Russo AD, Andria G, Parenti G: Lathosterolosis, a novel multiple-malformation/mental retardation syndrome due to deficiency of 3beta-hydroxysteroid-delta5-desaturase. Am J Hum Genet. 2002 Oct;71(4):952-8. Epub 2002 Aug 20.</reference_text><pubmed_id>12189593</pubmed_id></reference><reference><reference_text>Ho AC, Fung CW, Siu TS, Ma OC, Lam CW, Tam S, Wong VC: Lathosterolosis: a disorder of cholesterol biosynthesis resembling smith-lemli-opitz syndrome. JIMD Rep. 2014;12:129-34. doi: 10.1007/8904_2013_255. Epub 2013 Oct 20.</reference_text><pubmed_id>24142275</pubmed_id></reference></references></disease><disease>Partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Multiple sclerosis<references><reference><reference_text>Lutz NW, Viola A, Malikova I, Confort-Gouny S, Audoin B, Ranjeva JP, Pelletier J, Cozzone PJ: Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One. 2007 Jul 4;2(7):e595.</reference_text><pubmed_id>17611627</pubmed_id></reference><reference><reference_text>Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U, Hillert J, Bjorkhem I: Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med. 2004 Feb;42(2):186-91.</reference_text><pubmed_id>15061359</pubmed_id></reference><reference><reference_text>Leoni V, Lutjohann D, Masterman T: Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis. J Lipid Res. 2005 Feb;46(2):191-5. Epub 2004 Dec 1.</reference_text><pubmed_id>15576852</pubmed_id></reference><reference><reference_text>Calabrese V, Scapagnini G, Ravagna A, Bella R, Butterfield DA, Calvani M, Pennisi G, Giuffrida Stella AM: Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem Res. 2003 Sep;28(9):1321-8.</reference_text><pubmed_id>12938853</pubmed_id></reference><reference><reference_text>Shaw CE, Dunbar PR, Macaulay HA, Neale TJ: Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol. 1995 Jan;242(2):53-8.</reference_text><pubmed_id>7707089</pubmed_id></reference><reference><reference_text>Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.</reference_text><pubmed_id>17384003</pubmed_id></reference><reference><reference_text>Syburra C, Passi S: Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh (1999). 1999 May-Jun;71(3):112-5.</reference_text><pubmed_id>10609336</pubmed_id></reference><reference><reference_text>Forte G, Visconti A, Santucci S, Ghazaryan A, Figa-Talamanca L, Cannoni S, Bocca B, Pino A, Violante N, Alimonti A, Salvetti M, Ristori G: Quantification of chemical elements in blood of patients affected by multiple sclerosis. Ann Ist Super Sanita. 2005;41(2):213-6.</reference_text><pubmed_id>16244395</pubmed_id></reference><reference><reference_text>Toncev G, Milicic B, Toncev S, Samardzic G: Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol. 2002 May;9(3):221-6.</reference_text><pubmed_id>11985629</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, Bamonti F, Capello E, Mancardi GL, Scarpini E: Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res. 2010 May 28;1333:64-71. doi: 10.1016/j.brainres.2010.03.073. Epub 2010 Mar 27.</reference_text><pubmed_id>20347721</pubmed_id></reference><reference><reference_text>Matsushita T, Isobe N, Kawajiri M, Mogi M, Tsukuda K, Horiuchi M, Ohyagi Y, Kira J: CSF angiotensin II and angiotensin-converting enzyme levels in anti-aquaporin-4 autoimmunity. J Neurol Sci. 2010 Aug 15;295(1-2):41-5. doi: 10.1016/j.jns.2010.05.014. Epub 2010 Jun 11.</reference_text><pubmed_id>20541774</pubmed_id></reference><reference><reference_text>Ghabaee M, Jabedari B, Al-E-Eshagh N, Ghaffarpour M, Asadi F: Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients. Int J Neurosci. 2010 Apr;120(4):301-4. doi: 10.3109/00207451003695690.</reference_text><pubmed_id>20374079</pubmed_id></reference><reference><reference_text>Kawajiri M, Mogi M, Osoegawa M, Matsuoka T, Tsukuda K, Kohara K, Horiuchi M, Miki T, Kira JI: Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler. 2008 May;14(4):557-60. doi: 10.1177/1352458507085760.</reference_text><pubmed_id>18562510</pubmed_id></reference><reference><reference_text>Visconti A, Cotichini R, Cannoni S, Bocca B, Forte G, Ghazaryan A, Santucci S, D'Ippolito C, Stazi MA, Salvetti M, Alimonti A, Ristori G: Concentration of elements in serum of patients affected by multiple sclerosis with first demyelinating episode: a six-month longitudinal follow-up study. Ann Ist Super Sanita. 2005;41(2):217-22.</reference_text><pubmed_id>16244396</pubmed_id></reference></references></disease><disease>Inflammatory bowel disease<references><reference><reference_text>Lee T, Clavel T, Smirnov K, Schmidt A, Lagkouvardos I, Walker A, Lucio M, Michalke B, Schmitt-Kopplin P, Fedorak R, Haller D: Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. 2017 May;66(5):863-871. doi: 10.1136/gutjnl-2015-309940. Epub 2016 Feb 4.</reference_text><pubmed_id>26848182</pubmed_id></reference><reference><reference_text>Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158.</reference_text><pubmed_id>27609529</pubmed_id></reference></references></disease><disease>Colorectal cancer<references><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B: Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009 Apr;22(3):342-8. doi: 10.1002/nbm.1345.</reference_text><pubmed_id>19006102</pubmed_id></reference><reference><reference_text>Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP: Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One. 2013 Aug 6;8(8):e70803. doi: 10.1371/journal.pone.0070803. Print 2013.</reference_text><pubmed_id>23940645</pubmed_id></reference><reference><reference_text>Phua LC, Chue XP, Koh PK, Cheah PY, Ho HK, Chan EC: Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biol Ther. 2014 Apr;15(4):389-97. doi: 10.4161/cbt.27625. Epub 2014 Jan 14.</reference_text><pubmed_id>24424155</pubmed_id></reference><reference><reference_text>Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB: Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010 Feb 15;8:13. doi: 10.1186/1741-7015-8-13.</reference_text><pubmed_id>20156336</pubmed_id></reference><reference><reference_text>Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, Ni Y, Zhao A, Xu LX, Cai S, Jia W: Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res. 2009 Oct;8(10):4844-50. doi: 10.1021/pr9004162.</reference_text><pubmed_id>19678709</pubmed_id></reference><reference><reference_text>Cheng Y, Xie G, Chen T, Qiu Y, Zou X, Zheng M, Tan B, Feng B, Dong T, He P, Zhao L, Zhao A, Xu LX, Zhang Y, Jia W: Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res. 2012 Feb 3;11(2):1354-63. doi: 10.1021/pr201001a. Epub 2011 Dec 28.</reference_text><pubmed_id>22148915</pubmed_id></reference><reference><reference_text>Ni Y, Xie G, Jia W: Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res. 2014 Sep 5;13(9):3857-70. doi: 10.1021/pr500443c. Epub 2014 Aug 14.</reference_text><pubmed_id>25105552</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference><reference><reference_text>Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18.</reference_text><pubmed_id>25037050</pubmed_id></reference><reference><reference_text>Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016.</reference_text><pubmed_id>27015276</pubmed_id></reference><reference><reference_text>Lin Y, Ma C, Liu C, Wang Z, Yang J, Liu X, Shen Z, Wu R: NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer. Oncotarget. 2016 May 17;7(20):29454-64. doi: 10.18632/oncotarget.8762.</reference_text><pubmed_id>27107423</pubmed_id></reference><reference><reference_text>Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016.</reference_text><pubmed_id>27275383</pubmed_id></reference><reference><reference_text>Wang X, Wang J, Rao B, Deng L: Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals. Exp Ther Med. 2017 Jun;13(6):2848-2854. doi: 10.3892/etm.2017.4367. Epub 2017 Apr 20.</reference_text><pubmed_id>28587349</pubmed_id></reference><reference><reference_text>Silke Matysik, Caroline Ivanne Le Roy, Gerhard Liebisch, Sandrine Paule Claus. Metabolomics of fecal samples: A practical consideration. Trends in Food Science &amp; Technology. Vol. 57, Part B, Nov. 2016, p.244-255: http://www.sciencedirect.com/science/article/pii/S0924224416301984</reference_text><pubmed_id>28587349</pubmed_id></reference></references></disease><disease>Gallbladder disease<references><reference><reference_text>Lapidus A, Akerlund JE, Einarsson C: Gallbladder bile composition in patients with Crohn 's disease. World J Gastroenterol. 2006 Jan 7;12(1):70-4.</reference_text><pubmed_id>16440420</pubmed_id></reference><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference><reference><reference_text>Mizuno S, Tazuma S, Kajiyama G: Stabilization of biliary lipid particles by ursodeoxycholic acid. Prolonged nucleation time in human gallbladder bile. Dig Dis Sci. 1993 Apr;38(4):684-93.</reference_text><pubmed_id>8462368</pubmed_id></reference><reference><reference_text>Hillebrant CG, Axelson M, Bjorkhem I, Wang FH, Nyberg B, Einarsson C: Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients. Eur J Clin Invest. 1998 Apr;28(4):324-8.</reference_text><pubmed_id>9615912</pubmed_id></reference></references></disease><disease>Cholelithiasis<references><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference></references></disease><disease>Stomach cancer<references><reference><reference_text>Higashijima H, Ichimiya H, Nakano T, Yamashita H, Kuroki S, Satoh H, Chijiiwa K, Tanaka M: Deconjugation of bilirubin accelerates coprecipitation of cholesterol, fatty acids, and mucin in human bile--in vitro study. J Gastroenterol. 1996 Dec;31(6):828-35.</reference_text><pubmed_id>9027647</pubmed_id></reference><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Song H, Peng JS, Dong-Sheng Y, Yang ZL, Liu HL, Zeng YK, Shi XP, Lu BY: Serum metabolic profiling of human gastric cancer based on gas chromatography/mass spectrometry. Braz J Med Biol Res. 2012 Jan;45(1):78-85. Epub 2011 Nov 25.</reference_text><pubmed_id>22124703</pubmed_id></reference><reference><reference_text>Yu L, Aa J, Xu J, Sun M, Qian S, Cheng L, Yang S, Shi R: Metabolomic phenotype of gastric cancer and precancerous stages based on gas chromatography time-of-flight mass spectrometry. J Gastroenterol Hepatol. 2011 Aug;26(8):1290-7. doi: 10.1111/j.1440-1746.2011.06724.x.</reference_text><pubmed_id>21443661</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference></references></disease><disease>Acute myelogenous leukemia<references><reference><reference_text>Tatidis L, Vitols S, Gruber A, Paul C, Axelson M: Cholesterol catabolism in patients with acute myelogenous leukemia and hypocholesterolemia: suppressed levels of a circulating marker for bile acid synthesis. Cancer Lett. 2001 Sep 20;170(2):169-75.</reference_text><pubmed_id>11463495</pubmed_id></reference></references></disease><disease>Hypercholesterolemia<references><reference><reference_text>Thelen KM, Laaksonen R, Paiva H, Lehtimaki T, Lutjohann D: High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels. J Clin Pharmacol. 2006 Jul;46(7):812-6.</reference_text><pubmed_id>16809807</pubmed_id></reference><reference><reference_text>Tamasawa N, Tamasawa A, Takebe K: Higher levels of plasma cholesterol sulfate in patients with liver cirrhosis and hypercholesterolemia. Lipids. 1993 Sep;28(9):833-6.</reference_text><pubmed_id>8231659</pubmed_id></reference><reference><reference_text>Kim DH, Lee KJ, Heo GS: Analysis of cholesterol and cholesteryl esters in human serum using capillary supercritical fluid chromatography. J Chromatogr B Biomed Appl. 1994 Apr 22;655(1):1-8.</reference_text><pubmed_id>8061816</pubmed_id></reference><reference><reference_text>Authors unspecified: Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med. 1988 Jan;148(1):36-69.</reference_text><pubmed_id>3422148</pubmed_id></reference></references></disease><disease>Cholesteryl ester storage disease<references><reference><reference_text>Rassoul F, Richter V, Lohse P, Naumann A, Purschwitz K, Keller E: Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease. Int J Clin Pharmacol Ther. 2001 May;39(5):199-204.</reference_text><pubmed_id>11380065</pubmed_id></reference><reference><reference_text>Chatrath H, Keilin S, Attar BM: Cholesterol ester storage disease (CESD) diagnosed in an asymptomatic adult. Dig Dis Sci. 2009 Jan;54(1):168-73. doi: 10.1007/s10620-008-0310-2. Epub 2008 May 14.</reference_text><pubmed_id>18478331</pubmed_id></reference><reference><reference_text>Bernstein DL, Hulkova H, Bialer MG, Desnick RJ: Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol. 2013 Jun;58(6):1230-43. doi: 10.1016/j.jhep.2013.02.014. Epub 2013 Feb 26.</reference_text><pubmed_id>23485521</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Cystinosis<references><reference><reference_text>Ueda M, O'Brien K, Rosing DR, Ling A, Kleta R, McAreavey D, Bernardini I, Gahl WA: Coronary artery and other vascular calcifications in patients with cystinosis after kidney transplantation. Clin J Am Soc Nephrol. 2006 May;1(3):555-62. Epub 2006 Feb 8.</reference_text><pubmed_id>17699259</pubmed_id></reference><reference><reference_text>Gahl WA, Bernardini I, Dalakas M, Rizzo WB, Harper GS, Hoeg JM, Hurko O, Bernar J: Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome. J Clin Invest. 1988 Feb;81(2):549-60.</reference_text><pubmed_id>3276734</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Smith-Lemli-Opitz syndrome<references><reference><reference_text>van Rooij A, Nijenhuis AA, Wijburg FA, Schutgens RB: Highly increased CSF concentrations of cholesterol precursors in Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 1997 Aug;20(4):578-80.</reference_text><pubmed_id>9266395</pubmed_id></reference><reference><reference_text>Honda M, Tint GS, Honda A, Salen G, Shefer S, Batta AK, Matsuzaki Y, Tanaka N: Regulation of cholesterol biosynthetic pathway in patients with the Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2000 Jul;23(5):464-74.</reference_text><pubmed_id>10947201</pubmed_id></reference><reference><reference_text>Rossi M, Federico G, Corso G, Parenti G, Battagliese A, Frascogna AR, Della Casa R, Dello Russo A, Strisciuglio P, Saggese G, Andria G: Vitamin D status in patients affected by Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2005;28(1):69-80.</reference_text><pubmed_id>15702407</pubmed_id></reference><reference><reference_text>Johnson DW, ten Brink HJ, Jakobs C: A rapid screening procedure for cholesterol and dehydrocholesterol by electrospray ionization tandem mass spectrometry. J Lipid Res. 2001 Oct;42(10):1699-705.</reference_text><pubmed_id>11590227</pubmed_id></reference></references></disease><disease>Prostate cancer<references><reference><reference_text>Nyman DW, Suzanne Stratton M, Kopplin MJ, Dalkin BL, Nagle RB, Jay Gandolfi A: Selenium and selenomethionine levels in prostate cancer patients. Cancer Detect Prev. 2004;28(1):8-16.</reference_text><pubmed_id>15041072</pubmed_id></reference><reference><reference_text>Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, Egevad L, Tjonneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, Palli D, Vineis P, Tumino R, Berrino F, Kiemeney L, Bueno-de-Mesquita HB, Quiros JR, Gonzalez CA, Martinez C, Larranaga N, Chirlaque MD, Ardanaz E, Stattin P, Hallmans G, Khaw KT, Bingham S, Slimani N, Ferrari P, Rinaldi S, Riboli E: Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr. 2007 Sep;86(3):672-81.</reference_text><pubmed_id>17823432</pubmed_id></reference><reference><reference_text>Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762.</reference_text><pubmed_id>19212411</pubmed_id></reference><reference><reference_text>Puah CM, Williams G, Ghanadian R: Urinary unconjugated 5 alpha-androstane-3 alpha, 17 beta-diol in patients with prostatic tumours. Urol Res. 1982;10(2):81-4.</reference_text><pubmed_id>6180540</pubmed_id></reference><reference><reference_text>Thysell E, Surowiec I, Hornberg E, Crnalic S, Widmark A, Johansson AI, Stattin P, Bergh A, Moritz T, Antti H, Wikstrom P: Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One. 2010 Dec 3;5(12):e14175. doi: 10.1371/journal.pone.0014175.</reference_text><pubmed_id>21151972</pubmed_id></reference><reference><reference_text>Soliman LC, Hui Y, Hewavitharana AK, Chen DD: Monitoring potential prostate cancer biomarkers in urine by capillary electrophoresis-tandem mass spectrometry. J Chromatogr A. 2012 Dec 7;1267:162-9. doi: 10.1016/j.chroma.2012.07.021. Epub 2012 Jul 14.</reference_text><pubmed_id>22824219</pubmed_id></reference><reference><reference_text>Madu CO, Lu Y: Novel diagnostic biomarkers for prostate cancer. J Cancer. 2010 Oct 6;1:150-77.</reference_text><pubmed_id>20975847</pubmed_id></reference></references></disease><disease>Schizophrenia<references><reference><reference_text>Harnryd C, Bjerkenstedt L, Grimm VE, Sedvall G: Reduction of MOPEG levels in cerebrospinal fluid of psychotic women after electroconvulsive treatment. Psychopharmacology (Berl). 1979 Aug 8;64(2):131-4.</reference_text><pubmed_id>115032</pubmed_id></reference><reference><reference_text>Kobayashi K, Koide Y, Yoshino K, Shohmori T: [P-hydroxyphenylacetic acid concentrations in cerebrospinal fluid]. No To Shinkei. 1982 Aug;34(8):769-74.</reference_text><pubmed_id>7126379</pubmed_id></reference><reference><reference_text>Alfredsson G, Wiesel FA: Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology (Berl). 1989;99(3):322-7.</reference_text><pubmed_id>2480613</pubmed_id></reference><reference><reference_text>Heresco-Levy U, Bar G, Levin R, Ermilov M, Ebstein RP, Javitt DC: High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. Schizophr Res. 2007 Mar;91(1-3):14-21. Epub 2007 Feb 2.</reference_text><pubmed_id>17276036</pubmed_id></reference><reference><reference_text>Walker EF, Bonsall R, Walder DJ: Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis. Neuropsychiatry Neuropsychol Behav Neurol. 2002 Mar;15(1):10-7.</reference_text><pubmed_id>11877547</pubmed_id></reference><reference><reference_text>Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M: Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry. 2003 Jun;60(6):572-6.</reference_text><pubmed_id>12796220</pubmed_id></reference><reference><reference_text>Do KQ, Lauer CJ, Schreiber W, Zollinger M, Gutteck-Amsler U, Cuenod M, Holsboer F: gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem. 1995 Dec;65(6):2652-62.</reference_text><pubmed_id>7595563</pubmed_id></reference><reference><reference_text>Nikisch G, Baumann P, Wiedemann G, Kiessling B, Weisser H, Hertel A, Yoshitake T, Kehr J, Mathe AA: Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF. J Clin Psychopharmacol. 2010 Oct;30(5):496-503. doi: 10.1097/JCP.0b013e3181f2288e.</reference_text><pubmed_id>20814316</pubmed_id></reference><reference><reference_text>Fukushima T, Iizuka H, Yokota A, Suzuki T, Ohno C, Kono Y, Nishikiori M, Seki A, Ichiba H, Watanabe Y, Hongo S, Utsunomiya M, Nakatani M, Sadamoto K, Yoshio T: Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One. 2014 Jul 8;9(7):e101652. doi: 10.1371/journal.pone.0101652. eCollection 2014.</reference_text><pubmed_id>25004141</pubmed_id></reference><reference><reference_text>Koike S, Bundo M, Iwamoto K, Suga M, Kuwabara H, Ohashi Y, Shinoda K, Takano Y, Iwashiro N, Satomura Y, Nagai T, Natsubori T, Tada M, Yamasue H, Kasai K: A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study. Transl Psychiatry. 2014 Apr 8;4:e379. doi: 10.1038/tp.2014.19.</reference_text><pubmed_id>24713860</pubmed_id></reference><reference><reference_text>Ballesteros A, Summerfelt A, Du X, Jiang P, Chiappelli J, Tagamets M, O'Donnell P, Kochunov P, Hong LE: Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia. Clin Neurophysiol. 2013 Nov;124(11):2209-15. doi: 10.1016/j.clinph.2013.05.021. Epub 2013 Jun 30.</reference_text><pubmed_id>23823132</pubmed_id></reference><reference><reference_text>Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel FA: Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry. 1985 Sep;147:276-82.</reference_text><pubmed_id>2415198</pubmed_id></reference><reference><reference_text>Pickar D, Breier A, Hsiao JK, Doran AR, Wolkowitz OM, Pato CN, Konicki PE, Potter WZ: Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Arch Gen Psychiatry. 1990 Jul;47(7):641-8.</reference_text><pubmed_id>1694425</pubmed_id></reference><reference><reference_text>Prell GD, Green JP, Kaufmann CA, Khandelwal JK, Morrishow AM, Kirch DG, Linnoila M, Wyatt RJ: Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res. 1995 Jan;14(2):93-104.</reference_text><pubmed_id>7711000</pubmed_id></reference><reference><reference_text>Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B: Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology. 2009;59(2):123-9. doi: 10.1159/000213565. Epub 2009 Apr 22.</reference_text><pubmed_id>19390223</pubmed_id></reference><reference><reference_text>Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K, Cao Y, Wang X, Qiu Y, Su M, Zhao A, Wang P, Yang P, Wu J, Feng G, He L, Jia W, Wan C: Potential metabolite markers of schizophrenia. Mol Psychiatry. 2013 Jan;18(1):67-78. doi: 10.1038/mp.2011.131. Epub 2011 Oct 25.</reference_text><pubmed_id>22024767</pubmed_id></reference><reference><reference_text>Xuan J, Pan G, Qiu Y, Yang L, Su M, Liu Y, Chen J, Feng G, Fang Y, Jia W, Xing Q, He L: Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. J Proteome Res. 2011 Dec 2;10(12):5433-43. doi: 10.1021/pr2006796. Epub 2011 Nov  8.</reference_text><pubmed_id>22007635</pubmed_id></reference><reference><reference_text>Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM, Rothermundt M, Bogerts B, Koethe D, Kranaster L, Ohrmann P, Suslow T, McAllister G, Spain M, Barnes A, van Beveren NJ, Baron-Cohen S, Steiner J, Torrey FE, Yolken RH, Bahn S: Identification of a biological signature for schizophrenia in serum. Mol Psychiatry. 2012 May;17(5):494-502. doi: 10.1038/mp.2011.42. Epub 2011 Apr 12.</reference_text><pubmed_id>21483431</pubmed_id></reference><reference><reference_text>Mathe AA, Eberhard G, Saaf J, Wetterberg L: Plasma prostaglandin E2 metabolite--measured as 11-deoxy-15-keto-13,14-dihydro-11 beta,16 xi-cyclo-PGE2--in twins with schizophrenic disorder. Biol Psychiatry. 1986 Sep;21(11):1024-30.</reference_text><pubmed_id>3741918</pubmed_id></reference><reference><reference_text>Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N: Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct. 2002 Jun;20(2):171-5.</reference_text><pubmed_id>11979513</pubmed_id></reference><reference><reference_text>Zumarraga M, Davila R, Basterreche N, Arrue A, Goienetxea B, Zamalloa MI, Erkoreka L, Bustamante S, Inchausti L, Gonzalez-Torres MA, Guimon J: Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients. Neurochem Int. 2010 May-Jun;56(6-7):774-9. doi: 10.1016/j.neuint.2010.02.015. Epub 2010 Mar 4.</reference_text><pubmed_id>20206656</pubmed_id></reference><reference><reference_text>Peters JG: Dopamine, noradrenaline and serotonin spinal fluid metabolites in temporal lobe epileptic patients with schizophrenic symptomatology. Eur Neurol. 1979;18(1):15-8.</reference_text><pubmed_id>436860</pubmed_id></reference><reference><reference_text>Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, Rozen S, Krishnan RR, McEvoy J, Kaddurah-Daouk R: Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry. 2010 Sep;15(9):938-53. doi: 10.1038/mp.2009.33. Epub 2009 Apr 28.</reference_text><pubmed_id>19401681</pubmed_id></reference><reference><reference_text>Gattaz WF, Waldmeier P, Beckmann H: CSF monoamine metabolites in schizophrenic patients. Acta Psychiatr Scand. 1982 Nov;66(5):350-60.</reference_text><pubmed_id>6184954</pubmed_id></reference><reference><reference_text>Nilsson-Todd LK, Nordin C, Jonsson EG, Skogh E, Erhardt S: Cerebrospinal fluid kynurenic acid in male patients with schizophrenia - correlation with monoamine metabolites. Acta Neuropsychiatr. 2007 Feb;19(1):45-52. doi: 10.1111/j.1601-5215.2006.00170.x.</reference_text><pubmed_id>26952797</pubmed_id></reference><reference><reference_text>Cai HL, Li HD, Yan XZ, Sun B, Zhang Q, Yan M, Zhang WY, Jiang P, Zhu RH, Liu YP, Fang PF, Xu P, Yuan HY, Zhang XH, Hu L, Yang W, Ye HS: Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naive schizophrenia patients after treatment with risperidone. J Proteome Res. 2012 Aug 3;11(8):4338-50. doi: 10.1021/pr300459d. Epub 2012 Jul 26.</reference_text><pubmed_id>22800120</pubmed_id></reference><reference><reference_text>Al Awam K, Haussleiter IS, Dudley E, Donev R, Brune M, Juckel G, Thome J: Multiplatform metabolome and proteome profiling identifies serum metabolite and protein signatures as prospective biomarkers for schizophrenia. J Neural Transm (Vienna). 2015 Aug;122 Suppl 1:S111-22. doi: 10.1007/s00702-014-1224-0. Epub 2014 May 1.</reference_text><pubmed_id>24789758</pubmed_id></reference><reference><reference_text>Bicikova M, Hill M, Ripova D, Mohr P, Hampl R: Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia. J Steroid Biochem Mol Biol. 2013 Jan;133:77-83. doi: 10.1016/j.jsbmb.2012.08.009. Epub 2012 Aug 24.</reference_text><pubmed_id>22944140</pubmed_id></reference><reference><reference_text>He Y, Yu Z, Giegling I, Xie L, Hartmann AM, Prehn C, Adamski J, Kahn R, Li Y, Illig T, Wang-Sattler R, Rujescu D: Schizophrenia shows a unique metabolomics signature in plasma. Transl Psychiatry. 2012 Aug 14;2:e149. doi: 10.1038/tp.2012.76.</reference_text><pubmed_id>22892715</pubmed_id></reference><reference><reference_text>Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KR: Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):934-45. Epub 2007 Apr 17.</reference_text><pubmed_id>17440431</pubmed_id></reference><reference><reference_text>Fryar-Williams S, Strobel JE: Biomarkers of a five-domain translational substrate for schizophrenia and schizoaffective psychosis. Biomark Res. 2015 Feb 6;3:3. doi: 10.1186/s40364-015-0028-1. eCollection 2015.</reference_text><pubmed_id>25729574</pubmed_id></reference><reference><reference_text>Oresic M, Seppanen-Laakso T, Sun D, Tang J, Therman S, Viehman R, Mustonen U, van Erp TG, Hyotylainen T, Thompson P, Toga AW, Huttunen MO, Suvisaari J, Kaprio J, Lonnqvist J, Cannon TD: Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia. Genome Med. 2012 Jan 18;4(1):1. doi: 10.1186/gm300.</reference_text><pubmed_id>22257447</pubmed_id></reference></references></disease><disease>Primary hypomagnesemia<references><reference><reference_text>Jin-no Y, Kamiya Y, Okada M, Hirako M, Takada N, Kawaguchi M: Primary hypomagnesemia caused by isolated magnesium malabsorption: atypical case in adult. Intern Med. 1999 Mar;38(3):261-5.</reference_text><pubmed_id>10337938</pubmed_id></reference><reference><reference_text>Vainsel M, Vandevelde G, Smulders J, Vosters M, Hubain P, Loeb H: Tetany due to hypomagnesaemia with secondary hypocalcaemia. Arch Dis Child. 1970 Apr;45(240):254-8.</reference_text><pubmed_id>5419995</pubmed_id></reference><reference><reference_text>Shalev H, Phillip M, Galil A, Carmi R, Landau D: Clinical presentation and outcome in primary familial hypomagnesaemia. Arch Dis Child. 1998 Feb;78(2):127-30.</reference_text><pubmed_id>9579153</pubmed_id></reference><reference><reference_text>Kari JA, Farouq M, Alshaya HO: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Pediatr Nephrol. 2003 Jun;18(6):506-10. Epub 2003 Apr 29.</reference_text><pubmed_id>12720080</pubmed_id></reference></references></disease><disease>Hyperlipoproteinemia<references><reference><reference_text>Sinha S, Misra A, Kumar V, Jagannathan NR, Bal CS, Pandey RM, Singhania R, Deepak: Proton magnetic resonance spectroscopy and single photon emission computed tomography study of the brain in asymptomatic young hyperlipidaemic Asian Indians in North India show early abnormalities. Clin Endocrinol (Oxf). 2004 Aug;61(2):182-9.</reference_text><pubmed_id>15272912</pubmed_id></reference><reference><reference_text>Nelson RH: Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013 Mar</reference_text><pubmed_id>40(1):195-211. doi: 10.1016/j.pop.2012.11.003. Epub 2012 Dec  4.</pubmed_id></reference><reference><reference_text>Cantin B, Boudriau S, Bertrand M, Brun LD, Gagne C, Rogers PA, Ven Murthy MR, Lupien PJ, Julien P: Hemolysis in primary lipoprotein lipase deficiency. Metabolism. 1995 May;44(5):652-8.</reference_text><pubmed_id>7752915</pubmed_id></reference></references></disease><disease>Abetalipoproteinemia<references><reference><reference_text>Dawson G, Kruski AW, Scanu AM: Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J Lipid Res. 1976 Mar;17(2):125-31.</reference_text><pubmed_id>178813</pubmed_id></reference><reference><reference_text>Lazaro RP, Dentinger MP, Rodichok LD, Barron KD, Satya-Murti S: Muscle pathology in Bassen-Kornzweig syndrome and vitamin E deficiency. Am J Clin Pathol. 1986 Sep;86(3):378-87.</reference_text><pubmed_id>2944375</pubmed_id></reference></references></disease><disease>Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis<references><reference><reference_text>Breckenridge WC, Alaupovic P, Cox DW, Little JA: Apolipoprotein and lipoprotein concentrations in familial apolipoprotein C-II deficiency. Atherosclerosis. 1982 Aug;44(2):223-35.</reference_text><pubmed_id>7138621</pubmed_id></reference><reference><reference_text>Fukami M, Hasegawa T, Horikawa R, Ohashi T, Nishimura G, Homma K, Ogata T: Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr Res. 2006 Feb;59(2):276-80. doi: 10.1203/01.pdr.0000195825.31504.28.</reference_text><pubmed_id>16439592</pubmed_id></reference></references></disease><disease>Cerebrotendinous xanthomatosis<references><reference><reference_text>Halperin G, Elisaf M, Leitersdorf E, Harats D: A new method for determination of serum cholestanol by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2000 Jun 9;742(2):345-52.</reference_text><pubmed_id>10901139</pubmed_id></reference><reference><reference_text>Siman-Tov T, Meiner V, Gadoth N: Could steroids mask the diagnosis of cerebrotendinous xanthomatosis? J Neurol Sci. 2006 Apr 15;243(1-2):83-6. Epub 2006 Jan 30.</reference_text><pubmed_id>16445943</pubmed_id></reference><reference><reference_text>Agrawal NK, Garg S: Cerebrotendinous xanthomatosis: a rare disorder with a rare presentation. BMJ Case Rep. 2012 Sep 21;2012. pii: bcr-2012-006202. doi: 10.1136/bcr-2012-006202.</reference_text><pubmed_id>23001091</pubmed_id></reference></references></disease><disease>3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency<references><reference><reference_text>Thompson GN, Hsu BY, Pitt JJ, Treacy E, Stanley CA: Fasting hypoketotic coma in a child with deficiency of mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase. N Engl J Med. 1997 Oct 23;337(17):1203-7. doi: 10.1056/NEJM199710233371704.</reference_text><pubmed_id>9337379</pubmed_id></reference><reference><reference_text>Morris AA, Lascelles CV, Olpin SE, Lake BD, Leonard JV, Quant PA: Hepatic mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme a synthase deficiency. Pediatr Res. 1998 Sep;44(3):392-6. doi: 10.1203/00006450-199809000-00021.</reference_text><pubmed_id>9727719</pubmed_id></reference><reference><reference_text>Conboy E, Vairo F, Schultz M, Agre K, Ridsdale R, Deyle D, Oglesbee D, Gavrilov D, Klee EW, Lanpher B: Mitochondrial 3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency: Unique Presenting Laboratory Values and a Review of Biochemical and Clinical Features. JIMD Rep. 2017 Oct 14. doi: 10.1007/8904_2017_59.</reference_text><pubmed_id>29030856</pubmed_id></reference></references></disease><disease>Hypercholesterolemia, familial<references><reference><reference_text>Kwiterovich PO Jr, Fredrickson DS, Levy RI: Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest. 1974 May;53(5):1237-49. doi: 10.1172/JCI107670.</reference_text><pubmed_id>4363406</pubmed_id></reference></references></disease><disease>SC4MOL deficiency<references><reference><reference_text>He M, Kratz LE, Michel JJ, Vallejo AN, Ferris L, Kelley RI, Hoover JJ, Jukic D, Gibson KM, Wolfe LA, Ramachandran D, Zwick ME, Vockley J: Mutations in the human SC4MOL gene encoding a methyl sterol oxidase cause psoriasiform dermatitis, microcephaly, and developmental delay. J Clin Invest. 2011 Mar;121(3):976-84. doi: 10.1172/JCI42650.</reference_text><pubmed_id>21285510</pubmed_id></reference></references></disease><disease>Chondrodysplasia punctata, X-linked dominant<references><reference><reference_text>Aughton DJ, Kelley RI, Metzenberg A, Pureza V, Pauli RM: X-linked dominant chondrodysplasia punctata (CDPX2) caused by single gene mosaicism in a male. Am J Med Genet A. 2003 Jan 30;116A(3):255-60. doi: 10.1002/ajmg.a.10852.</reference_text><pubmed_id>12503102</pubmed_id></reference></references></disease><disease>Desmosterolosis<references><reference><reference_text>Andersson HC, Kratz L, Kelley R: Desmosterolosis presenting with multiple congenital anomalies and profound developmental delay. Am J Med Genet. 2002 Dec 15;113(4):315-9. doi: 10.1002/ajmg.b.10873.</reference_text><pubmed_id>12457401</pubmed_id></reference></references></disease><disease>Donohue Syndrome<references><reference><reference_text>Nijim Y, Awni Y, Adawi A, Bowirrat A: Classic Case Report of Donohue Syndrome (Leprechaunism; OMIM *246200): The Impact of Consanguineous Mating. Medicine (Baltimore). 2016 Feb;95(6):e2710. doi: 10.1097/MD.0000000000002710.</reference_text><pubmed_id>26871809</pubmed_id></reference></references></disease><disease>Leptin Deficiency or Dysfunction<references><reference><reference_text>Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O'Rahilly S: Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999 Sep 16;341(12):879-84. doi: 10.1056/NEJM199909163411204.</reference_text><pubmed_id>10486419</pubmed_id></reference></references></disease><disease>Duchenne Muscular Dystrophy<references><reference><reference_text>Nakagawa T, Takeuchi A, Kakiuchi R, Lee T, Yagi M, Awano H, Iijima K, Takeshima Y, Urade Y, Matsuo M: A prostaglandin D2 metabolite is elevated in the urine of Duchenne muscular dystrophy patients and increases further from 8 years old. Clin Chim Acta. 2013 Aug 23;423:10-4. doi: 10.1016/j.cca.2013.03.031. Epub 2013 Apr 19.</reference_text><pubmed_id>23603101</pubmed_id></reference><reference><reference_text>Srivastava NK, Pradhan S, Mittal B, Gowda GA: High resolution NMR based analysis of serum lipids in Duchenne muscular dystrophy patients and its possible diagnostic significance. NMR Biomed. 2010 Jan;23(1):13-22. doi: 10.1002/nbm.1419.</reference_text><pubmed_id>19787747</pubmed_id></reference><reference><reference_text>Horster I, Weigt-Usinger K, Carmann C, Chobanyan-Jurgens K, Kohler C, Schara U, Kayacelebi AA, Beckmann B, Tsikas D, Lucke T: The L-arginine/NO pathway and homoarginine are altered in Duchenne muscular dystrophy and improved by glucocorticoids. Amino Acids. 2015 Sep;47(9):1853-63. doi: 10.1007/s00726-015-2018-x. Epub 2015 Jun 12.</reference_text><pubmed_id>26066683</pubmed_id></reference></references></disease><disease>Lecithin:cholesterol Acyltransferase Deficiency<references><reference><reference_text>Idzior-Walus B, Sieradzki J, Kostner G, Malecki MT, Klupa T, Wesolowska T, Rostworowski W, Hartwich J, Walus M, Kiec AD, Naruszewicz M: Familial lecithin-cholesterol acyltransferase deficiency: biochemical characteristics and molecular analysis of a new LCAT mutation in a Polish family. Atherosclerosis. 2006 Apr;185(2):413-20. Epub 2005 Jul 26.</reference_text><pubmed_id>16051254</pubmed_id></reference></references></disease><disease>Lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lipodystrophy, Congenital Generalized<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Oculocerebrorenal syndrome<references><reference><reference_text>Charnas LR, Bernardini I, Rader D, Hoeg JM, Gahl WA: Clinical and laboratory findings in the oculocerebrorenal syndrome of Lowe, with special reference to growth and renal function. N Engl J Med. 1991 May 9;324(19):1318-25. doi: 10.1056/NEJM199105093241904.</reference_text><pubmed_id>2017228</pubmed_id></reference></references></disease><disease>Familial partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lathosterolosis<references><reference><reference_text>Brunetti-Pierri N, Corso G, Rossi M, Ferrari P, Balli F, Rivasi F, Annunziata I, Ballabio A, Russo AD, Andria G, Parenti G: Lathosterolosis, a novel multiple-malformation/mental retardation syndrome due to deficiency of 3beta-hydroxysteroid-delta5-desaturase. Am J Hum Genet. 2002 Oct;71(4):952-8. Epub 2002 Aug 20.</reference_text><pubmed_id>12189593</pubmed_id></reference><reference><reference_text>Ho AC, Fung CW, Siu TS, Ma OC, Lam CW, Tam S, Wong VC: Lathosterolosis: a disorder of cholesterol biosynthesis resembling smith-lemli-opitz syndrome. JIMD Rep. 2014;12:129-34. doi: 10.1007/8904_2013_255. Epub 2013 Oct 20.</reference_text><pubmed_id>24142275</pubmed_id></reference></references></disease><disease>Partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Multiple sclerosis<references><reference><reference_text>Lutz NW, Viola A, Malikova I, Confort-Gouny S, Audoin B, Ranjeva JP, Pelletier J, Cozzone PJ: Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One. 2007 Jul 4;2(7):e595.</reference_text><pubmed_id>17611627</pubmed_id></reference><reference><reference_text>Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U, Hillert J, Bjorkhem I: Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med. 2004 Feb;42(2):186-91.</reference_text><pubmed_id>15061359</pubmed_id></reference><reference><reference_text>Leoni V, Lutjohann D, Masterman T: Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis. J Lipid Res. 2005 Feb;46(2):191-5. Epub 2004 Dec 1.</reference_text><pubmed_id>15576852</pubmed_id></reference><reference><reference_text>Calabrese V, Scapagnini G, Ravagna A, Bella R, Butterfield DA, Calvani M, Pennisi G, Giuffrida Stella AM: Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem Res. 2003 Sep;28(9):1321-8.</reference_text><pubmed_id>12938853</pubmed_id></reference><reference><reference_text>Shaw CE, Dunbar PR, Macaulay HA, Neale TJ: Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol. 1995 Jan;242(2):53-8.</reference_text><pubmed_id>7707089</pubmed_id></reference><reference><reference_text>Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.</reference_text><pubmed_id>17384003</pubmed_id></reference><reference><reference_text>Syburra C, Passi S: Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh (1999). 1999 May-Jun;71(3):112-5.</reference_text><pubmed_id>10609336</pubmed_id></reference><reference><reference_text>Forte G, Visconti A, Santucci S, Ghazaryan A, Figa-Talamanca L, Cannoni S, Bocca B, Pino A, Violante N, Alimonti A, Salvetti M, Ristori G: Quantification of chemical elements in blood of patients affected by multiple sclerosis. Ann Ist Super Sanita. 2005;41(2):213-6.</reference_text><pubmed_id>16244395</pubmed_id></reference><reference><reference_text>Toncev G, Milicic B, Toncev S, Samardzic G: Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol. 2002 May;9(3):221-6.</reference_text><pubmed_id>11985629</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, Bamonti F, Capello E, Mancardi GL, Scarpini E: Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res. 2010 May 28;1333:64-71. doi: 10.1016/j.brainres.2010.03.073. Epub 2010 Mar 27.</reference_text><pubmed_id>20347721</pubmed_id></reference><reference><reference_text>Matsushita T, Isobe N, Kawajiri M, Mogi M, Tsukuda K, Horiuchi M, Ohyagi Y, Kira J: CSF angiotensin II and angiotensin-converting enzyme levels in anti-aquaporin-4 autoimmunity. J Neurol Sci. 2010 Aug 15;295(1-2):41-5. doi: 10.1016/j.jns.2010.05.014. Epub 2010 Jun 11.</reference_text><pubmed_id>20541774</pubmed_id></reference><reference><reference_text>Ghabaee M, Jabedari B, Al-E-Eshagh N, Ghaffarpour M, Asadi F: Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients. Int J Neurosci. 2010 Apr;120(4):301-4. doi: 10.3109/00207451003695690.</reference_text><pubmed_id>20374079</pubmed_id></reference><reference><reference_text>Kawajiri M, Mogi M, Osoegawa M, Matsuoka T, Tsukuda K, Kohara K, Horiuchi M, Miki T, Kira JI: Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler. 2008 May;14(4):557-60. doi: 10.1177/1352458507085760.</reference_text><pubmed_id>18562510</pubmed_id></reference><reference><reference_text>Visconti A, Cotichini R, Cannoni S, Bocca B, Forte G, Ghazaryan A, Santucci S, D'Ippolito C, Stazi MA, Salvetti M, Alimonti A, Ristori G: Concentration of elements in serum of patients affected by multiple sclerosis with first demyelinating episode: a six-month longitudinal follow-up study. Ann Ist Super Sanita. 2005;41(2):217-22.</reference_text><pubmed_id>16244396</pubmed_id></reference></references></disease><disease>Inflammatory bowel disease<references><reference><reference_text>Lee T, Clavel T, Smirnov K, Schmidt A, Lagkouvardos I, Walker A, Lucio M, Michalke B, Schmitt-Kopplin P, Fedorak R, Haller D: Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. 2017 May;66(5):863-871. doi: 10.1136/gutjnl-2015-309940. Epub 2016 Feb 4.</reference_text><pubmed_id>26848182</pubmed_id></reference><reference><reference_text>Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158.</reference_text><pubmed_id>27609529</pubmed_id></reference></references></disease><disease>Colorectal cancer<references><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B: Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009 Apr;22(3):342-8. doi: 10.1002/nbm.1345.</reference_text><pubmed_id>19006102</pubmed_id></reference><reference><reference_text>Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP: Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One. 2013 Aug 6;8(8):e70803. doi: 10.1371/journal.pone.0070803. Print 2013.</reference_text><pubmed_id>23940645</pubmed_id></reference><reference><reference_text>Phua LC, Chue XP, Koh PK, Cheah PY, Ho HK, Chan EC: Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biol Ther. 2014 Apr;15(4):389-97. doi: 10.4161/cbt.27625. Epub 2014 Jan 14.</reference_text><pubmed_id>24424155</pubmed_id></reference><reference><reference_text>Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB: Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010 Feb 15;8:13. doi: 10.1186/1741-7015-8-13.</reference_text><pubmed_id>20156336</pubmed_id></reference><reference><reference_text>Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, Ni Y, Zhao A, Xu LX, Cai S, Jia W: Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res. 2009 Oct;8(10):4844-50. doi: 10.1021/pr9004162.</reference_text><pubmed_id>19678709</pubmed_id></reference><reference><reference_text>Cheng Y, Xie G, Chen T, Qiu Y, Zou X, Zheng M, Tan B, Feng B, Dong T, He P, Zhao L, Zhao A, Xu LX, Zhang Y, Jia W: Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res. 2012 Feb 3;11(2):1354-63. doi: 10.1021/pr201001a. Epub 2011 Dec 28.</reference_text><pubmed_id>22148915</pubmed_id></reference><reference><reference_text>Ni Y, Xie G, Jia W: Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res. 2014 Sep 5;13(9):3857-70. doi: 10.1021/pr500443c. Epub 2014 Aug 14.</reference_text><pubmed_id>25105552</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference><reference><reference_text>Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18.</reference_text><pubmed_id>25037050</pubmed_id></reference><reference><reference_text>Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016.</reference_text><pubmed_id>27015276</pubmed_id></reference><reference><reference_text>Lin Y, Ma C, Liu C, Wang Z, Yang J, Liu X, Shen Z, Wu R: NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer. Oncotarget. 2016 May 17;7(20):29454-64. doi: 10.18632/oncotarget.8762.</reference_text><pubmed_id>27107423</pubmed_id></reference><reference><reference_text>Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016.</reference_text><pubmed_id>27275383</pubmed_id></reference><reference><reference_text>Wang X, Wang J, Rao B, Deng L: Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals. Exp Ther Med. 2017 Jun;13(6):2848-2854. doi: 10.3892/etm.2017.4367. Epub 2017 Apr 20.</reference_text><pubmed_id>28587349</pubmed_id></reference><reference><reference_text>Silke Matysik, Caroline Ivanne Le Roy, Gerhard Liebisch, Sandrine Paule Claus. Metabolomics of fecal samples: A practical consideration. Trends in Food Science &amp; Technology. Vol. 57, Part B, Nov. 2016, p.244-255: http://www.sciencedirect.com/science/article/pii/S0924224416301984</reference_text><pubmed_id>28587349</pubmed_id></reference></references></disease><disease>Gallbladder disease<references><reference><reference_text>Lapidus A, Akerlund JE, Einarsson C: Gallbladder bile composition in patients with Crohn 's disease. World J Gastroenterol. 2006 Jan 7;12(1):70-4.</reference_text><pubmed_id>16440420</pubmed_id></reference><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference><reference><reference_text>Mizuno S, Tazuma S, Kajiyama G: Stabilization of biliary lipid particles by ursodeoxycholic acid. Prolonged nucleation time in human gallbladder bile. Dig Dis Sci. 1993 Apr;38(4):684-93.</reference_text><pubmed_id>8462368</pubmed_id></reference><reference><reference_text>Hillebrant CG, Axelson M, Bjorkhem I, Wang FH, Nyberg B, Einarsson C: Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients. Eur J Clin Invest. 1998 Apr;28(4):324-8.</reference_text><pubmed_id>9615912</pubmed_id></reference></references></disease><disease>Cholelithiasis<references><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference></references></disease><disease>Stomach cancer<references><reference><reference_text>Higashijima H, Ichimiya H, Nakano T, Yamashita H, Kuroki S, Satoh H, Chijiiwa K, Tanaka M: Deconjugation of bilirubin accelerates coprecipitation of cholesterol, fatty acids, and mucin in human bile--in vitro study. J Gastroenterol. 1996 Dec;31(6):828-35.</reference_text><pubmed_id>9027647</pubmed_id></reference><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Song H, Peng JS, Dong-Sheng Y, Yang ZL, Liu HL, Zeng YK, Shi XP, Lu BY: Serum metabolic profiling of human gastric cancer based on gas chromatography/mass spectrometry. Braz J Med Biol Res. 2012 Jan;45(1):78-85. Epub 2011 Nov 25.</reference_text><pubmed_id>22124703</pubmed_id></reference><reference><reference_text>Yu L, Aa J, Xu J, Sun M, Qian S, Cheng L, Yang S, Shi R: Metabolomic phenotype of gastric cancer and precancerous stages based on gas chromatography time-of-flight mass spectrometry. J Gastroenterol Hepatol. 2011 Aug;26(8):1290-7. doi: 10.1111/j.1440-1746.2011.06724.x.</reference_text><pubmed_id>21443661</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference></references></disease><disease>Acute myelogenous leukemia<references><reference><reference_text>Tatidis L, Vitols S, Gruber A, Paul C, Axelson M: Cholesterol catabolism in patients with acute myelogenous leukemia and hypocholesterolemia: suppressed levels of a circulating marker for bile acid synthesis. Cancer Lett. 2001 Sep 20;170(2):169-75.</reference_text><pubmed_id>11463495</pubmed_id></reference></references></disease><disease>Hypercholesterolemia<references><reference><reference_text>Thelen KM, Laaksonen R, Paiva H, Lehtimaki T, Lutjohann D: High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels. J Clin Pharmacol. 2006 Jul;46(7):812-6.</reference_text><pubmed_id>16809807</pubmed_id></reference><reference><reference_text>Tamasawa N, Tamasawa A, Takebe K: Higher levels of plasma cholesterol sulfate in patients with liver cirrhosis and hypercholesterolemia. Lipids. 1993 Sep;28(9):833-6.</reference_text><pubmed_id>8231659</pubmed_id></reference><reference><reference_text>Kim DH, Lee KJ, Heo GS: Analysis of cholesterol and cholesteryl esters in human serum using capillary supercritical fluid chromatography. J Chromatogr B Biomed Appl. 1994 Apr 22;655(1):1-8.</reference_text><pubmed_id>8061816</pubmed_id></reference><reference><reference_text>Authors unspecified: Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med. 1988 Jan;148(1):36-69.</reference_text><pubmed_id>3422148</pubmed_id></reference></references></disease><disease>Cholesteryl ester storage disease<references><reference><reference_text>Rassoul F, Richter V, Lohse P, Naumann A, Purschwitz K, Keller E: Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease. Int J Clin Pharmacol Ther. 2001 May;39(5):199-204.</reference_text><pubmed_id>11380065</pubmed_id></reference><reference><reference_text>Chatrath H, Keilin S, Attar BM: Cholesterol ester storage disease (CESD) diagnosed in an asymptomatic adult. Dig Dis Sci. 2009 Jan;54(1):168-73. doi: 10.1007/s10620-008-0310-2. Epub 2008 May 14.</reference_text><pubmed_id>18478331</pubmed_id></reference><reference><reference_text>Bernstein DL, Hulkova H, Bialer MG, Desnick RJ: Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol. 2013 Jun;58(6):1230-43. doi: 10.1016/j.jhep.2013.02.014. Epub 2013 Feb 26.</reference_text><pubmed_id>23485521</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Cystinosis<references><reference><reference_text>Ueda M, O'Brien K, Rosing DR, Ling A, Kleta R, McAreavey D, Bernardini I, Gahl WA: Coronary artery and other vascular calcifications in patients with cystinosis after kidney transplantation. Clin J Am Soc Nephrol. 2006 May;1(3):555-62. Epub 2006 Feb 8.</reference_text><pubmed_id>17699259</pubmed_id></reference><reference><reference_text>Gahl WA, Bernardini I, Dalakas M, Rizzo WB, Harper GS, Hoeg JM, Hurko O, Bernar J: Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome. J Clin Invest. 1988 Feb;81(2):549-60.</reference_text><pubmed_id>3276734</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Smith-Lemli-Opitz syndrome<references><reference><reference_text>van Rooij A, Nijenhuis AA, Wijburg FA, Schutgens RB: Highly increased CSF concentrations of cholesterol precursors in Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 1997 Aug;20(4):578-80.</reference_text><pubmed_id>9266395</pubmed_id></reference><reference><reference_text>Honda M, Tint GS, Honda A, Salen G, Shefer S, Batta AK, Matsuzaki Y, Tanaka N: Regulation of cholesterol biosynthetic pathway in patients with the Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2000 Jul;23(5):464-74.</reference_text><pubmed_id>10947201</pubmed_id></reference><reference><reference_text>Rossi M, Federico G, Corso G, Parenti G, Battagliese A, Frascogna AR, Della Casa R, Dello Russo A, Strisciuglio P, Saggese G, Andria G: Vitamin D status in patients affected by Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2005;28(1):69-80.</reference_text><pubmed_id>15702407</pubmed_id></reference><reference><reference_text>Johnson DW, ten Brink HJ, Jakobs C: A rapid screening procedure for cholesterol and dehydrocholesterol by electrospray ionization tandem mass spectrometry. J Lipid Res. 2001 Oct;42(10):1699-705.</reference_text><pubmed_id>11590227</pubmed_id></reference></references></disease><disease>Prostate cancer<references><reference><reference_text>Nyman DW, Suzanne Stratton M, Kopplin MJ, Dalkin BL, Nagle RB, Jay Gandolfi A: Selenium and selenomethionine levels in prostate cancer patients. Cancer Detect Prev. 2004;28(1):8-16.</reference_text><pubmed_id>15041072</pubmed_id></reference><reference><reference_text>Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, Egevad L, Tjonneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, Palli D, Vineis P, Tumino R, Berrino F, Kiemeney L, Bueno-de-Mesquita HB, Quiros JR, Gonzalez CA, Martinez C, Larranaga N, Chirlaque MD, Ardanaz E, Stattin P, Hallmans G, Khaw KT, Bingham S, Slimani N, Ferrari P, Rinaldi S, Riboli E: Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr. 2007 Sep;86(3):672-81.</reference_text><pubmed_id>17823432</pubmed_id></reference><reference><reference_text>Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762.</reference_text><pubmed_id>19212411</pubmed_id></reference><reference><reference_text>Puah CM, Williams G, Ghanadian R: Urinary unconjugated 5 alpha-androstane-3 alpha, 17 beta-diol in patients with prostatic tumours. Urol Res. 1982;10(2):81-4.</reference_text><pubmed_id>6180540</pubmed_id></reference><reference><reference_text>Thysell E, Surowiec I, Hornberg E, Crnalic S, Widmark A, Johansson AI, Stattin P, Bergh A, Moritz T, Antti H, Wikstrom P: Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One. 2010 Dec 3;5(12):e14175. doi: 10.1371/journal.pone.0014175.</reference_text><pubmed_id>21151972</pubmed_id></reference><reference><reference_text>Soliman LC, Hui Y, Hewavitharana AK, Chen DD: Monitoring potential prostate cancer biomarkers in urine by capillary electrophoresis-tandem mass spectrometry. J Chromatogr A. 2012 Dec 7;1267:162-9. doi: 10.1016/j.chroma.2012.07.021. Epub 2012 Jul 14.</reference_text><pubmed_id>22824219</pubmed_id></reference><reference><reference_text>Madu CO, Lu Y: Novel diagnostic biomarkers for prostate cancer. J Cancer. 2010 Oct 6;1:150-77.</reference_text><pubmed_id>20975847</pubmed_id></reference></references></disease><disease>Schizophrenia<references><reference><reference_text>Harnryd C, Bjerkenstedt L, Grimm VE, Sedvall G: Reduction of MOPEG levels in cerebrospinal fluid of psychotic women after electroconvulsive treatment. Psychopharmacology (Berl). 1979 Aug 8;64(2):131-4.</reference_text><pubmed_id>115032</pubmed_id></reference><reference><reference_text>Kobayashi K, Koide Y, Yoshino K, Shohmori T: [P-hydroxyphenylacetic acid concentrations in cerebrospinal fluid]. No To Shinkei. 1982 Aug;34(8):769-74.</reference_text><pubmed_id>7126379</pubmed_id></reference><reference><reference_text>Alfredsson G, Wiesel FA: Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology (Berl). 1989;99(3):322-7.</reference_text><pubmed_id>2480613</pubmed_id></reference><reference><reference_text>Heresco-Levy U, Bar G, Levin R, Ermilov M, Ebstein RP, Javitt DC: High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. Schizophr Res. 2007 Mar;91(1-3):14-21. Epub 2007 Feb 2.</reference_text><pubmed_id>17276036</pubmed_id></reference><reference><reference_text>Walker EF, Bonsall R, Walder DJ: Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis. Neuropsychiatry Neuropsychol Behav Neurol. 2002 Mar;15(1):10-7.</reference_text><pubmed_id>11877547</pubmed_id></reference><reference><reference_text>Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M: Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry. 2003 Jun;60(6):572-6.</reference_text><pubmed_id>12796220</pubmed_id></reference><reference><reference_text>Do KQ, Lauer CJ, Schreiber W, Zollinger M, Gutteck-Amsler U, Cuenod M, Holsboer F: gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem. 1995 Dec;65(6):2652-62.</reference_text><pubmed_id>7595563</pubmed_id></reference><reference><reference_text>Nikisch G, Baumann P, Wiedemann G, Kiessling B, Weisser H, Hertel A, Yoshitake T, Kehr J, Mathe AA: Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF. J Clin Psychopharmacol. 2010 Oct;30(5):496-503. doi: 10.1097/JCP.0b013e3181f2288e.</reference_text><pubmed_id>20814316</pubmed_id></reference><reference><reference_text>Fukushima T, Iizuka H, Yokota A, Suzuki T, Ohno C, Kono Y, Nishikiori M, Seki A, Ichiba H, Watanabe Y, Hongo S, Utsunomiya M, Nakatani M, Sadamoto K, Yoshio T: Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One. 2014 Jul 8;9(7):e101652. doi: 10.1371/journal.pone.0101652. eCollection 2014.</reference_text><pubmed_id>25004141</pubmed_id></reference><reference><reference_text>Koike S, Bundo M, Iwamoto K, Suga M, Kuwabara H, Ohashi Y, Shinoda K, Takano Y, Iwashiro N, Satomura Y, Nagai T, Natsubori T, Tada M, Yamasue H, Kasai K: A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study. Transl Psychiatry. 2014 Apr 8;4:e379. doi: 10.1038/tp.2014.19.</reference_text><pubmed_id>24713860</pubmed_id></reference><reference><reference_text>Ballesteros A, Summerfelt A, Du X, Jiang P, Chiappelli J, Tagamets M, O'Donnell P, Kochunov P, Hong LE: Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia. Clin Neurophysiol. 2013 Nov;124(11):2209-15. doi: 10.1016/j.clinph.2013.05.021. Epub 2013 Jun 30.</reference_text><pubmed_id>23823132</pubmed_id></reference><reference><reference_text>Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel FA: Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry. 1985 Sep;147:276-82.</reference_text><pubmed_id>2415198</pubmed_id></reference><reference><reference_text>Pickar D, Breier A, Hsiao JK, Doran AR, Wolkowitz OM, Pato CN, Konicki PE, Potter WZ: Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Arch Gen Psychiatry. 1990 Jul;47(7):641-8.</reference_text><pubmed_id>1694425</pubmed_id></reference><reference><reference_text>Prell GD, Green JP, Kaufmann CA, Khandelwal JK, Morrishow AM, Kirch DG, Linnoila M, Wyatt RJ: Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res. 1995 Jan;14(2):93-104.</reference_text><pubmed_id>7711000</pubmed_id></reference><reference><reference_text>Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B: Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology. 2009;59(2):123-9. doi: 10.1159/000213565. Epub 2009 Apr 22.</reference_text><pubmed_id>19390223</pubmed_id></reference><reference><reference_text>Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K, Cao Y, Wang X, Qiu Y, Su M, Zhao A, Wang P, Yang P, Wu J, Feng G, He L, Jia W, Wan C: Potential metabolite markers of schizophrenia. Mol Psychiatry. 2013 Jan;18(1):67-78. doi: 10.1038/mp.2011.131. Epub 2011 Oct 25.</reference_text><pubmed_id>22024767</pubmed_id></reference><reference><reference_text>Xuan J, Pan G, Qiu Y, Yang L, Su M, Liu Y, Chen J, Feng G, Fang Y, Jia W, Xing Q, He L: Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. J Proteome Res. 2011 Dec 2;10(12):5433-43. doi: 10.1021/pr2006796. Epub 2011 Nov  8.</reference_text><pubmed_id>22007635</pubmed_id></reference><reference><reference_text>Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM, Rothermundt M, Bogerts B, Koethe D, Kranaster L, Ohrmann P, Suslow T, McAllister G, Spain M, Barnes A, van Beveren NJ, Baron-Cohen S, Steiner J, Torrey FE, Yolken RH, Bahn S: Identification of a biological signature for schizophrenia in serum. Mol Psychiatry. 2012 May;17(5):494-502. doi: 10.1038/mp.2011.42. Epub 2011 Apr 12.</reference_text><pubmed_id>21483431</pubmed_id></reference><reference><reference_text>Mathe AA, Eberhard G, Saaf J, Wetterberg L: Plasma prostaglandin E2 metabolite--measured as 11-deoxy-15-keto-13,14-dihydro-11 beta,16 xi-cyclo-PGE2--in twins with schizophrenic disorder. Biol Psychiatry. 1986 Sep;21(11):1024-30.</reference_text><pubmed_id>3741918</pubmed_id></reference><reference><reference_text>Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N: Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct. 2002 Jun;20(2):171-5.</reference_text><pubmed_id>11979513</pubmed_id></reference><reference><reference_text>Zumarraga M, Davila R, Basterreche N, Arrue A, Goienetxea B, Zamalloa MI, Erkoreka L, Bustamante S, Inchausti L, Gonzalez-Torres MA, Guimon J: Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients. Neurochem Int. 2010 May-Jun;56(6-7):774-9. doi: 10.1016/j.neuint.2010.02.015. Epub 2010 Mar 4.</reference_text><pubmed_id>20206656</pubmed_id></reference><reference><reference_text>Peters JG: Dopamine, noradrenaline and serotonin spinal fluid metabolites in temporal lobe epileptic patients with schizophrenic symptomatology. Eur Neurol. 1979;18(1):15-8.</reference_text><pubmed_id>436860</pubmed_id></reference><reference><reference_text>Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, Rozen S, Krishnan RR, McEvoy J, Kaddurah-Daouk R: Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry. 2010 Sep;15(9):938-53. doi: 10.1038/mp.2009.33. Epub 2009 Apr 28.</reference_text><pubmed_id>19401681</pubmed_id></reference><reference><reference_text>Gattaz WF, Waldmeier P, Beckmann H: CSF monoamine metabolites in schizophrenic patients. Acta Psychiatr Scand. 1982 Nov;66(5):350-60.</reference_text><pubmed_id>6184954</pubmed_id></reference><reference><reference_text>Nilsson-Todd LK, Nordin C, Jonsson EG, Skogh E, Erhardt S: Cerebrospinal fluid kynurenic acid in male patients with schizophrenia - correlation with monoamine metabolites. Acta Neuropsychiatr. 2007 Feb;19(1):45-52. doi: 10.1111/j.1601-5215.2006.00170.x.</reference_text><pubmed_id>26952797</pubmed_id></reference><reference><reference_text>Cai HL, Li HD, Yan XZ, Sun B, Zhang Q, Yan M, Zhang WY, Jiang P, Zhu RH, Liu YP, Fang PF, Xu P, Yuan HY, Zhang XH, Hu L, Yang W, Ye HS: Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naive schizophrenia patients after treatment with risperidone. J Proteome Res. 2012 Aug 3;11(8):4338-50. doi: 10.1021/pr300459d. Epub 2012 Jul 26.</reference_text><pubmed_id>22800120</pubmed_id></reference><reference><reference_text>Al Awam K, Haussleiter IS, Dudley E, Donev R, Brune M, Juckel G, Thome J: Multiplatform metabolome and proteome profiling identifies serum metabolite and protein signatures as prospective biomarkers for schizophrenia. J Neural Transm (Vienna). 2015 Aug;122 Suppl 1:S111-22. doi: 10.1007/s00702-014-1224-0. Epub 2014 May 1.</reference_text><pubmed_id>24789758</pubmed_id></reference><reference><reference_text>Bicikova M, Hill M, Ripova D, Mohr P, Hampl R: Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia. J Steroid Biochem Mol Biol. 2013 Jan;133:77-83. doi: 10.1016/j.jsbmb.2012.08.009. Epub 2012 Aug 24.</reference_text><pubmed_id>22944140</pubmed_id></reference><reference><reference_text>He Y, Yu Z, Giegling I, Xie L, Hartmann AM, Prehn C, Adamski J, Kahn R, Li Y, Illig T, Wang-Sattler R, Rujescu D: Schizophrenia shows a unique metabolomics signature in plasma. Transl Psychiatry. 2012 Aug 14;2:e149. doi: 10.1038/tp.2012.76.</reference_text><pubmed_id>22892715</pubmed_id></reference><reference><reference_text>Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KR: Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):934-45. Epub 2007 Apr 17.</reference_text><pubmed_id>17440431</pubmed_id></reference><reference><reference_text>Fryar-Williams S, Strobel JE: Biomarkers of a five-domain translational substrate for schizophrenia and schizoaffective psychosis. Biomark Res. 2015 Feb 6;3:3. doi: 10.1186/s40364-015-0028-1. eCollection 2015.</reference_text><pubmed_id>25729574</pubmed_id></reference><reference><reference_text>Oresic M, Seppanen-Laakso T, Sun D, Tang J, Therman S, Viehman R, Mustonen U, van Erp TG, Hyotylainen T, Thompson P, Toga AW, Huttunen MO, Suvisaari J, Kaprio J, Lonnqvist J, Cannon TD: Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia. Genome Med. 2012 Jan 18;4(1):1. doi: 10.1186/gm300.</reference_text><pubmed_id>22257447</pubmed_id></reference></references></disease><disease>Primary hypomagnesemia<references><reference><reference_text>Jin-no Y, Kamiya Y, Okada M, Hirako M, Takada N, Kawaguchi M: Primary hypomagnesemia caused by isolated magnesium malabsorption: atypical case in adult. Intern Med. 1999 Mar;38(3):261-5.</reference_text><pubmed_id>10337938</pubmed_id></reference><reference><reference_text>Vainsel M, Vandevelde G, Smulders J, Vosters M, Hubain P, Loeb H: Tetany due to hypomagnesaemia with secondary hypocalcaemia. Arch Dis Child. 1970 Apr;45(240):254-8.</reference_text><pubmed_id>5419995</pubmed_id></reference><reference><reference_text>Shalev H, Phillip M, Galil A, Carmi R, Landau D: Clinical presentation and outcome in primary familial hypomagnesaemia. Arch Dis Child. 1998 Feb;78(2):127-30.</reference_text><pubmed_id>9579153</pubmed_id></reference><reference><reference_text>Kari JA, Farouq M, Alshaya HO: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Pediatr Nephrol. 2003 Jun;18(6):506-10. Epub 2003 Apr 29.</reference_text><pubmed_id>12720080</pubmed_id></reference></references></disease><disease>Hyperlipoproteinemia<references><reference><reference_text>Sinha S, Misra A, Kumar V, Jagannathan NR, Bal CS, Pandey RM, Singhania R, Deepak: Proton magnetic resonance spectroscopy and single photon emission computed tomography study of the brain in asymptomatic young hyperlipidaemic Asian Indians in North India show early abnormalities. Clin Endocrinol (Oxf). 2004 Aug;61(2):182-9.</reference_text><pubmed_id>15272912</pubmed_id></reference><reference><reference_text>Nelson RH: Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013 Mar</reference_text><pubmed_id>40(1):195-211. doi: 10.1016/j.pop.2012.11.003. Epub 2012 Dec  4.</pubmed_id></reference><reference><reference_text>Cantin B, Boudriau S, Bertrand M, Brun LD, Gagne C, Rogers PA, Ven Murthy MR, Lupien PJ, Julien P: Hemolysis in primary lipoprotein lipase deficiency. Metabolism. 1995 May;44(5):652-8.</reference_text><pubmed_id>7752915</pubmed_id></reference></references></disease><disease>Abetalipoproteinemia<references><reference><reference_text>Dawson G, Kruski AW, Scanu AM: Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J Lipid Res. 1976 Mar;17(2):125-31.</reference_text><pubmed_id>178813</pubmed_id></reference><reference><reference_text>Lazaro RP, Dentinger MP, Rodichok LD, Barron KD, Satya-Murti S: Muscle pathology in Bassen-Kornzweig syndrome and vitamin E deficiency. Am J Clin Pathol. 1986 Sep;86(3):378-87.</reference_text><pubmed_id>2944375</pubmed_id></reference></references></disease><disease>Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis<references><reference><reference_text>Breckenridge WC, Alaupovic P, Cox DW, Little JA: Apolipoprotein and lipoprotein concentrations in familial apolipoprotein C-II deficiency. Atherosclerosis. 1982 Aug;44(2):223-35.</reference_text><pubmed_id>7138621</pubmed_id></reference><reference><reference_text>Fukami M, Hasegawa T, Horikawa R, Ohashi T, Nishimura G, Homma K, Ogata T: Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr Res. 2006 Feb;59(2):276-80. doi: 10.1203/01.pdr.0000195825.31504.28.</reference_text><pubmed_id>16439592</pubmed_id></reference></references></disease><disease>Cerebrotendinous xanthomatosis<references><reference><reference_text>Halperin G, Elisaf M, Leitersdorf E, Harats D: A new method for determination of serum cholestanol by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2000 Jun 9;742(2):345-52.</reference_text><pubmed_id>10901139</pubmed_id></reference><reference><reference_text>Siman-Tov T, Meiner V, Gadoth N: Could steroids mask the diagnosis of cerebrotendinous xanthomatosis? J Neurol Sci. 2006 Apr 15;243(1-2):83-6. Epub 2006 Jan 30.</reference_text><pubmed_id>16445943</pubmed_id></reference><reference><reference_text>Agrawal NK, Garg S: Cerebrotendinous xanthomatosis: a rare disorder with a rare presentation. BMJ Case Rep. 2012 Sep 21;2012. pii: bcr-2012-006202. doi: 10.1136/bcr-2012-006202.</reference_text><pubmed_id>23001091</pubmed_id></reference></references></disease><disease>3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency<references><reference><reference_text>Thompson GN, Hsu BY, Pitt JJ, Treacy E, Stanley CA: Fasting hypoketotic coma in a child with deficiency of mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase. N Engl J Med. 1997 Oct 23;337(17):1203-7. doi: 10.1056/NEJM199710233371704.</reference_text><pubmed_id>9337379</pubmed_id></reference><reference><reference_text>Morris AA, Lascelles CV, Olpin SE, Lake BD, Leonard JV, Quant PA: Hepatic mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme a synthase deficiency. Pediatr Res. 1998 Sep;44(3):392-6. doi: 10.1203/00006450-199809000-00021.</reference_text><pubmed_id>9727719</pubmed_id></reference><reference><reference_text>Conboy E, Vairo F, Schultz M, Agre K, Ridsdale R, Deyle D, Oglesbee D, Gavrilov D, Klee EW, Lanpher B: Mitochondrial 3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency: Unique Presenting Laboratory Values and a Review of Biochemical and Clinical Features. JIMD Rep. 2017 Oct 14. doi: 10.1007/8904_2017_59.</reference_text><pubmed_id>29030856</pubmed_id></reference></references></disease><disease>Hypercholesterolemia, familial<references><reference><reference_text>Kwiterovich PO Jr, Fredrickson DS, Levy RI: Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest. 1974 May;53(5):1237-49. doi: 10.1172/JCI107670.</reference_text><pubmed_id>4363406</pubmed_id></reference></references></disease><disease>SC4MOL deficiency<references><reference><reference_text>He M, Kratz LE, Michel JJ, Vallejo AN, Ferris L, Kelley RI, Hoover JJ, Jukic D, Gibson KM, Wolfe LA, Ramachandran D, Zwick ME, Vockley J: Mutations in the human SC4MOL gene encoding a methyl sterol oxidase cause psoriasiform dermatitis, microcephaly, and developmental delay. J Clin Invest. 2011 Mar;121(3):976-84. doi: 10.1172/JCI42650.</reference_text><pubmed_id>21285510</pubmed_id></reference></references></disease><disease>Chondrodysplasia punctata, X-linked dominant<references><reference><reference_text>Aughton DJ, Kelley RI, Metzenberg A, Pureza V, Pauli RM: X-linked dominant chondrodysplasia punctata (CDPX2) caused by single gene mosaicism in a male. Am J Med Genet A. 2003 Jan 30;116A(3):255-60. doi: 10.1002/ajmg.a.10852.</reference_text><pubmed_id>12503102</pubmed_id></reference></references></disease><disease>Desmosterolosis<references><reference><reference_text>Andersson HC, Kratz L, Kelley R: Desmosterolosis presenting with multiple congenital anomalies and profound developmental delay. Am J Med Genet. 2002 Dec 15;113(4):315-9. doi: 10.1002/ajmg.b.10873.</reference_text><pubmed_id>12457401</pubmed_id></reference></references></disease><disease>Donohue Syndrome<references><reference><reference_text>Nijim Y, Awni Y, Adawi A, Bowirrat A: Classic Case Report of Donohue Syndrome (Leprechaunism; OMIM *246200): The Impact of Consanguineous Mating. Medicine (Baltimore). 2016 Feb;95(6):e2710. doi: 10.1097/MD.0000000000002710.</reference_text><pubmed_id>26871809</pubmed_id></reference></references></disease><disease>Leptin Deficiency or Dysfunction<references><reference><reference_text>Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O'Rahilly S: Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999 Sep 16;341(12):879-84. doi: 10.1056/NEJM199909163411204.</reference_text><pubmed_id>10486419</pubmed_id></reference></references></disease><disease>Duchenne Muscular Dystrophy<references><reference><reference_text>Nakagawa T, Takeuchi A, Kakiuchi R, Lee T, Yagi M, Awano H, Iijima K, Takeshima Y, Urade Y, Matsuo M: A prostaglandin D2 metabolite is elevated in the urine of Duchenne muscular dystrophy patients and increases further from 8 years old. Clin Chim Acta. 2013 Aug 23;423:10-4. doi: 10.1016/j.cca.2013.03.031. Epub 2013 Apr 19.</reference_text><pubmed_id>23603101</pubmed_id></reference><reference><reference_text>Srivastava NK, Pradhan S, Mittal B, Gowda GA: High resolution NMR based analysis of serum lipids in Duchenne muscular dystrophy patients and its possible diagnostic significance. NMR Biomed. 2010 Jan;23(1):13-22. doi: 10.1002/nbm.1419.</reference_text><pubmed_id>19787747</pubmed_id></reference><reference><reference_text>Horster I, Weigt-Usinger K, Carmann C, Chobanyan-Jurgens K, Kohler C, Schara U, Kayacelebi AA, Beckmann B, Tsikas D, Lucke T: The L-arginine/NO pathway and homoarginine are altered in Duchenne muscular dystrophy and improved by glucocorticoids. Amino Acids. 2015 Sep;47(9):1853-63. doi: 10.1007/s00726-015-2018-x. Epub 2015 Jun 12.</reference_text><pubmed_id>26066683</pubmed_id></reference></references></disease><disease>Lecithin:cholesterol Acyltransferase Deficiency<references><reference><reference_text>Idzior-Walus B, Sieradzki J, Kostner G, Malecki MT, Klupa T, Wesolowska T, Rostworowski W, Hartwich J, Walus M, Kiec AD, Naruszewicz M: Familial lecithin-cholesterol acyltransferase deficiency: biochemical characteristics and molecular analysis of a new LCAT mutation in a Polish family. Atherosclerosis. 2006 Apr;185(2):413-20. Epub 2005 Jul 26.</reference_text><pubmed_id>16051254</pubmed_id></reference></references></disease><disease>Lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lipodystrophy, Congenital Generalized<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Oculocerebrorenal syndrome<references><reference><reference_text>Charnas LR, Bernardini I, Rader D, Hoeg JM, Gahl WA: Clinical and laboratory findings in the oculocerebrorenal syndrome of Lowe, with special reference to growth and renal function. N Engl J Med. 1991 May 9;324(19):1318-25. doi: 10.1056/NEJM199105093241904.</reference_text><pubmed_id>2017228</pubmed_id></reference></references></disease><disease>Familial partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lathosterolosis<references><reference><reference_text>Brunetti-Pierri N, Corso G, Rossi M, Ferrari P, Balli F, Rivasi F, Annunziata I, Ballabio A, Russo AD, Andria G, Parenti G: Lathosterolosis, a novel multiple-malformation/mental retardation syndrome due to deficiency of 3beta-hydroxysteroid-delta5-desaturase. Am J Hum Genet. 2002 Oct;71(4):952-8. Epub 2002 Aug 20.</reference_text><pubmed_id>12189593</pubmed_id></reference><reference><reference_text>Ho AC, Fung CW, Siu TS, Ma OC, Lam CW, Tam S, Wong VC: Lathosterolosis: a disorder of cholesterol biosynthesis resembling smith-lemli-opitz syndrome. JIMD Rep. 2014;12:129-34. doi: 10.1007/8904_2013_255. Epub 2013 Oct 20.</reference_text><pubmed_id>24142275</pubmed_id></reference></references></disease><disease>Partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Multiple sclerosis<references><reference><reference_text>Lutz NW, Viola A, Malikova I, Confort-Gouny S, Audoin B, Ranjeva JP, Pelletier J, Cozzone PJ: Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One. 2007 Jul 4;2(7):e595.</reference_text><pubmed_id>17611627</pubmed_id></reference><reference><reference_text>Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U, Hillert J, Bjorkhem I: Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med. 2004 Feb;42(2):186-91.</reference_text><pubmed_id>15061359</pubmed_id></reference><reference><reference_text>Leoni V, Lutjohann D, Masterman T: Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis. J Lipid Res. 2005 Feb;46(2):191-5. Epub 2004 Dec 1.</reference_text><pubmed_id>15576852</pubmed_id></reference><reference><reference_text>Calabrese V, Scapagnini G, Ravagna A, Bella R, Butterfield DA, Calvani M, Pennisi G, Giuffrida Stella AM: Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem Res. 2003 Sep;28(9):1321-8.</reference_text><pubmed_id>12938853</pubmed_id></reference><reference><reference_text>Shaw CE, Dunbar PR, Macaulay HA, Neale TJ: Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol. 1995 Jan;242(2):53-8.</reference_text><pubmed_id>7707089</pubmed_id></reference><reference><reference_text>Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.</reference_text><pubmed_id>17384003</pubmed_id></reference><reference><reference_text>Syburra C, Passi S: Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh (1999). 1999 May-Jun;71(3):112-5.</reference_text><pubmed_id>10609336</pubmed_id></reference><reference><reference_text>Forte G, Visconti A, Santucci S, Ghazaryan A, Figa-Talamanca L, Cannoni S, Bocca B, Pino A, Violante N, Alimonti A, Salvetti M, Ristori G: Quantification of chemical elements in blood of patients affected by multiple sclerosis. Ann Ist Super Sanita. 2005;41(2):213-6.</reference_text><pubmed_id>16244395</pubmed_id></reference><reference><reference_text>Toncev G, Milicic B, Toncev S, Samardzic G: Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol. 2002 May;9(3):221-6.</reference_text><pubmed_id>11985629</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, Bamonti F, Capello E, Mancardi GL, Scarpini E: Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res. 2010 May 28;1333:64-71. doi: 10.1016/j.brainres.2010.03.073. Epub 2010 Mar 27.</reference_text><pubmed_id>20347721</pubmed_id></reference><reference><reference_text>Matsushita T, Isobe N, Kawajiri M, Mogi M, Tsukuda K, Horiuchi M, Ohyagi Y, Kira J: CSF angiotensin II and angiotensin-converting enzyme levels in anti-aquaporin-4 autoimmunity. J Neurol Sci. 2010 Aug 15;295(1-2):41-5. doi: 10.1016/j.jns.2010.05.014. Epub 2010 Jun 11.</reference_text><pubmed_id>20541774</pubmed_id></reference><reference><reference_text>Ghabaee M, Jabedari B, Al-E-Eshagh N, Ghaffarpour M, Asadi F: Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients. Int J Neurosci. 2010 Apr;120(4):301-4. doi: 10.3109/00207451003695690.</reference_text><pubmed_id>20374079</pubmed_id></reference><reference><reference_text>Kawajiri M, Mogi M, Osoegawa M, Matsuoka T, Tsukuda K, Kohara K, Horiuchi M, Miki T, Kira JI: Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler. 2008 May;14(4):557-60. doi: 10.1177/1352458507085760.</reference_text><pubmed_id>18562510</pubmed_id></reference><reference><reference_text>Visconti A, Cotichini R, Cannoni S, Bocca B, Forte G, Ghazaryan A, Santucci S, D'Ippolito C, Stazi MA, Salvetti M, Alimonti A, Ristori G: Concentration of elements in serum of patients affected by multiple sclerosis with first demyelinating episode: a six-month longitudinal follow-up study. Ann Ist Super Sanita. 2005;41(2):217-22.</reference_text><pubmed_id>16244396</pubmed_id></reference></references></disease><disease>Inflammatory bowel disease<references><reference><reference_text>Lee T, Clavel T, Smirnov K, Schmidt A, Lagkouvardos I, Walker A, Lucio M, Michalke B, Schmitt-Kopplin P, Fedorak R, Haller D: Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. 2017 May;66(5):863-871. doi: 10.1136/gutjnl-2015-309940. Epub 2016 Feb 4.</reference_text><pubmed_id>26848182</pubmed_id></reference><reference><reference_text>Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158.</reference_text><pubmed_id>27609529</pubmed_id></reference></references></disease><disease>Colorectal cancer<references><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B: Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009 Apr;22(3):342-8. doi: 10.1002/nbm.1345.</reference_text><pubmed_id>19006102</pubmed_id></reference><reference><reference_text>Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP: Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One. 2013 Aug 6;8(8):e70803. doi: 10.1371/journal.pone.0070803. Print 2013.</reference_text><pubmed_id>23940645</pubmed_id></reference><reference><reference_text>Phua LC, Chue XP, Koh PK, Cheah PY, Ho HK, Chan EC: Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biol Ther. 2014 Apr;15(4):389-97. doi: 10.4161/cbt.27625. Epub 2014 Jan 14.</reference_text><pubmed_id>24424155</pubmed_id></reference><reference><reference_text>Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB: Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010 Feb 15;8:13. doi: 10.1186/1741-7015-8-13.</reference_text><pubmed_id>20156336</pubmed_id></reference><reference><reference_text>Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, Ni Y, Zhao A, Xu LX, Cai S, Jia W: Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res. 2009 Oct;8(10):4844-50. doi: 10.1021/pr9004162.</reference_text><pubmed_id>19678709</pubmed_id></reference><reference><reference_text>Cheng Y, Xie G, Chen T, Qiu Y, Zou X, Zheng M, Tan B, Feng B, Dong T, He P, Zhao L, Zhao A, Xu LX, Zhang Y, Jia W: Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res. 2012 Feb 3;11(2):1354-63. doi: 10.1021/pr201001a. Epub 2011 Dec 28.</reference_text><pubmed_id>22148915</pubmed_id></reference><reference><reference_text>Ni Y, Xie G, Jia W: Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res. 2014 Sep 5;13(9):3857-70. doi: 10.1021/pr500443c. Epub 2014 Aug 14.</reference_text><pubmed_id>25105552</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference><reference><reference_text>Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18.</reference_text><pubmed_id>25037050</pubmed_id></reference><reference><reference_text>Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016.</reference_text><pubmed_id>27015276</pubmed_id></reference><reference><reference_text>Lin Y, Ma C, Liu C, Wang Z, Yang J, Liu X, Shen Z, Wu R: NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer. Oncotarget. 2016 May 17;7(20):29454-64. doi: 10.18632/oncotarget.8762.</reference_text><pubmed_id>27107423</pubmed_id></reference><reference><reference_text>Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016.</reference_text><pubmed_id>27275383</pubmed_id></reference><reference><reference_text>Wang X, Wang J, Rao B, Deng L: Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals. Exp Ther Med. 2017 Jun;13(6):2848-2854. doi: 10.3892/etm.2017.4367. Epub 2017 Apr 20.</reference_text><pubmed_id>28587349</pubmed_id></reference><reference><reference_text>Silke Matysik, Caroline Ivanne Le Roy, Gerhard Liebisch, Sandrine Paule Claus. Metabolomics of fecal samples: A practical consideration. Trends in Food Science &amp; Technology. Vol. 57, Part B, Nov. 2016, p.244-255: http://www.sciencedirect.com/science/article/pii/S0924224416301984</reference_text><pubmed_id>28587349</pubmed_id></reference></references></disease><disease>Gallbladder disease<references><reference><reference_text>Lapidus A, Akerlund JE, Einarsson C: Gallbladder bile composition in patients with Crohn 's disease. World J Gastroenterol. 2006 Jan 7;12(1):70-4.</reference_text><pubmed_id>16440420</pubmed_id></reference><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference><reference><reference_text>Mizuno S, Tazuma S, Kajiyama G: Stabilization of biliary lipid particles by ursodeoxycholic acid. Prolonged nucleation time in human gallbladder bile. Dig Dis Sci. 1993 Apr;38(4):684-93.</reference_text><pubmed_id>8462368</pubmed_id></reference><reference><reference_text>Hillebrant CG, Axelson M, Bjorkhem I, Wang FH, Nyberg B, Einarsson C: Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients. Eur J Clin Invest. 1998 Apr;28(4):324-8.</reference_text><pubmed_id>9615912</pubmed_id></reference></references></disease><disease>Cholelithiasis<references><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference></references></disease><disease>Stomach cancer<references><reference><reference_text>Higashijima H, Ichimiya H, Nakano T, Yamashita H, Kuroki S, Satoh H, Chijiiwa K, Tanaka M: Deconjugation of bilirubin accelerates coprecipitation of cholesterol, fatty acids, and mucin in human bile--in vitro study. J Gastroenterol. 1996 Dec;31(6):828-35.</reference_text><pubmed_id>9027647</pubmed_id></reference><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Song H, Peng JS, Dong-Sheng Y, Yang ZL, Liu HL, Zeng YK, Shi XP, Lu BY: Serum metabolic profiling of human gastric cancer based on gas chromatography/mass spectrometry. Braz J Med Biol Res. 2012 Jan;45(1):78-85. Epub 2011 Nov 25.</reference_text><pubmed_id>22124703</pubmed_id></reference><reference><reference_text>Yu L, Aa J, Xu J, Sun M, Qian S, Cheng L, Yang S, Shi R: Metabolomic phenotype of gastric cancer and precancerous stages based on gas chromatography time-of-flight mass spectrometry. J Gastroenterol Hepatol. 2011 Aug;26(8):1290-7. doi: 10.1111/j.1440-1746.2011.06724.x.</reference_text><pubmed_id>21443661</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference></references></disease><disease>Acute myelogenous leukemia<references><reference><reference_text>Tatidis L, Vitols S, Gruber A, Paul C, Axelson M: Cholesterol catabolism in patients with acute myelogenous leukemia and hypocholesterolemia: suppressed levels of a circulating marker for bile acid synthesis. Cancer Lett. 2001 Sep 20;170(2):169-75.</reference_text><pubmed_id>11463495</pubmed_id></reference></references></disease><disease>Hypercholesterolemia<references><reference><reference_text>Thelen KM, Laaksonen R, Paiva H, Lehtimaki T, Lutjohann D: High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels. J Clin Pharmacol. 2006 Jul;46(7):812-6.</reference_text><pubmed_id>16809807</pubmed_id></reference><reference><reference_text>Tamasawa N, Tamasawa A, Takebe K: Higher levels of plasma cholesterol sulfate in patients with liver cirrhosis and hypercholesterolemia. Lipids. 1993 Sep;28(9):833-6.</reference_text><pubmed_id>8231659</pubmed_id></reference><reference><reference_text>Kim DH, Lee KJ, Heo GS: Analysis of cholesterol and cholesteryl esters in human serum using capillary supercritical fluid chromatography. J Chromatogr B Biomed Appl. 1994 Apr 22;655(1):1-8.</reference_text><pubmed_id>8061816</pubmed_id></reference><reference><reference_text>Authors unspecified: Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med. 1988 Jan;148(1):36-69.</reference_text><pubmed_id>3422148</pubmed_id></reference></references></disease><disease>Cholesteryl ester storage disease<references><reference><reference_text>Rassoul F, Richter V, Lohse P, Naumann A, Purschwitz K, Keller E: Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease. Int J Clin Pharmacol Ther. 2001 May;39(5):199-204.</reference_text><pubmed_id>11380065</pubmed_id></reference><reference><reference_text>Chatrath H, Keilin S, Attar BM: Cholesterol ester storage disease (CESD) diagnosed in an asymptomatic adult. Dig Dis Sci. 2009 Jan;54(1):168-73. doi: 10.1007/s10620-008-0310-2. Epub 2008 May 14.</reference_text><pubmed_id>18478331</pubmed_id></reference><reference><reference_text>Bernstein DL, Hulkova H, Bialer MG, Desnick RJ: Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol. 2013 Jun;58(6):1230-43. doi: 10.1016/j.jhep.2013.02.014. Epub 2013 Feb 26.</reference_text><pubmed_id>23485521</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Cystinosis<references><reference><reference_text>Ueda M, O'Brien K, Rosing DR, Ling A, Kleta R, McAreavey D, Bernardini I, Gahl WA: Coronary artery and other vascular calcifications in patients with cystinosis after kidney transplantation. Clin J Am Soc Nephrol. 2006 May;1(3):555-62. Epub 2006 Feb 8.</reference_text><pubmed_id>17699259</pubmed_id></reference><reference><reference_text>Gahl WA, Bernardini I, Dalakas M, Rizzo WB, Harper GS, Hoeg JM, Hurko O, Bernar J: Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome. J Clin Invest. 1988 Feb;81(2):549-60.</reference_text><pubmed_id>3276734</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Smith-Lemli-Opitz syndrome<references><reference><reference_text>van Rooij A, Nijenhuis AA, Wijburg FA, Schutgens RB: Highly increased CSF concentrations of cholesterol precursors in Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 1997 Aug;20(4):578-80.</reference_text><pubmed_id>9266395</pubmed_id></reference><reference><reference_text>Honda M, Tint GS, Honda A, Salen G, Shefer S, Batta AK, Matsuzaki Y, Tanaka N: Regulation of cholesterol biosynthetic pathway in patients with the Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2000 Jul;23(5):464-74.</reference_text><pubmed_id>10947201</pubmed_id></reference><reference><reference_text>Rossi M, Federico G, Corso G, Parenti G, Battagliese A, Frascogna AR, Della Casa R, Dello Russo A, Strisciuglio P, Saggese G, Andria G: Vitamin D status in patients affected by Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2005;28(1):69-80.</reference_text><pubmed_id>15702407</pubmed_id></reference><reference><reference_text>Johnson DW, ten Brink HJ, Jakobs C: A rapid screening procedure for cholesterol and dehydrocholesterol by electrospray ionization tandem mass spectrometry. J Lipid Res. 2001 Oct;42(10):1699-705.</reference_text><pubmed_id>11590227</pubmed_id></reference></references></disease><disease>Prostate cancer<references><reference><reference_text>Nyman DW, Suzanne Stratton M, Kopplin MJ, Dalkin BL, Nagle RB, Jay Gandolfi A: Selenium and selenomethionine levels in prostate cancer patients. Cancer Detect Prev. 2004;28(1):8-16.</reference_text><pubmed_id>15041072</pubmed_id></reference><reference><reference_text>Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, Egevad L, Tjonneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, Palli D, Vineis P, Tumino R, Berrino F, Kiemeney L, Bueno-de-Mesquita HB, Quiros JR, Gonzalez CA, Martinez C, Larranaga N, Chirlaque MD, Ardanaz E, Stattin P, Hallmans G, Khaw KT, Bingham S, Slimani N, Ferrari P, Rinaldi S, Riboli E: Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr. 2007 Sep;86(3):672-81.</reference_text><pubmed_id>17823432</pubmed_id></reference><reference><reference_text>Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762.</reference_text><pubmed_id>19212411</pubmed_id></reference><reference><reference_text>Puah CM, Williams G, Ghanadian R: Urinary unconjugated 5 alpha-androstane-3 alpha, 17 beta-diol in patients with prostatic tumours. Urol Res. 1982;10(2):81-4.</reference_text><pubmed_id>6180540</pubmed_id></reference><reference><reference_text>Thysell E, Surowiec I, Hornberg E, Crnalic S, Widmark A, Johansson AI, Stattin P, Bergh A, Moritz T, Antti H, Wikstrom P: Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One. 2010 Dec 3;5(12):e14175. doi: 10.1371/journal.pone.0014175.</reference_text><pubmed_id>21151972</pubmed_id></reference><reference><reference_text>Soliman LC, Hui Y, Hewavitharana AK, Chen DD: Monitoring potential prostate cancer biomarkers in urine by capillary electrophoresis-tandem mass spectrometry. J Chromatogr A. 2012 Dec 7;1267:162-9. doi: 10.1016/j.chroma.2012.07.021. Epub 2012 Jul 14.</reference_text><pubmed_id>22824219</pubmed_id></reference><reference><reference_text>Madu CO, Lu Y: Novel diagnostic biomarkers for prostate cancer. J Cancer. 2010 Oct 6;1:150-77.</reference_text><pubmed_id>20975847</pubmed_id></reference></references></disease><disease>Schizophrenia<references><reference><reference_text>Harnryd C, Bjerkenstedt L, Grimm VE, Sedvall G: Reduction of MOPEG levels in cerebrospinal fluid of psychotic women after electroconvulsive treatment. Psychopharmacology (Berl). 1979 Aug 8;64(2):131-4.</reference_text><pubmed_id>115032</pubmed_id></reference><reference><reference_text>Kobayashi K, Koide Y, Yoshino K, Shohmori T: [P-hydroxyphenylacetic acid concentrations in cerebrospinal fluid]. No To Shinkei. 1982 Aug;34(8):769-74.</reference_text><pubmed_id>7126379</pubmed_id></reference><reference><reference_text>Alfredsson G, Wiesel FA: Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology (Berl). 1989;99(3):322-7.</reference_text><pubmed_id>2480613</pubmed_id></reference><reference><reference_text>Heresco-Levy U, Bar G, Levin R, Ermilov M, Ebstein RP, Javitt DC: High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. Schizophr Res. 2007 Mar;91(1-3):14-21. Epub 2007 Feb 2.</reference_text><pubmed_id>17276036</pubmed_id></reference><reference><reference_text>Walker EF, Bonsall R, Walder DJ: Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis. Neuropsychiatry Neuropsychol Behav Neurol. 2002 Mar;15(1):10-7.</reference_text><pubmed_id>11877547</pubmed_id></reference><reference><reference_text>Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M: Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry. 2003 Jun;60(6):572-6.</reference_text><pubmed_id>12796220</pubmed_id></reference><reference><reference_text>Do KQ, Lauer CJ, Schreiber W, Zollinger M, Gutteck-Amsler U, Cuenod M, Holsboer F: gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem. 1995 Dec;65(6):2652-62.</reference_text><pubmed_id>7595563</pubmed_id></reference><reference><reference_text>Nikisch G, Baumann P, Wiedemann G, Kiessling B, Weisser H, Hertel A, Yoshitake T, Kehr J, Mathe AA: Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF. J Clin Psychopharmacol. 2010 Oct;30(5):496-503. doi: 10.1097/JCP.0b013e3181f2288e.</reference_text><pubmed_id>20814316</pubmed_id></reference><reference><reference_text>Fukushima T, Iizuka H, Yokota A, Suzuki T, Ohno C, Kono Y, Nishikiori M, Seki A, Ichiba H, Watanabe Y, Hongo S, Utsunomiya M, Nakatani M, Sadamoto K, Yoshio T: Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One. 2014 Jul 8;9(7):e101652. doi: 10.1371/journal.pone.0101652. eCollection 2014.</reference_text><pubmed_id>25004141</pubmed_id></reference><reference><reference_text>Koike S, Bundo M, Iwamoto K, Suga M, Kuwabara H, Ohashi Y, Shinoda K, Takano Y, Iwashiro N, Satomura Y, Nagai T, Natsubori T, Tada M, Yamasue H, Kasai K: A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study. Transl Psychiatry. 2014 Apr 8;4:e379. doi: 10.1038/tp.2014.19.</reference_text><pubmed_id>24713860</pubmed_id></reference><reference><reference_text>Ballesteros A, Summerfelt A, Du X, Jiang P, Chiappelli J, Tagamets M, O'Donnell P, Kochunov P, Hong LE: Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia. Clin Neurophysiol. 2013 Nov;124(11):2209-15. doi: 10.1016/j.clinph.2013.05.021. Epub 2013 Jun 30.</reference_text><pubmed_id>23823132</pubmed_id></reference><reference><reference_text>Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel FA: Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry. 1985 Sep;147:276-82.</reference_text><pubmed_id>2415198</pubmed_id></reference><reference><reference_text>Pickar D, Breier A, Hsiao JK, Doran AR, Wolkowitz OM, Pato CN, Konicki PE, Potter WZ: Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Arch Gen Psychiatry. 1990 Jul;47(7):641-8.</reference_text><pubmed_id>1694425</pubmed_id></reference><reference><reference_text>Prell GD, Green JP, Kaufmann CA, Khandelwal JK, Morrishow AM, Kirch DG, Linnoila M, Wyatt RJ: Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res. 1995 Jan;14(2):93-104.</reference_text><pubmed_id>7711000</pubmed_id></reference><reference><reference_text>Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B: Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology. 2009;59(2):123-9. doi: 10.1159/000213565. Epub 2009 Apr 22.</reference_text><pubmed_id>19390223</pubmed_id></reference><reference><reference_text>Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K, Cao Y, Wang X, Qiu Y, Su M, Zhao A, Wang P, Yang P, Wu J, Feng G, He L, Jia W, Wan C: Potential metabolite markers of schizophrenia. Mol Psychiatry. 2013 Jan;18(1):67-78. doi: 10.1038/mp.2011.131. Epub 2011 Oct 25.</reference_text><pubmed_id>22024767</pubmed_id></reference><reference><reference_text>Xuan J, Pan G, Qiu Y, Yang L, Su M, Liu Y, Chen J, Feng G, Fang Y, Jia W, Xing Q, He L: Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. J Proteome Res. 2011 Dec 2;10(12):5433-43. doi: 10.1021/pr2006796. Epub 2011 Nov  8.</reference_text><pubmed_id>22007635</pubmed_id></reference><reference><reference_text>Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM, Rothermundt M, Bogerts B, Koethe D, Kranaster L, Ohrmann P, Suslow T, McAllister G, Spain M, Barnes A, van Beveren NJ, Baron-Cohen S, Steiner J, Torrey FE, Yolken RH, Bahn S: Identification of a biological signature for schizophrenia in serum. Mol Psychiatry. 2012 May;17(5):494-502. doi: 10.1038/mp.2011.42. Epub 2011 Apr 12.</reference_text><pubmed_id>21483431</pubmed_id></reference><reference><reference_text>Mathe AA, Eberhard G, Saaf J, Wetterberg L: Plasma prostaglandin E2 metabolite--measured as 11-deoxy-15-keto-13,14-dihydro-11 beta,16 xi-cyclo-PGE2--in twins with schizophrenic disorder. Biol Psychiatry. 1986 Sep;21(11):1024-30.</reference_text><pubmed_id>3741918</pubmed_id></reference><reference><reference_text>Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N: Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct. 2002 Jun;20(2):171-5.</reference_text><pubmed_id>11979513</pubmed_id></reference><reference><reference_text>Zumarraga M, Davila R, Basterreche N, Arrue A, Goienetxea B, Zamalloa MI, Erkoreka L, Bustamante S, Inchausti L, Gonzalez-Torres MA, Guimon J: Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients. Neurochem Int. 2010 May-Jun;56(6-7):774-9. doi: 10.1016/j.neuint.2010.02.015. Epub 2010 Mar 4.</reference_text><pubmed_id>20206656</pubmed_id></reference><reference><reference_text>Peters JG: Dopamine, noradrenaline and serotonin spinal fluid metabolites in temporal lobe epileptic patients with schizophrenic symptomatology. Eur Neurol. 1979;18(1):15-8.</reference_text><pubmed_id>436860</pubmed_id></reference><reference><reference_text>Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, Rozen S, Krishnan RR, McEvoy J, Kaddurah-Daouk R: Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry. 2010 Sep;15(9):938-53. doi: 10.1038/mp.2009.33. Epub 2009 Apr 28.</reference_text><pubmed_id>19401681</pubmed_id></reference><reference><reference_text>Gattaz WF, Waldmeier P, Beckmann H: CSF monoamine metabolites in schizophrenic patients. Acta Psychiatr Scand. 1982 Nov;66(5):350-60.</reference_text><pubmed_id>6184954</pubmed_id></reference><reference><reference_text>Nilsson-Todd LK, Nordin C, Jonsson EG, Skogh E, Erhardt S: Cerebrospinal fluid kynurenic acid in male patients with schizophrenia - correlation with monoamine metabolites. Acta Neuropsychiatr. 2007 Feb;19(1):45-52. doi: 10.1111/j.1601-5215.2006.00170.x.</reference_text><pubmed_id>26952797</pubmed_id></reference><reference><reference_text>Cai HL, Li HD, Yan XZ, Sun B, Zhang Q, Yan M, Zhang WY, Jiang P, Zhu RH, Liu YP, Fang PF, Xu P, Yuan HY, Zhang XH, Hu L, Yang W, Ye HS: Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naive schizophrenia patients after treatment with risperidone. J Proteome Res. 2012 Aug 3;11(8):4338-50. doi: 10.1021/pr300459d. Epub 2012 Jul 26.</reference_text><pubmed_id>22800120</pubmed_id></reference><reference><reference_text>Al Awam K, Haussleiter IS, Dudley E, Donev R, Brune M, Juckel G, Thome J: Multiplatform metabolome and proteome profiling identifies serum metabolite and protein signatures as prospective biomarkers for schizophrenia. J Neural Transm (Vienna). 2015 Aug;122 Suppl 1:S111-22. doi: 10.1007/s00702-014-1224-0. Epub 2014 May 1.</reference_text><pubmed_id>24789758</pubmed_id></reference><reference><reference_text>Bicikova M, Hill M, Ripova D, Mohr P, Hampl R: Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia. J Steroid Biochem Mol Biol. 2013 Jan;133:77-83. doi: 10.1016/j.jsbmb.2012.08.009. Epub 2012 Aug 24.</reference_text><pubmed_id>22944140</pubmed_id></reference><reference><reference_text>He Y, Yu Z, Giegling I, Xie L, Hartmann AM, Prehn C, Adamski J, Kahn R, Li Y, Illig T, Wang-Sattler R, Rujescu D: Schizophrenia shows a unique metabolomics signature in plasma. Transl Psychiatry. 2012 Aug 14;2:e149. doi: 10.1038/tp.2012.76.</reference_text><pubmed_id>22892715</pubmed_id></reference><reference><reference_text>Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KR: Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):934-45. Epub 2007 Apr 17.</reference_text><pubmed_id>17440431</pubmed_id></reference><reference><reference_text>Fryar-Williams S, Strobel JE: Biomarkers of a five-domain translational substrate for schizophrenia and schizoaffective psychosis. Biomark Res. 2015 Feb 6;3:3. doi: 10.1186/s40364-015-0028-1. eCollection 2015.</reference_text><pubmed_id>25729574</pubmed_id></reference><reference><reference_text>Oresic M, Seppanen-Laakso T, Sun D, Tang J, Therman S, Viehman R, Mustonen U, van Erp TG, Hyotylainen T, Thompson P, Toga AW, Huttunen MO, Suvisaari J, Kaprio J, Lonnqvist J, Cannon TD: Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia. Genome Med. 2012 Jan 18;4(1):1. doi: 10.1186/gm300.</reference_text><pubmed_id>22257447</pubmed_id></reference></references></disease><disease>Primary hypomagnesemia<references><reference><reference_text>Jin-no Y, Kamiya Y, Okada M, Hirako M, Takada N, Kawaguchi M: Primary hypomagnesemia caused by isolated magnesium malabsorption: atypical case in adult. Intern Med. 1999 Mar;38(3):261-5.</reference_text><pubmed_id>10337938</pubmed_id></reference><reference><reference_text>Vainsel M, Vandevelde G, Smulders J, Vosters M, Hubain P, Loeb H: Tetany due to hypomagnesaemia with secondary hypocalcaemia. Arch Dis Child. 1970 Apr;45(240):254-8.</reference_text><pubmed_id>5419995</pubmed_id></reference><reference><reference_text>Shalev H, Phillip M, Galil A, Carmi R, Landau D: Clinical presentation and outcome in primary familial hypomagnesaemia. Arch Dis Child. 1998 Feb;78(2):127-30.</reference_text><pubmed_id>9579153</pubmed_id></reference><reference><reference_text>Kari JA, Farouq M, Alshaya HO: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Pediatr Nephrol. 2003 Jun;18(6):506-10. Epub 2003 Apr 29.</reference_text><pubmed_id>12720080</pubmed_id></reference></references></disease><disease>Hyperlipoproteinemia<references><reference><reference_text>Sinha S, Misra A, Kumar V, Jagannathan NR, Bal CS, Pandey RM, Singhania R, Deepak: Proton magnetic resonance spectroscopy and single photon emission computed tomography study of the brain in asymptomatic young hyperlipidaemic Asian Indians in North India show early abnormalities. Clin Endocrinol (Oxf). 2004 Aug;61(2):182-9.</reference_text><pubmed_id>15272912</pubmed_id></reference><reference><reference_text>Nelson RH: Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013 Mar</reference_text><pubmed_id>40(1):195-211. doi: 10.1016/j.pop.2012.11.003. Epub 2012 Dec  4.</pubmed_id></reference><reference><reference_text>Cantin B, Boudriau S, Bertrand M, Brun LD, Gagne C, Rogers PA, Ven Murthy MR, Lupien PJ, Julien P: Hemolysis in primary lipoprotein lipase deficiency. Metabolism. 1995 May;44(5):652-8.</reference_text><pubmed_id>7752915</pubmed_id></reference></references></disease><disease>Abetalipoproteinemia<references><reference><reference_text>Dawson G, Kruski AW, Scanu AM: Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J Lipid Res. 1976 Mar;17(2):125-31.</reference_text><pubmed_id>178813</pubmed_id></reference><reference><reference_text>Lazaro RP, Dentinger MP, Rodichok LD, Barron KD, Satya-Murti S: Muscle pathology in Bassen-Kornzweig syndrome and vitamin E deficiency. Am J Clin Pathol. 1986 Sep;86(3):378-87.</reference_text><pubmed_id>2944375</pubmed_id></reference></references></disease><disease>Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis<references><reference><reference_text>Breckenridge WC, Alaupovic P, Cox DW, Little JA: Apolipoprotein and lipoprotein concentrations in familial apolipoprotein C-II deficiency. Atherosclerosis. 1982 Aug;44(2):223-35.</reference_text><pubmed_id>7138621</pubmed_id></reference><reference><reference_text>Fukami M, Hasegawa T, Horikawa R, Ohashi T, Nishimura G, Homma K, Ogata T: Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr Res. 2006 Feb;59(2):276-80. doi: 10.1203/01.pdr.0000195825.31504.28.</reference_text><pubmed_id>16439592</pubmed_id></reference></references></disease><disease>Cerebrotendinous xanthomatosis<references><reference><reference_text>Halperin G, Elisaf M, Leitersdorf E, Harats D: A new method for determination of serum cholestanol by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2000 Jun 9;742(2):345-52.</reference_text><pubmed_id>10901139</pubmed_id></reference><reference><reference_text>Siman-Tov T, Meiner V, Gadoth N: Could steroids mask the diagnosis of cerebrotendinous xanthomatosis? J Neurol Sci. 2006 Apr 15;243(1-2):83-6. Epub 2006 Jan 30.</reference_text><pubmed_id>16445943</pubmed_id></reference><reference><reference_text>Agrawal NK, Garg S: Cerebrotendinous xanthomatosis: a rare disorder with a rare presentation. BMJ Case Rep. 2012 Sep 21;2012. pii: bcr-2012-006202. doi: 10.1136/bcr-2012-006202.</reference_text><pubmed_id>23001091</pubmed_id></reference></references></disease><disease>3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency<references><reference><reference_text>Thompson GN, Hsu BY, Pitt JJ, Treacy E, Stanley CA: Fasting hypoketotic coma in a child with deficiency of mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase. N Engl J Med. 1997 Oct 23;337(17):1203-7. doi: 10.1056/NEJM199710233371704.</reference_text><pubmed_id>9337379</pubmed_id></reference><reference><reference_text>Morris AA, Lascelles CV, Olpin SE, Lake BD, Leonard JV, Quant PA: Hepatic mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme a synthase deficiency. Pediatr Res. 1998 Sep;44(3):392-6. doi: 10.1203/00006450-199809000-00021.</reference_text><pubmed_id>9727719</pubmed_id></reference><reference><reference_text>Conboy E, Vairo F, Schultz M, Agre K, Ridsdale R, Deyle D, Oglesbee D, Gavrilov D, Klee EW, Lanpher B: Mitochondrial 3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency: Unique Presenting Laboratory Values and a Review of Biochemical and Clinical Features. JIMD Rep. 2017 Oct 14. doi: 10.1007/8904_2017_59.</reference_text><pubmed_id>29030856</pubmed_id></reference></references></disease><disease>Hypercholesterolemia, familial<references><reference><reference_text>Kwiterovich PO Jr, Fredrickson DS, Levy RI: Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest. 1974 May;53(5):1237-49. doi: 10.1172/JCI107670.</reference_text><pubmed_id>4363406</pubmed_id></reference></references></disease><disease>SC4MOL deficiency<references><reference><reference_text>He M, Kratz LE, Michel JJ, Vallejo AN, Ferris L, Kelley RI, Hoover JJ, Jukic D, Gibson KM, Wolfe LA, Ramachandran D, Zwick ME, Vockley J: Mutations in the human SC4MOL gene encoding a methyl sterol oxidase cause psoriasiform dermatitis, microcephaly, and developmental delay. J Clin Invest. 2011 Mar;121(3):976-84. doi: 10.1172/JCI42650.</reference_text><pubmed_id>21285510</pubmed_id></reference></references></disease><disease>Chondrodysplasia punctata, X-linked dominant<references><reference><reference_text>Aughton DJ, Kelley RI, Metzenberg A, Pureza V, Pauli RM: X-linked dominant chondrodysplasia punctata (CDPX2) caused by single gene mosaicism in a male. Am J Med Genet A. 2003 Jan 30;116A(3):255-60. doi: 10.1002/ajmg.a.10852.</reference_text><pubmed_id>12503102</pubmed_id></reference></references></disease><disease>Desmosterolosis<references><reference><reference_text>Andersson HC, Kratz L, Kelley R: Desmosterolosis presenting with multiple congenital anomalies and profound developmental delay. Am J Med Genet. 2002 Dec 15;113(4):315-9. doi: 10.1002/ajmg.b.10873.</reference_text><pubmed_id>12457401</pubmed_id></reference></references></disease><disease>Donohue Syndrome<references><reference><reference_text>Nijim Y, Awni Y, Adawi A, Bowirrat A: Classic Case Report of Donohue Syndrome (Leprechaunism; OMIM *246200): The Impact of Consanguineous Mating. Medicine (Baltimore). 2016 Feb;95(6):e2710. doi: 10.1097/MD.0000000000002710.</reference_text><pubmed_id>26871809</pubmed_id></reference></references></disease><disease>Leptin Deficiency or Dysfunction<references><reference><reference_text>Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O'Rahilly S: Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999 Sep 16;341(12):879-84. doi: 10.1056/NEJM199909163411204.</reference_text><pubmed_id>10486419</pubmed_id></reference></references></disease><disease>Duchenne Muscular Dystrophy<references><reference><reference_text>Nakagawa T, Takeuchi A, Kakiuchi R, Lee T, Yagi M, Awano H, Iijima K, Takeshima Y, Urade Y, Matsuo M: A prostaglandin D2 metabolite is elevated in the urine of Duchenne muscular dystrophy patients and increases further from 8 years old. Clin Chim Acta. 2013 Aug 23;423:10-4. doi: 10.1016/j.cca.2013.03.031. Epub 2013 Apr 19.</reference_text><pubmed_id>23603101</pubmed_id></reference><reference><reference_text>Srivastava NK, Pradhan S, Mittal B, Gowda GA: High resolution NMR based analysis of serum lipids in Duchenne muscular dystrophy patients and its possible diagnostic significance. NMR Biomed. 2010 Jan;23(1):13-22. doi: 10.1002/nbm.1419.</reference_text><pubmed_id>19787747</pubmed_id></reference><reference><reference_text>Horster I, Weigt-Usinger K, Carmann C, Chobanyan-Jurgens K, Kohler C, Schara U, Kayacelebi AA, Beckmann B, Tsikas D, Lucke T: The L-arginine/NO pathway and homoarginine are altered in Duchenne muscular dystrophy and improved by glucocorticoids. Amino Acids. 2015 Sep;47(9):1853-63. doi: 10.1007/s00726-015-2018-x. Epub 2015 Jun 12.</reference_text><pubmed_id>26066683</pubmed_id></reference></references></disease><disease>Lecithin:cholesterol Acyltransferase Deficiency<references><reference><reference_text>Idzior-Walus B, Sieradzki J, Kostner G, Malecki MT, Klupa T, Wesolowska T, Rostworowski W, Hartwich J, Walus M, Kiec AD, Naruszewicz M: Familial lecithin-cholesterol acyltransferase deficiency: biochemical characteristics and molecular analysis of a new LCAT mutation in a Polish family. Atherosclerosis. 2006 Apr;185(2):413-20. Epub 2005 Jul 26.</reference_text><pubmed_id>16051254</pubmed_id></reference></references></disease><disease>Lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lipodystrophy, Congenital Generalized<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Oculocerebrorenal syndrome<references><reference><reference_text>Charnas LR, Bernardini I, Rader D, Hoeg JM, Gahl WA: Clinical and laboratory findings in the oculocerebrorenal syndrome of Lowe, with special reference to growth and renal function. N Engl J Med. 1991 May 9;324(19):1318-25. doi: 10.1056/NEJM199105093241904.</reference_text><pubmed_id>2017228</pubmed_id></reference></references></disease><disease>Familial partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lathosterolosis<references><reference><reference_text>Brunetti-Pierri N, Corso G, Rossi M, Ferrari P, Balli F, Rivasi F, Annunziata I, Ballabio A, Russo AD, Andria G, Parenti G: Lathosterolosis, a novel multiple-malformation/mental retardation syndrome due to deficiency of 3beta-hydroxysteroid-delta5-desaturase. Am J Hum Genet. 2002 Oct;71(4):952-8. Epub 2002 Aug 20.</reference_text><pubmed_id>12189593</pubmed_id></reference><reference><reference_text>Ho AC, Fung CW, Siu TS, Ma OC, Lam CW, Tam S, Wong VC: Lathosterolosis: a disorder of cholesterol biosynthesis resembling smith-lemli-opitz syndrome. JIMD Rep. 2014;12:129-34. doi: 10.1007/8904_2013_255. Epub 2013 Oct 20.</reference_text><pubmed_id>24142275</pubmed_id></reference></references></disease><disease>Partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Multiple sclerosis<references><reference><reference_text>Lutz NW, Viola A, Malikova I, Confort-Gouny S, Audoin B, Ranjeva JP, Pelletier J, Cozzone PJ: Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One. 2007 Jul 4;2(7):e595.</reference_text><pubmed_id>17611627</pubmed_id></reference><reference><reference_text>Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U, Hillert J, Bjorkhem I: Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med. 2004 Feb;42(2):186-91.</reference_text><pubmed_id>15061359</pubmed_id></reference><reference><reference_text>Leoni V, Lutjohann D, Masterman T: Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis. J Lipid Res. 2005 Feb;46(2):191-5. Epub 2004 Dec 1.</reference_text><pubmed_id>15576852</pubmed_id></reference><reference><reference_text>Calabrese V, Scapagnini G, Ravagna A, Bella R, Butterfield DA, Calvani M, Pennisi G, Giuffrida Stella AM: Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem Res. 2003 Sep;28(9):1321-8.</reference_text><pubmed_id>12938853</pubmed_id></reference><reference><reference_text>Shaw CE, Dunbar PR, Macaulay HA, Neale TJ: Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol. 1995 Jan;242(2):53-8.</reference_text><pubmed_id>7707089</pubmed_id></reference><reference><reference_text>Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.</reference_text><pubmed_id>17384003</pubmed_id></reference><reference><reference_text>Syburra C, Passi S: Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh (1999). 1999 May-Jun;71(3):112-5.</reference_text><pubmed_id>10609336</pubmed_id></reference><reference><reference_text>Forte G, Visconti A, Santucci S, Ghazaryan A, Figa-Talamanca L, Cannoni S, Bocca B, Pino A, Violante N, Alimonti A, Salvetti M, Ristori G: Quantification of chemical elements in blood of patients affected by multiple sclerosis. Ann Ist Super Sanita. 2005;41(2):213-6.</reference_text><pubmed_id>16244395</pubmed_id></reference><reference><reference_text>Toncev G, Milicic B, Toncev S, Samardzic G: Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol. 2002 May;9(3):221-6.</reference_text><pubmed_id>11985629</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, Bamonti F, Capello E, Mancardi GL, Scarpini E: Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res. 2010 May 28;1333:64-71. doi: 10.1016/j.brainres.2010.03.073. Epub 2010 Mar 27.</reference_text><pubmed_id>20347721</pubmed_id></reference><reference><reference_text>Matsushita T, Isobe N, Kawajiri M, Mogi M, Tsukuda K, Horiuchi M, Ohyagi Y, Kira J: CSF angiotensin II and angiotensin-converting enzyme levels in anti-aquaporin-4 autoimmunity. J Neurol Sci. 2010 Aug 15;295(1-2):41-5. doi: 10.1016/j.jns.2010.05.014. Epub 2010 Jun 11.</reference_text><pubmed_id>20541774</pubmed_id></reference><reference><reference_text>Ghabaee M, Jabedari B, Al-E-Eshagh N, Ghaffarpour M, Asadi F: Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients. Int J Neurosci. 2010 Apr;120(4):301-4. doi: 10.3109/00207451003695690.</reference_text><pubmed_id>20374079</pubmed_id></reference><reference><reference_text>Kawajiri M, Mogi M, Osoegawa M, Matsuoka T, Tsukuda K, Kohara K, Horiuchi M, Miki T, Kira JI: Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler. 2008 May;14(4):557-60. doi: 10.1177/1352458507085760.</reference_text><pubmed_id>18562510</pubmed_id></reference><reference><reference_text>Visconti A, Cotichini R, Cannoni S, Bocca B, Forte G, Ghazaryan A, Santucci S, D'Ippolito C, Stazi MA, Salvetti M, Alimonti A, Ristori G: Concentration of elements in serum of patients affected by multiple sclerosis with first demyelinating episode: a six-month longitudinal follow-up study. Ann Ist Super Sanita. 2005;41(2):217-22.</reference_text><pubmed_id>16244396</pubmed_id></reference></references></disease><disease>Inflammatory bowel disease<references><reference><reference_text>Lee T, Clavel T, Smirnov K, Schmidt A, Lagkouvardos I, Walker A, Lucio M, Michalke B, Schmitt-Kopplin P, Fedorak R, Haller D: Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. 2017 May;66(5):863-871. doi: 10.1136/gutjnl-2015-309940. Epub 2016 Feb 4.</reference_text><pubmed_id>26848182</pubmed_id></reference><reference><reference_text>Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158.</reference_text><pubmed_id>27609529</pubmed_id></reference></references></disease><disease>Colorectal cancer<references><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B: Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009 Apr;22(3):342-8. doi: 10.1002/nbm.1345.</reference_text><pubmed_id>19006102</pubmed_id></reference><reference><reference_text>Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP: Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One. 2013 Aug 6;8(8):e70803. doi: 10.1371/journal.pone.0070803. Print 2013.</reference_text><pubmed_id>23940645</pubmed_id></reference><reference><reference_text>Phua LC, Chue XP, Koh PK, Cheah PY, Ho HK, Chan EC: Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biol Ther. 2014 Apr;15(4):389-97. doi: 10.4161/cbt.27625. Epub 2014 Jan 14.</reference_text><pubmed_id>24424155</pubmed_id></reference><reference><reference_text>Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB: Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010 Feb 15;8:13. doi: 10.1186/1741-7015-8-13.</reference_text><pubmed_id>20156336</pubmed_id></reference><reference><reference_text>Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, Ni Y, Zhao A, Xu LX, Cai S, Jia W: Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res. 2009 Oct;8(10):4844-50. doi: 10.1021/pr9004162.</reference_text><pubmed_id>19678709</pubmed_id></reference><reference><reference_text>Cheng Y, Xie G, Chen T, Qiu Y, Zou X, Zheng M, Tan B, Feng B, Dong T, He P, Zhao L, Zhao A, Xu LX, Zhang Y, Jia W: Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res. 2012 Feb 3;11(2):1354-63. doi: 10.1021/pr201001a. Epub 2011 Dec 28.</reference_text><pubmed_id>22148915</pubmed_id></reference><reference><reference_text>Ni Y, Xie G, Jia W: Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res. 2014 Sep 5;13(9):3857-70. doi: 10.1021/pr500443c. Epub 2014 Aug 14.</reference_text><pubmed_id>25105552</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference><reference><reference_text>Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18.</reference_text><pubmed_id>25037050</pubmed_id></reference><reference><reference_text>Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016.</reference_text><pubmed_id>27015276</pubmed_id></reference><reference><reference_text>Lin Y, Ma C, Liu C, Wang Z, Yang J, Liu X, Shen Z, Wu R: NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer. Oncotarget. 2016 May 17;7(20):29454-64. doi: 10.18632/oncotarget.8762.</reference_text><pubmed_id>27107423</pubmed_id></reference><reference><reference_text>Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016.</reference_text><pubmed_id>27275383</pubmed_id></reference><reference><reference_text>Wang X, Wang J, Rao B, Deng L: Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals. Exp Ther Med. 2017 Jun;13(6):2848-2854. doi: 10.3892/etm.2017.4367. Epub 2017 Apr 20.</reference_text><pubmed_id>28587349</pubmed_id></reference><reference><reference_text>Silke Matysik, Caroline Ivanne Le Roy, Gerhard Liebisch, Sandrine Paule Claus. Metabolomics of fecal samples: A practical consideration. Trends in Food Science &amp; Technology. Vol. 57, Part B, Nov. 2016, p.244-255: http://www.sciencedirect.com/science/article/pii/S0924224416301984</reference_text><pubmed_id>28587349</pubmed_id></reference></references></disease><disease>Gallbladder disease<references><reference><reference_text>Lapidus A, Akerlund JE, Einarsson C: Gallbladder bile composition in patients with Crohn 's disease. World J Gastroenterol. 2006 Jan 7;12(1):70-4.</reference_text><pubmed_id>16440420</pubmed_id></reference><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference><reference><reference_text>Mizuno S, Tazuma S, Kajiyama G: Stabilization of biliary lipid particles by ursodeoxycholic acid. Prolonged nucleation time in human gallbladder bile. Dig Dis Sci. 1993 Apr;38(4):684-93.</reference_text><pubmed_id>8462368</pubmed_id></reference><reference><reference_text>Hillebrant CG, Axelson M, Bjorkhem I, Wang FH, Nyberg B, Einarsson C: Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients. Eur J Clin Invest. 1998 Apr;28(4):324-8.</reference_text><pubmed_id>9615912</pubmed_id></reference></references></disease><disease>Cholelithiasis<references><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference></references></disease><disease>Stomach cancer<references><reference><reference_text>Higashijima H, Ichimiya H, Nakano T, Yamashita H, Kuroki S, Satoh H, Chijiiwa K, Tanaka M: Deconjugation of bilirubin accelerates coprecipitation of cholesterol, fatty acids, and mucin in human bile--in vitro study. J Gastroenterol. 1996 Dec;31(6):828-35.</reference_text><pubmed_id>9027647</pubmed_id></reference><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Song H, Peng JS, Dong-Sheng Y, Yang ZL, Liu HL, Zeng YK, Shi XP, Lu BY: Serum metabolic profiling of human gastric cancer based on gas chromatography/mass spectrometry. Braz J Med Biol Res. 2012 Jan;45(1):78-85. Epub 2011 Nov 25.</reference_text><pubmed_id>22124703</pubmed_id></reference><reference><reference_text>Yu L, Aa J, Xu J, Sun M, Qian S, Cheng L, Yang S, Shi R: Metabolomic phenotype of gastric cancer and precancerous stages based on gas chromatography time-of-flight mass spectrometry. J Gastroenterol Hepatol. 2011 Aug;26(8):1290-7. doi: 10.1111/j.1440-1746.2011.06724.x.</reference_text><pubmed_id>21443661</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference></references></disease><disease>Acute myelogenous leukemia<references><reference><reference_text>Tatidis L, Vitols S, Gruber A, Paul C, Axelson M: Cholesterol catabolism in patients with acute myelogenous leukemia and hypocholesterolemia: suppressed levels of a circulating marker for bile acid synthesis. Cancer Lett. 2001 Sep 20;170(2):169-75.</reference_text><pubmed_id>11463495</pubmed_id></reference></references></disease><disease>Hypercholesterolemia<references><reference><reference_text>Thelen KM, Laaksonen R, Paiva H, Lehtimaki T, Lutjohann D: High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels. J Clin Pharmacol. 2006 Jul;46(7):812-6.</reference_text><pubmed_id>16809807</pubmed_id></reference><reference><reference_text>Tamasawa N, Tamasawa A, Takebe K: Higher levels of plasma cholesterol sulfate in patients with liver cirrhosis and hypercholesterolemia. Lipids. 1993 Sep;28(9):833-6.</reference_text><pubmed_id>8231659</pubmed_id></reference><reference><reference_text>Kim DH, Lee KJ, Heo GS: Analysis of cholesterol and cholesteryl esters in human serum using capillary supercritical fluid chromatography. J Chromatogr B Biomed Appl. 1994 Apr 22;655(1):1-8.</reference_text><pubmed_id>8061816</pubmed_id></reference><reference><reference_text>Authors unspecified: Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med. 1988 Jan;148(1):36-69.</reference_text><pubmed_id>3422148</pubmed_id></reference></references></disease><disease>Cholesteryl ester storage disease<references><reference><reference_text>Rassoul F, Richter V, Lohse P, Naumann A, Purschwitz K, Keller E: Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease. Int J Clin Pharmacol Ther. 2001 May;39(5):199-204.</reference_text><pubmed_id>11380065</pubmed_id></reference><reference><reference_text>Chatrath H, Keilin S, Attar BM: Cholesterol ester storage disease (CESD) diagnosed in an asymptomatic adult. Dig Dis Sci. 2009 Jan;54(1):168-73. doi: 10.1007/s10620-008-0310-2. Epub 2008 May 14.</reference_text><pubmed_id>18478331</pubmed_id></reference><reference><reference_text>Bernstein DL, Hulkova H, Bialer MG, Desnick RJ: Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol. 2013 Jun;58(6):1230-43. doi: 10.1016/j.jhep.2013.02.014. Epub 2013 Feb 26.</reference_text><pubmed_id>23485521</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Cystinosis<references><reference><reference_text>Ueda M, O'Brien K, Rosing DR, Ling A, Kleta R, McAreavey D, Bernardini I, Gahl WA: Coronary artery and other vascular calcifications in patients with cystinosis after kidney transplantation. Clin J Am Soc Nephrol. 2006 May;1(3):555-62. Epub 2006 Feb 8.</reference_text><pubmed_id>17699259</pubmed_id></reference><reference><reference_text>Gahl WA, Bernardini I, Dalakas M, Rizzo WB, Harper GS, Hoeg JM, Hurko O, Bernar J: Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome. J Clin Invest. 1988 Feb;81(2):549-60.</reference_text><pubmed_id>3276734</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Smith-Lemli-Opitz syndrome<references><reference><reference_text>van Rooij A, Nijenhuis AA, Wijburg FA, Schutgens RB: Highly increased CSF concentrations of cholesterol precursors in Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 1997 Aug;20(4):578-80.</reference_text><pubmed_id>9266395</pubmed_id></reference><reference><reference_text>Honda M, Tint GS, Honda A, Salen G, Shefer S, Batta AK, Matsuzaki Y, Tanaka N: Regulation of cholesterol biosynthetic pathway in patients with the Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2000 Jul;23(5):464-74.</reference_text><pubmed_id>10947201</pubmed_id></reference><reference><reference_text>Rossi M, Federico G, Corso G, Parenti G, Battagliese A, Frascogna AR, Della Casa R, Dello Russo A, Strisciuglio P, Saggese G, Andria G: Vitamin D status in patients affected by Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2005;28(1):69-80.</reference_text><pubmed_id>15702407</pubmed_id></reference><reference><reference_text>Johnson DW, ten Brink HJ, Jakobs C: A rapid screening procedure for cholesterol and dehydrocholesterol by electrospray ionization tandem mass spectrometry. J Lipid Res. 2001 Oct;42(10):1699-705.</reference_text><pubmed_id>11590227</pubmed_id></reference></references></disease><disease>Prostate cancer<references><reference><reference_text>Nyman DW, Suzanne Stratton M, Kopplin MJ, Dalkin BL, Nagle RB, Jay Gandolfi A: Selenium and selenomethionine levels in prostate cancer patients. Cancer Detect Prev. 2004;28(1):8-16.</reference_text><pubmed_id>15041072</pubmed_id></reference><reference><reference_text>Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, Egevad L, Tjonneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, Palli D, Vineis P, Tumino R, Berrino F, Kiemeney L, Bueno-de-Mesquita HB, Quiros JR, Gonzalez CA, Martinez C, Larranaga N, Chirlaque MD, Ardanaz E, Stattin P, Hallmans G, Khaw KT, Bingham S, Slimani N, Ferrari P, Rinaldi S, Riboli E: Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr. 2007 Sep;86(3):672-81.</reference_text><pubmed_id>17823432</pubmed_id></reference><reference><reference_text>Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762.</reference_text><pubmed_id>19212411</pubmed_id></reference><reference><reference_text>Puah CM, Williams G, Ghanadian R: Urinary unconjugated 5 alpha-androstane-3 alpha, 17 beta-diol in patients with prostatic tumours. Urol Res. 1982;10(2):81-4.</reference_text><pubmed_id>6180540</pubmed_id></reference><reference><reference_text>Thysell E, Surowiec I, Hornberg E, Crnalic S, Widmark A, Johansson AI, Stattin P, Bergh A, Moritz T, Antti H, Wikstrom P: Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One. 2010 Dec 3;5(12):e14175. doi: 10.1371/journal.pone.0014175.</reference_text><pubmed_id>21151972</pubmed_id></reference><reference><reference_text>Soliman LC, Hui Y, Hewavitharana AK, Chen DD: Monitoring potential prostate cancer biomarkers in urine by capillary electrophoresis-tandem mass spectrometry. J Chromatogr A. 2012 Dec 7;1267:162-9. doi: 10.1016/j.chroma.2012.07.021. Epub 2012 Jul 14.</reference_text><pubmed_id>22824219</pubmed_id></reference><reference><reference_text>Madu CO, Lu Y: Novel diagnostic biomarkers for prostate cancer. J Cancer. 2010 Oct 6;1:150-77.</reference_text><pubmed_id>20975847</pubmed_id></reference></references></disease><disease>Schizophrenia<references><reference><reference_text>Harnryd C, Bjerkenstedt L, Grimm VE, Sedvall G: Reduction of MOPEG levels in cerebrospinal fluid of psychotic women after electroconvulsive treatment. Psychopharmacology (Berl). 1979 Aug 8;64(2):131-4.</reference_text><pubmed_id>115032</pubmed_id></reference><reference><reference_text>Kobayashi K, Koide Y, Yoshino K, Shohmori T: [P-hydroxyphenylacetic acid concentrations in cerebrospinal fluid]. No To Shinkei. 1982 Aug;34(8):769-74.</reference_text><pubmed_id>7126379</pubmed_id></reference><reference><reference_text>Alfredsson G, Wiesel FA: Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology (Berl). 1989;99(3):322-7.</reference_text><pubmed_id>2480613</pubmed_id></reference><reference><reference_text>Heresco-Levy U, Bar G, Levin R, Ermilov M, Ebstein RP, Javitt DC: High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. Schizophr Res. 2007 Mar;91(1-3):14-21. Epub 2007 Feb 2.</reference_text><pubmed_id>17276036</pubmed_id></reference><reference><reference_text>Walker EF, Bonsall R, Walder DJ: Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis. Neuropsychiatry Neuropsychol Behav Neurol. 2002 Mar;15(1):10-7.</reference_text><pubmed_id>11877547</pubmed_id></reference><reference><reference_text>Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M: Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry. 2003 Jun;60(6):572-6.</reference_text><pubmed_id>12796220</pubmed_id></reference><reference><reference_text>Do KQ, Lauer CJ, Schreiber W, Zollinger M, Gutteck-Amsler U, Cuenod M, Holsboer F: gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem. 1995 Dec;65(6):2652-62.</reference_text><pubmed_id>7595563</pubmed_id></reference><reference><reference_text>Nikisch G, Baumann P, Wiedemann G, Kiessling B, Weisser H, Hertel A, Yoshitake T, Kehr J, Mathe AA: Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF. J Clin Psychopharmacol. 2010 Oct;30(5):496-503. doi: 10.1097/JCP.0b013e3181f2288e.</reference_text><pubmed_id>20814316</pubmed_id></reference><reference><reference_text>Fukushima T, Iizuka H, Yokota A, Suzuki T, Ohno C, Kono Y, Nishikiori M, Seki A, Ichiba H, Watanabe Y, Hongo S, Utsunomiya M, Nakatani M, Sadamoto K, Yoshio T: Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One. 2014 Jul 8;9(7):e101652. doi: 10.1371/journal.pone.0101652. eCollection 2014.</reference_text><pubmed_id>25004141</pubmed_id></reference><reference><reference_text>Koike S, Bundo M, Iwamoto K, Suga M, Kuwabara H, Ohashi Y, Shinoda K, Takano Y, Iwashiro N, Satomura Y, Nagai T, Natsubori T, Tada M, Yamasue H, Kasai K: A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study. Transl Psychiatry. 2014 Apr 8;4:e379. doi: 10.1038/tp.2014.19.</reference_text><pubmed_id>24713860</pubmed_id></reference><reference><reference_text>Ballesteros A, Summerfelt A, Du X, Jiang P, Chiappelli J, Tagamets M, O'Donnell P, Kochunov P, Hong LE: Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia. Clin Neurophysiol. 2013 Nov;124(11):2209-15. doi: 10.1016/j.clinph.2013.05.021. Epub 2013 Jun 30.</reference_text><pubmed_id>23823132</pubmed_id></reference><reference><reference_text>Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel FA: Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry. 1985 Sep;147:276-82.</reference_text><pubmed_id>2415198</pubmed_id></reference><reference><reference_text>Pickar D, Breier A, Hsiao JK, Doran AR, Wolkowitz OM, Pato CN, Konicki PE, Potter WZ: Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Arch Gen Psychiatry. 1990 Jul;47(7):641-8.</reference_text><pubmed_id>1694425</pubmed_id></reference><reference><reference_text>Prell GD, Green JP, Kaufmann CA, Khandelwal JK, Morrishow AM, Kirch DG, Linnoila M, Wyatt RJ: Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res. 1995 Jan;14(2):93-104.</reference_text><pubmed_id>7711000</pubmed_id></reference><reference><reference_text>Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B: Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology. 2009;59(2):123-9. doi: 10.1159/000213565. Epub 2009 Apr 22.</reference_text><pubmed_id>19390223</pubmed_id></reference><reference><reference_text>Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K, Cao Y, Wang X, Qiu Y, Su M, Zhao A, Wang P, Yang P, Wu J, Feng G, He L, Jia W, Wan C: Potential metabolite markers of schizophrenia. Mol Psychiatry. 2013 Jan;18(1):67-78. doi: 10.1038/mp.2011.131. Epub 2011 Oct 25.</reference_text><pubmed_id>22024767</pubmed_id></reference><reference><reference_text>Xuan J, Pan G, Qiu Y, Yang L, Su M, Liu Y, Chen J, Feng G, Fang Y, Jia W, Xing Q, He L: Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. J Proteome Res. 2011 Dec 2;10(12):5433-43. doi: 10.1021/pr2006796. Epub 2011 Nov  8.</reference_text><pubmed_id>22007635</pubmed_id></reference><reference><reference_text>Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM, Rothermundt M, Bogerts B, Koethe D, Kranaster L, Ohrmann P, Suslow T, McAllister G, Spain M, Barnes A, van Beveren NJ, Baron-Cohen S, Steiner J, Torrey FE, Yolken RH, Bahn S: Identification of a biological signature for schizophrenia in serum. Mol Psychiatry. 2012 May;17(5):494-502. doi: 10.1038/mp.2011.42. Epub 2011 Apr 12.</reference_text><pubmed_id>21483431</pubmed_id></reference><reference><reference_text>Mathe AA, Eberhard G, Saaf J, Wetterberg L: Plasma prostaglandin E2 metabolite--measured as 11-deoxy-15-keto-13,14-dihydro-11 beta,16 xi-cyclo-PGE2--in twins with schizophrenic disorder. Biol Psychiatry. 1986 Sep;21(11):1024-30.</reference_text><pubmed_id>3741918</pubmed_id></reference><reference><reference_text>Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N: Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct. 2002 Jun;20(2):171-5.</reference_text><pubmed_id>11979513</pubmed_id></reference><reference><reference_text>Zumarraga M, Davila R, Basterreche N, Arrue A, Goienetxea B, Zamalloa MI, Erkoreka L, Bustamante S, Inchausti L, Gonzalez-Torres MA, Guimon J: Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients. Neurochem Int. 2010 May-Jun;56(6-7):774-9. doi: 10.1016/j.neuint.2010.02.015. Epub 2010 Mar 4.</reference_text><pubmed_id>20206656</pubmed_id></reference><reference><reference_text>Peters JG: Dopamine, noradrenaline and serotonin spinal fluid metabolites in temporal lobe epileptic patients with schizophrenic symptomatology. Eur Neurol. 1979;18(1):15-8.</reference_text><pubmed_id>436860</pubmed_id></reference><reference><reference_text>Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, Rozen S, Krishnan RR, McEvoy J, Kaddurah-Daouk R: Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry. 2010 Sep;15(9):938-53. doi: 10.1038/mp.2009.33. Epub 2009 Apr 28.</reference_text><pubmed_id>19401681</pubmed_id></reference><reference><reference_text>Gattaz WF, Waldmeier P, Beckmann H: CSF monoamine metabolites in schizophrenic patients. Acta Psychiatr Scand. 1982 Nov;66(5):350-60.</reference_text><pubmed_id>6184954</pubmed_id></reference><reference><reference_text>Nilsson-Todd LK, Nordin C, Jonsson EG, Skogh E, Erhardt S: Cerebrospinal fluid kynurenic acid in male patients with schizophrenia - correlation with monoamine metabolites. Acta Neuropsychiatr. 2007 Feb;19(1):45-52. doi: 10.1111/j.1601-5215.2006.00170.x.</reference_text><pubmed_id>26952797</pubmed_id></reference><reference><reference_text>Cai HL, Li HD, Yan XZ, Sun B, Zhang Q, Yan M, Zhang WY, Jiang P, Zhu RH, Liu YP, Fang PF, Xu P, Yuan HY, Zhang XH, Hu L, Yang W, Ye HS: Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naive schizophrenia patients after treatment with risperidone. J Proteome Res. 2012 Aug 3;11(8):4338-50. doi: 10.1021/pr300459d. Epub 2012 Jul 26.</reference_text><pubmed_id>22800120</pubmed_id></reference><reference><reference_text>Al Awam K, Haussleiter IS, Dudley E, Donev R, Brune M, Juckel G, Thome J: Multiplatform metabolome and proteome profiling identifies serum metabolite and protein signatures as prospective biomarkers for schizophrenia. J Neural Transm (Vienna). 2015 Aug;122 Suppl 1:S111-22. doi: 10.1007/s00702-014-1224-0. Epub 2014 May 1.</reference_text><pubmed_id>24789758</pubmed_id></reference><reference><reference_text>Bicikova M, Hill M, Ripova D, Mohr P, Hampl R: Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia. J Steroid Biochem Mol Biol. 2013 Jan;133:77-83. doi: 10.1016/j.jsbmb.2012.08.009. Epub 2012 Aug 24.</reference_text><pubmed_id>22944140</pubmed_id></reference><reference><reference_text>He Y, Yu Z, Giegling I, Xie L, Hartmann AM, Prehn C, Adamski J, Kahn R, Li Y, Illig T, Wang-Sattler R, Rujescu D: Schizophrenia shows a unique metabolomics signature in plasma. Transl Psychiatry. 2012 Aug 14;2:e149. doi: 10.1038/tp.2012.76.</reference_text><pubmed_id>22892715</pubmed_id></reference><reference><reference_text>Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KR: Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):934-45. Epub 2007 Apr 17.</reference_text><pubmed_id>17440431</pubmed_id></reference><reference><reference_text>Fryar-Williams S, Strobel JE: Biomarkers of a five-domain translational substrate for schizophrenia and schizoaffective psychosis. Biomark Res. 2015 Feb 6;3:3. doi: 10.1186/s40364-015-0028-1. eCollection 2015.</reference_text><pubmed_id>25729574</pubmed_id></reference><reference><reference_text>Oresic M, Seppanen-Laakso T, Sun D, Tang J, Therman S, Viehman R, Mustonen U, van Erp TG, Hyotylainen T, Thompson P, Toga AW, Huttunen MO, Suvisaari J, Kaprio J, Lonnqvist J, Cannon TD: Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia. Genome Med. 2012 Jan 18;4(1):1. doi: 10.1186/gm300.</reference_text><pubmed_id>22257447</pubmed_id></reference></references></disease><disease>Primary hypomagnesemia<references><reference><reference_text>Jin-no Y, Kamiya Y, Okada M, Hirako M, Takada N, Kawaguchi M: Primary hypomagnesemia caused by isolated magnesium malabsorption: atypical case in adult. Intern Med. 1999 Mar;38(3):261-5.</reference_text><pubmed_id>10337938</pubmed_id></reference><reference><reference_text>Vainsel M, Vandevelde G, Smulders J, Vosters M, Hubain P, Loeb H: Tetany due to hypomagnesaemia with secondary hypocalcaemia. Arch Dis Child. 1970 Apr;45(240):254-8.</reference_text><pubmed_id>5419995</pubmed_id></reference><reference><reference_text>Shalev H, Phillip M, Galil A, Carmi R, Landau D: Clinical presentation and outcome in primary familial hypomagnesaemia. Arch Dis Child. 1998 Feb;78(2):127-30.</reference_text><pubmed_id>9579153</pubmed_id></reference><reference><reference_text>Kari JA, Farouq M, Alshaya HO: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Pediatr Nephrol. 2003 Jun;18(6):506-10. Epub 2003 Apr 29.</reference_text><pubmed_id>12720080</pubmed_id></reference></references></disease><disease>Hyperlipoproteinemia<references><reference><reference_text>Sinha S, Misra A, Kumar V, Jagannathan NR, Bal CS, Pandey RM, Singhania R, Deepak: Proton magnetic resonance spectroscopy and single photon emission computed tomography study of the brain in asymptomatic young hyperlipidaemic Asian Indians in North India show early abnormalities. Clin Endocrinol (Oxf). 2004 Aug;61(2):182-9.</reference_text><pubmed_id>15272912</pubmed_id></reference><reference><reference_text>Nelson RH: Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013 Mar</reference_text><pubmed_id>40(1):195-211. doi: 10.1016/j.pop.2012.11.003. Epub 2012 Dec  4.</pubmed_id></reference><reference><reference_text>Cantin B, Boudriau S, Bertrand M, Brun LD, Gagne C, Rogers PA, Ven Murthy MR, Lupien PJ, Julien P: Hemolysis in primary lipoprotein lipase deficiency. Metabolism. 1995 May;44(5):652-8.</reference_text><pubmed_id>7752915</pubmed_id></reference></references></disease><disease>Abetalipoproteinemia<references><reference><reference_text>Dawson G, Kruski AW, Scanu AM: Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J Lipid Res. 1976 Mar;17(2):125-31.</reference_text><pubmed_id>178813</pubmed_id></reference><reference><reference_text>Lazaro RP, Dentinger MP, Rodichok LD, Barron KD, Satya-Murti S: Muscle pathology in Bassen-Kornzweig syndrome and vitamin E deficiency. Am J Clin Pathol. 1986 Sep;86(3):378-87.</reference_text><pubmed_id>2944375</pubmed_id></reference></references></disease><disease>Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis<references><reference><reference_text>Breckenridge WC, Alaupovic P, Cox DW, Little JA: Apolipoprotein and lipoprotein concentrations in familial apolipoprotein C-II deficiency. Atherosclerosis. 1982 Aug;44(2):223-35.</reference_text><pubmed_id>7138621</pubmed_id></reference><reference><reference_text>Fukami M, Hasegawa T, Horikawa R, Ohashi T, Nishimura G, Homma K, Ogata T: Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr Res. 2006 Feb;59(2):276-80. doi: 10.1203/01.pdr.0000195825.31504.28.</reference_text><pubmed_id>16439592</pubmed_id></reference></references></disease><disease>Cerebrotendinous xanthomatosis<references><reference><reference_text>Halperin G, Elisaf M, Leitersdorf E, Harats D: A new method for determination of serum cholestanol by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2000 Jun 9;742(2):345-52.</reference_text><pubmed_id>10901139</pubmed_id></reference><reference><reference_text>Siman-Tov T, Meiner V, Gadoth N: Could steroids mask the diagnosis of cerebrotendinous xanthomatosis? J Neurol Sci. 2006 Apr 15;243(1-2):83-6. Epub 2006 Jan 30.</reference_text><pubmed_id>16445943</pubmed_id></reference><reference><reference_text>Agrawal NK, Garg S: Cerebrotendinous xanthomatosis: a rare disorder with a rare presentation. BMJ Case Rep. 2012 Sep 21;2012. pii: bcr-2012-006202. doi: 10.1136/bcr-2012-006202.</reference_text><pubmed_id>23001091</pubmed_id></reference></references></disease><disease>3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency<references><reference><reference_text>Thompson GN, Hsu BY, Pitt JJ, Treacy E, Stanley CA: Fasting hypoketotic coma in a child with deficiency of mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase. N Engl J Med. 1997 Oct 23;337(17):1203-7. doi: 10.1056/NEJM199710233371704.</reference_text><pubmed_id>9337379</pubmed_id></reference><reference><reference_text>Morris AA, Lascelles CV, Olpin SE, Lake BD, Leonard JV, Quant PA: Hepatic mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme a synthase deficiency. Pediatr Res. 1998 Sep;44(3):392-6. doi: 10.1203/00006450-199809000-00021.</reference_text><pubmed_id>9727719</pubmed_id></reference><reference><reference_text>Conboy E, Vairo F, Schultz M, Agre K, Ridsdale R, Deyle D, Oglesbee D, Gavrilov D, Klee EW, Lanpher B: Mitochondrial 3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency: Unique Presenting Laboratory Values and a Review of Biochemical and Clinical Features. JIMD Rep. 2017 Oct 14. doi: 10.1007/8904_2017_59.</reference_text><pubmed_id>29030856</pubmed_id></reference></references></disease><disease>Hypercholesterolemia, familial<references><reference><reference_text>Kwiterovich PO Jr, Fredrickson DS, Levy RI: Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest. 1974 May;53(5):1237-49. doi: 10.1172/JCI107670.</reference_text><pubmed_id>4363406</pubmed_id></reference></references></disease><disease>SC4MOL deficiency<references><reference><reference_text>He M, Kratz LE, Michel JJ, Vallejo AN, Ferris L, Kelley RI, Hoover JJ, Jukic D, Gibson KM, Wolfe LA, Ramachandran D, Zwick ME, Vockley J: Mutations in the human SC4MOL gene encoding a methyl sterol oxidase cause psoriasiform dermatitis, microcephaly, and developmental delay. J Clin Invest. 2011 Mar;121(3):976-84. doi: 10.1172/JCI42650.</reference_text><pubmed_id>21285510</pubmed_id></reference></references></disease><disease>Chondrodysplasia punctata, X-linked dominant<references><reference><reference_text>Aughton DJ, Kelley RI, Metzenberg A, Pureza V, Pauli RM: X-linked dominant chondrodysplasia punctata (CDPX2) caused by single gene mosaicism in a male. Am J Med Genet A. 2003 Jan 30;116A(3):255-60. doi: 10.1002/ajmg.a.10852.</reference_text><pubmed_id>12503102</pubmed_id></reference></references></disease><disease>Desmosterolosis<references><reference><reference_text>Andersson HC, Kratz L, Kelley R: Desmosterolosis presenting with multiple congenital anomalies and profound developmental delay. Am J Med Genet. 2002 Dec 15;113(4):315-9. doi: 10.1002/ajmg.b.10873.</reference_text><pubmed_id>12457401</pubmed_id></reference></references></disease><disease>Donohue Syndrome<references><reference><reference_text>Nijim Y, Awni Y, Adawi A, Bowirrat A: Classic Case Report of Donohue Syndrome (Leprechaunism; OMIM *246200): The Impact of Consanguineous Mating. Medicine (Baltimore). 2016 Feb;95(6):e2710. doi: 10.1097/MD.0000000000002710.</reference_text><pubmed_id>26871809</pubmed_id></reference></references></disease><disease>Leptin Deficiency or Dysfunction<references><reference><reference_text>Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O'Rahilly S: Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999 Sep 16;341(12):879-84. doi: 10.1056/NEJM199909163411204.</reference_text><pubmed_id>10486419</pubmed_id></reference></references></disease><disease>Duchenne Muscular Dystrophy<references><reference><reference_text>Nakagawa T, Takeuchi A, Kakiuchi R, Lee T, Yagi M, Awano H, Iijima K, Takeshima Y, Urade Y, Matsuo M: A prostaglandin D2 metabolite is elevated in the urine of Duchenne muscular dystrophy patients and increases further from 8 years old. Clin Chim Acta. 2013 Aug 23;423:10-4. doi: 10.1016/j.cca.2013.03.031. Epub 2013 Apr 19.</reference_text><pubmed_id>23603101</pubmed_id></reference><reference><reference_text>Srivastava NK, Pradhan S, Mittal B, Gowda GA: High resolution NMR based analysis of serum lipids in Duchenne muscular dystrophy patients and its possible diagnostic significance. NMR Biomed. 2010 Jan;23(1):13-22. doi: 10.1002/nbm.1419.</reference_text><pubmed_id>19787747</pubmed_id></reference><reference><reference_text>Horster I, Weigt-Usinger K, Carmann C, Chobanyan-Jurgens K, Kohler C, Schara U, Kayacelebi AA, Beckmann B, Tsikas D, Lucke T: The L-arginine/NO pathway and homoarginine are altered in Duchenne muscular dystrophy and improved by glucocorticoids. Amino Acids. 2015 Sep;47(9):1853-63. doi: 10.1007/s00726-015-2018-x. Epub 2015 Jun 12.</reference_text><pubmed_id>26066683</pubmed_id></reference></references></disease><disease>Lecithin:cholesterol Acyltransferase Deficiency<references><reference><reference_text>Idzior-Walus B, Sieradzki J, Kostner G, Malecki MT, Klupa T, Wesolowska T, Rostworowski W, Hartwich J, Walus M, Kiec AD, Naruszewicz M: Familial lecithin-cholesterol acyltransferase deficiency: biochemical characteristics and molecular analysis of a new LCAT mutation in a Polish family. Atherosclerosis. 2006 Apr;185(2):413-20. Epub 2005 Jul 26.</reference_text><pubmed_id>16051254</pubmed_id></reference></references></disease><disease>Lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lipodystrophy, Congenital Generalized<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Oculocerebrorenal syndrome<references><reference><reference_text>Charnas LR, Bernardini I, Rader D, Hoeg JM, Gahl WA: Clinical and laboratory findings in the oculocerebrorenal syndrome of Lowe, with special reference to growth and renal function. N Engl J Med. 1991 May 9;324(19):1318-25. doi: 10.1056/NEJM199105093241904.</reference_text><pubmed_id>2017228</pubmed_id></reference></references></disease><disease>Familial partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lathosterolosis<references><reference><reference_text>Brunetti-Pierri N, Corso G, Rossi M, Ferrari P, Balli F, Rivasi F, Annunziata I, Ballabio A, Russo AD, Andria G, Parenti G: Lathosterolosis, a novel multiple-malformation/mental retardation syndrome due to deficiency of 3beta-hydroxysteroid-delta5-desaturase. Am J Hum Genet. 2002 Oct;71(4):952-8. Epub 2002 Aug 20.</reference_text><pubmed_id>12189593</pubmed_id></reference><reference><reference_text>Ho AC, Fung CW, Siu TS, Ma OC, Lam CW, Tam S, Wong VC: Lathosterolosis: a disorder of cholesterol biosynthesis resembling smith-lemli-opitz syndrome. JIMD Rep. 2014;12:129-34. doi: 10.1007/8904_2013_255. Epub 2013 Oct 20.</reference_text><pubmed_id>24142275</pubmed_id></reference></references></disease><disease>Partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Multiple sclerosis<references><reference><reference_text>Lutz NW, Viola A, Malikova I, Confort-Gouny S, Audoin B, Ranjeva JP, Pelletier J, Cozzone PJ: Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One. 2007 Jul 4;2(7):e595.</reference_text><pubmed_id>17611627</pubmed_id></reference><reference><reference_text>Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U, Hillert J, Bjorkhem I: Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med. 2004 Feb;42(2):186-91.</reference_text><pubmed_id>15061359</pubmed_id></reference><reference><reference_text>Leoni V, Lutjohann D, Masterman T: Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis. J Lipid Res. 2005 Feb;46(2):191-5. Epub 2004 Dec 1.</reference_text><pubmed_id>15576852</pubmed_id></reference><reference><reference_text>Calabrese V, Scapagnini G, Ravagna A, Bella R, Butterfield DA, Calvani M, Pennisi G, Giuffrida Stella AM: Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem Res. 2003 Sep;28(9):1321-8.</reference_text><pubmed_id>12938853</pubmed_id></reference><reference><reference_text>Shaw CE, Dunbar PR, Macaulay HA, Neale TJ: Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol. 1995 Jan;242(2):53-8.</reference_text><pubmed_id>7707089</pubmed_id></reference><reference><reference_text>Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.</reference_text><pubmed_id>17384003</pubmed_id></reference><reference><reference_text>Syburra C, Passi S: Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh (1999). 1999 May-Jun;71(3):112-5.</reference_text><pubmed_id>10609336</pubmed_id></reference><reference><reference_text>Forte G, Visconti A, Santucci S, Ghazaryan A, Figa-Talamanca L, Cannoni S, Bocca B, Pino A, Violante N, Alimonti A, Salvetti M, Ristori G: Quantification of chemical elements in blood of patients affected by multiple sclerosis. Ann Ist Super Sanita. 2005;41(2):213-6.</reference_text><pubmed_id>16244395</pubmed_id></reference><reference><reference_text>Toncev G, Milicic B, Toncev S, Samardzic G: Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol. 2002 May;9(3):221-6.</reference_text><pubmed_id>11985629</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, Bamonti F, Capello E, Mancardi GL, Scarpini E: Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res. 2010 May 28;1333:64-71. doi: 10.1016/j.brainres.2010.03.073. Epub 2010 Mar 27.</reference_text><pubmed_id>20347721</pubmed_id></reference><reference><reference_text>Matsushita T, Isobe N, Kawajiri M, Mogi M, Tsukuda K, Horiuchi M, Ohyagi Y, Kira J: CSF angiotensin II and angiotensin-converting enzyme levels in anti-aquaporin-4 autoimmunity. J Neurol Sci. 2010 Aug 15;295(1-2):41-5. doi: 10.1016/j.jns.2010.05.014. Epub 2010 Jun 11.</reference_text><pubmed_id>20541774</pubmed_id></reference><reference><reference_text>Ghabaee M, Jabedari B, Al-E-Eshagh N, Ghaffarpour M, Asadi F: Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients. Int J Neurosci. 2010 Apr;120(4):301-4. doi: 10.3109/00207451003695690.</reference_text><pubmed_id>20374079</pubmed_id></reference><reference><reference_text>Kawajiri M, Mogi M, Osoegawa M, Matsuoka T, Tsukuda K, Kohara K, Horiuchi M, Miki T, Kira JI: Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler. 2008 May;14(4):557-60. doi: 10.1177/1352458507085760.</reference_text><pubmed_id>18562510</pubmed_id></reference><reference><reference_text>Visconti A, Cotichini R, Cannoni S, Bocca B, Forte G, Ghazaryan A, Santucci S, D'Ippolito C, Stazi MA, Salvetti M, Alimonti A, Ristori G: Concentration of elements in serum of patients affected by multiple sclerosis with first demyelinating episode: a six-month longitudinal follow-up study. Ann Ist Super Sanita. 2005;41(2):217-22.</reference_text><pubmed_id>16244396</pubmed_id></reference></references></disease><disease>Inflammatory bowel disease<references><reference><reference_text>Lee T, Clavel T, Smirnov K, Schmidt A, Lagkouvardos I, Walker A, Lucio M, Michalke B, Schmitt-Kopplin P, Fedorak R, Haller D: Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. 2017 May;66(5):863-871. doi: 10.1136/gutjnl-2015-309940. Epub 2016 Feb 4.</reference_text><pubmed_id>26848182</pubmed_id></reference><reference><reference_text>Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158.</reference_text><pubmed_id>27609529</pubmed_id></reference></references></disease><disease>Colorectal cancer<references><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B: Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009 Apr;22(3):342-8. doi: 10.1002/nbm.1345.</reference_text><pubmed_id>19006102</pubmed_id></reference><reference><reference_text>Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP: Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One. 2013 Aug 6;8(8):e70803. doi: 10.1371/journal.pone.0070803. Print 2013.</reference_text><pubmed_id>23940645</pubmed_id></reference><reference><reference_text>Phua LC, Chue XP, Koh PK, Cheah PY, Ho HK, Chan EC: Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biol Ther. 2014 Apr;15(4):389-97. doi: 10.4161/cbt.27625. Epub 2014 Jan 14.</reference_text><pubmed_id>24424155</pubmed_id></reference><reference><reference_text>Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB: Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010 Feb 15;8:13. doi: 10.1186/1741-7015-8-13.</reference_text><pubmed_id>20156336</pubmed_id></reference><reference><reference_text>Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, Ni Y, Zhao A, Xu LX, Cai S, Jia W: Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res. 2009 Oct;8(10):4844-50. doi: 10.1021/pr9004162.</reference_text><pubmed_id>19678709</pubmed_id></reference><reference><reference_text>Cheng Y, Xie G, Chen T, Qiu Y, Zou X, Zheng M, Tan B, Feng B, Dong T, He P, Zhao L, Zhao A, Xu LX, Zhang Y, Jia W: Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res. 2012 Feb 3;11(2):1354-63. doi: 10.1021/pr201001a. Epub 2011 Dec 28.</reference_text><pubmed_id>22148915</pubmed_id></reference><reference><reference_text>Ni Y, Xie G, Jia W: Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res. 2014 Sep 5;13(9):3857-70. doi: 10.1021/pr500443c. Epub 2014 Aug 14.</reference_text><pubmed_id>25105552</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference><reference><reference_text>Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18.</reference_text><pubmed_id>25037050</pubmed_id></reference><reference><reference_text>Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016.</reference_text><pubmed_id>27015276</pubmed_id></reference><reference><reference_text>Lin Y, Ma C, Liu C, Wang Z, Yang J, Liu X, Shen Z, Wu R: NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer. Oncotarget. 2016 May 17;7(20):29454-64. doi: 10.18632/oncotarget.8762.</reference_text><pubmed_id>27107423</pubmed_id></reference><reference><reference_text>Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016.</reference_text><pubmed_id>27275383</pubmed_id></reference><reference><reference_text>Wang X, Wang J, Rao B, Deng L: Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals. Exp Ther Med. 2017 Jun;13(6):2848-2854. doi: 10.3892/etm.2017.4367. Epub 2017 Apr 20.</reference_text><pubmed_id>28587349</pubmed_id></reference><reference><reference_text>Silke Matysik, Caroline Ivanne Le Roy, Gerhard Liebisch, Sandrine Paule Claus. Metabolomics of fecal samples: A practical consideration. Trends in Food Science &amp; Technology. Vol. 57, Part B, Nov. 2016, p.244-255: http://www.sciencedirect.com/science/article/pii/S0924224416301984</reference_text><pubmed_id>28587349</pubmed_id></reference></references></disease><disease>Gallbladder disease<references><reference><reference_text>Lapidus A, Akerlund JE, Einarsson C: Gallbladder bile composition in patients with Crohn 's disease. World J Gastroenterol. 2006 Jan 7;12(1):70-4.</reference_text><pubmed_id>16440420</pubmed_id></reference><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference><reference><reference_text>Mizuno S, Tazuma S, Kajiyama G: Stabilization of biliary lipid particles by ursodeoxycholic acid. Prolonged nucleation time in human gallbladder bile. Dig Dis Sci. 1993 Apr;38(4):684-93.</reference_text><pubmed_id>8462368</pubmed_id></reference><reference><reference_text>Hillebrant CG, Axelson M, Bjorkhem I, Wang FH, Nyberg B, Einarsson C: Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients. Eur J Clin Invest. 1998 Apr;28(4):324-8.</reference_text><pubmed_id>9615912</pubmed_id></reference></references></disease><disease>Cholelithiasis<references><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference></references></disease><disease>Stomach cancer<references><reference><reference_text>Higashijima H, Ichimiya H, Nakano T, Yamashita H, Kuroki S, Satoh H, Chijiiwa K, Tanaka M: Deconjugation of bilirubin accelerates coprecipitation of cholesterol, fatty acids, and mucin in human bile--in vitro study. J Gastroenterol. 1996 Dec;31(6):828-35.</reference_text><pubmed_id>9027647</pubmed_id></reference><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Song H, Peng JS, Dong-Sheng Y, Yang ZL, Liu HL, Zeng YK, Shi XP, Lu BY: Serum metabolic profiling of human gastric cancer based on gas chromatography/mass spectrometry. Braz J Med Biol Res. 2012 Jan;45(1):78-85. Epub 2011 Nov 25.</reference_text><pubmed_id>22124703</pubmed_id></reference><reference><reference_text>Yu L, Aa J, Xu J, Sun M, Qian S, Cheng L, Yang S, Shi R: Metabolomic phenotype of gastric cancer and precancerous stages based on gas chromatography time-of-flight mass spectrometry. J Gastroenterol Hepatol. 2011 Aug;26(8):1290-7. doi: 10.1111/j.1440-1746.2011.06724.x.</reference_text><pubmed_id>21443661</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference></references></disease><disease>Acute myelogenous leukemia<references><reference><reference_text>Tatidis L, Vitols S, Gruber A, Paul C, Axelson M: Cholesterol catabolism in patients with acute myelogenous leukemia and hypocholesterolemia: suppressed levels of a circulating marker for bile acid synthesis. Cancer Lett. 2001 Sep 20;170(2):169-75.</reference_text><pubmed_id>11463495</pubmed_id></reference></references></disease><disease>Hypercholesterolemia<references><reference><reference_text>Thelen KM, Laaksonen R, Paiva H, Lehtimaki T, Lutjohann D: High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels. J Clin Pharmacol. 2006 Jul;46(7):812-6.</reference_text><pubmed_id>16809807</pubmed_id></reference><reference><reference_text>Tamasawa N, Tamasawa A, Takebe K: Higher levels of plasma cholesterol sulfate in patients with liver cirrhosis and hypercholesterolemia. Lipids. 1993 Sep;28(9):833-6.</reference_text><pubmed_id>8231659</pubmed_id></reference><reference><reference_text>Kim DH, Lee KJ, Heo GS: Analysis of cholesterol and cholesteryl esters in human serum using capillary supercritical fluid chromatography. J Chromatogr B Biomed Appl. 1994 Apr 22;655(1):1-8.</reference_text><pubmed_id>8061816</pubmed_id></reference><reference><reference_text>Authors unspecified: Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med. 1988 Jan;148(1):36-69.</reference_text><pubmed_id>3422148</pubmed_id></reference></references></disease><disease>Cholesteryl ester storage disease<references><reference><reference_text>Rassoul F, Richter V, Lohse P, Naumann A, Purschwitz K, Keller E: Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease. Int J Clin Pharmacol Ther. 2001 May;39(5):199-204.</reference_text><pubmed_id>11380065</pubmed_id></reference><reference><reference_text>Chatrath H, Keilin S, Attar BM: Cholesterol ester storage disease (CESD) diagnosed in an asymptomatic adult. Dig Dis Sci. 2009 Jan;54(1):168-73. doi: 10.1007/s10620-008-0310-2. Epub 2008 May 14.</reference_text><pubmed_id>18478331</pubmed_id></reference><reference><reference_text>Bernstein DL, Hulkova H, Bialer MG, Desnick RJ: Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol. 2013 Jun;58(6):1230-43. doi: 10.1016/j.jhep.2013.02.014. Epub 2013 Feb 26.</reference_text><pubmed_id>23485521</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Cystinosis<references><reference><reference_text>Ueda M, O'Brien K, Rosing DR, Ling A, Kleta R, McAreavey D, Bernardini I, Gahl WA: Coronary artery and other vascular calcifications in patients with cystinosis after kidney transplantation. Clin J Am Soc Nephrol. 2006 May;1(3):555-62. Epub 2006 Feb 8.</reference_text><pubmed_id>17699259</pubmed_id></reference><reference><reference_text>Gahl WA, Bernardini I, Dalakas M, Rizzo WB, Harper GS, Hoeg JM, Hurko O, Bernar J: Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome. J Clin Invest. 1988 Feb;81(2):549-60.</reference_text><pubmed_id>3276734</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Smith-Lemli-Opitz syndrome<references><reference><reference_text>van Rooij A, Nijenhuis AA, Wijburg FA, Schutgens RB: Highly increased CSF concentrations of cholesterol precursors in Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 1997 Aug;20(4):578-80.</reference_text><pubmed_id>9266395</pubmed_id></reference><reference><reference_text>Honda M, Tint GS, Honda A, Salen G, Shefer S, Batta AK, Matsuzaki Y, Tanaka N: Regulation of cholesterol biosynthetic pathway in patients with the Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2000 Jul;23(5):464-74.</reference_text><pubmed_id>10947201</pubmed_id></reference><reference><reference_text>Rossi M, Federico G, Corso G, Parenti G, Battagliese A, Frascogna AR, Della Casa R, Dello Russo A, Strisciuglio P, Saggese G, Andria G: Vitamin D status in patients affected by Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2005;28(1):69-80.</reference_text><pubmed_id>15702407</pubmed_id></reference><reference><reference_text>Johnson DW, ten Brink HJ, Jakobs C: A rapid screening procedure for cholesterol and dehydrocholesterol by electrospray ionization tandem mass spectrometry. J Lipid Res. 2001 Oct;42(10):1699-705.</reference_text><pubmed_id>11590227</pubmed_id></reference></references></disease><disease>Prostate cancer<references><reference><reference_text>Nyman DW, Suzanne Stratton M, Kopplin MJ, Dalkin BL, Nagle RB, Jay Gandolfi A: Selenium and selenomethionine levels in prostate cancer patients. Cancer Detect Prev. 2004;28(1):8-16.</reference_text><pubmed_id>15041072</pubmed_id></reference><reference><reference_text>Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, Egevad L, Tjonneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, Palli D, Vineis P, Tumino R, Berrino F, Kiemeney L, Bueno-de-Mesquita HB, Quiros JR, Gonzalez CA, Martinez C, Larranaga N, Chirlaque MD, Ardanaz E, Stattin P, Hallmans G, Khaw KT, Bingham S, Slimani N, Ferrari P, Rinaldi S, Riboli E: Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr. 2007 Sep;86(3):672-81.</reference_text><pubmed_id>17823432</pubmed_id></reference><reference><reference_text>Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762.</reference_text><pubmed_id>19212411</pubmed_id></reference><reference><reference_text>Puah CM, Williams G, Ghanadian R: Urinary unconjugated 5 alpha-androstane-3 alpha, 17 beta-diol in patients with prostatic tumours. Urol Res. 1982;10(2):81-4.</reference_text><pubmed_id>6180540</pubmed_id></reference><reference><reference_text>Thysell E, Surowiec I, Hornberg E, Crnalic S, Widmark A, Johansson AI, Stattin P, Bergh A, Moritz T, Antti H, Wikstrom P: Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One. 2010 Dec 3;5(12):e14175. doi: 10.1371/journal.pone.0014175.</reference_text><pubmed_id>21151972</pubmed_id></reference><reference><reference_text>Soliman LC, Hui Y, Hewavitharana AK, Chen DD: Monitoring potential prostate cancer biomarkers in urine by capillary electrophoresis-tandem mass spectrometry. J Chromatogr A. 2012 Dec 7;1267:162-9. doi: 10.1016/j.chroma.2012.07.021. Epub 2012 Jul 14.</reference_text><pubmed_id>22824219</pubmed_id></reference><reference><reference_text>Madu CO, Lu Y: Novel diagnostic biomarkers for prostate cancer. J Cancer. 2010 Oct 6;1:150-77.</reference_text><pubmed_id>20975847</pubmed_id></reference></references></disease><disease>Schizophrenia<references><reference><reference_text>Harnryd C, Bjerkenstedt L, Grimm VE, Sedvall G: Reduction of MOPEG levels in cerebrospinal fluid of psychotic women after electroconvulsive treatment. Psychopharmacology (Berl). 1979 Aug 8;64(2):131-4.</reference_text><pubmed_id>115032</pubmed_id></reference><reference><reference_text>Kobayashi K, Koide Y, Yoshino K, Shohmori T: [P-hydroxyphenylacetic acid concentrations in cerebrospinal fluid]. No To Shinkei. 1982 Aug;34(8):769-74.</reference_text><pubmed_id>7126379</pubmed_id></reference><reference><reference_text>Alfredsson G, Wiesel FA: Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology (Berl). 1989;99(3):322-7.</reference_text><pubmed_id>2480613</pubmed_id></reference><reference><reference_text>Heresco-Levy U, Bar G, Levin R, Ermilov M, Ebstein RP, Javitt DC: High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. Schizophr Res. 2007 Mar;91(1-3):14-21. Epub 2007 Feb 2.</reference_text><pubmed_id>17276036</pubmed_id></reference><reference><reference_text>Walker EF, Bonsall R, Walder DJ: Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis. Neuropsychiatry Neuropsychol Behav Neurol. 2002 Mar;15(1):10-7.</reference_text><pubmed_id>11877547</pubmed_id></reference><reference><reference_text>Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M: Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry. 2003 Jun;60(6):572-6.</reference_text><pubmed_id>12796220</pubmed_id></reference><reference><reference_text>Do KQ, Lauer CJ, Schreiber W, Zollinger M, Gutteck-Amsler U, Cuenod M, Holsboer F: gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem. 1995 Dec;65(6):2652-62.</reference_text><pubmed_id>7595563</pubmed_id></reference><reference><reference_text>Nikisch G, Baumann P, Wiedemann G, Kiessling B, Weisser H, Hertel A, Yoshitake T, Kehr J, Mathe AA: Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF. J Clin Psychopharmacol. 2010 Oct;30(5):496-503. doi: 10.1097/JCP.0b013e3181f2288e.</reference_text><pubmed_id>20814316</pubmed_id></reference><reference><reference_text>Fukushima T, Iizuka H, Yokota A, Suzuki T, Ohno C, Kono Y, Nishikiori M, Seki A, Ichiba H, Watanabe Y, Hongo S, Utsunomiya M, Nakatani M, Sadamoto K, Yoshio T: Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One. 2014 Jul 8;9(7):e101652. doi: 10.1371/journal.pone.0101652. eCollection 2014.</reference_text><pubmed_id>25004141</pubmed_id></reference><reference><reference_text>Koike S, Bundo M, Iwamoto K, Suga M, Kuwabara H, Ohashi Y, Shinoda K, Takano Y, Iwashiro N, Satomura Y, Nagai T, Natsubori T, Tada M, Yamasue H, Kasai K: A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study. Transl Psychiatry. 2014 Apr 8;4:e379. doi: 10.1038/tp.2014.19.</reference_text><pubmed_id>24713860</pubmed_id></reference><reference><reference_text>Ballesteros A, Summerfelt A, Du X, Jiang P, Chiappelli J, Tagamets M, O'Donnell P, Kochunov P, Hong LE: Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia. Clin Neurophysiol. 2013 Nov;124(11):2209-15. doi: 10.1016/j.clinph.2013.05.021. Epub 2013 Jun 30.</reference_text><pubmed_id>23823132</pubmed_id></reference><reference><reference_text>Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel FA: Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry. 1985 Sep;147:276-82.</reference_text><pubmed_id>2415198</pubmed_id></reference><reference><reference_text>Pickar D, Breier A, Hsiao JK, Doran AR, Wolkowitz OM, Pato CN, Konicki PE, Potter WZ: Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Arch Gen Psychiatry. 1990 Jul;47(7):641-8.</reference_text><pubmed_id>1694425</pubmed_id></reference><reference><reference_text>Prell GD, Green JP, Kaufmann CA, Khandelwal JK, Morrishow AM, Kirch DG, Linnoila M, Wyatt RJ: Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res. 1995 Jan;14(2):93-104.</reference_text><pubmed_id>7711000</pubmed_id></reference><reference><reference_text>Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B: Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology. 2009;59(2):123-9. doi: 10.1159/000213565. Epub 2009 Apr 22.</reference_text><pubmed_id>19390223</pubmed_id></reference><reference><reference_text>Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K, Cao Y, Wang X, Qiu Y, Su M, Zhao A, Wang P, Yang P, Wu J, Feng G, He L, Jia W, Wan C: Potential metabolite markers of schizophrenia. Mol Psychiatry. 2013 Jan;18(1):67-78. doi: 10.1038/mp.2011.131. Epub 2011 Oct 25.</reference_text><pubmed_id>22024767</pubmed_id></reference><reference><reference_text>Xuan J, Pan G, Qiu Y, Yang L, Su M, Liu Y, Chen J, Feng G, Fang Y, Jia W, Xing Q, He L: Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. J Proteome Res. 2011 Dec 2;10(12):5433-43. doi: 10.1021/pr2006796. Epub 2011 Nov  8.</reference_text><pubmed_id>22007635</pubmed_id></reference><reference><reference_text>Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM, Rothermundt M, Bogerts B, Koethe D, Kranaster L, Ohrmann P, Suslow T, McAllister G, Spain M, Barnes A, van Beveren NJ, Baron-Cohen S, Steiner J, Torrey FE, Yolken RH, Bahn S: Identification of a biological signature for schizophrenia in serum. Mol Psychiatry. 2012 May;17(5):494-502. doi: 10.1038/mp.2011.42. Epub 2011 Apr 12.</reference_text><pubmed_id>21483431</pubmed_id></reference><reference><reference_text>Mathe AA, Eberhard G, Saaf J, Wetterberg L: Plasma prostaglandin E2 metabolite--measured as 11-deoxy-15-keto-13,14-dihydro-11 beta,16 xi-cyclo-PGE2--in twins with schizophrenic disorder. Biol Psychiatry. 1986 Sep;21(11):1024-30.</reference_text><pubmed_id>3741918</pubmed_id></reference><reference><reference_text>Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N: Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct. 2002 Jun;20(2):171-5.</reference_text><pubmed_id>11979513</pubmed_id></reference><reference><reference_text>Zumarraga M, Davila R, Basterreche N, Arrue A, Goienetxea B, Zamalloa MI, Erkoreka L, Bustamante S, Inchausti L, Gonzalez-Torres MA, Guimon J: Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients. Neurochem Int. 2010 May-Jun;56(6-7):774-9. doi: 10.1016/j.neuint.2010.02.015. Epub 2010 Mar 4.</reference_text><pubmed_id>20206656</pubmed_id></reference><reference><reference_text>Peters JG: Dopamine, noradrenaline and serotonin spinal fluid metabolites in temporal lobe epileptic patients with schizophrenic symptomatology. Eur Neurol. 1979;18(1):15-8.</reference_text><pubmed_id>436860</pubmed_id></reference><reference><reference_text>Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, Rozen S, Krishnan RR, McEvoy J, Kaddurah-Daouk R: Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry. 2010 Sep;15(9):938-53. doi: 10.1038/mp.2009.33. Epub 2009 Apr 28.</reference_text><pubmed_id>19401681</pubmed_id></reference><reference><reference_text>Gattaz WF, Waldmeier P, Beckmann H: CSF monoamine metabolites in schizophrenic patients. Acta Psychiatr Scand. 1982 Nov;66(5):350-60.</reference_text><pubmed_id>6184954</pubmed_id></reference><reference><reference_text>Nilsson-Todd LK, Nordin C, Jonsson EG, Skogh E, Erhardt S: Cerebrospinal fluid kynurenic acid in male patients with schizophrenia - correlation with monoamine metabolites. Acta Neuropsychiatr. 2007 Feb;19(1):45-52. doi: 10.1111/j.1601-5215.2006.00170.x.</reference_text><pubmed_id>26952797</pubmed_id></reference><reference><reference_text>Cai HL, Li HD, Yan XZ, Sun B, Zhang Q, Yan M, Zhang WY, Jiang P, Zhu RH, Liu YP, Fang PF, Xu P, Yuan HY, Zhang XH, Hu L, Yang W, Ye HS: Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naive schizophrenia patients after treatment with risperidone. J Proteome Res. 2012 Aug 3;11(8):4338-50. doi: 10.1021/pr300459d. Epub 2012 Jul 26.</reference_text><pubmed_id>22800120</pubmed_id></reference><reference><reference_text>Al Awam K, Haussleiter IS, Dudley E, Donev R, Brune M, Juckel G, Thome J: Multiplatform metabolome and proteome profiling identifies serum metabolite and protein signatures as prospective biomarkers for schizophrenia. J Neural Transm (Vienna). 2015 Aug;122 Suppl 1:S111-22. doi: 10.1007/s00702-014-1224-0. Epub 2014 May 1.</reference_text><pubmed_id>24789758</pubmed_id></reference><reference><reference_text>Bicikova M, Hill M, Ripova D, Mohr P, Hampl R: Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia. J Steroid Biochem Mol Biol. 2013 Jan;133:77-83. doi: 10.1016/j.jsbmb.2012.08.009. Epub 2012 Aug 24.</reference_text><pubmed_id>22944140</pubmed_id></reference><reference><reference_text>He Y, Yu Z, Giegling I, Xie L, Hartmann AM, Prehn C, Adamski J, Kahn R, Li Y, Illig T, Wang-Sattler R, Rujescu D: Schizophrenia shows a unique metabolomics signature in plasma. Transl Psychiatry. 2012 Aug 14;2:e149. doi: 10.1038/tp.2012.76.</reference_text><pubmed_id>22892715</pubmed_id></reference><reference><reference_text>Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KR: Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):934-45. Epub 2007 Apr 17.</reference_text><pubmed_id>17440431</pubmed_id></reference><reference><reference_text>Fryar-Williams S, Strobel JE: Biomarkers of a five-domain translational substrate for schizophrenia and schizoaffective psychosis. Biomark Res. 2015 Feb 6;3:3. doi: 10.1186/s40364-015-0028-1. eCollection 2015.</reference_text><pubmed_id>25729574</pubmed_id></reference><reference><reference_text>Oresic M, Seppanen-Laakso T, Sun D, Tang J, Therman S, Viehman R, Mustonen U, van Erp TG, Hyotylainen T, Thompson P, Toga AW, Huttunen MO, Suvisaari J, Kaprio J, Lonnqvist J, Cannon TD: Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia. Genome Med. 2012 Jan 18;4(1):1. doi: 10.1186/gm300.</reference_text><pubmed_id>22257447</pubmed_id></reference></references></disease><disease>Primary hypomagnesemia<references><reference><reference_text>Jin-no Y, Kamiya Y, Okada M, Hirako M, Takada N, Kawaguchi M: Primary hypomagnesemia caused by isolated magnesium malabsorption: atypical case in adult. Intern Med. 1999 Mar;38(3):261-5.</reference_text><pubmed_id>10337938</pubmed_id></reference><reference><reference_text>Vainsel M, Vandevelde G, Smulders J, Vosters M, Hubain P, Loeb H: Tetany due to hypomagnesaemia with secondary hypocalcaemia. Arch Dis Child. 1970 Apr;45(240):254-8.</reference_text><pubmed_id>5419995</pubmed_id></reference><reference><reference_text>Shalev H, Phillip M, Galil A, Carmi R, Landau D: Clinical presentation and outcome in primary familial hypomagnesaemia. Arch Dis Child. 1998 Feb;78(2):127-30.</reference_text><pubmed_id>9579153</pubmed_id></reference><reference><reference_text>Kari JA, Farouq M, Alshaya HO: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Pediatr Nephrol. 2003 Jun;18(6):506-10. Epub 2003 Apr 29.</reference_text><pubmed_id>12720080</pubmed_id></reference></references></disease><disease>Hyperlipoproteinemia<references><reference><reference_text>Sinha S, Misra A, Kumar V, Jagannathan NR, Bal CS, Pandey RM, Singhania R, Deepak: Proton magnetic resonance spectroscopy and single photon emission computed tomography study of the brain in asymptomatic young hyperlipidaemic Asian Indians in North India show early abnormalities. Clin Endocrinol (Oxf). 2004 Aug;61(2):182-9.</reference_text><pubmed_id>15272912</pubmed_id></reference><reference><reference_text>Nelson RH: Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013 Mar</reference_text><pubmed_id>40(1):195-211. doi: 10.1016/j.pop.2012.11.003. Epub 2012 Dec  4.</pubmed_id></reference><reference><reference_text>Cantin B, Boudriau S, Bertrand M, Brun LD, Gagne C, Rogers PA, Ven Murthy MR, Lupien PJ, Julien P: Hemolysis in primary lipoprotein lipase deficiency. Metabolism. 1995 May;44(5):652-8.</reference_text><pubmed_id>7752915</pubmed_id></reference></references></disease><disease>Abetalipoproteinemia<references><reference><reference_text>Dawson G, Kruski AW, Scanu AM: Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J Lipid Res. 1976 Mar;17(2):125-31.</reference_text><pubmed_id>178813</pubmed_id></reference><reference><reference_text>Lazaro RP, Dentinger MP, Rodichok LD, Barron KD, Satya-Murti S: Muscle pathology in Bassen-Kornzweig syndrome and vitamin E deficiency. Am J Clin Pathol. 1986 Sep;86(3):378-87.</reference_text><pubmed_id>2944375</pubmed_id></reference></references></disease><disease>Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis<references><reference><reference_text>Breckenridge WC, Alaupovic P, Cox DW, Little JA: Apolipoprotein and lipoprotein concentrations in familial apolipoprotein C-II deficiency. Atherosclerosis. 1982 Aug;44(2):223-35.</reference_text><pubmed_id>7138621</pubmed_id></reference><reference><reference_text>Fukami M, Hasegawa T, Horikawa R, Ohashi T, Nishimura G, Homma K, Ogata T: Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr Res. 2006 Feb;59(2):276-80. doi: 10.1203/01.pdr.0000195825.31504.28.</reference_text><pubmed_id>16439592</pubmed_id></reference></references></disease><disease>Cerebrotendinous xanthomatosis<references><reference><reference_text>Halperin G, Elisaf M, Leitersdorf E, Harats D: A new method for determination of serum cholestanol by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2000 Jun 9;742(2):345-52.</reference_text><pubmed_id>10901139</pubmed_id></reference><reference><reference_text>Siman-Tov T, Meiner V, Gadoth N: Could steroids mask the diagnosis of cerebrotendinous xanthomatosis? J Neurol Sci. 2006 Apr 15;243(1-2):83-6. Epub 2006 Jan 30.</reference_text><pubmed_id>16445943</pubmed_id></reference><reference><reference_text>Agrawal NK, Garg S: Cerebrotendinous xanthomatosis: a rare disorder with a rare presentation. BMJ Case Rep. 2012 Sep 21;2012. pii: bcr-2012-006202. doi: 10.1136/bcr-2012-006202.</reference_text><pubmed_id>23001091</pubmed_id></reference></references></disease><disease>3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency<references><reference><reference_text>Thompson GN, Hsu BY, Pitt JJ, Treacy E, Stanley CA: Fasting hypoketotic coma in a child with deficiency of mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase. N Engl J Med. 1997 Oct 23;337(17):1203-7. doi: 10.1056/NEJM199710233371704.</reference_text><pubmed_id>9337379</pubmed_id></reference><reference><reference_text>Morris AA, Lascelles CV, Olpin SE, Lake BD, Leonard JV, Quant PA: Hepatic mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme a synthase deficiency. Pediatr Res. 1998 Sep;44(3):392-6. doi: 10.1203/00006450-199809000-00021.</reference_text><pubmed_id>9727719</pubmed_id></reference><reference><reference_text>Conboy E, Vairo F, Schultz M, Agre K, Ridsdale R, Deyle D, Oglesbee D, Gavrilov D, Klee EW, Lanpher B: Mitochondrial 3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency: Unique Presenting Laboratory Values and a Review of Biochemical and Clinical Features. JIMD Rep. 2017 Oct 14. doi: 10.1007/8904_2017_59.</reference_text><pubmed_id>29030856</pubmed_id></reference></references></disease><disease>Hypercholesterolemia, familial<references><reference><reference_text>Kwiterovich PO Jr, Fredrickson DS, Levy RI: Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest. 1974 May;53(5):1237-49. doi: 10.1172/JCI107670.</reference_text><pubmed_id>4363406</pubmed_id></reference></references></disease><disease>SC4MOL deficiency<references><reference><reference_text>He M, Kratz LE, Michel JJ, Vallejo AN, Ferris L, Kelley RI, Hoover JJ, Jukic D, Gibson KM, Wolfe LA, Ramachandran D, Zwick ME, Vockley J: Mutations in the human SC4MOL gene encoding a methyl sterol oxidase cause psoriasiform dermatitis, microcephaly, and developmental delay. J Clin Invest. 2011 Mar;121(3):976-84. doi: 10.1172/JCI42650.</reference_text><pubmed_id>21285510</pubmed_id></reference></references></disease><disease>Chondrodysplasia punctata, X-linked dominant<references><reference><reference_text>Aughton DJ, Kelley RI, Metzenberg A, Pureza V, Pauli RM: X-linked dominant chondrodysplasia punctata (CDPX2) caused by single gene mosaicism in a male. Am J Med Genet A. 2003 Jan 30;116A(3):255-60. doi: 10.1002/ajmg.a.10852.</reference_text><pubmed_id>12503102</pubmed_id></reference></references></disease><disease>Desmosterolosis<references><reference><reference_text>Andersson HC, Kratz L, Kelley R: Desmosterolosis presenting with multiple congenital anomalies and profound developmental delay. Am J Med Genet. 2002 Dec 15;113(4):315-9. doi: 10.1002/ajmg.b.10873.</reference_text><pubmed_id>12457401</pubmed_id></reference></references></disease><disease>Donohue Syndrome<references><reference><reference_text>Nijim Y, Awni Y, Adawi A, Bowirrat A: Classic Case Report of Donohue Syndrome (Leprechaunism; OMIM *246200): The Impact of Consanguineous Mating. Medicine (Baltimore). 2016 Feb;95(6):e2710. doi: 10.1097/MD.0000000000002710.</reference_text><pubmed_id>26871809</pubmed_id></reference></references></disease><disease>Leptin Deficiency or Dysfunction<references><reference><reference_text>Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O'Rahilly S: Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999 Sep 16;341(12):879-84. doi: 10.1056/NEJM199909163411204.</reference_text><pubmed_id>10486419</pubmed_id></reference></references></disease><disease>Duchenne Muscular Dystrophy<references><reference><reference_text>Nakagawa T, Takeuchi A, Kakiuchi R, Lee T, Yagi M, Awano H, Iijima K, Takeshima Y, Urade Y, Matsuo M: A prostaglandin D2 metabolite is elevated in the urine of Duchenne muscular dystrophy patients and increases further from 8 years old. Clin Chim Acta. 2013 Aug 23;423:10-4. doi: 10.1016/j.cca.2013.03.031. Epub 2013 Apr 19.</reference_text><pubmed_id>23603101</pubmed_id></reference><reference><reference_text>Srivastava NK, Pradhan S, Mittal B, Gowda GA: High resolution NMR based analysis of serum lipids in Duchenne muscular dystrophy patients and its possible diagnostic significance. NMR Biomed. 2010 Jan;23(1):13-22. doi: 10.1002/nbm.1419.</reference_text><pubmed_id>19787747</pubmed_id></reference><reference><reference_text>Horster I, Weigt-Usinger K, Carmann C, Chobanyan-Jurgens K, Kohler C, Schara U, Kayacelebi AA, Beckmann B, Tsikas D, Lucke T: The L-arginine/NO pathway and homoarginine are altered in Duchenne muscular dystrophy and improved by glucocorticoids. Amino Acids. 2015 Sep;47(9):1853-63. doi: 10.1007/s00726-015-2018-x. Epub 2015 Jun 12.</reference_text><pubmed_id>26066683</pubmed_id></reference></references></disease><disease>Lecithin:cholesterol Acyltransferase Deficiency<references><reference><reference_text>Idzior-Walus B, Sieradzki J, Kostner G, Malecki MT, Klupa T, Wesolowska T, Rostworowski W, Hartwich J, Walus M, Kiec AD, Naruszewicz M: Familial lecithin-cholesterol acyltransferase deficiency: biochemical characteristics and molecular analysis of a new LCAT mutation in a Polish family. Atherosclerosis. 2006 Apr;185(2):413-20. Epub 2005 Jul 26.</reference_text><pubmed_id>16051254</pubmed_id></reference></references></disease><disease>Lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lipodystrophy, Congenital Generalized<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Oculocerebrorenal syndrome<references><reference><reference_text>Charnas LR, Bernardini I, Rader D, Hoeg JM, Gahl WA: Clinical and laboratory findings in the oculocerebrorenal syndrome of Lowe, with special reference to growth and renal function. N Engl J Med. 1991 May 9;324(19):1318-25. doi: 10.1056/NEJM199105093241904.</reference_text><pubmed_id>2017228</pubmed_id></reference></references></disease><disease>Familial partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lathosterolosis<references><reference><reference_text>Brunetti-Pierri N, Corso G, Rossi M, Ferrari P, Balli F, Rivasi F, Annunziata I, Ballabio A, Russo AD, Andria G, Parenti G: Lathosterolosis, a novel multiple-malformation/mental retardation syndrome due to deficiency of 3beta-hydroxysteroid-delta5-desaturase. Am J Hum Genet. 2002 Oct;71(4):952-8. Epub 2002 Aug 20.</reference_text><pubmed_id>12189593</pubmed_id></reference><reference><reference_text>Ho AC, Fung CW, Siu TS, Ma OC, Lam CW, Tam S, Wong VC: Lathosterolosis: a disorder of cholesterol biosynthesis resembling smith-lemli-opitz syndrome. JIMD Rep. 2014;12:129-34. doi: 10.1007/8904_2013_255. Epub 2013 Oct 20.</reference_text><pubmed_id>24142275</pubmed_id></reference></references></disease><disease>Partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Multiple sclerosis<references><reference><reference_text>Lutz NW, Viola A, Malikova I, Confort-Gouny S, Audoin B, Ranjeva JP, Pelletier J, Cozzone PJ: Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One. 2007 Jul 4;2(7):e595.</reference_text><pubmed_id>17611627</pubmed_id></reference><reference><reference_text>Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U, Hillert J, Bjorkhem I: Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med. 2004 Feb;42(2):186-91.</reference_text><pubmed_id>15061359</pubmed_id></reference><reference><reference_text>Leoni V, Lutjohann D, Masterman T: Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis. J Lipid Res. 2005 Feb;46(2):191-5. Epub 2004 Dec 1.</reference_text><pubmed_id>15576852</pubmed_id></reference><reference><reference_text>Calabrese V, Scapagnini G, Ravagna A, Bella R, Butterfield DA, Calvani M, Pennisi G, Giuffrida Stella AM: Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem Res. 2003 Sep;28(9):1321-8.</reference_text><pubmed_id>12938853</pubmed_id></reference><reference><reference_text>Shaw CE, Dunbar PR, Macaulay HA, Neale TJ: Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol. 1995 Jan;242(2):53-8.</reference_text><pubmed_id>7707089</pubmed_id></reference><reference><reference_text>Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.</reference_text><pubmed_id>17384003</pubmed_id></reference><reference><reference_text>Syburra C, Passi S: Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh (1999). 1999 May-Jun;71(3):112-5.</reference_text><pubmed_id>10609336</pubmed_id></reference><reference><reference_text>Forte G, Visconti A, Santucci S, Ghazaryan A, Figa-Talamanca L, Cannoni S, Bocca B, Pino A, Violante N, Alimonti A, Salvetti M, Ristori G: Quantification of chemical elements in blood of patients affected by multiple sclerosis. Ann Ist Super Sanita. 2005;41(2):213-6.</reference_text><pubmed_id>16244395</pubmed_id></reference><reference><reference_text>Toncev G, Milicic B, Toncev S, Samardzic G: Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol. 2002 May;9(3):221-6.</reference_text><pubmed_id>11985629</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, Bamonti F, Capello E, Mancardi GL, Scarpini E: Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res. 2010 May 28;1333:64-71. doi: 10.1016/j.brainres.2010.03.073. Epub 2010 Mar 27.</reference_text><pubmed_id>20347721</pubmed_id></reference><reference><reference_text>Matsushita T, Isobe N, Kawajiri M, Mogi M, Tsukuda K, Horiuchi M, Ohyagi Y, Kira J: CSF angiotensin II and angiotensin-converting enzyme levels in anti-aquaporin-4 autoimmunity. J Neurol Sci. 2010 Aug 15;295(1-2):41-5. doi: 10.1016/j.jns.2010.05.014. Epub 2010 Jun 11.</reference_text><pubmed_id>20541774</pubmed_id></reference><reference><reference_text>Ghabaee M, Jabedari B, Al-E-Eshagh N, Ghaffarpour M, Asadi F: Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients. Int J Neurosci. 2010 Apr;120(4):301-4. doi: 10.3109/00207451003695690.</reference_text><pubmed_id>20374079</pubmed_id></reference><reference><reference_text>Kawajiri M, Mogi M, Osoegawa M, Matsuoka T, Tsukuda K, Kohara K, Horiuchi M, Miki T, Kira JI: Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler. 2008 May;14(4):557-60. doi: 10.1177/1352458507085760.</reference_text><pubmed_id>18562510</pubmed_id></reference><reference><reference_text>Visconti A, Cotichini R, Cannoni S, Bocca B, Forte G, Ghazaryan A, Santucci S, D'Ippolito C, Stazi MA, Salvetti M, Alimonti A, Ristori G: Concentration of elements in serum of patients affected by multiple sclerosis with first demyelinating episode: a six-month longitudinal follow-up study. Ann Ist Super Sanita. 2005;41(2):217-22.</reference_text><pubmed_id>16244396</pubmed_id></reference></references></disease><disease>Inflammatory bowel disease<references><reference><reference_text>Lee T, Clavel T, Smirnov K, Schmidt A, Lagkouvardos I, Walker A, Lucio M, Michalke B, Schmitt-Kopplin P, Fedorak R, Haller D: Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. 2017 May;66(5):863-871. doi: 10.1136/gutjnl-2015-309940. Epub 2016 Feb 4.</reference_text><pubmed_id>26848182</pubmed_id></reference><reference><reference_text>Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158.</reference_text><pubmed_id>27609529</pubmed_id></reference></references></disease><disease>Colorectal cancer<references><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B: Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009 Apr;22(3):342-8. doi: 10.1002/nbm.1345.</reference_text><pubmed_id>19006102</pubmed_id></reference><reference><reference_text>Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP: Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One. 2013 Aug 6;8(8):e70803. doi: 10.1371/journal.pone.0070803. Print 2013.</reference_text><pubmed_id>23940645</pubmed_id></reference><reference><reference_text>Phua LC, Chue XP, Koh PK, Cheah PY, Ho HK, Chan EC: Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biol Ther. 2014 Apr;15(4):389-97. doi: 10.4161/cbt.27625. Epub 2014 Jan 14.</reference_text><pubmed_id>24424155</pubmed_id></reference><reference><reference_text>Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB: Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010 Feb 15;8:13. doi: 10.1186/1741-7015-8-13.</reference_text><pubmed_id>20156336</pubmed_id></reference><reference><reference_text>Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, Ni Y, Zhao A, Xu LX, Cai S, Jia W: Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res. 2009 Oct;8(10):4844-50. doi: 10.1021/pr9004162.</reference_text><pubmed_id>19678709</pubmed_id></reference><reference><reference_text>Cheng Y, Xie G, Chen T, Qiu Y, Zou X, Zheng M, Tan B, Feng B, Dong T, He P, Zhao L, Zhao A, Xu LX, Zhang Y, Jia W: Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res. 2012 Feb 3;11(2):1354-63. doi: 10.1021/pr201001a. Epub 2011 Dec 28.</reference_text><pubmed_id>22148915</pubmed_id></reference><reference><reference_text>Ni Y, Xie G, Jia W: Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res. 2014 Sep 5;13(9):3857-70. doi: 10.1021/pr500443c. Epub 2014 Aug 14.</reference_text><pubmed_id>25105552</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference><reference><reference_text>Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18.</reference_text><pubmed_id>25037050</pubmed_id></reference><reference><reference_text>Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016.</reference_text><pubmed_id>27015276</pubmed_id></reference><reference><reference_text>Lin Y, Ma C, Liu C, Wang Z, Yang J, Liu X, Shen Z, Wu R: NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer. Oncotarget. 2016 May 17;7(20):29454-64. doi: 10.18632/oncotarget.8762.</reference_text><pubmed_id>27107423</pubmed_id></reference><reference><reference_text>Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016.</reference_text><pubmed_id>27275383</pubmed_id></reference><reference><reference_text>Wang X, Wang J, Rao B, Deng L: Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals. Exp Ther Med. 2017 Jun;13(6):2848-2854. doi: 10.3892/etm.2017.4367. Epub 2017 Apr 20.</reference_text><pubmed_id>28587349</pubmed_id></reference><reference><reference_text>Silke Matysik, Caroline Ivanne Le Roy, Gerhard Liebisch, Sandrine Paule Claus. Metabolomics of fecal samples: A practical consideration. Trends in Food Science &amp; Technology. Vol. 57, Part B, Nov. 2016, p.244-255: http://www.sciencedirect.com/science/article/pii/S0924224416301984</reference_text><pubmed_id>28587349</pubmed_id></reference></references></disease><disease>Gallbladder disease<references><reference><reference_text>Lapidus A, Akerlund JE, Einarsson C: Gallbladder bile composition in patients with Crohn 's disease. World J Gastroenterol. 2006 Jan 7;12(1):70-4.</reference_text><pubmed_id>16440420</pubmed_id></reference><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference><reference><reference_text>Mizuno S, Tazuma S, Kajiyama G: Stabilization of biliary lipid particles by ursodeoxycholic acid. Prolonged nucleation time in human gallbladder bile. Dig Dis Sci. 1993 Apr;38(4):684-93.</reference_text><pubmed_id>8462368</pubmed_id></reference><reference><reference_text>Hillebrant CG, Axelson M, Bjorkhem I, Wang FH, Nyberg B, Einarsson C: Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients. Eur J Clin Invest. 1998 Apr;28(4):324-8.</reference_text><pubmed_id>9615912</pubmed_id></reference></references></disease><disease>Cholelithiasis<references><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference></references></disease><disease>Stomach cancer<references><reference><reference_text>Higashijima H, Ichimiya H, Nakano T, Yamashita H, Kuroki S, Satoh H, Chijiiwa K, Tanaka M: Deconjugation of bilirubin accelerates coprecipitation of cholesterol, fatty acids, and mucin in human bile--in vitro study. J Gastroenterol. 1996 Dec;31(6):828-35.</reference_text><pubmed_id>9027647</pubmed_id></reference><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Song H, Peng JS, Dong-Sheng Y, Yang ZL, Liu HL, Zeng YK, Shi XP, Lu BY: Serum metabolic profiling of human gastric cancer based on gas chromatography/mass spectrometry. Braz J Med Biol Res. 2012 Jan;45(1):78-85. Epub 2011 Nov 25.</reference_text><pubmed_id>22124703</pubmed_id></reference><reference><reference_text>Yu L, Aa J, Xu J, Sun M, Qian S, Cheng L, Yang S, Shi R: Metabolomic phenotype of gastric cancer and precancerous stages based on gas chromatography time-of-flight mass spectrometry. J Gastroenterol Hepatol. 2011 Aug;26(8):1290-7. doi: 10.1111/j.1440-1746.2011.06724.x.</reference_text><pubmed_id>21443661</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference></references></disease><disease>Acute myelogenous leukemia<references><reference><reference_text>Tatidis L, Vitols S, Gruber A, Paul C, Axelson M: Cholesterol catabolism in patients with acute myelogenous leukemia and hypocholesterolemia: suppressed levels of a circulating marker for bile acid synthesis. Cancer Lett. 2001 Sep 20;170(2):169-75.</reference_text><pubmed_id>11463495</pubmed_id></reference></references></disease><disease>Hypercholesterolemia<references><reference><reference_text>Thelen KM, Laaksonen R, Paiva H, Lehtimaki T, Lutjohann D: High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels. J Clin Pharmacol. 2006 Jul;46(7):812-6.</reference_text><pubmed_id>16809807</pubmed_id></reference><reference><reference_text>Tamasawa N, Tamasawa A, Takebe K: Higher levels of plasma cholesterol sulfate in patients with liver cirrhosis and hypercholesterolemia. Lipids. 1993 Sep;28(9):833-6.</reference_text><pubmed_id>8231659</pubmed_id></reference><reference><reference_text>Kim DH, Lee KJ, Heo GS: Analysis of cholesterol and cholesteryl esters in human serum using capillary supercritical fluid chromatography. J Chromatogr B Biomed Appl. 1994 Apr 22;655(1):1-8.</reference_text><pubmed_id>8061816</pubmed_id></reference><reference><reference_text>Authors unspecified: Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med. 1988 Jan;148(1):36-69.</reference_text><pubmed_id>3422148</pubmed_id></reference></references></disease><disease>Cholesteryl ester storage disease<references><reference><reference_text>Rassoul F, Richter V, Lohse P, Naumann A, Purschwitz K, Keller E: Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease. Int J Clin Pharmacol Ther. 2001 May;39(5):199-204.</reference_text><pubmed_id>11380065</pubmed_id></reference><reference><reference_text>Chatrath H, Keilin S, Attar BM: Cholesterol ester storage disease (CESD) diagnosed in an asymptomatic adult. Dig Dis Sci. 2009 Jan;54(1):168-73. doi: 10.1007/s10620-008-0310-2. Epub 2008 May 14.</reference_text><pubmed_id>18478331</pubmed_id></reference><reference><reference_text>Bernstein DL, Hulkova H, Bialer MG, Desnick RJ: Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol. 2013 Jun;58(6):1230-43. doi: 10.1016/j.jhep.2013.02.014. Epub 2013 Feb 26.</reference_text><pubmed_id>23485521</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Cystinosis<references><reference><reference_text>Ueda M, O'Brien K, Rosing DR, Ling A, Kleta R, McAreavey D, Bernardini I, Gahl WA: Coronary artery and other vascular calcifications in patients with cystinosis after kidney transplantation. Clin J Am Soc Nephrol. 2006 May;1(3):555-62. Epub 2006 Feb 8.</reference_text><pubmed_id>17699259</pubmed_id></reference><reference><reference_text>Gahl WA, Bernardini I, Dalakas M, Rizzo WB, Harper GS, Hoeg JM, Hurko O, Bernar J: Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome. J Clin Invest. 1988 Feb;81(2):549-60.</reference_text><pubmed_id>3276734</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Smith-Lemli-Opitz syndrome<references><reference><reference_text>van Rooij A, Nijenhuis AA, Wijburg FA, Schutgens RB: Highly increased CSF concentrations of cholesterol precursors in Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 1997 Aug;20(4):578-80.</reference_text><pubmed_id>9266395</pubmed_id></reference><reference><reference_text>Honda M, Tint GS, Honda A, Salen G, Shefer S, Batta AK, Matsuzaki Y, Tanaka N: Regulation of cholesterol biosynthetic pathway in patients with the Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2000 Jul;23(5):464-74.</reference_text><pubmed_id>10947201</pubmed_id></reference><reference><reference_text>Rossi M, Federico G, Corso G, Parenti G, Battagliese A, Frascogna AR, Della Casa R, Dello Russo A, Strisciuglio P, Saggese G, Andria G: Vitamin D status in patients affected by Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2005;28(1):69-80.</reference_text><pubmed_id>15702407</pubmed_id></reference><reference><reference_text>Johnson DW, ten Brink HJ, Jakobs C: A rapid screening procedure for cholesterol and dehydrocholesterol by electrospray ionization tandem mass spectrometry. J Lipid Res. 2001 Oct;42(10):1699-705.</reference_text><pubmed_id>11590227</pubmed_id></reference></references></disease><disease>Prostate cancer<references><reference><reference_text>Nyman DW, Suzanne Stratton M, Kopplin MJ, Dalkin BL, Nagle RB, Jay Gandolfi A: Selenium and selenomethionine levels in prostate cancer patients. Cancer Detect Prev. 2004;28(1):8-16.</reference_text><pubmed_id>15041072</pubmed_id></reference><reference><reference_text>Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, Egevad L, Tjonneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, Palli D, Vineis P, Tumino R, Berrino F, Kiemeney L, Bueno-de-Mesquita HB, Quiros JR, Gonzalez CA, Martinez C, Larranaga N, Chirlaque MD, Ardanaz E, Stattin P, Hallmans G, Khaw KT, Bingham S, Slimani N, Ferrari P, Rinaldi S, Riboli E: Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr. 2007 Sep;86(3):672-81.</reference_text><pubmed_id>17823432</pubmed_id></reference><reference><reference_text>Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762.</reference_text><pubmed_id>19212411</pubmed_id></reference><reference><reference_text>Puah CM, Williams G, Ghanadian R: Urinary unconjugated 5 alpha-androstane-3 alpha, 17 beta-diol in patients with prostatic tumours. Urol Res. 1982;10(2):81-4.</reference_text><pubmed_id>6180540</pubmed_id></reference><reference><reference_text>Thysell E, Surowiec I, Hornberg E, Crnalic S, Widmark A, Johansson AI, Stattin P, Bergh A, Moritz T, Antti H, Wikstrom P: Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One. 2010 Dec 3;5(12):e14175. doi: 10.1371/journal.pone.0014175.</reference_text><pubmed_id>21151972</pubmed_id></reference><reference><reference_text>Soliman LC, Hui Y, Hewavitharana AK, Chen DD: Monitoring potential prostate cancer biomarkers in urine by capillary electrophoresis-tandem mass spectrometry. J Chromatogr A. 2012 Dec 7;1267:162-9. doi: 10.1016/j.chroma.2012.07.021. Epub 2012 Jul 14.</reference_text><pubmed_id>22824219</pubmed_id></reference><reference><reference_text>Madu CO, Lu Y: Novel diagnostic biomarkers for prostate cancer. J Cancer. 2010 Oct 6;1:150-77.</reference_text><pubmed_id>20975847</pubmed_id></reference></references></disease><disease>Schizophrenia<references><reference><reference_text>Harnryd C, Bjerkenstedt L, Grimm VE, Sedvall G: Reduction of MOPEG levels in cerebrospinal fluid of psychotic women after electroconvulsive treatment. Psychopharmacology (Berl). 1979 Aug 8;64(2):131-4.</reference_text><pubmed_id>115032</pubmed_id></reference><reference><reference_text>Kobayashi K, Koide Y, Yoshino K, Shohmori T: [P-hydroxyphenylacetic acid concentrations in cerebrospinal fluid]. No To Shinkei. 1982 Aug;34(8):769-74.</reference_text><pubmed_id>7126379</pubmed_id></reference><reference><reference_text>Alfredsson G, Wiesel FA: Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology (Berl). 1989;99(3):322-7.</reference_text><pubmed_id>2480613</pubmed_id></reference><reference><reference_text>Heresco-Levy U, Bar G, Levin R, Ermilov M, Ebstein RP, Javitt DC: High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. Schizophr Res. 2007 Mar;91(1-3):14-21. Epub 2007 Feb 2.</reference_text><pubmed_id>17276036</pubmed_id></reference><reference><reference_text>Walker EF, Bonsall R, Walder DJ: Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis. Neuropsychiatry Neuropsychol Behav Neurol. 2002 Mar;15(1):10-7.</reference_text><pubmed_id>11877547</pubmed_id></reference><reference><reference_text>Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M: Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry. 2003 Jun;60(6):572-6.</reference_text><pubmed_id>12796220</pubmed_id></reference><reference><reference_text>Do KQ, Lauer CJ, Schreiber W, Zollinger M, Gutteck-Amsler U, Cuenod M, Holsboer F: gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem. 1995 Dec;65(6):2652-62.</reference_text><pubmed_id>7595563</pubmed_id></reference><reference><reference_text>Nikisch G, Baumann P, Wiedemann G, Kiessling B, Weisser H, Hertel A, Yoshitake T, Kehr J, Mathe AA: Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF. J Clin Psychopharmacol. 2010 Oct;30(5):496-503. doi: 10.1097/JCP.0b013e3181f2288e.</reference_text><pubmed_id>20814316</pubmed_id></reference><reference><reference_text>Fukushima T, Iizuka H, Yokota A, Suzuki T, Ohno C, Kono Y, Nishikiori M, Seki A, Ichiba H, Watanabe Y, Hongo S, Utsunomiya M, Nakatani M, Sadamoto K, Yoshio T: Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One. 2014 Jul 8;9(7):e101652. doi: 10.1371/journal.pone.0101652. eCollection 2014.</reference_text><pubmed_id>25004141</pubmed_id></reference><reference><reference_text>Koike S, Bundo M, Iwamoto K, Suga M, Kuwabara H, Ohashi Y, Shinoda K, Takano Y, Iwashiro N, Satomura Y, Nagai T, Natsubori T, Tada M, Yamasue H, Kasai K: A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study. Transl Psychiatry. 2014 Apr 8;4:e379. doi: 10.1038/tp.2014.19.</reference_text><pubmed_id>24713860</pubmed_id></reference><reference><reference_text>Ballesteros A, Summerfelt A, Du X, Jiang P, Chiappelli J, Tagamets M, O'Donnell P, Kochunov P, Hong LE: Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia. Clin Neurophysiol. 2013 Nov;124(11):2209-15. doi: 10.1016/j.clinph.2013.05.021. Epub 2013 Jun 30.</reference_text><pubmed_id>23823132</pubmed_id></reference><reference><reference_text>Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel FA: Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry. 1985 Sep;147:276-82.</reference_text><pubmed_id>2415198</pubmed_id></reference><reference><reference_text>Pickar D, Breier A, Hsiao JK, Doran AR, Wolkowitz OM, Pato CN, Konicki PE, Potter WZ: Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Arch Gen Psychiatry. 1990 Jul;47(7):641-8.</reference_text><pubmed_id>1694425</pubmed_id></reference><reference><reference_text>Prell GD, Green JP, Kaufmann CA, Khandelwal JK, Morrishow AM, Kirch DG, Linnoila M, Wyatt RJ: Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res. 1995 Jan;14(2):93-104.</reference_text><pubmed_id>7711000</pubmed_id></reference><reference><reference_text>Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B: Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology. 2009;59(2):123-9. doi: 10.1159/000213565. Epub 2009 Apr 22.</reference_text><pubmed_id>19390223</pubmed_id></reference><reference><reference_text>Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K, Cao Y, Wang X, Qiu Y, Su M, Zhao A, Wang P, Yang P, Wu J, Feng G, He L, Jia W, Wan C: Potential metabolite markers of schizophrenia. Mol Psychiatry. 2013 Jan;18(1):67-78. doi: 10.1038/mp.2011.131. Epub 2011 Oct 25.</reference_text><pubmed_id>22024767</pubmed_id></reference><reference><reference_text>Xuan J, Pan G, Qiu Y, Yang L, Su M, Liu Y, Chen J, Feng G, Fang Y, Jia W, Xing Q, He L: Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. J Proteome Res. 2011 Dec 2;10(12):5433-43. doi: 10.1021/pr2006796. Epub 2011 Nov  8.</reference_text><pubmed_id>22007635</pubmed_id></reference><reference><reference_text>Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM, Rothermundt M, Bogerts B, Koethe D, Kranaster L, Ohrmann P, Suslow T, McAllister G, Spain M, Barnes A, van Beveren NJ, Baron-Cohen S, Steiner J, Torrey FE, Yolken RH, Bahn S: Identification of a biological signature for schizophrenia in serum. Mol Psychiatry. 2012 May;17(5):494-502. doi: 10.1038/mp.2011.42. Epub 2011 Apr 12.</reference_text><pubmed_id>21483431</pubmed_id></reference><reference><reference_text>Mathe AA, Eberhard G, Saaf J, Wetterberg L: Plasma prostaglandin E2 metabolite--measured as 11-deoxy-15-keto-13,14-dihydro-11 beta,16 xi-cyclo-PGE2--in twins with schizophrenic disorder. Biol Psychiatry. 1986 Sep;21(11):1024-30.</reference_text><pubmed_id>3741918</pubmed_id></reference><reference><reference_text>Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N: Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct. 2002 Jun;20(2):171-5.</reference_text><pubmed_id>11979513</pubmed_id></reference><reference><reference_text>Zumarraga M, Davila R, Basterreche N, Arrue A, Goienetxea B, Zamalloa MI, Erkoreka L, Bustamante S, Inchausti L, Gonzalez-Torres MA, Guimon J: Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients. Neurochem Int. 2010 May-Jun;56(6-7):774-9. doi: 10.1016/j.neuint.2010.02.015. Epub 2010 Mar 4.</reference_text><pubmed_id>20206656</pubmed_id></reference><reference><reference_text>Peters JG: Dopamine, noradrenaline and serotonin spinal fluid metabolites in temporal lobe epileptic patients with schizophrenic symptomatology. Eur Neurol. 1979;18(1):15-8.</reference_text><pubmed_id>436860</pubmed_id></reference><reference><reference_text>Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, Rozen S, Krishnan RR, McEvoy J, Kaddurah-Daouk R: Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry. 2010 Sep;15(9):938-53. doi: 10.1038/mp.2009.33. Epub 2009 Apr 28.</reference_text><pubmed_id>19401681</pubmed_id></reference><reference><reference_text>Gattaz WF, Waldmeier P, Beckmann H: CSF monoamine metabolites in schizophrenic patients. Acta Psychiatr Scand. 1982 Nov;66(5):350-60.</reference_text><pubmed_id>6184954</pubmed_id></reference><reference><reference_text>Nilsson-Todd LK, Nordin C, Jonsson EG, Skogh E, Erhardt S: Cerebrospinal fluid kynurenic acid in male patients with schizophrenia - correlation with monoamine metabolites. Acta Neuropsychiatr. 2007 Feb;19(1):45-52. doi: 10.1111/j.1601-5215.2006.00170.x.</reference_text><pubmed_id>26952797</pubmed_id></reference><reference><reference_text>Cai HL, Li HD, Yan XZ, Sun B, Zhang Q, Yan M, Zhang WY, Jiang P, Zhu RH, Liu YP, Fang PF, Xu P, Yuan HY, Zhang XH, Hu L, Yang W, Ye HS: Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naive schizophrenia patients after treatment with risperidone. J Proteome Res. 2012 Aug 3;11(8):4338-50. doi: 10.1021/pr300459d. Epub 2012 Jul 26.</reference_text><pubmed_id>22800120</pubmed_id></reference><reference><reference_text>Al Awam K, Haussleiter IS, Dudley E, Donev R, Brune M, Juckel G, Thome J: Multiplatform metabolome and proteome profiling identifies serum metabolite and protein signatures as prospective biomarkers for schizophrenia. J Neural Transm (Vienna). 2015 Aug;122 Suppl 1:S111-22. doi: 10.1007/s00702-014-1224-0. Epub 2014 May 1.</reference_text><pubmed_id>24789758</pubmed_id></reference><reference><reference_text>Bicikova M, Hill M, Ripova D, Mohr P, Hampl R: Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia. J Steroid Biochem Mol Biol. 2013 Jan;133:77-83. doi: 10.1016/j.jsbmb.2012.08.009. Epub 2012 Aug 24.</reference_text><pubmed_id>22944140</pubmed_id></reference><reference><reference_text>He Y, Yu Z, Giegling I, Xie L, Hartmann AM, Prehn C, Adamski J, Kahn R, Li Y, Illig T, Wang-Sattler R, Rujescu D: Schizophrenia shows a unique metabolomics signature in plasma. Transl Psychiatry. 2012 Aug 14;2:e149. doi: 10.1038/tp.2012.76.</reference_text><pubmed_id>22892715</pubmed_id></reference><reference><reference_text>Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KR: Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):934-45. Epub 2007 Apr 17.</reference_text><pubmed_id>17440431</pubmed_id></reference><reference><reference_text>Fryar-Williams S, Strobel JE: Biomarkers of a five-domain translational substrate for schizophrenia and schizoaffective psychosis. Biomark Res. 2015 Feb 6;3:3. doi: 10.1186/s40364-015-0028-1. eCollection 2015.</reference_text><pubmed_id>25729574</pubmed_id></reference><reference><reference_text>Oresic M, Seppanen-Laakso T, Sun D, Tang J, Therman S, Viehman R, Mustonen U, van Erp TG, Hyotylainen T, Thompson P, Toga AW, Huttunen MO, Suvisaari J, Kaprio J, Lonnqvist J, Cannon TD: Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia. Genome Med. 2012 Jan 18;4(1):1. doi: 10.1186/gm300.</reference_text><pubmed_id>22257447</pubmed_id></reference></references></disease><disease>Primary hypomagnesemia<references><reference><reference_text>Jin-no Y, Kamiya Y, Okada M, Hirako M, Takada N, Kawaguchi M: Primary hypomagnesemia caused by isolated magnesium malabsorption: atypical case in adult. Intern Med. 1999 Mar;38(3):261-5.</reference_text><pubmed_id>10337938</pubmed_id></reference><reference><reference_text>Vainsel M, Vandevelde G, Smulders J, Vosters M, Hubain P, Loeb H: Tetany due to hypomagnesaemia with secondary hypocalcaemia. Arch Dis Child. 1970 Apr;45(240):254-8.</reference_text><pubmed_id>5419995</pubmed_id></reference><reference><reference_text>Shalev H, Phillip M, Galil A, Carmi R, Landau D: Clinical presentation and outcome in primary familial hypomagnesaemia. Arch Dis Child. 1998 Feb;78(2):127-30.</reference_text><pubmed_id>9579153</pubmed_id></reference><reference><reference_text>Kari JA, Farouq M, Alshaya HO: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Pediatr Nephrol. 2003 Jun;18(6):506-10. Epub 2003 Apr 29.</reference_text><pubmed_id>12720080</pubmed_id></reference></references></disease><disease>Hyperlipoproteinemia<references><reference><reference_text>Sinha S, Misra A, Kumar V, Jagannathan NR, Bal CS, Pandey RM, Singhania R, Deepak: Proton magnetic resonance spectroscopy and single photon emission computed tomography study of the brain in asymptomatic young hyperlipidaemic Asian Indians in North India show early abnormalities. Clin Endocrinol (Oxf). 2004 Aug;61(2):182-9.</reference_text><pubmed_id>15272912</pubmed_id></reference><reference><reference_text>Nelson RH: Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013 Mar</reference_text><pubmed_id>40(1):195-211. doi: 10.1016/j.pop.2012.11.003. Epub 2012 Dec  4.</pubmed_id></reference><reference><reference_text>Cantin B, Boudriau S, Bertrand M, Brun LD, Gagne C, Rogers PA, Ven Murthy MR, Lupien PJ, Julien P: Hemolysis in primary lipoprotein lipase deficiency. Metabolism. 1995 May;44(5):652-8.</reference_text><pubmed_id>7752915</pubmed_id></reference></references></disease><disease>Abetalipoproteinemia<references><reference><reference_text>Dawson G, Kruski AW, Scanu AM: Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J Lipid Res. 1976 Mar;17(2):125-31.</reference_text><pubmed_id>178813</pubmed_id></reference><reference><reference_text>Lazaro RP, Dentinger MP, Rodichok LD, Barron KD, Satya-Murti S: Muscle pathology in Bassen-Kornzweig syndrome and vitamin E deficiency. Am J Clin Pathol. 1986 Sep;86(3):378-87.</reference_text><pubmed_id>2944375</pubmed_id></reference></references></disease><disease>Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis<references><reference><reference_text>Breckenridge WC, Alaupovic P, Cox DW, Little JA: Apolipoprotein and lipoprotein concentrations in familial apolipoprotein C-II deficiency. Atherosclerosis. 1982 Aug;44(2):223-35.</reference_text><pubmed_id>7138621</pubmed_id></reference><reference><reference_text>Fukami M, Hasegawa T, Horikawa R, Ohashi T, Nishimura G, Homma K, Ogata T: Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr Res. 2006 Feb;59(2):276-80. doi: 10.1203/01.pdr.0000195825.31504.28.</reference_text><pubmed_id>16439592</pubmed_id></reference></references></disease><disease>Cerebrotendinous xanthomatosis<references><reference><reference_text>Halperin G, Elisaf M, Leitersdorf E, Harats D: A new method for determination of serum cholestanol by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2000 Jun 9;742(2):345-52.</reference_text><pubmed_id>10901139</pubmed_id></reference><reference><reference_text>Siman-Tov T, Meiner V, Gadoth N: Could steroids mask the diagnosis of cerebrotendinous xanthomatosis? J Neurol Sci. 2006 Apr 15;243(1-2):83-6. Epub 2006 Jan 30.</reference_text><pubmed_id>16445943</pubmed_id></reference><reference><reference_text>Agrawal NK, Garg S: Cerebrotendinous xanthomatosis: a rare disorder with a rare presentation. BMJ Case Rep. 2012 Sep 21;2012. pii: bcr-2012-006202. doi: 10.1136/bcr-2012-006202.</reference_text><pubmed_id>23001091</pubmed_id></reference></references></disease><disease>3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency<references><reference><reference_text>Thompson GN, Hsu BY, Pitt JJ, Treacy E, Stanley CA: Fasting hypoketotic coma in a child with deficiency of mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase. N Engl J Med. 1997 Oct 23;337(17):1203-7. doi: 10.1056/NEJM199710233371704.</reference_text><pubmed_id>9337379</pubmed_id></reference><reference><reference_text>Morris AA, Lascelles CV, Olpin SE, Lake BD, Leonard JV, Quant PA: Hepatic mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme a synthase deficiency. Pediatr Res. 1998 Sep;44(3):392-6. doi: 10.1203/00006450-199809000-00021.</reference_text><pubmed_id>9727719</pubmed_id></reference><reference><reference_text>Conboy E, Vairo F, Schultz M, Agre K, Ridsdale R, Deyle D, Oglesbee D, Gavrilov D, Klee EW, Lanpher B: Mitochondrial 3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency: Unique Presenting Laboratory Values and a Review of Biochemical and Clinical Features. JIMD Rep. 2017 Oct 14. doi: 10.1007/8904_2017_59.</reference_text><pubmed_id>29030856</pubmed_id></reference></references></disease><disease>Hypercholesterolemia, familial<references><reference><reference_text>Kwiterovich PO Jr, Fredrickson DS, Levy RI: Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest. 1974 May;53(5):1237-49. doi: 10.1172/JCI107670.</reference_text><pubmed_id>4363406</pubmed_id></reference></references></disease><disease>SC4MOL deficiency<references><reference><reference_text>He M, Kratz LE, Michel JJ, Vallejo AN, Ferris L, Kelley RI, Hoover JJ, Jukic D, Gibson KM, Wolfe LA, Ramachandran D, Zwick ME, Vockley J: Mutations in the human SC4MOL gene encoding a methyl sterol oxidase cause psoriasiform dermatitis, microcephaly, and developmental delay. J Clin Invest. 2011 Mar;121(3):976-84. doi: 10.1172/JCI42650.</reference_text><pubmed_id>21285510</pubmed_id></reference></references></disease><disease>Chondrodysplasia punctata, X-linked dominant<references><reference><reference_text>Aughton DJ, Kelley RI, Metzenberg A, Pureza V, Pauli RM: X-linked dominant chondrodysplasia punctata (CDPX2) caused by single gene mosaicism in a male. Am J Med Genet A. 2003 Jan 30;116A(3):255-60. doi: 10.1002/ajmg.a.10852.</reference_text><pubmed_id>12503102</pubmed_id></reference></references></disease><disease>Desmosterolosis<references><reference><reference_text>Andersson HC, Kratz L, Kelley R: Desmosterolosis presenting with multiple congenital anomalies and profound developmental delay. Am J Med Genet. 2002 Dec 15;113(4):315-9. doi: 10.1002/ajmg.b.10873.</reference_text><pubmed_id>12457401</pubmed_id></reference></references></disease><disease>Donohue Syndrome<references><reference><reference_text>Nijim Y, Awni Y, Adawi A, Bowirrat A: Classic Case Report of Donohue Syndrome (Leprechaunism; OMIM *246200): The Impact of Consanguineous Mating. Medicine (Baltimore). 2016 Feb;95(6):e2710. doi: 10.1097/MD.0000000000002710.</reference_text><pubmed_id>26871809</pubmed_id></reference></references></disease><disease>Leptin Deficiency or Dysfunction<references><reference><reference_text>Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O'Rahilly S: Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999 Sep 16;341(12):879-84. doi: 10.1056/NEJM199909163411204.</reference_text><pubmed_id>10486419</pubmed_id></reference></references></disease><disease>Duchenne Muscular Dystrophy<references><reference><reference_text>Nakagawa T, Takeuchi A, Kakiuchi R, Lee T, Yagi M, Awano H, Iijima K, Takeshima Y, Urade Y, Matsuo M: A prostaglandin D2 metabolite is elevated in the urine of Duchenne muscular dystrophy patients and increases further from 8 years old. Clin Chim Acta. 2013 Aug 23;423:10-4. doi: 10.1016/j.cca.2013.03.031. Epub 2013 Apr 19.</reference_text><pubmed_id>23603101</pubmed_id></reference><reference><reference_text>Srivastava NK, Pradhan S, Mittal B, Gowda GA: High resolution NMR based analysis of serum lipids in Duchenne muscular dystrophy patients and its possible diagnostic significance. NMR Biomed. 2010 Jan;23(1):13-22. doi: 10.1002/nbm.1419.</reference_text><pubmed_id>19787747</pubmed_id></reference><reference><reference_text>Horster I, Weigt-Usinger K, Carmann C, Chobanyan-Jurgens K, Kohler C, Schara U, Kayacelebi AA, Beckmann B, Tsikas D, Lucke T: The L-arginine/NO pathway and homoarginine are altered in Duchenne muscular dystrophy and improved by glucocorticoids. Amino Acids. 2015 Sep;47(9):1853-63. doi: 10.1007/s00726-015-2018-x. Epub 2015 Jun 12.</reference_text><pubmed_id>26066683</pubmed_id></reference></references></disease><disease>Lecithin:cholesterol Acyltransferase Deficiency<references><reference><reference_text>Idzior-Walus B, Sieradzki J, Kostner G, Malecki MT, Klupa T, Wesolowska T, Rostworowski W, Hartwich J, Walus M, Kiec AD, Naruszewicz M: Familial lecithin-cholesterol acyltransferase deficiency: biochemical characteristics and molecular analysis of a new LCAT mutation in a Polish family. Atherosclerosis. 2006 Apr;185(2):413-20. Epub 2005 Jul 26.</reference_text><pubmed_id>16051254</pubmed_id></reference></references></disease><disease>Lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lipodystrophy, Congenital Generalized<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Oculocerebrorenal syndrome<references><reference><reference_text>Charnas LR, Bernardini I, Rader D, Hoeg JM, Gahl WA: Clinical and laboratory findings in the oculocerebrorenal syndrome of Lowe, with special reference to growth and renal function. N Engl J Med. 1991 May 9;324(19):1318-25. doi: 10.1056/NEJM199105093241904.</reference_text><pubmed_id>2017228</pubmed_id></reference></references></disease><disease>Familial partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lathosterolosis<references><reference><reference_text>Brunetti-Pierri N, Corso G, Rossi M, Ferrari P, Balli F, Rivasi F, Annunziata I, Ballabio A, Russo AD, Andria G, Parenti G: Lathosterolosis, a novel multiple-malformation/mental retardation syndrome due to deficiency of 3beta-hydroxysteroid-delta5-desaturase. Am J Hum Genet. 2002 Oct;71(4):952-8. Epub 2002 Aug 20.</reference_text><pubmed_id>12189593</pubmed_id></reference><reference><reference_text>Ho AC, Fung CW, Siu TS, Ma OC, Lam CW, Tam S, Wong VC: Lathosterolosis: a disorder of cholesterol biosynthesis resembling smith-lemli-opitz syndrome. JIMD Rep. 2014;12:129-34. doi: 10.1007/8904_2013_255. Epub 2013 Oct 20.</reference_text><pubmed_id>24142275</pubmed_id></reference></references></disease><disease>Partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Multiple sclerosis<references><reference><reference_text>Lutz NW, Viola A, Malikova I, Confort-Gouny S, Audoin B, Ranjeva JP, Pelletier J, Cozzone PJ: Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One. 2007 Jul 4;2(7):e595.</reference_text><pubmed_id>17611627</pubmed_id></reference><reference><reference_text>Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U, Hillert J, Bjorkhem I: Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med. 2004 Feb;42(2):186-91.</reference_text><pubmed_id>15061359</pubmed_id></reference><reference><reference_text>Leoni V, Lutjohann D, Masterman T: Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis. J Lipid Res. 2005 Feb;46(2):191-5. Epub 2004 Dec 1.</reference_text><pubmed_id>15576852</pubmed_id></reference><reference><reference_text>Calabrese V, Scapagnini G, Ravagna A, Bella R, Butterfield DA, Calvani M, Pennisi G, Giuffrida Stella AM: Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem Res. 2003 Sep;28(9):1321-8.</reference_text><pubmed_id>12938853</pubmed_id></reference><reference><reference_text>Shaw CE, Dunbar PR, Macaulay HA, Neale TJ: Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol. 1995 Jan;242(2):53-8.</reference_text><pubmed_id>7707089</pubmed_id></reference><reference><reference_text>Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.</reference_text><pubmed_id>17384003</pubmed_id></reference><reference><reference_text>Syburra C, Passi S: Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh (1999). 1999 May-Jun;71(3):112-5.</reference_text><pubmed_id>10609336</pubmed_id></reference><reference><reference_text>Forte G, Visconti A, Santucci S, Ghazaryan A, Figa-Talamanca L, Cannoni S, Bocca B, Pino A, Violante N, Alimonti A, Salvetti M, Ristori G: Quantification of chemical elements in blood of patients affected by multiple sclerosis. Ann Ist Super Sanita. 2005;41(2):213-6.</reference_text><pubmed_id>16244395</pubmed_id></reference><reference><reference_text>Toncev G, Milicic B, Toncev S, Samardzic G: Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol. 2002 May;9(3):221-6.</reference_text><pubmed_id>11985629</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, Bamonti F, Capello E, Mancardi GL, Scarpini E: Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res. 2010 May 28;1333:64-71. doi: 10.1016/j.brainres.2010.03.073. Epub 2010 Mar 27.</reference_text><pubmed_id>20347721</pubmed_id></reference><reference><reference_text>Matsushita T, Isobe N, Kawajiri M, Mogi M, Tsukuda K, Horiuchi M, Ohyagi Y, Kira J: CSF angiotensin II and angiotensin-converting enzyme levels in anti-aquaporin-4 autoimmunity. J Neurol Sci. 2010 Aug 15;295(1-2):41-5. doi: 10.1016/j.jns.2010.05.014. Epub 2010 Jun 11.</reference_text><pubmed_id>20541774</pubmed_id></reference><reference><reference_text>Ghabaee M, Jabedari B, Al-E-Eshagh N, Ghaffarpour M, Asadi F: Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients. Int J Neurosci. 2010 Apr;120(4):301-4. doi: 10.3109/00207451003695690.</reference_text><pubmed_id>20374079</pubmed_id></reference><reference><reference_text>Kawajiri M, Mogi M, Osoegawa M, Matsuoka T, Tsukuda K, Kohara K, Horiuchi M, Miki T, Kira JI: Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler. 2008 May;14(4):557-60. doi: 10.1177/1352458507085760.</reference_text><pubmed_id>18562510</pubmed_id></reference><reference><reference_text>Visconti A, Cotichini R, Cannoni S, Bocca B, Forte G, Ghazaryan A, Santucci S, D'Ippolito C, Stazi MA, Salvetti M, Alimonti A, Ristori G: Concentration of elements in serum of patients affected by multiple sclerosis with first demyelinating episode: a six-month longitudinal follow-up study. Ann Ist Super Sanita. 2005;41(2):217-22.</reference_text><pubmed_id>16244396</pubmed_id></reference></references></disease><disease>Inflammatory bowel disease<references><reference><reference_text>Lee T, Clavel T, Smirnov K, Schmidt A, Lagkouvardos I, Walker A, Lucio M, Michalke B, Schmitt-Kopplin P, Fedorak R, Haller D: Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. 2017 May;66(5):863-871. doi: 10.1136/gutjnl-2015-309940. Epub 2016 Feb 4.</reference_text><pubmed_id>26848182</pubmed_id></reference><reference><reference_text>Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158.</reference_text><pubmed_id>27609529</pubmed_id></reference></references></disease><disease>Colorectal cancer<references><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B: Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009 Apr;22(3):342-8. doi: 10.1002/nbm.1345.</reference_text><pubmed_id>19006102</pubmed_id></reference><reference><reference_text>Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP: Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One. 2013 Aug 6;8(8):e70803. doi: 10.1371/journal.pone.0070803. Print 2013.</reference_text><pubmed_id>23940645</pubmed_id></reference><reference><reference_text>Phua LC, Chue XP, Koh PK, Cheah PY, Ho HK, Chan EC: Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biol Ther. 2014 Apr;15(4):389-97. doi: 10.4161/cbt.27625. Epub 2014 Jan 14.</reference_text><pubmed_id>24424155</pubmed_id></reference><reference><reference_text>Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB: Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010 Feb 15;8:13. doi: 10.1186/1741-7015-8-13.</reference_text><pubmed_id>20156336</pubmed_id></reference><reference><reference_text>Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, Ni Y, Zhao A, Xu LX, Cai S, Jia W: Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res. 2009 Oct;8(10):4844-50. doi: 10.1021/pr9004162.</reference_text><pubmed_id>19678709</pubmed_id></reference><reference><reference_text>Cheng Y, Xie G, Chen T, Qiu Y, Zou X, Zheng M, Tan B, Feng B, Dong T, He P, Zhao L, Zhao A, Xu LX, Zhang Y, Jia W: Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res. 2012 Feb 3;11(2):1354-63. doi: 10.1021/pr201001a. Epub 2011 Dec 28.</reference_text><pubmed_id>22148915</pubmed_id></reference><reference><reference_text>Ni Y, Xie G, Jia W: Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res. 2014 Sep 5;13(9):3857-70. doi: 10.1021/pr500443c. Epub 2014 Aug 14.</reference_text><pubmed_id>25105552</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference><reference><reference_text>Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18.</reference_text><pubmed_id>25037050</pubmed_id></reference><reference><reference_text>Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016.</reference_text><pubmed_id>27015276</pubmed_id></reference><reference><reference_text>Lin Y, Ma C, Liu C, Wang Z, Yang J, Liu X, Shen Z, Wu R: NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer. Oncotarget. 2016 May 17;7(20):29454-64. doi: 10.18632/oncotarget.8762.</reference_text><pubmed_id>27107423</pubmed_id></reference><reference><reference_text>Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016.</reference_text><pubmed_id>27275383</pubmed_id></reference><reference><reference_text>Wang X, Wang J, Rao B, Deng L: Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals. Exp Ther Med. 2017 Jun;13(6):2848-2854. doi: 10.3892/etm.2017.4367. Epub 2017 Apr 20.</reference_text><pubmed_id>28587349</pubmed_id></reference><reference><reference_text>Silke Matysik, Caroline Ivanne Le Roy, Gerhard Liebisch, Sandrine Paule Claus. Metabolomics of fecal samples: A practical consideration. Trends in Food Science &amp; Technology. Vol. 57, Part B, Nov. 2016, p.244-255: http://www.sciencedirect.com/science/article/pii/S0924224416301984</reference_text><pubmed_id>28587349</pubmed_id></reference></references></disease><disease>Gallbladder disease<references><reference><reference_text>Lapidus A, Akerlund JE, Einarsson C: Gallbladder bile composition in patients with Crohn 's disease. World J Gastroenterol. 2006 Jan 7;12(1):70-4.</reference_text><pubmed_id>16440420</pubmed_id></reference><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference><reference><reference_text>Mizuno S, Tazuma S, Kajiyama G: Stabilization of biliary lipid particles by ursodeoxycholic acid. Prolonged nucleation time in human gallbladder bile. Dig Dis Sci. 1993 Apr;38(4):684-93.</reference_text><pubmed_id>8462368</pubmed_id></reference><reference><reference_text>Hillebrant CG, Axelson M, Bjorkhem I, Wang FH, Nyberg B, Einarsson C: Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients. Eur J Clin Invest. 1998 Apr;28(4):324-8.</reference_text><pubmed_id>9615912</pubmed_id></reference></references></disease><disease>Cholelithiasis<references><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference></references></disease><disease>Stomach cancer<references><reference><reference_text>Higashijima H, Ichimiya H, Nakano T, Yamashita H, Kuroki S, Satoh H, Chijiiwa K, Tanaka M: Deconjugation of bilirubin accelerates coprecipitation of cholesterol, fatty acids, and mucin in human bile--in vitro study. J Gastroenterol. 1996 Dec;31(6):828-35.</reference_text><pubmed_id>9027647</pubmed_id></reference><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Song H, Peng JS, Dong-Sheng Y, Yang ZL, Liu HL, Zeng YK, Shi XP, Lu BY: Serum metabolic profiling of human gastric cancer based on gas chromatography/mass spectrometry. Braz J Med Biol Res. 2012 Jan;45(1):78-85. Epub 2011 Nov 25.</reference_text><pubmed_id>22124703</pubmed_id></reference><reference><reference_text>Yu L, Aa J, Xu J, Sun M, Qian S, Cheng L, Yang S, Shi R: Metabolomic phenotype of gastric cancer and precancerous stages based on gas chromatography time-of-flight mass spectrometry. J Gastroenterol Hepatol. 2011 Aug;26(8):1290-7. doi: 10.1111/j.1440-1746.2011.06724.x.</reference_text><pubmed_id>21443661</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference></references></disease><disease>Acute myelogenous leukemia<references><reference><reference_text>Tatidis L, Vitols S, Gruber A, Paul C, Axelson M: Cholesterol catabolism in patients with acute myelogenous leukemia and hypocholesterolemia: suppressed levels of a circulating marker for bile acid synthesis. Cancer Lett. 2001 Sep 20;170(2):169-75.</reference_text><pubmed_id>11463495</pubmed_id></reference></references></disease><disease>Hypercholesterolemia<references><reference><reference_text>Thelen KM, Laaksonen R, Paiva H, Lehtimaki T, Lutjohann D: High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels. J Clin Pharmacol. 2006 Jul;46(7):812-6.</reference_text><pubmed_id>16809807</pubmed_id></reference><reference><reference_text>Tamasawa N, Tamasawa A, Takebe K: Higher levels of plasma cholesterol sulfate in patients with liver cirrhosis and hypercholesterolemia. Lipids. 1993 Sep;28(9):833-6.</reference_text><pubmed_id>8231659</pubmed_id></reference><reference><reference_text>Kim DH, Lee KJ, Heo GS: Analysis of cholesterol and cholesteryl esters in human serum using capillary supercritical fluid chromatography. J Chromatogr B Biomed Appl. 1994 Apr 22;655(1):1-8.</reference_text><pubmed_id>8061816</pubmed_id></reference><reference><reference_text>Authors unspecified: Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med. 1988 Jan;148(1):36-69.</reference_text><pubmed_id>3422148</pubmed_id></reference></references></disease><disease>Cholesteryl ester storage disease<references><reference><reference_text>Rassoul F, Richter V, Lohse P, Naumann A, Purschwitz K, Keller E: Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease. Int J Clin Pharmacol Ther. 2001 May;39(5):199-204.</reference_text><pubmed_id>11380065</pubmed_id></reference><reference><reference_text>Chatrath H, Keilin S, Attar BM: Cholesterol ester storage disease (CESD) diagnosed in an asymptomatic adult. Dig Dis Sci. 2009 Jan;54(1):168-73. doi: 10.1007/s10620-008-0310-2. Epub 2008 May 14.</reference_text><pubmed_id>18478331</pubmed_id></reference><reference><reference_text>Bernstein DL, Hulkova H, Bialer MG, Desnick RJ: Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol. 2013 Jun;58(6):1230-43. doi: 10.1016/j.jhep.2013.02.014. Epub 2013 Feb 26.</reference_text><pubmed_id>23485521</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Cystinosis<references><reference><reference_text>Ueda M, O'Brien K, Rosing DR, Ling A, Kleta R, McAreavey D, Bernardini I, Gahl WA: Coronary artery and other vascular calcifications in patients with cystinosis after kidney transplantation. Clin J Am Soc Nephrol. 2006 May;1(3):555-62. Epub 2006 Feb 8.</reference_text><pubmed_id>17699259</pubmed_id></reference><reference><reference_text>Gahl WA, Bernardini I, Dalakas M, Rizzo WB, Harper GS, Hoeg JM, Hurko O, Bernar J: Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome. J Clin Invest. 1988 Feb;81(2):549-60.</reference_text><pubmed_id>3276734</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Smith-Lemli-Opitz syndrome<references><reference><reference_text>van Rooij A, Nijenhuis AA, Wijburg FA, Schutgens RB: Highly increased CSF concentrations of cholesterol precursors in Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 1997 Aug;20(4):578-80.</reference_text><pubmed_id>9266395</pubmed_id></reference><reference><reference_text>Honda M, Tint GS, Honda A, Salen G, Shefer S, Batta AK, Matsuzaki Y, Tanaka N: Regulation of cholesterol biosynthetic pathway in patients with the Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2000 Jul;23(5):464-74.</reference_text><pubmed_id>10947201</pubmed_id></reference><reference><reference_text>Rossi M, Federico G, Corso G, Parenti G, Battagliese A, Frascogna AR, Della Casa R, Dello Russo A, Strisciuglio P, Saggese G, Andria G: Vitamin D status in patients affected by Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2005;28(1):69-80.</reference_text><pubmed_id>15702407</pubmed_id></reference><reference><reference_text>Johnson DW, ten Brink HJ, Jakobs C: A rapid screening procedure for cholesterol and dehydrocholesterol by electrospray ionization tandem mass spectrometry. J Lipid Res. 2001 Oct;42(10):1699-705.</reference_text><pubmed_id>11590227</pubmed_id></reference></references></disease><disease>Prostate cancer<references><reference><reference_text>Nyman DW, Suzanne Stratton M, Kopplin MJ, Dalkin BL, Nagle RB, Jay Gandolfi A: Selenium and selenomethionine levels in prostate cancer patients. Cancer Detect Prev. 2004;28(1):8-16.</reference_text><pubmed_id>15041072</pubmed_id></reference><reference><reference_text>Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, Egevad L, Tjonneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, Palli D, Vineis P, Tumino R, Berrino F, Kiemeney L, Bueno-de-Mesquita HB, Quiros JR, Gonzalez CA, Martinez C, Larranaga N, Chirlaque MD, Ardanaz E, Stattin P, Hallmans G, Khaw KT, Bingham S, Slimani N, Ferrari P, Rinaldi S, Riboli E: Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr. 2007 Sep;86(3):672-81.</reference_text><pubmed_id>17823432</pubmed_id></reference><reference><reference_text>Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762.</reference_text><pubmed_id>19212411</pubmed_id></reference><reference><reference_text>Puah CM, Williams G, Ghanadian R: Urinary unconjugated 5 alpha-androstane-3 alpha, 17 beta-diol in patients with prostatic tumours. Urol Res. 1982;10(2):81-4.</reference_text><pubmed_id>6180540</pubmed_id></reference><reference><reference_text>Thysell E, Surowiec I, Hornberg E, Crnalic S, Widmark A, Johansson AI, Stattin P, Bergh A, Moritz T, Antti H, Wikstrom P: Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One. 2010 Dec 3;5(12):e14175. doi: 10.1371/journal.pone.0014175.</reference_text><pubmed_id>21151972</pubmed_id></reference><reference><reference_text>Soliman LC, Hui Y, Hewavitharana AK, Chen DD: Monitoring potential prostate cancer biomarkers in urine by capillary electrophoresis-tandem mass spectrometry. J Chromatogr A. 2012 Dec 7;1267:162-9. doi: 10.1016/j.chroma.2012.07.021. Epub 2012 Jul 14.</reference_text><pubmed_id>22824219</pubmed_id></reference><reference><reference_text>Madu CO, Lu Y: Novel diagnostic biomarkers for prostate cancer. J Cancer. 2010 Oct 6;1:150-77.</reference_text><pubmed_id>20975847</pubmed_id></reference></references></disease><disease>Schizophrenia<references><reference><reference_text>Harnryd C, Bjerkenstedt L, Grimm VE, Sedvall G: Reduction of MOPEG levels in cerebrospinal fluid of psychotic women after electroconvulsive treatment. Psychopharmacology (Berl). 1979 Aug 8;64(2):131-4.</reference_text><pubmed_id>115032</pubmed_id></reference><reference><reference_text>Kobayashi K, Koide Y, Yoshino K, Shohmori T: [P-hydroxyphenylacetic acid concentrations in cerebrospinal fluid]. No To Shinkei. 1982 Aug;34(8):769-74.</reference_text><pubmed_id>7126379</pubmed_id></reference><reference><reference_text>Alfredsson G, Wiesel FA: Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology (Berl). 1989;99(3):322-7.</reference_text><pubmed_id>2480613</pubmed_id></reference><reference><reference_text>Heresco-Levy U, Bar G, Levin R, Ermilov M, Ebstein RP, Javitt DC: High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. Schizophr Res. 2007 Mar;91(1-3):14-21. Epub 2007 Feb 2.</reference_text><pubmed_id>17276036</pubmed_id></reference><reference><reference_text>Walker EF, Bonsall R, Walder DJ: Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis. Neuropsychiatry Neuropsychol Behav Neurol. 2002 Mar;15(1):10-7.</reference_text><pubmed_id>11877547</pubmed_id></reference><reference><reference_text>Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M: Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry. 2003 Jun;60(6):572-6.</reference_text><pubmed_id>12796220</pubmed_id></reference><reference><reference_text>Do KQ, Lauer CJ, Schreiber W, Zollinger M, Gutteck-Amsler U, Cuenod M, Holsboer F: gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem. 1995 Dec;65(6):2652-62.</reference_text><pubmed_id>7595563</pubmed_id></reference><reference><reference_text>Nikisch G, Baumann P, Wiedemann G, Kiessling B, Weisser H, Hertel A, Yoshitake T, Kehr J, Mathe AA: Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF. J Clin Psychopharmacol. 2010 Oct;30(5):496-503. doi: 10.1097/JCP.0b013e3181f2288e.</reference_text><pubmed_id>20814316</pubmed_id></reference><reference><reference_text>Fukushima T, Iizuka H, Yokota A, Suzuki T, Ohno C, Kono Y, Nishikiori M, Seki A, Ichiba H, Watanabe Y, Hongo S, Utsunomiya M, Nakatani M, Sadamoto K, Yoshio T: Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One. 2014 Jul 8;9(7):e101652. doi: 10.1371/journal.pone.0101652. eCollection 2014.</reference_text><pubmed_id>25004141</pubmed_id></reference><reference><reference_text>Koike S, Bundo M, Iwamoto K, Suga M, Kuwabara H, Ohashi Y, Shinoda K, Takano Y, Iwashiro N, Satomura Y, Nagai T, Natsubori T, Tada M, Yamasue H, Kasai K: A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study. Transl Psychiatry. 2014 Apr 8;4:e379. doi: 10.1038/tp.2014.19.</reference_text><pubmed_id>24713860</pubmed_id></reference><reference><reference_text>Ballesteros A, Summerfelt A, Du X, Jiang P, Chiappelli J, Tagamets M, O'Donnell P, Kochunov P, Hong LE: Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia. Clin Neurophysiol. 2013 Nov;124(11):2209-15. doi: 10.1016/j.clinph.2013.05.021. Epub 2013 Jun 30.</reference_text><pubmed_id>23823132</pubmed_id></reference><reference><reference_text>Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel FA: Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry. 1985 Sep;147:276-82.</reference_text><pubmed_id>2415198</pubmed_id></reference><reference><reference_text>Pickar D, Breier A, Hsiao JK, Doran AR, Wolkowitz OM, Pato CN, Konicki PE, Potter WZ: Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Arch Gen Psychiatry. 1990 Jul;47(7):641-8.</reference_text><pubmed_id>1694425</pubmed_id></reference><reference><reference_text>Prell GD, Green JP, Kaufmann CA, Khandelwal JK, Morrishow AM, Kirch DG, Linnoila M, Wyatt RJ: Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res. 1995 Jan;14(2):93-104.</reference_text><pubmed_id>7711000</pubmed_id></reference><reference><reference_text>Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B: Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology. 2009;59(2):123-9. doi: 10.1159/000213565. Epub 2009 Apr 22.</reference_text><pubmed_id>19390223</pubmed_id></reference><reference><reference_text>Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K, Cao Y, Wang X, Qiu Y, Su M, Zhao A, Wang P, Yang P, Wu J, Feng G, He L, Jia W, Wan C: Potential metabolite markers of schizophrenia. Mol Psychiatry. 2013 Jan;18(1):67-78. doi: 10.1038/mp.2011.131. Epub 2011 Oct 25.</reference_text><pubmed_id>22024767</pubmed_id></reference><reference><reference_text>Xuan J, Pan G, Qiu Y, Yang L, Su M, Liu Y, Chen J, Feng G, Fang Y, Jia W, Xing Q, He L: Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. J Proteome Res. 2011 Dec 2;10(12):5433-43. doi: 10.1021/pr2006796. Epub 2011 Nov  8.</reference_text><pubmed_id>22007635</pubmed_id></reference><reference><reference_text>Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM, Rothermundt M, Bogerts B, Koethe D, Kranaster L, Ohrmann P, Suslow T, McAllister G, Spain M, Barnes A, van Beveren NJ, Baron-Cohen S, Steiner J, Torrey FE, Yolken RH, Bahn S: Identification of a biological signature for schizophrenia in serum. Mol Psychiatry. 2012 May;17(5):494-502. doi: 10.1038/mp.2011.42. Epub 2011 Apr 12.</reference_text><pubmed_id>21483431</pubmed_id></reference><reference><reference_text>Mathe AA, Eberhard G, Saaf J, Wetterberg L: Plasma prostaglandin E2 metabolite--measured as 11-deoxy-15-keto-13,14-dihydro-11 beta,16 xi-cyclo-PGE2--in twins with schizophrenic disorder. Biol Psychiatry. 1986 Sep;21(11):1024-30.</reference_text><pubmed_id>3741918</pubmed_id></reference><reference><reference_text>Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N: Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct. 2002 Jun;20(2):171-5.</reference_text><pubmed_id>11979513</pubmed_id></reference><reference><reference_text>Zumarraga M, Davila R, Basterreche N, Arrue A, Goienetxea B, Zamalloa MI, Erkoreka L, Bustamante S, Inchausti L, Gonzalez-Torres MA, Guimon J: Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients. Neurochem Int. 2010 May-Jun;56(6-7):774-9. doi: 10.1016/j.neuint.2010.02.015. Epub 2010 Mar 4.</reference_text><pubmed_id>20206656</pubmed_id></reference><reference><reference_text>Peters JG: Dopamine, noradrenaline and serotonin spinal fluid metabolites in temporal lobe epileptic patients with schizophrenic symptomatology. Eur Neurol. 1979;18(1):15-8.</reference_text><pubmed_id>436860</pubmed_id></reference><reference><reference_text>Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, Rozen S, Krishnan RR, McEvoy J, Kaddurah-Daouk R: Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry. 2010 Sep;15(9):938-53. doi: 10.1038/mp.2009.33. Epub 2009 Apr 28.</reference_text><pubmed_id>19401681</pubmed_id></reference><reference><reference_text>Gattaz WF, Waldmeier P, Beckmann H: CSF monoamine metabolites in schizophrenic patients. Acta Psychiatr Scand. 1982 Nov;66(5):350-60.</reference_text><pubmed_id>6184954</pubmed_id></reference><reference><reference_text>Nilsson-Todd LK, Nordin C, Jonsson EG, Skogh E, Erhardt S: Cerebrospinal fluid kynurenic acid in male patients with schizophrenia - correlation with monoamine metabolites. Acta Neuropsychiatr. 2007 Feb;19(1):45-52. doi: 10.1111/j.1601-5215.2006.00170.x.</reference_text><pubmed_id>26952797</pubmed_id></reference><reference><reference_text>Cai HL, Li HD, Yan XZ, Sun B, Zhang Q, Yan M, Zhang WY, Jiang P, Zhu RH, Liu YP, Fang PF, Xu P, Yuan HY, Zhang XH, Hu L, Yang W, Ye HS: Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naive schizophrenia patients after treatment with risperidone. J Proteome Res. 2012 Aug 3;11(8):4338-50. doi: 10.1021/pr300459d. Epub 2012 Jul 26.</reference_text><pubmed_id>22800120</pubmed_id></reference><reference><reference_text>Al Awam K, Haussleiter IS, Dudley E, Donev R, Brune M, Juckel G, Thome J: Multiplatform metabolome and proteome profiling identifies serum metabolite and protein signatures as prospective biomarkers for schizophrenia. J Neural Transm (Vienna). 2015 Aug;122 Suppl 1:S111-22. doi: 10.1007/s00702-014-1224-0. Epub 2014 May 1.</reference_text><pubmed_id>24789758</pubmed_id></reference><reference><reference_text>Bicikova M, Hill M, Ripova D, Mohr P, Hampl R: Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia. J Steroid Biochem Mol Biol. 2013 Jan;133:77-83. doi: 10.1016/j.jsbmb.2012.08.009. Epub 2012 Aug 24.</reference_text><pubmed_id>22944140</pubmed_id></reference><reference><reference_text>He Y, Yu Z, Giegling I, Xie L, Hartmann AM, Prehn C, Adamski J, Kahn R, Li Y, Illig T, Wang-Sattler R, Rujescu D: Schizophrenia shows a unique metabolomics signature in plasma. Transl Psychiatry. 2012 Aug 14;2:e149. doi: 10.1038/tp.2012.76.</reference_text><pubmed_id>22892715</pubmed_id></reference><reference><reference_text>Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KR: Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):934-45. Epub 2007 Apr 17.</reference_text><pubmed_id>17440431</pubmed_id></reference><reference><reference_text>Fryar-Williams S, Strobel JE: Biomarkers of a five-domain translational substrate for schizophrenia and schizoaffective psychosis. Biomark Res. 2015 Feb 6;3:3. doi: 10.1186/s40364-015-0028-1. eCollection 2015.</reference_text><pubmed_id>25729574</pubmed_id></reference><reference><reference_text>Oresic M, Seppanen-Laakso T, Sun D, Tang J, Therman S, Viehman R, Mustonen U, van Erp TG, Hyotylainen T, Thompson P, Toga AW, Huttunen MO, Suvisaari J, Kaprio J, Lonnqvist J, Cannon TD: Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia. Genome Med. 2012 Jan 18;4(1):1. doi: 10.1186/gm300.</reference_text><pubmed_id>22257447</pubmed_id></reference></references></disease><disease>Primary hypomagnesemia<references><reference><reference_text>Jin-no Y, Kamiya Y, Okada M, Hirako M, Takada N, Kawaguchi M: Primary hypomagnesemia caused by isolated magnesium malabsorption: atypical case in adult. Intern Med. 1999 Mar;38(3):261-5.</reference_text><pubmed_id>10337938</pubmed_id></reference><reference><reference_text>Vainsel M, Vandevelde G, Smulders J, Vosters M, Hubain P, Loeb H: Tetany due to hypomagnesaemia with secondary hypocalcaemia. Arch Dis Child. 1970 Apr;45(240):254-8.</reference_text><pubmed_id>5419995</pubmed_id></reference><reference><reference_text>Shalev H, Phillip M, Galil A, Carmi R, Landau D: Clinical presentation and outcome in primary familial hypomagnesaemia. Arch Dis Child. 1998 Feb;78(2):127-30.</reference_text><pubmed_id>9579153</pubmed_id></reference><reference><reference_text>Kari JA, Farouq M, Alshaya HO: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Pediatr Nephrol. 2003 Jun;18(6):506-10. Epub 2003 Apr 29.</reference_text><pubmed_id>12720080</pubmed_id></reference></references></disease><disease>Hyperlipoproteinemia<references><reference><reference_text>Sinha S, Misra A, Kumar V, Jagannathan NR, Bal CS, Pandey RM, Singhania R, Deepak: Proton magnetic resonance spectroscopy and single photon emission computed tomography study of the brain in asymptomatic young hyperlipidaemic Asian Indians in North India show early abnormalities. Clin Endocrinol (Oxf). 2004 Aug;61(2):182-9.</reference_text><pubmed_id>15272912</pubmed_id></reference><reference><reference_text>Nelson RH: Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013 Mar</reference_text><pubmed_id>40(1):195-211. doi: 10.1016/j.pop.2012.11.003. Epub 2012 Dec  4.</pubmed_id></reference><reference><reference_text>Cantin B, Boudriau S, Bertrand M, Brun LD, Gagne C, Rogers PA, Ven Murthy MR, Lupien PJ, Julien P: Hemolysis in primary lipoprotein lipase deficiency. Metabolism. 1995 May;44(5):652-8.</reference_text><pubmed_id>7752915</pubmed_id></reference></references></disease><disease>Abetalipoproteinemia<references><reference><reference_text>Dawson G, Kruski AW, Scanu AM: Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J Lipid Res. 1976 Mar;17(2):125-31.</reference_text><pubmed_id>178813</pubmed_id></reference><reference><reference_text>Lazaro RP, Dentinger MP, Rodichok LD, Barron KD, Satya-Murti S: Muscle pathology in Bassen-Kornzweig syndrome and vitamin E deficiency. Am J Clin Pathol. 1986 Sep;86(3):378-87.</reference_text><pubmed_id>2944375</pubmed_id></reference></references></disease><disease>Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis<references><reference><reference_text>Breckenridge WC, Alaupovic P, Cox DW, Little JA: Apolipoprotein and lipoprotein concentrations in familial apolipoprotein C-II deficiency. Atherosclerosis. 1982 Aug;44(2):223-35.</reference_text><pubmed_id>7138621</pubmed_id></reference><reference><reference_text>Fukami M, Hasegawa T, Horikawa R, Ohashi T, Nishimura G, Homma K, Ogata T: Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr Res. 2006 Feb;59(2):276-80. doi: 10.1203/01.pdr.0000195825.31504.28.</reference_text><pubmed_id>16439592</pubmed_id></reference></references></disease><disease>Cerebrotendinous xanthomatosis<references><reference><reference_text>Halperin G, Elisaf M, Leitersdorf E, Harats D: A new method for determination of serum cholestanol by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2000 Jun 9;742(2):345-52.</reference_text><pubmed_id>10901139</pubmed_id></reference><reference><reference_text>Siman-Tov T, Meiner V, Gadoth N: Could steroids mask the diagnosis of cerebrotendinous xanthomatosis? J Neurol Sci. 2006 Apr 15;243(1-2):83-6. Epub 2006 Jan 30.</reference_text><pubmed_id>16445943</pubmed_id></reference><reference><reference_text>Agrawal NK, Garg S: Cerebrotendinous xanthomatosis: a rare disorder with a rare presentation. BMJ Case Rep. 2012 Sep 21;2012. pii: bcr-2012-006202. doi: 10.1136/bcr-2012-006202.</reference_text><pubmed_id>23001091</pubmed_id></reference></references></disease><disease>3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency<references><reference><reference_text>Thompson GN, Hsu BY, Pitt JJ, Treacy E, Stanley CA: Fasting hypoketotic coma in a child with deficiency of mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase. N Engl J Med. 1997 Oct 23;337(17):1203-7. doi: 10.1056/NEJM199710233371704.</reference_text><pubmed_id>9337379</pubmed_id></reference><reference><reference_text>Morris AA, Lascelles CV, Olpin SE, Lake BD, Leonard JV, Quant PA: Hepatic mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme a synthase deficiency. Pediatr Res. 1998 Sep;44(3):392-6. doi: 10.1203/00006450-199809000-00021.</reference_text><pubmed_id>9727719</pubmed_id></reference><reference><reference_text>Conboy E, Vairo F, Schultz M, Agre K, Ridsdale R, Deyle D, Oglesbee D, Gavrilov D, Klee EW, Lanpher B: Mitochondrial 3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency: Unique Presenting Laboratory Values and a Review of Biochemical and Clinical Features. JIMD Rep. 2017 Oct 14. doi: 10.1007/8904_2017_59.</reference_text><pubmed_id>29030856</pubmed_id></reference></references></disease><disease>Hypercholesterolemia, familial<references><reference><reference_text>Kwiterovich PO Jr, Fredrickson DS, Levy RI: Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest. 1974 May;53(5):1237-49. doi: 10.1172/JCI107670.</reference_text><pubmed_id>4363406</pubmed_id></reference></references></disease><disease>SC4MOL deficiency<references><reference><reference_text>He M, Kratz LE, Michel JJ, Vallejo AN, Ferris L, Kelley RI, Hoover JJ, Jukic D, Gibson KM, Wolfe LA, Ramachandran D, Zwick ME, Vockley J: Mutations in the human SC4MOL gene encoding a methyl sterol oxidase cause psoriasiform dermatitis, microcephaly, and developmental delay. J Clin Invest. 2011 Mar;121(3):976-84. doi: 10.1172/JCI42650.</reference_text><pubmed_id>21285510</pubmed_id></reference></references></disease><disease>Chondrodysplasia punctata, X-linked dominant<references><reference><reference_text>Aughton DJ, Kelley RI, Metzenberg A, Pureza V, Pauli RM: X-linked dominant chondrodysplasia punctata (CDPX2) caused by single gene mosaicism in a male. Am J Med Genet A. 2003 Jan 30;116A(3):255-60. doi: 10.1002/ajmg.a.10852.</reference_text><pubmed_id>12503102</pubmed_id></reference></references></disease><disease>Desmosterolosis<references><reference><reference_text>Andersson HC, Kratz L, Kelley R: Desmosterolosis presenting with multiple congenital anomalies and profound developmental delay. Am J Med Genet. 2002 Dec 15;113(4):315-9. doi: 10.1002/ajmg.b.10873.</reference_text><pubmed_id>12457401</pubmed_id></reference></references></disease><disease>Donohue Syndrome<references><reference><reference_text>Nijim Y, Awni Y, Adawi A, Bowirrat A: Classic Case Report of Donohue Syndrome (Leprechaunism; OMIM *246200): The Impact of Consanguineous Mating. Medicine (Baltimore). 2016 Feb;95(6):e2710. doi: 10.1097/MD.0000000000002710.</reference_text><pubmed_id>26871809</pubmed_id></reference></references></disease><disease>Leptin Deficiency or Dysfunction<references><reference><reference_text>Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O'Rahilly S: Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999 Sep 16;341(12):879-84. doi: 10.1056/NEJM199909163411204.</reference_text><pubmed_id>10486419</pubmed_id></reference></references></disease><disease>Duchenne Muscular Dystrophy<references><reference><reference_text>Nakagawa T, Takeuchi A, Kakiuchi R, Lee T, Yagi M, Awano H, Iijima K, Takeshima Y, Urade Y, Matsuo M: A prostaglandin D2 metabolite is elevated in the urine of Duchenne muscular dystrophy patients and increases further from 8 years old. Clin Chim Acta. 2013 Aug 23;423:10-4. doi: 10.1016/j.cca.2013.03.031. Epub 2013 Apr 19.</reference_text><pubmed_id>23603101</pubmed_id></reference><reference><reference_text>Srivastava NK, Pradhan S, Mittal B, Gowda GA: High resolution NMR based analysis of serum lipids in Duchenne muscular dystrophy patients and its possible diagnostic significance. NMR Biomed. 2010 Jan;23(1):13-22. doi: 10.1002/nbm.1419.</reference_text><pubmed_id>19787747</pubmed_id></reference><reference><reference_text>Horster I, Weigt-Usinger K, Carmann C, Chobanyan-Jurgens K, Kohler C, Schara U, Kayacelebi AA, Beckmann B, Tsikas D, Lucke T: The L-arginine/NO pathway and homoarginine are altered in Duchenne muscular dystrophy and improved by glucocorticoids. Amino Acids. 2015 Sep;47(9):1853-63. doi: 10.1007/s00726-015-2018-x. Epub 2015 Jun 12.</reference_text><pubmed_id>26066683</pubmed_id></reference></references></disease><disease>Lecithin:cholesterol Acyltransferase Deficiency<references><reference><reference_text>Idzior-Walus B, Sieradzki J, Kostner G, Malecki MT, Klupa T, Wesolowska T, Rostworowski W, Hartwich J, Walus M, Kiec AD, Naruszewicz M: Familial lecithin-cholesterol acyltransferase deficiency: biochemical characteristics and molecular analysis of a new LCAT mutation in a Polish family. Atherosclerosis. 2006 Apr;185(2):413-20. Epub 2005 Jul 26.</reference_text><pubmed_id>16051254</pubmed_id></reference></references></disease><disease>Lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lipodystrophy, Congenital Generalized<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Oculocerebrorenal syndrome<references><reference><reference_text>Charnas LR, Bernardini I, Rader D, Hoeg JM, Gahl WA: Clinical and laboratory findings in the oculocerebrorenal syndrome of Lowe, with special reference to growth and renal function. N Engl J Med. 1991 May 9;324(19):1318-25. doi: 10.1056/NEJM199105093241904.</reference_text><pubmed_id>2017228</pubmed_id></reference></references></disease><disease>Familial partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lathosterolosis<references><reference><reference_text>Brunetti-Pierri N, Corso G, Rossi M, Ferrari P, Balli F, Rivasi F, Annunziata I, Ballabio A, Russo AD, Andria G, Parenti G: Lathosterolosis, a novel multiple-malformation/mental retardation syndrome due to deficiency of 3beta-hydroxysteroid-delta5-desaturase. Am J Hum Genet. 2002 Oct;71(4):952-8. Epub 2002 Aug 20.</reference_text><pubmed_id>12189593</pubmed_id></reference><reference><reference_text>Ho AC, Fung CW, Siu TS, Ma OC, Lam CW, Tam S, Wong VC: Lathosterolosis: a disorder of cholesterol biosynthesis resembling smith-lemli-opitz syndrome. JIMD Rep. 2014;12:129-34. doi: 10.1007/8904_2013_255. Epub 2013 Oct 20.</reference_text><pubmed_id>24142275</pubmed_id></reference></references></disease><disease>Partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Multiple sclerosis<references><reference><reference_text>Lutz NW, Viola A, Malikova I, Confort-Gouny S, Audoin B, Ranjeva JP, Pelletier J, Cozzone PJ: Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One. 2007 Jul 4;2(7):e595.</reference_text><pubmed_id>17611627</pubmed_id></reference><reference><reference_text>Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U, Hillert J, Bjorkhem I: Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med. 2004 Feb;42(2):186-91.</reference_text><pubmed_id>15061359</pubmed_id></reference><reference><reference_text>Leoni V, Lutjohann D, Masterman T: Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis. J Lipid Res. 2005 Feb;46(2):191-5. Epub 2004 Dec 1.</reference_text><pubmed_id>15576852</pubmed_id></reference><reference><reference_text>Calabrese V, Scapagnini G, Ravagna A, Bella R, Butterfield DA, Calvani M, Pennisi G, Giuffrida Stella AM: Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem Res. 2003 Sep;28(9):1321-8.</reference_text><pubmed_id>12938853</pubmed_id></reference><reference><reference_text>Shaw CE, Dunbar PR, Macaulay HA, Neale TJ: Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol. 1995 Jan;242(2):53-8.</reference_text><pubmed_id>7707089</pubmed_id></reference><reference><reference_text>Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.</reference_text><pubmed_id>17384003</pubmed_id></reference><reference><reference_text>Syburra C, Passi S: Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh (1999). 1999 May-Jun;71(3):112-5.</reference_text><pubmed_id>10609336</pubmed_id></reference><reference><reference_text>Forte G, Visconti A, Santucci S, Ghazaryan A, Figa-Talamanca L, Cannoni S, Bocca B, Pino A, Violante N, Alimonti A, Salvetti M, Ristori G: Quantification of chemical elements in blood of patients affected by multiple sclerosis. Ann Ist Super Sanita. 2005;41(2):213-6.</reference_text><pubmed_id>16244395</pubmed_id></reference><reference><reference_text>Toncev G, Milicic B, Toncev S, Samardzic G: Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol. 2002 May;9(3):221-6.</reference_text><pubmed_id>11985629</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, Bamonti F, Capello E, Mancardi GL, Scarpini E: Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res. 2010 May 28;1333:64-71. doi: 10.1016/j.brainres.2010.03.073. Epub 2010 Mar 27.</reference_text><pubmed_id>20347721</pubmed_id></reference><reference><reference_text>Matsushita T, Isobe N, Kawajiri M, Mogi M, Tsukuda K, Horiuchi M, Ohyagi Y, Kira J: CSF angiotensin II and angiotensin-converting enzyme levels in anti-aquaporin-4 autoimmunity. J Neurol Sci. 2010 Aug 15;295(1-2):41-5. doi: 10.1016/j.jns.2010.05.014. Epub 2010 Jun 11.</reference_text><pubmed_id>20541774</pubmed_id></reference><reference><reference_text>Ghabaee M, Jabedari B, Al-E-Eshagh N, Ghaffarpour M, Asadi F: Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients. Int J Neurosci. 2010 Apr;120(4):301-4. doi: 10.3109/00207451003695690.</reference_text><pubmed_id>20374079</pubmed_id></reference><reference><reference_text>Kawajiri M, Mogi M, Osoegawa M, Matsuoka T, Tsukuda K, Kohara K, Horiuchi M, Miki T, Kira JI: Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler. 2008 May;14(4):557-60. doi: 10.1177/1352458507085760.</reference_text><pubmed_id>18562510</pubmed_id></reference><reference><reference_text>Visconti A, Cotichini R, Cannoni S, Bocca B, Forte G, Ghazaryan A, Santucci S, D'Ippolito C, Stazi MA, Salvetti M, Alimonti A, Ristori G: Concentration of elements in serum of patients affected by multiple sclerosis with first demyelinating episode: a six-month longitudinal follow-up study. Ann Ist Super Sanita. 2005;41(2):217-22.</reference_text><pubmed_id>16244396</pubmed_id></reference></references></disease><disease>Inflammatory bowel disease<references><reference><reference_text>Lee T, Clavel T, Smirnov K, Schmidt A, Lagkouvardos I, Walker A, Lucio M, Michalke B, Schmitt-Kopplin P, Fedorak R, Haller D: Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. 2017 May;66(5):863-871. doi: 10.1136/gutjnl-2015-309940. Epub 2016 Feb 4.</reference_text><pubmed_id>26848182</pubmed_id></reference><reference><reference_text>Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158.</reference_text><pubmed_id>27609529</pubmed_id></reference></references></disease><disease>Colorectal cancer<references><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B: Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009 Apr;22(3):342-8. doi: 10.1002/nbm.1345.</reference_text><pubmed_id>19006102</pubmed_id></reference><reference><reference_text>Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP: Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One. 2013 Aug 6;8(8):e70803. doi: 10.1371/journal.pone.0070803. Print 2013.</reference_text><pubmed_id>23940645</pubmed_id></reference><reference><reference_text>Phua LC, Chue XP, Koh PK, Cheah PY, Ho HK, Chan EC: Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biol Ther. 2014 Apr;15(4):389-97. doi: 10.4161/cbt.27625. Epub 2014 Jan 14.</reference_text><pubmed_id>24424155</pubmed_id></reference><reference><reference_text>Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB: Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010 Feb 15;8:13. doi: 10.1186/1741-7015-8-13.</reference_text><pubmed_id>20156336</pubmed_id></reference><reference><reference_text>Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, Ni Y, Zhao A, Xu LX, Cai S, Jia W: Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res. 2009 Oct;8(10):4844-50. doi: 10.1021/pr9004162.</reference_text><pubmed_id>19678709</pubmed_id></reference><reference><reference_text>Cheng Y, Xie G, Chen T, Qiu Y, Zou X, Zheng M, Tan B, Feng B, Dong T, He P, Zhao L, Zhao A, Xu LX, Zhang Y, Jia W: Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res. 2012 Feb 3;11(2):1354-63. doi: 10.1021/pr201001a. Epub 2011 Dec 28.</reference_text><pubmed_id>22148915</pubmed_id></reference><reference><reference_text>Ni Y, Xie G, Jia W: Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res. 2014 Sep 5;13(9):3857-70. doi: 10.1021/pr500443c. Epub 2014 Aug 14.</reference_text><pubmed_id>25105552</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference><reference><reference_text>Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18.</reference_text><pubmed_id>25037050</pubmed_id></reference><reference><reference_text>Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016.</reference_text><pubmed_id>27015276</pubmed_id></reference><reference><reference_text>Lin Y, Ma C, Liu C, Wang Z, Yang J, Liu X, Shen Z, Wu R: NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer. Oncotarget. 2016 May 17;7(20):29454-64. doi: 10.18632/oncotarget.8762.</reference_text><pubmed_id>27107423</pubmed_id></reference><reference><reference_text>Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016.</reference_text><pubmed_id>27275383</pubmed_id></reference><reference><reference_text>Wang X, Wang J, Rao B, Deng L: Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals. Exp Ther Med. 2017 Jun;13(6):2848-2854. doi: 10.3892/etm.2017.4367. Epub 2017 Apr 20.</reference_text><pubmed_id>28587349</pubmed_id></reference><reference><reference_text>Silke Matysik, Caroline Ivanne Le Roy, Gerhard Liebisch, Sandrine Paule Claus. Metabolomics of fecal samples: A practical consideration. Trends in Food Science &amp; Technology. Vol. 57, Part B, Nov. 2016, p.244-255: http://www.sciencedirect.com/science/article/pii/S0924224416301984</reference_text><pubmed_id>28587349</pubmed_id></reference></references></disease><disease>Gallbladder disease<references><reference><reference_text>Lapidus A, Akerlund JE, Einarsson C: Gallbladder bile composition in patients with Crohn 's disease. World J Gastroenterol. 2006 Jan 7;12(1):70-4.</reference_text><pubmed_id>16440420</pubmed_id></reference><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference><reference><reference_text>Mizuno S, Tazuma S, Kajiyama G: Stabilization of biliary lipid particles by ursodeoxycholic acid. Prolonged nucleation time in human gallbladder bile. Dig Dis Sci. 1993 Apr;38(4):684-93.</reference_text><pubmed_id>8462368</pubmed_id></reference><reference><reference_text>Hillebrant CG, Axelson M, Bjorkhem I, Wang FH, Nyberg B, Einarsson C: Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients. Eur J Clin Invest. 1998 Apr;28(4):324-8.</reference_text><pubmed_id>9615912</pubmed_id></reference></references></disease><disease>Cholelithiasis<references><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference></references></disease><disease>Stomach cancer<references><reference><reference_text>Higashijima H, Ichimiya H, Nakano T, Yamashita H, Kuroki S, Satoh H, Chijiiwa K, Tanaka M: Deconjugation of bilirubin accelerates coprecipitation of cholesterol, fatty acids, and mucin in human bile--in vitro study. J Gastroenterol. 1996 Dec;31(6):828-35.</reference_text><pubmed_id>9027647</pubmed_id></reference><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Song H, Peng JS, Dong-Sheng Y, Yang ZL, Liu HL, Zeng YK, Shi XP, Lu BY: Serum metabolic profiling of human gastric cancer based on gas chromatography/mass spectrometry. Braz J Med Biol Res. 2012 Jan;45(1):78-85. Epub 2011 Nov 25.</reference_text><pubmed_id>22124703</pubmed_id></reference><reference><reference_text>Yu L, Aa J, Xu J, Sun M, Qian S, Cheng L, Yang S, Shi R: Metabolomic phenotype of gastric cancer and precancerous stages based on gas chromatography time-of-flight mass spectrometry. J Gastroenterol Hepatol. 2011 Aug;26(8):1290-7. doi: 10.1111/j.1440-1746.2011.06724.x.</reference_text><pubmed_id>21443661</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference></references></disease><disease>Acute myelogenous leukemia<references><reference><reference_text>Tatidis L, Vitols S, Gruber A, Paul C, Axelson M: Cholesterol catabolism in patients with acute myelogenous leukemia and hypocholesterolemia: suppressed levels of a circulating marker for bile acid synthesis. Cancer Lett. 2001 Sep 20;170(2):169-75.</reference_text><pubmed_id>11463495</pubmed_id></reference></references></disease><disease>Hypercholesterolemia<references><reference><reference_text>Thelen KM, Laaksonen R, Paiva H, Lehtimaki T, Lutjohann D: High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels. J Clin Pharmacol. 2006 Jul;46(7):812-6.</reference_text><pubmed_id>16809807</pubmed_id></reference><reference><reference_text>Tamasawa N, Tamasawa A, Takebe K: Higher levels of plasma cholesterol sulfate in patients with liver cirrhosis and hypercholesterolemia. Lipids. 1993 Sep;28(9):833-6.</reference_text><pubmed_id>8231659</pubmed_id></reference><reference><reference_text>Kim DH, Lee KJ, Heo GS: Analysis of cholesterol and cholesteryl esters in human serum using capillary supercritical fluid chromatography. J Chromatogr B Biomed Appl. 1994 Apr 22;655(1):1-8.</reference_text><pubmed_id>8061816</pubmed_id></reference><reference><reference_text>Authors unspecified: Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med. 1988 Jan;148(1):36-69.</reference_text><pubmed_id>3422148</pubmed_id></reference></references></disease><disease>Cholesteryl ester storage disease<references><reference><reference_text>Rassoul F, Richter V, Lohse P, Naumann A, Purschwitz K, Keller E: Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease. Int J Clin Pharmacol Ther. 2001 May;39(5):199-204.</reference_text><pubmed_id>11380065</pubmed_id></reference><reference><reference_text>Chatrath H, Keilin S, Attar BM: Cholesterol ester storage disease (CESD) diagnosed in an asymptomatic adult. Dig Dis Sci. 2009 Jan;54(1):168-73. doi: 10.1007/s10620-008-0310-2. Epub 2008 May 14.</reference_text><pubmed_id>18478331</pubmed_id></reference><reference><reference_text>Bernstein DL, Hulkova H, Bialer MG, Desnick RJ: Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol. 2013 Jun;58(6):1230-43. doi: 10.1016/j.jhep.2013.02.014. Epub 2013 Feb 26.</reference_text><pubmed_id>23485521</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Cystinosis<references><reference><reference_text>Ueda M, O'Brien K, Rosing DR, Ling A, Kleta R, McAreavey D, Bernardini I, Gahl WA: Coronary artery and other vascular calcifications in patients with cystinosis after kidney transplantation. Clin J Am Soc Nephrol. 2006 May;1(3):555-62. Epub 2006 Feb 8.</reference_text><pubmed_id>17699259</pubmed_id></reference><reference><reference_text>Gahl WA, Bernardini I, Dalakas M, Rizzo WB, Harper GS, Hoeg JM, Hurko O, Bernar J: Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome. J Clin Invest. 1988 Feb;81(2):549-60.</reference_text><pubmed_id>3276734</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Smith-Lemli-Opitz syndrome<references><reference><reference_text>van Rooij A, Nijenhuis AA, Wijburg FA, Schutgens RB: Highly increased CSF concentrations of cholesterol precursors in Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 1997 Aug;20(4):578-80.</reference_text><pubmed_id>9266395</pubmed_id></reference><reference><reference_text>Honda M, Tint GS, Honda A, Salen G, Shefer S, Batta AK, Matsuzaki Y, Tanaka N: Regulation of cholesterol biosynthetic pathway in patients with the Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2000 Jul;23(5):464-74.</reference_text><pubmed_id>10947201</pubmed_id></reference><reference><reference_text>Rossi M, Federico G, Corso G, Parenti G, Battagliese A, Frascogna AR, Della Casa R, Dello Russo A, Strisciuglio P, Saggese G, Andria G: Vitamin D status in patients affected by Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2005;28(1):69-80.</reference_text><pubmed_id>15702407</pubmed_id></reference><reference><reference_text>Johnson DW, ten Brink HJ, Jakobs C: A rapid screening procedure for cholesterol and dehydrocholesterol by electrospray ionization tandem mass spectrometry. J Lipid Res. 2001 Oct;42(10):1699-705.</reference_text><pubmed_id>11590227</pubmed_id></reference></references></disease><disease>Prostate cancer<references><reference><reference_text>Nyman DW, Suzanne Stratton M, Kopplin MJ, Dalkin BL, Nagle RB, Jay Gandolfi A: Selenium and selenomethionine levels in prostate cancer patients. Cancer Detect Prev. 2004;28(1):8-16.</reference_text><pubmed_id>15041072</pubmed_id></reference><reference><reference_text>Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, Egevad L, Tjonneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, Palli D, Vineis P, Tumino R, Berrino F, Kiemeney L, Bueno-de-Mesquita HB, Quiros JR, Gonzalez CA, Martinez C, Larranaga N, Chirlaque MD, Ardanaz E, Stattin P, Hallmans G, Khaw KT, Bingham S, Slimani N, Ferrari P, Rinaldi S, Riboli E: Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr. 2007 Sep;86(3):672-81.</reference_text><pubmed_id>17823432</pubmed_id></reference><reference><reference_text>Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762.</reference_text><pubmed_id>19212411</pubmed_id></reference><reference><reference_text>Puah CM, Williams G, Ghanadian R: Urinary unconjugated 5 alpha-androstane-3 alpha, 17 beta-diol in patients with prostatic tumours. Urol Res. 1982;10(2):81-4.</reference_text><pubmed_id>6180540</pubmed_id></reference><reference><reference_text>Thysell E, Surowiec I, Hornberg E, Crnalic S, Widmark A, Johansson AI, Stattin P, Bergh A, Moritz T, Antti H, Wikstrom P: Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One. 2010 Dec 3;5(12):e14175. doi: 10.1371/journal.pone.0014175.</reference_text><pubmed_id>21151972</pubmed_id></reference><reference><reference_text>Soliman LC, Hui Y, Hewavitharana AK, Chen DD: Monitoring potential prostate cancer biomarkers in urine by capillary electrophoresis-tandem mass spectrometry. J Chromatogr A. 2012 Dec 7;1267:162-9. doi: 10.1016/j.chroma.2012.07.021. Epub 2012 Jul 14.</reference_text><pubmed_id>22824219</pubmed_id></reference><reference><reference_text>Madu CO, Lu Y: Novel diagnostic biomarkers for prostate cancer. J Cancer. 2010 Oct 6;1:150-77.</reference_text><pubmed_id>20975847</pubmed_id></reference></references></disease><disease>Schizophrenia<references><reference><reference_text>Harnryd C, Bjerkenstedt L, Grimm VE, Sedvall G: Reduction of MOPEG levels in cerebrospinal fluid of psychotic women after electroconvulsive treatment. Psychopharmacology (Berl). 1979 Aug 8;64(2):131-4.</reference_text><pubmed_id>115032</pubmed_id></reference><reference><reference_text>Kobayashi K, Koide Y, Yoshino K, Shohmori T: [P-hydroxyphenylacetic acid concentrations in cerebrospinal fluid]. No To Shinkei. 1982 Aug;34(8):769-74.</reference_text><pubmed_id>7126379</pubmed_id></reference><reference><reference_text>Alfredsson G, Wiesel FA: Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology (Berl). 1989;99(3):322-7.</reference_text><pubmed_id>2480613</pubmed_id></reference><reference><reference_text>Heresco-Levy U, Bar G, Levin R, Ermilov M, Ebstein RP, Javitt DC: High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. Schizophr Res. 2007 Mar;91(1-3):14-21. Epub 2007 Feb 2.</reference_text><pubmed_id>17276036</pubmed_id></reference><reference><reference_text>Walker EF, Bonsall R, Walder DJ: Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis. Neuropsychiatry Neuropsychol Behav Neurol. 2002 Mar;15(1):10-7.</reference_text><pubmed_id>11877547</pubmed_id></reference><reference><reference_text>Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M: Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry. 2003 Jun;60(6):572-6.</reference_text><pubmed_id>12796220</pubmed_id></reference><reference><reference_text>Do KQ, Lauer CJ, Schreiber W, Zollinger M, Gutteck-Amsler U, Cuenod M, Holsboer F: gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem. 1995 Dec;65(6):2652-62.</reference_text><pubmed_id>7595563</pubmed_id></reference><reference><reference_text>Nikisch G, Baumann P, Wiedemann G, Kiessling B, Weisser H, Hertel A, Yoshitake T, Kehr J, Mathe AA: Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF. J Clin Psychopharmacol. 2010 Oct;30(5):496-503. doi: 10.1097/JCP.0b013e3181f2288e.</reference_text><pubmed_id>20814316</pubmed_id></reference><reference><reference_text>Fukushima T, Iizuka H, Yokota A, Suzuki T, Ohno C, Kono Y, Nishikiori M, Seki A, Ichiba H, Watanabe Y, Hongo S, Utsunomiya M, Nakatani M, Sadamoto K, Yoshio T: Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One. 2014 Jul 8;9(7):e101652. doi: 10.1371/journal.pone.0101652. eCollection 2014.</reference_text><pubmed_id>25004141</pubmed_id></reference><reference><reference_text>Koike S, Bundo M, Iwamoto K, Suga M, Kuwabara H, Ohashi Y, Shinoda K, Takano Y, Iwashiro N, Satomura Y, Nagai T, Natsubori T, Tada M, Yamasue H, Kasai K: A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study. Transl Psychiatry. 2014 Apr 8;4:e379. doi: 10.1038/tp.2014.19.</reference_text><pubmed_id>24713860</pubmed_id></reference><reference><reference_text>Ballesteros A, Summerfelt A, Du X, Jiang P, Chiappelli J, Tagamets M, O'Donnell P, Kochunov P, Hong LE: Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia. Clin Neurophysiol. 2013 Nov;124(11):2209-15. doi: 10.1016/j.clinph.2013.05.021. Epub 2013 Jun 30.</reference_text><pubmed_id>23823132</pubmed_id></reference><reference><reference_text>Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel FA: Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry. 1985 Sep;147:276-82.</reference_text><pubmed_id>2415198</pubmed_id></reference><reference><reference_text>Pickar D, Breier A, Hsiao JK, Doran AR, Wolkowitz OM, Pato CN, Konicki PE, Potter WZ: Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Arch Gen Psychiatry. 1990 Jul;47(7):641-8.</reference_text><pubmed_id>1694425</pubmed_id></reference><reference><reference_text>Prell GD, Green JP, Kaufmann CA, Khandelwal JK, Morrishow AM, Kirch DG, Linnoila M, Wyatt RJ: Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res. 1995 Jan;14(2):93-104.</reference_text><pubmed_id>7711000</pubmed_id></reference><reference><reference_text>Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B: Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology. 2009;59(2):123-9. doi: 10.1159/000213565. Epub 2009 Apr 22.</reference_text><pubmed_id>19390223</pubmed_id></reference><reference><reference_text>Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K, Cao Y, Wang X, Qiu Y, Su M, Zhao A, Wang P, Yang P, Wu J, Feng G, He L, Jia W, Wan C: Potential metabolite markers of schizophrenia. Mol Psychiatry. 2013 Jan;18(1):67-78. doi: 10.1038/mp.2011.131. Epub 2011 Oct 25.</reference_text><pubmed_id>22024767</pubmed_id></reference><reference><reference_text>Xuan J, Pan G, Qiu Y, Yang L, Su M, Liu Y, Chen J, Feng G, Fang Y, Jia W, Xing Q, He L: Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. J Proteome Res. 2011 Dec 2;10(12):5433-43. doi: 10.1021/pr2006796. Epub 2011 Nov  8.</reference_text><pubmed_id>22007635</pubmed_id></reference><reference><reference_text>Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM, Rothermundt M, Bogerts B, Koethe D, Kranaster L, Ohrmann P, Suslow T, McAllister G, Spain M, Barnes A, van Beveren NJ, Baron-Cohen S, Steiner J, Torrey FE, Yolken RH, Bahn S: Identification of a biological signature for schizophrenia in serum. Mol Psychiatry. 2012 May;17(5):494-502. doi: 10.1038/mp.2011.42. Epub 2011 Apr 12.</reference_text><pubmed_id>21483431</pubmed_id></reference><reference><reference_text>Mathe AA, Eberhard G, Saaf J, Wetterberg L: Plasma prostaglandin E2 metabolite--measured as 11-deoxy-15-keto-13,14-dihydro-11 beta,16 xi-cyclo-PGE2--in twins with schizophrenic disorder. Biol Psychiatry. 1986 Sep;21(11):1024-30.</reference_text><pubmed_id>3741918</pubmed_id></reference><reference><reference_text>Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N: Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct. 2002 Jun;20(2):171-5.</reference_text><pubmed_id>11979513</pubmed_id></reference><reference><reference_text>Zumarraga M, Davila R, Basterreche N, Arrue A, Goienetxea B, Zamalloa MI, Erkoreka L, Bustamante S, Inchausti L, Gonzalez-Torres MA, Guimon J: Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients. Neurochem Int. 2010 May-Jun;56(6-7):774-9. doi: 10.1016/j.neuint.2010.02.015. Epub 2010 Mar 4.</reference_text><pubmed_id>20206656</pubmed_id></reference><reference><reference_text>Peters JG: Dopamine, noradrenaline and serotonin spinal fluid metabolites in temporal lobe epileptic patients with schizophrenic symptomatology. Eur Neurol. 1979;18(1):15-8.</reference_text><pubmed_id>436860</pubmed_id></reference><reference><reference_text>Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, Rozen S, Krishnan RR, McEvoy J, Kaddurah-Daouk R: Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry. 2010 Sep;15(9):938-53. doi: 10.1038/mp.2009.33. Epub 2009 Apr 28.</reference_text><pubmed_id>19401681</pubmed_id></reference><reference><reference_text>Gattaz WF, Waldmeier P, Beckmann H: CSF monoamine metabolites in schizophrenic patients. Acta Psychiatr Scand. 1982 Nov;66(5):350-60.</reference_text><pubmed_id>6184954</pubmed_id></reference><reference><reference_text>Nilsson-Todd LK, Nordin C, Jonsson EG, Skogh E, Erhardt S: Cerebrospinal fluid kynurenic acid in male patients with schizophrenia - correlation with monoamine metabolites. Acta Neuropsychiatr. 2007 Feb;19(1):45-52. doi: 10.1111/j.1601-5215.2006.00170.x.</reference_text><pubmed_id>26952797</pubmed_id></reference><reference><reference_text>Cai HL, Li HD, Yan XZ, Sun B, Zhang Q, Yan M, Zhang WY, Jiang P, Zhu RH, Liu YP, Fang PF, Xu P, Yuan HY, Zhang XH, Hu L, Yang W, Ye HS: Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naive schizophrenia patients after treatment with risperidone. J Proteome Res. 2012 Aug 3;11(8):4338-50. doi: 10.1021/pr300459d. Epub 2012 Jul 26.</reference_text><pubmed_id>22800120</pubmed_id></reference><reference><reference_text>Al Awam K, Haussleiter IS, Dudley E, Donev R, Brune M, Juckel G, Thome J: Multiplatform metabolome and proteome profiling identifies serum metabolite and protein signatures as prospective biomarkers for schizophrenia. J Neural Transm (Vienna). 2015 Aug;122 Suppl 1:S111-22. doi: 10.1007/s00702-014-1224-0. Epub 2014 May 1.</reference_text><pubmed_id>24789758</pubmed_id></reference><reference><reference_text>Bicikova M, Hill M, Ripova D, Mohr P, Hampl R: Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia. J Steroid Biochem Mol Biol. 2013 Jan;133:77-83. doi: 10.1016/j.jsbmb.2012.08.009. Epub 2012 Aug 24.</reference_text><pubmed_id>22944140</pubmed_id></reference><reference><reference_text>He Y, Yu Z, Giegling I, Xie L, Hartmann AM, Prehn C, Adamski J, Kahn R, Li Y, Illig T, Wang-Sattler R, Rujescu D: Schizophrenia shows a unique metabolomics signature in plasma. Transl Psychiatry. 2012 Aug 14;2:e149. doi: 10.1038/tp.2012.76.</reference_text><pubmed_id>22892715</pubmed_id></reference><reference><reference_text>Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KR: Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):934-45. Epub 2007 Apr 17.</reference_text><pubmed_id>17440431</pubmed_id></reference><reference><reference_text>Fryar-Williams S, Strobel JE: Biomarkers of a five-domain translational substrate for schizophrenia and schizoaffective psychosis. Biomark Res. 2015 Feb 6;3:3. doi: 10.1186/s40364-015-0028-1. eCollection 2015.</reference_text><pubmed_id>25729574</pubmed_id></reference><reference><reference_text>Oresic M, Seppanen-Laakso T, Sun D, Tang J, Therman S, Viehman R, Mustonen U, van Erp TG, Hyotylainen T, Thompson P, Toga AW, Huttunen MO, Suvisaari J, Kaprio J, Lonnqvist J, Cannon TD: Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia. Genome Med. 2012 Jan 18;4(1):1. doi: 10.1186/gm300.</reference_text><pubmed_id>22257447</pubmed_id></reference></references></disease><disease>Primary hypomagnesemia<references><reference><reference_text>Jin-no Y, Kamiya Y, Okada M, Hirako M, Takada N, Kawaguchi M: Primary hypomagnesemia caused by isolated magnesium malabsorption: atypical case in adult. Intern Med. 1999 Mar;38(3):261-5.</reference_text><pubmed_id>10337938</pubmed_id></reference><reference><reference_text>Vainsel M, Vandevelde G, Smulders J, Vosters M, Hubain P, Loeb H: Tetany due to hypomagnesaemia with secondary hypocalcaemia. Arch Dis Child. 1970 Apr;45(240):254-8.</reference_text><pubmed_id>5419995</pubmed_id></reference><reference><reference_text>Shalev H, Phillip M, Galil A, Carmi R, Landau D: Clinical presentation and outcome in primary familial hypomagnesaemia. Arch Dis Child. 1998 Feb;78(2):127-30.</reference_text><pubmed_id>9579153</pubmed_id></reference><reference><reference_text>Kari JA, Farouq M, Alshaya HO: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Pediatr Nephrol. 2003 Jun;18(6):506-10. Epub 2003 Apr 29.</reference_text><pubmed_id>12720080</pubmed_id></reference></references></disease><disease>Hyperlipoproteinemia<references><reference><reference_text>Sinha S, Misra A, Kumar V, Jagannathan NR, Bal CS, Pandey RM, Singhania R, Deepak: Proton magnetic resonance spectroscopy and single photon emission computed tomography study of the brain in asymptomatic young hyperlipidaemic Asian Indians in North India show early abnormalities. Clin Endocrinol (Oxf). 2004 Aug;61(2):182-9.</reference_text><pubmed_id>15272912</pubmed_id></reference><reference><reference_text>Nelson RH: Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013 Mar</reference_text><pubmed_id>40(1):195-211. doi: 10.1016/j.pop.2012.11.003. Epub 2012 Dec  4.</pubmed_id></reference><reference><reference_text>Cantin B, Boudriau S, Bertrand M, Brun LD, Gagne C, Rogers PA, Ven Murthy MR, Lupien PJ, Julien P: Hemolysis in primary lipoprotein lipase deficiency. Metabolism. 1995 May;44(5):652-8.</reference_text><pubmed_id>7752915</pubmed_id></reference></references></disease><disease>Abetalipoproteinemia<references><reference><reference_text>Dawson G, Kruski AW, Scanu AM: Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J Lipid Res. 1976 Mar;17(2):125-31.</reference_text><pubmed_id>178813</pubmed_id></reference><reference><reference_text>Lazaro RP, Dentinger MP, Rodichok LD, Barron KD, Satya-Murti S: Muscle pathology in Bassen-Kornzweig syndrome and vitamin E deficiency. Am J Clin Pathol. 1986 Sep;86(3):378-87.</reference_text><pubmed_id>2944375</pubmed_id></reference></references></disease><disease>Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis<references><reference><reference_text>Breckenridge WC, Alaupovic P, Cox DW, Little JA: Apolipoprotein and lipoprotein concentrations in familial apolipoprotein C-II deficiency. Atherosclerosis. 1982 Aug;44(2):223-35.</reference_text><pubmed_id>7138621</pubmed_id></reference><reference><reference_text>Fukami M, Hasegawa T, Horikawa R, Ohashi T, Nishimura G, Homma K, Ogata T: Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr Res. 2006 Feb;59(2):276-80. doi: 10.1203/01.pdr.0000195825.31504.28.</reference_text><pubmed_id>16439592</pubmed_id></reference></references></disease><disease>Cerebrotendinous xanthomatosis<references><reference><reference_text>Halperin G, Elisaf M, Leitersdorf E, Harats D: A new method for determination of serum cholestanol by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2000 Jun 9;742(2):345-52.</reference_text><pubmed_id>10901139</pubmed_id></reference><reference><reference_text>Siman-Tov T, Meiner V, Gadoth N: Could steroids mask the diagnosis of cerebrotendinous xanthomatosis? J Neurol Sci. 2006 Apr 15;243(1-2):83-6. Epub 2006 Jan 30.</reference_text><pubmed_id>16445943</pubmed_id></reference><reference><reference_text>Agrawal NK, Garg S: Cerebrotendinous xanthomatosis: a rare disorder with a rare presentation. BMJ Case Rep. 2012 Sep 21;2012. pii: bcr-2012-006202. doi: 10.1136/bcr-2012-006202.</reference_text><pubmed_id>23001091</pubmed_id></reference></references></disease><disease>3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency<references><reference><reference_text>Thompson GN, Hsu BY, Pitt JJ, Treacy E, Stanley CA: Fasting hypoketotic coma in a child with deficiency of mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase. N Engl J Med. 1997 Oct 23;337(17):1203-7. doi: 10.1056/NEJM199710233371704.</reference_text><pubmed_id>9337379</pubmed_id></reference><reference><reference_text>Morris AA, Lascelles CV, Olpin SE, Lake BD, Leonard JV, Quant PA: Hepatic mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme a synthase deficiency. Pediatr Res. 1998 Sep;44(3):392-6. doi: 10.1203/00006450-199809000-00021.</reference_text><pubmed_id>9727719</pubmed_id></reference><reference><reference_text>Conboy E, Vairo F, Schultz M, Agre K, Ridsdale R, Deyle D, Oglesbee D, Gavrilov D, Klee EW, Lanpher B: Mitochondrial 3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency: Unique Presenting Laboratory Values and a Review of Biochemical and Clinical Features. JIMD Rep. 2017 Oct 14. doi: 10.1007/8904_2017_59.</reference_text><pubmed_id>29030856</pubmed_id></reference></references></disease><disease>Hypercholesterolemia, familial<references><reference><reference_text>Kwiterovich PO Jr, Fredrickson DS, Levy RI: Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest. 1974 May;53(5):1237-49. doi: 10.1172/JCI107670.</reference_text><pubmed_id>4363406</pubmed_id></reference></references></disease><disease>SC4MOL deficiency<references><reference><reference_text>He M, Kratz LE, Michel JJ, Vallejo AN, Ferris L, Kelley RI, Hoover JJ, Jukic D, Gibson KM, Wolfe LA, Ramachandran D, Zwick ME, Vockley J: Mutations in the human SC4MOL gene encoding a methyl sterol oxidase cause psoriasiform dermatitis, microcephaly, and developmental delay. J Clin Invest. 2011 Mar;121(3):976-84. doi: 10.1172/JCI42650.</reference_text><pubmed_id>21285510</pubmed_id></reference></references></disease><disease>Chondrodysplasia punctata, X-linked dominant<references><reference><reference_text>Aughton DJ, Kelley RI, Metzenberg A, Pureza V, Pauli RM: X-linked dominant chondrodysplasia punctata (CDPX2) caused by single gene mosaicism in a male. Am J Med Genet A. 2003 Jan 30;116A(3):255-60. doi: 10.1002/ajmg.a.10852.</reference_text><pubmed_id>12503102</pubmed_id></reference></references></disease><disease>Desmosterolosis<references><reference><reference_text>Andersson HC, Kratz L, Kelley R: Desmosterolosis presenting with multiple congenital anomalies and profound developmental delay. Am J Med Genet. 2002 Dec 15;113(4):315-9. doi: 10.1002/ajmg.b.10873.</reference_text><pubmed_id>12457401</pubmed_id></reference></references></disease><disease>Donohue Syndrome<references><reference><reference_text>Nijim Y, Awni Y, Adawi A, Bowirrat A: Classic Case Report of Donohue Syndrome (Leprechaunism; OMIM *246200): The Impact of Consanguineous Mating. Medicine (Baltimore). 2016 Feb;95(6):e2710. doi: 10.1097/MD.0000000000002710.</reference_text><pubmed_id>26871809</pubmed_id></reference></references></disease><disease>Leptin Deficiency or Dysfunction<references><reference><reference_text>Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O'Rahilly S: Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999 Sep 16;341(12):879-84. doi: 10.1056/NEJM199909163411204.</reference_text><pubmed_id>10486419</pubmed_id></reference></references></disease><disease>Duchenne Muscular Dystrophy<references><reference><reference_text>Nakagawa T, Takeuchi A, Kakiuchi R, Lee T, Yagi M, Awano H, Iijima K, Takeshima Y, Urade Y, Matsuo M: A prostaglandin D2 metabolite is elevated in the urine of Duchenne muscular dystrophy patients and increases further from 8 years old. Clin Chim Acta. 2013 Aug 23;423:10-4. doi: 10.1016/j.cca.2013.03.031. Epub 2013 Apr 19.</reference_text><pubmed_id>23603101</pubmed_id></reference><reference><reference_text>Srivastava NK, Pradhan S, Mittal B, Gowda GA: High resolution NMR based analysis of serum lipids in Duchenne muscular dystrophy patients and its possible diagnostic significance. NMR Biomed. 2010 Jan;23(1):13-22. doi: 10.1002/nbm.1419.</reference_text><pubmed_id>19787747</pubmed_id></reference><reference><reference_text>Horster I, Weigt-Usinger K, Carmann C, Chobanyan-Jurgens K, Kohler C, Schara U, Kayacelebi AA, Beckmann B, Tsikas D, Lucke T: The L-arginine/NO pathway and homoarginine are altered in Duchenne muscular dystrophy and improved by glucocorticoids. Amino Acids. 2015 Sep;47(9):1853-63. doi: 10.1007/s00726-015-2018-x. Epub 2015 Jun 12.</reference_text><pubmed_id>26066683</pubmed_id></reference></references></disease><disease>Lecithin:cholesterol Acyltransferase Deficiency<references><reference><reference_text>Idzior-Walus B, Sieradzki J, Kostner G, Malecki MT, Klupa T, Wesolowska T, Rostworowski W, Hartwich J, Walus M, Kiec AD, Naruszewicz M: Familial lecithin-cholesterol acyltransferase deficiency: biochemical characteristics and molecular analysis of a new LCAT mutation in a Polish family. Atherosclerosis. 2006 Apr;185(2):413-20. Epub 2005 Jul 26.</reference_text><pubmed_id>16051254</pubmed_id></reference></references></disease><disease>Lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lipodystrophy, Congenital Generalized<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Oculocerebrorenal syndrome<references><reference><reference_text>Charnas LR, Bernardini I, Rader D, Hoeg JM, Gahl WA: Clinical and laboratory findings in the oculocerebrorenal syndrome of Lowe, with special reference to growth and renal function. N Engl J Med. 1991 May 9;324(19):1318-25. doi: 10.1056/NEJM199105093241904.</reference_text><pubmed_id>2017228</pubmed_id></reference></references></disease><disease>Familial partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lathosterolosis<references><reference><reference_text>Brunetti-Pierri N, Corso G, Rossi M, Ferrari P, Balli F, Rivasi F, Annunziata I, Ballabio A, Russo AD, Andria G, Parenti G: Lathosterolosis, a novel multiple-malformation/mental retardation syndrome due to deficiency of 3beta-hydroxysteroid-delta5-desaturase. Am J Hum Genet. 2002 Oct;71(4):952-8. Epub 2002 Aug 20.</reference_text><pubmed_id>12189593</pubmed_id></reference><reference><reference_text>Ho AC, Fung CW, Siu TS, Ma OC, Lam CW, Tam S, Wong VC: Lathosterolosis: a disorder of cholesterol biosynthesis resembling smith-lemli-opitz syndrome. JIMD Rep. 2014;12:129-34. doi: 10.1007/8904_2013_255. Epub 2013 Oct 20.</reference_text><pubmed_id>24142275</pubmed_id></reference></references></disease><disease>Partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Multiple sclerosis<references><reference><reference_text>Lutz NW, Viola A, Malikova I, Confort-Gouny S, Audoin B, Ranjeva JP, Pelletier J, Cozzone PJ: Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One. 2007 Jul 4;2(7):e595.</reference_text><pubmed_id>17611627</pubmed_id></reference><reference><reference_text>Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U, Hillert J, Bjorkhem I: Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med. 2004 Feb;42(2):186-91.</reference_text><pubmed_id>15061359</pubmed_id></reference><reference><reference_text>Leoni V, Lutjohann D, Masterman T: Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis. J Lipid Res. 2005 Feb;46(2):191-5. Epub 2004 Dec 1.</reference_text><pubmed_id>15576852</pubmed_id></reference><reference><reference_text>Calabrese V, Scapagnini G, Ravagna A, Bella R, Butterfield DA, Calvani M, Pennisi G, Giuffrida Stella AM: Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem Res. 2003 Sep;28(9):1321-8.</reference_text><pubmed_id>12938853</pubmed_id></reference><reference><reference_text>Shaw CE, Dunbar PR, Macaulay HA, Neale TJ: Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol. 1995 Jan;242(2):53-8.</reference_text><pubmed_id>7707089</pubmed_id></reference><reference><reference_text>Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.</reference_text><pubmed_id>17384003</pubmed_id></reference><reference><reference_text>Syburra C, Passi S: Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh (1999). 1999 May-Jun;71(3):112-5.</reference_text><pubmed_id>10609336</pubmed_id></reference><reference><reference_text>Forte G, Visconti A, Santucci S, Ghazaryan A, Figa-Talamanca L, Cannoni S, Bocca B, Pino A, Violante N, Alimonti A, Salvetti M, Ristori G: Quantification of chemical elements in blood of patients affected by multiple sclerosis. Ann Ist Super Sanita. 2005;41(2):213-6.</reference_text><pubmed_id>16244395</pubmed_id></reference><reference><reference_text>Toncev G, Milicic B, Toncev S, Samardzic G: Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol. 2002 May;9(3):221-6.</reference_text><pubmed_id>11985629</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, Bamonti F, Capello E, Mancardi GL, Scarpini E: Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res. 2010 May 28;1333:64-71. doi: 10.1016/j.brainres.2010.03.073. Epub 2010 Mar 27.</reference_text><pubmed_id>20347721</pubmed_id></reference><reference><reference_text>Matsushita T, Isobe N, Kawajiri M, Mogi M, Tsukuda K, Horiuchi M, Ohyagi Y, Kira J: CSF angiotensin II and angiotensin-converting enzyme levels in anti-aquaporin-4 autoimmunity. J Neurol Sci. 2010 Aug 15;295(1-2):41-5. doi: 10.1016/j.jns.2010.05.014. Epub 2010 Jun 11.</reference_text><pubmed_id>20541774</pubmed_id></reference><reference><reference_text>Ghabaee M, Jabedari B, Al-E-Eshagh N, Ghaffarpour M, Asadi F: Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients. Int J Neurosci. 2010 Apr;120(4):301-4. doi: 10.3109/00207451003695690.</reference_text><pubmed_id>20374079</pubmed_id></reference><reference><reference_text>Kawajiri M, Mogi M, Osoegawa M, Matsuoka T, Tsukuda K, Kohara K, Horiuchi M, Miki T, Kira JI: Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler. 2008 May;14(4):557-60. doi: 10.1177/1352458507085760.</reference_text><pubmed_id>18562510</pubmed_id></reference><reference><reference_text>Visconti A, Cotichini R, Cannoni S, Bocca B, Forte G, Ghazaryan A, Santucci S, D'Ippolito C, Stazi MA, Salvetti M, Alimonti A, Ristori G: Concentration of elements in serum of patients affected by multiple sclerosis with first demyelinating episode: a six-month longitudinal follow-up study. Ann Ist Super Sanita. 2005;41(2):217-22.</reference_text><pubmed_id>16244396</pubmed_id></reference></references></disease><disease>Inflammatory bowel disease<references><reference><reference_text>Lee T, Clavel T, Smirnov K, Schmidt A, Lagkouvardos I, Walker A, Lucio M, Michalke B, Schmitt-Kopplin P, Fedorak R, Haller D: Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. 2017 May;66(5):863-871. doi: 10.1136/gutjnl-2015-309940. Epub 2016 Feb 4.</reference_text><pubmed_id>26848182</pubmed_id></reference><reference><reference_text>Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158.</reference_text><pubmed_id>27609529</pubmed_id></reference></references></disease><disease>Colorectal cancer<references><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B: Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009 Apr;22(3):342-8. doi: 10.1002/nbm.1345.</reference_text><pubmed_id>19006102</pubmed_id></reference><reference><reference_text>Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP: Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One. 2013 Aug 6;8(8):e70803. doi: 10.1371/journal.pone.0070803. Print 2013.</reference_text><pubmed_id>23940645</pubmed_id></reference><reference><reference_text>Phua LC, Chue XP, Koh PK, Cheah PY, Ho HK, Chan EC: Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biol Ther. 2014 Apr;15(4):389-97. doi: 10.4161/cbt.27625. Epub 2014 Jan 14.</reference_text><pubmed_id>24424155</pubmed_id></reference><reference><reference_text>Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB: Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010 Feb 15;8:13. doi: 10.1186/1741-7015-8-13.</reference_text><pubmed_id>20156336</pubmed_id></reference><reference><reference_text>Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, Ni Y, Zhao A, Xu LX, Cai S, Jia W: Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res. 2009 Oct;8(10):4844-50. doi: 10.1021/pr9004162.</reference_text><pubmed_id>19678709</pubmed_id></reference><reference><reference_text>Cheng Y, Xie G, Chen T, Qiu Y, Zou X, Zheng M, Tan B, Feng B, Dong T, He P, Zhao L, Zhao A, Xu LX, Zhang Y, Jia W: Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res. 2012 Feb 3;11(2):1354-63. doi: 10.1021/pr201001a. Epub 2011 Dec 28.</reference_text><pubmed_id>22148915</pubmed_id></reference><reference><reference_text>Ni Y, Xie G, Jia W: Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res. 2014 Sep 5;13(9):3857-70. doi: 10.1021/pr500443c. Epub 2014 Aug 14.</reference_text><pubmed_id>25105552</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference><reference><reference_text>Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18.</reference_text><pubmed_id>25037050</pubmed_id></reference><reference><reference_text>Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016.</reference_text><pubmed_id>27015276</pubmed_id></reference><reference><reference_text>Lin Y, Ma C, Liu C, Wang Z, Yang J, Liu X, Shen Z, Wu R: NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer. Oncotarget. 2016 May 17;7(20):29454-64. doi: 10.18632/oncotarget.8762.</reference_text><pubmed_id>27107423</pubmed_id></reference><reference><reference_text>Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016.</reference_text><pubmed_id>27275383</pubmed_id></reference><reference><reference_text>Wang X, Wang J, Rao B, Deng L: Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals. Exp Ther Med. 2017 Jun;13(6):2848-2854. doi: 10.3892/etm.2017.4367. Epub 2017 Apr 20.</reference_text><pubmed_id>28587349</pubmed_id></reference><reference><reference_text>Silke Matysik, Caroline Ivanne Le Roy, Gerhard Liebisch, Sandrine Paule Claus. Metabolomics of fecal samples: A practical consideration. Trends in Food Science &amp; Technology. Vol. 57, Part B, Nov. 2016, p.244-255: http://www.sciencedirect.com/science/article/pii/S0924224416301984</reference_text><pubmed_id>28587349</pubmed_id></reference></references></disease><disease>Gallbladder disease<references><reference><reference_text>Lapidus A, Akerlund JE, Einarsson C: Gallbladder bile composition in patients with Crohn 's disease. World J Gastroenterol. 2006 Jan 7;12(1):70-4.</reference_text><pubmed_id>16440420</pubmed_id></reference><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference><reference><reference_text>Mizuno S, Tazuma S, Kajiyama G: Stabilization of biliary lipid particles by ursodeoxycholic acid. Prolonged nucleation time in human gallbladder bile. Dig Dis Sci. 1993 Apr;38(4):684-93.</reference_text><pubmed_id>8462368</pubmed_id></reference><reference><reference_text>Hillebrant CG, Axelson M, Bjorkhem I, Wang FH, Nyberg B, Einarsson C: Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients. Eur J Clin Invest. 1998 Apr;28(4):324-8.</reference_text><pubmed_id>9615912</pubmed_id></reference></references></disease><disease>Cholelithiasis<references><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference></references></disease><disease>Stomach cancer<references><reference><reference_text>Higashijima H, Ichimiya H, Nakano T, Yamashita H, Kuroki S, Satoh H, Chijiiwa K, Tanaka M: Deconjugation of bilirubin accelerates coprecipitation of cholesterol, fatty acids, and mucin in human bile--in vitro study. J Gastroenterol. 1996 Dec;31(6):828-35.</reference_text><pubmed_id>9027647</pubmed_id></reference><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Song H, Peng JS, Dong-Sheng Y, Yang ZL, Liu HL, Zeng YK, Shi XP, Lu BY: Serum metabolic profiling of human gastric cancer based on gas chromatography/mass spectrometry. Braz J Med Biol Res. 2012 Jan;45(1):78-85. Epub 2011 Nov 25.</reference_text><pubmed_id>22124703</pubmed_id></reference><reference><reference_text>Yu L, Aa J, Xu J, Sun M, Qian S, Cheng L, Yang S, Shi R: Metabolomic phenotype of gastric cancer and precancerous stages based on gas chromatography time-of-flight mass spectrometry. J Gastroenterol Hepatol. 2011 Aug;26(8):1290-7. doi: 10.1111/j.1440-1746.2011.06724.x.</reference_text><pubmed_id>21443661</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference></references></disease><disease>Acute myelogenous leukemia<references><reference><reference_text>Tatidis L, Vitols S, Gruber A, Paul C, Axelson M: Cholesterol catabolism in patients with acute myelogenous leukemia and hypocholesterolemia: suppressed levels of a circulating marker for bile acid synthesis. Cancer Lett. 2001 Sep 20;170(2):169-75.</reference_text><pubmed_id>11463495</pubmed_id></reference></references></disease><disease>Hypercholesterolemia<references><reference><reference_text>Thelen KM, Laaksonen R, Paiva H, Lehtimaki T, Lutjohann D: High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels. J Clin Pharmacol. 2006 Jul;46(7):812-6.</reference_text><pubmed_id>16809807</pubmed_id></reference><reference><reference_text>Tamasawa N, Tamasawa A, Takebe K: Higher levels of plasma cholesterol sulfate in patients with liver cirrhosis and hypercholesterolemia. Lipids. 1993 Sep;28(9):833-6.</reference_text><pubmed_id>8231659</pubmed_id></reference><reference><reference_text>Kim DH, Lee KJ, Heo GS: Analysis of cholesterol and cholesteryl esters in human serum using capillary supercritical fluid chromatography. J Chromatogr B Biomed Appl. 1994 Apr 22;655(1):1-8.</reference_text><pubmed_id>8061816</pubmed_id></reference><reference><reference_text>Authors unspecified: Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med. 1988 Jan;148(1):36-69.</reference_text><pubmed_id>3422148</pubmed_id></reference></references></disease><disease>Cholesteryl ester storage disease<references><reference><reference_text>Rassoul F, Richter V, Lohse P, Naumann A, Purschwitz K, Keller E: Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease. Int J Clin Pharmacol Ther. 2001 May;39(5):199-204.</reference_text><pubmed_id>11380065</pubmed_id></reference><reference><reference_text>Chatrath H, Keilin S, Attar BM: Cholesterol ester storage disease (CESD) diagnosed in an asymptomatic adult. Dig Dis Sci. 2009 Jan;54(1):168-73. doi: 10.1007/s10620-008-0310-2. Epub 2008 May 14.</reference_text><pubmed_id>18478331</pubmed_id></reference><reference><reference_text>Bernstein DL, Hulkova H, Bialer MG, Desnick RJ: Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol. 2013 Jun;58(6):1230-43. doi: 10.1016/j.jhep.2013.02.014. Epub 2013 Feb 26.</reference_text><pubmed_id>23485521</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Cystinosis<references><reference><reference_text>Ueda M, O'Brien K, Rosing DR, Ling A, Kleta R, McAreavey D, Bernardini I, Gahl WA: Coronary artery and other vascular calcifications in patients with cystinosis after kidney transplantation. Clin J Am Soc Nephrol. 2006 May;1(3):555-62. Epub 2006 Feb 8.</reference_text><pubmed_id>17699259</pubmed_id></reference><reference><reference_text>Gahl WA, Bernardini I, Dalakas M, Rizzo WB, Harper GS, Hoeg JM, Hurko O, Bernar J: Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome. J Clin Invest. 1988 Feb;81(2):549-60.</reference_text><pubmed_id>3276734</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Smith-Lemli-Opitz syndrome<references><reference><reference_text>van Rooij A, Nijenhuis AA, Wijburg FA, Schutgens RB: Highly increased CSF concentrations of cholesterol precursors in Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 1997 Aug;20(4):578-80.</reference_text><pubmed_id>9266395</pubmed_id></reference><reference><reference_text>Honda M, Tint GS, Honda A, Salen G, Shefer S, Batta AK, Matsuzaki Y, Tanaka N: Regulation of cholesterol biosynthetic pathway in patients with the Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2000 Jul;23(5):464-74.</reference_text><pubmed_id>10947201</pubmed_id></reference><reference><reference_text>Rossi M, Federico G, Corso G, Parenti G, Battagliese A, Frascogna AR, Della Casa R, Dello Russo A, Strisciuglio P, Saggese G, Andria G: Vitamin D status in patients affected by Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2005;28(1):69-80.</reference_text><pubmed_id>15702407</pubmed_id></reference><reference><reference_text>Johnson DW, ten Brink HJ, Jakobs C: A rapid screening procedure for cholesterol and dehydrocholesterol by electrospray ionization tandem mass spectrometry. J Lipid Res. 2001 Oct;42(10):1699-705.</reference_text><pubmed_id>11590227</pubmed_id></reference></references></disease><disease>Prostate cancer<references><reference><reference_text>Nyman DW, Suzanne Stratton M, Kopplin MJ, Dalkin BL, Nagle RB, Jay Gandolfi A: Selenium and selenomethionine levels in prostate cancer patients. Cancer Detect Prev. 2004;28(1):8-16.</reference_text><pubmed_id>15041072</pubmed_id></reference><reference><reference_text>Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, Egevad L, Tjonneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, Palli D, Vineis P, Tumino R, Berrino F, Kiemeney L, Bueno-de-Mesquita HB, Quiros JR, Gonzalez CA, Martinez C, Larranaga N, Chirlaque MD, Ardanaz E, Stattin P, Hallmans G, Khaw KT, Bingham S, Slimani N, Ferrari P, Rinaldi S, Riboli E: Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr. 2007 Sep;86(3):672-81.</reference_text><pubmed_id>17823432</pubmed_id></reference><reference><reference_text>Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762.</reference_text><pubmed_id>19212411</pubmed_id></reference><reference><reference_text>Puah CM, Williams G, Ghanadian R: Urinary unconjugated 5 alpha-androstane-3 alpha, 17 beta-diol in patients with prostatic tumours. Urol Res. 1982;10(2):81-4.</reference_text><pubmed_id>6180540</pubmed_id></reference><reference><reference_text>Thysell E, Surowiec I, Hornberg E, Crnalic S, Widmark A, Johansson AI, Stattin P, Bergh A, Moritz T, Antti H, Wikstrom P: Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One. 2010 Dec 3;5(12):e14175. doi: 10.1371/journal.pone.0014175.</reference_text><pubmed_id>21151972</pubmed_id></reference><reference><reference_text>Soliman LC, Hui Y, Hewavitharana AK, Chen DD: Monitoring potential prostate cancer biomarkers in urine by capillary electrophoresis-tandem mass spectrometry. J Chromatogr A. 2012 Dec 7;1267:162-9. doi: 10.1016/j.chroma.2012.07.021. Epub 2012 Jul 14.</reference_text><pubmed_id>22824219</pubmed_id></reference><reference><reference_text>Madu CO, Lu Y: Novel diagnostic biomarkers for prostate cancer. J Cancer. 2010 Oct 6;1:150-77.</reference_text><pubmed_id>20975847</pubmed_id></reference></references></disease><disease>Schizophrenia<references><reference><reference_text>Harnryd C, Bjerkenstedt L, Grimm VE, Sedvall G: Reduction of MOPEG levels in cerebrospinal fluid of psychotic women after electroconvulsive treatment. Psychopharmacology (Berl). 1979 Aug 8;64(2):131-4.</reference_text><pubmed_id>115032</pubmed_id></reference><reference><reference_text>Kobayashi K, Koide Y, Yoshino K, Shohmori T: [P-hydroxyphenylacetic acid concentrations in cerebrospinal fluid]. No To Shinkei. 1982 Aug;34(8):769-74.</reference_text><pubmed_id>7126379</pubmed_id></reference><reference><reference_text>Alfredsson G, Wiesel FA: Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology (Berl). 1989;99(3):322-7.</reference_text><pubmed_id>2480613</pubmed_id></reference><reference><reference_text>Heresco-Levy U, Bar G, Levin R, Ermilov M, Ebstein RP, Javitt DC: High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. Schizophr Res. 2007 Mar;91(1-3):14-21. Epub 2007 Feb 2.</reference_text><pubmed_id>17276036</pubmed_id></reference><reference><reference_text>Walker EF, Bonsall R, Walder DJ: Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis. Neuropsychiatry Neuropsychol Behav Neurol. 2002 Mar;15(1):10-7.</reference_text><pubmed_id>11877547</pubmed_id></reference><reference><reference_text>Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M: Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry. 2003 Jun;60(6):572-6.</reference_text><pubmed_id>12796220</pubmed_id></reference><reference><reference_text>Do KQ, Lauer CJ, Schreiber W, Zollinger M, Gutteck-Amsler U, Cuenod M, Holsboer F: gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem. 1995 Dec;65(6):2652-62.</reference_text><pubmed_id>7595563</pubmed_id></reference><reference><reference_text>Nikisch G, Baumann P, Wiedemann G, Kiessling B, Weisser H, Hertel A, Yoshitake T, Kehr J, Mathe AA: Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF. J Clin Psychopharmacol. 2010 Oct;30(5):496-503. doi: 10.1097/JCP.0b013e3181f2288e.</reference_text><pubmed_id>20814316</pubmed_id></reference><reference><reference_text>Fukushima T, Iizuka H, Yokota A, Suzuki T, Ohno C, Kono Y, Nishikiori M, Seki A, Ichiba H, Watanabe Y, Hongo S, Utsunomiya M, Nakatani M, Sadamoto K, Yoshio T: Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One. 2014 Jul 8;9(7):e101652. doi: 10.1371/journal.pone.0101652. eCollection 2014.</reference_text><pubmed_id>25004141</pubmed_id></reference><reference><reference_text>Koike S, Bundo M, Iwamoto K, Suga M, Kuwabara H, Ohashi Y, Shinoda K, Takano Y, Iwashiro N, Satomura Y, Nagai T, Natsubori T, Tada M, Yamasue H, Kasai K: A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study. Transl Psychiatry. 2014 Apr 8;4:e379. doi: 10.1038/tp.2014.19.</reference_text><pubmed_id>24713860</pubmed_id></reference><reference><reference_text>Ballesteros A, Summerfelt A, Du X, Jiang P, Chiappelli J, Tagamets M, O'Donnell P, Kochunov P, Hong LE: Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia. Clin Neurophysiol. 2013 Nov;124(11):2209-15. doi: 10.1016/j.clinph.2013.05.021. Epub 2013 Jun 30.</reference_text><pubmed_id>23823132</pubmed_id></reference><reference><reference_text>Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel FA: Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry. 1985 Sep;147:276-82.</reference_text><pubmed_id>2415198</pubmed_id></reference><reference><reference_text>Pickar D, Breier A, Hsiao JK, Doran AR, Wolkowitz OM, Pato CN, Konicki PE, Potter WZ: Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Arch Gen Psychiatry. 1990 Jul;47(7):641-8.</reference_text><pubmed_id>1694425</pubmed_id></reference><reference><reference_text>Prell GD, Green JP, Kaufmann CA, Khandelwal JK, Morrishow AM, Kirch DG, Linnoila M, Wyatt RJ: Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res. 1995 Jan;14(2):93-104.</reference_text><pubmed_id>7711000</pubmed_id></reference><reference><reference_text>Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B: Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology. 2009;59(2):123-9. doi: 10.1159/000213565. Epub 2009 Apr 22.</reference_text><pubmed_id>19390223</pubmed_id></reference><reference><reference_text>Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K, Cao Y, Wang X, Qiu Y, Su M, Zhao A, Wang P, Yang P, Wu J, Feng G, He L, Jia W, Wan C: Potential metabolite markers of schizophrenia. Mol Psychiatry. 2013 Jan;18(1):67-78. doi: 10.1038/mp.2011.131. Epub 2011 Oct 25.</reference_text><pubmed_id>22024767</pubmed_id></reference><reference><reference_text>Xuan J, Pan G, Qiu Y, Yang L, Su M, Liu Y, Chen J, Feng G, Fang Y, Jia W, Xing Q, He L: Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. J Proteome Res. 2011 Dec 2;10(12):5433-43. doi: 10.1021/pr2006796. Epub 2011 Nov  8.</reference_text><pubmed_id>22007635</pubmed_id></reference><reference><reference_text>Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM, Rothermundt M, Bogerts B, Koethe D, Kranaster L, Ohrmann P, Suslow T, McAllister G, Spain M, Barnes A, van Beveren NJ, Baron-Cohen S, Steiner J, Torrey FE, Yolken RH, Bahn S: Identification of a biological signature for schizophrenia in serum. Mol Psychiatry. 2012 May;17(5):494-502. doi: 10.1038/mp.2011.42. Epub 2011 Apr 12.</reference_text><pubmed_id>21483431</pubmed_id></reference><reference><reference_text>Mathe AA, Eberhard G, Saaf J, Wetterberg L: Plasma prostaglandin E2 metabolite--measured as 11-deoxy-15-keto-13,14-dihydro-11 beta,16 xi-cyclo-PGE2--in twins with schizophrenic disorder. Biol Psychiatry. 1986 Sep;21(11):1024-30.</reference_text><pubmed_id>3741918</pubmed_id></reference><reference><reference_text>Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N: Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct. 2002 Jun;20(2):171-5.</reference_text><pubmed_id>11979513</pubmed_id></reference><reference><reference_text>Zumarraga M, Davila R, Basterreche N, Arrue A, Goienetxea B, Zamalloa MI, Erkoreka L, Bustamante S, Inchausti L, Gonzalez-Torres MA, Guimon J: Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients. Neurochem Int. 2010 May-Jun;56(6-7):774-9. doi: 10.1016/j.neuint.2010.02.015. Epub 2010 Mar 4.</reference_text><pubmed_id>20206656</pubmed_id></reference><reference><reference_text>Peters JG: Dopamine, noradrenaline and serotonin spinal fluid metabolites in temporal lobe epileptic patients with schizophrenic symptomatology. Eur Neurol. 1979;18(1):15-8.</reference_text><pubmed_id>436860</pubmed_id></reference><reference><reference_text>Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, Rozen S, Krishnan RR, McEvoy J, Kaddurah-Daouk R: Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry. 2010 Sep;15(9):938-53. doi: 10.1038/mp.2009.33. Epub 2009 Apr 28.</reference_text><pubmed_id>19401681</pubmed_id></reference><reference><reference_text>Gattaz WF, Waldmeier P, Beckmann H: CSF monoamine metabolites in schizophrenic patients. Acta Psychiatr Scand. 1982 Nov;66(5):350-60.</reference_text><pubmed_id>6184954</pubmed_id></reference><reference><reference_text>Nilsson-Todd LK, Nordin C, Jonsson EG, Skogh E, Erhardt S: Cerebrospinal fluid kynurenic acid in male patients with schizophrenia - correlation with monoamine metabolites. Acta Neuropsychiatr. 2007 Feb;19(1):45-52. doi: 10.1111/j.1601-5215.2006.00170.x.</reference_text><pubmed_id>26952797</pubmed_id></reference><reference><reference_text>Cai HL, Li HD, Yan XZ, Sun B, Zhang Q, Yan M, Zhang WY, Jiang P, Zhu RH, Liu YP, Fang PF, Xu P, Yuan HY, Zhang XH, Hu L, Yang W, Ye HS: Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naive schizophrenia patients after treatment with risperidone. J Proteome Res. 2012 Aug 3;11(8):4338-50. doi: 10.1021/pr300459d. Epub 2012 Jul 26.</reference_text><pubmed_id>22800120</pubmed_id></reference><reference><reference_text>Al Awam K, Haussleiter IS, Dudley E, Donev R, Brune M, Juckel G, Thome J: Multiplatform metabolome and proteome profiling identifies serum metabolite and protein signatures as prospective biomarkers for schizophrenia. J Neural Transm (Vienna). 2015 Aug;122 Suppl 1:S111-22. doi: 10.1007/s00702-014-1224-0. Epub 2014 May 1.</reference_text><pubmed_id>24789758</pubmed_id></reference><reference><reference_text>Bicikova M, Hill M, Ripova D, Mohr P, Hampl R: Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia. J Steroid Biochem Mol Biol. 2013 Jan;133:77-83. doi: 10.1016/j.jsbmb.2012.08.009. Epub 2012 Aug 24.</reference_text><pubmed_id>22944140</pubmed_id></reference><reference><reference_text>He Y, Yu Z, Giegling I, Xie L, Hartmann AM, Prehn C, Adamski J, Kahn R, Li Y, Illig T, Wang-Sattler R, Rujescu D: Schizophrenia shows a unique metabolomics signature in plasma. Transl Psychiatry. 2012 Aug 14;2:e149. doi: 10.1038/tp.2012.76.</reference_text><pubmed_id>22892715</pubmed_id></reference><reference><reference_text>Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KR: Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):934-45. Epub 2007 Apr 17.</reference_text><pubmed_id>17440431</pubmed_id></reference><reference><reference_text>Fryar-Williams S, Strobel JE: Biomarkers of a five-domain translational substrate for schizophrenia and schizoaffective psychosis. Biomark Res. 2015 Feb 6;3:3. doi: 10.1186/s40364-015-0028-1. eCollection 2015.</reference_text><pubmed_id>25729574</pubmed_id></reference><reference><reference_text>Oresic M, Seppanen-Laakso T, Sun D, Tang J, Therman S, Viehman R, Mustonen U, van Erp TG, Hyotylainen T, Thompson P, Toga AW, Huttunen MO, Suvisaari J, Kaprio J, Lonnqvist J, Cannon TD: Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia. Genome Med. 2012 Jan 18;4(1):1. doi: 10.1186/gm300.</reference_text><pubmed_id>22257447</pubmed_id></reference></references></disease><disease>Primary hypomagnesemia<references><reference><reference_text>Jin-no Y, Kamiya Y, Okada M, Hirako M, Takada N, Kawaguchi M: Primary hypomagnesemia caused by isolated magnesium malabsorption: atypical case in adult. Intern Med. 1999 Mar;38(3):261-5.</reference_text><pubmed_id>10337938</pubmed_id></reference><reference><reference_text>Vainsel M, Vandevelde G, Smulders J, Vosters M, Hubain P, Loeb H: Tetany due to hypomagnesaemia with secondary hypocalcaemia. Arch Dis Child. 1970 Apr;45(240):254-8.</reference_text><pubmed_id>5419995</pubmed_id></reference><reference><reference_text>Shalev H, Phillip M, Galil A, Carmi R, Landau D: Clinical presentation and outcome in primary familial hypomagnesaemia. Arch Dis Child. 1998 Feb;78(2):127-30.</reference_text><pubmed_id>9579153</pubmed_id></reference><reference><reference_text>Kari JA, Farouq M, Alshaya HO: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Pediatr Nephrol. 2003 Jun;18(6):506-10. Epub 2003 Apr 29.</reference_text><pubmed_id>12720080</pubmed_id></reference></references></disease><disease>Hyperlipoproteinemia<references><reference><reference_text>Sinha S, Misra A, Kumar V, Jagannathan NR, Bal CS, Pandey RM, Singhania R, Deepak: Proton magnetic resonance spectroscopy and single photon emission computed tomography study of the brain in asymptomatic young hyperlipidaemic Asian Indians in North India show early abnormalities. Clin Endocrinol (Oxf). 2004 Aug;61(2):182-9.</reference_text><pubmed_id>15272912</pubmed_id></reference><reference><reference_text>Nelson RH: Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013 Mar</reference_text><pubmed_id>40(1):195-211. doi: 10.1016/j.pop.2012.11.003. Epub 2012 Dec  4.</pubmed_id></reference><reference><reference_text>Cantin B, Boudriau S, Bertrand M, Brun LD, Gagne C, Rogers PA, Ven Murthy MR, Lupien PJ, Julien P: Hemolysis in primary lipoprotein lipase deficiency. Metabolism. 1995 May;44(5):652-8.</reference_text><pubmed_id>7752915</pubmed_id></reference></references></disease><disease>Abetalipoproteinemia<references><reference><reference_text>Dawson G, Kruski AW, Scanu AM: Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J Lipid Res. 1976 Mar;17(2):125-31.</reference_text><pubmed_id>178813</pubmed_id></reference><reference><reference_text>Lazaro RP, Dentinger MP, Rodichok LD, Barron KD, Satya-Murti S: Muscle pathology in Bassen-Kornzweig syndrome and vitamin E deficiency. Am J Clin Pathol. 1986 Sep;86(3):378-87.</reference_text><pubmed_id>2944375</pubmed_id></reference></references></disease><disease>Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis<references><reference><reference_text>Breckenridge WC, Alaupovic P, Cox DW, Little JA: Apolipoprotein and lipoprotein concentrations in familial apolipoprotein C-II deficiency. Atherosclerosis. 1982 Aug;44(2):223-35.</reference_text><pubmed_id>7138621</pubmed_id></reference><reference><reference_text>Fukami M, Hasegawa T, Horikawa R, Ohashi T, Nishimura G, Homma K, Ogata T: Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr Res. 2006 Feb;59(2):276-80. doi: 10.1203/01.pdr.0000195825.31504.28.</reference_text><pubmed_id>16439592</pubmed_id></reference></references></disease><disease>Cerebrotendinous xanthomatosis<references><reference><reference_text>Halperin G, Elisaf M, Leitersdorf E, Harats D: A new method for determination of serum cholestanol by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2000 Jun 9;742(2):345-52.</reference_text><pubmed_id>10901139</pubmed_id></reference><reference><reference_text>Siman-Tov T, Meiner V, Gadoth N: Could steroids mask the diagnosis of cerebrotendinous xanthomatosis? J Neurol Sci. 2006 Apr 15;243(1-2):83-6. Epub 2006 Jan 30.</reference_text><pubmed_id>16445943</pubmed_id></reference><reference><reference_text>Agrawal NK, Garg S: Cerebrotendinous xanthomatosis: a rare disorder with a rare presentation. BMJ Case Rep. 2012 Sep 21;2012. pii: bcr-2012-006202. doi: 10.1136/bcr-2012-006202.</reference_text><pubmed_id>23001091</pubmed_id></reference></references></disease><disease>3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency<references><reference><reference_text>Thompson GN, Hsu BY, Pitt JJ, Treacy E, Stanley CA: Fasting hypoketotic coma in a child with deficiency of mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase. N Engl J Med. 1997 Oct 23;337(17):1203-7. doi: 10.1056/NEJM199710233371704.</reference_text><pubmed_id>9337379</pubmed_id></reference><reference><reference_text>Morris AA, Lascelles CV, Olpin SE, Lake BD, Leonard JV, Quant PA: Hepatic mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme a synthase deficiency. Pediatr Res. 1998 Sep;44(3):392-6. doi: 10.1203/00006450-199809000-00021.</reference_text><pubmed_id>9727719</pubmed_id></reference><reference><reference_text>Conboy E, Vairo F, Schultz M, Agre K, Ridsdale R, Deyle D, Oglesbee D, Gavrilov D, Klee EW, Lanpher B: Mitochondrial 3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency: Unique Presenting Laboratory Values and a Review of Biochemical and Clinical Features. JIMD Rep. 2017 Oct 14. doi: 10.1007/8904_2017_59.</reference_text><pubmed_id>29030856</pubmed_id></reference></references></disease><disease>Hypercholesterolemia, familial<references><reference><reference_text>Kwiterovich PO Jr, Fredrickson DS, Levy RI: Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest. 1974 May;53(5):1237-49. doi: 10.1172/JCI107670.</reference_text><pubmed_id>4363406</pubmed_id></reference></references></disease><disease>SC4MOL deficiency<references><reference><reference_text>He M, Kratz LE, Michel JJ, Vallejo AN, Ferris L, Kelley RI, Hoover JJ, Jukic D, Gibson KM, Wolfe LA, Ramachandran D, Zwick ME, Vockley J: Mutations in the human SC4MOL gene encoding a methyl sterol oxidase cause psoriasiform dermatitis, microcephaly, and developmental delay. J Clin Invest. 2011 Mar;121(3):976-84. doi: 10.1172/JCI42650.</reference_text><pubmed_id>21285510</pubmed_id></reference></references></disease><disease>Chondrodysplasia punctata, X-linked dominant<references><reference><reference_text>Aughton DJ, Kelley RI, Metzenberg A, Pureza V, Pauli RM: X-linked dominant chondrodysplasia punctata (CDPX2) caused by single gene mosaicism in a male. Am J Med Genet A. 2003 Jan 30;116A(3):255-60. doi: 10.1002/ajmg.a.10852.</reference_text><pubmed_id>12503102</pubmed_id></reference></references></disease><disease>Desmosterolosis<references><reference><reference_text>Andersson HC, Kratz L, Kelley R: Desmosterolosis presenting with multiple congenital anomalies and profound developmental delay. Am J Med Genet. 2002 Dec 15;113(4):315-9. doi: 10.1002/ajmg.b.10873.</reference_text><pubmed_id>12457401</pubmed_id></reference></references></disease><disease>Donohue Syndrome<references><reference><reference_text>Nijim Y, Awni Y, Adawi A, Bowirrat A: Classic Case Report of Donohue Syndrome (Leprechaunism; OMIM *246200): The Impact of Consanguineous Mating. Medicine (Baltimore). 2016 Feb;95(6):e2710. doi: 10.1097/MD.0000000000002710.</reference_text><pubmed_id>26871809</pubmed_id></reference></references></disease><disease>Leptin Deficiency or Dysfunction<references><reference><reference_text>Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O'Rahilly S: Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999 Sep 16;341(12):879-84. doi: 10.1056/NEJM199909163411204.</reference_text><pubmed_id>10486419</pubmed_id></reference></references></disease><disease>Duchenne Muscular Dystrophy<references><reference><reference_text>Nakagawa T, Takeuchi A, Kakiuchi R, Lee T, Yagi M, Awano H, Iijima K, Takeshima Y, Urade Y, Matsuo M: A prostaglandin D2 metabolite is elevated in the urine of Duchenne muscular dystrophy patients and increases further from 8 years old. Clin Chim Acta. 2013 Aug 23;423:10-4. doi: 10.1016/j.cca.2013.03.031. Epub 2013 Apr 19.</reference_text><pubmed_id>23603101</pubmed_id></reference><reference><reference_text>Srivastava NK, Pradhan S, Mittal B, Gowda GA: High resolution NMR based analysis of serum lipids in Duchenne muscular dystrophy patients and its possible diagnostic significance. NMR Biomed. 2010 Jan;23(1):13-22. doi: 10.1002/nbm.1419.</reference_text><pubmed_id>19787747</pubmed_id></reference><reference><reference_text>Horster I, Weigt-Usinger K, Carmann C, Chobanyan-Jurgens K, Kohler C, Schara U, Kayacelebi AA, Beckmann B, Tsikas D, Lucke T: The L-arginine/NO pathway and homoarginine are altered in Duchenne muscular dystrophy and improved by glucocorticoids. Amino Acids. 2015 Sep;47(9):1853-63. doi: 10.1007/s00726-015-2018-x. Epub 2015 Jun 12.</reference_text><pubmed_id>26066683</pubmed_id></reference></references></disease><disease>Lecithin:cholesterol Acyltransferase Deficiency<references><reference><reference_text>Idzior-Walus B, Sieradzki J, Kostner G, Malecki MT, Klupa T, Wesolowska T, Rostworowski W, Hartwich J, Walus M, Kiec AD, Naruszewicz M: Familial lecithin-cholesterol acyltransferase deficiency: biochemical characteristics and molecular analysis of a new LCAT mutation in a Polish family. Atherosclerosis. 2006 Apr;185(2):413-20. Epub 2005 Jul 26.</reference_text><pubmed_id>16051254</pubmed_id></reference></references></disease><disease>Lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lipodystrophy, Congenital Generalized<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Oculocerebrorenal syndrome<references><reference><reference_text>Charnas LR, Bernardini I, Rader D, Hoeg JM, Gahl WA: Clinical and laboratory findings in the oculocerebrorenal syndrome of Lowe, with special reference to growth and renal function. N Engl J Med. 1991 May 9;324(19):1318-25. doi: 10.1056/NEJM199105093241904.</reference_text><pubmed_id>2017228</pubmed_id></reference></references></disease><disease>Familial partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lathosterolosis<references><reference><reference_text>Brunetti-Pierri N, Corso G, Rossi M, Ferrari P, Balli F, Rivasi F, Annunziata I, Ballabio A, Russo AD, Andria G, Parenti G: Lathosterolosis, a novel multiple-malformation/mental retardation syndrome due to deficiency of 3beta-hydroxysteroid-delta5-desaturase. Am J Hum Genet. 2002 Oct;71(4):952-8. Epub 2002 Aug 20.</reference_text><pubmed_id>12189593</pubmed_id></reference><reference><reference_text>Ho AC, Fung CW, Siu TS, Ma OC, Lam CW, Tam S, Wong VC: Lathosterolosis: a disorder of cholesterol biosynthesis resembling smith-lemli-opitz syndrome. JIMD Rep. 2014;12:129-34. doi: 10.1007/8904_2013_255. Epub 2013 Oct 20.</reference_text><pubmed_id>24142275</pubmed_id></reference></references></disease><disease>Partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Multiple sclerosis<references><reference><reference_text>Lutz NW, Viola A, Malikova I, Confort-Gouny S, Audoin B, Ranjeva JP, Pelletier J, Cozzone PJ: Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One. 2007 Jul 4;2(7):e595.</reference_text><pubmed_id>17611627</pubmed_id></reference><reference><reference_text>Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U, Hillert J, Bjorkhem I: Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med. 2004 Feb;42(2):186-91.</reference_text><pubmed_id>15061359</pubmed_id></reference><reference><reference_text>Leoni V, Lutjohann D, Masterman T: Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis. J Lipid Res. 2005 Feb;46(2):191-5. Epub 2004 Dec 1.</reference_text><pubmed_id>15576852</pubmed_id></reference><reference><reference_text>Calabrese V, Scapagnini G, Ravagna A, Bella R, Butterfield DA, Calvani M, Pennisi G, Giuffrida Stella AM: Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem Res. 2003 Sep;28(9):1321-8.</reference_text><pubmed_id>12938853</pubmed_id></reference><reference><reference_text>Shaw CE, Dunbar PR, Macaulay HA, Neale TJ: Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol. 1995 Jan;242(2):53-8.</reference_text><pubmed_id>7707089</pubmed_id></reference><reference><reference_text>Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.</reference_text><pubmed_id>17384003</pubmed_id></reference><reference><reference_text>Syburra C, Passi S: Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh (1999). 1999 May-Jun;71(3):112-5.</reference_text><pubmed_id>10609336</pubmed_id></reference><reference><reference_text>Forte G, Visconti A, Santucci S, Ghazaryan A, Figa-Talamanca L, Cannoni S, Bocca B, Pino A, Violante N, Alimonti A, Salvetti M, Ristori G: Quantification of chemical elements in blood of patients affected by multiple sclerosis. Ann Ist Super Sanita. 2005;41(2):213-6.</reference_text><pubmed_id>16244395</pubmed_id></reference><reference><reference_text>Toncev G, Milicic B, Toncev S, Samardzic G: Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol. 2002 May;9(3):221-6.</reference_text><pubmed_id>11985629</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, Bamonti F, Capello E, Mancardi GL, Scarpini E: Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res. 2010 May 28;1333:64-71. doi: 10.1016/j.brainres.2010.03.073. Epub 2010 Mar 27.</reference_text><pubmed_id>20347721</pubmed_id></reference><reference><reference_text>Matsushita T, Isobe N, Kawajiri M, Mogi M, Tsukuda K, Horiuchi M, Ohyagi Y, Kira J: CSF angiotensin II and angiotensin-converting enzyme levels in anti-aquaporin-4 autoimmunity. J Neurol Sci. 2010 Aug 15;295(1-2):41-5. doi: 10.1016/j.jns.2010.05.014. Epub 2010 Jun 11.</reference_text><pubmed_id>20541774</pubmed_id></reference><reference><reference_text>Ghabaee M, Jabedari B, Al-E-Eshagh N, Ghaffarpour M, Asadi F: Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients. Int J Neurosci. 2010 Apr;120(4):301-4. doi: 10.3109/00207451003695690.</reference_text><pubmed_id>20374079</pubmed_id></reference><reference><reference_text>Kawajiri M, Mogi M, Osoegawa M, Matsuoka T, Tsukuda K, Kohara K, Horiuchi M, Miki T, Kira JI: Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler. 2008 May;14(4):557-60. doi: 10.1177/1352458507085760.</reference_text><pubmed_id>18562510</pubmed_id></reference><reference><reference_text>Visconti A, Cotichini R, Cannoni S, Bocca B, Forte G, Ghazaryan A, Santucci S, D'Ippolito C, Stazi MA, Salvetti M, Alimonti A, Ristori G: Concentration of elements in serum of patients affected by multiple sclerosis with first demyelinating episode: a six-month longitudinal follow-up study. Ann Ist Super Sanita. 2005;41(2):217-22.</reference_text><pubmed_id>16244396</pubmed_id></reference></references></disease><disease>Inflammatory bowel disease<references><reference><reference_text>Lee T, Clavel T, Smirnov K, Schmidt A, Lagkouvardos I, Walker A, Lucio M, Michalke B, Schmitt-Kopplin P, Fedorak R, Haller D: Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. 2017 May;66(5):863-871. doi: 10.1136/gutjnl-2015-309940. Epub 2016 Feb 4.</reference_text><pubmed_id>26848182</pubmed_id></reference><reference><reference_text>Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158.</reference_text><pubmed_id>27609529</pubmed_id></reference></references></disease><disease>Colorectal cancer<references><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B: Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009 Apr;22(3):342-8. doi: 10.1002/nbm.1345.</reference_text><pubmed_id>19006102</pubmed_id></reference><reference><reference_text>Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP: Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One. 2013 Aug 6;8(8):e70803. doi: 10.1371/journal.pone.0070803. Print 2013.</reference_text><pubmed_id>23940645</pubmed_id></reference><reference><reference_text>Phua LC, Chue XP, Koh PK, Cheah PY, Ho HK, Chan EC: Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biol Ther. 2014 Apr;15(4):389-97. doi: 10.4161/cbt.27625. Epub 2014 Jan 14.</reference_text><pubmed_id>24424155</pubmed_id></reference><reference><reference_text>Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB: Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010 Feb 15;8:13. doi: 10.1186/1741-7015-8-13.</reference_text><pubmed_id>20156336</pubmed_id></reference><reference><reference_text>Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, Ni Y, Zhao A, Xu LX, Cai S, Jia W: Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res. 2009 Oct;8(10):4844-50. doi: 10.1021/pr9004162.</reference_text><pubmed_id>19678709</pubmed_id></reference><reference><reference_text>Cheng Y, Xie G, Chen T, Qiu Y, Zou X, Zheng M, Tan B, Feng B, Dong T, He P, Zhao L, Zhao A, Xu LX, Zhang Y, Jia W: Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res. 2012 Feb 3;11(2):1354-63. doi: 10.1021/pr201001a. Epub 2011 Dec 28.</reference_text><pubmed_id>22148915</pubmed_id></reference><reference><reference_text>Ni Y, Xie G, Jia W: Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res. 2014 Sep 5;13(9):3857-70. doi: 10.1021/pr500443c. Epub 2014 Aug 14.</reference_text><pubmed_id>25105552</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference><reference><reference_text>Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18.</reference_text><pubmed_id>25037050</pubmed_id></reference><reference><reference_text>Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016.</reference_text><pubmed_id>27015276</pubmed_id></reference><reference><reference_text>Lin Y, Ma C, Liu C, Wang Z, Yang J, Liu X, Shen Z, Wu R: NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer. Oncotarget. 2016 May 17;7(20):29454-64. doi: 10.18632/oncotarget.8762.</reference_text><pubmed_id>27107423</pubmed_id></reference><reference><reference_text>Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016.</reference_text><pubmed_id>27275383</pubmed_id></reference><reference><reference_text>Wang X, Wang J, Rao B, Deng L: Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals. Exp Ther Med. 2017 Jun;13(6):2848-2854. doi: 10.3892/etm.2017.4367. Epub 2017 Apr 20.</reference_text><pubmed_id>28587349</pubmed_id></reference><reference><reference_text>Silke Matysik, Caroline Ivanne Le Roy, Gerhard Liebisch, Sandrine Paule Claus. Metabolomics of fecal samples: A practical consideration. Trends in Food Science &amp; Technology. Vol. 57, Part B, Nov. 2016, p.244-255: http://www.sciencedirect.com/science/article/pii/S0924224416301984</reference_text><pubmed_id>28587349</pubmed_id></reference></references></disease><disease>Gallbladder disease<references><reference><reference_text>Lapidus A, Akerlund JE, Einarsson C: Gallbladder bile composition in patients with Crohn 's disease. World J Gastroenterol. 2006 Jan 7;12(1):70-4.</reference_text><pubmed_id>16440420</pubmed_id></reference><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference><reference><reference_text>Mizuno S, Tazuma S, Kajiyama G: Stabilization of biliary lipid particles by ursodeoxycholic acid. Prolonged nucleation time in human gallbladder bile. Dig Dis Sci. 1993 Apr;38(4):684-93.</reference_text><pubmed_id>8462368</pubmed_id></reference><reference><reference_text>Hillebrant CG, Axelson M, Bjorkhem I, Wang FH, Nyberg B, Einarsson C: Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients. Eur J Clin Invest. 1998 Apr;28(4):324-8.</reference_text><pubmed_id>9615912</pubmed_id></reference></references></disease><disease>Cholelithiasis<references><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference></references></disease><disease>Stomach cancer<references><reference><reference_text>Higashijima H, Ichimiya H, Nakano T, Yamashita H, Kuroki S, Satoh H, Chijiiwa K, Tanaka M: Deconjugation of bilirubin accelerates coprecipitation of cholesterol, fatty acids, and mucin in human bile--in vitro study. J Gastroenterol. 1996 Dec;31(6):828-35.</reference_text><pubmed_id>9027647</pubmed_id></reference><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Song H, Peng JS, Dong-Sheng Y, Yang ZL, Liu HL, Zeng YK, Shi XP, Lu BY: Serum metabolic profiling of human gastric cancer based on gas chromatography/mass spectrometry. Braz J Med Biol Res. 2012 Jan;45(1):78-85. Epub 2011 Nov 25.</reference_text><pubmed_id>22124703</pubmed_id></reference><reference><reference_text>Yu L, Aa J, Xu J, Sun M, Qian S, Cheng L, Yang S, Shi R: Metabolomic phenotype of gastric cancer and precancerous stages based on gas chromatography time-of-flight mass spectrometry. J Gastroenterol Hepatol. 2011 Aug;26(8):1290-7. doi: 10.1111/j.1440-1746.2011.06724.x.</reference_text><pubmed_id>21443661</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference></references></disease><disease>Acute myelogenous leukemia<references><reference><reference_text>Tatidis L, Vitols S, Gruber A, Paul C, Axelson M: Cholesterol catabolism in patients with acute myelogenous leukemia and hypocholesterolemia: suppressed levels of a circulating marker for bile acid synthesis. Cancer Lett. 2001 Sep 20;170(2):169-75.</reference_text><pubmed_id>11463495</pubmed_id></reference></references></disease><disease>Hypercholesterolemia<references><reference><reference_text>Thelen KM, Laaksonen R, Paiva H, Lehtimaki T, Lutjohann D: High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels. J Clin Pharmacol. 2006 Jul;46(7):812-6.</reference_text><pubmed_id>16809807</pubmed_id></reference><reference><reference_text>Tamasawa N, Tamasawa A, Takebe K: Higher levels of plasma cholesterol sulfate in patients with liver cirrhosis and hypercholesterolemia. Lipids. 1993 Sep;28(9):833-6.</reference_text><pubmed_id>8231659</pubmed_id></reference><reference><reference_text>Kim DH, Lee KJ, Heo GS: Analysis of cholesterol and cholesteryl esters in human serum using capillary supercritical fluid chromatography. J Chromatogr B Biomed Appl. 1994 Apr 22;655(1):1-8.</reference_text><pubmed_id>8061816</pubmed_id></reference><reference><reference_text>Authors unspecified: Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med. 1988 Jan;148(1):36-69.</reference_text><pubmed_id>3422148</pubmed_id></reference></references></disease><disease>Cholesteryl ester storage disease<references><reference><reference_text>Rassoul F, Richter V, Lohse P, Naumann A, Purschwitz K, Keller E: Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease. Int J Clin Pharmacol Ther. 2001 May;39(5):199-204.</reference_text><pubmed_id>11380065</pubmed_id></reference><reference><reference_text>Chatrath H, Keilin S, Attar BM: Cholesterol ester storage disease (CESD) diagnosed in an asymptomatic adult. Dig Dis Sci. 2009 Jan;54(1):168-73. doi: 10.1007/s10620-008-0310-2. Epub 2008 May 14.</reference_text><pubmed_id>18478331</pubmed_id></reference><reference><reference_text>Bernstein DL, Hulkova H, Bialer MG, Desnick RJ: Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol. 2013 Jun;58(6):1230-43. doi: 10.1016/j.jhep.2013.02.014. Epub 2013 Feb 26.</reference_text><pubmed_id>23485521</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Cystinosis<references><reference><reference_text>Ueda M, O'Brien K, Rosing DR, Ling A, Kleta R, McAreavey D, Bernardini I, Gahl WA: Coronary artery and other vascular calcifications in patients with cystinosis after kidney transplantation. Clin J Am Soc Nephrol. 2006 May;1(3):555-62. Epub 2006 Feb 8.</reference_text><pubmed_id>17699259</pubmed_id></reference><reference><reference_text>Gahl WA, Bernardini I, Dalakas M, Rizzo WB, Harper GS, Hoeg JM, Hurko O, Bernar J: Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome. J Clin Invest. 1988 Feb;81(2):549-60.</reference_text><pubmed_id>3276734</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Smith-Lemli-Opitz syndrome<references><reference><reference_text>van Rooij A, Nijenhuis AA, Wijburg FA, Schutgens RB: Highly increased CSF concentrations of cholesterol precursors in Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 1997 Aug;20(4):578-80.</reference_text><pubmed_id>9266395</pubmed_id></reference><reference><reference_text>Honda M, Tint GS, Honda A, Salen G, Shefer S, Batta AK, Matsuzaki Y, Tanaka N: Regulation of cholesterol biosynthetic pathway in patients with the Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2000 Jul;23(5):464-74.</reference_text><pubmed_id>10947201</pubmed_id></reference><reference><reference_text>Rossi M, Federico G, Corso G, Parenti G, Battagliese A, Frascogna AR, Della Casa R, Dello Russo A, Strisciuglio P, Saggese G, Andria G: Vitamin D status in patients affected by Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2005;28(1):69-80.</reference_text><pubmed_id>15702407</pubmed_id></reference><reference><reference_text>Johnson DW, ten Brink HJ, Jakobs C: A rapid screening procedure for cholesterol and dehydrocholesterol by electrospray ionization tandem mass spectrometry. J Lipid Res. 2001 Oct;42(10):1699-705.</reference_text><pubmed_id>11590227</pubmed_id></reference></references></disease><disease>Prostate cancer<references><reference><reference_text>Nyman DW, Suzanne Stratton M, Kopplin MJ, Dalkin BL, Nagle RB, Jay Gandolfi A: Selenium and selenomethionine levels in prostate cancer patients. Cancer Detect Prev. 2004;28(1):8-16.</reference_text><pubmed_id>15041072</pubmed_id></reference><reference><reference_text>Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, Egevad L, Tjonneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, Palli D, Vineis P, Tumino R, Berrino F, Kiemeney L, Bueno-de-Mesquita HB, Quiros JR, Gonzalez CA, Martinez C, Larranaga N, Chirlaque MD, Ardanaz E, Stattin P, Hallmans G, Khaw KT, Bingham S, Slimani N, Ferrari P, Rinaldi S, Riboli E: Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr. 2007 Sep;86(3):672-81.</reference_text><pubmed_id>17823432</pubmed_id></reference><reference><reference_text>Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762.</reference_text><pubmed_id>19212411</pubmed_id></reference><reference><reference_text>Puah CM, Williams G, Ghanadian R: Urinary unconjugated 5 alpha-androstane-3 alpha, 17 beta-diol in patients with prostatic tumours. Urol Res. 1982;10(2):81-4.</reference_text><pubmed_id>6180540</pubmed_id></reference><reference><reference_text>Thysell E, Surowiec I, Hornberg E, Crnalic S, Widmark A, Johansson AI, Stattin P, Bergh A, Moritz T, Antti H, Wikstrom P: Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One. 2010 Dec 3;5(12):e14175. doi: 10.1371/journal.pone.0014175.</reference_text><pubmed_id>21151972</pubmed_id></reference><reference><reference_text>Soliman LC, Hui Y, Hewavitharana AK, Chen DD: Monitoring potential prostate cancer biomarkers in urine by capillary electrophoresis-tandem mass spectrometry. J Chromatogr A. 2012 Dec 7;1267:162-9. doi: 10.1016/j.chroma.2012.07.021. Epub 2012 Jul 14.</reference_text><pubmed_id>22824219</pubmed_id></reference><reference><reference_text>Madu CO, Lu Y: Novel diagnostic biomarkers for prostate cancer. J Cancer. 2010 Oct 6;1:150-77.</reference_text><pubmed_id>20975847</pubmed_id></reference></references></disease><disease>Schizophrenia<references><reference><reference_text>Harnryd C, Bjerkenstedt L, Grimm VE, Sedvall G: Reduction of MOPEG levels in cerebrospinal fluid of psychotic women after electroconvulsive treatment. Psychopharmacology (Berl). 1979 Aug 8;64(2):131-4.</reference_text><pubmed_id>115032</pubmed_id></reference><reference><reference_text>Kobayashi K, Koide Y, Yoshino K, Shohmori T: [P-hydroxyphenylacetic acid concentrations in cerebrospinal fluid]. No To Shinkei. 1982 Aug;34(8):769-74.</reference_text><pubmed_id>7126379</pubmed_id></reference><reference><reference_text>Alfredsson G, Wiesel FA: Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology (Berl). 1989;99(3):322-7.</reference_text><pubmed_id>2480613</pubmed_id></reference><reference><reference_text>Heresco-Levy U, Bar G, Levin R, Ermilov M, Ebstein RP, Javitt DC: High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. Schizophr Res. 2007 Mar;91(1-3):14-21. Epub 2007 Feb 2.</reference_text><pubmed_id>17276036</pubmed_id></reference><reference><reference_text>Walker EF, Bonsall R, Walder DJ: Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis. Neuropsychiatry Neuropsychol Behav Neurol. 2002 Mar;15(1):10-7.</reference_text><pubmed_id>11877547</pubmed_id></reference><reference><reference_text>Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M: Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry. 2003 Jun;60(6):572-6.</reference_text><pubmed_id>12796220</pubmed_id></reference><reference><reference_text>Do KQ, Lauer CJ, Schreiber W, Zollinger M, Gutteck-Amsler U, Cuenod M, Holsboer F: gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem. 1995 Dec;65(6):2652-62.</reference_text><pubmed_id>7595563</pubmed_id></reference><reference><reference_text>Nikisch G, Baumann P, Wiedemann G, Kiessling B, Weisser H, Hertel A, Yoshitake T, Kehr J, Mathe AA: Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF. J Clin Psychopharmacol. 2010 Oct;30(5):496-503. doi: 10.1097/JCP.0b013e3181f2288e.</reference_text><pubmed_id>20814316</pubmed_id></reference><reference><reference_text>Fukushima T, Iizuka H, Yokota A, Suzuki T, Ohno C, Kono Y, Nishikiori M, Seki A, Ichiba H, Watanabe Y, Hongo S, Utsunomiya M, Nakatani M, Sadamoto K, Yoshio T: Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One. 2014 Jul 8;9(7):e101652. doi: 10.1371/journal.pone.0101652. eCollection 2014.</reference_text><pubmed_id>25004141</pubmed_id></reference><reference><reference_text>Koike S, Bundo M, Iwamoto K, Suga M, Kuwabara H, Ohashi Y, Shinoda K, Takano Y, Iwashiro N, Satomura Y, Nagai T, Natsubori T, Tada M, Yamasue H, Kasai K: A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study. Transl Psychiatry. 2014 Apr 8;4:e379. doi: 10.1038/tp.2014.19.</reference_text><pubmed_id>24713860</pubmed_id></reference><reference><reference_text>Ballesteros A, Summerfelt A, Du X, Jiang P, Chiappelli J, Tagamets M, O'Donnell P, Kochunov P, Hong LE: Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia. Clin Neurophysiol. 2013 Nov;124(11):2209-15. doi: 10.1016/j.clinph.2013.05.021. Epub 2013 Jun 30.</reference_text><pubmed_id>23823132</pubmed_id></reference><reference><reference_text>Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel FA: Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry. 1985 Sep;147:276-82.</reference_text><pubmed_id>2415198</pubmed_id></reference><reference><reference_text>Pickar D, Breier A, Hsiao JK, Doran AR, Wolkowitz OM, Pato CN, Konicki PE, Potter WZ: Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Arch Gen Psychiatry. 1990 Jul;47(7):641-8.</reference_text><pubmed_id>1694425</pubmed_id></reference><reference><reference_text>Prell GD, Green JP, Kaufmann CA, Khandelwal JK, Morrishow AM, Kirch DG, Linnoila M, Wyatt RJ: Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res. 1995 Jan;14(2):93-104.</reference_text><pubmed_id>7711000</pubmed_id></reference><reference><reference_text>Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B: Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology. 2009;59(2):123-9. doi: 10.1159/000213565. Epub 2009 Apr 22.</reference_text><pubmed_id>19390223</pubmed_id></reference><reference><reference_text>Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K, Cao Y, Wang X, Qiu Y, Su M, Zhao A, Wang P, Yang P, Wu J, Feng G, He L, Jia W, Wan C: Potential metabolite markers of schizophrenia. Mol Psychiatry. 2013 Jan;18(1):67-78. doi: 10.1038/mp.2011.131. Epub 2011 Oct 25.</reference_text><pubmed_id>22024767</pubmed_id></reference><reference><reference_text>Xuan J, Pan G, Qiu Y, Yang L, Su M, Liu Y, Chen J, Feng G, Fang Y, Jia W, Xing Q, He L: Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. J Proteome Res. 2011 Dec 2;10(12):5433-43. doi: 10.1021/pr2006796. Epub 2011 Nov  8.</reference_text><pubmed_id>22007635</pubmed_id></reference><reference><reference_text>Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM, Rothermundt M, Bogerts B, Koethe D, Kranaster L, Ohrmann P, Suslow T, McAllister G, Spain M, Barnes A, van Beveren NJ, Baron-Cohen S, Steiner J, Torrey FE, Yolken RH, Bahn S: Identification of a biological signature for schizophrenia in serum. Mol Psychiatry. 2012 May;17(5):494-502. doi: 10.1038/mp.2011.42. Epub 2011 Apr 12.</reference_text><pubmed_id>21483431</pubmed_id></reference><reference><reference_text>Mathe AA, Eberhard G, Saaf J, Wetterberg L: Plasma prostaglandin E2 metabolite--measured as 11-deoxy-15-keto-13,14-dihydro-11 beta,16 xi-cyclo-PGE2--in twins with schizophrenic disorder. Biol Psychiatry. 1986 Sep;21(11):1024-30.</reference_text><pubmed_id>3741918</pubmed_id></reference><reference><reference_text>Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N: Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct. 2002 Jun;20(2):171-5.</reference_text><pubmed_id>11979513</pubmed_id></reference><reference><reference_text>Zumarraga M, Davila R, Basterreche N, Arrue A, Goienetxea B, Zamalloa MI, Erkoreka L, Bustamante S, Inchausti L, Gonzalez-Torres MA, Guimon J: Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients. Neurochem Int. 2010 May-Jun;56(6-7):774-9. doi: 10.1016/j.neuint.2010.02.015. Epub 2010 Mar 4.</reference_text><pubmed_id>20206656</pubmed_id></reference><reference><reference_text>Peters JG: Dopamine, noradrenaline and serotonin spinal fluid metabolites in temporal lobe epileptic patients with schizophrenic symptomatology. Eur Neurol. 1979;18(1):15-8.</reference_text><pubmed_id>436860</pubmed_id></reference><reference><reference_text>Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, Rozen S, Krishnan RR, McEvoy J, Kaddurah-Daouk R: Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry. 2010 Sep;15(9):938-53. doi: 10.1038/mp.2009.33. Epub 2009 Apr 28.</reference_text><pubmed_id>19401681</pubmed_id></reference><reference><reference_text>Gattaz WF, Waldmeier P, Beckmann H: CSF monoamine metabolites in schizophrenic patients. Acta Psychiatr Scand. 1982 Nov;66(5):350-60.</reference_text><pubmed_id>6184954</pubmed_id></reference><reference><reference_text>Nilsson-Todd LK, Nordin C, Jonsson EG, Skogh E, Erhardt S: Cerebrospinal fluid kynurenic acid in male patients with schizophrenia - correlation with monoamine metabolites. Acta Neuropsychiatr. 2007 Feb;19(1):45-52. doi: 10.1111/j.1601-5215.2006.00170.x.</reference_text><pubmed_id>26952797</pubmed_id></reference><reference><reference_text>Cai HL, Li HD, Yan XZ, Sun B, Zhang Q, Yan M, Zhang WY, Jiang P, Zhu RH, Liu YP, Fang PF, Xu P, Yuan HY, Zhang XH, Hu L, Yang W, Ye HS: Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naive schizophrenia patients after treatment with risperidone. J Proteome Res. 2012 Aug 3;11(8):4338-50. doi: 10.1021/pr300459d. Epub 2012 Jul 26.</reference_text><pubmed_id>22800120</pubmed_id></reference><reference><reference_text>Al Awam K, Haussleiter IS, Dudley E, Donev R, Brune M, Juckel G, Thome J: Multiplatform metabolome and proteome profiling identifies serum metabolite and protein signatures as prospective biomarkers for schizophrenia. J Neural Transm (Vienna). 2015 Aug;122 Suppl 1:S111-22. doi: 10.1007/s00702-014-1224-0. Epub 2014 May 1.</reference_text><pubmed_id>24789758</pubmed_id></reference><reference><reference_text>Bicikova M, Hill M, Ripova D, Mohr P, Hampl R: Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia. J Steroid Biochem Mol Biol. 2013 Jan;133:77-83. doi: 10.1016/j.jsbmb.2012.08.009. Epub 2012 Aug 24.</reference_text><pubmed_id>22944140</pubmed_id></reference><reference><reference_text>He Y, Yu Z, Giegling I, Xie L, Hartmann AM, Prehn C, Adamski J, Kahn R, Li Y, Illig T, Wang-Sattler R, Rujescu D: Schizophrenia shows a unique metabolomics signature in plasma. Transl Psychiatry. 2012 Aug 14;2:e149. doi: 10.1038/tp.2012.76.</reference_text><pubmed_id>22892715</pubmed_id></reference><reference><reference_text>Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KR: Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):934-45. Epub 2007 Apr 17.</reference_text><pubmed_id>17440431</pubmed_id></reference><reference><reference_text>Fryar-Williams S, Strobel JE: Biomarkers of a five-domain translational substrate for schizophrenia and schizoaffective psychosis. Biomark Res. 2015 Feb 6;3:3. doi: 10.1186/s40364-015-0028-1. eCollection 2015.</reference_text><pubmed_id>25729574</pubmed_id></reference><reference><reference_text>Oresic M, Seppanen-Laakso T, Sun D, Tang J, Therman S, Viehman R, Mustonen U, van Erp TG, Hyotylainen T, Thompson P, Toga AW, Huttunen MO, Suvisaari J, Kaprio J, Lonnqvist J, Cannon TD: Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia. Genome Med. 2012 Jan 18;4(1):1. doi: 10.1186/gm300.</reference_text><pubmed_id>22257447</pubmed_id></reference></references></disease><disease>Primary hypomagnesemia<references><reference><reference_text>Jin-no Y, Kamiya Y, Okada M, Hirako M, Takada N, Kawaguchi M: Primary hypomagnesemia caused by isolated magnesium malabsorption: atypical case in adult. Intern Med. 1999 Mar;38(3):261-5.</reference_text><pubmed_id>10337938</pubmed_id></reference><reference><reference_text>Vainsel M, Vandevelde G, Smulders J, Vosters M, Hubain P, Loeb H: Tetany due to hypomagnesaemia with secondary hypocalcaemia. Arch Dis Child. 1970 Apr;45(240):254-8.</reference_text><pubmed_id>5419995</pubmed_id></reference><reference><reference_text>Shalev H, Phillip M, Galil A, Carmi R, Landau D: Clinical presentation and outcome in primary familial hypomagnesaemia. Arch Dis Child. 1998 Feb;78(2):127-30.</reference_text><pubmed_id>9579153</pubmed_id></reference><reference><reference_text>Kari JA, Farouq M, Alshaya HO: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Pediatr Nephrol. 2003 Jun;18(6):506-10. Epub 2003 Apr 29.</reference_text><pubmed_id>12720080</pubmed_id></reference></references></disease><disease>Hyperlipoproteinemia<references><reference><reference_text>Sinha S, Misra A, Kumar V, Jagannathan NR, Bal CS, Pandey RM, Singhania R, Deepak: Proton magnetic resonance spectroscopy and single photon emission computed tomography study of the brain in asymptomatic young hyperlipidaemic Asian Indians in North India show early abnormalities. Clin Endocrinol (Oxf). 2004 Aug;61(2):182-9.</reference_text><pubmed_id>15272912</pubmed_id></reference><reference><reference_text>Nelson RH: Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013 Mar</reference_text><pubmed_id>40(1):195-211. doi: 10.1016/j.pop.2012.11.003. Epub 2012 Dec  4.</pubmed_id></reference><reference><reference_text>Cantin B, Boudriau S, Bertrand M, Brun LD, Gagne C, Rogers PA, Ven Murthy MR, Lupien PJ, Julien P: Hemolysis in primary lipoprotein lipase deficiency. Metabolism. 1995 May;44(5):652-8.</reference_text><pubmed_id>7752915</pubmed_id></reference></references></disease><disease>Abetalipoproteinemia<references><reference><reference_text>Dawson G, Kruski AW, Scanu AM: Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J Lipid Res. 1976 Mar;17(2):125-31.</reference_text><pubmed_id>178813</pubmed_id></reference><reference><reference_text>Lazaro RP, Dentinger MP, Rodichok LD, Barron KD, Satya-Murti S: Muscle pathology in Bassen-Kornzweig syndrome and vitamin E deficiency. Am J Clin Pathol. 1986 Sep;86(3):378-87.</reference_text><pubmed_id>2944375</pubmed_id></reference></references></disease><disease>Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis<references><reference><reference_text>Breckenridge WC, Alaupovic P, Cox DW, Little JA: Apolipoprotein and lipoprotein concentrations in familial apolipoprotein C-II deficiency. Atherosclerosis. 1982 Aug;44(2):223-35.</reference_text><pubmed_id>7138621</pubmed_id></reference><reference><reference_text>Fukami M, Hasegawa T, Horikawa R, Ohashi T, Nishimura G, Homma K, Ogata T: Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr Res. 2006 Feb;59(2):276-80. doi: 10.1203/01.pdr.0000195825.31504.28.</reference_text><pubmed_id>16439592</pubmed_id></reference></references></disease><disease>Cerebrotendinous xanthomatosis<references><reference><reference_text>Halperin G, Elisaf M, Leitersdorf E, Harats D: A new method for determination of serum cholestanol by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2000 Jun 9;742(2):345-52.</reference_text><pubmed_id>10901139</pubmed_id></reference><reference><reference_text>Siman-Tov T, Meiner V, Gadoth N: Could steroids mask the diagnosis of cerebrotendinous xanthomatosis? J Neurol Sci. 2006 Apr 15;243(1-2):83-6. Epub 2006 Jan 30.</reference_text><pubmed_id>16445943</pubmed_id></reference><reference><reference_text>Agrawal NK, Garg S: Cerebrotendinous xanthomatosis: a rare disorder with a rare presentation. BMJ Case Rep. 2012 Sep 21;2012. pii: bcr-2012-006202. doi: 10.1136/bcr-2012-006202.</reference_text><pubmed_id>23001091</pubmed_id></reference></references></disease><disease>3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency<references><reference><reference_text>Thompson GN, Hsu BY, Pitt JJ, Treacy E, Stanley CA: Fasting hypoketotic coma in a child with deficiency of mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase. N Engl J Med. 1997 Oct 23;337(17):1203-7. doi: 10.1056/NEJM199710233371704.</reference_text><pubmed_id>9337379</pubmed_id></reference><reference><reference_text>Morris AA, Lascelles CV, Olpin SE, Lake BD, Leonard JV, Quant PA: Hepatic mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme a synthase deficiency. Pediatr Res. 1998 Sep;44(3):392-6. doi: 10.1203/00006450-199809000-00021.</reference_text><pubmed_id>9727719</pubmed_id></reference><reference><reference_text>Conboy E, Vairo F, Schultz M, Agre K, Ridsdale R, Deyle D, Oglesbee D, Gavrilov D, Klee EW, Lanpher B: Mitochondrial 3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency: Unique Presenting Laboratory Values and a Review of Biochemical and Clinical Features. JIMD Rep. 2017 Oct 14. doi: 10.1007/8904_2017_59.</reference_text><pubmed_id>29030856</pubmed_id></reference></references></disease><disease>Hypercholesterolemia, familial<references><reference><reference_text>Kwiterovich PO Jr, Fredrickson DS, Levy RI: Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest. 1974 May;53(5):1237-49. doi: 10.1172/JCI107670.</reference_text><pubmed_id>4363406</pubmed_id></reference></references></disease><disease>SC4MOL deficiency<references><reference><reference_text>He M, Kratz LE, Michel JJ, Vallejo AN, Ferris L, Kelley RI, Hoover JJ, Jukic D, Gibson KM, Wolfe LA, Ramachandran D, Zwick ME, Vockley J: Mutations in the human SC4MOL gene encoding a methyl sterol oxidase cause psoriasiform dermatitis, microcephaly, and developmental delay. J Clin Invest. 2011 Mar;121(3):976-84. doi: 10.1172/JCI42650.</reference_text><pubmed_id>21285510</pubmed_id></reference></references></disease><disease>Chondrodysplasia punctata, X-linked dominant<references><reference><reference_text>Aughton DJ, Kelley RI, Metzenberg A, Pureza V, Pauli RM: X-linked dominant chondrodysplasia punctata (CDPX2) caused by single gene mosaicism in a male. Am J Med Genet A. 2003 Jan 30;116A(3):255-60. doi: 10.1002/ajmg.a.10852.</reference_text><pubmed_id>12503102</pubmed_id></reference></references></disease><disease>Desmosterolosis<references><reference><reference_text>Andersson HC, Kratz L, Kelley R: Desmosterolosis presenting with multiple congenital anomalies and profound developmental delay. Am J Med Genet. 2002 Dec 15;113(4):315-9. doi: 10.1002/ajmg.b.10873.</reference_text><pubmed_id>12457401</pubmed_id></reference></references></disease><disease>Donohue Syndrome<references><reference><reference_text>Nijim Y, Awni Y, Adawi A, Bowirrat A: Classic Case Report of Donohue Syndrome (Leprechaunism; OMIM *246200): The Impact of Consanguineous Mating. Medicine (Baltimore). 2016 Feb;95(6):e2710. doi: 10.1097/MD.0000000000002710.</reference_text><pubmed_id>26871809</pubmed_id></reference></references></disease><disease>Leptin Deficiency or Dysfunction<references><reference><reference_text>Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O'Rahilly S: Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999 Sep 16;341(12):879-84. doi: 10.1056/NEJM199909163411204.</reference_text><pubmed_id>10486419</pubmed_id></reference></references></disease><disease>Duchenne Muscular Dystrophy<references><reference><reference_text>Nakagawa T, Takeuchi A, Kakiuchi R, Lee T, Yagi M, Awano H, Iijima K, Takeshima Y, Urade Y, Matsuo M: A prostaglandin D2 metabolite is elevated in the urine of Duchenne muscular dystrophy patients and increases further from 8 years old. Clin Chim Acta. 2013 Aug 23;423:10-4. doi: 10.1016/j.cca.2013.03.031. Epub 2013 Apr 19.</reference_text><pubmed_id>23603101</pubmed_id></reference><reference><reference_text>Srivastava NK, Pradhan S, Mittal B, Gowda GA: High resolution NMR based analysis of serum lipids in Duchenne muscular dystrophy patients and its possible diagnostic significance. NMR Biomed. 2010 Jan;23(1):13-22. doi: 10.1002/nbm.1419.</reference_text><pubmed_id>19787747</pubmed_id></reference><reference><reference_text>Horster I, Weigt-Usinger K, Carmann C, Chobanyan-Jurgens K, Kohler C, Schara U, Kayacelebi AA, Beckmann B, Tsikas D, Lucke T: The L-arginine/NO pathway and homoarginine are altered in Duchenne muscular dystrophy and improved by glucocorticoids. Amino Acids. 2015 Sep;47(9):1853-63. doi: 10.1007/s00726-015-2018-x. Epub 2015 Jun 12.</reference_text><pubmed_id>26066683</pubmed_id></reference></references></disease><disease>Lecithin:cholesterol Acyltransferase Deficiency<references><reference><reference_text>Idzior-Walus B, Sieradzki J, Kostner G, Malecki MT, Klupa T, Wesolowska T, Rostworowski W, Hartwich J, Walus M, Kiec AD, Naruszewicz M: Familial lecithin-cholesterol acyltransferase deficiency: biochemical characteristics and molecular analysis of a new LCAT mutation in a Polish family. Atherosclerosis. 2006 Apr;185(2):413-20. Epub 2005 Jul 26.</reference_text><pubmed_id>16051254</pubmed_id></reference></references></disease><disease>Lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lipodystrophy, Congenital Generalized<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Oculocerebrorenal syndrome<references><reference><reference_text>Charnas LR, Bernardini I, Rader D, Hoeg JM, Gahl WA: Clinical and laboratory findings in the oculocerebrorenal syndrome of Lowe, with special reference to growth and renal function. N Engl J Med. 1991 May 9;324(19):1318-25. doi: 10.1056/NEJM199105093241904.</reference_text><pubmed_id>2017228</pubmed_id></reference></references></disease><disease>Familial partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lathosterolosis<references><reference><reference_text>Brunetti-Pierri N, Corso G, Rossi M, Ferrari P, Balli F, Rivasi F, Annunziata I, Ballabio A, Russo AD, Andria G, Parenti G: Lathosterolosis, a novel multiple-malformation/mental retardation syndrome due to deficiency of 3beta-hydroxysteroid-delta5-desaturase. Am J Hum Genet. 2002 Oct;71(4):952-8. Epub 2002 Aug 20.</reference_text><pubmed_id>12189593</pubmed_id></reference><reference><reference_text>Ho AC, Fung CW, Siu TS, Ma OC, Lam CW, Tam S, Wong VC: Lathosterolosis: a disorder of cholesterol biosynthesis resembling smith-lemli-opitz syndrome. JIMD Rep. 2014;12:129-34. doi: 10.1007/8904_2013_255. Epub 2013 Oct 20.</reference_text><pubmed_id>24142275</pubmed_id></reference></references></disease><disease>Partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Multiple sclerosis<references><reference><reference_text>Lutz NW, Viola A, Malikova I, Confort-Gouny S, Audoin B, Ranjeva JP, Pelletier J, Cozzone PJ: Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One. 2007 Jul 4;2(7):e595.</reference_text><pubmed_id>17611627</pubmed_id></reference><reference><reference_text>Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U, Hillert J, Bjorkhem I: Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med. 2004 Feb;42(2):186-91.</reference_text><pubmed_id>15061359</pubmed_id></reference><reference><reference_text>Leoni V, Lutjohann D, Masterman T: Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis. J Lipid Res. 2005 Feb;46(2):191-5. Epub 2004 Dec 1.</reference_text><pubmed_id>15576852</pubmed_id></reference><reference><reference_text>Calabrese V, Scapagnini G, Ravagna A, Bella R, Butterfield DA, Calvani M, Pennisi G, Giuffrida Stella AM: Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem Res. 2003 Sep;28(9):1321-8.</reference_text><pubmed_id>12938853</pubmed_id></reference><reference><reference_text>Shaw CE, Dunbar PR, Macaulay HA, Neale TJ: Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol. 1995 Jan;242(2):53-8.</reference_text><pubmed_id>7707089</pubmed_id></reference><reference><reference_text>Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.</reference_text><pubmed_id>17384003</pubmed_id></reference><reference><reference_text>Syburra C, Passi S: Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh (1999). 1999 May-Jun;71(3):112-5.</reference_text><pubmed_id>10609336</pubmed_id></reference><reference><reference_text>Forte G, Visconti A, Santucci S, Ghazaryan A, Figa-Talamanca L, Cannoni S, Bocca B, Pino A, Violante N, Alimonti A, Salvetti M, Ristori G: Quantification of chemical elements in blood of patients affected by multiple sclerosis. Ann Ist Super Sanita. 2005;41(2):213-6.</reference_text><pubmed_id>16244395</pubmed_id></reference><reference><reference_text>Toncev G, Milicic B, Toncev S, Samardzic G: Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol. 2002 May;9(3):221-6.</reference_text><pubmed_id>11985629</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, Bamonti F, Capello E, Mancardi GL, Scarpini E: Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res. 2010 May 28;1333:64-71. doi: 10.1016/j.brainres.2010.03.073. Epub 2010 Mar 27.</reference_text><pubmed_id>20347721</pubmed_id></reference><reference><reference_text>Matsushita T, Isobe N, Kawajiri M, Mogi M, Tsukuda K, Horiuchi M, Ohyagi Y, Kira J: CSF angiotensin II and angiotensin-converting enzyme levels in anti-aquaporin-4 autoimmunity. J Neurol Sci. 2010 Aug 15;295(1-2):41-5. doi: 10.1016/j.jns.2010.05.014. Epub 2010 Jun 11.</reference_text><pubmed_id>20541774</pubmed_id></reference><reference><reference_text>Ghabaee M, Jabedari B, Al-E-Eshagh N, Ghaffarpour M, Asadi F: Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients. Int J Neurosci. 2010 Apr;120(4):301-4. doi: 10.3109/00207451003695690.</reference_text><pubmed_id>20374079</pubmed_id></reference><reference><reference_text>Kawajiri M, Mogi M, Osoegawa M, Matsuoka T, Tsukuda K, Kohara K, Horiuchi M, Miki T, Kira JI: Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler. 2008 May;14(4):557-60. doi: 10.1177/1352458507085760.</reference_text><pubmed_id>18562510</pubmed_id></reference><reference><reference_text>Visconti A, Cotichini R, Cannoni S, Bocca B, Forte G, Ghazaryan A, Santucci S, D'Ippolito C, Stazi MA, Salvetti M, Alimonti A, Ristori G: Concentration of elements in serum of patients affected by multiple sclerosis with first demyelinating episode: a six-month longitudinal follow-up study. Ann Ist Super Sanita. 2005;41(2):217-22.</reference_text><pubmed_id>16244396</pubmed_id></reference></references></disease><disease>Inflammatory bowel disease<references><reference><reference_text>Lee T, Clavel T, Smirnov K, Schmidt A, Lagkouvardos I, Walker A, Lucio M, Michalke B, Schmitt-Kopplin P, Fedorak R, Haller D: Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. 2017 May;66(5):863-871. doi: 10.1136/gutjnl-2015-309940. Epub 2016 Feb 4.</reference_text><pubmed_id>26848182</pubmed_id></reference><reference><reference_text>Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158.</reference_text><pubmed_id>27609529</pubmed_id></reference></references></disease><disease>Colorectal cancer<references><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B: Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009 Apr;22(3):342-8. doi: 10.1002/nbm.1345.</reference_text><pubmed_id>19006102</pubmed_id></reference><reference><reference_text>Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP: Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One. 2013 Aug 6;8(8):e70803. doi: 10.1371/journal.pone.0070803. Print 2013.</reference_text><pubmed_id>23940645</pubmed_id></reference><reference><reference_text>Phua LC, Chue XP, Koh PK, Cheah PY, Ho HK, Chan EC: Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biol Ther. 2014 Apr;15(4):389-97. doi: 10.4161/cbt.27625. Epub 2014 Jan 14.</reference_text><pubmed_id>24424155</pubmed_id></reference><reference><reference_text>Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB: Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010 Feb 15;8:13. doi: 10.1186/1741-7015-8-13.</reference_text><pubmed_id>20156336</pubmed_id></reference><reference><reference_text>Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, Ni Y, Zhao A, Xu LX, Cai S, Jia W: Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res. 2009 Oct;8(10):4844-50. doi: 10.1021/pr9004162.</reference_text><pubmed_id>19678709</pubmed_id></reference><reference><reference_text>Cheng Y, Xie G, Chen T, Qiu Y, Zou X, Zheng M, Tan B, Feng B, Dong T, He P, Zhao L, Zhao A, Xu LX, Zhang Y, Jia W: Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res. 2012 Feb 3;11(2):1354-63. doi: 10.1021/pr201001a. Epub 2011 Dec 28.</reference_text><pubmed_id>22148915</pubmed_id></reference><reference><reference_text>Ni Y, Xie G, Jia W: Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res. 2014 Sep 5;13(9):3857-70. doi: 10.1021/pr500443c. Epub 2014 Aug 14.</reference_text><pubmed_id>25105552</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference><reference><reference_text>Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18.</reference_text><pubmed_id>25037050</pubmed_id></reference><reference><reference_text>Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016.</reference_text><pubmed_id>27015276</pubmed_id></reference><reference><reference_text>Lin Y, Ma C, Liu C, Wang Z, Yang J, Liu X, Shen Z, Wu R: NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer. Oncotarget. 2016 May 17;7(20):29454-64. doi: 10.18632/oncotarget.8762.</reference_text><pubmed_id>27107423</pubmed_id></reference><reference><reference_text>Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016.</reference_text><pubmed_id>27275383</pubmed_id></reference><reference><reference_text>Wang X, Wang J, Rao B, Deng L: Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals. Exp Ther Med. 2017 Jun;13(6):2848-2854. doi: 10.3892/etm.2017.4367. Epub 2017 Apr 20.</reference_text><pubmed_id>28587349</pubmed_id></reference><reference><reference_text>Silke Matysik, Caroline Ivanne Le Roy, Gerhard Liebisch, Sandrine Paule Claus. Metabolomics of fecal samples: A practical consideration. Trends in Food Science &amp; Technology. Vol. 57, Part B, Nov. 2016, p.244-255: http://www.sciencedirect.com/science/article/pii/S0924224416301984</reference_text><pubmed_id>28587349</pubmed_id></reference></references></disease><disease>Gallbladder disease<references><reference><reference_text>Lapidus A, Akerlund JE, Einarsson C: Gallbladder bile composition in patients with Crohn 's disease. World J Gastroenterol. 2006 Jan 7;12(1):70-4.</reference_text><pubmed_id>16440420</pubmed_id></reference><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference><reference><reference_text>Mizuno S, Tazuma S, Kajiyama G: Stabilization of biliary lipid particles by ursodeoxycholic acid. Prolonged nucleation time in human gallbladder bile. Dig Dis Sci. 1993 Apr;38(4):684-93.</reference_text><pubmed_id>8462368</pubmed_id></reference><reference><reference_text>Hillebrant CG, Axelson M, Bjorkhem I, Wang FH, Nyberg B, Einarsson C: Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients. Eur J Clin Invest. 1998 Apr;28(4):324-8.</reference_text><pubmed_id>9615912</pubmed_id></reference></references></disease><disease>Cholelithiasis<references><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference></references></disease><disease>Stomach cancer<references><reference><reference_text>Higashijima H, Ichimiya H, Nakano T, Yamashita H, Kuroki S, Satoh H, Chijiiwa K, Tanaka M: Deconjugation of bilirubin accelerates coprecipitation of cholesterol, fatty acids, and mucin in human bile--in vitro study. J Gastroenterol. 1996 Dec;31(6):828-35.</reference_text><pubmed_id>9027647</pubmed_id></reference><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Song H, Peng JS, Dong-Sheng Y, Yang ZL, Liu HL, Zeng YK, Shi XP, Lu BY: Serum metabolic profiling of human gastric cancer based on gas chromatography/mass spectrometry. Braz J Med Biol Res. 2012 Jan;45(1):78-85. Epub 2011 Nov 25.</reference_text><pubmed_id>22124703</pubmed_id></reference><reference><reference_text>Yu L, Aa J, Xu J, Sun M, Qian S, Cheng L, Yang S, Shi R: Metabolomic phenotype of gastric cancer and precancerous stages based on gas chromatography time-of-flight mass spectrometry. J Gastroenterol Hepatol. 2011 Aug;26(8):1290-7. doi: 10.1111/j.1440-1746.2011.06724.x.</reference_text><pubmed_id>21443661</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference></references></disease><disease>Acute myelogenous leukemia<references><reference><reference_text>Tatidis L, Vitols S, Gruber A, Paul C, Axelson M: Cholesterol catabolism in patients with acute myelogenous leukemia and hypocholesterolemia: suppressed levels of a circulating marker for bile acid synthesis. Cancer Lett. 2001 Sep 20;170(2):169-75.</reference_text><pubmed_id>11463495</pubmed_id></reference></references></disease><disease>Hypercholesterolemia<references><reference><reference_text>Thelen KM, Laaksonen R, Paiva H, Lehtimaki T, Lutjohann D: High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels. J Clin Pharmacol. 2006 Jul;46(7):812-6.</reference_text><pubmed_id>16809807</pubmed_id></reference><reference><reference_text>Tamasawa N, Tamasawa A, Takebe K: Higher levels of plasma cholesterol sulfate in patients with liver cirrhosis and hypercholesterolemia. Lipids. 1993 Sep;28(9):833-6.</reference_text><pubmed_id>8231659</pubmed_id></reference><reference><reference_text>Kim DH, Lee KJ, Heo GS: Analysis of cholesterol and cholesteryl esters in human serum using capillary supercritical fluid chromatography. J Chromatogr B Biomed Appl. 1994 Apr 22;655(1):1-8.</reference_text><pubmed_id>8061816</pubmed_id></reference><reference><reference_text>Authors unspecified: Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med. 1988 Jan;148(1):36-69.</reference_text><pubmed_id>3422148</pubmed_id></reference></references></disease><disease>Cholesteryl ester storage disease<references><reference><reference_text>Rassoul F, Richter V, Lohse P, Naumann A, Purschwitz K, Keller E: Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease. Int J Clin Pharmacol Ther. 2001 May;39(5):199-204.</reference_text><pubmed_id>11380065</pubmed_id></reference><reference><reference_text>Chatrath H, Keilin S, Attar BM: Cholesterol ester storage disease (CESD) diagnosed in an asymptomatic adult. Dig Dis Sci. 2009 Jan;54(1):168-73. doi: 10.1007/s10620-008-0310-2. Epub 2008 May 14.</reference_text><pubmed_id>18478331</pubmed_id></reference><reference><reference_text>Bernstein DL, Hulkova H, Bialer MG, Desnick RJ: Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol. 2013 Jun;58(6):1230-43. doi: 10.1016/j.jhep.2013.02.014. Epub 2013 Feb 26.</reference_text><pubmed_id>23485521</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Cystinosis<references><reference><reference_text>Ueda M, O'Brien K, Rosing DR, Ling A, Kleta R, McAreavey D, Bernardini I, Gahl WA: Coronary artery and other vascular calcifications in patients with cystinosis after kidney transplantation. Clin J Am Soc Nephrol. 2006 May;1(3):555-62. Epub 2006 Feb 8.</reference_text><pubmed_id>17699259</pubmed_id></reference><reference><reference_text>Gahl WA, Bernardini I, Dalakas M, Rizzo WB, Harper GS, Hoeg JM, Hurko O, Bernar J: Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome. J Clin Invest. 1988 Feb;81(2):549-60.</reference_text><pubmed_id>3276734</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Smith-Lemli-Opitz syndrome<references><reference><reference_text>van Rooij A, Nijenhuis AA, Wijburg FA, Schutgens RB: Highly increased CSF concentrations of cholesterol precursors in Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 1997 Aug;20(4):578-80.</reference_text><pubmed_id>9266395</pubmed_id></reference><reference><reference_text>Honda M, Tint GS, Honda A, Salen G, Shefer S, Batta AK, Matsuzaki Y, Tanaka N: Regulation of cholesterol biosynthetic pathway in patients with the Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2000 Jul;23(5):464-74.</reference_text><pubmed_id>10947201</pubmed_id></reference><reference><reference_text>Rossi M, Federico G, Corso G, Parenti G, Battagliese A, Frascogna AR, Della Casa R, Dello Russo A, Strisciuglio P, Saggese G, Andria G: Vitamin D status in patients affected by Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2005;28(1):69-80.</reference_text><pubmed_id>15702407</pubmed_id></reference><reference><reference_text>Johnson DW, ten Brink HJ, Jakobs C: A rapid screening procedure for cholesterol and dehydrocholesterol by electrospray ionization tandem mass spectrometry. J Lipid Res. 2001 Oct;42(10):1699-705.</reference_text><pubmed_id>11590227</pubmed_id></reference></references></disease><disease>Prostate cancer<references><reference><reference_text>Nyman DW, Suzanne Stratton M, Kopplin MJ, Dalkin BL, Nagle RB, Jay Gandolfi A: Selenium and selenomethionine levels in prostate cancer patients. Cancer Detect Prev. 2004;28(1):8-16.</reference_text><pubmed_id>15041072</pubmed_id></reference><reference><reference_text>Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, Egevad L, Tjonneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, Palli D, Vineis P, Tumino R, Berrino F, Kiemeney L, Bueno-de-Mesquita HB, Quiros JR, Gonzalez CA, Martinez C, Larranaga N, Chirlaque MD, Ardanaz E, Stattin P, Hallmans G, Khaw KT, Bingham S, Slimani N, Ferrari P, Rinaldi S, Riboli E: Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr. 2007 Sep;86(3):672-81.</reference_text><pubmed_id>17823432</pubmed_id></reference><reference><reference_text>Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762.</reference_text><pubmed_id>19212411</pubmed_id></reference><reference><reference_text>Puah CM, Williams G, Ghanadian R: Urinary unconjugated 5 alpha-androstane-3 alpha, 17 beta-diol in patients with prostatic tumours. Urol Res. 1982;10(2):81-4.</reference_text><pubmed_id>6180540</pubmed_id></reference><reference><reference_text>Thysell E, Surowiec I, Hornberg E, Crnalic S, Widmark A, Johansson AI, Stattin P, Bergh A, Moritz T, Antti H, Wikstrom P: Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One. 2010 Dec 3;5(12):e14175. doi: 10.1371/journal.pone.0014175.</reference_text><pubmed_id>21151972</pubmed_id></reference><reference><reference_text>Soliman LC, Hui Y, Hewavitharana AK, Chen DD: Monitoring potential prostate cancer biomarkers in urine by capillary electrophoresis-tandem mass spectrometry. J Chromatogr A. 2012 Dec 7;1267:162-9. doi: 10.1016/j.chroma.2012.07.021. Epub 2012 Jul 14.</reference_text><pubmed_id>22824219</pubmed_id></reference><reference><reference_text>Madu CO, Lu Y: Novel diagnostic biomarkers for prostate cancer. J Cancer. 2010 Oct 6;1:150-77.</reference_text><pubmed_id>20975847</pubmed_id></reference></references></disease><disease>Schizophrenia<references><reference><reference_text>Harnryd C, Bjerkenstedt L, Grimm VE, Sedvall G: Reduction of MOPEG levels in cerebrospinal fluid of psychotic women after electroconvulsive treatment. Psychopharmacology (Berl). 1979 Aug 8;64(2):131-4.</reference_text><pubmed_id>115032</pubmed_id></reference><reference><reference_text>Kobayashi K, Koide Y, Yoshino K, Shohmori T: [P-hydroxyphenylacetic acid concentrations in cerebrospinal fluid]. No To Shinkei. 1982 Aug;34(8):769-74.</reference_text><pubmed_id>7126379</pubmed_id></reference><reference><reference_text>Alfredsson G, Wiesel FA: Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology (Berl). 1989;99(3):322-7.</reference_text><pubmed_id>2480613</pubmed_id></reference><reference><reference_text>Heresco-Levy U, Bar G, Levin R, Ermilov M, Ebstein RP, Javitt DC: High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. Schizophr Res. 2007 Mar;91(1-3):14-21. Epub 2007 Feb 2.</reference_text><pubmed_id>17276036</pubmed_id></reference><reference><reference_text>Walker EF, Bonsall R, Walder DJ: Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis. Neuropsychiatry Neuropsychol Behav Neurol. 2002 Mar;15(1):10-7.</reference_text><pubmed_id>11877547</pubmed_id></reference><reference><reference_text>Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M: Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry. 2003 Jun;60(6):572-6.</reference_text><pubmed_id>12796220</pubmed_id></reference><reference><reference_text>Do KQ, Lauer CJ, Schreiber W, Zollinger M, Gutteck-Amsler U, Cuenod M, Holsboer F: gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem. 1995 Dec;65(6):2652-62.</reference_text><pubmed_id>7595563</pubmed_id></reference><reference><reference_text>Nikisch G, Baumann P, Wiedemann G, Kiessling B, Weisser H, Hertel A, Yoshitake T, Kehr J, Mathe AA: Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF. J Clin Psychopharmacol. 2010 Oct;30(5):496-503. doi: 10.1097/JCP.0b013e3181f2288e.</reference_text><pubmed_id>20814316</pubmed_id></reference><reference><reference_text>Fukushima T, Iizuka H, Yokota A, Suzuki T, Ohno C, Kono Y, Nishikiori M, Seki A, Ichiba H, Watanabe Y, Hongo S, Utsunomiya M, Nakatani M, Sadamoto K, Yoshio T: Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One. 2014 Jul 8;9(7):e101652. doi: 10.1371/journal.pone.0101652. eCollection 2014.</reference_text><pubmed_id>25004141</pubmed_id></reference><reference><reference_text>Koike S, Bundo M, Iwamoto K, Suga M, Kuwabara H, Ohashi Y, Shinoda K, Takano Y, Iwashiro N, Satomura Y, Nagai T, Natsubori T, Tada M, Yamasue H, Kasai K: A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study. Transl Psychiatry. 2014 Apr 8;4:e379. doi: 10.1038/tp.2014.19.</reference_text><pubmed_id>24713860</pubmed_id></reference><reference><reference_text>Ballesteros A, Summerfelt A, Du X, Jiang P, Chiappelli J, Tagamets M, O'Donnell P, Kochunov P, Hong LE: Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia. Clin Neurophysiol. 2013 Nov;124(11):2209-15. doi: 10.1016/j.clinph.2013.05.021. Epub 2013 Jun 30.</reference_text><pubmed_id>23823132</pubmed_id></reference><reference><reference_text>Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel FA: Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry. 1985 Sep;147:276-82.</reference_text><pubmed_id>2415198</pubmed_id></reference><reference><reference_text>Pickar D, Breier A, Hsiao JK, Doran AR, Wolkowitz OM, Pato CN, Konicki PE, Potter WZ: Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Arch Gen Psychiatry. 1990 Jul;47(7):641-8.</reference_text><pubmed_id>1694425</pubmed_id></reference><reference><reference_text>Prell GD, Green JP, Kaufmann CA, Khandelwal JK, Morrishow AM, Kirch DG, Linnoila M, Wyatt RJ: Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res. 1995 Jan;14(2):93-104.</reference_text><pubmed_id>7711000</pubmed_id></reference><reference><reference_text>Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B: Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology. 2009;59(2):123-9. doi: 10.1159/000213565. Epub 2009 Apr 22.</reference_text><pubmed_id>19390223</pubmed_id></reference><reference><reference_text>Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K, Cao Y, Wang X, Qiu Y, Su M, Zhao A, Wang P, Yang P, Wu J, Feng G, He L, Jia W, Wan C: Potential metabolite markers of schizophrenia. Mol Psychiatry. 2013 Jan;18(1):67-78. doi: 10.1038/mp.2011.131. Epub 2011 Oct 25.</reference_text><pubmed_id>22024767</pubmed_id></reference><reference><reference_text>Xuan J, Pan G, Qiu Y, Yang L, Su M, Liu Y, Chen J, Feng G, Fang Y, Jia W, Xing Q, He L: Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. J Proteome Res. 2011 Dec 2;10(12):5433-43. doi: 10.1021/pr2006796. Epub 2011 Nov  8.</reference_text><pubmed_id>22007635</pubmed_id></reference><reference><reference_text>Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM, Rothermundt M, Bogerts B, Koethe D, Kranaster L, Ohrmann P, Suslow T, McAllister G, Spain M, Barnes A, van Beveren NJ, Baron-Cohen S, Steiner J, Torrey FE, Yolken RH, Bahn S: Identification of a biological signature for schizophrenia in serum. Mol Psychiatry. 2012 May;17(5):494-502. doi: 10.1038/mp.2011.42. Epub 2011 Apr 12.</reference_text><pubmed_id>21483431</pubmed_id></reference><reference><reference_text>Mathe AA, Eberhard G, Saaf J, Wetterberg L: Plasma prostaglandin E2 metabolite--measured as 11-deoxy-15-keto-13,14-dihydro-11 beta,16 xi-cyclo-PGE2--in twins with schizophrenic disorder. Biol Psychiatry. 1986 Sep;21(11):1024-30.</reference_text><pubmed_id>3741918</pubmed_id></reference><reference><reference_text>Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N: Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct. 2002 Jun;20(2):171-5.</reference_text><pubmed_id>11979513</pubmed_id></reference><reference><reference_text>Zumarraga M, Davila R, Basterreche N, Arrue A, Goienetxea B, Zamalloa MI, Erkoreka L, Bustamante S, Inchausti L, Gonzalez-Torres MA, Guimon J: Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients. Neurochem Int. 2010 May-Jun;56(6-7):774-9. doi: 10.1016/j.neuint.2010.02.015. Epub 2010 Mar 4.</reference_text><pubmed_id>20206656</pubmed_id></reference><reference><reference_text>Peters JG: Dopamine, noradrenaline and serotonin spinal fluid metabolites in temporal lobe epileptic patients with schizophrenic symptomatology. Eur Neurol. 1979;18(1):15-8.</reference_text><pubmed_id>436860</pubmed_id></reference><reference><reference_text>Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, Rozen S, Krishnan RR, McEvoy J, Kaddurah-Daouk R: Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry. 2010 Sep;15(9):938-53. doi: 10.1038/mp.2009.33. Epub 2009 Apr 28.</reference_text><pubmed_id>19401681</pubmed_id></reference><reference><reference_text>Gattaz WF, Waldmeier P, Beckmann H: CSF monoamine metabolites in schizophrenic patients. Acta Psychiatr Scand. 1982 Nov;66(5):350-60.</reference_text><pubmed_id>6184954</pubmed_id></reference><reference><reference_text>Nilsson-Todd LK, Nordin C, Jonsson EG, Skogh E, Erhardt S: Cerebrospinal fluid kynurenic acid in male patients with schizophrenia - correlation with monoamine metabolites. Acta Neuropsychiatr. 2007 Feb;19(1):45-52. doi: 10.1111/j.1601-5215.2006.00170.x.</reference_text><pubmed_id>26952797</pubmed_id></reference><reference><reference_text>Cai HL, Li HD, Yan XZ, Sun B, Zhang Q, Yan M, Zhang WY, Jiang P, Zhu RH, Liu YP, Fang PF, Xu P, Yuan HY, Zhang XH, Hu L, Yang W, Ye HS: Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naive schizophrenia patients after treatment with risperidone. J Proteome Res. 2012 Aug 3;11(8):4338-50. doi: 10.1021/pr300459d. Epub 2012 Jul 26.</reference_text><pubmed_id>22800120</pubmed_id></reference><reference><reference_text>Al Awam K, Haussleiter IS, Dudley E, Donev R, Brune M, Juckel G, Thome J: Multiplatform metabolome and proteome profiling identifies serum metabolite and protein signatures as prospective biomarkers for schizophrenia. J Neural Transm (Vienna). 2015 Aug;122 Suppl 1:S111-22. doi: 10.1007/s00702-014-1224-0. Epub 2014 May 1.</reference_text><pubmed_id>24789758</pubmed_id></reference><reference><reference_text>Bicikova M, Hill M, Ripova D, Mohr P, Hampl R: Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia. J Steroid Biochem Mol Biol. 2013 Jan;133:77-83. doi: 10.1016/j.jsbmb.2012.08.009. Epub 2012 Aug 24.</reference_text><pubmed_id>22944140</pubmed_id></reference><reference><reference_text>He Y, Yu Z, Giegling I, Xie L, Hartmann AM, Prehn C, Adamski J, Kahn R, Li Y, Illig T, Wang-Sattler R, Rujescu D: Schizophrenia shows a unique metabolomics signature in plasma. Transl Psychiatry. 2012 Aug 14;2:e149. doi: 10.1038/tp.2012.76.</reference_text><pubmed_id>22892715</pubmed_id></reference><reference><reference_text>Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KR: Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):934-45. Epub 2007 Apr 17.</reference_text><pubmed_id>17440431</pubmed_id></reference><reference><reference_text>Fryar-Williams S, Strobel JE: Biomarkers of a five-domain translational substrate for schizophrenia and schizoaffective psychosis. Biomark Res. 2015 Feb 6;3:3. doi: 10.1186/s40364-015-0028-1. eCollection 2015.</reference_text><pubmed_id>25729574</pubmed_id></reference><reference><reference_text>Oresic M, Seppanen-Laakso T, Sun D, Tang J, Therman S, Viehman R, Mustonen U, van Erp TG, Hyotylainen T, Thompson P, Toga AW, Huttunen MO, Suvisaari J, Kaprio J, Lonnqvist J, Cannon TD: Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia. Genome Med. 2012 Jan 18;4(1):1. doi: 10.1186/gm300.</reference_text><pubmed_id>22257447</pubmed_id></reference></references></disease><disease>Primary hypomagnesemia<references><reference><reference_text>Jin-no Y, Kamiya Y, Okada M, Hirako M, Takada N, Kawaguchi M: Primary hypomagnesemia caused by isolated magnesium malabsorption: atypical case in adult. Intern Med. 1999 Mar;38(3):261-5.</reference_text><pubmed_id>10337938</pubmed_id></reference><reference><reference_text>Vainsel M, Vandevelde G, Smulders J, Vosters M, Hubain P, Loeb H: Tetany due to hypomagnesaemia with secondary hypocalcaemia. Arch Dis Child. 1970 Apr;45(240):254-8.</reference_text><pubmed_id>5419995</pubmed_id></reference><reference><reference_text>Shalev H, Phillip M, Galil A, Carmi R, Landau D: Clinical presentation and outcome in primary familial hypomagnesaemia. Arch Dis Child. 1998 Feb;78(2):127-30.</reference_text><pubmed_id>9579153</pubmed_id></reference><reference><reference_text>Kari JA, Farouq M, Alshaya HO: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Pediatr Nephrol. 2003 Jun;18(6):506-10. Epub 2003 Apr 29.</reference_text><pubmed_id>12720080</pubmed_id></reference></references></disease><disease>Hyperlipoproteinemia<references><reference><reference_text>Sinha S, Misra A, Kumar V, Jagannathan NR, Bal CS, Pandey RM, Singhania R, Deepak: Proton magnetic resonance spectroscopy and single photon emission computed tomography study of the brain in asymptomatic young hyperlipidaemic Asian Indians in North India show early abnormalities. Clin Endocrinol (Oxf). 2004 Aug;61(2):182-9.</reference_text><pubmed_id>15272912</pubmed_id></reference><reference><reference_text>Nelson RH: Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013 Mar</reference_text><pubmed_id>40(1):195-211. doi: 10.1016/j.pop.2012.11.003. Epub 2012 Dec  4.</pubmed_id></reference><reference><reference_text>Cantin B, Boudriau S, Bertrand M, Brun LD, Gagne C, Rogers PA, Ven Murthy MR, Lupien PJ, Julien P: Hemolysis in primary lipoprotein lipase deficiency. Metabolism. 1995 May;44(5):652-8.</reference_text><pubmed_id>7752915</pubmed_id></reference></references></disease><disease>Abetalipoproteinemia<references><reference><reference_text>Dawson G, Kruski AW, Scanu AM: Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J Lipid Res. 1976 Mar;17(2):125-31.</reference_text><pubmed_id>178813</pubmed_id></reference><reference><reference_text>Lazaro RP, Dentinger MP, Rodichok LD, Barron KD, Satya-Murti S: Muscle pathology in Bassen-Kornzweig syndrome and vitamin E deficiency. Am J Clin Pathol. 1986 Sep;86(3):378-87.</reference_text><pubmed_id>2944375</pubmed_id></reference></references></disease><disease>Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis<references><reference><reference_text>Breckenridge WC, Alaupovic P, Cox DW, Little JA: Apolipoprotein and lipoprotein concentrations in familial apolipoprotein C-II deficiency. Atherosclerosis. 1982 Aug;44(2):223-35.</reference_text><pubmed_id>7138621</pubmed_id></reference><reference><reference_text>Fukami M, Hasegawa T, Horikawa R, Ohashi T, Nishimura G, Homma K, Ogata T: Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr Res. 2006 Feb;59(2):276-80. doi: 10.1203/01.pdr.0000195825.31504.28.</reference_text><pubmed_id>16439592</pubmed_id></reference></references></disease><disease>Cerebrotendinous xanthomatosis<references><reference><reference_text>Halperin G, Elisaf M, Leitersdorf E, Harats D: A new method for determination of serum cholestanol by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2000 Jun 9;742(2):345-52.</reference_text><pubmed_id>10901139</pubmed_id></reference><reference><reference_text>Siman-Tov T, Meiner V, Gadoth N: Could steroids mask the diagnosis of cerebrotendinous xanthomatosis? J Neurol Sci. 2006 Apr 15;243(1-2):83-6. Epub 2006 Jan 30.</reference_text><pubmed_id>16445943</pubmed_id></reference><reference><reference_text>Agrawal NK, Garg S: Cerebrotendinous xanthomatosis: a rare disorder with a rare presentation. BMJ Case Rep. 2012 Sep 21;2012. pii: bcr-2012-006202. doi: 10.1136/bcr-2012-006202.</reference_text><pubmed_id>23001091</pubmed_id></reference></references></disease><disease>3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency<references><reference><reference_text>Thompson GN, Hsu BY, Pitt JJ, Treacy E, Stanley CA: Fasting hypoketotic coma in a child with deficiency of mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase. N Engl J Med. 1997 Oct 23;337(17):1203-7. doi: 10.1056/NEJM199710233371704.</reference_text><pubmed_id>9337379</pubmed_id></reference><reference><reference_text>Morris AA, Lascelles CV, Olpin SE, Lake BD, Leonard JV, Quant PA: Hepatic mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme a synthase deficiency. Pediatr Res. 1998 Sep;44(3):392-6. doi: 10.1203/00006450-199809000-00021.</reference_text><pubmed_id>9727719</pubmed_id></reference><reference><reference_text>Conboy E, Vairo F, Schultz M, Agre K, Ridsdale R, Deyle D, Oglesbee D, Gavrilov D, Klee EW, Lanpher B: Mitochondrial 3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency: Unique Presenting Laboratory Values and a Review of Biochemical and Clinical Features. JIMD Rep. 2017 Oct 14. doi: 10.1007/8904_2017_59.</reference_text><pubmed_id>29030856</pubmed_id></reference></references></disease><disease>Hypercholesterolemia, familial<references><reference><reference_text>Kwiterovich PO Jr, Fredrickson DS, Levy RI: Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest. 1974 May;53(5):1237-49. doi: 10.1172/JCI107670.</reference_text><pubmed_id>4363406</pubmed_id></reference></references></disease><disease>SC4MOL deficiency<references><reference><reference_text>He M, Kratz LE, Michel JJ, Vallejo AN, Ferris L, Kelley RI, Hoover JJ, Jukic D, Gibson KM, Wolfe LA, Ramachandran D, Zwick ME, Vockley J: Mutations in the human SC4MOL gene encoding a methyl sterol oxidase cause psoriasiform dermatitis, microcephaly, and developmental delay. J Clin Invest. 2011 Mar;121(3):976-84. doi: 10.1172/JCI42650.</reference_text><pubmed_id>21285510</pubmed_id></reference></references></disease><disease>Chondrodysplasia punctata, X-linked dominant<references><reference><reference_text>Aughton DJ, Kelley RI, Metzenberg A, Pureza V, Pauli RM: X-linked dominant chondrodysplasia punctata (CDPX2) caused by single gene mosaicism in a male. Am J Med Genet A. 2003 Jan 30;116A(3):255-60. doi: 10.1002/ajmg.a.10852.</reference_text><pubmed_id>12503102</pubmed_id></reference></references></disease><disease>Desmosterolosis<references><reference><reference_text>Andersson HC, Kratz L, Kelley R: Desmosterolosis presenting with multiple congenital anomalies and profound developmental delay. Am J Med Genet. 2002 Dec 15;113(4):315-9. doi: 10.1002/ajmg.b.10873.</reference_text><pubmed_id>12457401</pubmed_id></reference></references></disease><disease>Donohue Syndrome<references><reference><reference_text>Nijim Y, Awni Y, Adawi A, Bowirrat A: Classic Case Report of Donohue Syndrome (Leprechaunism; OMIM *246200): The Impact of Consanguineous Mating. Medicine (Baltimore). 2016 Feb;95(6):e2710. doi: 10.1097/MD.0000000000002710.</reference_text><pubmed_id>26871809</pubmed_id></reference></references></disease><disease>Leptin Deficiency or Dysfunction<references><reference><reference_text>Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O'Rahilly S: Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999 Sep 16;341(12):879-84. doi: 10.1056/NEJM199909163411204.</reference_text><pubmed_id>10486419</pubmed_id></reference></references></disease><disease>Duchenne Muscular Dystrophy<references><reference><reference_text>Nakagawa T, Takeuchi A, Kakiuchi R, Lee T, Yagi M, Awano H, Iijima K, Takeshima Y, Urade Y, Matsuo M: A prostaglandin D2 metabolite is elevated in the urine of Duchenne muscular dystrophy patients and increases further from 8 years old. Clin Chim Acta. 2013 Aug 23;423:10-4. doi: 10.1016/j.cca.2013.03.031. Epub 2013 Apr 19.</reference_text><pubmed_id>23603101</pubmed_id></reference><reference><reference_text>Srivastava NK, Pradhan S, Mittal B, Gowda GA: High resolution NMR based analysis of serum lipids in Duchenne muscular dystrophy patients and its possible diagnostic significance. NMR Biomed. 2010 Jan;23(1):13-22. doi: 10.1002/nbm.1419.</reference_text><pubmed_id>19787747</pubmed_id></reference><reference><reference_text>Horster I, Weigt-Usinger K, Carmann C, Chobanyan-Jurgens K, Kohler C, Schara U, Kayacelebi AA, Beckmann B, Tsikas D, Lucke T: The L-arginine/NO pathway and homoarginine are altered in Duchenne muscular dystrophy and improved by glucocorticoids. Amino Acids. 2015 Sep;47(9):1853-63. doi: 10.1007/s00726-015-2018-x. Epub 2015 Jun 12.</reference_text><pubmed_id>26066683</pubmed_id></reference></references></disease><disease>Lecithin:cholesterol Acyltransferase Deficiency<references><reference><reference_text>Idzior-Walus B, Sieradzki J, Kostner G, Malecki MT, Klupa T, Wesolowska T, Rostworowski W, Hartwich J, Walus M, Kiec AD, Naruszewicz M: Familial lecithin-cholesterol acyltransferase deficiency: biochemical characteristics and molecular analysis of a new LCAT mutation in a Polish family. Atherosclerosis. 2006 Apr;185(2):413-20. Epub 2005 Jul 26.</reference_text><pubmed_id>16051254</pubmed_id></reference></references></disease><disease>Lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lipodystrophy, Congenital Generalized<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Oculocerebrorenal syndrome<references><reference><reference_text>Charnas LR, Bernardini I, Rader D, Hoeg JM, Gahl WA: Clinical and laboratory findings in the oculocerebrorenal syndrome of Lowe, with special reference to growth and renal function. N Engl J Med. 1991 May 9;324(19):1318-25. doi: 10.1056/NEJM199105093241904.</reference_text><pubmed_id>2017228</pubmed_id></reference></references></disease><disease>Familial partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lathosterolosis<references><reference><reference_text>Brunetti-Pierri N, Corso G, Rossi M, Ferrari P, Balli F, Rivasi F, Annunziata I, Ballabio A, Russo AD, Andria G, Parenti G: Lathosterolosis, a novel multiple-malformation/mental retardation syndrome due to deficiency of 3beta-hydroxysteroid-delta5-desaturase. Am J Hum Genet. 2002 Oct;71(4):952-8. Epub 2002 Aug 20.</reference_text><pubmed_id>12189593</pubmed_id></reference><reference><reference_text>Ho AC, Fung CW, Siu TS, Ma OC, Lam CW, Tam S, Wong VC: Lathosterolosis: a disorder of cholesterol biosynthesis resembling smith-lemli-opitz syndrome. JIMD Rep. 2014;12:129-34. doi: 10.1007/8904_2013_255. Epub 2013 Oct 20.</reference_text><pubmed_id>24142275</pubmed_id></reference></references></disease><disease>Partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Multiple sclerosis<references><reference><reference_text>Lutz NW, Viola A, Malikova I, Confort-Gouny S, Audoin B, Ranjeva JP, Pelletier J, Cozzone PJ: Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One. 2007 Jul 4;2(7):e595.</reference_text><pubmed_id>17611627</pubmed_id></reference><reference><reference_text>Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U, Hillert J, Bjorkhem I: Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med. 2004 Feb;42(2):186-91.</reference_text><pubmed_id>15061359</pubmed_id></reference><reference><reference_text>Leoni V, Lutjohann D, Masterman T: Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis. J Lipid Res. 2005 Feb;46(2):191-5. Epub 2004 Dec 1.</reference_text><pubmed_id>15576852</pubmed_id></reference><reference><reference_text>Calabrese V, Scapagnini G, Ravagna A, Bella R, Butterfield DA, Calvani M, Pennisi G, Giuffrida Stella AM: Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem Res. 2003 Sep;28(9):1321-8.</reference_text><pubmed_id>12938853</pubmed_id></reference><reference><reference_text>Shaw CE, Dunbar PR, Macaulay HA, Neale TJ: Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol. 1995 Jan;242(2):53-8.</reference_text><pubmed_id>7707089</pubmed_id></reference><reference><reference_text>Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.</reference_text><pubmed_id>17384003</pubmed_id></reference><reference><reference_text>Syburra C, Passi S: Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh (1999). 1999 May-Jun;71(3):112-5.</reference_text><pubmed_id>10609336</pubmed_id></reference><reference><reference_text>Forte G, Visconti A, Santucci S, Ghazaryan A, Figa-Talamanca L, Cannoni S, Bocca B, Pino A, Violante N, Alimonti A, Salvetti M, Ristori G: Quantification of chemical elements in blood of patients affected by multiple sclerosis. Ann Ist Super Sanita. 2005;41(2):213-6.</reference_text><pubmed_id>16244395</pubmed_id></reference><reference><reference_text>Toncev G, Milicic B, Toncev S, Samardzic G: Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol. 2002 May;9(3):221-6.</reference_text><pubmed_id>11985629</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, Bamonti F, Capello E, Mancardi GL, Scarpini E: Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res. 2010 May 28;1333:64-71. doi: 10.1016/j.brainres.2010.03.073. Epub 2010 Mar 27.</reference_text><pubmed_id>20347721</pubmed_id></reference><reference><reference_text>Matsushita T, Isobe N, Kawajiri M, Mogi M, Tsukuda K, Horiuchi M, Ohyagi Y, Kira J: CSF angiotensin II and angiotensin-converting enzyme levels in anti-aquaporin-4 autoimmunity. J Neurol Sci. 2010 Aug 15;295(1-2):41-5. doi: 10.1016/j.jns.2010.05.014. Epub 2010 Jun 11.</reference_text><pubmed_id>20541774</pubmed_id></reference><reference><reference_text>Ghabaee M, Jabedari B, Al-E-Eshagh N, Ghaffarpour M, Asadi F: Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients. Int J Neurosci. 2010 Apr;120(4):301-4. doi: 10.3109/00207451003695690.</reference_text><pubmed_id>20374079</pubmed_id></reference><reference><reference_text>Kawajiri M, Mogi M, Osoegawa M, Matsuoka T, Tsukuda K, Kohara K, Horiuchi M, Miki T, Kira JI: Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler. 2008 May;14(4):557-60. doi: 10.1177/1352458507085760.</reference_text><pubmed_id>18562510</pubmed_id></reference><reference><reference_text>Visconti A, Cotichini R, Cannoni S, Bocca B, Forte G, Ghazaryan A, Santucci S, D'Ippolito C, Stazi MA, Salvetti M, Alimonti A, Ristori G: Concentration of elements in serum of patients affected by multiple sclerosis with first demyelinating episode: a six-month longitudinal follow-up study. Ann Ist Super Sanita. 2005;41(2):217-22.</reference_text><pubmed_id>16244396</pubmed_id></reference></references></disease><disease>Inflammatory bowel disease<references><reference><reference_text>Lee T, Clavel T, Smirnov K, Schmidt A, Lagkouvardos I, Walker A, Lucio M, Michalke B, Schmitt-Kopplin P, Fedorak R, Haller D: Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. 2017 May;66(5):863-871. doi: 10.1136/gutjnl-2015-309940. Epub 2016 Feb 4.</reference_text><pubmed_id>26848182</pubmed_id></reference><reference><reference_text>Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158.</reference_text><pubmed_id>27609529</pubmed_id></reference></references></disease><disease>Colorectal cancer<references><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B: Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009 Apr;22(3):342-8. doi: 10.1002/nbm.1345.</reference_text><pubmed_id>19006102</pubmed_id></reference><reference><reference_text>Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP: Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One. 2013 Aug 6;8(8):e70803. doi: 10.1371/journal.pone.0070803. Print 2013.</reference_text><pubmed_id>23940645</pubmed_id></reference><reference><reference_text>Phua LC, Chue XP, Koh PK, Cheah PY, Ho HK, Chan EC: Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biol Ther. 2014 Apr;15(4):389-97. doi: 10.4161/cbt.27625. Epub 2014 Jan 14.</reference_text><pubmed_id>24424155</pubmed_id></reference><reference><reference_text>Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB: Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010 Feb 15;8:13. doi: 10.1186/1741-7015-8-13.</reference_text><pubmed_id>20156336</pubmed_id></reference><reference><reference_text>Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, Ni Y, Zhao A, Xu LX, Cai S, Jia W: Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res. 2009 Oct;8(10):4844-50. doi: 10.1021/pr9004162.</reference_text><pubmed_id>19678709</pubmed_id></reference><reference><reference_text>Cheng Y, Xie G, Chen T, Qiu Y, Zou X, Zheng M, Tan B, Feng B, Dong T, He P, Zhao L, Zhao A, Xu LX, Zhang Y, Jia W: Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res. 2012 Feb 3;11(2):1354-63. doi: 10.1021/pr201001a. Epub 2011 Dec 28.</reference_text><pubmed_id>22148915</pubmed_id></reference><reference><reference_text>Ni Y, Xie G, Jia W: Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res. 2014 Sep 5;13(9):3857-70. doi: 10.1021/pr500443c. Epub 2014 Aug 14.</reference_text><pubmed_id>25105552</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference><reference><reference_text>Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18.</reference_text><pubmed_id>25037050</pubmed_id></reference><reference><reference_text>Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016.</reference_text><pubmed_id>27015276</pubmed_id></reference><reference><reference_text>Lin Y, Ma C, Liu C, Wang Z, Yang J, Liu X, Shen Z, Wu R: NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer. Oncotarget. 2016 May 17;7(20):29454-64. doi: 10.18632/oncotarget.8762.</reference_text><pubmed_id>27107423</pubmed_id></reference><reference><reference_text>Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016.</reference_text><pubmed_id>27275383</pubmed_id></reference><reference><reference_text>Wang X, Wang J, Rao B, Deng L: Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals. Exp Ther Med. 2017 Jun;13(6):2848-2854. doi: 10.3892/etm.2017.4367. Epub 2017 Apr 20.</reference_text><pubmed_id>28587349</pubmed_id></reference><reference><reference_text>Silke Matysik, Caroline Ivanne Le Roy, Gerhard Liebisch, Sandrine Paule Claus. Metabolomics of fecal samples: A practical consideration. Trends in Food Science &amp; Technology. Vol. 57, Part B, Nov. 2016, p.244-255: http://www.sciencedirect.com/science/article/pii/S0924224416301984</reference_text><pubmed_id>28587349</pubmed_id></reference></references></disease><disease>Gallbladder disease<references><reference><reference_text>Lapidus A, Akerlund JE, Einarsson C: Gallbladder bile composition in patients with Crohn 's disease. World J Gastroenterol. 2006 Jan 7;12(1):70-4.</reference_text><pubmed_id>16440420</pubmed_id></reference><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference><reference><reference_text>Mizuno S, Tazuma S, Kajiyama G: Stabilization of biliary lipid particles by ursodeoxycholic acid. Prolonged nucleation time in human gallbladder bile. Dig Dis Sci. 1993 Apr;38(4):684-93.</reference_text><pubmed_id>8462368</pubmed_id></reference><reference><reference_text>Hillebrant CG, Axelson M, Bjorkhem I, Wang FH, Nyberg B, Einarsson C: Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients. Eur J Clin Invest. 1998 Apr;28(4):324-8.</reference_text><pubmed_id>9615912</pubmed_id></reference></references></disease><disease>Cholelithiasis<references><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference></references></disease><disease>Stomach cancer<references><reference><reference_text>Higashijima H, Ichimiya H, Nakano T, Yamashita H, Kuroki S, Satoh H, Chijiiwa K, Tanaka M: Deconjugation of bilirubin accelerates coprecipitation of cholesterol, fatty acids, and mucin in human bile--in vitro study. J Gastroenterol. 1996 Dec;31(6):828-35.</reference_text><pubmed_id>9027647</pubmed_id></reference><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Song H, Peng JS, Dong-Sheng Y, Yang ZL, Liu HL, Zeng YK, Shi XP, Lu BY: Serum metabolic profiling of human gastric cancer based on gas chromatography/mass spectrometry. Braz J Med Biol Res. 2012 Jan;45(1):78-85. Epub 2011 Nov 25.</reference_text><pubmed_id>22124703</pubmed_id></reference><reference><reference_text>Yu L, Aa J, Xu J, Sun M, Qian S, Cheng L, Yang S, Shi R: Metabolomic phenotype of gastric cancer and precancerous stages based on gas chromatography time-of-flight mass spectrometry. J Gastroenterol Hepatol. 2011 Aug;26(8):1290-7. doi: 10.1111/j.1440-1746.2011.06724.x.</reference_text><pubmed_id>21443661</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference></references></disease><disease>Acute myelogenous leukemia<references><reference><reference_text>Tatidis L, Vitols S, Gruber A, Paul C, Axelson M: Cholesterol catabolism in patients with acute myelogenous leukemia and hypocholesterolemia: suppressed levels of a circulating marker for bile acid synthesis. Cancer Lett. 2001 Sep 20;170(2):169-75.</reference_text><pubmed_id>11463495</pubmed_id></reference></references></disease><disease>Hypercholesterolemia<references><reference><reference_text>Thelen KM, Laaksonen R, Paiva H, Lehtimaki T, Lutjohann D: High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels. J Clin Pharmacol. 2006 Jul;46(7):812-6.</reference_text><pubmed_id>16809807</pubmed_id></reference><reference><reference_text>Tamasawa N, Tamasawa A, Takebe K: Higher levels of plasma cholesterol sulfate in patients with liver cirrhosis and hypercholesterolemia. Lipids. 1993 Sep;28(9):833-6.</reference_text><pubmed_id>8231659</pubmed_id></reference><reference><reference_text>Kim DH, Lee KJ, Heo GS: Analysis of cholesterol and cholesteryl esters in human serum using capillary supercritical fluid chromatography. J Chromatogr B Biomed Appl. 1994 Apr 22;655(1):1-8.</reference_text><pubmed_id>8061816</pubmed_id></reference><reference><reference_text>Authors unspecified: Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med. 1988 Jan;148(1):36-69.</reference_text><pubmed_id>3422148</pubmed_id></reference></references></disease><disease>Cholesteryl ester storage disease<references><reference><reference_text>Rassoul F, Richter V, Lohse P, Naumann A, Purschwitz K, Keller E: Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease. Int J Clin Pharmacol Ther. 2001 May;39(5):199-204.</reference_text><pubmed_id>11380065</pubmed_id></reference><reference><reference_text>Chatrath H, Keilin S, Attar BM: Cholesterol ester storage disease (CESD) diagnosed in an asymptomatic adult. Dig Dis Sci. 2009 Jan;54(1):168-73. doi: 10.1007/s10620-008-0310-2. Epub 2008 May 14.</reference_text><pubmed_id>18478331</pubmed_id></reference><reference><reference_text>Bernstein DL, Hulkova H, Bialer MG, Desnick RJ: Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol. 2013 Jun;58(6):1230-43. doi: 10.1016/j.jhep.2013.02.014. Epub 2013 Feb 26.</reference_text><pubmed_id>23485521</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Cystinosis<references><reference><reference_text>Ueda M, O'Brien K, Rosing DR, Ling A, Kleta R, McAreavey D, Bernardini I, Gahl WA: Coronary artery and other vascular calcifications in patients with cystinosis after kidney transplantation. Clin J Am Soc Nephrol. 2006 May;1(3):555-62. Epub 2006 Feb 8.</reference_text><pubmed_id>17699259</pubmed_id></reference><reference><reference_text>Gahl WA, Bernardini I, Dalakas M, Rizzo WB, Harper GS, Hoeg JM, Hurko O, Bernar J: Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome. J Clin Invest. 1988 Feb;81(2):549-60.</reference_text><pubmed_id>3276734</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Smith-Lemli-Opitz syndrome<references><reference><reference_text>van Rooij A, Nijenhuis AA, Wijburg FA, Schutgens RB: Highly increased CSF concentrations of cholesterol precursors in Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 1997 Aug;20(4):578-80.</reference_text><pubmed_id>9266395</pubmed_id></reference><reference><reference_text>Honda M, Tint GS, Honda A, Salen G, Shefer S, Batta AK, Matsuzaki Y, Tanaka N: Regulation of cholesterol biosynthetic pathway in patients with the Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2000 Jul;23(5):464-74.</reference_text><pubmed_id>10947201</pubmed_id></reference><reference><reference_text>Rossi M, Federico G, Corso G, Parenti G, Battagliese A, Frascogna AR, Della Casa R, Dello Russo A, Strisciuglio P, Saggese G, Andria G: Vitamin D status in patients affected by Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2005;28(1):69-80.</reference_text><pubmed_id>15702407</pubmed_id></reference><reference><reference_text>Johnson DW, ten Brink HJ, Jakobs C: A rapid screening procedure for cholesterol and dehydrocholesterol by electrospray ionization tandem mass spectrometry. J Lipid Res. 2001 Oct;42(10):1699-705.</reference_text><pubmed_id>11590227</pubmed_id></reference></references></disease><disease>Prostate cancer<references><reference><reference_text>Nyman DW, Suzanne Stratton M, Kopplin MJ, Dalkin BL, Nagle RB, Jay Gandolfi A: Selenium and selenomethionine levels in prostate cancer patients. Cancer Detect Prev. 2004;28(1):8-16.</reference_text><pubmed_id>15041072</pubmed_id></reference><reference><reference_text>Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, Egevad L, Tjonneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, Palli D, Vineis P, Tumino R, Berrino F, Kiemeney L, Bueno-de-Mesquita HB, Quiros JR, Gonzalez CA, Martinez C, Larranaga N, Chirlaque MD, Ardanaz E, Stattin P, Hallmans G, Khaw KT, Bingham S, Slimani N, Ferrari P, Rinaldi S, Riboli E: Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr. 2007 Sep;86(3):672-81.</reference_text><pubmed_id>17823432</pubmed_id></reference><reference><reference_text>Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762.</reference_text><pubmed_id>19212411</pubmed_id></reference><reference><reference_text>Puah CM, Williams G, Ghanadian R: Urinary unconjugated 5 alpha-androstane-3 alpha, 17 beta-diol in patients with prostatic tumours. Urol Res. 1982;10(2):81-4.</reference_text><pubmed_id>6180540</pubmed_id></reference><reference><reference_text>Thysell E, Surowiec I, Hornberg E, Crnalic S, Widmark A, Johansson AI, Stattin P, Bergh A, Moritz T, Antti H, Wikstrom P: Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One. 2010 Dec 3;5(12):e14175. doi: 10.1371/journal.pone.0014175.</reference_text><pubmed_id>21151972</pubmed_id></reference><reference><reference_text>Soliman LC, Hui Y, Hewavitharana AK, Chen DD: Monitoring potential prostate cancer biomarkers in urine by capillary electrophoresis-tandem mass spectrometry. J Chromatogr A. 2012 Dec 7;1267:162-9. doi: 10.1016/j.chroma.2012.07.021. Epub 2012 Jul 14.</reference_text><pubmed_id>22824219</pubmed_id></reference><reference><reference_text>Madu CO, Lu Y: Novel diagnostic biomarkers for prostate cancer. J Cancer. 2010 Oct 6;1:150-77.</reference_text><pubmed_id>20975847</pubmed_id></reference></references></disease><disease>Schizophrenia<references><reference><reference_text>Harnryd C, Bjerkenstedt L, Grimm VE, Sedvall G: Reduction of MOPEG levels in cerebrospinal fluid of psychotic women after electroconvulsive treatment. Psychopharmacology (Berl). 1979 Aug 8;64(2):131-4.</reference_text><pubmed_id>115032</pubmed_id></reference><reference><reference_text>Kobayashi K, Koide Y, Yoshino K, Shohmori T: [P-hydroxyphenylacetic acid concentrations in cerebrospinal fluid]. No To Shinkei. 1982 Aug;34(8):769-74.</reference_text><pubmed_id>7126379</pubmed_id></reference><reference><reference_text>Alfredsson G, Wiesel FA: Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology (Berl). 1989;99(3):322-7.</reference_text><pubmed_id>2480613</pubmed_id></reference><reference><reference_text>Heresco-Levy U, Bar G, Levin R, Ermilov M, Ebstein RP, Javitt DC: High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. Schizophr Res. 2007 Mar;91(1-3):14-21. Epub 2007 Feb 2.</reference_text><pubmed_id>17276036</pubmed_id></reference><reference><reference_text>Walker EF, Bonsall R, Walder DJ: Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis. Neuropsychiatry Neuropsychol Behav Neurol. 2002 Mar;15(1):10-7.</reference_text><pubmed_id>11877547</pubmed_id></reference><reference><reference_text>Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M: Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry. 2003 Jun;60(6):572-6.</reference_text><pubmed_id>12796220</pubmed_id></reference><reference><reference_text>Do KQ, Lauer CJ, Schreiber W, Zollinger M, Gutteck-Amsler U, Cuenod M, Holsboer F: gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem. 1995 Dec;65(6):2652-62.</reference_text><pubmed_id>7595563</pubmed_id></reference><reference><reference_text>Nikisch G, Baumann P, Wiedemann G, Kiessling B, Weisser H, Hertel A, Yoshitake T, Kehr J, Mathe AA: Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF. J Clin Psychopharmacol. 2010 Oct;30(5):496-503. doi: 10.1097/JCP.0b013e3181f2288e.</reference_text><pubmed_id>20814316</pubmed_id></reference><reference><reference_text>Fukushima T, Iizuka H, Yokota A, Suzuki T, Ohno C, Kono Y, Nishikiori M, Seki A, Ichiba H, Watanabe Y, Hongo S, Utsunomiya M, Nakatani M, Sadamoto K, Yoshio T: Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One. 2014 Jul 8;9(7):e101652. doi: 10.1371/journal.pone.0101652. eCollection 2014.</reference_text><pubmed_id>25004141</pubmed_id></reference><reference><reference_text>Koike S, Bundo M, Iwamoto K, Suga M, Kuwabara H, Ohashi Y, Shinoda K, Takano Y, Iwashiro N, Satomura Y, Nagai T, Natsubori T, Tada M, Yamasue H, Kasai K: A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study. Transl Psychiatry. 2014 Apr 8;4:e379. doi: 10.1038/tp.2014.19.</reference_text><pubmed_id>24713860</pubmed_id></reference><reference><reference_text>Ballesteros A, Summerfelt A, Du X, Jiang P, Chiappelli J, Tagamets M, O'Donnell P, Kochunov P, Hong LE: Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia. Clin Neurophysiol. 2013 Nov;124(11):2209-15. doi: 10.1016/j.clinph.2013.05.021. Epub 2013 Jun 30.</reference_text><pubmed_id>23823132</pubmed_id></reference><reference><reference_text>Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel FA: Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry. 1985 Sep;147:276-82.</reference_text><pubmed_id>2415198</pubmed_id></reference><reference><reference_text>Pickar D, Breier A, Hsiao JK, Doran AR, Wolkowitz OM, Pato CN, Konicki PE, Potter WZ: Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Arch Gen Psychiatry. 1990 Jul;47(7):641-8.</reference_text><pubmed_id>1694425</pubmed_id></reference><reference><reference_text>Prell GD, Green JP, Kaufmann CA, Khandelwal JK, Morrishow AM, Kirch DG, Linnoila M, Wyatt RJ: Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res. 1995 Jan;14(2):93-104.</reference_text><pubmed_id>7711000</pubmed_id></reference><reference><reference_text>Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B: Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology. 2009;59(2):123-9. doi: 10.1159/000213565. Epub 2009 Apr 22.</reference_text><pubmed_id>19390223</pubmed_id></reference><reference><reference_text>Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K, Cao Y, Wang X, Qiu Y, Su M, Zhao A, Wang P, Yang P, Wu J, Feng G, He L, Jia W, Wan C: Potential metabolite markers of schizophrenia. Mol Psychiatry. 2013 Jan;18(1):67-78. doi: 10.1038/mp.2011.131. Epub 2011 Oct 25.</reference_text><pubmed_id>22024767</pubmed_id></reference><reference><reference_text>Xuan J, Pan G, Qiu Y, Yang L, Su M, Liu Y, Chen J, Feng G, Fang Y, Jia W, Xing Q, He L: Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. J Proteome Res. 2011 Dec 2;10(12):5433-43. doi: 10.1021/pr2006796. Epub 2011 Nov  8.</reference_text><pubmed_id>22007635</pubmed_id></reference><reference><reference_text>Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM, Rothermundt M, Bogerts B, Koethe D, Kranaster L, Ohrmann P, Suslow T, McAllister G, Spain M, Barnes A, van Beveren NJ, Baron-Cohen S, Steiner J, Torrey FE, Yolken RH, Bahn S: Identification of a biological signature for schizophrenia in serum. Mol Psychiatry. 2012 May;17(5):494-502. doi: 10.1038/mp.2011.42. Epub 2011 Apr 12.</reference_text><pubmed_id>21483431</pubmed_id></reference><reference><reference_text>Mathe AA, Eberhard G, Saaf J, Wetterberg L: Plasma prostaglandin E2 metabolite--measured as 11-deoxy-15-keto-13,14-dihydro-11 beta,16 xi-cyclo-PGE2--in twins with schizophrenic disorder. Biol Psychiatry. 1986 Sep;21(11):1024-30.</reference_text><pubmed_id>3741918</pubmed_id></reference><reference><reference_text>Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N: Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct. 2002 Jun;20(2):171-5.</reference_text><pubmed_id>11979513</pubmed_id></reference><reference><reference_text>Zumarraga M, Davila R, Basterreche N, Arrue A, Goienetxea B, Zamalloa MI, Erkoreka L, Bustamante S, Inchausti L, Gonzalez-Torres MA, Guimon J: Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients. Neurochem Int. 2010 May-Jun;56(6-7):774-9. doi: 10.1016/j.neuint.2010.02.015. Epub 2010 Mar 4.</reference_text><pubmed_id>20206656</pubmed_id></reference><reference><reference_text>Peters JG: Dopamine, noradrenaline and serotonin spinal fluid metabolites in temporal lobe epileptic patients with schizophrenic symptomatology. Eur Neurol. 1979;18(1):15-8.</reference_text><pubmed_id>436860</pubmed_id></reference><reference><reference_text>Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, Rozen S, Krishnan RR, McEvoy J, Kaddurah-Daouk R: Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry. 2010 Sep;15(9):938-53. doi: 10.1038/mp.2009.33. Epub 2009 Apr 28.</reference_text><pubmed_id>19401681</pubmed_id></reference><reference><reference_text>Gattaz WF, Waldmeier P, Beckmann H: CSF monoamine metabolites in schizophrenic patients. Acta Psychiatr Scand. 1982 Nov;66(5):350-60.</reference_text><pubmed_id>6184954</pubmed_id></reference><reference><reference_text>Nilsson-Todd LK, Nordin C, Jonsson EG, Skogh E, Erhardt S: Cerebrospinal fluid kynurenic acid in male patients with schizophrenia - correlation with monoamine metabolites. Acta Neuropsychiatr. 2007 Feb;19(1):45-52. doi: 10.1111/j.1601-5215.2006.00170.x.</reference_text><pubmed_id>26952797</pubmed_id></reference><reference><reference_text>Cai HL, Li HD, Yan XZ, Sun B, Zhang Q, Yan M, Zhang WY, Jiang P, Zhu RH, Liu YP, Fang PF, Xu P, Yuan HY, Zhang XH, Hu L, Yang W, Ye HS: Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naive schizophrenia patients after treatment with risperidone. J Proteome Res. 2012 Aug 3;11(8):4338-50. doi: 10.1021/pr300459d. Epub 2012 Jul 26.</reference_text><pubmed_id>22800120</pubmed_id></reference><reference><reference_text>Al Awam K, Haussleiter IS, Dudley E, Donev R, Brune M, Juckel G, Thome J: Multiplatform metabolome and proteome profiling identifies serum metabolite and protein signatures as prospective biomarkers for schizophrenia. J Neural Transm (Vienna). 2015 Aug;122 Suppl 1:S111-22. doi: 10.1007/s00702-014-1224-0. Epub 2014 May 1.</reference_text><pubmed_id>24789758</pubmed_id></reference><reference><reference_text>Bicikova M, Hill M, Ripova D, Mohr P, Hampl R: Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia. J Steroid Biochem Mol Biol. 2013 Jan;133:77-83. doi: 10.1016/j.jsbmb.2012.08.009. Epub 2012 Aug 24.</reference_text><pubmed_id>22944140</pubmed_id></reference><reference><reference_text>He Y, Yu Z, Giegling I, Xie L, Hartmann AM, Prehn C, Adamski J, Kahn R, Li Y, Illig T, Wang-Sattler R, Rujescu D: Schizophrenia shows a unique metabolomics signature in plasma. Transl Psychiatry. 2012 Aug 14;2:e149. doi: 10.1038/tp.2012.76.</reference_text><pubmed_id>22892715</pubmed_id></reference><reference><reference_text>Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KR: Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):934-45. Epub 2007 Apr 17.</reference_text><pubmed_id>17440431</pubmed_id></reference><reference><reference_text>Fryar-Williams S, Strobel JE: Biomarkers of a five-domain translational substrate for schizophrenia and schizoaffective psychosis. Biomark Res. 2015 Feb 6;3:3. doi: 10.1186/s40364-015-0028-1. eCollection 2015.</reference_text><pubmed_id>25729574</pubmed_id></reference><reference><reference_text>Oresic M, Seppanen-Laakso T, Sun D, Tang J, Therman S, Viehman R, Mustonen U, van Erp TG, Hyotylainen T, Thompson P, Toga AW, Huttunen MO, Suvisaari J, Kaprio J, Lonnqvist J, Cannon TD: Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia. Genome Med. 2012 Jan 18;4(1):1. doi: 10.1186/gm300.</reference_text><pubmed_id>22257447</pubmed_id></reference></references></disease><disease>Primary hypomagnesemia<references><reference><reference_text>Jin-no Y, Kamiya Y, Okada M, Hirako M, Takada N, Kawaguchi M: Primary hypomagnesemia caused by isolated magnesium malabsorption: atypical case in adult. Intern Med. 1999 Mar;38(3):261-5.</reference_text><pubmed_id>10337938</pubmed_id></reference><reference><reference_text>Vainsel M, Vandevelde G, Smulders J, Vosters M, Hubain P, Loeb H: Tetany due to hypomagnesaemia with secondary hypocalcaemia. Arch Dis Child. 1970 Apr;45(240):254-8.</reference_text><pubmed_id>5419995</pubmed_id></reference><reference><reference_text>Shalev H, Phillip M, Galil A, Carmi R, Landau D: Clinical presentation and outcome in primary familial hypomagnesaemia. Arch Dis Child. 1998 Feb;78(2):127-30.</reference_text><pubmed_id>9579153</pubmed_id></reference><reference><reference_text>Kari JA, Farouq M, Alshaya HO: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Pediatr Nephrol. 2003 Jun;18(6):506-10. Epub 2003 Apr 29.</reference_text><pubmed_id>12720080</pubmed_id></reference></references></disease><disease>Hyperlipoproteinemia<references><reference><reference_text>Sinha S, Misra A, Kumar V, Jagannathan NR, Bal CS, Pandey RM, Singhania R, Deepak: Proton magnetic resonance spectroscopy and single photon emission computed tomography study of the brain in asymptomatic young hyperlipidaemic Asian Indians in North India show early abnormalities. Clin Endocrinol (Oxf). 2004 Aug;61(2):182-9.</reference_text><pubmed_id>15272912</pubmed_id></reference><reference><reference_text>Nelson RH: Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013 Mar</reference_text><pubmed_id>40(1):195-211. doi: 10.1016/j.pop.2012.11.003. Epub 2012 Dec  4.</pubmed_id></reference><reference><reference_text>Cantin B, Boudriau S, Bertrand M, Brun LD, Gagne C, Rogers PA, Ven Murthy MR, Lupien PJ, Julien P: Hemolysis in primary lipoprotein lipase deficiency. Metabolism. 1995 May;44(5):652-8.</reference_text><pubmed_id>7752915</pubmed_id></reference></references></disease><disease>Abetalipoproteinemia<references><reference><reference_text>Dawson G, Kruski AW, Scanu AM: Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J Lipid Res. 1976 Mar;17(2):125-31.</reference_text><pubmed_id>178813</pubmed_id></reference><reference><reference_text>Lazaro RP, Dentinger MP, Rodichok LD, Barron KD, Satya-Murti S: Muscle pathology in Bassen-Kornzweig syndrome and vitamin E deficiency. Am J Clin Pathol. 1986 Sep;86(3):378-87.</reference_text><pubmed_id>2944375</pubmed_id></reference></references></disease><disease>Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis<references><reference><reference_text>Breckenridge WC, Alaupovic P, Cox DW, Little JA: Apolipoprotein and lipoprotein concentrations in familial apolipoprotein C-II deficiency. Atherosclerosis. 1982 Aug;44(2):223-35.</reference_text><pubmed_id>7138621</pubmed_id></reference><reference><reference_text>Fukami M, Hasegawa T, Horikawa R, Ohashi T, Nishimura G, Homma K, Ogata T: Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr Res. 2006 Feb;59(2):276-80. doi: 10.1203/01.pdr.0000195825.31504.28.</reference_text><pubmed_id>16439592</pubmed_id></reference></references></disease><disease>Cerebrotendinous xanthomatosis<references><reference><reference_text>Halperin G, Elisaf M, Leitersdorf E, Harats D: A new method for determination of serum cholestanol by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2000 Jun 9;742(2):345-52.</reference_text><pubmed_id>10901139</pubmed_id></reference><reference><reference_text>Siman-Tov T, Meiner V, Gadoth N: Could steroids mask the diagnosis of cerebrotendinous xanthomatosis? J Neurol Sci. 2006 Apr 15;243(1-2):83-6. Epub 2006 Jan 30.</reference_text><pubmed_id>16445943</pubmed_id></reference><reference><reference_text>Agrawal NK, Garg S: Cerebrotendinous xanthomatosis: a rare disorder with a rare presentation. BMJ Case Rep. 2012 Sep 21;2012. pii: bcr-2012-006202. doi: 10.1136/bcr-2012-006202.</reference_text><pubmed_id>23001091</pubmed_id></reference></references></disease><disease>3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency<references><reference><reference_text>Thompson GN, Hsu BY, Pitt JJ, Treacy E, Stanley CA: Fasting hypoketotic coma in a child with deficiency of mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase. N Engl J Med. 1997 Oct 23;337(17):1203-7. doi: 10.1056/NEJM199710233371704.</reference_text><pubmed_id>9337379</pubmed_id></reference><reference><reference_text>Morris AA, Lascelles CV, Olpin SE, Lake BD, Leonard JV, Quant PA: Hepatic mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme a synthase deficiency. Pediatr Res. 1998 Sep;44(3):392-6. doi: 10.1203/00006450-199809000-00021.</reference_text><pubmed_id>9727719</pubmed_id></reference><reference><reference_text>Conboy E, Vairo F, Schultz M, Agre K, Ridsdale R, Deyle D, Oglesbee D, Gavrilov D, Klee EW, Lanpher B: Mitochondrial 3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency: Unique Presenting Laboratory Values and a Review of Biochemical and Clinical Features. JIMD Rep. 2017 Oct 14. doi: 10.1007/8904_2017_59.</reference_text><pubmed_id>29030856</pubmed_id></reference></references></disease><disease>Hypercholesterolemia, familial<references><reference><reference_text>Kwiterovich PO Jr, Fredrickson DS, Levy RI: Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest. 1974 May;53(5):1237-49. doi: 10.1172/JCI107670.</reference_text><pubmed_id>4363406</pubmed_id></reference></references></disease><disease>SC4MOL deficiency<references><reference><reference_text>He M, Kratz LE, Michel JJ, Vallejo AN, Ferris L, Kelley RI, Hoover JJ, Jukic D, Gibson KM, Wolfe LA, Ramachandran D, Zwick ME, Vockley J: Mutations in the human SC4MOL gene encoding a methyl sterol oxidase cause psoriasiform dermatitis, microcephaly, and developmental delay. J Clin Invest. 2011 Mar;121(3):976-84. doi: 10.1172/JCI42650.</reference_text><pubmed_id>21285510</pubmed_id></reference></references></disease><disease>Chondrodysplasia punctata, X-linked dominant<references><reference><reference_text>Aughton DJ, Kelley RI, Metzenberg A, Pureza V, Pauli RM: X-linked dominant chondrodysplasia punctata (CDPX2) caused by single gene mosaicism in a male. Am J Med Genet A. 2003 Jan 30;116A(3):255-60. doi: 10.1002/ajmg.a.10852.</reference_text><pubmed_id>12503102</pubmed_id></reference></references></disease><disease>Desmosterolosis<references><reference><reference_text>Andersson HC, Kratz L, Kelley R: Desmosterolosis presenting with multiple congenital anomalies and profound developmental delay. Am J Med Genet. 2002 Dec 15;113(4):315-9. doi: 10.1002/ajmg.b.10873.</reference_text><pubmed_id>12457401</pubmed_id></reference></references></disease><disease>Donohue Syndrome<references><reference><reference_text>Nijim Y, Awni Y, Adawi A, Bowirrat A: Classic Case Report of Donohue Syndrome (Leprechaunism; OMIM *246200): The Impact of Consanguineous Mating. Medicine (Baltimore). 2016 Feb;95(6):e2710. doi: 10.1097/MD.0000000000002710.</reference_text><pubmed_id>26871809</pubmed_id></reference></references></disease><disease>Leptin Deficiency or Dysfunction<references><reference><reference_text>Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O'Rahilly S: Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999 Sep 16;341(12):879-84. doi: 10.1056/NEJM199909163411204.</reference_text><pubmed_id>10486419</pubmed_id></reference></references></disease><disease>Duchenne Muscular Dystrophy<references><reference><reference_text>Nakagawa T, Takeuchi A, Kakiuchi R, Lee T, Yagi M, Awano H, Iijima K, Takeshima Y, Urade Y, Matsuo M: A prostaglandin D2 metabolite is elevated in the urine of Duchenne muscular dystrophy patients and increases further from 8 years old. Clin Chim Acta. 2013 Aug 23;423:10-4. doi: 10.1016/j.cca.2013.03.031. Epub 2013 Apr 19.</reference_text><pubmed_id>23603101</pubmed_id></reference><reference><reference_text>Srivastava NK, Pradhan S, Mittal B, Gowda GA: High resolution NMR based analysis of serum lipids in Duchenne muscular dystrophy patients and its possible diagnostic significance. NMR Biomed. 2010 Jan;23(1):13-22. doi: 10.1002/nbm.1419.</reference_text><pubmed_id>19787747</pubmed_id></reference><reference><reference_text>Horster I, Weigt-Usinger K, Carmann C, Chobanyan-Jurgens K, Kohler C, Schara U, Kayacelebi AA, Beckmann B, Tsikas D, Lucke T: The L-arginine/NO pathway and homoarginine are altered in Duchenne muscular dystrophy and improved by glucocorticoids. Amino Acids. 2015 Sep;47(9):1853-63. doi: 10.1007/s00726-015-2018-x. Epub 2015 Jun 12.</reference_text><pubmed_id>26066683</pubmed_id></reference></references></disease><disease>Lecithin:cholesterol Acyltransferase Deficiency<references><reference><reference_text>Idzior-Walus B, Sieradzki J, Kostner G, Malecki MT, Klupa T, Wesolowska T, Rostworowski W, Hartwich J, Walus M, Kiec AD, Naruszewicz M: Familial lecithin-cholesterol acyltransferase deficiency: biochemical characteristics and molecular analysis of a new LCAT mutation in a Polish family. Atherosclerosis. 2006 Apr;185(2):413-20. Epub 2005 Jul 26.</reference_text><pubmed_id>16051254</pubmed_id></reference></references></disease><disease>Lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lipodystrophy, Congenital Generalized<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Oculocerebrorenal syndrome<references><reference><reference_text>Charnas LR, Bernardini I, Rader D, Hoeg JM, Gahl WA: Clinical and laboratory findings in the oculocerebrorenal syndrome of Lowe, with special reference to growth and renal function. N Engl J Med. 1991 May 9;324(19):1318-25. doi: 10.1056/NEJM199105093241904.</reference_text><pubmed_id>2017228</pubmed_id></reference></references></disease><disease>Familial partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lathosterolosis<references><reference><reference_text>Brunetti-Pierri N, Corso G, Rossi M, Ferrari P, Balli F, Rivasi F, Annunziata I, Ballabio A, Russo AD, Andria G, Parenti G: Lathosterolosis, a novel multiple-malformation/mental retardation syndrome due to deficiency of 3beta-hydroxysteroid-delta5-desaturase. Am J Hum Genet. 2002 Oct;71(4):952-8. Epub 2002 Aug 20.</reference_text><pubmed_id>12189593</pubmed_id></reference><reference><reference_text>Ho AC, Fung CW, Siu TS, Ma OC, Lam CW, Tam S, Wong VC: Lathosterolosis: a disorder of cholesterol biosynthesis resembling smith-lemli-opitz syndrome. JIMD Rep. 2014;12:129-34. doi: 10.1007/8904_2013_255. Epub 2013 Oct 20.</reference_text><pubmed_id>24142275</pubmed_id></reference></references></disease><disease>Partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Multiple sclerosis<references><reference><reference_text>Lutz NW, Viola A, Malikova I, Confort-Gouny S, Audoin B, Ranjeva JP, Pelletier J, Cozzone PJ: Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One. 2007 Jul 4;2(7):e595.</reference_text><pubmed_id>17611627</pubmed_id></reference><reference><reference_text>Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U, Hillert J, Bjorkhem I: Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med. 2004 Feb;42(2):186-91.</reference_text><pubmed_id>15061359</pubmed_id></reference><reference><reference_text>Leoni V, Lutjohann D, Masterman T: Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis. J Lipid Res. 2005 Feb;46(2):191-5. Epub 2004 Dec 1.</reference_text><pubmed_id>15576852</pubmed_id></reference><reference><reference_text>Calabrese V, Scapagnini G, Ravagna A, Bella R, Butterfield DA, Calvani M, Pennisi G, Giuffrida Stella AM: Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem Res. 2003 Sep;28(9):1321-8.</reference_text><pubmed_id>12938853</pubmed_id></reference><reference><reference_text>Shaw CE, Dunbar PR, Macaulay HA, Neale TJ: Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol. 1995 Jan;242(2):53-8.</reference_text><pubmed_id>7707089</pubmed_id></reference><reference><reference_text>Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.</reference_text><pubmed_id>17384003</pubmed_id></reference><reference><reference_text>Syburra C, Passi S: Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh (1999). 1999 May-Jun;71(3):112-5.</reference_text><pubmed_id>10609336</pubmed_id></reference><reference><reference_text>Forte G, Visconti A, Santucci S, Ghazaryan A, Figa-Talamanca L, Cannoni S, Bocca B, Pino A, Violante N, Alimonti A, Salvetti M, Ristori G: Quantification of chemical elements in blood of patients affected by multiple sclerosis. Ann Ist Super Sanita. 2005;41(2):213-6.</reference_text><pubmed_id>16244395</pubmed_id></reference><reference><reference_text>Toncev G, Milicic B, Toncev S, Samardzic G: Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol. 2002 May;9(3):221-6.</reference_text><pubmed_id>11985629</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, Bamonti F, Capello E, Mancardi GL, Scarpini E: Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res. 2010 May 28;1333:64-71. doi: 10.1016/j.brainres.2010.03.073. Epub 2010 Mar 27.</reference_text><pubmed_id>20347721</pubmed_id></reference><reference><reference_text>Matsushita T, Isobe N, Kawajiri M, Mogi M, Tsukuda K, Horiuchi M, Ohyagi Y, Kira J: CSF angiotensin II and angiotensin-converting enzyme levels in anti-aquaporin-4 autoimmunity. J Neurol Sci. 2010 Aug 15;295(1-2):41-5. doi: 10.1016/j.jns.2010.05.014. Epub 2010 Jun 11.</reference_text><pubmed_id>20541774</pubmed_id></reference><reference><reference_text>Ghabaee M, Jabedari B, Al-E-Eshagh N, Ghaffarpour M, Asadi F: Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients. Int J Neurosci. 2010 Apr;120(4):301-4. doi: 10.3109/00207451003695690.</reference_text><pubmed_id>20374079</pubmed_id></reference><reference><reference_text>Kawajiri M, Mogi M, Osoegawa M, Matsuoka T, Tsukuda K, Kohara K, Horiuchi M, Miki T, Kira JI: Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler. 2008 May;14(4):557-60. doi: 10.1177/1352458507085760.</reference_text><pubmed_id>18562510</pubmed_id></reference><reference><reference_text>Visconti A, Cotichini R, Cannoni S, Bocca B, Forte G, Ghazaryan A, Santucci S, D'Ippolito C, Stazi MA, Salvetti M, Alimonti A, Ristori G: Concentration of elements in serum of patients affected by multiple sclerosis with first demyelinating episode: a six-month longitudinal follow-up study. Ann Ist Super Sanita. 2005;41(2):217-22.</reference_text><pubmed_id>16244396</pubmed_id></reference></references></disease><disease>Inflammatory bowel disease<references><reference><reference_text>Lee T, Clavel T, Smirnov K, Schmidt A, Lagkouvardos I, Walker A, Lucio M, Michalke B, Schmitt-Kopplin P, Fedorak R, Haller D: Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. 2017 May;66(5):863-871. doi: 10.1136/gutjnl-2015-309940. Epub 2016 Feb 4.</reference_text><pubmed_id>26848182</pubmed_id></reference><reference><reference_text>Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158.</reference_text><pubmed_id>27609529</pubmed_id></reference></references></disease><disease>Colorectal cancer<references><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B: Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009 Apr;22(3):342-8. doi: 10.1002/nbm.1345.</reference_text><pubmed_id>19006102</pubmed_id></reference><reference><reference_text>Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP: Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One. 2013 Aug 6;8(8):e70803. doi: 10.1371/journal.pone.0070803. Print 2013.</reference_text><pubmed_id>23940645</pubmed_id></reference><reference><reference_text>Phua LC, Chue XP, Koh PK, Cheah PY, Ho HK, Chan EC: Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biol Ther. 2014 Apr;15(4):389-97. doi: 10.4161/cbt.27625. Epub 2014 Jan 14.</reference_text><pubmed_id>24424155</pubmed_id></reference><reference><reference_text>Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB: Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010 Feb 15;8:13. doi: 10.1186/1741-7015-8-13.</reference_text><pubmed_id>20156336</pubmed_id></reference><reference><reference_text>Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, Ni Y, Zhao A, Xu LX, Cai S, Jia W: Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res. 2009 Oct;8(10):4844-50. doi: 10.1021/pr9004162.</reference_text><pubmed_id>19678709</pubmed_id></reference><reference><reference_text>Cheng Y, Xie G, Chen T, Qiu Y, Zou X, Zheng M, Tan B, Feng B, Dong T, He P, Zhao L, Zhao A, Xu LX, Zhang Y, Jia W: Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res. 2012 Feb 3;11(2):1354-63. doi: 10.1021/pr201001a. Epub 2011 Dec 28.</reference_text><pubmed_id>22148915</pubmed_id></reference><reference><reference_text>Ni Y, Xie G, Jia W: Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res. 2014 Sep 5;13(9):3857-70. doi: 10.1021/pr500443c. Epub 2014 Aug 14.</reference_text><pubmed_id>25105552</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference><reference><reference_text>Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18.</reference_text><pubmed_id>25037050</pubmed_id></reference><reference><reference_text>Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016.</reference_text><pubmed_id>27015276</pubmed_id></reference><reference><reference_text>Lin Y, Ma C, Liu C, Wang Z, Yang J, Liu X, Shen Z, Wu R: NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer. Oncotarget. 2016 May 17;7(20):29454-64. doi: 10.18632/oncotarget.8762.</reference_text><pubmed_id>27107423</pubmed_id></reference><reference><reference_text>Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016.</reference_text><pubmed_id>27275383</pubmed_id></reference><reference><reference_text>Wang X, Wang J, Rao B, Deng L: Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals. Exp Ther Med. 2017 Jun;13(6):2848-2854. doi: 10.3892/etm.2017.4367. Epub 2017 Apr 20.</reference_text><pubmed_id>28587349</pubmed_id></reference><reference><reference_text>Silke Matysik, Caroline Ivanne Le Roy, Gerhard Liebisch, Sandrine Paule Claus. Metabolomics of fecal samples: A practical consideration. Trends in Food Science &amp; Technology. Vol. 57, Part B, Nov. 2016, p.244-255: http://www.sciencedirect.com/science/article/pii/S0924224416301984</reference_text><pubmed_id>28587349</pubmed_id></reference></references></disease><disease>Gallbladder disease<references><reference><reference_text>Lapidus A, Akerlund JE, Einarsson C: Gallbladder bile composition in patients with Crohn 's disease. World J Gastroenterol. 2006 Jan 7;12(1):70-4.</reference_text><pubmed_id>16440420</pubmed_id></reference><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference><reference><reference_text>Mizuno S, Tazuma S, Kajiyama G: Stabilization of biliary lipid particles by ursodeoxycholic acid. Prolonged nucleation time in human gallbladder bile. Dig Dis Sci. 1993 Apr;38(4):684-93.</reference_text><pubmed_id>8462368</pubmed_id></reference><reference><reference_text>Hillebrant CG, Axelson M, Bjorkhem I, Wang FH, Nyberg B, Einarsson C: Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients. Eur J Clin Invest. 1998 Apr;28(4):324-8.</reference_text><pubmed_id>9615912</pubmed_id></reference></references></disease><disease>Cholelithiasis<references><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference></references></disease><disease>Stomach cancer<references><reference><reference_text>Higashijima H, Ichimiya H, Nakano T, Yamashita H, Kuroki S, Satoh H, Chijiiwa K, Tanaka M: Deconjugation of bilirubin accelerates coprecipitation of cholesterol, fatty acids, and mucin in human bile--in vitro study. J Gastroenterol. 1996 Dec;31(6):828-35.</reference_text><pubmed_id>9027647</pubmed_id></reference><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Song H, Peng JS, Dong-Sheng Y, Yang ZL, Liu HL, Zeng YK, Shi XP, Lu BY: Serum metabolic profiling of human gastric cancer based on gas chromatography/mass spectrometry. Braz J Med Biol Res. 2012 Jan;45(1):78-85. Epub 2011 Nov 25.</reference_text><pubmed_id>22124703</pubmed_id></reference><reference><reference_text>Yu L, Aa J, Xu J, Sun M, Qian S, Cheng L, Yang S, Shi R: Metabolomic phenotype of gastric cancer and precancerous stages based on gas chromatography time-of-flight mass spectrometry. J Gastroenterol Hepatol. 2011 Aug;26(8):1290-7. doi: 10.1111/j.1440-1746.2011.06724.x.</reference_text><pubmed_id>21443661</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference></references></disease><disease>Acute myelogenous leukemia<references><reference><reference_text>Tatidis L, Vitols S, Gruber A, Paul C, Axelson M: Cholesterol catabolism in patients with acute myelogenous leukemia and hypocholesterolemia: suppressed levels of a circulating marker for bile acid synthesis. Cancer Lett. 2001 Sep 20;170(2):169-75.</reference_text><pubmed_id>11463495</pubmed_id></reference></references></disease><disease>Hypercholesterolemia<references><reference><reference_text>Thelen KM, Laaksonen R, Paiva H, Lehtimaki T, Lutjohann D: High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels. J Clin Pharmacol. 2006 Jul;46(7):812-6.</reference_text><pubmed_id>16809807</pubmed_id></reference><reference><reference_text>Tamasawa N, Tamasawa A, Takebe K: Higher levels of plasma cholesterol sulfate in patients with liver cirrhosis and hypercholesterolemia. Lipids. 1993 Sep;28(9):833-6.</reference_text><pubmed_id>8231659</pubmed_id></reference><reference><reference_text>Kim DH, Lee KJ, Heo GS: Analysis of cholesterol and cholesteryl esters in human serum using capillary supercritical fluid chromatography. J Chromatogr B Biomed Appl. 1994 Apr 22;655(1):1-8.</reference_text><pubmed_id>8061816</pubmed_id></reference><reference><reference_text>Authors unspecified: Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med. 1988 Jan;148(1):36-69.</reference_text><pubmed_id>3422148</pubmed_id></reference></references></disease><disease>Cholesteryl ester storage disease<references><reference><reference_text>Rassoul F, Richter V, Lohse P, Naumann A, Purschwitz K, Keller E: Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease. Int J Clin Pharmacol Ther. 2001 May;39(5):199-204.</reference_text><pubmed_id>11380065</pubmed_id></reference><reference><reference_text>Chatrath H, Keilin S, Attar BM: Cholesterol ester storage disease (CESD) diagnosed in an asymptomatic adult. Dig Dis Sci. 2009 Jan;54(1):168-73. doi: 10.1007/s10620-008-0310-2. Epub 2008 May 14.</reference_text><pubmed_id>18478331</pubmed_id></reference><reference><reference_text>Bernstein DL, Hulkova H, Bialer MG, Desnick RJ: Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol. 2013 Jun;58(6):1230-43. doi: 10.1016/j.jhep.2013.02.014. Epub 2013 Feb 26.</reference_text><pubmed_id>23485521</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Cystinosis<references><reference><reference_text>Ueda M, O'Brien K, Rosing DR, Ling A, Kleta R, McAreavey D, Bernardini I, Gahl WA: Coronary artery and other vascular calcifications in patients with cystinosis after kidney transplantation. Clin J Am Soc Nephrol. 2006 May;1(3):555-62. Epub 2006 Feb 8.</reference_text><pubmed_id>17699259</pubmed_id></reference><reference><reference_text>Gahl WA, Bernardini I, Dalakas M, Rizzo WB, Harper GS, Hoeg JM, Hurko O, Bernar J: Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome. J Clin Invest. 1988 Feb;81(2):549-60.</reference_text><pubmed_id>3276734</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Smith-Lemli-Opitz syndrome<references><reference><reference_text>van Rooij A, Nijenhuis AA, Wijburg FA, Schutgens RB: Highly increased CSF concentrations of cholesterol precursors in Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 1997 Aug;20(4):578-80.</reference_text><pubmed_id>9266395</pubmed_id></reference><reference><reference_text>Honda M, Tint GS, Honda A, Salen G, Shefer S, Batta AK, Matsuzaki Y, Tanaka N: Regulation of cholesterol biosynthetic pathway in patients with the Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2000 Jul;23(5):464-74.</reference_text><pubmed_id>10947201</pubmed_id></reference><reference><reference_text>Rossi M, Federico G, Corso G, Parenti G, Battagliese A, Frascogna AR, Della Casa R, Dello Russo A, Strisciuglio P, Saggese G, Andria G: Vitamin D status in patients affected by Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2005;28(1):69-80.</reference_text><pubmed_id>15702407</pubmed_id></reference><reference><reference_text>Johnson DW, ten Brink HJ, Jakobs C: A rapid screening procedure for cholesterol and dehydrocholesterol by electrospray ionization tandem mass spectrometry. J Lipid Res. 2001 Oct;42(10):1699-705.</reference_text><pubmed_id>11590227</pubmed_id></reference></references></disease><disease>Prostate cancer<references><reference><reference_text>Nyman DW, Suzanne Stratton M, Kopplin MJ, Dalkin BL, Nagle RB, Jay Gandolfi A: Selenium and selenomethionine levels in prostate cancer patients. Cancer Detect Prev. 2004;28(1):8-16.</reference_text><pubmed_id>15041072</pubmed_id></reference><reference><reference_text>Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, Egevad L, Tjonneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, Palli D, Vineis P, Tumino R, Berrino F, Kiemeney L, Bueno-de-Mesquita HB, Quiros JR, Gonzalez CA, Martinez C, Larranaga N, Chirlaque MD, Ardanaz E, Stattin P, Hallmans G, Khaw KT, Bingham S, Slimani N, Ferrari P, Rinaldi S, Riboli E: Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr. 2007 Sep;86(3):672-81.</reference_text><pubmed_id>17823432</pubmed_id></reference><reference><reference_text>Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762.</reference_text><pubmed_id>19212411</pubmed_id></reference><reference><reference_text>Puah CM, Williams G, Ghanadian R: Urinary unconjugated 5 alpha-androstane-3 alpha, 17 beta-diol in patients with prostatic tumours. Urol Res. 1982;10(2):81-4.</reference_text><pubmed_id>6180540</pubmed_id></reference><reference><reference_text>Thysell E, Surowiec I, Hornberg E, Crnalic S, Widmark A, Johansson AI, Stattin P, Bergh A, Moritz T, Antti H, Wikstrom P: Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One. 2010 Dec 3;5(12):e14175. doi: 10.1371/journal.pone.0014175.</reference_text><pubmed_id>21151972</pubmed_id></reference><reference><reference_text>Soliman LC, Hui Y, Hewavitharana AK, Chen DD: Monitoring potential prostate cancer biomarkers in urine by capillary electrophoresis-tandem mass spectrometry. J Chromatogr A. 2012 Dec 7;1267:162-9. doi: 10.1016/j.chroma.2012.07.021. Epub 2012 Jul 14.</reference_text><pubmed_id>22824219</pubmed_id></reference><reference><reference_text>Madu CO, Lu Y: Novel diagnostic biomarkers for prostate cancer. J Cancer. 2010 Oct 6;1:150-77.</reference_text><pubmed_id>20975847</pubmed_id></reference></references></disease><disease>Schizophrenia<references><reference><reference_text>Harnryd C, Bjerkenstedt L, Grimm VE, Sedvall G: Reduction of MOPEG levels in cerebrospinal fluid of psychotic women after electroconvulsive treatment. Psychopharmacology (Berl). 1979 Aug 8;64(2):131-4.</reference_text><pubmed_id>115032</pubmed_id></reference><reference><reference_text>Kobayashi K, Koide Y, Yoshino K, Shohmori T: [P-hydroxyphenylacetic acid concentrations in cerebrospinal fluid]. No To Shinkei. 1982 Aug;34(8):769-74.</reference_text><pubmed_id>7126379</pubmed_id></reference><reference><reference_text>Alfredsson G, Wiesel FA: Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology (Berl). 1989;99(3):322-7.</reference_text><pubmed_id>2480613</pubmed_id></reference><reference><reference_text>Heresco-Levy U, Bar G, Levin R, Ermilov M, Ebstein RP, Javitt DC: High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. Schizophr Res. 2007 Mar;91(1-3):14-21. Epub 2007 Feb 2.</reference_text><pubmed_id>17276036</pubmed_id></reference><reference><reference_text>Walker EF, Bonsall R, Walder DJ: Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis. Neuropsychiatry Neuropsychol Behav Neurol. 2002 Mar;15(1):10-7.</reference_text><pubmed_id>11877547</pubmed_id></reference><reference><reference_text>Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M: Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry. 2003 Jun;60(6):572-6.</reference_text><pubmed_id>12796220</pubmed_id></reference><reference><reference_text>Do KQ, Lauer CJ, Schreiber W, Zollinger M, Gutteck-Amsler U, Cuenod M, Holsboer F: gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem. 1995 Dec;65(6):2652-62.</reference_text><pubmed_id>7595563</pubmed_id></reference><reference><reference_text>Nikisch G, Baumann P, Wiedemann G, Kiessling B, Weisser H, Hertel A, Yoshitake T, Kehr J, Mathe AA: Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF. J Clin Psychopharmacol. 2010 Oct;30(5):496-503. doi: 10.1097/JCP.0b013e3181f2288e.</reference_text><pubmed_id>20814316</pubmed_id></reference><reference><reference_text>Fukushima T, Iizuka H, Yokota A, Suzuki T, Ohno C, Kono Y, Nishikiori M, Seki A, Ichiba H, Watanabe Y, Hongo S, Utsunomiya M, Nakatani M, Sadamoto K, Yoshio T: Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One. 2014 Jul 8;9(7):e101652. doi: 10.1371/journal.pone.0101652. eCollection 2014.</reference_text><pubmed_id>25004141</pubmed_id></reference><reference><reference_text>Koike S, Bundo M, Iwamoto K, Suga M, Kuwabara H, Ohashi Y, Shinoda K, Takano Y, Iwashiro N, Satomura Y, Nagai T, Natsubori T, Tada M, Yamasue H, Kasai K: A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study. Transl Psychiatry. 2014 Apr 8;4:e379. doi: 10.1038/tp.2014.19.</reference_text><pubmed_id>24713860</pubmed_id></reference><reference><reference_text>Ballesteros A, Summerfelt A, Du X, Jiang P, Chiappelli J, Tagamets M, O'Donnell P, Kochunov P, Hong LE: Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia. Clin Neurophysiol. 2013 Nov;124(11):2209-15. doi: 10.1016/j.clinph.2013.05.021. Epub 2013 Jun 30.</reference_text><pubmed_id>23823132</pubmed_id></reference><reference><reference_text>Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel FA: Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry. 1985 Sep;147:276-82.</reference_text><pubmed_id>2415198</pubmed_id></reference><reference><reference_text>Pickar D, Breier A, Hsiao JK, Doran AR, Wolkowitz OM, Pato CN, Konicki PE, Potter WZ: Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Arch Gen Psychiatry. 1990 Jul;47(7):641-8.</reference_text><pubmed_id>1694425</pubmed_id></reference><reference><reference_text>Prell GD, Green JP, Kaufmann CA, Khandelwal JK, Morrishow AM, Kirch DG, Linnoila M, Wyatt RJ: Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res. 1995 Jan;14(2):93-104.</reference_text><pubmed_id>7711000</pubmed_id></reference><reference><reference_text>Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B: Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology. 2009;59(2):123-9. doi: 10.1159/000213565. Epub 2009 Apr 22.</reference_text><pubmed_id>19390223</pubmed_id></reference><reference><reference_text>Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K, Cao Y, Wang X, Qiu Y, Su M, Zhao A, Wang P, Yang P, Wu J, Feng G, He L, Jia W, Wan C: Potential metabolite markers of schizophrenia. Mol Psychiatry. 2013 Jan;18(1):67-78. doi: 10.1038/mp.2011.131. Epub 2011 Oct 25.</reference_text><pubmed_id>22024767</pubmed_id></reference><reference><reference_text>Xuan J, Pan G, Qiu Y, Yang L, Su M, Liu Y, Chen J, Feng G, Fang Y, Jia W, Xing Q, He L: Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. J Proteome Res. 2011 Dec 2;10(12):5433-43. doi: 10.1021/pr2006796. Epub 2011 Nov  8.</reference_text><pubmed_id>22007635</pubmed_id></reference><reference><reference_text>Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM, Rothermundt M, Bogerts B, Koethe D, Kranaster L, Ohrmann P, Suslow T, McAllister G, Spain M, Barnes A, van Beveren NJ, Baron-Cohen S, Steiner J, Torrey FE, Yolken RH, Bahn S: Identification of a biological signature for schizophrenia in serum. Mol Psychiatry. 2012 May;17(5):494-502. doi: 10.1038/mp.2011.42. Epub 2011 Apr 12.</reference_text><pubmed_id>21483431</pubmed_id></reference><reference><reference_text>Mathe AA, Eberhard G, Saaf J, Wetterberg L: Plasma prostaglandin E2 metabolite--measured as 11-deoxy-15-keto-13,14-dihydro-11 beta,16 xi-cyclo-PGE2--in twins with schizophrenic disorder. Biol Psychiatry. 1986 Sep;21(11):1024-30.</reference_text><pubmed_id>3741918</pubmed_id></reference><reference><reference_text>Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N: Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct. 2002 Jun;20(2):171-5.</reference_text><pubmed_id>11979513</pubmed_id></reference><reference><reference_text>Zumarraga M, Davila R, Basterreche N, Arrue A, Goienetxea B, Zamalloa MI, Erkoreka L, Bustamante S, Inchausti L, Gonzalez-Torres MA, Guimon J: Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients. Neurochem Int. 2010 May-Jun;56(6-7):774-9. doi: 10.1016/j.neuint.2010.02.015. Epub 2010 Mar 4.</reference_text><pubmed_id>20206656</pubmed_id></reference><reference><reference_text>Peters JG: Dopamine, noradrenaline and serotonin spinal fluid metabolites in temporal lobe epileptic patients with schizophrenic symptomatology. Eur Neurol. 1979;18(1):15-8.</reference_text><pubmed_id>436860</pubmed_id></reference><reference><reference_text>Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, Rozen S, Krishnan RR, McEvoy J, Kaddurah-Daouk R: Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry. 2010 Sep;15(9):938-53. doi: 10.1038/mp.2009.33. Epub 2009 Apr 28.</reference_text><pubmed_id>19401681</pubmed_id></reference><reference><reference_text>Gattaz WF, Waldmeier P, Beckmann H: CSF monoamine metabolites in schizophrenic patients. Acta Psychiatr Scand. 1982 Nov;66(5):350-60.</reference_text><pubmed_id>6184954</pubmed_id></reference><reference><reference_text>Nilsson-Todd LK, Nordin C, Jonsson EG, Skogh E, Erhardt S: Cerebrospinal fluid kynurenic acid in male patients with schizophrenia - correlation with monoamine metabolites. Acta Neuropsychiatr. 2007 Feb;19(1):45-52. doi: 10.1111/j.1601-5215.2006.00170.x.</reference_text><pubmed_id>26952797</pubmed_id></reference><reference><reference_text>Cai HL, Li HD, Yan XZ, Sun B, Zhang Q, Yan M, Zhang WY, Jiang P, Zhu RH, Liu YP, Fang PF, Xu P, Yuan HY, Zhang XH, Hu L, Yang W, Ye HS: Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naive schizophrenia patients after treatment with risperidone. J Proteome Res. 2012 Aug 3;11(8):4338-50. doi: 10.1021/pr300459d. Epub 2012 Jul 26.</reference_text><pubmed_id>22800120</pubmed_id></reference><reference><reference_text>Al Awam K, Haussleiter IS, Dudley E, Donev R, Brune M, Juckel G, Thome J: Multiplatform metabolome and proteome profiling identifies serum metabolite and protein signatures as prospective biomarkers for schizophrenia. J Neural Transm (Vienna). 2015 Aug;122 Suppl 1:S111-22. doi: 10.1007/s00702-014-1224-0. Epub 2014 May 1.</reference_text><pubmed_id>24789758</pubmed_id></reference><reference><reference_text>Bicikova M, Hill M, Ripova D, Mohr P, Hampl R: Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia. J Steroid Biochem Mol Biol. 2013 Jan;133:77-83. doi: 10.1016/j.jsbmb.2012.08.009. Epub 2012 Aug 24.</reference_text><pubmed_id>22944140</pubmed_id></reference><reference><reference_text>He Y, Yu Z, Giegling I, Xie L, Hartmann AM, Prehn C, Adamski J, Kahn R, Li Y, Illig T, Wang-Sattler R, Rujescu D: Schizophrenia shows a unique metabolomics signature in plasma. Transl Psychiatry. 2012 Aug 14;2:e149. doi: 10.1038/tp.2012.76.</reference_text><pubmed_id>22892715</pubmed_id></reference><reference><reference_text>Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KR: Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):934-45. Epub 2007 Apr 17.</reference_text><pubmed_id>17440431</pubmed_id></reference><reference><reference_text>Fryar-Williams S, Strobel JE: Biomarkers of a five-domain translational substrate for schizophrenia and schizoaffective psychosis. Biomark Res. 2015 Feb 6;3:3. doi: 10.1186/s40364-015-0028-1. eCollection 2015.</reference_text><pubmed_id>25729574</pubmed_id></reference><reference><reference_text>Oresic M, Seppanen-Laakso T, Sun D, Tang J, Therman S, Viehman R, Mustonen U, van Erp TG, Hyotylainen T, Thompson P, Toga AW, Huttunen MO, Suvisaari J, Kaprio J, Lonnqvist J, Cannon TD: Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia. Genome Med. 2012 Jan 18;4(1):1. doi: 10.1186/gm300.</reference_text><pubmed_id>22257447</pubmed_id></reference></references></disease><disease>Primary hypomagnesemia<references><reference><reference_text>Jin-no Y, Kamiya Y, Okada M, Hirako M, Takada N, Kawaguchi M: Primary hypomagnesemia caused by isolated magnesium malabsorption: atypical case in adult. Intern Med. 1999 Mar;38(3):261-5.</reference_text><pubmed_id>10337938</pubmed_id></reference><reference><reference_text>Vainsel M, Vandevelde G, Smulders J, Vosters M, Hubain P, Loeb H: Tetany due to hypomagnesaemia with secondary hypocalcaemia. Arch Dis Child. 1970 Apr;45(240):254-8.</reference_text><pubmed_id>5419995</pubmed_id></reference><reference><reference_text>Shalev H, Phillip M, Galil A, Carmi R, Landau D: Clinical presentation and outcome in primary familial hypomagnesaemia. Arch Dis Child. 1998 Feb;78(2):127-30.</reference_text><pubmed_id>9579153</pubmed_id></reference><reference><reference_text>Kari JA, Farouq M, Alshaya HO: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Pediatr Nephrol. 2003 Jun;18(6):506-10. Epub 2003 Apr 29.</reference_text><pubmed_id>12720080</pubmed_id></reference></references></disease><disease>Hyperlipoproteinemia<references><reference><reference_text>Sinha S, Misra A, Kumar V, Jagannathan NR, Bal CS, Pandey RM, Singhania R, Deepak: Proton magnetic resonance spectroscopy and single photon emission computed tomography study of the brain in asymptomatic young hyperlipidaemic Asian Indians in North India show early abnormalities. Clin Endocrinol (Oxf). 2004 Aug;61(2):182-9.</reference_text><pubmed_id>15272912</pubmed_id></reference><reference><reference_text>Nelson RH: Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013 Mar</reference_text><pubmed_id>40(1):195-211. doi: 10.1016/j.pop.2012.11.003. Epub 2012 Dec  4.</pubmed_id></reference><reference><reference_text>Cantin B, Boudriau S, Bertrand M, Brun LD, Gagne C, Rogers PA, Ven Murthy MR, Lupien PJ, Julien P: Hemolysis in primary lipoprotein lipase deficiency. Metabolism. 1995 May;44(5):652-8.</reference_text><pubmed_id>7752915</pubmed_id></reference></references></disease><disease>Abetalipoproteinemia<references><reference><reference_text>Dawson G, Kruski AW, Scanu AM: Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J Lipid Res. 1976 Mar;17(2):125-31.</reference_text><pubmed_id>178813</pubmed_id></reference><reference><reference_text>Lazaro RP, Dentinger MP, Rodichok LD, Barron KD, Satya-Murti S: Muscle pathology in Bassen-Kornzweig syndrome and vitamin E deficiency. Am J Clin Pathol. 1986 Sep;86(3):378-87.</reference_text><pubmed_id>2944375</pubmed_id></reference></references></disease><disease>Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis<references><reference><reference_text>Breckenridge WC, Alaupovic P, Cox DW, Little JA: Apolipoprotein and lipoprotein concentrations in familial apolipoprotein C-II deficiency. Atherosclerosis. 1982 Aug;44(2):223-35.</reference_text><pubmed_id>7138621</pubmed_id></reference><reference><reference_text>Fukami M, Hasegawa T, Horikawa R, Ohashi T, Nishimura G, Homma K, Ogata T: Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr Res. 2006 Feb;59(2):276-80. doi: 10.1203/01.pdr.0000195825.31504.28.</reference_text><pubmed_id>16439592</pubmed_id></reference></references></disease><disease>Cerebrotendinous xanthomatosis<references><reference><reference_text>Halperin G, Elisaf M, Leitersdorf E, Harats D: A new method for determination of serum cholestanol by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2000 Jun 9;742(2):345-52.</reference_text><pubmed_id>10901139</pubmed_id></reference><reference><reference_text>Siman-Tov T, Meiner V, Gadoth N: Could steroids mask the diagnosis of cerebrotendinous xanthomatosis? J Neurol Sci. 2006 Apr 15;243(1-2):83-6. Epub 2006 Jan 30.</reference_text><pubmed_id>16445943</pubmed_id></reference><reference><reference_text>Agrawal NK, Garg S: Cerebrotendinous xanthomatosis: a rare disorder with a rare presentation. BMJ Case Rep. 2012 Sep 21;2012. pii: bcr-2012-006202. doi: 10.1136/bcr-2012-006202.</reference_text><pubmed_id>23001091</pubmed_id></reference></references></disease><disease>3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency<references><reference><reference_text>Thompson GN, Hsu BY, Pitt JJ, Treacy E, Stanley CA: Fasting hypoketotic coma in a child with deficiency of mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase. N Engl J Med. 1997 Oct 23;337(17):1203-7. doi: 10.1056/NEJM199710233371704.</reference_text><pubmed_id>9337379</pubmed_id></reference><reference><reference_text>Morris AA, Lascelles CV, Olpin SE, Lake BD, Leonard JV, Quant PA: Hepatic mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme a synthase deficiency. Pediatr Res. 1998 Sep;44(3):392-6. doi: 10.1203/00006450-199809000-00021.</reference_text><pubmed_id>9727719</pubmed_id></reference><reference><reference_text>Conboy E, Vairo F, Schultz M, Agre K, Ridsdale R, Deyle D, Oglesbee D, Gavrilov D, Klee EW, Lanpher B: Mitochondrial 3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency: Unique Presenting Laboratory Values and a Review of Biochemical and Clinical Features. JIMD Rep. 2017 Oct 14. doi: 10.1007/8904_2017_59.</reference_text><pubmed_id>29030856</pubmed_id></reference></references></disease><disease>Hypercholesterolemia, familial<references><reference><reference_text>Kwiterovich PO Jr, Fredrickson DS, Levy RI: Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest. 1974 May;53(5):1237-49. doi: 10.1172/JCI107670.</reference_text><pubmed_id>4363406</pubmed_id></reference></references></disease><disease>SC4MOL deficiency<references><reference><reference_text>He M, Kratz LE, Michel JJ, Vallejo AN, Ferris L, Kelley RI, Hoover JJ, Jukic D, Gibson KM, Wolfe LA, Ramachandran D, Zwick ME, Vockley J: Mutations in the human SC4MOL gene encoding a methyl sterol oxidase cause psoriasiform dermatitis, microcephaly, and developmental delay. J Clin Invest. 2011 Mar;121(3):976-84. doi: 10.1172/JCI42650.</reference_text><pubmed_id>21285510</pubmed_id></reference></references></disease><disease>Chondrodysplasia punctata, X-linked dominant<references><reference><reference_text>Aughton DJ, Kelley RI, Metzenberg A, Pureza V, Pauli RM: X-linked dominant chondrodysplasia punctata (CDPX2) caused by single gene mosaicism in a male. Am J Med Genet A. 2003 Jan 30;116A(3):255-60. doi: 10.1002/ajmg.a.10852.</reference_text><pubmed_id>12503102</pubmed_id></reference></references></disease><disease>Desmosterolosis<references><reference><reference_text>Andersson HC, Kratz L, Kelley R: Desmosterolosis presenting with multiple congenital anomalies and profound developmental delay. Am J Med Genet. 2002 Dec 15;113(4):315-9. doi: 10.1002/ajmg.b.10873.</reference_text><pubmed_id>12457401</pubmed_id></reference></references></disease><disease>Donohue Syndrome<references><reference><reference_text>Nijim Y, Awni Y, Adawi A, Bowirrat A: Classic Case Report of Donohue Syndrome (Leprechaunism; OMIM *246200): The Impact of Consanguineous Mating. Medicine (Baltimore). 2016 Feb;95(6):e2710. doi: 10.1097/MD.0000000000002710.</reference_text><pubmed_id>26871809</pubmed_id></reference></references></disease><disease>Leptin Deficiency or Dysfunction<references><reference><reference_text>Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O'Rahilly S: Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999 Sep 16;341(12):879-84. doi: 10.1056/NEJM199909163411204.</reference_text><pubmed_id>10486419</pubmed_id></reference></references></disease><disease>Duchenne Muscular Dystrophy<references><reference><reference_text>Nakagawa T, Takeuchi A, Kakiuchi R, Lee T, Yagi M, Awano H, Iijima K, Takeshima Y, Urade Y, Matsuo M: A prostaglandin D2 metabolite is elevated in the urine of Duchenne muscular dystrophy patients and increases further from 8 years old. Clin Chim Acta. 2013 Aug 23;423:10-4. doi: 10.1016/j.cca.2013.03.031. Epub 2013 Apr 19.</reference_text><pubmed_id>23603101</pubmed_id></reference><reference><reference_text>Srivastava NK, Pradhan S, Mittal B, Gowda GA: High resolution NMR based analysis of serum lipids in Duchenne muscular dystrophy patients and its possible diagnostic significance. NMR Biomed. 2010 Jan;23(1):13-22. doi: 10.1002/nbm.1419.</reference_text><pubmed_id>19787747</pubmed_id></reference><reference><reference_text>Horster I, Weigt-Usinger K, Carmann C, Chobanyan-Jurgens K, Kohler C, Schara U, Kayacelebi AA, Beckmann B, Tsikas D, Lucke T: The L-arginine/NO pathway and homoarginine are altered in Duchenne muscular dystrophy and improved by glucocorticoids. Amino Acids. 2015 Sep;47(9):1853-63. doi: 10.1007/s00726-015-2018-x. Epub 2015 Jun 12.</reference_text><pubmed_id>26066683</pubmed_id></reference></references></disease><disease>Lecithin:cholesterol Acyltransferase Deficiency<references><reference><reference_text>Idzior-Walus B, Sieradzki J, Kostner G, Malecki MT, Klupa T, Wesolowska T, Rostworowski W, Hartwich J, Walus M, Kiec AD, Naruszewicz M: Familial lecithin-cholesterol acyltransferase deficiency: biochemical characteristics and molecular analysis of a new LCAT mutation in a Polish family. Atherosclerosis. 2006 Apr;185(2):413-20. Epub 2005 Jul 26.</reference_text><pubmed_id>16051254</pubmed_id></reference></references></disease><disease>Lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lipodystrophy, Congenital Generalized<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Oculocerebrorenal syndrome<references><reference><reference_text>Charnas LR, Bernardini I, Rader D, Hoeg JM, Gahl WA: Clinical and laboratory findings in the oculocerebrorenal syndrome of Lowe, with special reference to growth and renal function. N Engl J Med. 1991 May 9;324(19):1318-25. doi: 10.1056/NEJM199105093241904.</reference_text><pubmed_id>2017228</pubmed_id></reference></references></disease><disease>Familial partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lathosterolosis<references><reference><reference_text>Brunetti-Pierri N, Corso G, Rossi M, Ferrari P, Balli F, Rivasi F, Annunziata I, Ballabio A, Russo AD, Andria G, Parenti G: Lathosterolosis, a novel multiple-malformation/mental retardation syndrome due to deficiency of 3beta-hydroxysteroid-delta5-desaturase. Am J Hum Genet. 2002 Oct;71(4):952-8. Epub 2002 Aug 20.</reference_text><pubmed_id>12189593</pubmed_id></reference><reference><reference_text>Ho AC, Fung CW, Siu TS, Ma OC, Lam CW, Tam S, Wong VC: Lathosterolosis: a disorder of cholesterol biosynthesis resembling smith-lemli-opitz syndrome. JIMD Rep. 2014;12:129-34. doi: 10.1007/8904_2013_255. Epub 2013 Oct 20.</reference_text><pubmed_id>24142275</pubmed_id></reference></references></disease><disease>Partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Multiple sclerosis<references><reference><reference_text>Lutz NW, Viola A, Malikova I, Confort-Gouny S, Audoin B, Ranjeva JP, Pelletier J, Cozzone PJ: Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One. 2007 Jul 4;2(7):e595.</reference_text><pubmed_id>17611627</pubmed_id></reference><reference><reference_text>Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U, Hillert J, Bjorkhem I: Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med. 2004 Feb;42(2):186-91.</reference_text><pubmed_id>15061359</pubmed_id></reference><reference><reference_text>Leoni V, Lutjohann D, Masterman T: Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis. J Lipid Res. 2005 Feb;46(2):191-5. Epub 2004 Dec 1.</reference_text><pubmed_id>15576852</pubmed_id></reference><reference><reference_text>Calabrese V, Scapagnini G, Ravagna A, Bella R, Butterfield DA, Calvani M, Pennisi G, Giuffrida Stella AM: Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem Res. 2003 Sep;28(9):1321-8.</reference_text><pubmed_id>12938853</pubmed_id></reference><reference><reference_text>Shaw CE, Dunbar PR, Macaulay HA, Neale TJ: Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol. 1995 Jan;242(2):53-8.</reference_text><pubmed_id>7707089</pubmed_id></reference><reference><reference_text>Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.</reference_text><pubmed_id>17384003</pubmed_id></reference><reference><reference_text>Syburra C, Passi S: Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh (1999). 1999 May-Jun;71(3):112-5.</reference_text><pubmed_id>10609336</pubmed_id></reference><reference><reference_text>Forte G, Visconti A, Santucci S, Ghazaryan A, Figa-Talamanca L, Cannoni S, Bocca B, Pino A, Violante N, Alimonti A, Salvetti M, Ristori G: Quantification of chemical elements in blood of patients affected by multiple sclerosis. Ann Ist Super Sanita. 2005;41(2):213-6.</reference_text><pubmed_id>16244395</pubmed_id></reference><reference><reference_text>Toncev G, Milicic B, Toncev S, Samardzic G: Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol. 2002 May;9(3):221-6.</reference_text><pubmed_id>11985629</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, Bamonti F, Capello E, Mancardi GL, Scarpini E: Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res. 2010 May 28;1333:64-71. doi: 10.1016/j.brainres.2010.03.073. Epub 2010 Mar 27.</reference_text><pubmed_id>20347721</pubmed_id></reference><reference><reference_text>Matsushita T, Isobe N, Kawajiri M, Mogi M, Tsukuda K, Horiuchi M, Ohyagi Y, Kira J: CSF angiotensin II and angiotensin-converting enzyme levels in anti-aquaporin-4 autoimmunity. J Neurol Sci. 2010 Aug 15;295(1-2):41-5. doi: 10.1016/j.jns.2010.05.014. Epub 2010 Jun 11.</reference_text><pubmed_id>20541774</pubmed_id></reference><reference><reference_text>Ghabaee M, Jabedari B, Al-E-Eshagh N, Ghaffarpour M, Asadi F: Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients. Int J Neurosci. 2010 Apr;120(4):301-4. doi: 10.3109/00207451003695690.</reference_text><pubmed_id>20374079</pubmed_id></reference><reference><reference_text>Kawajiri M, Mogi M, Osoegawa M, Matsuoka T, Tsukuda K, Kohara K, Horiuchi M, Miki T, Kira JI: Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler. 2008 May;14(4):557-60. doi: 10.1177/1352458507085760.</reference_text><pubmed_id>18562510</pubmed_id></reference><reference><reference_text>Visconti A, Cotichini R, Cannoni S, Bocca B, Forte G, Ghazaryan A, Santucci S, D'Ippolito C, Stazi MA, Salvetti M, Alimonti A, Ristori G: Concentration of elements in serum of patients affected by multiple sclerosis with first demyelinating episode: a six-month longitudinal follow-up study. Ann Ist Super Sanita. 2005;41(2):217-22.</reference_text><pubmed_id>16244396</pubmed_id></reference></references></disease><disease>Inflammatory bowel disease<references><reference><reference_text>Lee T, Clavel T, Smirnov K, Schmidt A, Lagkouvardos I, Walker A, Lucio M, Michalke B, Schmitt-Kopplin P, Fedorak R, Haller D: Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. 2017 May;66(5):863-871. doi: 10.1136/gutjnl-2015-309940. Epub 2016 Feb 4.</reference_text><pubmed_id>26848182</pubmed_id></reference><reference><reference_text>Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158.</reference_text><pubmed_id>27609529</pubmed_id></reference></references></disease><disease>Colorectal cancer<references><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B: Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009 Apr;22(3):342-8. doi: 10.1002/nbm.1345.</reference_text><pubmed_id>19006102</pubmed_id></reference><reference><reference_text>Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP: Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One. 2013 Aug 6;8(8):e70803. doi: 10.1371/journal.pone.0070803. Print 2013.</reference_text><pubmed_id>23940645</pubmed_id></reference><reference><reference_text>Phua LC, Chue XP, Koh PK, Cheah PY, Ho HK, Chan EC: Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biol Ther. 2014 Apr;15(4):389-97. doi: 10.4161/cbt.27625. Epub 2014 Jan 14.</reference_text><pubmed_id>24424155</pubmed_id></reference><reference><reference_text>Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB: Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010 Feb 15;8:13. doi: 10.1186/1741-7015-8-13.</reference_text><pubmed_id>20156336</pubmed_id></reference><reference><reference_text>Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, Ni Y, Zhao A, Xu LX, Cai S, Jia W: Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res. 2009 Oct;8(10):4844-50. doi: 10.1021/pr9004162.</reference_text><pubmed_id>19678709</pubmed_id></reference><reference><reference_text>Cheng Y, Xie G, Chen T, Qiu Y, Zou X, Zheng M, Tan B, Feng B, Dong T, He P, Zhao L, Zhao A, Xu LX, Zhang Y, Jia W: Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res. 2012 Feb 3;11(2):1354-63. doi: 10.1021/pr201001a. Epub 2011 Dec 28.</reference_text><pubmed_id>22148915</pubmed_id></reference><reference><reference_text>Ni Y, Xie G, Jia W: Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res. 2014 Sep 5;13(9):3857-70. doi: 10.1021/pr500443c. Epub 2014 Aug 14.</reference_text><pubmed_id>25105552</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference><reference><reference_text>Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18.</reference_text><pubmed_id>25037050</pubmed_id></reference><reference><reference_text>Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016.</reference_text><pubmed_id>27015276</pubmed_id></reference><reference><reference_text>Lin Y, Ma C, Liu C, Wang Z, Yang J, Liu X, Shen Z, Wu R: NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer. Oncotarget. 2016 May 17;7(20):29454-64. doi: 10.18632/oncotarget.8762.</reference_text><pubmed_id>27107423</pubmed_id></reference><reference><reference_text>Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016.</reference_text><pubmed_id>27275383</pubmed_id></reference><reference><reference_text>Wang X, Wang J, Rao B, Deng L: Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals. Exp Ther Med. 2017 Jun;13(6):2848-2854. doi: 10.3892/etm.2017.4367. Epub 2017 Apr 20.</reference_text><pubmed_id>28587349</pubmed_id></reference><reference><reference_text>Silke Matysik, Caroline Ivanne Le Roy, Gerhard Liebisch, Sandrine Paule Claus. Metabolomics of fecal samples: A practical consideration. Trends in Food Science &amp; Technology. Vol. 57, Part B, Nov. 2016, p.244-255: http://www.sciencedirect.com/science/article/pii/S0924224416301984</reference_text><pubmed_id>28587349</pubmed_id></reference></references></disease><disease>Gallbladder disease<references><reference><reference_text>Lapidus A, Akerlund JE, Einarsson C: Gallbladder bile composition in patients with Crohn 's disease. World J Gastroenterol. 2006 Jan 7;12(1):70-4.</reference_text><pubmed_id>16440420</pubmed_id></reference><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference><reference><reference_text>Mizuno S, Tazuma S, Kajiyama G: Stabilization of biliary lipid particles by ursodeoxycholic acid. Prolonged nucleation time in human gallbladder bile. Dig Dis Sci. 1993 Apr;38(4):684-93.</reference_text><pubmed_id>8462368</pubmed_id></reference><reference><reference_text>Hillebrant CG, Axelson M, Bjorkhem I, Wang FH, Nyberg B, Einarsson C: Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients. Eur J Clin Invest. 1998 Apr;28(4):324-8.</reference_text><pubmed_id>9615912</pubmed_id></reference></references></disease><disease>Cholelithiasis<references><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference></references></disease><disease>Stomach cancer<references><reference><reference_text>Higashijima H, Ichimiya H, Nakano T, Yamashita H, Kuroki S, Satoh H, Chijiiwa K, Tanaka M: Deconjugation of bilirubin accelerates coprecipitation of cholesterol, fatty acids, and mucin in human bile--in vitro study. J Gastroenterol. 1996 Dec;31(6):828-35.</reference_text><pubmed_id>9027647</pubmed_id></reference><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Song H, Peng JS, Dong-Sheng Y, Yang ZL, Liu HL, Zeng YK, Shi XP, Lu BY: Serum metabolic profiling of human gastric cancer based on gas chromatography/mass spectrometry. Braz J Med Biol Res. 2012 Jan;45(1):78-85. Epub 2011 Nov 25.</reference_text><pubmed_id>22124703</pubmed_id></reference><reference><reference_text>Yu L, Aa J, Xu J, Sun M, Qian S, Cheng L, Yang S, Shi R: Metabolomic phenotype of gastric cancer and precancerous stages based on gas chromatography time-of-flight mass spectrometry. J Gastroenterol Hepatol. 2011 Aug;26(8):1290-7. doi: 10.1111/j.1440-1746.2011.06724.x.</reference_text><pubmed_id>21443661</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference></references></disease><disease>Acute myelogenous leukemia<references><reference><reference_text>Tatidis L, Vitols S, Gruber A, Paul C, Axelson M: Cholesterol catabolism in patients with acute myelogenous leukemia and hypocholesterolemia: suppressed levels of a circulating marker for bile acid synthesis. Cancer Lett. 2001 Sep 20;170(2):169-75.</reference_text><pubmed_id>11463495</pubmed_id></reference></references></disease><disease>Hypercholesterolemia<references><reference><reference_text>Thelen KM, Laaksonen R, Paiva H, Lehtimaki T, Lutjohann D: High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels. J Clin Pharmacol. 2006 Jul;46(7):812-6.</reference_text><pubmed_id>16809807</pubmed_id></reference><reference><reference_text>Tamasawa N, Tamasawa A, Takebe K: Higher levels of plasma cholesterol sulfate in patients with liver cirrhosis and hypercholesterolemia. Lipids. 1993 Sep;28(9):833-6.</reference_text><pubmed_id>8231659</pubmed_id></reference><reference><reference_text>Kim DH, Lee KJ, Heo GS: Analysis of cholesterol and cholesteryl esters in human serum using capillary supercritical fluid chromatography. J Chromatogr B Biomed Appl. 1994 Apr 22;655(1):1-8.</reference_text><pubmed_id>8061816</pubmed_id></reference><reference><reference_text>Authors unspecified: Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med. 1988 Jan;148(1):36-69.</reference_text><pubmed_id>3422148</pubmed_id></reference></references></disease><disease>Cholesteryl ester storage disease<references><reference><reference_text>Rassoul F, Richter V, Lohse P, Naumann A, Purschwitz K, Keller E: Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease. Int J Clin Pharmacol Ther. 2001 May;39(5):199-204.</reference_text><pubmed_id>11380065</pubmed_id></reference><reference><reference_text>Chatrath H, Keilin S, Attar BM: Cholesterol ester storage disease (CESD) diagnosed in an asymptomatic adult. Dig Dis Sci. 2009 Jan;54(1):168-73. doi: 10.1007/s10620-008-0310-2. Epub 2008 May 14.</reference_text><pubmed_id>18478331</pubmed_id></reference><reference><reference_text>Bernstein DL, Hulkova H, Bialer MG, Desnick RJ: Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol. 2013 Jun;58(6):1230-43. doi: 10.1016/j.jhep.2013.02.014. Epub 2013 Feb 26.</reference_text><pubmed_id>23485521</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Cystinosis<references><reference><reference_text>Ueda M, O'Brien K, Rosing DR, Ling A, Kleta R, McAreavey D, Bernardini I, Gahl WA: Coronary artery and other vascular calcifications in patients with cystinosis after kidney transplantation. Clin J Am Soc Nephrol. 2006 May;1(3):555-62. Epub 2006 Feb 8.</reference_text><pubmed_id>17699259</pubmed_id></reference><reference><reference_text>Gahl WA, Bernardini I, Dalakas M, Rizzo WB, Harper GS, Hoeg JM, Hurko O, Bernar J: Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome. J Clin Invest. 1988 Feb;81(2):549-60.</reference_text><pubmed_id>3276734</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Smith-Lemli-Opitz syndrome<references><reference><reference_text>van Rooij A, Nijenhuis AA, Wijburg FA, Schutgens RB: Highly increased CSF concentrations of cholesterol precursors in Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 1997 Aug;20(4):578-80.</reference_text><pubmed_id>9266395</pubmed_id></reference><reference><reference_text>Honda M, Tint GS, Honda A, Salen G, Shefer S, Batta AK, Matsuzaki Y, Tanaka N: Regulation of cholesterol biosynthetic pathway in patients with the Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2000 Jul;23(5):464-74.</reference_text><pubmed_id>10947201</pubmed_id></reference><reference><reference_text>Rossi M, Federico G, Corso G, Parenti G, Battagliese A, Frascogna AR, Della Casa R, Dello Russo A, Strisciuglio P, Saggese G, Andria G: Vitamin D status in patients affected by Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2005;28(1):69-80.</reference_text><pubmed_id>15702407</pubmed_id></reference><reference><reference_text>Johnson DW, ten Brink HJ, Jakobs C: A rapid screening procedure for cholesterol and dehydrocholesterol by electrospray ionization tandem mass spectrometry. J Lipid Res. 2001 Oct;42(10):1699-705.</reference_text><pubmed_id>11590227</pubmed_id></reference></references></disease><disease>Prostate cancer<references><reference><reference_text>Nyman DW, Suzanne Stratton M, Kopplin MJ, Dalkin BL, Nagle RB, Jay Gandolfi A: Selenium and selenomethionine levels in prostate cancer patients. Cancer Detect Prev. 2004;28(1):8-16.</reference_text><pubmed_id>15041072</pubmed_id></reference><reference><reference_text>Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, Egevad L, Tjonneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, Palli D, Vineis P, Tumino R, Berrino F, Kiemeney L, Bueno-de-Mesquita HB, Quiros JR, Gonzalez CA, Martinez C, Larranaga N, Chirlaque MD, Ardanaz E, Stattin P, Hallmans G, Khaw KT, Bingham S, Slimani N, Ferrari P, Rinaldi S, Riboli E: Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr. 2007 Sep;86(3):672-81.</reference_text><pubmed_id>17823432</pubmed_id></reference><reference><reference_text>Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762.</reference_text><pubmed_id>19212411</pubmed_id></reference><reference><reference_text>Puah CM, Williams G, Ghanadian R: Urinary unconjugated 5 alpha-androstane-3 alpha, 17 beta-diol in patients with prostatic tumours. Urol Res. 1982;10(2):81-4.</reference_text><pubmed_id>6180540</pubmed_id></reference><reference><reference_text>Thysell E, Surowiec I, Hornberg E, Crnalic S, Widmark A, Johansson AI, Stattin P, Bergh A, Moritz T, Antti H, Wikstrom P: Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One. 2010 Dec 3;5(12):e14175. doi: 10.1371/journal.pone.0014175.</reference_text><pubmed_id>21151972</pubmed_id></reference><reference><reference_text>Soliman LC, Hui Y, Hewavitharana AK, Chen DD: Monitoring potential prostate cancer biomarkers in urine by capillary electrophoresis-tandem mass spectrometry. J Chromatogr A. 2012 Dec 7;1267:162-9. doi: 10.1016/j.chroma.2012.07.021. Epub 2012 Jul 14.</reference_text><pubmed_id>22824219</pubmed_id></reference><reference><reference_text>Madu CO, Lu Y: Novel diagnostic biomarkers for prostate cancer. J Cancer. 2010 Oct 6;1:150-77.</reference_text><pubmed_id>20975847</pubmed_id></reference></references></disease><disease>Schizophrenia<references><reference><reference_text>Harnryd C, Bjerkenstedt L, Grimm VE, Sedvall G: Reduction of MOPEG levels in cerebrospinal fluid of psychotic women after electroconvulsive treatment. Psychopharmacology (Berl). 1979 Aug 8;64(2):131-4.</reference_text><pubmed_id>115032</pubmed_id></reference><reference><reference_text>Kobayashi K, Koide Y, Yoshino K, Shohmori T: [P-hydroxyphenylacetic acid concentrations in cerebrospinal fluid]. No To Shinkei. 1982 Aug;34(8):769-74.</reference_text><pubmed_id>7126379</pubmed_id></reference><reference><reference_text>Alfredsson G, Wiesel FA: Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology (Berl). 1989;99(3):322-7.</reference_text><pubmed_id>2480613</pubmed_id></reference><reference><reference_text>Heresco-Levy U, Bar G, Levin R, Ermilov M, Ebstein RP, Javitt DC: High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. Schizophr Res. 2007 Mar;91(1-3):14-21. Epub 2007 Feb 2.</reference_text><pubmed_id>17276036</pubmed_id></reference><reference><reference_text>Walker EF, Bonsall R, Walder DJ: Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis. Neuropsychiatry Neuropsychol Behav Neurol. 2002 Mar;15(1):10-7.</reference_text><pubmed_id>11877547</pubmed_id></reference><reference><reference_text>Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M: Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry. 2003 Jun;60(6):572-6.</reference_text><pubmed_id>12796220</pubmed_id></reference><reference><reference_text>Do KQ, Lauer CJ, Schreiber W, Zollinger M, Gutteck-Amsler U, Cuenod M, Holsboer F: gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem. 1995 Dec;65(6):2652-62.</reference_text><pubmed_id>7595563</pubmed_id></reference><reference><reference_text>Nikisch G, Baumann P, Wiedemann G, Kiessling B, Weisser H, Hertel A, Yoshitake T, Kehr J, Mathe AA: Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF. J Clin Psychopharmacol. 2010 Oct;30(5):496-503. doi: 10.1097/JCP.0b013e3181f2288e.</reference_text><pubmed_id>20814316</pubmed_id></reference><reference><reference_text>Fukushima T, Iizuka H, Yokota A, Suzuki T, Ohno C, Kono Y, Nishikiori M, Seki A, Ichiba H, Watanabe Y, Hongo S, Utsunomiya M, Nakatani M, Sadamoto K, Yoshio T: Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One. 2014 Jul 8;9(7):e101652. doi: 10.1371/journal.pone.0101652. eCollection 2014.</reference_text><pubmed_id>25004141</pubmed_id></reference><reference><reference_text>Koike S, Bundo M, Iwamoto K, Suga M, Kuwabara H, Ohashi Y, Shinoda K, Takano Y, Iwashiro N, Satomura Y, Nagai T, Natsubori T, Tada M, Yamasue H, Kasai K: A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study. Transl Psychiatry. 2014 Apr 8;4:e379. doi: 10.1038/tp.2014.19.</reference_text><pubmed_id>24713860</pubmed_id></reference><reference><reference_text>Ballesteros A, Summerfelt A, Du X, Jiang P, Chiappelli J, Tagamets M, O'Donnell P, Kochunov P, Hong LE: Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia. Clin Neurophysiol. 2013 Nov;124(11):2209-15. doi: 10.1016/j.clinph.2013.05.021. Epub 2013 Jun 30.</reference_text><pubmed_id>23823132</pubmed_id></reference><reference><reference_text>Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel FA: Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry. 1985 Sep;147:276-82.</reference_text><pubmed_id>2415198</pubmed_id></reference><reference><reference_text>Pickar D, Breier A, Hsiao JK, Doran AR, Wolkowitz OM, Pato CN, Konicki PE, Potter WZ: Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Arch Gen Psychiatry. 1990 Jul;47(7):641-8.</reference_text><pubmed_id>1694425</pubmed_id></reference><reference><reference_text>Prell GD, Green JP, Kaufmann CA, Khandelwal JK, Morrishow AM, Kirch DG, Linnoila M, Wyatt RJ: Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res. 1995 Jan;14(2):93-104.</reference_text><pubmed_id>7711000</pubmed_id></reference><reference><reference_text>Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B: Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology. 2009;59(2):123-9. doi: 10.1159/000213565. Epub 2009 Apr 22.</reference_text><pubmed_id>19390223</pubmed_id></reference><reference><reference_text>Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K, Cao Y, Wang X, Qiu Y, Su M, Zhao A, Wang P, Yang P, Wu J, Feng G, He L, Jia W, Wan C: Potential metabolite markers of schizophrenia. Mol Psychiatry. 2013 Jan;18(1):67-78. doi: 10.1038/mp.2011.131. Epub 2011 Oct 25.</reference_text><pubmed_id>22024767</pubmed_id></reference><reference><reference_text>Xuan J, Pan G, Qiu Y, Yang L, Su M, Liu Y, Chen J, Feng G, Fang Y, Jia W, Xing Q, He L: Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. J Proteome Res. 2011 Dec 2;10(12):5433-43. doi: 10.1021/pr2006796. Epub 2011 Nov  8.</reference_text><pubmed_id>22007635</pubmed_id></reference><reference><reference_text>Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM, Rothermundt M, Bogerts B, Koethe D, Kranaster L, Ohrmann P, Suslow T, McAllister G, Spain M, Barnes A, van Beveren NJ, Baron-Cohen S, Steiner J, Torrey FE, Yolken RH, Bahn S: Identification of a biological signature for schizophrenia in serum. Mol Psychiatry. 2012 May;17(5):494-502. doi: 10.1038/mp.2011.42. Epub 2011 Apr 12.</reference_text><pubmed_id>21483431</pubmed_id></reference><reference><reference_text>Mathe AA, Eberhard G, Saaf J, Wetterberg L: Plasma prostaglandin E2 metabolite--measured as 11-deoxy-15-keto-13,14-dihydro-11 beta,16 xi-cyclo-PGE2--in twins with schizophrenic disorder. Biol Psychiatry. 1986 Sep;21(11):1024-30.</reference_text><pubmed_id>3741918</pubmed_id></reference><reference><reference_text>Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N: Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct. 2002 Jun;20(2):171-5.</reference_text><pubmed_id>11979513</pubmed_id></reference><reference><reference_text>Zumarraga M, Davila R, Basterreche N, Arrue A, Goienetxea B, Zamalloa MI, Erkoreka L, Bustamante S, Inchausti L, Gonzalez-Torres MA, Guimon J: Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients. Neurochem Int. 2010 May-Jun;56(6-7):774-9. doi: 10.1016/j.neuint.2010.02.015. Epub 2010 Mar 4.</reference_text><pubmed_id>20206656</pubmed_id></reference><reference><reference_text>Peters JG: Dopamine, noradrenaline and serotonin spinal fluid metabolites in temporal lobe epileptic patients with schizophrenic symptomatology. Eur Neurol. 1979;18(1):15-8.</reference_text><pubmed_id>436860</pubmed_id></reference><reference><reference_text>Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, Rozen S, Krishnan RR, McEvoy J, Kaddurah-Daouk R: Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry. 2010 Sep;15(9):938-53. doi: 10.1038/mp.2009.33. Epub 2009 Apr 28.</reference_text><pubmed_id>19401681</pubmed_id></reference><reference><reference_text>Gattaz WF, Waldmeier P, Beckmann H: CSF monoamine metabolites in schizophrenic patients. Acta Psychiatr Scand. 1982 Nov;66(5):350-60.</reference_text><pubmed_id>6184954</pubmed_id></reference><reference><reference_text>Nilsson-Todd LK, Nordin C, Jonsson EG, Skogh E, Erhardt S: Cerebrospinal fluid kynurenic acid in male patients with schizophrenia - correlation with monoamine metabolites. Acta Neuropsychiatr. 2007 Feb;19(1):45-52. doi: 10.1111/j.1601-5215.2006.00170.x.</reference_text><pubmed_id>26952797</pubmed_id></reference><reference><reference_text>Cai HL, Li HD, Yan XZ, Sun B, Zhang Q, Yan M, Zhang WY, Jiang P, Zhu RH, Liu YP, Fang PF, Xu P, Yuan HY, Zhang XH, Hu L, Yang W, Ye HS: Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naive schizophrenia patients after treatment with risperidone. J Proteome Res. 2012 Aug 3;11(8):4338-50. doi: 10.1021/pr300459d. Epub 2012 Jul 26.</reference_text><pubmed_id>22800120</pubmed_id></reference><reference><reference_text>Al Awam K, Haussleiter IS, Dudley E, Donev R, Brune M, Juckel G, Thome J: Multiplatform metabolome and proteome profiling identifies serum metabolite and protein signatures as prospective biomarkers for schizophrenia. J Neural Transm (Vienna). 2015 Aug;122 Suppl 1:S111-22. doi: 10.1007/s00702-014-1224-0. Epub 2014 May 1.</reference_text><pubmed_id>24789758</pubmed_id></reference><reference><reference_text>Bicikova M, Hill M, Ripova D, Mohr P, Hampl R: Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia. J Steroid Biochem Mol Biol. 2013 Jan;133:77-83. doi: 10.1016/j.jsbmb.2012.08.009. Epub 2012 Aug 24.</reference_text><pubmed_id>22944140</pubmed_id></reference><reference><reference_text>He Y, Yu Z, Giegling I, Xie L, Hartmann AM, Prehn C, Adamski J, Kahn R, Li Y, Illig T, Wang-Sattler R, Rujescu D: Schizophrenia shows a unique metabolomics signature in plasma. Transl Psychiatry. 2012 Aug 14;2:e149. doi: 10.1038/tp.2012.76.</reference_text><pubmed_id>22892715</pubmed_id></reference><reference><reference_text>Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KR: Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):934-45. Epub 2007 Apr 17.</reference_text><pubmed_id>17440431</pubmed_id></reference><reference><reference_text>Fryar-Williams S, Strobel JE: Biomarkers of a five-domain translational substrate for schizophrenia and schizoaffective psychosis. Biomark Res. 2015 Feb 6;3:3. doi: 10.1186/s40364-015-0028-1. eCollection 2015.</reference_text><pubmed_id>25729574</pubmed_id></reference><reference><reference_text>Oresic M, Seppanen-Laakso T, Sun D, Tang J, Therman S, Viehman R, Mustonen U, van Erp TG, Hyotylainen T, Thompson P, Toga AW, Huttunen MO, Suvisaari J, Kaprio J, Lonnqvist J, Cannon TD: Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia. Genome Med. 2012 Jan 18;4(1):1. doi: 10.1186/gm300.</reference_text><pubmed_id>22257447</pubmed_id></reference></references></disease><disease>Primary hypomagnesemia<references><reference><reference_text>Jin-no Y, Kamiya Y, Okada M, Hirako M, Takada N, Kawaguchi M: Primary hypomagnesemia caused by isolated magnesium malabsorption: atypical case in adult. Intern Med. 1999 Mar;38(3):261-5.</reference_text><pubmed_id>10337938</pubmed_id></reference><reference><reference_text>Vainsel M, Vandevelde G, Smulders J, Vosters M, Hubain P, Loeb H: Tetany due to hypomagnesaemia with secondary hypocalcaemia. Arch Dis Child. 1970 Apr;45(240):254-8.</reference_text><pubmed_id>5419995</pubmed_id></reference><reference><reference_text>Shalev H, Phillip M, Galil A, Carmi R, Landau D: Clinical presentation and outcome in primary familial hypomagnesaemia. Arch Dis Child. 1998 Feb;78(2):127-30.</reference_text><pubmed_id>9579153</pubmed_id></reference><reference><reference_text>Kari JA, Farouq M, Alshaya HO: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Pediatr Nephrol. 2003 Jun;18(6):506-10. Epub 2003 Apr 29.</reference_text><pubmed_id>12720080</pubmed_id></reference></references></disease><disease>Hyperlipoproteinemia<references><reference><reference_text>Sinha S, Misra A, Kumar V, Jagannathan NR, Bal CS, Pandey RM, Singhania R, Deepak: Proton magnetic resonance spectroscopy and single photon emission computed tomography study of the brain in asymptomatic young hyperlipidaemic Asian Indians in North India show early abnormalities. Clin Endocrinol (Oxf). 2004 Aug;61(2):182-9.</reference_text><pubmed_id>15272912</pubmed_id></reference><reference><reference_text>Nelson RH: Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013 Mar</reference_text><pubmed_id>40(1):195-211. doi: 10.1016/j.pop.2012.11.003. Epub 2012 Dec  4.</pubmed_id></reference><reference><reference_text>Cantin B, Boudriau S, Bertrand M, Brun LD, Gagne C, Rogers PA, Ven Murthy MR, Lupien PJ, Julien P: Hemolysis in primary lipoprotein lipase deficiency. Metabolism. 1995 May;44(5):652-8.</reference_text><pubmed_id>7752915</pubmed_id></reference></references></disease><disease>Abetalipoproteinemia<references><reference><reference_text>Dawson G, Kruski AW, Scanu AM: Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J Lipid Res. 1976 Mar;17(2):125-31.</reference_text><pubmed_id>178813</pubmed_id></reference><reference><reference_text>Lazaro RP, Dentinger MP, Rodichok LD, Barron KD, Satya-Murti S: Muscle pathology in Bassen-Kornzweig syndrome and vitamin E deficiency. Am J Clin Pathol. 1986 Sep;86(3):378-87.</reference_text><pubmed_id>2944375</pubmed_id></reference></references></disease><disease>Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis<references><reference><reference_text>Breckenridge WC, Alaupovic P, Cox DW, Little JA: Apolipoprotein and lipoprotein concentrations in familial apolipoprotein C-II deficiency. Atherosclerosis. 1982 Aug;44(2):223-35.</reference_text><pubmed_id>7138621</pubmed_id></reference><reference><reference_text>Fukami M, Hasegawa T, Horikawa R, Ohashi T, Nishimura G, Homma K, Ogata T: Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr Res. 2006 Feb;59(2):276-80. doi: 10.1203/01.pdr.0000195825.31504.28.</reference_text><pubmed_id>16439592</pubmed_id></reference></references></disease><disease>Cerebrotendinous xanthomatosis<references><reference><reference_text>Halperin G, Elisaf M, Leitersdorf E, Harats D: A new method for determination of serum cholestanol by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2000 Jun 9;742(2):345-52.</reference_text><pubmed_id>10901139</pubmed_id></reference><reference><reference_text>Siman-Tov T, Meiner V, Gadoth N: Could steroids mask the diagnosis of cerebrotendinous xanthomatosis? J Neurol Sci. 2006 Apr 15;243(1-2):83-6. Epub 2006 Jan 30.</reference_text><pubmed_id>16445943</pubmed_id></reference><reference><reference_text>Agrawal NK, Garg S: Cerebrotendinous xanthomatosis: a rare disorder with a rare presentation. BMJ Case Rep. 2012 Sep 21;2012. pii: bcr-2012-006202. doi: 10.1136/bcr-2012-006202.</reference_text><pubmed_id>23001091</pubmed_id></reference></references></disease><disease>3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency<references><reference><reference_text>Thompson GN, Hsu BY, Pitt JJ, Treacy E, Stanley CA: Fasting hypoketotic coma in a child with deficiency of mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase. N Engl J Med. 1997 Oct 23;337(17):1203-7. doi: 10.1056/NEJM199710233371704.</reference_text><pubmed_id>9337379</pubmed_id></reference><reference><reference_text>Morris AA, Lascelles CV, Olpin SE, Lake BD, Leonard JV, Quant PA: Hepatic mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme a synthase deficiency. Pediatr Res. 1998 Sep;44(3):392-6. doi: 10.1203/00006450-199809000-00021.</reference_text><pubmed_id>9727719</pubmed_id></reference><reference><reference_text>Conboy E, Vairo F, Schultz M, Agre K, Ridsdale R, Deyle D, Oglesbee D, Gavrilov D, Klee EW, Lanpher B: Mitochondrial 3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency: Unique Presenting Laboratory Values and a Review of Biochemical and Clinical Features. JIMD Rep. 2017 Oct 14. doi: 10.1007/8904_2017_59.</reference_text><pubmed_id>29030856</pubmed_id></reference></references></disease><disease>Hypercholesterolemia, familial<references><reference><reference_text>Kwiterovich PO Jr, Fredrickson DS, Levy RI: Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest. 1974 May;53(5):1237-49. doi: 10.1172/JCI107670.</reference_text><pubmed_id>4363406</pubmed_id></reference></references></disease><disease>SC4MOL deficiency<references><reference><reference_text>He M, Kratz LE, Michel JJ, Vallejo AN, Ferris L, Kelley RI, Hoover JJ, Jukic D, Gibson KM, Wolfe LA, Ramachandran D, Zwick ME, Vockley J: Mutations in the human SC4MOL gene encoding a methyl sterol oxidase cause psoriasiform dermatitis, microcephaly, and developmental delay. J Clin Invest. 2011 Mar;121(3):976-84. doi: 10.1172/JCI42650.</reference_text><pubmed_id>21285510</pubmed_id></reference></references></disease><disease>Chondrodysplasia punctata, X-linked dominant<references><reference><reference_text>Aughton DJ, Kelley RI, Metzenberg A, Pureza V, Pauli RM: X-linked dominant chondrodysplasia punctata (CDPX2) caused by single gene mosaicism in a male. Am J Med Genet A. 2003 Jan 30;116A(3):255-60. doi: 10.1002/ajmg.a.10852.</reference_text><pubmed_id>12503102</pubmed_id></reference></references></disease><disease>Desmosterolosis<references><reference><reference_text>Andersson HC, Kratz L, Kelley R: Desmosterolosis presenting with multiple congenital anomalies and profound developmental delay. Am J Med Genet. 2002 Dec 15;113(4):315-9. doi: 10.1002/ajmg.b.10873.</reference_text><pubmed_id>12457401</pubmed_id></reference></references></disease><disease>Donohue Syndrome<references><reference><reference_text>Nijim Y, Awni Y, Adawi A, Bowirrat A: Classic Case Report of Donohue Syndrome (Leprechaunism; OMIM *246200): The Impact of Consanguineous Mating. Medicine (Baltimore). 2016 Feb;95(6):e2710. doi: 10.1097/MD.0000000000002710.</reference_text><pubmed_id>26871809</pubmed_id></reference></references></disease><disease>Leptin Deficiency or Dysfunction<references><reference><reference_text>Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O'Rahilly S: Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999 Sep 16;341(12):879-84. doi: 10.1056/NEJM199909163411204.</reference_text><pubmed_id>10486419</pubmed_id></reference></references></disease><disease>Duchenne Muscular Dystrophy<references><reference><reference_text>Nakagawa T, Takeuchi A, Kakiuchi R, Lee T, Yagi M, Awano H, Iijima K, Takeshima Y, Urade Y, Matsuo M: A prostaglandin D2 metabolite is elevated in the urine of Duchenne muscular dystrophy patients and increases further from 8 years old. Clin Chim Acta. 2013 Aug 23;423:10-4. doi: 10.1016/j.cca.2013.03.031. Epub 2013 Apr 19.</reference_text><pubmed_id>23603101</pubmed_id></reference><reference><reference_text>Srivastava NK, Pradhan S, Mittal B, Gowda GA: High resolution NMR based analysis of serum lipids in Duchenne muscular dystrophy patients and its possible diagnostic significance. NMR Biomed. 2010 Jan;23(1):13-22. doi: 10.1002/nbm.1419.</reference_text><pubmed_id>19787747</pubmed_id></reference><reference><reference_text>Horster I, Weigt-Usinger K, Carmann C, Chobanyan-Jurgens K, Kohler C, Schara U, Kayacelebi AA, Beckmann B, Tsikas D, Lucke T: The L-arginine/NO pathway and homoarginine are altered in Duchenne muscular dystrophy and improved by glucocorticoids. Amino Acids. 2015 Sep;47(9):1853-63. doi: 10.1007/s00726-015-2018-x. Epub 2015 Jun 12.</reference_text><pubmed_id>26066683</pubmed_id></reference></references></disease><disease>Lecithin:cholesterol Acyltransferase Deficiency<references><reference><reference_text>Idzior-Walus B, Sieradzki J, Kostner G, Malecki MT, Klupa T, Wesolowska T, Rostworowski W, Hartwich J, Walus M, Kiec AD, Naruszewicz M: Familial lecithin-cholesterol acyltransferase deficiency: biochemical characteristics and molecular analysis of a new LCAT mutation in a Polish family. Atherosclerosis. 2006 Apr;185(2):413-20. Epub 2005 Jul 26.</reference_text><pubmed_id>16051254</pubmed_id></reference></references></disease><disease>Lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lipodystrophy, Congenital Generalized<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Oculocerebrorenal syndrome<references><reference><reference_text>Charnas LR, Bernardini I, Rader D, Hoeg JM, Gahl WA: Clinical and laboratory findings in the oculocerebrorenal syndrome of Lowe, with special reference to growth and renal function. N Engl J Med. 1991 May 9;324(19):1318-25. doi: 10.1056/NEJM199105093241904.</reference_text><pubmed_id>2017228</pubmed_id></reference></references></disease><disease>Familial partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lathosterolosis<references><reference><reference_text>Brunetti-Pierri N, Corso G, Rossi M, Ferrari P, Balli F, Rivasi F, Annunziata I, Ballabio A, Russo AD, Andria G, Parenti G: Lathosterolosis, a novel multiple-malformation/mental retardation syndrome due to deficiency of 3beta-hydroxysteroid-delta5-desaturase. Am J Hum Genet. 2002 Oct;71(4):952-8. Epub 2002 Aug 20.</reference_text><pubmed_id>12189593</pubmed_id></reference><reference><reference_text>Ho AC, Fung CW, Siu TS, Ma OC, Lam CW, Tam S, Wong VC: Lathosterolosis: a disorder of cholesterol biosynthesis resembling smith-lemli-opitz syndrome. JIMD Rep. 2014;12:129-34. doi: 10.1007/8904_2013_255. Epub 2013 Oct 20.</reference_text><pubmed_id>24142275</pubmed_id></reference></references></disease><disease>Partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Multiple sclerosis<references><reference><reference_text>Lutz NW, Viola A, Malikova I, Confort-Gouny S, Audoin B, Ranjeva JP, Pelletier J, Cozzone PJ: Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One. 2007 Jul 4;2(7):e595.</reference_text><pubmed_id>17611627</pubmed_id></reference><reference><reference_text>Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U, Hillert J, Bjorkhem I: Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med. 2004 Feb;42(2):186-91.</reference_text><pubmed_id>15061359</pubmed_id></reference><reference><reference_text>Leoni V, Lutjohann D, Masterman T: Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis. J Lipid Res. 2005 Feb;46(2):191-5. Epub 2004 Dec 1.</reference_text><pubmed_id>15576852</pubmed_id></reference><reference><reference_text>Calabrese V, Scapagnini G, Ravagna A, Bella R, Butterfield DA, Calvani M, Pennisi G, Giuffrida Stella AM: Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem Res. 2003 Sep;28(9):1321-8.</reference_text><pubmed_id>12938853</pubmed_id></reference><reference><reference_text>Shaw CE, Dunbar PR, Macaulay HA, Neale TJ: Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol. 1995 Jan;242(2):53-8.</reference_text><pubmed_id>7707089</pubmed_id></reference><reference><reference_text>Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.</reference_text><pubmed_id>17384003</pubmed_id></reference><reference><reference_text>Syburra C, Passi S: Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh (1999). 1999 May-Jun;71(3):112-5.</reference_text><pubmed_id>10609336</pubmed_id></reference><reference><reference_text>Forte G, Visconti A, Santucci S, Ghazaryan A, Figa-Talamanca L, Cannoni S, Bocca B, Pino A, Violante N, Alimonti A, Salvetti M, Ristori G: Quantification of chemical elements in blood of patients affected by multiple sclerosis. Ann Ist Super Sanita. 2005;41(2):213-6.</reference_text><pubmed_id>16244395</pubmed_id></reference><reference><reference_text>Toncev G, Milicic B, Toncev S, Samardzic G: Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol. 2002 May;9(3):221-6.</reference_text><pubmed_id>11985629</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, Bamonti F, Capello E, Mancardi GL, Scarpini E: Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res. 2010 May 28;1333:64-71. doi: 10.1016/j.brainres.2010.03.073. Epub 2010 Mar 27.</reference_text><pubmed_id>20347721</pubmed_id></reference><reference><reference_text>Matsushita T, Isobe N, Kawajiri M, Mogi M, Tsukuda K, Horiuchi M, Ohyagi Y, Kira J: CSF angiotensin II and angiotensin-converting enzyme levels in anti-aquaporin-4 autoimmunity. J Neurol Sci. 2010 Aug 15;295(1-2):41-5. doi: 10.1016/j.jns.2010.05.014. Epub 2010 Jun 11.</reference_text><pubmed_id>20541774</pubmed_id></reference><reference><reference_text>Ghabaee M, Jabedari B, Al-E-Eshagh N, Ghaffarpour M, Asadi F: Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients. Int J Neurosci. 2010 Apr;120(4):301-4. doi: 10.3109/00207451003695690.</reference_text><pubmed_id>20374079</pubmed_id></reference><reference><reference_text>Kawajiri M, Mogi M, Osoegawa M, Matsuoka T, Tsukuda K, Kohara K, Horiuchi M, Miki T, Kira JI: Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler. 2008 May;14(4):557-60. doi: 10.1177/1352458507085760.</reference_text><pubmed_id>18562510</pubmed_id></reference><reference><reference_text>Visconti A, Cotichini R, Cannoni S, Bocca B, Forte G, Ghazaryan A, Santucci S, D'Ippolito C, Stazi MA, Salvetti M, Alimonti A, Ristori G: Concentration of elements in serum of patients affected by multiple sclerosis with first demyelinating episode: a six-month longitudinal follow-up study. Ann Ist Super Sanita. 2005;41(2):217-22.</reference_text><pubmed_id>16244396</pubmed_id></reference></references></disease><disease>Inflammatory bowel disease<references><reference><reference_text>Lee T, Clavel T, Smirnov K, Schmidt A, Lagkouvardos I, Walker A, Lucio M, Michalke B, Schmitt-Kopplin P, Fedorak R, Haller D: Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. 2017 May;66(5):863-871. doi: 10.1136/gutjnl-2015-309940. Epub 2016 Feb 4.</reference_text><pubmed_id>26848182</pubmed_id></reference><reference><reference_text>Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158.</reference_text><pubmed_id>27609529</pubmed_id></reference></references></disease><disease>Colorectal cancer<references><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B: Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009 Apr;22(3):342-8. doi: 10.1002/nbm.1345.</reference_text><pubmed_id>19006102</pubmed_id></reference><reference><reference_text>Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP: Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One. 2013 Aug 6;8(8):e70803. doi: 10.1371/journal.pone.0070803. Print 2013.</reference_text><pubmed_id>23940645</pubmed_id></reference><reference><reference_text>Phua LC, Chue XP, Koh PK, Cheah PY, Ho HK, Chan EC: Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biol Ther. 2014 Apr;15(4):389-97. doi: 10.4161/cbt.27625. Epub 2014 Jan 14.</reference_text><pubmed_id>24424155</pubmed_id></reference><reference><reference_text>Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB: Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010 Feb 15;8:13. doi: 10.1186/1741-7015-8-13.</reference_text><pubmed_id>20156336</pubmed_id></reference><reference><reference_text>Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, Ni Y, Zhao A, Xu LX, Cai S, Jia W: Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res. 2009 Oct;8(10):4844-50. doi: 10.1021/pr9004162.</reference_text><pubmed_id>19678709</pubmed_id></reference><reference><reference_text>Cheng Y, Xie G, Chen T, Qiu Y, Zou X, Zheng M, Tan B, Feng B, Dong T, He P, Zhao L, Zhao A, Xu LX, Zhang Y, Jia W: Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res. 2012 Feb 3;11(2):1354-63. doi: 10.1021/pr201001a. Epub 2011 Dec 28.</reference_text><pubmed_id>22148915</pubmed_id></reference><reference><reference_text>Ni Y, Xie G, Jia W: Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res. 2014 Sep 5;13(9):3857-70. doi: 10.1021/pr500443c. Epub 2014 Aug 14.</reference_text><pubmed_id>25105552</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference><reference><reference_text>Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18.</reference_text><pubmed_id>25037050</pubmed_id></reference><reference><reference_text>Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016.</reference_text><pubmed_id>27015276</pubmed_id></reference><reference><reference_text>Lin Y, Ma C, Liu C, Wang Z, Yang J, Liu X, Shen Z, Wu R: NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer. Oncotarget. 2016 May 17;7(20):29454-64. doi: 10.18632/oncotarget.8762.</reference_text><pubmed_id>27107423</pubmed_id></reference><reference><reference_text>Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016.</reference_text><pubmed_id>27275383</pubmed_id></reference><reference><reference_text>Wang X, Wang J, Rao B, Deng L: Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals. Exp Ther Med. 2017 Jun;13(6):2848-2854. doi: 10.3892/etm.2017.4367. Epub 2017 Apr 20.</reference_text><pubmed_id>28587349</pubmed_id></reference><reference><reference_text>Silke Matysik, Caroline Ivanne Le Roy, Gerhard Liebisch, Sandrine Paule Claus. Metabolomics of fecal samples: A practical consideration. Trends in Food Science &amp; Technology. Vol. 57, Part B, Nov. 2016, p.244-255: http://www.sciencedirect.com/science/article/pii/S0924224416301984</reference_text><pubmed_id>28587349</pubmed_id></reference></references></disease><disease>Gallbladder disease<references><reference><reference_text>Lapidus A, Akerlund JE, Einarsson C: Gallbladder bile composition in patients with Crohn 's disease. World J Gastroenterol. 2006 Jan 7;12(1):70-4.</reference_text><pubmed_id>16440420</pubmed_id></reference><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference><reference><reference_text>Mizuno S, Tazuma S, Kajiyama G: Stabilization of biliary lipid particles by ursodeoxycholic acid. Prolonged nucleation time in human gallbladder bile. Dig Dis Sci. 1993 Apr;38(4):684-93.</reference_text><pubmed_id>8462368</pubmed_id></reference><reference><reference_text>Hillebrant CG, Axelson M, Bjorkhem I, Wang FH, Nyberg B, Einarsson C: Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients. Eur J Clin Invest. 1998 Apr;28(4):324-8.</reference_text><pubmed_id>9615912</pubmed_id></reference></references></disease><disease>Cholelithiasis<references><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference></references></disease><disease>Stomach cancer<references><reference><reference_text>Higashijima H, Ichimiya H, Nakano T, Yamashita H, Kuroki S, Satoh H, Chijiiwa K, Tanaka M: Deconjugation of bilirubin accelerates coprecipitation of cholesterol, fatty acids, and mucin in human bile--in vitro study. J Gastroenterol. 1996 Dec;31(6):828-35.</reference_text><pubmed_id>9027647</pubmed_id></reference><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Song H, Peng JS, Dong-Sheng Y, Yang ZL, Liu HL, Zeng YK, Shi XP, Lu BY: Serum metabolic profiling of human gastric cancer based on gas chromatography/mass spectrometry. Braz J Med Biol Res. 2012 Jan;45(1):78-85. Epub 2011 Nov 25.</reference_text><pubmed_id>22124703</pubmed_id></reference><reference><reference_text>Yu L, Aa J, Xu J, Sun M, Qian S, Cheng L, Yang S, Shi R: Metabolomic phenotype of gastric cancer and precancerous stages based on gas chromatography time-of-flight mass spectrometry. J Gastroenterol Hepatol. 2011 Aug;26(8):1290-7. doi: 10.1111/j.1440-1746.2011.06724.x.</reference_text><pubmed_id>21443661</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference></references></disease><disease>Acute myelogenous leukemia<references><reference><reference_text>Tatidis L, Vitols S, Gruber A, Paul C, Axelson M: Cholesterol catabolism in patients with acute myelogenous leukemia and hypocholesterolemia: suppressed levels of a circulating marker for bile acid synthesis. Cancer Lett. 2001 Sep 20;170(2):169-75.</reference_text><pubmed_id>11463495</pubmed_id></reference></references></disease><disease>Hypercholesterolemia<references><reference><reference_text>Thelen KM, Laaksonen R, Paiva H, Lehtimaki T, Lutjohann D: High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels. J Clin Pharmacol. 2006 Jul;46(7):812-6.</reference_text><pubmed_id>16809807</pubmed_id></reference><reference><reference_text>Tamasawa N, Tamasawa A, Takebe K: Higher levels of plasma cholesterol sulfate in patients with liver cirrhosis and hypercholesterolemia. Lipids. 1993 Sep;28(9):833-6.</reference_text><pubmed_id>8231659</pubmed_id></reference><reference><reference_text>Kim DH, Lee KJ, Heo GS: Analysis of cholesterol and cholesteryl esters in human serum using capillary supercritical fluid chromatography. J Chromatogr B Biomed Appl. 1994 Apr 22;655(1):1-8.</reference_text><pubmed_id>8061816</pubmed_id></reference><reference><reference_text>Authors unspecified: Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med. 1988 Jan;148(1):36-69.</reference_text><pubmed_id>3422148</pubmed_id></reference></references></disease><disease>Cholesteryl ester storage disease<references><reference><reference_text>Rassoul F, Richter V, Lohse P, Naumann A, Purschwitz K, Keller E: Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease. Int J Clin Pharmacol Ther. 2001 May;39(5):199-204.</reference_text><pubmed_id>11380065</pubmed_id></reference><reference><reference_text>Chatrath H, Keilin S, Attar BM: Cholesterol ester storage disease (CESD) diagnosed in an asymptomatic adult. Dig Dis Sci. 2009 Jan;54(1):168-73. doi: 10.1007/s10620-008-0310-2. Epub 2008 May 14.</reference_text><pubmed_id>18478331</pubmed_id></reference><reference><reference_text>Bernstein DL, Hulkova H, Bialer MG, Desnick RJ: Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol. 2013 Jun;58(6):1230-43. doi: 10.1016/j.jhep.2013.02.014. Epub 2013 Feb 26.</reference_text><pubmed_id>23485521</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Cystinosis<references><reference><reference_text>Ueda M, O'Brien K, Rosing DR, Ling A, Kleta R, McAreavey D, Bernardini I, Gahl WA: Coronary artery and other vascular calcifications in patients with cystinosis after kidney transplantation. Clin J Am Soc Nephrol. 2006 May;1(3):555-62. Epub 2006 Feb 8.</reference_text><pubmed_id>17699259</pubmed_id></reference><reference><reference_text>Gahl WA, Bernardini I, Dalakas M, Rizzo WB, Harper GS, Hoeg JM, Hurko O, Bernar J: Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome. J Clin Invest. 1988 Feb;81(2):549-60.</reference_text><pubmed_id>3276734</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Smith-Lemli-Opitz syndrome<references><reference><reference_text>van Rooij A, Nijenhuis AA, Wijburg FA, Schutgens RB: Highly increased CSF concentrations of cholesterol precursors in Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 1997 Aug;20(4):578-80.</reference_text><pubmed_id>9266395</pubmed_id></reference><reference><reference_text>Honda M, Tint GS, Honda A, Salen G, Shefer S, Batta AK, Matsuzaki Y, Tanaka N: Regulation of cholesterol biosynthetic pathway in patients with the Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2000 Jul;23(5):464-74.</reference_text><pubmed_id>10947201</pubmed_id></reference><reference><reference_text>Rossi M, Federico G, Corso G, Parenti G, Battagliese A, Frascogna AR, Della Casa R, Dello Russo A, Strisciuglio P, Saggese G, Andria G: Vitamin D status in patients affected by Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2005;28(1):69-80.</reference_text><pubmed_id>15702407</pubmed_id></reference><reference><reference_text>Johnson DW, ten Brink HJ, Jakobs C: A rapid screening procedure for cholesterol and dehydrocholesterol by electrospray ionization tandem mass spectrometry. J Lipid Res. 2001 Oct;42(10):1699-705.</reference_text><pubmed_id>11590227</pubmed_id></reference></references></disease><disease>Prostate cancer<references><reference><reference_text>Nyman DW, Suzanne Stratton M, Kopplin MJ, Dalkin BL, Nagle RB, Jay Gandolfi A: Selenium and selenomethionine levels in prostate cancer patients. Cancer Detect Prev. 2004;28(1):8-16.</reference_text><pubmed_id>15041072</pubmed_id></reference><reference><reference_text>Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, Egevad L, Tjonneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, Palli D, Vineis P, Tumino R, Berrino F, Kiemeney L, Bueno-de-Mesquita HB, Quiros JR, Gonzalez CA, Martinez C, Larranaga N, Chirlaque MD, Ardanaz E, Stattin P, Hallmans G, Khaw KT, Bingham S, Slimani N, Ferrari P, Rinaldi S, Riboli E: Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr. 2007 Sep;86(3):672-81.</reference_text><pubmed_id>17823432</pubmed_id></reference><reference><reference_text>Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762.</reference_text><pubmed_id>19212411</pubmed_id></reference><reference><reference_text>Puah CM, Williams G, Ghanadian R: Urinary unconjugated 5 alpha-androstane-3 alpha, 17 beta-diol in patients with prostatic tumours. Urol Res. 1982;10(2):81-4.</reference_text><pubmed_id>6180540</pubmed_id></reference><reference><reference_text>Thysell E, Surowiec I, Hornberg E, Crnalic S, Widmark A, Johansson AI, Stattin P, Bergh A, Moritz T, Antti H, Wikstrom P: Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One. 2010 Dec 3;5(12):e14175. doi: 10.1371/journal.pone.0014175.</reference_text><pubmed_id>21151972</pubmed_id></reference><reference><reference_text>Soliman LC, Hui Y, Hewavitharana AK, Chen DD: Monitoring potential prostate cancer biomarkers in urine by capillary electrophoresis-tandem mass spectrometry. J Chromatogr A. 2012 Dec 7;1267:162-9. doi: 10.1016/j.chroma.2012.07.021. Epub 2012 Jul 14.</reference_text><pubmed_id>22824219</pubmed_id></reference><reference><reference_text>Madu CO, Lu Y: Novel diagnostic biomarkers for prostate cancer. J Cancer. 2010 Oct 6;1:150-77.</reference_text><pubmed_id>20975847</pubmed_id></reference></references></disease><disease>Schizophrenia<references><reference><reference_text>Harnryd C, Bjerkenstedt L, Grimm VE, Sedvall G: Reduction of MOPEG levels in cerebrospinal fluid of psychotic women after electroconvulsive treatment. Psychopharmacology (Berl). 1979 Aug 8;64(2):131-4.</reference_text><pubmed_id>115032</pubmed_id></reference><reference><reference_text>Kobayashi K, Koide Y, Yoshino K, Shohmori T: [P-hydroxyphenylacetic acid concentrations in cerebrospinal fluid]. No To Shinkei. 1982 Aug;34(8):769-74.</reference_text><pubmed_id>7126379</pubmed_id></reference><reference><reference_text>Alfredsson G, Wiesel FA: Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology (Berl). 1989;99(3):322-7.</reference_text><pubmed_id>2480613</pubmed_id></reference><reference><reference_text>Heresco-Levy U, Bar G, Levin R, Ermilov M, Ebstein RP, Javitt DC: High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. Schizophr Res. 2007 Mar;91(1-3):14-21. Epub 2007 Feb 2.</reference_text><pubmed_id>17276036</pubmed_id></reference><reference><reference_text>Walker EF, Bonsall R, Walder DJ: Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis. Neuropsychiatry Neuropsychol Behav Neurol. 2002 Mar;15(1):10-7.</reference_text><pubmed_id>11877547</pubmed_id></reference><reference><reference_text>Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M: Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry. 2003 Jun;60(6):572-6.</reference_text><pubmed_id>12796220</pubmed_id></reference><reference><reference_text>Do KQ, Lauer CJ, Schreiber W, Zollinger M, Gutteck-Amsler U, Cuenod M, Holsboer F: gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem. 1995 Dec;65(6):2652-62.</reference_text><pubmed_id>7595563</pubmed_id></reference><reference><reference_text>Nikisch G, Baumann P, Wiedemann G, Kiessling B, Weisser H, Hertel A, Yoshitake T, Kehr J, Mathe AA: Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF. J Clin Psychopharmacol. 2010 Oct;30(5):496-503. doi: 10.1097/JCP.0b013e3181f2288e.</reference_text><pubmed_id>20814316</pubmed_id></reference><reference><reference_text>Fukushima T, Iizuka H, Yokota A, Suzuki T, Ohno C, Kono Y, Nishikiori M, Seki A, Ichiba H, Watanabe Y, Hongo S, Utsunomiya M, Nakatani M, Sadamoto K, Yoshio T: Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One. 2014 Jul 8;9(7):e101652. doi: 10.1371/journal.pone.0101652. eCollection 2014.</reference_text><pubmed_id>25004141</pubmed_id></reference><reference><reference_text>Koike S, Bundo M, Iwamoto K, Suga M, Kuwabara H, Ohashi Y, Shinoda K, Takano Y, Iwashiro N, Satomura Y, Nagai T, Natsubori T, Tada M, Yamasue H, Kasai K: A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study. Transl Psychiatry. 2014 Apr 8;4:e379. doi: 10.1038/tp.2014.19.</reference_text><pubmed_id>24713860</pubmed_id></reference><reference><reference_text>Ballesteros A, Summerfelt A, Du X, Jiang P, Chiappelli J, Tagamets M, O'Donnell P, Kochunov P, Hong LE: Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia. Clin Neurophysiol. 2013 Nov;124(11):2209-15. doi: 10.1016/j.clinph.2013.05.021. Epub 2013 Jun 30.</reference_text><pubmed_id>23823132</pubmed_id></reference><reference><reference_text>Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel FA: Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry. 1985 Sep;147:276-82.</reference_text><pubmed_id>2415198</pubmed_id></reference><reference><reference_text>Pickar D, Breier A, Hsiao JK, Doran AR, Wolkowitz OM, Pato CN, Konicki PE, Potter WZ: Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Arch Gen Psychiatry. 1990 Jul;47(7):641-8.</reference_text><pubmed_id>1694425</pubmed_id></reference><reference><reference_text>Prell GD, Green JP, Kaufmann CA, Khandelwal JK, Morrishow AM, Kirch DG, Linnoila M, Wyatt RJ: Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res. 1995 Jan;14(2):93-104.</reference_text><pubmed_id>7711000</pubmed_id></reference><reference><reference_text>Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B: Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology. 2009;59(2):123-9. doi: 10.1159/000213565. Epub 2009 Apr 22.</reference_text><pubmed_id>19390223</pubmed_id></reference><reference><reference_text>Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K, Cao Y, Wang X, Qiu Y, Su M, Zhao A, Wang P, Yang P, Wu J, Feng G, He L, Jia W, Wan C: Potential metabolite markers of schizophrenia. Mol Psychiatry. 2013 Jan;18(1):67-78. doi: 10.1038/mp.2011.131. Epub 2011 Oct 25.</reference_text><pubmed_id>22024767</pubmed_id></reference><reference><reference_text>Xuan J, Pan G, Qiu Y, Yang L, Su M, Liu Y, Chen J, Feng G, Fang Y, Jia W, Xing Q, He L: Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. J Proteome Res. 2011 Dec 2;10(12):5433-43. doi: 10.1021/pr2006796. Epub 2011 Nov  8.</reference_text><pubmed_id>22007635</pubmed_id></reference><reference><reference_text>Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM, Rothermundt M, Bogerts B, Koethe D, Kranaster L, Ohrmann P, Suslow T, McAllister G, Spain M, Barnes A, van Beveren NJ, Baron-Cohen S, Steiner J, Torrey FE, Yolken RH, Bahn S: Identification of a biological signature for schizophrenia in serum. Mol Psychiatry. 2012 May;17(5):494-502. doi: 10.1038/mp.2011.42. Epub 2011 Apr 12.</reference_text><pubmed_id>21483431</pubmed_id></reference><reference><reference_text>Mathe AA, Eberhard G, Saaf J, Wetterberg L: Plasma prostaglandin E2 metabolite--measured as 11-deoxy-15-keto-13,14-dihydro-11 beta,16 xi-cyclo-PGE2--in twins with schizophrenic disorder. Biol Psychiatry. 1986 Sep;21(11):1024-30.</reference_text><pubmed_id>3741918</pubmed_id></reference><reference><reference_text>Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N: Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct. 2002 Jun;20(2):171-5.</reference_text><pubmed_id>11979513</pubmed_id></reference><reference><reference_text>Zumarraga M, Davila R, Basterreche N, Arrue A, Goienetxea B, Zamalloa MI, Erkoreka L, Bustamante S, Inchausti L, Gonzalez-Torres MA, Guimon J: Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients. Neurochem Int. 2010 May-Jun;56(6-7):774-9. doi: 10.1016/j.neuint.2010.02.015. Epub 2010 Mar 4.</reference_text><pubmed_id>20206656</pubmed_id></reference><reference><reference_text>Peters JG: Dopamine, noradrenaline and serotonin spinal fluid metabolites in temporal lobe epileptic patients with schizophrenic symptomatology. Eur Neurol. 1979;18(1):15-8.</reference_text><pubmed_id>436860</pubmed_id></reference><reference><reference_text>Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, Rozen S, Krishnan RR, McEvoy J, Kaddurah-Daouk R: Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry. 2010 Sep;15(9):938-53. doi: 10.1038/mp.2009.33. Epub 2009 Apr 28.</reference_text><pubmed_id>19401681</pubmed_id></reference><reference><reference_text>Gattaz WF, Waldmeier P, Beckmann H: CSF monoamine metabolites in schizophrenic patients. Acta Psychiatr Scand. 1982 Nov;66(5):350-60.</reference_text><pubmed_id>6184954</pubmed_id></reference><reference><reference_text>Nilsson-Todd LK, Nordin C, Jonsson EG, Skogh E, Erhardt S: Cerebrospinal fluid kynurenic acid in male patients with schizophrenia - correlation with monoamine metabolites. Acta Neuropsychiatr. 2007 Feb;19(1):45-52. doi: 10.1111/j.1601-5215.2006.00170.x.</reference_text><pubmed_id>26952797</pubmed_id></reference><reference><reference_text>Cai HL, Li HD, Yan XZ, Sun B, Zhang Q, Yan M, Zhang WY, Jiang P, Zhu RH, Liu YP, Fang PF, Xu P, Yuan HY, Zhang XH, Hu L, Yang W, Ye HS: Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naive schizophrenia patients after treatment with risperidone. J Proteome Res. 2012 Aug 3;11(8):4338-50. doi: 10.1021/pr300459d. Epub 2012 Jul 26.</reference_text><pubmed_id>22800120</pubmed_id></reference><reference><reference_text>Al Awam K, Haussleiter IS, Dudley E, Donev R, Brune M, Juckel G, Thome J: Multiplatform metabolome and proteome profiling identifies serum metabolite and protein signatures as prospective biomarkers for schizophrenia. J Neural Transm (Vienna). 2015 Aug;122 Suppl 1:S111-22. doi: 10.1007/s00702-014-1224-0. Epub 2014 May 1.</reference_text><pubmed_id>24789758</pubmed_id></reference><reference><reference_text>Bicikova M, Hill M, Ripova D, Mohr P, Hampl R: Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia. J Steroid Biochem Mol Biol. 2013 Jan;133:77-83. doi: 10.1016/j.jsbmb.2012.08.009. Epub 2012 Aug 24.</reference_text><pubmed_id>22944140</pubmed_id></reference><reference><reference_text>He Y, Yu Z, Giegling I, Xie L, Hartmann AM, Prehn C, Adamski J, Kahn R, Li Y, Illig T, Wang-Sattler R, Rujescu D: Schizophrenia shows a unique metabolomics signature in plasma. Transl Psychiatry. 2012 Aug 14;2:e149. doi: 10.1038/tp.2012.76.</reference_text><pubmed_id>22892715</pubmed_id></reference><reference><reference_text>Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KR: Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):934-45. Epub 2007 Apr 17.</reference_text><pubmed_id>17440431</pubmed_id></reference><reference><reference_text>Fryar-Williams S, Strobel JE: Biomarkers of a five-domain translational substrate for schizophrenia and schizoaffective psychosis. Biomark Res. 2015 Feb 6;3:3. doi: 10.1186/s40364-015-0028-1. eCollection 2015.</reference_text><pubmed_id>25729574</pubmed_id></reference><reference><reference_text>Oresic M, Seppanen-Laakso T, Sun D, Tang J, Therman S, Viehman R, Mustonen U, van Erp TG, Hyotylainen T, Thompson P, Toga AW, Huttunen MO, Suvisaari J, Kaprio J, Lonnqvist J, Cannon TD: Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia. Genome Med. 2012 Jan 18;4(1):1. doi: 10.1186/gm300.</reference_text><pubmed_id>22257447</pubmed_id></reference></references></disease><disease>Primary hypomagnesemia<references><reference><reference_text>Jin-no Y, Kamiya Y, Okada M, Hirako M, Takada N, Kawaguchi M: Primary hypomagnesemia caused by isolated magnesium malabsorption: atypical case in adult. Intern Med. 1999 Mar;38(3):261-5.</reference_text><pubmed_id>10337938</pubmed_id></reference><reference><reference_text>Vainsel M, Vandevelde G, Smulders J, Vosters M, Hubain P, Loeb H: Tetany due to hypomagnesaemia with secondary hypocalcaemia. Arch Dis Child. 1970 Apr;45(240):254-8.</reference_text><pubmed_id>5419995</pubmed_id></reference><reference><reference_text>Shalev H, Phillip M, Galil A, Carmi R, Landau D: Clinical presentation and outcome in primary familial hypomagnesaemia. Arch Dis Child. 1998 Feb;78(2):127-30.</reference_text><pubmed_id>9579153</pubmed_id></reference><reference><reference_text>Kari JA, Farouq M, Alshaya HO: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Pediatr Nephrol. 2003 Jun;18(6):506-10. Epub 2003 Apr 29.</reference_text><pubmed_id>12720080</pubmed_id></reference></references></disease><disease>Hyperlipoproteinemia<references><reference><reference_text>Sinha S, Misra A, Kumar V, Jagannathan NR, Bal CS, Pandey RM, Singhania R, Deepak: Proton magnetic resonance spectroscopy and single photon emission computed tomography study of the brain in asymptomatic young hyperlipidaemic Asian Indians in North India show early abnormalities. Clin Endocrinol (Oxf). 2004 Aug;61(2):182-9.</reference_text><pubmed_id>15272912</pubmed_id></reference><reference><reference_text>Nelson RH: Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013 Mar</reference_text><pubmed_id>40(1):195-211. doi: 10.1016/j.pop.2012.11.003. Epub 2012 Dec  4.</pubmed_id></reference><reference><reference_text>Cantin B, Boudriau S, Bertrand M, Brun LD, Gagne C, Rogers PA, Ven Murthy MR, Lupien PJ, Julien P: Hemolysis in primary lipoprotein lipase deficiency. Metabolism. 1995 May;44(5):652-8.</reference_text><pubmed_id>7752915</pubmed_id></reference></references></disease><disease>Abetalipoproteinemia<references><reference><reference_text>Dawson G, Kruski AW, Scanu AM: Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J Lipid Res. 1976 Mar;17(2):125-31.</reference_text><pubmed_id>178813</pubmed_id></reference><reference><reference_text>Lazaro RP, Dentinger MP, Rodichok LD, Barron KD, Satya-Murti S: Muscle pathology in Bassen-Kornzweig syndrome and vitamin E deficiency. Am J Clin Pathol. 1986 Sep;86(3):378-87.</reference_text><pubmed_id>2944375</pubmed_id></reference></references></disease><disease>Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis<references><reference><reference_text>Breckenridge WC, Alaupovic P, Cox DW, Little JA: Apolipoprotein and lipoprotein concentrations in familial apolipoprotein C-II deficiency. Atherosclerosis. 1982 Aug;44(2):223-35.</reference_text><pubmed_id>7138621</pubmed_id></reference><reference><reference_text>Fukami M, Hasegawa T, Horikawa R, Ohashi T, Nishimura G, Homma K, Ogata T: Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr Res. 2006 Feb;59(2):276-80. doi: 10.1203/01.pdr.0000195825.31504.28.</reference_text><pubmed_id>16439592</pubmed_id></reference></references></disease><disease>Cerebrotendinous xanthomatosis<references><reference><reference_text>Halperin G, Elisaf M, Leitersdorf E, Harats D: A new method for determination of serum cholestanol by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2000 Jun 9;742(2):345-52.</reference_text><pubmed_id>10901139</pubmed_id></reference><reference><reference_text>Siman-Tov T, Meiner V, Gadoth N: Could steroids mask the diagnosis of cerebrotendinous xanthomatosis? J Neurol Sci. 2006 Apr 15;243(1-2):83-6. Epub 2006 Jan 30.</reference_text><pubmed_id>16445943</pubmed_id></reference><reference><reference_text>Agrawal NK, Garg S: Cerebrotendinous xanthomatosis: a rare disorder with a rare presentation. BMJ Case Rep. 2012 Sep 21;2012. pii: bcr-2012-006202. doi: 10.1136/bcr-2012-006202.</reference_text><pubmed_id>23001091</pubmed_id></reference></references></disease><disease>3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency<references><reference><reference_text>Thompson GN, Hsu BY, Pitt JJ, Treacy E, Stanley CA: Fasting hypoketotic coma in a child with deficiency of mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase. N Engl J Med. 1997 Oct 23;337(17):1203-7. doi: 10.1056/NEJM199710233371704.</reference_text><pubmed_id>9337379</pubmed_id></reference><reference><reference_text>Morris AA, Lascelles CV, Olpin SE, Lake BD, Leonard JV, Quant PA: Hepatic mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme a synthase deficiency. Pediatr Res. 1998 Sep;44(3):392-6. doi: 10.1203/00006450-199809000-00021.</reference_text><pubmed_id>9727719</pubmed_id></reference><reference><reference_text>Conboy E, Vairo F, Schultz M, Agre K, Ridsdale R, Deyle D, Oglesbee D, Gavrilov D, Klee EW, Lanpher B: Mitochondrial 3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency: Unique Presenting Laboratory Values and a Review of Biochemical and Clinical Features. JIMD Rep. 2017 Oct 14. doi: 10.1007/8904_2017_59.</reference_text><pubmed_id>29030856</pubmed_id></reference></references></disease><disease>Hypercholesterolemia, familial<references><reference><reference_text>Kwiterovich PO Jr, Fredrickson DS, Levy RI: Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest. 1974 May;53(5):1237-49. doi: 10.1172/JCI107670.</reference_text><pubmed_id>4363406</pubmed_id></reference></references></disease><disease>SC4MOL deficiency<references><reference><reference_text>He M, Kratz LE, Michel JJ, Vallejo AN, Ferris L, Kelley RI, Hoover JJ, Jukic D, Gibson KM, Wolfe LA, Ramachandran D, Zwick ME, Vockley J: Mutations in the human SC4MOL gene encoding a methyl sterol oxidase cause psoriasiform dermatitis, microcephaly, and developmental delay. J Clin Invest. 2011 Mar;121(3):976-84. doi: 10.1172/JCI42650.</reference_text><pubmed_id>21285510</pubmed_id></reference></references></disease><disease>Chondrodysplasia punctata, X-linked dominant<references><reference><reference_text>Aughton DJ, Kelley RI, Metzenberg A, Pureza V, Pauli RM: X-linked dominant chondrodysplasia punctata (CDPX2) caused by single gene mosaicism in a male. Am J Med Genet A. 2003 Jan 30;116A(3):255-60. doi: 10.1002/ajmg.a.10852.</reference_text><pubmed_id>12503102</pubmed_id></reference></references></disease><disease>Desmosterolosis<references><reference><reference_text>Andersson HC, Kratz L, Kelley R: Desmosterolosis presenting with multiple congenital anomalies and profound developmental delay. Am J Med Genet. 2002 Dec 15;113(4):315-9. doi: 10.1002/ajmg.b.10873.</reference_text><pubmed_id>12457401</pubmed_id></reference></references></disease><disease>Donohue Syndrome<references><reference><reference_text>Nijim Y, Awni Y, Adawi A, Bowirrat A: Classic Case Report of Donohue Syndrome (Leprechaunism; OMIM *246200): The Impact of Consanguineous Mating. Medicine (Baltimore). 2016 Feb;95(6):e2710. doi: 10.1097/MD.0000000000002710.</reference_text><pubmed_id>26871809</pubmed_id></reference></references></disease><disease>Leptin Deficiency or Dysfunction<references><reference><reference_text>Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O'Rahilly S: Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999 Sep 16;341(12):879-84. doi: 10.1056/NEJM199909163411204.</reference_text><pubmed_id>10486419</pubmed_id></reference></references></disease><disease>Duchenne Muscular Dystrophy<references><reference><reference_text>Nakagawa T, Takeuchi A, Kakiuchi R, Lee T, Yagi M, Awano H, Iijima K, Takeshima Y, Urade Y, Matsuo M: A prostaglandin D2 metabolite is elevated in the urine of Duchenne muscular dystrophy patients and increases further from 8 years old. Clin Chim Acta. 2013 Aug 23;423:10-4. doi: 10.1016/j.cca.2013.03.031. Epub 2013 Apr 19.</reference_text><pubmed_id>23603101</pubmed_id></reference><reference><reference_text>Srivastava NK, Pradhan S, Mittal B, Gowda GA: High resolution NMR based analysis of serum lipids in Duchenne muscular dystrophy patients and its possible diagnostic significance. NMR Biomed. 2010 Jan;23(1):13-22. doi: 10.1002/nbm.1419.</reference_text><pubmed_id>19787747</pubmed_id></reference><reference><reference_text>Horster I, Weigt-Usinger K, Carmann C, Chobanyan-Jurgens K, Kohler C, Schara U, Kayacelebi AA, Beckmann B, Tsikas D, Lucke T: The L-arginine/NO pathway and homoarginine are altered in Duchenne muscular dystrophy and improved by glucocorticoids. Amino Acids. 2015 Sep;47(9):1853-63. doi: 10.1007/s00726-015-2018-x. Epub 2015 Jun 12.</reference_text><pubmed_id>26066683</pubmed_id></reference></references></disease><disease>Lecithin:cholesterol Acyltransferase Deficiency<references><reference><reference_text>Idzior-Walus B, Sieradzki J, Kostner G, Malecki MT, Klupa T, Wesolowska T, Rostworowski W, Hartwich J, Walus M, Kiec AD, Naruszewicz M: Familial lecithin-cholesterol acyltransferase deficiency: biochemical characteristics and molecular analysis of a new LCAT mutation in a Polish family. Atherosclerosis. 2006 Apr;185(2):413-20. Epub 2005 Jul 26.</reference_text><pubmed_id>16051254</pubmed_id></reference></references></disease><disease>Lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lipodystrophy, Congenital Generalized<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Oculocerebrorenal syndrome<references><reference><reference_text>Charnas LR, Bernardini I, Rader D, Hoeg JM, Gahl WA: Clinical and laboratory findings in the oculocerebrorenal syndrome of Lowe, with special reference to growth and renal function. N Engl J Med. 1991 May 9;324(19):1318-25. doi: 10.1056/NEJM199105093241904.</reference_text><pubmed_id>2017228</pubmed_id></reference></references></disease><disease>Familial partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lathosterolosis<references><reference><reference_text>Brunetti-Pierri N, Corso G, Rossi M, Ferrari P, Balli F, Rivasi F, Annunziata I, Ballabio A, Russo AD, Andria G, Parenti G: Lathosterolosis, a novel multiple-malformation/mental retardation syndrome due to deficiency of 3beta-hydroxysteroid-delta5-desaturase. Am J Hum Genet. 2002 Oct;71(4):952-8. Epub 2002 Aug 20.</reference_text><pubmed_id>12189593</pubmed_id></reference><reference><reference_text>Ho AC, Fung CW, Siu TS, Ma OC, Lam CW, Tam S, Wong VC: Lathosterolosis: a disorder of cholesterol biosynthesis resembling smith-lemli-opitz syndrome. JIMD Rep. 2014;12:129-34. doi: 10.1007/8904_2013_255. Epub 2013 Oct 20.</reference_text><pubmed_id>24142275</pubmed_id></reference></references></disease><disease>Partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Multiple sclerosis<references><reference><reference_text>Lutz NW, Viola A, Malikova I, Confort-Gouny S, Audoin B, Ranjeva JP, Pelletier J, Cozzone PJ: Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One. 2007 Jul 4;2(7):e595.</reference_text><pubmed_id>17611627</pubmed_id></reference><reference><reference_text>Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U, Hillert J, Bjorkhem I: Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med. 2004 Feb;42(2):186-91.</reference_text><pubmed_id>15061359</pubmed_id></reference><reference><reference_text>Leoni V, Lutjohann D, Masterman T: Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis. J Lipid Res. 2005 Feb;46(2):191-5. Epub 2004 Dec 1.</reference_text><pubmed_id>15576852</pubmed_id></reference><reference><reference_text>Calabrese V, Scapagnini G, Ravagna A, Bella R, Butterfield DA, Calvani M, Pennisi G, Giuffrida Stella AM: Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem Res. 2003 Sep;28(9):1321-8.</reference_text><pubmed_id>12938853</pubmed_id></reference><reference><reference_text>Shaw CE, Dunbar PR, Macaulay HA, Neale TJ: Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol. 1995 Jan;242(2):53-8.</reference_text><pubmed_id>7707089</pubmed_id></reference><reference><reference_text>Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.</reference_text><pubmed_id>17384003</pubmed_id></reference><reference><reference_text>Syburra C, Passi S: Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh (1999). 1999 May-Jun;71(3):112-5.</reference_text><pubmed_id>10609336</pubmed_id></reference><reference><reference_text>Forte G, Visconti A, Santucci S, Ghazaryan A, Figa-Talamanca L, Cannoni S, Bocca B, Pino A, Violante N, Alimonti A, Salvetti M, Ristori G: Quantification of chemical elements in blood of patients affected by multiple sclerosis. Ann Ist Super Sanita. 2005;41(2):213-6.</reference_text><pubmed_id>16244395</pubmed_id></reference><reference><reference_text>Toncev G, Milicic B, Toncev S, Samardzic G: Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol. 2002 May;9(3):221-6.</reference_text><pubmed_id>11985629</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, Bamonti F, Capello E, Mancardi GL, Scarpini E: Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res. 2010 May 28;1333:64-71. doi: 10.1016/j.brainres.2010.03.073. Epub 2010 Mar 27.</reference_text><pubmed_id>20347721</pubmed_id></reference><reference><reference_text>Matsushita T, Isobe N, Kawajiri M, Mogi M, Tsukuda K, Horiuchi M, Ohyagi Y, Kira J: CSF angiotensin II and angiotensin-converting enzyme levels in anti-aquaporin-4 autoimmunity. J Neurol Sci. 2010 Aug 15;295(1-2):41-5. doi: 10.1016/j.jns.2010.05.014. Epub 2010 Jun 11.</reference_text><pubmed_id>20541774</pubmed_id></reference><reference><reference_text>Ghabaee M, Jabedari B, Al-E-Eshagh N, Ghaffarpour M, Asadi F: Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients. Int J Neurosci. 2010 Apr;120(4):301-4. doi: 10.3109/00207451003695690.</reference_text><pubmed_id>20374079</pubmed_id></reference><reference><reference_text>Kawajiri M, Mogi M, Osoegawa M, Matsuoka T, Tsukuda K, Kohara K, Horiuchi M, Miki T, Kira JI: Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler. 2008 May;14(4):557-60. doi: 10.1177/1352458507085760.</reference_text><pubmed_id>18562510</pubmed_id></reference><reference><reference_text>Visconti A, Cotichini R, Cannoni S, Bocca B, Forte G, Ghazaryan A, Santucci S, D'Ippolito C, Stazi MA, Salvetti M, Alimonti A, Ristori G: Concentration of elements in serum of patients affected by multiple sclerosis with first demyelinating episode: a six-month longitudinal follow-up study. Ann Ist Super Sanita. 2005;41(2):217-22.</reference_text><pubmed_id>16244396</pubmed_id></reference></references></disease><disease>Inflammatory bowel disease<references><reference><reference_text>Lee T, Clavel T, Smirnov K, Schmidt A, Lagkouvardos I, Walker A, Lucio M, Michalke B, Schmitt-Kopplin P, Fedorak R, Haller D: Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. 2017 May;66(5):863-871. doi: 10.1136/gutjnl-2015-309940. Epub 2016 Feb 4.</reference_text><pubmed_id>26848182</pubmed_id></reference><reference><reference_text>Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158.</reference_text><pubmed_id>27609529</pubmed_id></reference></references></disease><disease>Colorectal cancer<references><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B: Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009 Apr;22(3):342-8. doi: 10.1002/nbm.1345.</reference_text><pubmed_id>19006102</pubmed_id></reference><reference><reference_text>Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP: Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One. 2013 Aug 6;8(8):e70803. doi: 10.1371/journal.pone.0070803. Print 2013.</reference_text><pubmed_id>23940645</pubmed_id></reference><reference><reference_text>Phua LC, Chue XP, Koh PK, Cheah PY, Ho HK, Chan EC: Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biol Ther. 2014 Apr;15(4):389-97. doi: 10.4161/cbt.27625. Epub 2014 Jan 14.</reference_text><pubmed_id>24424155</pubmed_id></reference><reference><reference_text>Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB: Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010 Feb 15;8:13. doi: 10.1186/1741-7015-8-13.</reference_text><pubmed_id>20156336</pubmed_id></reference><reference><reference_text>Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, Ni Y, Zhao A, Xu LX, Cai S, Jia W: Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res. 2009 Oct;8(10):4844-50. doi: 10.1021/pr9004162.</reference_text><pubmed_id>19678709</pubmed_id></reference><reference><reference_text>Cheng Y, Xie G, Chen T, Qiu Y, Zou X, Zheng M, Tan B, Feng B, Dong T, He P, Zhao L, Zhao A, Xu LX, Zhang Y, Jia W: Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res. 2012 Feb 3;11(2):1354-63. doi: 10.1021/pr201001a. Epub 2011 Dec 28.</reference_text><pubmed_id>22148915</pubmed_id></reference><reference><reference_text>Ni Y, Xie G, Jia W: Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res. 2014 Sep 5;13(9):3857-70. doi: 10.1021/pr500443c. Epub 2014 Aug 14.</reference_text><pubmed_id>25105552</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference><reference><reference_text>Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18.</reference_text><pubmed_id>25037050</pubmed_id></reference><reference><reference_text>Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016.</reference_text><pubmed_id>27015276</pubmed_id></reference><reference><reference_text>Lin Y, Ma C, Liu C, Wang Z, Yang J, Liu X, Shen Z, Wu R: NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer. Oncotarget. 2016 May 17;7(20):29454-64. doi: 10.18632/oncotarget.8762.</reference_text><pubmed_id>27107423</pubmed_id></reference><reference><reference_text>Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016.</reference_text><pubmed_id>27275383</pubmed_id></reference><reference><reference_text>Wang X, Wang J, Rao B, Deng L: Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals. Exp Ther Med. 2017 Jun;13(6):2848-2854. doi: 10.3892/etm.2017.4367. Epub 2017 Apr 20.</reference_text><pubmed_id>28587349</pubmed_id></reference><reference><reference_text>Silke Matysik, Caroline Ivanne Le Roy, Gerhard Liebisch, Sandrine Paule Claus. Metabolomics of fecal samples: A practical consideration. Trends in Food Science &amp; Technology. Vol. 57, Part B, Nov. 2016, p.244-255: http://www.sciencedirect.com/science/article/pii/S0924224416301984</reference_text><pubmed_id>28587349</pubmed_id></reference></references></disease><disease>Gallbladder disease<references><reference><reference_text>Lapidus A, Akerlund JE, Einarsson C: Gallbladder bile composition in patients with Crohn 's disease. World J Gastroenterol. 2006 Jan 7;12(1):70-4.</reference_text><pubmed_id>16440420</pubmed_id></reference><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference><reference><reference_text>Mizuno S, Tazuma S, Kajiyama G: Stabilization of biliary lipid particles by ursodeoxycholic acid. Prolonged nucleation time in human gallbladder bile. Dig Dis Sci. 1993 Apr;38(4):684-93.</reference_text><pubmed_id>8462368</pubmed_id></reference><reference><reference_text>Hillebrant CG, Axelson M, Bjorkhem I, Wang FH, Nyberg B, Einarsson C: Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients. Eur J Clin Invest. 1998 Apr;28(4):324-8.</reference_text><pubmed_id>9615912</pubmed_id></reference></references></disease><disease>Cholelithiasis<references><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference></references></disease><disease>Stomach cancer<references><reference><reference_text>Higashijima H, Ichimiya H, Nakano T, Yamashita H, Kuroki S, Satoh H, Chijiiwa K, Tanaka M: Deconjugation of bilirubin accelerates coprecipitation of cholesterol, fatty acids, and mucin in human bile--in vitro study. J Gastroenterol. 1996 Dec;31(6):828-35.</reference_text><pubmed_id>9027647</pubmed_id></reference><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Song H, Peng JS, Dong-Sheng Y, Yang ZL, Liu HL, Zeng YK, Shi XP, Lu BY: Serum metabolic profiling of human gastric cancer based on gas chromatography/mass spectrometry. Braz J Med Biol Res. 2012 Jan;45(1):78-85. Epub 2011 Nov 25.</reference_text><pubmed_id>22124703</pubmed_id></reference><reference><reference_text>Yu L, Aa J, Xu J, Sun M, Qian S, Cheng L, Yang S, Shi R: Metabolomic phenotype of gastric cancer and precancerous stages based on gas chromatography time-of-flight mass spectrometry. J Gastroenterol Hepatol. 2011 Aug;26(8):1290-7. doi: 10.1111/j.1440-1746.2011.06724.x.</reference_text><pubmed_id>21443661</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference></references></disease><disease>Acute myelogenous leukemia<references><reference><reference_text>Tatidis L, Vitols S, Gruber A, Paul C, Axelson M: Cholesterol catabolism in patients with acute myelogenous leukemia and hypocholesterolemia: suppressed levels of a circulating marker for bile acid synthesis. Cancer Lett. 2001 Sep 20;170(2):169-75.</reference_text><pubmed_id>11463495</pubmed_id></reference></references></disease><disease>Hypercholesterolemia<references><reference><reference_text>Thelen KM, Laaksonen R, Paiva H, Lehtimaki T, Lutjohann D: High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels. J Clin Pharmacol. 2006 Jul;46(7):812-6.</reference_text><pubmed_id>16809807</pubmed_id></reference><reference><reference_text>Tamasawa N, Tamasawa A, Takebe K: Higher levels of plasma cholesterol sulfate in patients with liver cirrhosis and hypercholesterolemia. Lipids. 1993 Sep;28(9):833-6.</reference_text><pubmed_id>8231659</pubmed_id></reference><reference><reference_text>Kim DH, Lee KJ, Heo GS: Analysis of cholesterol and cholesteryl esters in human serum using capillary supercritical fluid chromatography. J Chromatogr B Biomed Appl. 1994 Apr 22;655(1):1-8.</reference_text><pubmed_id>8061816</pubmed_id></reference><reference><reference_text>Authors unspecified: Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med. 1988 Jan;148(1):36-69.</reference_text><pubmed_id>3422148</pubmed_id></reference></references></disease><disease>Cholesteryl ester storage disease<references><reference><reference_text>Rassoul F, Richter V, Lohse P, Naumann A, Purschwitz K, Keller E: Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease. Int J Clin Pharmacol Ther. 2001 May;39(5):199-204.</reference_text><pubmed_id>11380065</pubmed_id></reference><reference><reference_text>Chatrath H, Keilin S, Attar BM: Cholesterol ester storage disease (CESD) diagnosed in an asymptomatic adult. Dig Dis Sci. 2009 Jan;54(1):168-73. doi: 10.1007/s10620-008-0310-2. Epub 2008 May 14.</reference_text><pubmed_id>18478331</pubmed_id></reference><reference><reference_text>Bernstein DL, Hulkova H, Bialer MG, Desnick RJ: Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol. 2013 Jun;58(6):1230-43. doi: 10.1016/j.jhep.2013.02.014. Epub 2013 Feb 26.</reference_text><pubmed_id>23485521</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Cystinosis<references><reference><reference_text>Ueda M, O'Brien K, Rosing DR, Ling A, Kleta R, McAreavey D, Bernardini I, Gahl WA: Coronary artery and other vascular calcifications in patients with cystinosis after kidney transplantation. Clin J Am Soc Nephrol. 2006 May;1(3):555-62. Epub 2006 Feb 8.</reference_text><pubmed_id>17699259</pubmed_id></reference><reference><reference_text>Gahl WA, Bernardini I, Dalakas M, Rizzo WB, Harper GS, Hoeg JM, Hurko O, Bernar J: Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome. J Clin Invest. 1988 Feb;81(2):549-60.</reference_text><pubmed_id>3276734</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Smith-Lemli-Opitz syndrome<references><reference><reference_text>van Rooij A, Nijenhuis AA, Wijburg FA, Schutgens RB: Highly increased CSF concentrations of cholesterol precursors in Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 1997 Aug;20(4):578-80.</reference_text><pubmed_id>9266395</pubmed_id></reference><reference><reference_text>Honda M, Tint GS, Honda A, Salen G, Shefer S, Batta AK, Matsuzaki Y, Tanaka N: Regulation of cholesterol biosynthetic pathway in patients with the Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2000 Jul;23(5):464-74.</reference_text><pubmed_id>10947201</pubmed_id></reference><reference><reference_text>Rossi M, Federico G, Corso G, Parenti G, Battagliese A, Frascogna AR, Della Casa R, Dello Russo A, Strisciuglio P, Saggese G, Andria G: Vitamin D status in patients affected by Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2005;28(1):69-80.</reference_text><pubmed_id>15702407</pubmed_id></reference><reference><reference_text>Johnson DW, ten Brink HJ, Jakobs C: A rapid screening procedure for cholesterol and dehydrocholesterol by electrospray ionization tandem mass spectrometry. J Lipid Res. 2001 Oct;42(10):1699-705.</reference_text><pubmed_id>11590227</pubmed_id></reference></references></disease><disease>Prostate cancer<references><reference><reference_text>Nyman DW, Suzanne Stratton M, Kopplin MJ, Dalkin BL, Nagle RB, Jay Gandolfi A: Selenium and selenomethionine levels in prostate cancer patients. Cancer Detect Prev. 2004;28(1):8-16.</reference_text><pubmed_id>15041072</pubmed_id></reference><reference><reference_text>Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, Egevad L, Tjonneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, Palli D, Vineis P, Tumino R, Berrino F, Kiemeney L, Bueno-de-Mesquita HB, Quiros JR, Gonzalez CA, Martinez C, Larranaga N, Chirlaque MD, Ardanaz E, Stattin P, Hallmans G, Khaw KT, Bingham S, Slimani N, Ferrari P, Rinaldi S, Riboli E: Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr. 2007 Sep;86(3):672-81.</reference_text><pubmed_id>17823432</pubmed_id></reference><reference><reference_text>Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762.</reference_text><pubmed_id>19212411</pubmed_id></reference><reference><reference_text>Puah CM, Williams G, Ghanadian R: Urinary unconjugated 5 alpha-androstane-3 alpha, 17 beta-diol in patients with prostatic tumours. Urol Res. 1982;10(2):81-4.</reference_text><pubmed_id>6180540</pubmed_id></reference><reference><reference_text>Thysell E, Surowiec I, Hornberg E, Crnalic S, Widmark A, Johansson AI, Stattin P, Bergh A, Moritz T, Antti H, Wikstrom P: Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One. 2010 Dec 3;5(12):e14175. doi: 10.1371/journal.pone.0014175.</reference_text><pubmed_id>21151972</pubmed_id></reference><reference><reference_text>Soliman LC, Hui Y, Hewavitharana AK, Chen DD: Monitoring potential prostate cancer biomarkers in urine by capillary electrophoresis-tandem mass spectrometry. J Chromatogr A. 2012 Dec 7;1267:162-9. doi: 10.1016/j.chroma.2012.07.021. Epub 2012 Jul 14.</reference_text><pubmed_id>22824219</pubmed_id></reference><reference><reference_text>Madu CO, Lu Y: Novel diagnostic biomarkers for prostate cancer. J Cancer. 2010 Oct 6;1:150-77.</reference_text><pubmed_id>20975847</pubmed_id></reference></references></disease><disease>Schizophrenia<references><reference><reference_text>Harnryd C, Bjerkenstedt L, Grimm VE, Sedvall G: Reduction of MOPEG levels in cerebrospinal fluid of psychotic women after electroconvulsive treatment. Psychopharmacology (Berl). 1979 Aug 8;64(2):131-4.</reference_text><pubmed_id>115032</pubmed_id></reference><reference><reference_text>Kobayashi K, Koide Y, Yoshino K, Shohmori T: [P-hydroxyphenylacetic acid concentrations in cerebrospinal fluid]. No To Shinkei. 1982 Aug;34(8):769-74.</reference_text><pubmed_id>7126379</pubmed_id></reference><reference><reference_text>Alfredsson G, Wiesel FA: Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology (Berl). 1989;99(3):322-7.</reference_text><pubmed_id>2480613</pubmed_id></reference><reference><reference_text>Heresco-Levy U, Bar G, Levin R, Ermilov M, Ebstein RP, Javitt DC: High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. Schizophr Res. 2007 Mar;91(1-3):14-21. Epub 2007 Feb 2.</reference_text><pubmed_id>17276036</pubmed_id></reference><reference><reference_text>Walker EF, Bonsall R, Walder DJ: Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis. Neuropsychiatry Neuropsychol Behav Neurol. 2002 Mar;15(1):10-7.</reference_text><pubmed_id>11877547</pubmed_id></reference><reference><reference_text>Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M: Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry. 2003 Jun;60(6):572-6.</reference_text><pubmed_id>12796220</pubmed_id></reference><reference><reference_text>Do KQ, Lauer CJ, Schreiber W, Zollinger M, Gutteck-Amsler U, Cuenod M, Holsboer F: gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem. 1995 Dec;65(6):2652-62.</reference_text><pubmed_id>7595563</pubmed_id></reference><reference><reference_text>Nikisch G, Baumann P, Wiedemann G, Kiessling B, Weisser H, Hertel A, Yoshitake T, Kehr J, Mathe AA: Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF. J Clin Psychopharmacol. 2010 Oct;30(5):496-503. doi: 10.1097/JCP.0b013e3181f2288e.</reference_text><pubmed_id>20814316</pubmed_id></reference><reference><reference_text>Fukushima T, Iizuka H, Yokota A, Suzuki T, Ohno C, Kono Y, Nishikiori M, Seki A, Ichiba H, Watanabe Y, Hongo S, Utsunomiya M, Nakatani M, Sadamoto K, Yoshio T: Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One. 2014 Jul 8;9(7):e101652. doi: 10.1371/journal.pone.0101652. eCollection 2014.</reference_text><pubmed_id>25004141</pubmed_id></reference><reference><reference_text>Koike S, Bundo M, Iwamoto K, Suga M, Kuwabara H, Ohashi Y, Shinoda K, Takano Y, Iwashiro N, Satomura Y, Nagai T, Natsubori T, Tada M, Yamasue H, Kasai K: A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study. Transl Psychiatry. 2014 Apr 8;4:e379. doi: 10.1038/tp.2014.19.</reference_text><pubmed_id>24713860</pubmed_id></reference><reference><reference_text>Ballesteros A, Summerfelt A, Du X, Jiang P, Chiappelli J, Tagamets M, O'Donnell P, Kochunov P, Hong LE: Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia. Clin Neurophysiol. 2013 Nov;124(11):2209-15. doi: 10.1016/j.clinph.2013.05.021. Epub 2013 Jun 30.</reference_text><pubmed_id>23823132</pubmed_id></reference><reference><reference_text>Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel FA: Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry. 1985 Sep;147:276-82.</reference_text><pubmed_id>2415198</pubmed_id></reference><reference><reference_text>Pickar D, Breier A, Hsiao JK, Doran AR, Wolkowitz OM, Pato CN, Konicki PE, Potter WZ: Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Arch Gen Psychiatry. 1990 Jul;47(7):641-8.</reference_text><pubmed_id>1694425</pubmed_id></reference><reference><reference_text>Prell GD, Green JP, Kaufmann CA, Khandelwal JK, Morrishow AM, Kirch DG, Linnoila M, Wyatt RJ: Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res. 1995 Jan;14(2):93-104.</reference_text><pubmed_id>7711000</pubmed_id></reference><reference><reference_text>Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B: Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology. 2009;59(2):123-9. doi: 10.1159/000213565. Epub 2009 Apr 22.</reference_text><pubmed_id>19390223</pubmed_id></reference><reference><reference_text>Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K, Cao Y, Wang X, Qiu Y, Su M, Zhao A, Wang P, Yang P, Wu J, Feng G, He L, Jia W, Wan C: Potential metabolite markers of schizophrenia. Mol Psychiatry. 2013 Jan;18(1):67-78. doi: 10.1038/mp.2011.131. Epub 2011 Oct 25.</reference_text><pubmed_id>22024767</pubmed_id></reference><reference><reference_text>Xuan J, Pan G, Qiu Y, Yang L, Su M, Liu Y, Chen J, Feng G, Fang Y, Jia W, Xing Q, He L: Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. J Proteome Res. 2011 Dec 2;10(12):5433-43. doi: 10.1021/pr2006796. Epub 2011 Nov  8.</reference_text><pubmed_id>22007635</pubmed_id></reference><reference><reference_text>Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM, Rothermundt M, Bogerts B, Koethe D, Kranaster L, Ohrmann P, Suslow T, McAllister G, Spain M, Barnes A, van Beveren NJ, Baron-Cohen S, Steiner J, Torrey FE, Yolken RH, Bahn S: Identification of a biological signature for schizophrenia in serum. Mol Psychiatry. 2012 May;17(5):494-502. doi: 10.1038/mp.2011.42. Epub 2011 Apr 12.</reference_text><pubmed_id>21483431</pubmed_id></reference><reference><reference_text>Mathe AA, Eberhard G, Saaf J, Wetterberg L: Plasma prostaglandin E2 metabolite--measured as 11-deoxy-15-keto-13,14-dihydro-11 beta,16 xi-cyclo-PGE2--in twins with schizophrenic disorder. Biol Psychiatry. 1986 Sep;21(11):1024-30.</reference_text><pubmed_id>3741918</pubmed_id></reference><reference><reference_text>Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N: Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct. 2002 Jun;20(2):171-5.</reference_text><pubmed_id>11979513</pubmed_id></reference><reference><reference_text>Zumarraga M, Davila R, Basterreche N, Arrue A, Goienetxea B, Zamalloa MI, Erkoreka L, Bustamante S, Inchausti L, Gonzalez-Torres MA, Guimon J: Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients. Neurochem Int. 2010 May-Jun;56(6-7):774-9. doi: 10.1016/j.neuint.2010.02.015. Epub 2010 Mar 4.</reference_text><pubmed_id>20206656</pubmed_id></reference><reference><reference_text>Peters JG: Dopamine, noradrenaline and serotonin spinal fluid metabolites in temporal lobe epileptic patients with schizophrenic symptomatology. Eur Neurol. 1979;18(1):15-8.</reference_text><pubmed_id>436860</pubmed_id></reference><reference><reference_text>Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, Rozen S, Krishnan RR, McEvoy J, Kaddurah-Daouk R: Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry. 2010 Sep;15(9):938-53. doi: 10.1038/mp.2009.33. Epub 2009 Apr 28.</reference_text><pubmed_id>19401681</pubmed_id></reference><reference><reference_text>Gattaz WF, Waldmeier P, Beckmann H: CSF monoamine metabolites in schizophrenic patients. Acta Psychiatr Scand. 1982 Nov;66(5):350-60.</reference_text><pubmed_id>6184954</pubmed_id></reference><reference><reference_text>Nilsson-Todd LK, Nordin C, Jonsson EG, Skogh E, Erhardt S: Cerebrospinal fluid kynurenic acid in male patients with schizophrenia - correlation with monoamine metabolites. Acta Neuropsychiatr. 2007 Feb;19(1):45-52. doi: 10.1111/j.1601-5215.2006.00170.x.</reference_text><pubmed_id>26952797</pubmed_id></reference><reference><reference_text>Cai HL, Li HD, Yan XZ, Sun B, Zhang Q, Yan M, Zhang WY, Jiang P, Zhu RH, Liu YP, Fang PF, Xu P, Yuan HY, Zhang XH, Hu L, Yang W, Ye HS: Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naive schizophrenia patients after treatment with risperidone. J Proteome Res. 2012 Aug 3;11(8):4338-50. doi: 10.1021/pr300459d. Epub 2012 Jul 26.</reference_text><pubmed_id>22800120</pubmed_id></reference><reference><reference_text>Al Awam K, Haussleiter IS, Dudley E, Donev R, Brune M, Juckel G, Thome J: Multiplatform metabolome and proteome profiling identifies serum metabolite and protein signatures as prospective biomarkers for schizophrenia. J Neural Transm (Vienna). 2015 Aug;122 Suppl 1:S111-22. doi: 10.1007/s00702-014-1224-0. Epub 2014 May 1.</reference_text><pubmed_id>24789758</pubmed_id></reference><reference><reference_text>Bicikova M, Hill M, Ripova D, Mohr P, Hampl R: Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia. J Steroid Biochem Mol Biol. 2013 Jan;133:77-83. doi: 10.1016/j.jsbmb.2012.08.009. Epub 2012 Aug 24.</reference_text><pubmed_id>22944140</pubmed_id></reference><reference><reference_text>He Y, Yu Z, Giegling I, Xie L, Hartmann AM, Prehn C, Adamski J, Kahn R, Li Y, Illig T, Wang-Sattler R, Rujescu D: Schizophrenia shows a unique metabolomics signature in plasma. Transl Psychiatry. 2012 Aug 14;2:e149. doi: 10.1038/tp.2012.76.</reference_text><pubmed_id>22892715</pubmed_id></reference><reference><reference_text>Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KR: Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):934-45. Epub 2007 Apr 17.</reference_text><pubmed_id>17440431</pubmed_id></reference><reference><reference_text>Fryar-Williams S, Strobel JE: Biomarkers of a five-domain translational substrate for schizophrenia and schizoaffective psychosis. Biomark Res. 2015 Feb 6;3:3. doi: 10.1186/s40364-015-0028-1. eCollection 2015.</reference_text><pubmed_id>25729574</pubmed_id></reference><reference><reference_text>Oresic M, Seppanen-Laakso T, Sun D, Tang J, Therman S, Viehman R, Mustonen U, van Erp TG, Hyotylainen T, Thompson P, Toga AW, Huttunen MO, Suvisaari J, Kaprio J, Lonnqvist J, Cannon TD: Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia. Genome Med. 2012 Jan 18;4(1):1. doi: 10.1186/gm300.</reference_text><pubmed_id>22257447</pubmed_id></reference></references></disease><disease>Primary hypomagnesemia<references><reference><reference_text>Jin-no Y, Kamiya Y, Okada M, Hirako M, Takada N, Kawaguchi M: Primary hypomagnesemia caused by isolated magnesium malabsorption: atypical case in adult. Intern Med. 1999 Mar;38(3):261-5.</reference_text><pubmed_id>10337938</pubmed_id></reference><reference><reference_text>Vainsel M, Vandevelde G, Smulders J, Vosters M, Hubain P, Loeb H: Tetany due to hypomagnesaemia with secondary hypocalcaemia. Arch Dis Child. 1970 Apr;45(240):254-8.</reference_text><pubmed_id>5419995</pubmed_id></reference><reference><reference_text>Shalev H, Phillip M, Galil A, Carmi R, Landau D: Clinical presentation and outcome in primary familial hypomagnesaemia. Arch Dis Child. 1998 Feb;78(2):127-30.</reference_text><pubmed_id>9579153</pubmed_id></reference><reference><reference_text>Kari JA, Farouq M, Alshaya HO: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Pediatr Nephrol. 2003 Jun;18(6):506-10. Epub 2003 Apr 29.</reference_text><pubmed_id>12720080</pubmed_id></reference></references></disease><disease>Hyperlipoproteinemia<references><reference><reference_text>Sinha S, Misra A, Kumar V, Jagannathan NR, Bal CS, Pandey RM, Singhania R, Deepak: Proton magnetic resonance spectroscopy and single photon emission computed tomography study of the brain in asymptomatic young hyperlipidaemic Asian Indians in North India show early abnormalities. Clin Endocrinol (Oxf). 2004 Aug;61(2):182-9.</reference_text><pubmed_id>15272912</pubmed_id></reference><reference><reference_text>Nelson RH: Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013 Mar</reference_text><pubmed_id>40(1):195-211. doi: 10.1016/j.pop.2012.11.003. Epub 2012 Dec  4.</pubmed_id></reference><reference><reference_text>Cantin B, Boudriau S, Bertrand M, Brun LD, Gagne C, Rogers PA, Ven Murthy MR, Lupien PJ, Julien P: Hemolysis in primary lipoprotein lipase deficiency. Metabolism. 1995 May;44(5):652-8.</reference_text><pubmed_id>7752915</pubmed_id></reference></references></disease><disease>Abetalipoproteinemia<references><reference><reference_text>Dawson G, Kruski AW, Scanu AM: Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J Lipid Res. 1976 Mar;17(2):125-31.</reference_text><pubmed_id>178813</pubmed_id></reference><reference><reference_text>Lazaro RP, Dentinger MP, Rodichok LD, Barron KD, Satya-Murti S: Muscle pathology in Bassen-Kornzweig syndrome and vitamin E deficiency. Am J Clin Pathol. 1986 Sep;86(3):378-87.</reference_text><pubmed_id>2944375</pubmed_id></reference></references></disease><disease>Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis<references><reference><reference_text>Breckenridge WC, Alaupovic P, Cox DW, Little JA: Apolipoprotein and lipoprotein concentrations in familial apolipoprotein C-II deficiency. Atherosclerosis. 1982 Aug;44(2):223-35.</reference_text><pubmed_id>7138621</pubmed_id></reference><reference><reference_text>Fukami M, Hasegawa T, Horikawa R, Ohashi T, Nishimura G, Homma K, Ogata T: Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr Res. 2006 Feb;59(2):276-80. doi: 10.1203/01.pdr.0000195825.31504.28.</reference_text><pubmed_id>16439592</pubmed_id></reference></references></disease><disease>Cerebrotendinous xanthomatosis<references><reference><reference_text>Halperin G, Elisaf M, Leitersdorf E, Harats D: A new method for determination of serum cholestanol by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2000 Jun 9;742(2):345-52.</reference_text><pubmed_id>10901139</pubmed_id></reference><reference><reference_text>Siman-Tov T, Meiner V, Gadoth N: Could steroids mask the diagnosis of cerebrotendinous xanthomatosis? J Neurol Sci. 2006 Apr 15;243(1-2):83-6. Epub 2006 Jan 30.</reference_text><pubmed_id>16445943</pubmed_id></reference><reference><reference_text>Agrawal NK, Garg S: Cerebrotendinous xanthomatosis: a rare disorder with a rare presentation. BMJ Case Rep. 2012 Sep 21;2012. pii: bcr-2012-006202. doi: 10.1136/bcr-2012-006202.</reference_text><pubmed_id>23001091</pubmed_id></reference></references></disease><disease>3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency<references><reference><reference_text>Thompson GN, Hsu BY, Pitt JJ, Treacy E, Stanley CA: Fasting hypoketotic coma in a child with deficiency of mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase. N Engl J Med. 1997 Oct 23;337(17):1203-7. doi: 10.1056/NEJM199710233371704.</reference_text><pubmed_id>9337379</pubmed_id></reference><reference><reference_text>Morris AA, Lascelles CV, Olpin SE, Lake BD, Leonard JV, Quant PA: Hepatic mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme a synthase deficiency. Pediatr Res. 1998 Sep;44(3):392-6. doi: 10.1203/00006450-199809000-00021.</reference_text><pubmed_id>9727719</pubmed_id></reference><reference><reference_text>Conboy E, Vairo F, Schultz M, Agre K, Ridsdale R, Deyle D, Oglesbee D, Gavrilov D, Klee EW, Lanpher B: Mitochondrial 3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency: Unique Presenting Laboratory Values and a Review of Biochemical and Clinical Features. JIMD Rep. 2017 Oct 14. doi: 10.1007/8904_2017_59.</reference_text><pubmed_id>29030856</pubmed_id></reference></references></disease><disease>Hypercholesterolemia, familial<references><reference><reference_text>Kwiterovich PO Jr, Fredrickson DS, Levy RI: Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest. 1974 May;53(5):1237-49. doi: 10.1172/JCI107670.</reference_text><pubmed_id>4363406</pubmed_id></reference></references></disease><disease>SC4MOL deficiency<references><reference><reference_text>He M, Kratz LE, Michel JJ, Vallejo AN, Ferris L, Kelley RI, Hoover JJ, Jukic D, Gibson KM, Wolfe LA, Ramachandran D, Zwick ME, Vockley J: Mutations in the human SC4MOL gene encoding a methyl sterol oxidase cause psoriasiform dermatitis, microcephaly, and developmental delay. J Clin Invest. 2011 Mar;121(3):976-84. doi: 10.1172/JCI42650.</reference_text><pubmed_id>21285510</pubmed_id></reference></references></disease><disease>Chondrodysplasia punctata, X-linked dominant<references><reference><reference_text>Aughton DJ, Kelley RI, Metzenberg A, Pureza V, Pauli RM: X-linked dominant chondrodysplasia punctata (CDPX2) caused by single gene mosaicism in a male. Am J Med Genet A. 2003 Jan 30;116A(3):255-60. doi: 10.1002/ajmg.a.10852.</reference_text><pubmed_id>12503102</pubmed_id></reference></references></disease><disease>Desmosterolosis<references><reference><reference_text>Andersson HC, Kratz L, Kelley R: Desmosterolosis presenting with multiple congenital anomalies and profound developmental delay. Am J Med Genet. 2002 Dec 15;113(4):315-9. doi: 10.1002/ajmg.b.10873.</reference_text><pubmed_id>12457401</pubmed_id></reference></references></disease><disease>Donohue Syndrome<references><reference><reference_text>Nijim Y, Awni Y, Adawi A, Bowirrat A: Classic Case Report of Donohue Syndrome (Leprechaunism; OMIM *246200): The Impact of Consanguineous Mating. Medicine (Baltimore). 2016 Feb;95(6):e2710. doi: 10.1097/MD.0000000000002710.</reference_text><pubmed_id>26871809</pubmed_id></reference></references></disease><disease>Leptin Deficiency or Dysfunction<references><reference><reference_text>Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O'Rahilly S: Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999 Sep 16;341(12):879-84. doi: 10.1056/NEJM199909163411204.</reference_text><pubmed_id>10486419</pubmed_id></reference></references></disease><disease>Duchenne Muscular Dystrophy<references><reference><reference_text>Nakagawa T, Takeuchi A, Kakiuchi R, Lee T, Yagi M, Awano H, Iijima K, Takeshima Y, Urade Y, Matsuo M: A prostaglandin D2 metabolite is elevated in the urine of Duchenne muscular dystrophy patients and increases further from 8 years old. Clin Chim Acta. 2013 Aug 23;423:10-4. doi: 10.1016/j.cca.2013.03.031. Epub 2013 Apr 19.</reference_text><pubmed_id>23603101</pubmed_id></reference><reference><reference_text>Srivastava NK, Pradhan S, Mittal B, Gowda GA: High resolution NMR based analysis of serum lipids in Duchenne muscular dystrophy patients and its possible diagnostic significance. NMR Biomed. 2010 Jan;23(1):13-22. doi: 10.1002/nbm.1419.</reference_text><pubmed_id>19787747</pubmed_id></reference><reference><reference_text>Horster I, Weigt-Usinger K, Carmann C, Chobanyan-Jurgens K, Kohler C, Schara U, Kayacelebi AA, Beckmann B, Tsikas D, Lucke T: The L-arginine/NO pathway and homoarginine are altered in Duchenne muscular dystrophy and improved by glucocorticoids. Amino Acids. 2015 Sep;47(9):1853-63. doi: 10.1007/s00726-015-2018-x. Epub 2015 Jun 12.</reference_text><pubmed_id>26066683</pubmed_id></reference></references></disease><disease>Lecithin:cholesterol Acyltransferase Deficiency<references><reference><reference_text>Idzior-Walus B, Sieradzki J, Kostner G, Malecki MT, Klupa T, Wesolowska T, Rostworowski W, Hartwich J, Walus M, Kiec AD, Naruszewicz M: Familial lecithin-cholesterol acyltransferase deficiency: biochemical characteristics and molecular analysis of a new LCAT mutation in a Polish family. Atherosclerosis. 2006 Apr;185(2):413-20. Epub 2005 Jul 26.</reference_text><pubmed_id>16051254</pubmed_id></reference></references></disease><disease>Lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lipodystrophy, Congenital Generalized<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Oculocerebrorenal syndrome<references><reference><reference_text>Charnas LR, Bernardini I, Rader D, Hoeg JM, Gahl WA: Clinical and laboratory findings in the oculocerebrorenal syndrome of Lowe, with special reference to growth and renal function. N Engl J Med. 1991 May 9;324(19):1318-25. doi: 10.1056/NEJM199105093241904.</reference_text><pubmed_id>2017228</pubmed_id></reference></references></disease><disease>Familial partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lathosterolosis<references><reference><reference_text>Brunetti-Pierri N, Corso G, Rossi M, Ferrari P, Balli F, Rivasi F, Annunziata I, Ballabio A, Russo AD, Andria G, Parenti G: Lathosterolosis, a novel multiple-malformation/mental retardation syndrome due to deficiency of 3beta-hydroxysteroid-delta5-desaturase. Am J Hum Genet. 2002 Oct;71(4):952-8. Epub 2002 Aug 20.</reference_text><pubmed_id>12189593</pubmed_id></reference><reference><reference_text>Ho AC, Fung CW, Siu TS, Ma OC, Lam CW, Tam S, Wong VC: Lathosterolosis: a disorder of cholesterol biosynthesis resembling smith-lemli-opitz syndrome. JIMD Rep. 2014;12:129-34. doi: 10.1007/8904_2013_255. Epub 2013 Oct 20.</reference_text><pubmed_id>24142275</pubmed_id></reference></references></disease><disease>Partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Multiple sclerosis<references><reference><reference_text>Lutz NW, Viola A, Malikova I, Confort-Gouny S, Audoin B, Ranjeva JP, Pelletier J, Cozzone PJ: Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One. 2007 Jul 4;2(7):e595.</reference_text><pubmed_id>17611627</pubmed_id></reference><reference><reference_text>Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U, Hillert J, Bjorkhem I: Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med. 2004 Feb;42(2):186-91.</reference_text><pubmed_id>15061359</pubmed_id></reference><reference><reference_text>Leoni V, Lutjohann D, Masterman T: Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis. J Lipid Res. 2005 Feb;46(2):191-5. Epub 2004 Dec 1.</reference_text><pubmed_id>15576852</pubmed_id></reference><reference><reference_text>Calabrese V, Scapagnini G, Ravagna A, Bella R, Butterfield DA, Calvani M, Pennisi G, Giuffrida Stella AM: Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem Res. 2003 Sep;28(9):1321-8.</reference_text><pubmed_id>12938853</pubmed_id></reference><reference><reference_text>Shaw CE, Dunbar PR, Macaulay HA, Neale TJ: Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol. 1995 Jan;242(2):53-8.</reference_text><pubmed_id>7707089</pubmed_id></reference><reference><reference_text>Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.</reference_text><pubmed_id>17384003</pubmed_id></reference><reference><reference_text>Syburra C, Passi S: Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh (1999). 1999 May-Jun;71(3):112-5.</reference_text><pubmed_id>10609336</pubmed_id></reference><reference><reference_text>Forte G, Visconti A, Santucci S, Ghazaryan A, Figa-Talamanca L, Cannoni S, Bocca B, Pino A, Violante N, Alimonti A, Salvetti M, Ristori G: Quantification of chemical elements in blood of patients affected by multiple sclerosis. Ann Ist Super Sanita. 2005;41(2):213-6.</reference_text><pubmed_id>16244395</pubmed_id></reference><reference><reference_text>Toncev G, Milicic B, Toncev S, Samardzic G: Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol. 2002 May;9(3):221-6.</reference_text><pubmed_id>11985629</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, Bamonti F, Capello E, Mancardi GL, Scarpini E: Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res. 2010 May 28;1333:64-71. doi: 10.1016/j.brainres.2010.03.073. Epub 2010 Mar 27.</reference_text><pubmed_id>20347721</pubmed_id></reference><reference><reference_text>Matsushita T, Isobe N, Kawajiri M, Mogi M, Tsukuda K, Horiuchi M, Ohyagi Y, Kira J: CSF angiotensin II and angiotensin-converting enzyme levels in anti-aquaporin-4 autoimmunity. J Neurol Sci. 2010 Aug 15;295(1-2):41-5. doi: 10.1016/j.jns.2010.05.014. Epub 2010 Jun 11.</reference_text><pubmed_id>20541774</pubmed_id></reference><reference><reference_text>Ghabaee M, Jabedari B, Al-E-Eshagh N, Ghaffarpour M, Asadi F: Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients. Int J Neurosci. 2010 Apr;120(4):301-4. doi: 10.3109/00207451003695690.</reference_text><pubmed_id>20374079</pubmed_id></reference><reference><reference_text>Kawajiri M, Mogi M, Osoegawa M, Matsuoka T, Tsukuda K, Kohara K, Horiuchi M, Miki T, Kira JI: Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler. 2008 May;14(4):557-60. doi: 10.1177/1352458507085760.</reference_text><pubmed_id>18562510</pubmed_id></reference><reference><reference_text>Visconti A, Cotichini R, Cannoni S, Bocca B, Forte G, Ghazaryan A, Santucci S, D'Ippolito C, Stazi MA, Salvetti M, Alimonti A, Ristori G: Concentration of elements in serum of patients affected by multiple sclerosis with first demyelinating episode: a six-month longitudinal follow-up study. Ann Ist Super Sanita. 2005;41(2):217-22.</reference_text><pubmed_id>16244396</pubmed_id></reference></references></disease><disease>Inflammatory bowel disease<references><reference><reference_text>Lee T, Clavel T, Smirnov K, Schmidt A, Lagkouvardos I, Walker A, Lucio M, Michalke B, Schmitt-Kopplin P, Fedorak R, Haller D: Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. 2017 May;66(5):863-871. doi: 10.1136/gutjnl-2015-309940. Epub 2016 Feb 4.</reference_text><pubmed_id>26848182</pubmed_id></reference><reference><reference_text>Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158.</reference_text><pubmed_id>27609529</pubmed_id></reference></references></disease><disease>Colorectal cancer<references><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B: Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009 Apr;22(3):342-8. doi: 10.1002/nbm.1345.</reference_text><pubmed_id>19006102</pubmed_id></reference><reference><reference_text>Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP: Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One. 2013 Aug 6;8(8):e70803. doi: 10.1371/journal.pone.0070803. Print 2013.</reference_text><pubmed_id>23940645</pubmed_id></reference><reference><reference_text>Phua LC, Chue XP, Koh PK, Cheah PY, Ho HK, Chan EC: Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biol Ther. 2014 Apr;15(4):389-97. doi: 10.4161/cbt.27625. Epub 2014 Jan 14.</reference_text><pubmed_id>24424155</pubmed_id></reference><reference><reference_text>Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB: Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010 Feb 15;8:13. doi: 10.1186/1741-7015-8-13.</reference_text><pubmed_id>20156336</pubmed_id></reference><reference><reference_text>Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, Ni Y, Zhao A, Xu LX, Cai S, Jia W: Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res. 2009 Oct;8(10):4844-50. doi: 10.1021/pr9004162.</reference_text><pubmed_id>19678709</pubmed_id></reference><reference><reference_text>Cheng Y, Xie G, Chen T, Qiu Y, Zou X, Zheng M, Tan B, Feng B, Dong T, He P, Zhao L, Zhao A, Xu LX, Zhang Y, Jia W: Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res. 2012 Feb 3;11(2):1354-63. doi: 10.1021/pr201001a. Epub 2011 Dec 28.</reference_text><pubmed_id>22148915</pubmed_id></reference><reference><reference_text>Ni Y, Xie G, Jia W: Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res. 2014 Sep 5;13(9):3857-70. doi: 10.1021/pr500443c. Epub 2014 Aug 14.</reference_text><pubmed_id>25105552</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference><reference><reference_text>Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18.</reference_text><pubmed_id>25037050</pubmed_id></reference><reference><reference_text>Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016.</reference_text><pubmed_id>27015276</pubmed_id></reference><reference><reference_text>Lin Y, Ma C, Liu C, Wang Z, Yang J, Liu X, Shen Z, Wu R: NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer. Oncotarget. 2016 May 17;7(20):29454-64. doi: 10.18632/oncotarget.8762.</reference_text><pubmed_id>27107423</pubmed_id></reference><reference><reference_text>Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016.</reference_text><pubmed_id>27275383</pubmed_id></reference><reference><reference_text>Wang X, Wang J, Rao B, Deng L: Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals. Exp Ther Med. 2017 Jun;13(6):2848-2854. doi: 10.3892/etm.2017.4367. Epub 2017 Apr 20.</reference_text><pubmed_id>28587349</pubmed_id></reference><reference><reference_text>Silke Matysik, Caroline Ivanne Le Roy, Gerhard Liebisch, Sandrine Paule Claus. Metabolomics of fecal samples: A practical consideration. Trends in Food Science &amp; Technology. Vol. 57, Part B, Nov. 2016, p.244-255: http://www.sciencedirect.com/science/article/pii/S0924224416301984</reference_text><pubmed_id>28587349</pubmed_id></reference></references></disease><disease>Gallbladder disease<references><reference><reference_text>Lapidus A, Akerlund JE, Einarsson C: Gallbladder bile composition in patients with Crohn 's disease. World J Gastroenterol. 2006 Jan 7;12(1):70-4.</reference_text><pubmed_id>16440420</pubmed_id></reference><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference><reference><reference_text>Mizuno S, Tazuma S, Kajiyama G: Stabilization of biliary lipid particles by ursodeoxycholic acid. Prolonged nucleation time in human gallbladder bile. Dig Dis Sci. 1993 Apr;38(4):684-93.</reference_text><pubmed_id>8462368</pubmed_id></reference><reference><reference_text>Hillebrant CG, Axelson M, Bjorkhem I, Wang FH, Nyberg B, Einarsson C: Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients. Eur J Clin Invest. 1998 Apr;28(4):324-8.</reference_text><pubmed_id>9615912</pubmed_id></reference></references></disease><disease>Cholelithiasis<references><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference></references></disease><disease>Stomach cancer<references><reference><reference_text>Higashijima H, Ichimiya H, Nakano T, Yamashita H, Kuroki S, Satoh H, Chijiiwa K, Tanaka M: Deconjugation of bilirubin accelerates coprecipitation of cholesterol, fatty acids, and mucin in human bile--in vitro study. J Gastroenterol. 1996 Dec;31(6):828-35.</reference_text><pubmed_id>9027647</pubmed_id></reference><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Song H, Peng JS, Dong-Sheng Y, Yang ZL, Liu HL, Zeng YK, Shi XP, Lu BY: Serum metabolic profiling of human gastric cancer based on gas chromatography/mass spectrometry. Braz J Med Biol Res. 2012 Jan;45(1):78-85. Epub 2011 Nov 25.</reference_text><pubmed_id>22124703</pubmed_id></reference><reference><reference_text>Yu L, Aa J, Xu J, Sun M, Qian S, Cheng L, Yang S, Shi R: Metabolomic phenotype of gastric cancer and precancerous stages based on gas chromatography time-of-flight mass spectrometry. J Gastroenterol Hepatol. 2011 Aug;26(8):1290-7. doi: 10.1111/j.1440-1746.2011.06724.x.</reference_text><pubmed_id>21443661</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference></references></disease><disease>Acute myelogenous leukemia<references><reference><reference_text>Tatidis L, Vitols S, Gruber A, Paul C, Axelson M: Cholesterol catabolism in patients with acute myelogenous leukemia and hypocholesterolemia: suppressed levels of a circulating marker for bile acid synthesis. Cancer Lett. 2001 Sep 20;170(2):169-75.</reference_text><pubmed_id>11463495</pubmed_id></reference></references></disease><disease>Hypercholesterolemia<references><reference><reference_text>Thelen KM, Laaksonen R, Paiva H, Lehtimaki T, Lutjohann D: High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels. J Clin Pharmacol. 2006 Jul;46(7):812-6.</reference_text><pubmed_id>16809807</pubmed_id></reference><reference><reference_text>Tamasawa N, Tamasawa A, Takebe K: Higher levels of plasma cholesterol sulfate in patients with liver cirrhosis and hypercholesterolemia. Lipids. 1993 Sep;28(9):833-6.</reference_text><pubmed_id>8231659</pubmed_id></reference><reference><reference_text>Kim DH, Lee KJ, Heo GS: Analysis of cholesterol and cholesteryl esters in human serum using capillary supercritical fluid chromatography. J Chromatogr B Biomed Appl. 1994 Apr 22;655(1):1-8.</reference_text><pubmed_id>8061816</pubmed_id></reference><reference><reference_text>Authors unspecified: Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med. 1988 Jan;148(1):36-69.</reference_text><pubmed_id>3422148</pubmed_id></reference></references></disease><disease>Cholesteryl ester storage disease<references><reference><reference_text>Rassoul F, Richter V, Lohse P, Naumann A, Purschwitz K, Keller E: Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease. Int J Clin Pharmacol Ther. 2001 May;39(5):199-204.</reference_text><pubmed_id>11380065</pubmed_id></reference><reference><reference_text>Chatrath H, Keilin S, Attar BM: Cholesterol ester storage disease (CESD) diagnosed in an asymptomatic adult. Dig Dis Sci. 2009 Jan;54(1):168-73. doi: 10.1007/s10620-008-0310-2. Epub 2008 May 14.</reference_text><pubmed_id>18478331</pubmed_id></reference><reference><reference_text>Bernstein DL, Hulkova H, Bialer MG, Desnick RJ: Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol. 2013 Jun;58(6):1230-43. doi: 10.1016/j.jhep.2013.02.014. Epub 2013 Feb 26.</reference_text><pubmed_id>23485521</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Cystinosis<references><reference><reference_text>Ueda M, O'Brien K, Rosing DR, Ling A, Kleta R, McAreavey D, Bernardini I, Gahl WA: Coronary artery and other vascular calcifications in patients with cystinosis after kidney transplantation. Clin J Am Soc Nephrol. 2006 May;1(3):555-62. Epub 2006 Feb 8.</reference_text><pubmed_id>17699259</pubmed_id></reference><reference><reference_text>Gahl WA, Bernardini I, Dalakas M, Rizzo WB, Harper GS, Hoeg JM, Hurko O, Bernar J: Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome. J Clin Invest. 1988 Feb;81(2):549-60.</reference_text><pubmed_id>3276734</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Smith-Lemli-Opitz syndrome<references><reference><reference_text>van Rooij A, Nijenhuis AA, Wijburg FA, Schutgens RB: Highly increased CSF concentrations of cholesterol precursors in Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 1997 Aug;20(4):578-80.</reference_text><pubmed_id>9266395</pubmed_id></reference><reference><reference_text>Honda M, Tint GS, Honda A, Salen G, Shefer S, Batta AK, Matsuzaki Y, Tanaka N: Regulation of cholesterol biosynthetic pathway in patients with the Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2000 Jul;23(5):464-74.</reference_text><pubmed_id>10947201</pubmed_id></reference><reference><reference_text>Rossi M, Federico G, Corso G, Parenti G, Battagliese A, Frascogna AR, Della Casa R, Dello Russo A, Strisciuglio P, Saggese G, Andria G: Vitamin D status in patients affected by Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2005;28(1):69-80.</reference_text><pubmed_id>15702407</pubmed_id></reference><reference><reference_text>Johnson DW, ten Brink HJ, Jakobs C: A rapid screening procedure for cholesterol and dehydrocholesterol by electrospray ionization tandem mass spectrometry. J Lipid Res. 2001 Oct;42(10):1699-705.</reference_text><pubmed_id>11590227</pubmed_id></reference></references></disease><disease>Prostate cancer<references><reference><reference_text>Nyman DW, Suzanne Stratton M, Kopplin MJ, Dalkin BL, Nagle RB, Jay Gandolfi A: Selenium and selenomethionine levels in prostate cancer patients. Cancer Detect Prev. 2004;28(1):8-16.</reference_text><pubmed_id>15041072</pubmed_id></reference><reference><reference_text>Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, Egevad L, Tjonneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, Palli D, Vineis P, Tumino R, Berrino F, Kiemeney L, Bueno-de-Mesquita HB, Quiros JR, Gonzalez CA, Martinez C, Larranaga N, Chirlaque MD, Ardanaz E, Stattin P, Hallmans G, Khaw KT, Bingham S, Slimani N, Ferrari P, Rinaldi S, Riboli E: Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr. 2007 Sep;86(3):672-81.</reference_text><pubmed_id>17823432</pubmed_id></reference><reference><reference_text>Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762.</reference_text><pubmed_id>19212411</pubmed_id></reference><reference><reference_text>Puah CM, Williams G, Ghanadian R: Urinary unconjugated 5 alpha-androstane-3 alpha, 17 beta-diol in patients with prostatic tumours. Urol Res. 1982;10(2):81-4.</reference_text><pubmed_id>6180540</pubmed_id></reference><reference><reference_text>Thysell E, Surowiec I, Hornberg E, Crnalic S, Widmark A, Johansson AI, Stattin P, Bergh A, Moritz T, Antti H, Wikstrom P: Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One. 2010 Dec 3;5(12):e14175. doi: 10.1371/journal.pone.0014175.</reference_text><pubmed_id>21151972</pubmed_id></reference><reference><reference_text>Soliman LC, Hui Y, Hewavitharana AK, Chen DD: Monitoring potential prostate cancer biomarkers in urine by capillary electrophoresis-tandem mass spectrometry. J Chromatogr A. 2012 Dec 7;1267:162-9. doi: 10.1016/j.chroma.2012.07.021. Epub 2012 Jul 14.</reference_text><pubmed_id>22824219</pubmed_id></reference><reference><reference_text>Madu CO, Lu Y: Novel diagnostic biomarkers for prostate cancer. J Cancer. 2010 Oct 6;1:150-77.</reference_text><pubmed_id>20975847</pubmed_id></reference></references></disease><disease>Schizophrenia<references><reference><reference_text>Harnryd C, Bjerkenstedt L, Grimm VE, Sedvall G: Reduction of MOPEG levels in cerebrospinal fluid of psychotic women after electroconvulsive treatment. Psychopharmacology (Berl). 1979 Aug 8;64(2):131-4.</reference_text><pubmed_id>115032</pubmed_id></reference><reference><reference_text>Kobayashi K, Koide Y, Yoshino K, Shohmori T: [P-hydroxyphenylacetic acid concentrations in cerebrospinal fluid]. No To Shinkei. 1982 Aug;34(8):769-74.</reference_text><pubmed_id>7126379</pubmed_id></reference><reference><reference_text>Alfredsson G, Wiesel FA: Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology (Berl). 1989;99(3):322-7.</reference_text><pubmed_id>2480613</pubmed_id></reference><reference><reference_text>Heresco-Levy U, Bar G, Levin R, Ermilov M, Ebstein RP, Javitt DC: High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. Schizophr Res. 2007 Mar;91(1-3):14-21. Epub 2007 Feb 2.</reference_text><pubmed_id>17276036</pubmed_id></reference><reference><reference_text>Walker EF, Bonsall R, Walder DJ: Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis. Neuropsychiatry Neuropsychol Behav Neurol. 2002 Mar;15(1):10-7.</reference_text><pubmed_id>11877547</pubmed_id></reference><reference><reference_text>Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M: Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry. 2003 Jun;60(6):572-6.</reference_text><pubmed_id>12796220</pubmed_id></reference><reference><reference_text>Do KQ, Lauer CJ, Schreiber W, Zollinger M, Gutteck-Amsler U, Cuenod M, Holsboer F: gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem. 1995 Dec;65(6):2652-62.</reference_text><pubmed_id>7595563</pubmed_id></reference><reference><reference_text>Nikisch G, Baumann P, Wiedemann G, Kiessling B, Weisser H, Hertel A, Yoshitake T, Kehr J, Mathe AA: Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF. J Clin Psychopharmacol. 2010 Oct;30(5):496-503. doi: 10.1097/JCP.0b013e3181f2288e.</reference_text><pubmed_id>20814316</pubmed_id></reference><reference><reference_text>Fukushima T, Iizuka H, Yokota A, Suzuki T, Ohno C, Kono Y, Nishikiori M, Seki A, Ichiba H, Watanabe Y, Hongo S, Utsunomiya M, Nakatani M, Sadamoto K, Yoshio T: Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One. 2014 Jul 8;9(7):e101652. doi: 10.1371/journal.pone.0101652. eCollection 2014.</reference_text><pubmed_id>25004141</pubmed_id></reference><reference><reference_text>Koike S, Bundo M, Iwamoto K, Suga M, Kuwabara H, Ohashi Y, Shinoda K, Takano Y, Iwashiro N, Satomura Y, Nagai T, Natsubori T, Tada M, Yamasue H, Kasai K: A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study. Transl Psychiatry. 2014 Apr 8;4:e379. doi: 10.1038/tp.2014.19.</reference_text><pubmed_id>24713860</pubmed_id></reference><reference><reference_text>Ballesteros A, Summerfelt A, Du X, Jiang P, Chiappelli J, Tagamets M, O'Donnell P, Kochunov P, Hong LE: Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia. Clin Neurophysiol. 2013 Nov;124(11):2209-15. doi: 10.1016/j.clinph.2013.05.021. Epub 2013 Jun 30.</reference_text><pubmed_id>23823132</pubmed_id></reference><reference><reference_text>Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel FA: Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry. 1985 Sep;147:276-82.</reference_text><pubmed_id>2415198</pubmed_id></reference><reference><reference_text>Pickar D, Breier A, Hsiao JK, Doran AR, Wolkowitz OM, Pato CN, Konicki PE, Potter WZ: Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Arch Gen Psychiatry. 1990 Jul;47(7):641-8.</reference_text><pubmed_id>1694425</pubmed_id></reference><reference><reference_text>Prell GD, Green JP, Kaufmann CA, Khandelwal JK, Morrishow AM, Kirch DG, Linnoila M, Wyatt RJ: Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res. 1995 Jan;14(2):93-104.</reference_text><pubmed_id>7711000</pubmed_id></reference><reference><reference_text>Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B: Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology. 2009;59(2):123-9. doi: 10.1159/000213565. Epub 2009 Apr 22.</reference_text><pubmed_id>19390223</pubmed_id></reference><reference><reference_text>Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K, Cao Y, Wang X, Qiu Y, Su M, Zhao A, Wang P, Yang P, Wu J, Feng G, He L, Jia W, Wan C: Potential metabolite markers of schizophrenia. Mol Psychiatry. 2013 Jan;18(1):67-78. doi: 10.1038/mp.2011.131. Epub 2011 Oct 25.</reference_text><pubmed_id>22024767</pubmed_id></reference><reference><reference_text>Xuan J, Pan G, Qiu Y, Yang L, Su M, Liu Y, Chen J, Feng G, Fang Y, Jia W, Xing Q, He L: Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. J Proteome Res. 2011 Dec 2;10(12):5433-43. doi: 10.1021/pr2006796. Epub 2011 Nov  8.</reference_text><pubmed_id>22007635</pubmed_id></reference><reference><reference_text>Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM, Rothermundt M, Bogerts B, Koethe D, Kranaster L, Ohrmann P, Suslow T, McAllister G, Spain M, Barnes A, van Beveren NJ, Baron-Cohen S, Steiner J, Torrey FE, Yolken RH, Bahn S: Identification of a biological signature for schizophrenia in serum. Mol Psychiatry. 2012 May;17(5):494-502. doi: 10.1038/mp.2011.42. Epub 2011 Apr 12.</reference_text><pubmed_id>21483431</pubmed_id></reference><reference><reference_text>Mathe AA, Eberhard G, Saaf J, Wetterberg L: Plasma prostaglandin E2 metabolite--measured as 11-deoxy-15-keto-13,14-dihydro-11 beta,16 xi-cyclo-PGE2--in twins with schizophrenic disorder. Biol Psychiatry. 1986 Sep;21(11):1024-30.</reference_text><pubmed_id>3741918</pubmed_id></reference><reference><reference_text>Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N: Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct. 2002 Jun;20(2):171-5.</reference_text><pubmed_id>11979513</pubmed_id></reference><reference><reference_text>Zumarraga M, Davila R, Basterreche N, Arrue A, Goienetxea B, Zamalloa MI, Erkoreka L, Bustamante S, Inchausti L, Gonzalez-Torres MA, Guimon J: Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients. Neurochem Int. 2010 May-Jun;56(6-7):774-9. doi: 10.1016/j.neuint.2010.02.015. Epub 2010 Mar 4.</reference_text><pubmed_id>20206656</pubmed_id></reference><reference><reference_text>Peters JG: Dopamine, noradrenaline and serotonin spinal fluid metabolites in temporal lobe epileptic patients with schizophrenic symptomatology. Eur Neurol. 1979;18(1):15-8.</reference_text><pubmed_id>436860</pubmed_id></reference><reference><reference_text>Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, Rozen S, Krishnan RR, McEvoy J, Kaddurah-Daouk R: Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry. 2010 Sep;15(9):938-53. doi: 10.1038/mp.2009.33. Epub 2009 Apr 28.</reference_text><pubmed_id>19401681</pubmed_id></reference><reference><reference_text>Gattaz WF, Waldmeier P, Beckmann H: CSF monoamine metabolites in schizophrenic patients. Acta Psychiatr Scand. 1982 Nov;66(5):350-60.</reference_text><pubmed_id>6184954</pubmed_id></reference><reference><reference_text>Nilsson-Todd LK, Nordin C, Jonsson EG, Skogh E, Erhardt S: Cerebrospinal fluid kynurenic acid in male patients with schizophrenia - correlation with monoamine metabolites. Acta Neuropsychiatr. 2007 Feb;19(1):45-52. doi: 10.1111/j.1601-5215.2006.00170.x.</reference_text><pubmed_id>26952797</pubmed_id></reference><reference><reference_text>Cai HL, Li HD, Yan XZ, Sun B, Zhang Q, Yan M, Zhang WY, Jiang P, Zhu RH, Liu YP, Fang PF, Xu P, Yuan HY, Zhang XH, Hu L, Yang W, Ye HS: Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naive schizophrenia patients after treatment with risperidone. J Proteome Res. 2012 Aug 3;11(8):4338-50. doi: 10.1021/pr300459d. Epub 2012 Jul 26.</reference_text><pubmed_id>22800120</pubmed_id></reference><reference><reference_text>Al Awam K, Haussleiter IS, Dudley E, Donev R, Brune M, Juckel G, Thome J: Multiplatform metabolome and proteome profiling identifies serum metabolite and protein signatures as prospective biomarkers for schizophrenia. J Neural Transm (Vienna). 2015 Aug;122 Suppl 1:S111-22. doi: 10.1007/s00702-014-1224-0. Epub 2014 May 1.</reference_text><pubmed_id>24789758</pubmed_id></reference><reference><reference_text>Bicikova M, Hill M, Ripova D, Mohr P, Hampl R: Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia. J Steroid Biochem Mol Biol. 2013 Jan;133:77-83. doi: 10.1016/j.jsbmb.2012.08.009. Epub 2012 Aug 24.</reference_text><pubmed_id>22944140</pubmed_id></reference><reference><reference_text>He Y, Yu Z, Giegling I, Xie L, Hartmann AM, Prehn C, Adamski J, Kahn R, Li Y, Illig T, Wang-Sattler R, Rujescu D: Schizophrenia shows a unique metabolomics signature in plasma. Transl Psychiatry. 2012 Aug 14;2:e149. doi: 10.1038/tp.2012.76.</reference_text><pubmed_id>22892715</pubmed_id></reference><reference><reference_text>Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KR: Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):934-45. Epub 2007 Apr 17.</reference_text><pubmed_id>17440431</pubmed_id></reference><reference><reference_text>Fryar-Williams S, Strobel JE: Biomarkers of a five-domain translational substrate for schizophrenia and schizoaffective psychosis. Biomark Res. 2015 Feb 6;3:3. doi: 10.1186/s40364-015-0028-1. eCollection 2015.</reference_text><pubmed_id>25729574</pubmed_id></reference><reference><reference_text>Oresic M, Seppanen-Laakso T, Sun D, Tang J, Therman S, Viehman R, Mustonen U, van Erp TG, Hyotylainen T, Thompson P, Toga AW, Huttunen MO, Suvisaari J, Kaprio J, Lonnqvist J, Cannon TD: Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia. Genome Med. 2012 Jan 18;4(1):1. doi: 10.1186/gm300.</reference_text><pubmed_id>22257447</pubmed_id></reference></references></disease><disease>Primary hypomagnesemia<references><reference><reference_text>Jin-no Y, Kamiya Y, Okada M, Hirako M, Takada N, Kawaguchi M: Primary hypomagnesemia caused by isolated magnesium malabsorption: atypical case in adult. Intern Med. 1999 Mar;38(3):261-5.</reference_text><pubmed_id>10337938</pubmed_id></reference><reference><reference_text>Vainsel M, Vandevelde G, Smulders J, Vosters M, Hubain P, Loeb H: Tetany due to hypomagnesaemia with secondary hypocalcaemia. Arch Dis Child. 1970 Apr;45(240):254-8.</reference_text><pubmed_id>5419995</pubmed_id></reference><reference><reference_text>Shalev H, Phillip M, Galil A, Carmi R, Landau D: Clinical presentation and outcome in primary familial hypomagnesaemia. Arch Dis Child. 1998 Feb;78(2):127-30.</reference_text><pubmed_id>9579153</pubmed_id></reference><reference><reference_text>Kari JA, Farouq M, Alshaya HO: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Pediatr Nephrol. 2003 Jun;18(6):506-10. Epub 2003 Apr 29.</reference_text><pubmed_id>12720080</pubmed_id></reference></references></disease><disease>Hyperlipoproteinemia<references><reference><reference_text>Sinha S, Misra A, Kumar V, Jagannathan NR, Bal CS, Pandey RM, Singhania R, Deepak: Proton magnetic resonance spectroscopy and single photon emission computed tomography study of the brain in asymptomatic young hyperlipidaemic Asian Indians in North India show early abnormalities. Clin Endocrinol (Oxf). 2004 Aug;61(2):182-9.</reference_text><pubmed_id>15272912</pubmed_id></reference><reference><reference_text>Nelson RH: Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013 Mar</reference_text><pubmed_id>40(1):195-211. doi: 10.1016/j.pop.2012.11.003. Epub 2012 Dec  4.</pubmed_id></reference><reference><reference_text>Cantin B, Boudriau S, Bertrand M, Brun LD, Gagne C, Rogers PA, Ven Murthy MR, Lupien PJ, Julien P: Hemolysis in primary lipoprotein lipase deficiency. Metabolism. 1995 May;44(5):652-8.</reference_text><pubmed_id>7752915</pubmed_id></reference></references></disease><disease>Abetalipoproteinemia<references><reference><reference_text>Dawson G, Kruski AW, Scanu AM: Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J Lipid Res. 1976 Mar;17(2):125-31.</reference_text><pubmed_id>178813</pubmed_id></reference><reference><reference_text>Lazaro RP, Dentinger MP, Rodichok LD, Barron KD, Satya-Murti S: Muscle pathology in Bassen-Kornzweig syndrome and vitamin E deficiency. Am J Clin Pathol. 1986 Sep;86(3):378-87.</reference_text><pubmed_id>2944375</pubmed_id></reference></references></disease><disease>Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis<references><reference><reference_text>Breckenridge WC, Alaupovic P, Cox DW, Little JA: Apolipoprotein and lipoprotein concentrations in familial apolipoprotein C-II deficiency. Atherosclerosis. 1982 Aug;44(2):223-35.</reference_text><pubmed_id>7138621</pubmed_id></reference><reference><reference_text>Fukami M, Hasegawa T, Horikawa R, Ohashi T, Nishimura G, Homma K, Ogata T: Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr Res. 2006 Feb;59(2):276-80. doi: 10.1203/01.pdr.0000195825.31504.28.</reference_text><pubmed_id>16439592</pubmed_id></reference></references></disease><disease>Cerebrotendinous xanthomatosis<references><reference><reference_text>Halperin G, Elisaf M, Leitersdorf E, Harats D: A new method for determination of serum cholestanol by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2000 Jun 9;742(2):345-52.</reference_text><pubmed_id>10901139</pubmed_id></reference><reference><reference_text>Siman-Tov T, Meiner V, Gadoth N: Could steroids mask the diagnosis of cerebrotendinous xanthomatosis? J Neurol Sci. 2006 Apr 15;243(1-2):83-6. Epub 2006 Jan 30.</reference_text><pubmed_id>16445943</pubmed_id></reference><reference><reference_text>Agrawal NK, Garg S: Cerebrotendinous xanthomatosis: a rare disorder with a rare presentation. BMJ Case Rep. 2012 Sep 21;2012. pii: bcr-2012-006202. doi: 10.1136/bcr-2012-006202.</reference_text><pubmed_id>23001091</pubmed_id></reference></references></disease><disease>3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency<references><reference><reference_text>Thompson GN, Hsu BY, Pitt JJ, Treacy E, Stanley CA: Fasting hypoketotic coma in a child with deficiency of mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase. N Engl J Med. 1997 Oct 23;337(17):1203-7. doi: 10.1056/NEJM199710233371704.</reference_text><pubmed_id>9337379</pubmed_id></reference><reference><reference_text>Morris AA, Lascelles CV, Olpin SE, Lake BD, Leonard JV, Quant PA: Hepatic mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme a synthase deficiency. Pediatr Res. 1998 Sep;44(3):392-6. doi: 10.1203/00006450-199809000-00021.</reference_text><pubmed_id>9727719</pubmed_id></reference><reference><reference_text>Conboy E, Vairo F, Schultz M, Agre K, Ridsdale R, Deyle D, Oglesbee D, Gavrilov D, Klee EW, Lanpher B: Mitochondrial 3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency: Unique Presenting Laboratory Values and a Review of Biochemical and Clinical Features. JIMD Rep. 2017 Oct 14. doi: 10.1007/8904_2017_59.</reference_text><pubmed_id>29030856</pubmed_id></reference></references></disease><disease>Hypercholesterolemia, familial<references><reference><reference_text>Kwiterovich PO Jr, Fredrickson DS, Levy RI: Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest. 1974 May;53(5):1237-49. doi: 10.1172/JCI107670.</reference_text><pubmed_id>4363406</pubmed_id></reference></references></disease><disease>SC4MOL deficiency<references><reference><reference_text>He M, Kratz LE, Michel JJ, Vallejo AN, Ferris L, Kelley RI, Hoover JJ, Jukic D, Gibson KM, Wolfe LA, Ramachandran D, Zwick ME, Vockley J: Mutations in the human SC4MOL gene encoding a methyl sterol oxidase cause psoriasiform dermatitis, microcephaly, and developmental delay. J Clin Invest. 2011 Mar;121(3):976-84. doi: 10.1172/JCI42650.</reference_text><pubmed_id>21285510</pubmed_id></reference></references></disease><disease>Chondrodysplasia punctata, X-linked dominant<references><reference><reference_text>Aughton DJ, Kelley RI, Metzenberg A, Pureza V, Pauli RM: X-linked dominant chondrodysplasia punctata (CDPX2) caused by single gene mosaicism in a male. Am J Med Genet A. 2003 Jan 30;116A(3):255-60. doi: 10.1002/ajmg.a.10852.</reference_text><pubmed_id>12503102</pubmed_id></reference></references></disease><disease>Desmosterolosis<references><reference><reference_text>Andersson HC, Kratz L, Kelley R: Desmosterolosis presenting with multiple congenital anomalies and profound developmental delay. Am J Med Genet. 2002 Dec 15;113(4):315-9. doi: 10.1002/ajmg.b.10873.</reference_text><pubmed_id>12457401</pubmed_id></reference></references></disease><disease>Donohue Syndrome<references><reference><reference_text>Nijim Y, Awni Y, Adawi A, Bowirrat A: Classic Case Report of Donohue Syndrome (Leprechaunism; OMIM *246200): The Impact of Consanguineous Mating. Medicine (Baltimore). 2016 Feb;95(6):e2710. doi: 10.1097/MD.0000000000002710.</reference_text><pubmed_id>26871809</pubmed_id></reference></references></disease><disease>Leptin Deficiency or Dysfunction<references><reference><reference_text>Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O'Rahilly S: Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999 Sep 16;341(12):879-84. doi: 10.1056/NEJM199909163411204.</reference_text><pubmed_id>10486419</pubmed_id></reference></references></disease><disease>Duchenne Muscular Dystrophy<references><reference><reference_text>Nakagawa T, Takeuchi A, Kakiuchi R, Lee T, Yagi M, Awano H, Iijima K, Takeshima Y, Urade Y, Matsuo M: A prostaglandin D2 metabolite is elevated in the urine of Duchenne muscular dystrophy patients and increases further from 8 years old. Clin Chim Acta. 2013 Aug 23;423:10-4. doi: 10.1016/j.cca.2013.03.031. Epub 2013 Apr 19.</reference_text><pubmed_id>23603101</pubmed_id></reference><reference><reference_text>Srivastava NK, Pradhan S, Mittal B, Gowda GA: High resolution NMR based analysis of serum lipids in Duchenne muscular dystrophy patients and its possible diagnostic significance. NMR Biomed. 2010 Jan;23(1):13-22. doi: 10.1002/nbm.1419.</reference_text><pubmed_id>19787747</pubmed_id></reference><reference><reference_text>Horster I, Weigt-Usinger K, Carmann C, Chobanyan-Jurgens K, Kohler C, Schara U, Kayacelebi AA, Beckmann B, Tsikas D, Lucke T: The L-arginine/NO pathway and homoarginine are altered in Duchenne muscular dystrophy and improved by glucocorticoids. Amino Acids. 2015 Sep;47(9):1853-63. doi: 10.1007/s00726-015-2018-x. Epub 2015 Jun 12.</reference_text><pubmed_id>26066683</pubmed_id></reference></references></disease><disease>Lecithin:cholesterol Acyltransferase Deficiency<references><reference><reference_text>Idzior-Walus B, Sieradzki J, Kostner G, Malecki MT, Klupa T, Wesolowska T, Rostworowski W, Hartwich J, Walus M, Kiec AD, Naruszewicz M: Familial lecithin-cholesterol acyltransferase deficiency: biochemical characteristics and molecular analysis of a new LCAT mutation in a Polish family. Atherosclerosis. 2006 Apr;185(2):413-20. Epub 2005 Jul 26.</reference_text><pubmed_id>16051254</pubmed_id></reference></references></disease><disease>Lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lipodystrophy, Congenital Generalized<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Oculocerebrorenal syndrome<references><reference><reference_text>Charnas LR, Bernardini I, Rader D, Hoeg JM, Gahl WA: Clinical and laboratory findings in the oculocerebrorenal syndrome of Lowe, with special reference to growth and renal function. N Engl J Med. 1991 May 9;324(19):1318-25. doi: 10.1056/NEJM199105093241904.</reference_text><pubmed_id>2017228</pubmed_id></reference></references></disease><disease>Familial partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lathosterolosis<references><reference><reference_text>Brunetti-Pierri N, Corso G, Rossi M, Ferrari P, Balli F, Rivasi F, Annunziata I, Ballabio A, Russo AD, Andria G, Parenti G: Lathosterolosis, a novel multiple-malformation/mental retardation syndrome due to deficiency of 3beta-hydroxysteroid-delta5-desaturase. Am J Hum Genet. 2002 Oct;71(4):952-8. Epub 2002 Aug 20.</reference_text><pubmed_id>12189593</pubmed_id></reference><reference><reference_text>Ho AC, Fung CW, Siu TS, Ma OC, Lam CW, Tam S, Wong VC: Lathosterolosis: a disorder of cholesterol biosynthesis resembling smith-lemli-opitz syndrome. JIMD Rep. 2014;12:129-34. doi: 10.1007/8904_2013_255. Epub 2013 Oct 20.</reference_text><pubmed_id>24142275</pubmed_id></reference></references></disease><disease>Partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Multiple sclerosis<references><reference><reference_text>Lutz NW, Viola A, Malikova I, Confort-Gouny S, Audoin B, Ranjeva JP, Pelletier J, Cozzone PJ: Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One. 2007 Jul 4;2(7):e595.</reference_text><pubmed_id>17611627</pubmed_id></reference><reference><reference_text>Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U, Hillert J, Bjorkhem I: Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med. 2004 Feb;42(2):186-91.</reference_text><pubmed_id>15061359</pubmed_id></reference><reference><reference_text>Leoni V, Lutjohann D, Masterman T: Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis. J Lipid Res. 2005 Feb;46(2):191-5. Epub 2004 Dec 1.</reference_text><pubmed_id>15576852</pubmed_id></reference><reference><reference_text>Calabrese V, Scapagnini G, Ravagna A, Bella R, Butterfield DA, Calvani M, Pennisi G, Giuffrida Stella AM: Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem Res. 2003 Sep;28(9):1321-8.</reference_text><pubmed_id>12938853</pubmed_id></reference><reference><reference_text>Shaw CE, Dunbar PR, Macaulay HA, Neale TJ: Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol. 1995 Jan;242(2):53-8.</reference_text><pubmed_id>7707089</pubmed_id></reference><reference><reference_text>Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.</reference_text><pubmed_id>17384003</pubmed_id></reference><reference><reference_text>Syburra C, Passi S: Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh (1999). 1999 May-Jun;71(3):112-5.</reference_text><pubmed_id>10609336</pubmed_id></reference><reference><reference_text>Forte G, Visconti A, Santucci S, Ghazaryan A, Figa-Talamanca L, Cannoni S, Bocca B, Pino A, Violante N, Alimonti A, Salvetti M, Ristori G: Quantification of chemical elements in blood of patients affected by multiple sclerosis. Ann Ist Super Sanita. 2005;41(2):213-6.</reference_text><pubmed_id>16244395</pubmed_id></reference><reference><reference_text>Toncev G, Milicic B, Toncev S, Samardzic G: Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol. 2002 May;9(3):221-6.</reference_text><pubmed_id>11985629</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, Bamonti F, Capello E, Mancardi GL, Scarpini E: Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res. 2010 May 28;1333:64-71. doi: 10.1016/j.brainres.2010.03.073. Epub 2010 Mar 27.</reference_text><pubmed_id>20347721</pubmed_id></reference><reference><reference_text>Matsushita T, Isobe N, Kawajiri M, Mogi M, Tsukuda K, Horiuchi M, Ohyagi Y, Kira J: CSF angiotensin II and angiotensin-converting enzyme levels in anti-aquaporin-4 autoimmunity. J Neurol Sci. 2010 Aug 15;295(1-2):41-5. doi: 10.1016/j.jns.2010.05.014. Epub 2010 Jun 11.</reference_text><pubmed_id>20541774</pubmed_id></reference><reference><reference_text>Ghabaee M, Jabedari B, Al-E-Eshagh N, Ghaffarpour M, Asadi F: Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients. Int J Neurosci. 2010 Apr;120(4):301-4. doi: 10.3109/00207451003695690.</reference_text><pubmed_id>20374079</pubmed_id></reference><reference><reference_text>Kawajiri M, Mogi M, Osoegawa M, Matsuoka T, Tsukuda K, Kohara K, Horiuchi M, Miki T, Kira JI: Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler. 2008 May;14(4):557-60. doi: 10.1177/1352458507085760.</reference_text><pubmed_id>18562510</pubmed_id></reference><reference><reference_text>Visconti A, Cotichini R, Cannoni S, Bocca B, Forte G, Ghazaryan A, Santucci S, D'Ippolito C, Stazi MA, Salvetti M, Alimonti A, Ristori G: Concentration of elements in serum of patients affected by multiple sclerosis with first demyelinating episode: a six-month longitudinal follow-up study. Ann Ist Super Sanita. 2005;41(2):217-22.</reference_text><pubmed_id>16244396</pubmed_id></reference></references></disease><disease>Inflammatory bowel disease<references><reference><reference_text>Lee T, Clavel T, Smirnov K, Schmidt A, Lagkouvardos I, Walker A, Lucio M, Michalke B, Schmitt-Kopplin P, Fedorak R, Haller D: Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. 2017 May;66(5):863-871. doi: 10.1136/gutjnl-2015-309940. Epub 2016 Feb 4.</reference_text><pubmed_id>26848182</pubmed_id></reference><reference><reference_text>Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158.</reference_text><pubmed_id>27609529</pubmed_id></reference></references></disease><disease>Colorectal cancer<references><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B: Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009 Apr;22(3):342-8. doi: 10.1002/nbm.1345.</reference_text><pubmed_id>19006102</pubmed_id></reference><reference><reference_text>Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP: Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One. 2013 Aug 6;8(8):e70803. doi: 10.1371/journal.pone.0070803. Print 2013.</reference_text><pubmed_id>23940645</pubmed_id></reference><reference><reference_text>Phua LC, Chue XP, Koh PK, Cheah PY, Ho HK, Chan EC: Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biol Ther. 2014 Apr;15(4):389-97. doi: 10.4161/cbt.27625. Epub 2014 Jan 14.</reference_text><pubmed_id>24424155</pubmed_id></reference><reference><reference_text>Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB: Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010 Feb 15;8:13. doi: 10.1186/1741-7015-8-13.</reference_text><pubmed_id>20156336</pubmed_id></reference><reference><reference_text>Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, Ni Y, Zhao A, Xu LX, Cai S, Jia W: Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res. 2009 Oct;8(10):4844-50. doi: 10.1021/pr9004162.</reference_text><pubmed_id>19678709</pubmed_id></reference><reference><reference_text>Cheng Y, Xie G, Chen T, Qiu Y, Zou X, Zheng M, Tan B, Feng B, Dong T, He P, Zhao L, Zhao A, Xu LX, Zhang Y, Jia W: Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res. 2012 Feb 3;11(2):1354-63. doi: 10.1021/pr201001a. Epub 2011 Dec 28.</reference_text><pubmed_id>22148915</pubmed_id></reference><reference><reference_text>Ni Y, Xie G, Jia W: Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res. 2014 Sep 5;13(9):3857-70. doi: 10.1021/pr500443c. Epub 2014 Aug 14.</reference_text><pubmed_id>25105552</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference><reference><reference_text>Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18.</reference_text><pubmed_id>25037050</pubmed_id></reference><reference><reference_text>Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016.</reference_text><pubmed_id>27015276</pubmed_id></reference><reference><reference_text>Lin Y, Ma C, Liu C, Wang Z, Yang J, Liu X, Shen Z, Wu R: NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer. Oncotarget. 2016 May 17;7(20):29454-64. doi: 10.18632/oncotarget.8762.</reference_text><pubmed_id>27107423</pubmed_id></reference><reference><reference_text>Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016.</reference_text><pubmed_id>27275383</pubmed_id></reference><reference><reference_text>Wang X, Wang J, Rao B, Deng L: Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals. Exp Ther Med. 2017 Jun;13(6):2848-2854. doi: 10.3892/etm.2017.4367. Epub 2017 Apr 20.</reference_text><pubmed_id>28587349</pubmed_id></reference><reference><reference_text>Silke Matysik, Caroline Ivanne Le Roy, Gerhard Liebisch, Sandrine Paule Claus. Metabolomics of fecal samples: A practical consideration. Trends in Food Science &amp; Technology. Vol. 57, Part B, Nov. 2016, p.244-255: http://www.sciencedirect.com/science/article/pii/S0924224416301984</reference_text><pubmed_id>28587349</pubmed_id></reference></references></disease><disease>Gallbladder disease<references><reference><reference_text>Lapidus A, Akerlund JE, Einarsson C: Gallbladder bile composition in patients with Crohn 's disease. World J Gastroenterol. 2006 Jan 7;12(1):70-4.</reference_text><pubmed_id>16440420</pubmed_id></reference><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference><reference><reference_text>Mizuno S, Tazuma S, Kajiyama G: Stabilization of biliary lipid particles by ursodeoxycholic acid. Prolonged nucleation time in human gallbladder bile. Dig Dis Sci. 1993 Apr;38(4):684-93.</reference_text><pubmed_id>8462368</pubmed_id></reference><reference><reference_text>Hillebrant CG, Axelson M, Bjorkhem I, Wang FH, Nyberg B, Einarsson C: Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients. Eur J Clin Invest. 1998 Apr;28(4):324-8.</reference_text><pubmed_id>9615912</pubmed_id></reference></references></disease><disease>Cholelithiasis<references><reference><reference_text>Miettinen TE, Kesaniemi YA, Gylling H, Jarvinen H, Silvennoinen E, Miettinen TA: Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones. Hepatology. 1996 Feb;23(2):274-80.</reference_text><pubmed_id>8591852</pubmed_id></reference></references></disease><disease>Stomach cancer<references><reference><reference_text>Higashijima H, Ichimiya H, Nakano T, Yamashita H, Kuroki S, Satoh H, Chijiiwa K, Tanaka M: Deconjugation of bilirubin accelerates coprecipitation of cholesterol, fatty acids, and mucin in human bile--in vitro study. J Gastroenterol. 1996 Dec;31(6):828-35.</reference_text><pubmed_id>9027647</pubmed_id></reference><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Song H, Peng JS, Dong-Sheng Y, Yang ZL, Liu HL, Zeng YK, Shi XP, Lu BY: Serum metabolic profiling of human gastric cancer based on gas chromatography/mass spectrometry. Braz J Med Biol Res. 2012 Jan;45(1):78-85. Epub 2011 Nov 25.</reference_text><pubmed_id>22124703</pubmed_id></reference><reference><reference_text>Yu L, Aa J, Xu J, Sun M, Qian S, Cheng L, Yang S, Shi R: Metabolomic phenotype of gastric cancer and precancerous stages based on gas chromatography time-of-flight mass spectrometry. J Gastroenterol Hepatol. 2011 Aug;26(8):1290-7. doi: 10.1111/j.1440-1746.2011.06724.x.</reference_text><pubmed_id>21443661</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference></references></disease><disease>Acute myelogenous leukemia<references><reference><reference_text>Tatidis L, Vitols S, Gruber A, Paul C, Axelson M: Cholesterol catabolism in patients with acute myelogenous leukemia and hypocholesterolemia: suppressed levels of a circulating marker for bile acid synthesis. Cancer Lett. 2001 Sep 20;170(2):169-75.</reference_text><pubmed_id>11463495</pubmed_id></reference></references></disease><disease>Hypercholesterolemia<references><reference><reference_text>Thelen KM, Laaksonen R, Paiva H, Lehtimaki T, Lutjohann D: High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels. J Clin Pharmacol. 2006 Jul;46(7):812-6.</reference_text><pubmed_id>16809807</pubmed_id></reference><reference><reference_text>Tamasawa N, Tamasawa A, Takebe K: Higher levels of plasma cholesterol sulfate in patients with liver cirrhosis and hypercholesterolemia. Lipids. 1993 Sep;28(9):833-6.</reference_text><pubmed_id>8231659</pubmed_id></reference><reference><reference_text>Kim DH, Lee KJ, Heo GS: Analysis of cholesterol and cholesteryl esters in human serum using capillary supercritical fluid chromatography. J Chromatogr B Biomed Appl. 1994 Apr 22;655(1):1-8.</reference_text><pubmed_id>8061816</pubmed_id></reference><reference><reference_text>Authors unspecified: Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med. 1988 Jan;148(1):36-69.</reference_text><pubmed_id>3422148</pubmed_id></reference></references></disease><disease>Cholesteryl ester storage disease<references><reference><reference_text>Rassoul F, Richter V, Lohse P, Naumann A, Purschwitz K, Keller E: Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease. Int J Clin Pharmacol Ther. 2001 May;39(5):199-204.</reference_text><pubmed_id>11380065</pubmed_id></reference><reference><reference_text>Chatrath H, Keilin S, Attar BM: Cholesterol ester storage disease (CESD) diagnosed in an asymptomatic adult. Dig Dis Sci. 2009 Jan;54(1):168-73. doi: 10.1007/s10620-008-0310-2. Epub 2008 May 14.</reference_text><pubmed_id>18478331</pubmed_id></reference><reference><reference_text>Bernstein DL, Hulkova H, Bialer MG, Desnick RJ: Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol. 2013 Jun;58(6):1230-43. doi: 10.1016/j.jhep.2013.02.014. Epub 2013 Feb 26.</reference_text><pubmed_id>23485521</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Cystinosis<references><reference><reference_text>Ueda M, O'Brien K, Rosing DR, Ling A, Kleta R, McAreavey D, Bernardini I, Gahl WA: Coronary artery and other vascular calcifications in patients with cystinosis after kidney transplantation. Clin J Am Soc Nephrol. 2006 May;1(3):555-62. Epub 2006 Feb 8.</reference_text><pubmed_id>17699259</pubmed_id></reference><reference><reference_text>Gahl WA, Bernardini I, Dalakas M, Rizzo WB, Harper GS, Hoeg JM, Hurko O, Bernar J: Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome. J Clin Invest. 1988 Feb;81(2):549-60.</reference_text><pubmed_id>3276734</pubmed_id></reference><reference><reference_text>MetaGene: Metabolic &amp; Genetic Information Center (MIC: http://www.metagene.de)</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Smith-Lemli-Opitz syndrome<references><reference><reference_text>van Rooij A, Nijenhuis AA, Wijburg FA, Schutgens RB: Highly increased CSF concentrations of cholesterol precursors in Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 1997 Aug;20(4):578-80.</reference_text><pubmed_id>9266395</pubmed_id></reference><reference><reference_text>Honda M, Tint GS, Honda A, Salen G, Shefer S, Batta AK, Matsuzaki Y, Tanaka N: Regulation of cholesterol biosynthetic pathway in patients with the Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2000 Jul;23(5):464-74.</reference_text><pubmed_id>10947201</pubmed_id></reference><reference><reference_text>Rossi M, Federico G, Corso G, Parenti G, Battagliese A, Frascogna AR, Della Casa R, Dello Russo A, Strisciuglio P, Saggese G, Andria G: Vitamin D status in patients affected by Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2005;28(1):69-80.</reference_text><pubmed_id>15702407</pubmed_id></reference><reference><reference_text>Johnson DW, ten Brink HJ, Jakobs C: A rapid screening procedure for cholesterol and dehydrocholesterol by electrospray ionization tandem mass spectrometry. J Lipid Res. 2001 Oct;42(10):1699-705.</reference_text><pubmed_id>11590227</pubmed_id></reference></references></disease><disease>Prostate cancer<references><reference><reference_text>Nyman DW, Suzanne Stratton M, Kopplin MJ, Dalkin BL, Nagle RB, Jay Gandolfi A: Selenium and selenomethionine levels in prostate cancer patients. Cancer Detect Prev. 2004;28(1):8-16.</reference_text><pubmed_id>15041072</pubmed_id></reference><reference><reference_text>Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, Egevad L, Tjonneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, Palli D, Vineis P, Tumino R, Berrino F, Kiemeney L, Bueno-de-Mesquita HB, Quiros JR, Gonzalez CA, Martinez C, Larranaga N, Chirlaque MD, Ardanaz E, Stattin P, Hallmans G, Khaw KT, Bingham S, Slimani N, Ferrari P, Rinaldi S, Riboli E: Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr. 2007 Sep;86(3):672-81.</reference_text><pubmed_id>17823432</pubmed_id></reference><reference><reference_text>Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762.</reference_text><pubmed_id>19212411</pubmed_id></reference><reference><reference_text>Puah CM, Williams G, Ghanadian R: Urinary unconjugated 5 alpha-androstane-3 alpha, 17 beta-diol in patients with prostatic tumours. Urol Res. 1982;10(2):81-4.</reference_text><pubmed_id>6180540</pubmed_id></reference><reference><reference_text>Thysell E, Surowiec I, Hornberg E, Crnalic S, Widmark A, Johansson AI, Stattin P, Bergh A, Moritz T, Antti H, Wikstrom P: Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One. 2010 Dec 3;5(12):e14175. doi: 10.1371/journal.pone.0014175.</reference_text><pubmed_id>21151972</pubmed_id></reference><reference><reference_text>Soliman LC, Hui Y, Hewavitharana AK, Chen DD: Monitoring potential prostate cancer biomarkers in urine by capillary electrophoresis-tandem mass spectrometry. J Chromatogr A. 2012 Dec 7;1267:162-9. doi: 10.1016/j.chroma.2012.07.021. Epub 2012 Jul 14.</reference_text><pubmed_id>22824219</pubmed_id></reference><reference><reference_text>Madu CO, Lu Y: Novel diagnostic biomarkers for prostate cancer. J Cancer. 2010 Oct 6;1:150-77.</reference_text><pubmed_id>20975847</pubmed_id></reference></references></disease><disease>Schizophrenia<references><reference><reference_text>Harnryd C, Bjerkenstedt L, Grimm VE, Sedvall G: Reduction of MOPEG levels in cerebrospinal fluid of psychotic women after electroconvulsive treatment. Psychopharmacology (Berl). 1979 Aug 8;64(2):131-4.</reference_text><pubmed_id>115032</pubmed_id></reference><reference><reference_text>Kobayashi K, Koide Y, Yoshino K, Shohmori T: [P-hydroxyphenylacetic acid concentrations in cerebrospinal fluid]. No To Shinkei. 1982 Aug;34(8):769-74.</reference_text><pubmed_id>7126379</pubmed_id></reference><reference><reference_text>Alfredsson G, Wiesel FA: Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology (Berl). 1989;99(3):322-7.</reference_text><pubmed_id>2480613</pubmed_id></reference><reference><reference_text>Heresco-Levy U, Bar G, Levin R, Ermilov M, Ebstein RP, Javitt DC: High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. Schizophr Res. 2007 Mar;91(1-3):14-21. Epub 2007 Feb 2.</reference_text><pubmed_id>17276036</pubmed_id></reference><reference><reference_text>Walker EF, Bonsall R, Walder DJ: Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis. Neuropsychiatry Neuropsychol Behav Neurol. 2002 Mar;15(1):10-7.</reference_text><pubmed_id>11877547</pubmed_id></reference><reference><reference_text>Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M: Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry. 2003 Jun;60(6):572-6.</reference_text><pubmed_id>12796220</pubmed_id></reference><reference><reference_text>Do KQ, Lauer CJ, Schreiber W, Zollinger M, Gutteck-Amsler U, Cuenod M, Holsboer F: gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem. 1995 Dec;65(6):2652-62.</reference_text><pubmed_id>7595563</pubmed_id></reference><reference><reference_text>Nikisch G, Baumann P, Wiedemann G, Kiessling B, Weisser H, Hertel A, Yoshitake T, Kehr J, Mathe AA: Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF. J Clin Psychopharmacol. 2010 Oct;30(5):496-503. doi: 10.1097/JCP.0b013e3181f2288e.</reference_text><pubmed_id>20814316</pubmed_id></reference><reference><reference_text>Fukushima T, Iizuka H, Yokota A, Suzuki T, Ohno C, Kono Y, Nishikiori M, Seki A, Ichiba H, Watanabe Y, Hongo S, Utsunomiya M, Nakatani M, Sadamoto K, Yoshio T: Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One. 2014 Jul 8;9(7):e101652. doi: 10.1371/journal.pone.0101652. eCollection 2014.</reference_text><pubmed_id>25004141</pubmed_id></reference><reference><reference_text>Koike S, Bundo M, Iwamoto K, Suga M, Kuwabara H, Ohashi Y, Shinoda K, Takano Y, Iwashiro N, Satomura Y, Nagai T, Natsubori T, Tada M, Yamasue H, Kasai K: A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study. Transl Psychiatry. 2014 Apr 8;4:e379. doi: 10.1038/tp.2014.19.</reference_text><pubmed_id>24713860</pubmed_id></reference><reference><reference_text>Ballesteros A, Summerfelt A, Du X, Jiang P, Chiappelli J, Tagamets M, O'Donnell P, Kochunov P, Hong LE: Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia. Clin Neurophysiol. 2013 Nov;124(11):2209-15. doi: 10.1016/j.clinph.2013.05.021. Epub 2013 Jun 30.</reference_text><pubmed_id>23823132</pubmed_id></reference><reference><reference_text>Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel FA: Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry. 1985 Sep;147:276-82.</reference_text><pubmed_id>2415198</pubmed_id></reference><reference><reference_text>Pickar D, Breier A, Hsiao JK, Doran AR, Wolkowitz OM, Pato CN, Konicki PE, Potter WZ: Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Arch Gen Psychiatry. 1990 Jul;47(7):641-8.</reference_text><pubmed_id>1694425</pubmed_id></reference><reference><reference_text>Prell GD, Green JP, Kaufmann CA, Khandelwal JK, Morrishow AM, Kirch DG, Linnoila M, Wyatt RJ: Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res. 1995 Jan;14(2):93-104.</reference_text><pubmed_id>7711000</pubmed_id></reference><reference><reference_text>Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B: Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology. 2009;59(2):123-9. doi: 10.1159/000213565. Epub 2009 Apr 22.</reference_text><pubmed_id>19390223</pubmed_id></reference><reference><reference_text>Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K, Cao Y, Wang X, Qiu Y, Su M, Zhao A, Wang P, Yang P, Wu J, Feng G, He L, Jia W, Wan C: Potential metabolite markers of schizophrenia. Mol Psychiatry. 2013 Jan;18(1):67-78. doi: 10.1038/mp.2011.131. Epub 2011 Oct 25.</reference_text><pubmed_id>22024767</pubmed_id></reference><reference><reference_text>Xuan J, Pan G, Qiu Y, Yang L, Su M, Liu Y, Chen J, Feng G, Fang Y, Jia W, Xing Q, He L: Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. J Proteome Res. 2011 Dec 2;10(12):5433-43. doi: 10.1021/pr2006796. Epub 2011 Nov  8.</reference_text><pubmed_id>22007635</pubmed_id></reference><reference><reference_text>Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM, Rothermundt M, Bogerts B, Koethe D, Kranaster L, Ohrmann P, Suslow T, McAllister G, Spain M, Barnes A, van Beveren NJ, Baron-Cohen S, Steiner J, Torrey FE, Yolken RH, Bahn S: Identification of a biological signature for schizophrenia in serum. Mol Psychiatry. 2012 May;17(5):494-502. doi: 10.1038/mp.2011.42. Epub 2011 Apr 12.</reference_text><pubmed_id>21483431</pubmed_id></reference><reference><reference_text>Mathe AA, Eberhard G, Saaf J, Wetterberg L: Plasma prostaglandin E2 metabolite--measured as 11-deoxy-15-keto-13,14-dihydro-11 beta,16 xi-cyclo-PGE2--in twins with schizophrenic disorder. Biol Psychiatry. 1986 Sep;21(11):1024-30.</reference_text><pubmed_id>3741918</pubmed_id></reference><reference><reference_text>Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N: Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct. 2002 Jun;20(2):171-5.</reference_text><pubmed_id>11979513</pubmed_id></reference><reference><reference_text>Zumarraga M, Davila R, Basterreche N, Arrue A, Goienetxea B, Zamalloa MI, Erkoreka L, Bustamante S, Inchausti L, Gonzalez-Torres MA, Guimon J: Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients. Neurochem Int. 2010 May-Jun;56(6-7):774-9. doi: 10.1016/j.neuint.2010.02.015. Epub 2010 Mar 4.</reference_text><pubmed_id>20206656</pubmed_id></reference><reference><reference_text>Peters JG: Dopamine, noradrenaline and serotonin spinal fluid metabolites in temporal lobe epileptic patients with schizophrenic symptomatology. Eur Neurol. 1979;18(1):15-8.</reference_text><pubmed_id>436860</pubmed_id></reference><reference><reference_text>Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, Rozen S, Krishnan RR, McEvoy J, Kaddurah-Daouk R: Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry. 2010 Sep;15(9):938-53. doi: 10.1038/mp.2009.33. Epub 2009 Apr 28.</reference_text><pubmed_id>19401681</pubmed_id></reference><reference><reference_text>Gattaz WF, Waldmeier P, Beckmann H: CSF monoamine metabolites in schizophrenic patients. Acta Psychiatr Scand. 1982 Nov;66(5):350-60.</reference_text><pubmed_id>6184954</pubmed_id></reference><reference><reference_text>Nilsson-Todd LK, Nordin C, Jonsson EG, Skogh E, Erhardt S: Cerebrospinal fluid kynurenic acid in male patients with schizophrenia - correlation with monoamine metabolites. Acta Neuropsychiatr. 2007 Feb;19(1):45-52. doi: 10.1111/j.1601-5215.2006.00170.x.</reference_text><pubmed_id>26952797</pubmed_id></reference><reference><reference_text>Cai HL, Li HD, Yan XZ, Sun B, Zhang Q, Yan M, Zhang WY, Jiang P, Zhu RH, Liu YP, Fang PF, Xu P, Yuan HY, Zhang XH, Hu L, Yang W, Ye HS: Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naive schizophrenia patients after treatment with risperidone. J Proteome Res. 2012 Aug 3;11(8):4338-50. doi: 10.1021/pr300459d. Epub 2012 Jul 26.</reference_text><pubmed_id>22800120</pubmed_id></reference><reference><reference_text>Al Awam K, Haussleiter IS, Dudley E, Donev R, Brune M, Juckel G, Thome J: Multiplatform metabolome and proteome profiling identifies serum metabolite and protein signatures as prospective biomarkers for schizophrenia. J Neural Transm (Vienna). 2015 Aug;122 Suppl 1:S111-22. doi: 10.1007/s00702-014-1224-0. Epub 2014 May 1.</reference_text><pubmed_id>24789758</pubmed_id></reference><reference><reference_text>Bicikova M, Hill M, Ripova D, Mohr P, Hampl R: Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia. J Steroid Biochem Mol Biol. 2013 Jan;133:77-83. doi: 10.1016/j.jsbmb.2012.08.009. Epub 2012 Aug 24.</reference_text><pubmed_id>22944140</pubmed_id></reference><reference><reference_text>He Y, Yu Z, Giegling I, Xie L, Hartmann AM, Prehn C, Adamski J, Kahn R, Li Y, Illig T, Wang-Sattler R, Rujescu D: Schizophrenia shows a unique metabolomics signature in plasma. Transl Psychiatry. 2012 Aug 14;2:e149. doi: 10.1038/tp.2012.76.</reference_text><pubmed_id>22892715</pubmed_id></reference><reference><reference_text>Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KR: Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):934-45. Epub 2007 Apr 17.</reference_text><pubmed_id>17440431</pubmed_id></reference><reference><reference_text>Fryar-Williams S, Strobel JE: Biomarkers of a five-domain translational substrate for schizophrenia and schizoaffective psychosis. Biomark Res. 2015 Feb 6;3:3. doi: 10.1186/s40364-015-0028-1. eCollection 2015.</reference_text><pubmed_id>25729574</pubmed_id></reference><reference><reference_text>Oresic M, Seppanen-Laakso T, Sun D, Tang J, Therman S, Viehman R, Mustonen U, van Erp TG, Hyotylainen T, Thompson P, Toga AW, Huttunen MO, Suvisaari J, Kaprio J, Lonnqvist J, Cannon TD: Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia. Genome Med. 2012 Jan 18;4(1):1. doi: 10.1186/gm300.</reference_text><pubmed_id>22257447</pubmed_id></reference></references></disease><disease>Primary hypomagnesemia<references><reference><reference_text>Jin-no Y, Kamiya Y, Okada M, Hirako M, Takada N, Kawaguchi M: Primary hypomagnesemia caused by isolated magnesium malabsorption: atypical case in adult. Intern Med. 1999 Mar;38(3):261-5.</reference_text><pubmed_id>10337938</pubmed_id></reference><reference><reference_text>Vainsel M, Vandevelde G, Smulders J, Vosters M, Hubain P, Loeb H: Tetany due to hypomagnesaemia with secondary hypocalcaemia. Arch Dis Child. 1970 Apr;45(240):254-8.</reference_text><pubmed_id>5419995</pubmed_id></reference><reference><reference_text>Shalev H, Phillip M, Galil A, Carmi R, Landau D: Clinical presentation and outcome in primary familial hypomagnesaemia. Arch Dis Child. 1998 Feb;78(2):127-30.</reference_text><pubmed_id>9579153</pubmed_id></reference><reference><reference_text>Kari JA, Farouq M, Alshaya HO: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Pediatr Nephrol. 2003 Jun;18(6):506-10. Epub 2003 Apr 29.</reference_text><pubmed_id>12720080</pubmed_id></reference></references></disease><disease>Hyperlipoproteinemia<references><reference><reference_text>Sinha S, Misra A, Kumar V, Jagannathan NR, Bal CS, Pandey RM, Singhania R, Deepak: Proton magnetic resonance spectroscopy and single photon emission computed tomography study of the brain in asymptomatic young hyperlipidaemic Asian Indians in North India show early abnormalities. Clin Endocrinol (Oxf). 2004 Aug;61(2):182-9.</reference_text><pubmed_id>15272912</pubmed_id></reference><reference><reference_text>Nelson RH: Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013 Mar</reference_text><pubmed_id>40(1):195-211. doi: 10.1016/j.pop.2012.11.003. Epub 2012 Dec  4.</pubmed_id></reference><reference><reference_text>Cantin B, Boudriau S, Bertrand M, Brun LD, Gagne C, Rogers PA, Ven Murthy MR, Lupien PJ, Julien P: Hemolysis in primary lipoprotein lipase deficiency. Metabolism. 1995 May;44(5):652-8.</reference_text><pubmed_id>7752915</pubmed_id></reference></references></disease><disease>Abetalipoproteinemia<references><reference><reference_text>Dawson G, Kruski AW, Scanu AM: Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J Lipid Res. 1976 Mar;17(2):125-31.</reference_text><pubmed_id>178813</pubmed_id></reference><reference><reference_text>Lazaro RP, Dentinger MP, Rodichok LD, Barron KD, Satya-Murti S: Muscle pathology in Bassen-Kornzweig syndrome and vitamin E deficiency. Am J Clin Pathol. 1986 Sep;86(3):378-87.</reference_text><pubmed_id>2944375</pubmed_id></reference></references></disease><disease>Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis<references><reference><reference_text>Breckenridge WC, Alaupovic P, Cox DW, Little JA: Apolipoprotein and lipoprotein concentrations in familial apolipoprotein C-II deficiency. Atherosclerosis. 1982 Aug;44(2):223-35.</reference_text><pubmed_id>7138621</pubmed_id></reference><reference><reference_text>Fukami M, Hasegawa T, Horikawa R, Ohashi T, Nishimura G, Homma K, Ogata T: Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr Res. 2006 Feb;59(2):276-80. doi: 10.1203/01.pdr.0000195825.31504.28.</reference_text><pubmed_id>16439592</pubmed_id></reference></references></disease><disease>Cerebrotendinous xanthomatosis<references><reference><reference_text>Halperin G, Elisaf M, Leitersdorf E, Harats D: A new method for determination of serum cholestanol by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2000 Jun 9;742(2):345-52.</reference_text><pubmed_id>10901139</pubmed_id></reference><reference><reference_text>Siman-Tov T, Meiner V, Gadoth N: Could steroids mask the diagnosis of cerebrotendinous xanthomatosis? J Neurol Sci. 2006 Apr 15;243(1-2):83-6. Epub 2006 Jan 30.</reference_text><pubmed_id>16445943</pubmed_id></reference><reference><reference_text>Agrawal NK, Garg S: Cerebrotendinous xanthomatosis: a rare disorder with a rare presentation. BMJ Case Rep. 2012 Sep 21;2012. pii: bcr-2012-006202. doi: 10.1136/bcr-2012-006202.</reference_text><pubmed_id>23001091</pubmed_id></reference></references></disease><disease>3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency<references><reference><reference_text>Thompson GN, Hsu BY, Pitt JJ, Treacy E, Stanley CA: Fasting hypoketotic coma in a child with deficiency of mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase. N Engl J Med. 1997 Oct 23;337(17):1203-7. doi: 10.1056/NEJM199710233371704.</reference_text><pubmed_id>9337379</pubmed_id></reference><reference><reference_text>Morris AA, Lascelles CV, Olpin SE, Lake BD, Leonard JV, Quant PA: Hepatic mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme a synthase deficiency. Pediatr Res. 1998 Sep;44(3):392-6. doi: 10.1203/00006450-199809000-00021.</reference_text><pubmed_id>9727719</pubmed_id></reference><reference><reference_text>Conboy E, Vairo F, Schultz M, Agre K, Ridsdale R, Deyle D, Oglesbee D, Gavrilov D, Klee EW, Lanpher B: Mitochondrial 3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency: Unique Presenting Laboratory Values and a Review of Biochemical and Clinical Features. JIMD Rep. 2017 Oct 14. doi: 10.1007/8904_2017_59.</reference_text><pubmed_id>29030856</pubmed_id></reference></references></disease><disease>Hypercholesterolemia, familial<references><reference><reference_text>Kwiterovich PO Jr, Fredrickson DS, Levy RI: Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest. 1974 May;53(5):1237-49. doi: 10.1172/JCI107670.</reference_text><pubmed_id>4363406</pubmed_id></reference></references></disease><disease>SC4MOL deficiency<references><reference><reference_text>He M, Kratz LE, Michel JJ, Vallejo AN, Ferris L, Kelley RI, Hoover JJ, Jukic D, Gibson KM, Wolfe LA, Ramachandran D, Zwick ME, Vockley J: Mutations in the human SC4MOL gene encoding a methyl sterol oxidase cause psoriasiform dermatitis, microcephaly, and developmental delay. J Clin Invest. 2011 Mar;121(3):976-84. doi: 10.1172/JCI42650.</reference_text><pubmed_id>21285510</pubmed_id></reference></references></disease><disease>Chondrodysplasia punctata, X-linked dominant<references><reference><reference_text>Aughton DJ, Kelley RI, Metzenberg A, Pureza V, Pauli RM: X-linked dominant chondrodysplasia punctata (CDPX2) caused by single gene mosaicism in a male. Am J Med Genet A. 2003 Jan 30;116A(3):255-60. doi: 10.1002/ajmg.a.10852.</reference_text><pubmed_id>12503102</pubmed_id></reference></references></disease><disease>Desmosterolosis<references><reference><reference_text>Andersson HC, Kratz L, Kelley R: Desmosterolosis presenting with multiple congenital anomalies and profound developmental delay. Am J Med Genet. 2002 Dec 15;113(4):315-9. doi: 10.1002/ajmg.b.10873.</reference_text><pubmed_id>12457401</pubmed_id></reference></references></disease><disease>Donohue Syndrome<references><reference><reference_text>Nijim Y, Awni Y, Adawi A, Bowirrat A: Classic Case Report of Donohue Syndrome (Leprechaunism; OMIM *246200): The Impact of Consanguineous Mating. Medicine (Baltimore). 2016 Feb;95(6):e2710. doi: 10.1097/MD.0000000000002710.</reference_text><pubmed_id>26871809</pubmed_id></reference></references></disease><disease>Leptin Deficiency or Dysfunction<references><reference><reference_text>Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O'Rahilly S: Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999 Sep 16;341(12):879-84. doi: 10.1056/NEJM199909163411204.</reference_text><pubmed_id>10486419</pubmed_id></reference></references></disease><disease>Duchenne Muscular Dystrophy<references><reference><reference_text>Nakagawa T, Takeuchi A, Kakiuchi R, Lee T, Yagi M, Awano H, Iijima K, Takeshima Y, Urade Y, Matsuo M: A prostaglandin D2 metabolite is elevated in the urine of Duchenne muscular dystrophy patients and increases further from 8 years old. Clin Chim Acta. 2013 Aug 23;423:10-4. doi: 10.1016/j.cca.2013.03.031. Epub 2013 Apr 19.</reference_text><pubmed_id>23603101</pubmed_id></reference><reference><reference_text>Srivastava NK, Pradhan S, Mittal B, Gowda GA: High resolution NMR based analysis of serum lipids in Duchenne muscular dystrophy patients and its possible diagnostic significance. NMR Biomed. 2010 Jan;23(1):13-22. doi: 10.1002/nbm.1419.</reference_text><pubmed_id>19787747</pubmed_id></reference><reference><reference_text>Horster I, Weigt-Usinger K, Carmann C, Chobanyan-Jurgens K, Kohler C, Schara U, Kayacelebi AA, Beckmann B, Tsikas D, Lucke T: The L-arginine/NO pathway and homoarginine are altered in Duchenne muscular dystrophy and improved by glucocorticoids. Amino Acids. 2015 Sep;47(9):1853-63. doi: 10.1007/s00726-015-2018-x. Epub 2015 Jun 12.</reference_text><pubmed_id>26066683</pubmed_id></reference></references></disease><disease>Lecithin:cholesterol Acyltransferase Deficiency<references><reference><reference_text>Idzior-Walus B, Sieradzki J, Kostner G, Malecki MT, Klupa T, Wesolowska T, Rostworowski W, Hartwich J, Walus M, Kiec AD, Naruszewicz M: Familial lecithin-cholesterol acyltransferase deficiency: biochemical characteristics and molecular analysis of a new LCAT mutation in a Polish family. Atherosclerosis. 2006 Apr;185(2):413-20. Epub 2005 Jul 26.</reference_text><pubmed_id>16051254</pubmed_id></reference></references></disease><disease>Lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lipodystrophy, Congenital Generalized<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Oculocerebrorenal syndrome<references><reference><reference_text>Charnas LR, Bernardini I, Rader D, Hoeg JM, Gahl WA: Clinical and laboratory findings in the oculocerebrorenal syndrome of Lowe, with special reference to growth and renal function. N Engl J Med. 1991 May 9;324(19):1318-25. doi: 10.1056/NEJM199105093241904.</reference_text><pubmed_id>2017228</pubmed_id></reference></references></disease><disease>Familial partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Lathosterolosis<references><reference><reference_text>Brunetti-Pierri N, Corso G, Rossi M, Ferrari P, Balli F, Rivasi F, Annunziata I, Ballabio A, Russo AD, Andria G, Parenti G: Lathosterolosis, a novel multiple-malformation/mental retardation syndrome due to deficiency of 3beta-hydroxysteroid-delta5-desaturase. Am J Hum Genet. 2002 Oct;71(4):952-8. Epub 2002 Aug 20.</reference_text><pubmed_id>12189593</pubmed_id></reference><reference><reference_text>Ho AC, Fung CW, Siu TS, Ma OC, Lam CW, Tam S, Wong VC: Lathosterolosis: a disorder of cholesterol biosynthesis resembling smith-lemli-opitz syndrome. JIMD Rep. 2014;12:129-34. doi: 10.1007/8904_2013_255. Epub 2013 Oct 20.</reference_text><pubmed_id>24142275</pubmed_id></reference></references></disease><disease>Partial lipodystrophy<references><reference><reference_text>Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, Bilen H, Nur B, Demir L, Onay H, Akinci B: Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun 1.</reference_text><pubmed_id>28754454</pubmed_id></reference></references></disease><disease>Multiple sclerosis<references><reference><reference_text>Lutz NW, Viola A, Malikova I, Confort-Gouny S, Audoin B, Ranjeva JP, Pelletier J, Cozzone PJ: Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One. 2007 Jul 4;2(7):e595.</reference_text><pubmed_id>17611627</pubmed_id></reference><reference><reference_text>Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U, Hillert J, Bjorkhem I: Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med. 2004 Feb;42(2):186-91.</reference_text><pubmed_id>15061359</pubmed_id></reference><reference><reference_text>Leoni V, Lutjohann D, Masterman T: Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis. J Lipid Res. 2005 Feb;46(2):191-5. Epub 2004 Dec 1.</reference_text><pubmed_id>15576852</pubmed_id></reference><reference><reference_text>Calabrese V, Scapagnini G, Ravagna A, Bella R, Butterfield DA, Calvani M, Pennisi G, Giuffrida Stella AM: Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem Res. 2003 Sep;28(9):1321-8.</reference_text><pubmed_id>12938853</pubmed_id></reference><reference><reference_text>Shaw CE, Dunbar PR, Macaulay HA, Neale TJ: Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol. 1995 Jan;242(2):53-8.</reference_text><pubmed_id>7707089</pubmed_id></reference><reference><reference_text>Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.</reference_text><pubmed_id>17384003</pubmed_id></reference><reference><reference_text>Syburra C, Passi S: Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh (1999). 1999 May-Jun;71(3):112-5.</reference_text><pubmed_id>10609336</pubmed_id></reference><reference><reference_text>Forte G, Visconti A, Santucci S, Ghazaryan A, Figa-Talamanca L, Cannoni S, Bocca B, Pino A, Violante N, Alimonti A, Salvetti M, Ristori G: Quantification of chemical elements in blood of patients affected by multiple sclerosis. Ann Ist Super Sanita. 2005;41(2):213-6.</reference_text><pubmed_id>16244395</pubmed_id></reference><reference><reference_text>Toncev G, Milicic B, Toncev S, Samardzic G: Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol. 2002 May;9(3):221-6.</reference_text><pubmed_id>11985629</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, Bamonti F, Capello E, Mancardi GL, Scarpini E: Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res. 2010 May 28;1333:64-71. doi: 10.1016/j.brainres.2010.03.073. Epub 2010 Mar 27.</reference_text><pubmed_id>20347721</pubmed_id></reference><reference><reference_text>Matsushita T, Isobe N, Kawajiri M, Mogi M, Tsukuda K, Horiuchi M, Ohyagi Y, Kira J: CSF angiotensin II and angiotensin-converting enzyme levels in anti-aquaporin-4 autoimmunity. J Neurol Sci. 2010 Aug 15;295(1-2):41-5. doi: 10.1016/j.jns.2010.05.014. Epub 2010 Jun 11.</reference_text><pubmed_id>20541774</pubmed_id></reference><reference><reference_text>Ghabaee M, Jabedari B, Al-E-Eshagh N, Ghaffarpour M, Asadi F: Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients. Int J Neurosci. 2010 Apr;120(4):301-4. doi: 10.3109/00207451003695690.</reference_text><pubmed_id>20374079</pubmed_id></reference><reference><reference_text>Kawajiri M, Mogi M, Osoegawa M, Matsuoka T, Tsukuda K, Kohara K, Horiuchi M, Miki T, Kira JI: Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler. 2008 May;14(4):557-60. doi: 10.1177/1352458507085760.</reference_text><pubmed_id>18562510</pubmed_id></reference><reference><reference_text>Visconti A, Cotichini R, Cannoni S, Bocca B, Forte G, Ghazaryan A, Santucci S, D'Ippolito C, Stazi MA, Salvetti M, Alimonti A, Ristori G: Concentration of elements in serum of patients affected by multiple sclerosis with first demyelinating episode: a six-month longitudinal follow-up study. Ann Ist Super Sanita. 2005;41(2):217-22.</reference_text><pubmed_id>16244396</pubmed_id></reference></references></disease><disease>Inflammatory bowel disease<references><reference><reference_text>Lee T, Clavel T, Smirnov K, Schmidt A, Lagkouvardos I, Walker A, Lucio M, Michalke B, Schmitt-Kopplin P, Fedorak R, Haller D: Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. 2017 May;66(5):863-871. doi: 10.1136/gutjnl-2015-309940. Epub 2016 Feb 4.</reference_text><pubmed_id>26848182</pubmed_id></reference><reference><reference_text>Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158.</reference_text><pubmed_id>27609529</pubmed_id></reference></references></disease><disease>Colorectal cancer<references><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B: Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009 Apr;22(3):342-8. doi: 10.1002/nbm.1345.</reference_text><pubmed_id>19006102</pubmed_id></reference><reference><reference_text>Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP: Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One. 2013 Aug 6;8(8):e70803. doi: 10.1371/journal.pone.0070803. Print 2013.</reference_text><pubmed_id>23940645</pubmed_id></reference><reference><reference_text>Phua LC, Chue XP, Koh PK, Cheah PY, Ho HK, Chan EC: Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biol Ther. 2014 Apr;15(4):389-97. doi: 10.4161/cbt.27625. Epub 2014 Jan 14.</reference_text><pubmed_id>24424155</pubmed_id></reference><reference><reference_text>Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB: Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010 Feb 15;8:13. doi: 10.1186/1741-7015-8-13.</reference_text><pubmed_id>20156336</pubmed_id></reference><reference><reference_text>Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, Ni Y, Zhao A, Xu LX, Cai S, Jia W: Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res. 2009 Oct;8(10):4844-50. doi: 10.1021/pr9004162.</reference_text><pubmed_id>19678709</pubmed_id></reference><reference><reference_text>Cheng Y, Xie G, Chen T, Qiu Y, Zou X, Zheng M, Tan B, Feng B, Dong T, He P, Zhao L, Zhao A, Xu LX, Zhang Y, Jia W: Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res. 2012 Feb 3;11(2):1354-63. doi: 10.1021/pr201001a. Epub 2011 Dec 28.</reference_text><pubmed_id>22148915</pubmed_id></reference><reference><reference_text>Ni Y, Xie G, Jia W: Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res. 2014 Sep 5;13(9):3857-70. doi: 10.1021/pr500443c. Epub 2014 Aug 14.</reference_text><pubmed_id>25105552</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference><reference><reference_text>Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18.</reference_text><pubmed_id>25037050</pubmed_id></reference><reference><reference_text>Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016.</reference_text><pubmed_id>27015276</pubmed_id></reference><reference><reference_text>Lin Y, Ma C, Liu C, Wang Z, Yang J, Liu X, Shen Z, Wu R: NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer. Oncotarget. 2016 May 17;7(20):29454-64. doi: 10.18632/oncotarget.8762.</reference_text><pubmed_id>27107423</pubmed_id></reference><reference><reference_text>Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016.</reference_text><pubmed_id>27275383</pubmed_id></reference><reference><reference_text>Wang X, Wang J, Rao B, Deng L: Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals. Exp Ther Med. 2017 Jun;13(6):2848-2854. doi: 10.3892/etm.2017.4367. Epub 2017 Apr 20.</reference_text><pubmed_id>28587349</pubmed_id></reference><reference><reference_text>Silke Matysik, Caroline Ivanne Le Roy, Gerhard Liebisch, Sandrine Paule Claus. Metabolomics of fecal samples: A practical consideration. Trends in Food Science &amp; Technology. Vol. 57, Part B, Nov. 2016, p.244-255: http://www.sciencedirect.com/science/article/pii/S0924224416301984</reference_text><pubmed_id>28587349</pubmed_id></reference></references></disease></diseases></range></ranges></Metabolites>